WO2012068406A2 - Use of hematopoietic growth factor mimetics - Google Patents

Use of hematopoietic growth factor mimetics Download PDF

Info

Publication number
WO2012068406A2
WO2012068406A2 PCT/US2011/061247 US2011061247W WO2012068406A2 WO 2012068406 A2 WO2012068406 A2 WO 2012068406A2 US 2011061247 W US2011061247 W US 2011061247W WO 2012068406 A2 WO2012068406 A2 WO 2012068406A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
group
alkyl
aryl
heteroaryl
Prior art date
Application number
PCT/US2011/061247
Other languages
French (fr)
Other versions
WO2012068406A3 (en
Inventor
Reid P. Bissonnette
Andrew R. Hudson
Keith B. Marschke
Deepa Rungta
Lin Zhi
Original Assignee
Ligand Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Incorporated filed Critical Ligand Pharmaceuticals Incorporated
Priority to US13/885,148 priority Critical patent/US20140243324A1/en
Priority to CN2011800627578A priority patent/CN103282034A/en
Priority to EP11793596.5A priority patent/EP2642994A2/en
Priority to JP2013540029A priority patent/JP6261340B2/en
Publication of WO2012068406A2 publication Critical patent/WO2012068406A2/en
Publication of WO2012068406A3 publication Critical patent/WO2012068406A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Definitions

  • the present invention relates to uses of small molecule mimetics of hematopoietic growth factors.
  • the present invention relates to uses of small molecule mimetics of erythropoietin.
  • Hematopoietic growth factors include a family of biological molecules such as glycoproteins with important regulatory functions in the processes of proliferation, differentiation, and functional activation of hematopoietic progenitors and mature blood cells.
  • HGF compounds can be potent regulators of blood cell proliferation and development in the bone marrow. They are able to augment hematopoiesis when bone marrow dysfunction exists. Recombinant DNA technology has made it possible to clone the genes responsible for many of these factors.
  • EPO glycoprotein hormone erythropoietin
  • EPO is an essential viability and growth factor for the erythrocytic progenitors. EPO acts primarily to rescue differentiating erythroid cells from cell death, i.e., apoptosis, to increase their survival.
  • EPO is a member of the family of class I cytokines which fold into a compact globular structure consisting of 4 oc-helical bundles, thus while its molecular mass is 30.4 kDa, EPO migrates with an apparent size of 34-38 kDa on SDS- polyacrylamide gels.
  • EPO peptide core of 165 amino acids suffices for receptor-binding and in vitro stimulation of erythropoiesis, while the carbohydrate portion (40% of the total molecule) is required for the in vivo survival of the hormone.
  • the 4 carbohydrate chains of EPO have been analyzed in detail.
  • the 3 complex-type N-linked oligosaccharides at asparagines 24, 38 and 83 appear involved in stabilizing EPO in circulation.
  • EPO is mainly produced by hepatocytes. After birth, almost all circulating EPO originates from peritubular fibroblast-like cells located in the cortex of the kidneys.
  • Transcription factors of the GATA-family may be important in the control of the time-specific and tissue- specific expression of the EPO gene.
  • EPO mRNA In adults, minor amounts of EPO mRNA are expressed in liver parenchyma, spleen, lung, testis and brain. In brain, EPO exerts neurotrophic and neuroprotective effects, which are separate from the action of circulating EPO on erythropoietic tissues. See e.g., Jelkmann, W., Internal Medicine Vol. 43, No.8 (August 2004).
  • EPO binds to the homodimeric EPO receptor to act synergistically with several growth factors (e.g., SCF, GM-CSF, 1L-3, and IGF-1) to cause the maturation and proliferation of erythroid progenitor cells and their subsequent differentiation into red blood cells (RBCs).
  • growth factors e.g., SCF, GM-CSF, 1L-3, and IGF-1
  • This process is mediated by a number of intracellular signaling pathways, for example, STAT5, Ras/MAPK and PI3K-GATA 1.
  • EPO receptor binding induces a conformational change in the homodimer leading to the phosphorylation and activation of EPO receptor-associated JAK2 kinase, which results in tyrosine phosphorylation of the EPO receptor as well as the activation of several downstream signaling pathways, including STAT5, STAT3, STAT1, Ras/MAPK, P13K1AKT and GATA1.
  • EPO EPO-like erythropoiesis stimulating agents
  • All four forms of EPO are synthetic proteins produced by recombinant DNA technology in mammalian cells into which the human erythropoietin gene has been introduced, and include Epoetin alfa (marketed as Epogen® and Procrit® and identical to endogenous EPO), Epoetin beta (marketed only in Europe as NeoRecormon®), Darbepoetin Alfa (marketed as Aranesp®) and a methoxy polyethylene glycol-conjugated form of epoetin beta (marketed as Micera®).
  • Epoetin alfa marketed as Epogen® and Procrit® and identical to endogenous EPO
  • Epoetin beta marketed only in Europe as NeoRecormon®
  • Darbepoetin Alfa marketed as Aranesp®
  • Micera® methoxy polyethylene glycol-conjugated form of epoetin beta
  • Darbepoetin Alfa differs from endogenous EPO by containing two more N-linked oligosaccharide chains.
  • HematideTM is a synthetic dimeric PEG-modified peptide-based erythropoiesis stimulating agent immunologically distinct from EPO but which is believed to bind and activate EPO receptor signaling in a manner indistinguishable from EPO.
  • CNTO-530 is a 58 kD EPO receptor agonist that links two EMP-1 (erythropoietin mimetic peptide- 1) peptides to a proprietary MIMETIBODY (Ig Fc domain fusion protein) scaffold. It bears no homology to EPO, yet activates EPO receptor signaling in a manner similar to EPO.
  • Some embodiments provided herein include use of a non-peptidyl small molecule mimetic of EPO in the preparation of a medicament for the treatment of a disorder associated with erythropoiesis by administering an initial effective amount of the mimetic of EPO, and a second effective amount of the mimetic of EPO, wherein the initial and the second effective amounts are substantially the same.
  • the medicament is for the treatment of a disorder associated with erythropoiesis by further administering a third effective amount of the mimetic of EPO that is substantially the same as the initial and second effective amounts.
  • the medicament is for the treatment of a disorder associated with erythropoiesis by further administering one or more subsequent effective amounts of the mimetic of EPO that is substantially the same as the initial, second, and third effective amounts.
  • the initial and the second effective amounts are the same.
  • the medicament is for the treatment of a disorder associated with erythropoiesis by administering a series of effective amounts that are substantially the same at least daily, at least weekly, or at least monthly.
  • Some embodiemtns include use of a non-peptidyl small molecule mimetic of EPO in the preparation of a medicament for the treatment of a disorder associated with erythropoiesis without titration of the amount of the mimetic of EPO administered.
  • the medicament is for the treatment of a disorder associated with erythropoiesis by administering at least two successive effective amounts of the mimetic of EPO.
  • the medicament is for the treatment of a disorder associated with erythropoiesis without titration over a period of time for administration that is daily, weekly, or monthly.
  • the disorder associated with erythropoiesis comprises anemia.
  • the anemia is associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, anemia of chronic disease, congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or ⁇ infection.
  • the mimetic of EPO is an EPO receptor partial agonist.
  • the mimetic of EPO activates EPO receptor signaling through the PI3K-GATA1 pathway.
  • Some embodiments include a non-peptidyl small molecule mimetic of EPO for use in the treatment of a disorder associated with erythropoiesis by administering an initial effective amount of the mimetic of EPO, and a second effective amount of the mimetic of EPO, wherein the initial and the second effective amounts are substantially the same.
  • Some embodiments include use of a mimetic of EPO in the treatment of a disorder associated with erythropoiesis by further administering one or more subsequent effective amounts of the mimetic of EPO that is substantially the same as the initial and second effective amounts.
  • the initial and the second effective amounts are the same.
  • Some embodiments include use of a mimetic of EPO in the treatment of a disorder associated with erythropoiesis by administering a series of effective amounts that are substantially the same at least daily, at least weekly, or at least monthly.
  • Some embodiments include a non-peptidyl small molecule mimetic of EPO for use in the treatment of a disorder associated with erythropoiesis without titration of the amount of the mimetic of EPO administered.
  • Some embodiments include use of a mimetic of EPO for use in the treatment of a disorder associated with erythropoiesis by administering at least two successive effective amounts of the mimetic of EPO. [0027] Some embodiments include use of a mimetic of EPO for use in the treatment of a disorder associated with erythropoiesis without titration over a period of time for administration that is daily, weekly, or monthly.
  • the disorder associated with erythropoiesis comprises anemia.
  • the anemia is associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, anemia of chronic disease, congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or ⁇ infection.
  • the mimetic of EPO is an EPO receptor partial agonist.
  • the mimetic of EPO activates EPO receptor signaling through the PI3K-GATA1 pathway.
  • Some embodiments include a method of treating a disorder associated with erythropoiesis in a patient in need of such treatment, said method comprising: administering an initial effective amount of a non-peptidyl small molecule mimetic of EPO to the patient; and administering a second effective amount of the mimetic of EPO to the patient, wherein the initial and the second effective amounts are substantially the same.
  • Some embodiments include comprising administering a third effective amount of the mimetic of EPO to the patient that is substantially the same as the initial and second effective amounts.
  • Some embodiments include administering one or more subsequent effective amounts of the mimetic of EPO to the patient that is substantially the same as the initial, second, and third effective amounts.
  • the initial and the second effective amounts are the same.
  • Some embodiments include administering a series of effective amounts that are substantially the same to the patient at least daily, at least weekly, or at least monthly.
  • Some embodiments include a method of treating a disorder associated with erythropoiesis to a patient in need of such treatment, said method comprising: administering an effective amount of a non-peptidyl small molecule mimetic of EPO to the patient, wherein the amount administered to the patient is not titrated over the period of time for administration.
  • one or more subsequent effective amounts of the mimetic of EPO are administered to said patient.
  • the period of time for administration includes administration daily, weekly, or monthly.
  • the disorder associated with erythropoiesis comprises anemia.
  • the anemia is associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, anemia of chronic disease, congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or ⁇ infection.
  • the mimetic of EPO is an EPO receptor partial agonist.
  • the mimetic of EPO activates EPO receptor signaling through the PI3K-GATA1 pathway.
  • the EPO mimetic comprises a compound of Formula I) having the structure:
  • the mimetic of EPO comprises a compound of Formula II) having the structure:
  • the mimetic of EPO comprises a compound of Formula (III) having the structure:
  • the mimetic of EPO comprises a compound of Formula (IV) having the structure:
  • the mimetic of EPO comprises a compound of Formula V) having the structure:
  • the mimetic of EPO comprises a compound of Formula VI) having the structure:
  • the mimetic of EPO comprises a compound of Formula (VII) having the structure:
  • the mimetic of EPO comprises a compound of Formula (IX) having the structure:
  • the mimetic of EPO comprises a compound of Formula (X) having the structure:
  • FIG. 1 shows a schematic diagram of pathways related to the EPO receptor. Such pathways include the proteins JAK2, NFKB, IKB, MAPK, ERK, STAT5,
  • FIG. 2 shows a diagram of changes in GATA1 and GATA2 activity as erythroid development progresses and cell proliferation decreases as cell differentiation increases.
  • the erythroid development pathway includes the cells: EMP, BFU-E, CFU-E,
  • FIG. 3 shows a graph of percentage efficacy of experimental compounds relative to EPO vs. concentration of experimental compounds.
  • ⁇ recombinant human EPO (rHuEPO); A : compound 101; ⁇ : compound 102).
  • Normal serum EPO concentration is about 0.01 U/ml (range: 0.006 - 0.032 U/ml).
  • FIG. 4 shows a graph of percentage differentiation of CD235a+ cells relative to number of cells treated with 2.0 U/ml recombinant human EPO (rHuEPO) for cells treated with various experimental compounds.
  • FIG. 5A shows a graph of phosphorylation of the EPO receptor after 15 minutes or 45 minutes treatment with 10 nM Compound 102, 100 nM Compound 102, or control (vehicle).
  • FIG. 5B shows a graph of fold- stimulation of P13K after 60 minutes treatment with EPO, Compound 101, or control (vehicle).
  • FIG. 5C shows fold stimulation of GATA1 after 60 minutes treatment with EPO, Compound 101, or control (vehicle).
  • FIG. 6A shows the results of an electrophoretic mobility shift assay for GATA1 in UT7 cells after 30 minute treatments with test compounds.
  • FIG. 6B shows a graph of binding intensity for GATA1 in UT7 cells after 30 minute treatments with test compounds.
  • FIG. 7 shows a graph of relative cell viability of an EPO dependent cell line treated with EPO receptor siRNA, GATA1 siRNA, or no siRNA. Cells were further treated with 1 U/ml EPO, 30 nM Compound 101, or control (vehicle).
  • the present invention relates to methods and uses of certain compounds and compositions with activity that modulate activity of the EPO receptor.
  • certain compounds and compositions that modulate activity of the EPO also include erythropoiesis stimulating activity.
  • compounds and compositions that modulate activity of the EPO receptor can include non-peptidyl small molecule mimetic s of EPO.
  • EPO acts on the homodimeric EPO receptor to stimulate proliferation of erythroid progenitor cells and induce their survival and differentiation into red blood cells.
  • Various recombinant human EPO derivatives also known as erythropoiesis- stimulating agents, are marketed or in clinical development for the treatment of anemia due to renal failure or cancer chemotherapy.
  • treatment with erythropoiesis- stimulating agent is associated with an increased risk of adverse cardiovascular complications in patients with kidney disease, and may be related to an increase in mortality in cancer patients, when it is used to increase hemoglobin levels above 13.0 g/dl (Rizzo JD, et al.
  • Some embodiments of the present invention relate to the use of a non- peptidyl small molecules that selectively activate EPO receptor function. It has been discovered that some selective agonists display an efficacy partial to the maximal effect induced by EPO. Accordingly, some compounds and compositions provided herein are most advantageous in at least the lack excessive erythropoietic stimulation that may contribute to the adverse effects of erythropoiesis-stimulating agents. In addition, some compounds and compositions provided herein include further advantages over conventional erythropoiesis-stimulating agents.
  • some compounds and compositions provided herein are less likely to stimulate the production of neutralizing antibodies, can be orally administrable, thus eliminating the need for injections, have longer serum half-life, have an increased bioavailability, and/or can be produced at a lower cost than erythropoiesis-stimulating agents.
  • the EPO receptor is a 59 kDa homodimeric protein and is a member of the cytokine receptor family. Binding of EPO to the EPO receptor induces a conformational change resulting in the autophosphorylation of kinases such as Jak2, and activation of several intracellular signaling pathways (FIG. 1).
  • the intracellular signaling pathways include ⁇ / ⁇ , Ras/MAPK/ERK, STAT5, P 13/AKT/G ATA 1 pathways associated with cellular functions such as anti-apoptosis, proliferation, and differentiation of erythroid progenitor cells into red blood cells (Richmond TD, et al. 2005 Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 15:146-155).
  • compositions and methods provided herein can be used to treat disorders associated with anemia, such as chronic kidney disease, congestive heart failure, rheumatoid arthritis, and other chronic inflammatory diseases.
  • anemia is a frequent complication in patients with cancer, oftentimes due to impaired EPO production, bone marrow response, iron availability, and red blood cell survival (Adamson JW. 2008 The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2008:159-65).
  • Anemia may also be associated with chemotherapy, especially when platinum-based therapy is used.
  • erythropoiesis-stimulating agent can increase the risk of tumor growth and shorten survival in anemic cancer patients (Rizzo JD, et al. 2008 Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guidelines update. J Clin Oncol 26:132-149)
  • Additional advantages associated with some of the compounds and compositions provided herein relate to the selective activation of particular pathways.
  • Some of the compounds and compositions provided herein selectively signal through one or more of the intracellular signaling pathways modulated by the EPO receptor.
  • some of the compounds and compositions provided herein selectively signal through the P13/AKT/GATA1 that is associated with differentiation of bone marrow hematopoietic cells (BM-HCs) into erythrocytes.
  • BM-HCs bone marrow hematopoietic cells
  • the survival of erythroid progenitor cells and their terminal differentiation into RBCs is associated with EPO/EPO receptor interactions and GATAl transcription factor activity (FIG. 2).
  • the erythroid development pathway includes cells at various stages such as: EMP, BFU-E, CFU-E, pro-erythroblast, basophilic erythroblast, polychromatic erythroblast, orthochromatic erythroblast, reticulocyte, and erythrocyte.
  • An increase in GATAl cellular levels causes erythroid cells to develop the erythrocyte phenotype (e.g., expression of hemoglobin), and triggers the transition of rapidly proliferating erythroid progenitor cells to mature erythroid cells (Ferreira R, et al. 2005 GATAl function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol 25:1215-27).
  • the selective activation of particular pathways and not other pathways may reduce the risk of tumor growth in cancer patients The risk of tumor growth may be increased and survival may be shortened in cancer patients when particular pathways are stimulated.
  • Drug titration can include administering an initial dose of a drug comprising relatively small dosage, then monitoring the patient's side effects, and subsequently increasing the dosage of the drug until the targeted benefits are achieved or until the patient's side effects meet or exceed a desired threshold. The dosage is increased until the patient's side effects increase to the point that they are judged to warrant no further increase in dosage or that the patient reaches a maximum recommended dosage.
  • Drug titration techniques require face-to-face interaction with medical personnel, which consumes resources and is inconvenient for the patient.
  • compositions provided herein with partial EPO receptor modulatory activity may not require a drug titration procedure. Accordingly, some embodiments of the present invention include administering certain compounds and compositions provided herein without a drug titration procedure.
  • Standard chemical symbols are used interchangeably with the full names represented by such symbols. Thus, for example, the terms "hydrogen” and “H” are understood to have identical meaning.
  • Standard techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection).
  • Reactions and purification techniques may be performed e.g., using kits according to manufacturer's specifications or as commonly accomplished in the art or as described herein.
  • the foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al. Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference in its entirety for any purpose.
  • selective binding compound refers to a compound that selectively binds to any portion of one or more target.
  • selective HGF receptor binding compound refers to a compound that selectively binds to any portion of a HGF receptor.
  • selective EPO receptor binding compound refers to a compound that selectively binds to any portion of a EPO receptor.
  • selective binding refers to the ability of a selective binding compound to bind to a target receptor with greater affinity than it binds to a non-target receptor.
  • selective binding refers to binding to a target with an affinity that is at least 10, 50, 100, 250, 500, or 1000 times greater than the affinity for a non-target.
  • target receptor refers to a receptor or a portion of a receptor capable of being bound by a selective binding compound.
  • a target receptor is a HGF receptor.
  • a target receptor is an EPO receptor.
  • modulator refers to a compound that alters an activity.
  • a modulator may cause an increase or decrease in the magnitude of a certain activity compared to the magnitude of the activity in the absence of the modulator.
  • a modulator is an inhibitor, which decreases the magnitude of one or more activities.
  • an inhibitor completely prevents one or more biological activities.
  • a modulator is an activator, which increases the magnitude of at least one activity.
  • the presence of a modulator results in an activity that does not occur in the absence of the modulator.
  • selective modulator refers to a compound that selectively modulates a target activity.
  • selective HGF modulator refers to a compound that selectively modulates at least one HGF activity.
  • selective HGF modulator includes, but is not limited to "HGF mimic” which refers to a compound, the presence of which results in at least one HGF activity.
  • selective EPO receptor modulator refers to a compound that selectively modulates at least one EPO receptor activity.
  • selective EPO receptor modulator includes, but is not limited to "EPO mimic” which refers to a compound, the presence of which results in at least one EPO receptor activity.
  • selective modulates refers to the ability of a selective modulator to modulate a target activity to a greater extent than it modulates a non-target activity.
  • target activity refers to a biological activity capable of being modulated by a selective modulator.
  • Certain exemplary target activities include, but are not limited to, binding affinity, signal transduction, enzymatic activity, the proliferation and/or differentiation of progenitor cells, generation of platelets, and alleviation of symptoms of a disease or condition.
  • HGF activity refers to a biological activity that results, either directly or indirectly from the presence of HGF.
  • exemplary HGF activities include, but are not limited to, proliferation and or differentiation of progenitor cells to produce platelets; hematopoiesis; growth and/or development of glial cells; repair of nerve cells; and alleviation of thrombocytopenia.
  • an example of HGF activity is EPO receptor activity.
  • receptor mediated activity refers to any biological activity that results, either directly or indirectly, from binding of a ligand to a receptor.
  • agonist refers to a compound, the presence of which results in a biological activity of a receptor that is the same as the biological activity resulting from the presence of a naturally occurring ligand for the receptor.
  • partial agonist refers to a compound, the presence of which results in a biological activity of a receptor that is of the same type as that resulting from the presence of a naturally occurring ligand for the receptor, but of a lower magnitude.
  • partial EPO receptor agonist refers to a compound, the presence of which results in a biological activity of EPO receptor that is of the same type as that resulting from the presence of naturally occurring EPO, but which is less than the maximum effect induced by EPO.
  • antagonist refers to a compound, the presence of which results in a decrease in the magnitude of a biological activity of a receptor. In certain embodiments, the presence of an antagonist results in complete inhibition of a biological activity of a receptor.
  • alkyl refers to a branched or unbranched fully saturated acyclic aliphatic hydrocarbon group.
  • An alkyl may be branched or straight chain.
  • Alkyls may be substituted or unsubstituted.
  • Alkyls include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, and the like, each of which may be optionally substituted.
  • an alkyl comprises 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., "1 to 20 carbon atoms” means that an alkyl group may comprise only 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the term “alkyl” also includes instances where no numerical range of carbon atoms is designated).
  • An alkyl may be designated as "Ci-C 6 alkyl" or similar designations.
  • CrC 4 alkyl indicates an alkyl having one, two, three, or four carbon atoms, e.g., the alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, zso-butyl, sec-butyl, and tert-butyl.
  • alkenyl used herein refers to a monovalent straight or branched chain aliphatic hydrocarbon radical of from two to twenty carbon atoms containing at least one carbon-carbon double bond including, but not limited to, 1- propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl, and the like.
  • an alkenyl comprises 2 to 20 carbon atoms (whenever it appears herein, a numerical range such as “2 to 20” refers to each integer in the given range; e.g., "2 to 20 carbon atoms” means that an alkenyl group may comprise only 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the term “alkenyl” also includes instances where no numerical range of carbon atoms is designated).
  • An alkenyl may be designated as "C 2 -C6 alkenyl" or similar designations.
  • C 2 -C 4 alkenyl indicates an alkenyl having two, three, or four carbon atoms, e.g., the alkenyl is selected from ethenyl, propenyl, and butenyl.
  • alkynyl used herein refers to a monovalent straight or branched chain aliphatic hydrocarbon radical of from two to twenty carbon atoms containing at least one carbon-carbon triple bond including, but not limited to, 1- propynyl, 1-butynyl, 2-butynyl, and the like.
  • an alkynyl comprises 2 to 20 carbon atoms (whenever it appears herein, a numerical range such as “2 to 20” refers to each integer in the given range; e.g., "2 to 20 carbon atoms” means that an alkynyl group may comprise only 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the term “alkynyl” also includes instances where no numerical range of carbon atoms is designated).
  • An alkynyl may be designated as "C 2 -C 6 alkynyl" or similar designations.
  • C 2 -C 4 alkynyl indicates an alkenyl having two, three, or four carbon atoms, e.g., the alkenyl is selected from ethynyl, propynyl, and butynyl.
  • cycloalkyl used herein refers to saturated aliphatic ring system radical having three to twenty carbon atoms.
  • a cycloalkyl refers to monocyclic and polycyclic saturated aliphatic ring system including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[4.4.0]decanyl, bicyclo[2.2.1]heptanyl, adamantyl, norbornyl, and the like.
  • a cycloalkyl comprises 3 to 20 carbon atoms (whenever it appears herein, a numerical range such as “3 to 20” refers to each integer in the given range; e.g., "3 to 20 carbon atoms” means that a cycloalkyl group may comprise only 3 carbon atoms, etc., up to and including 20 carbon atoms, although the term “cycloalkyl” also includes instances where no numerical range of carbon atoms is designated).
  • a cycloalkyl may be designated as "C 3 -C 7 cycloalkyl" or similar designations.
  • C 3 -C 6 cycloalkyl indicates an alkenyl having two, three, four, five or six carbon atoms, e.g., the cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • cycloalkenyl refers to aliphatic ring system radical having three to twenty carbon atoms having at least one carbon-carbon double bond in the ring.
  • a cycloalkenyl refers to monocyclic and polycyclic unsaturated aliphatic ring system including, but are not limited to, cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, bicyclo[3.1.0]hexyl, norbornylenyl, ⁇ , -bicyclopentenyl, and the like.
  • a cycloalkenyl comprises 3 to 20 carbon atoms (whenever it appears herein, a numerical range such as “3 to 20” refers to each integer in the given range; e.g., "3 to 20 carbon atoms” means that a cycloalkenyl group may comprise only 3 carbon atoms, etc., up to and including 20 carbon atoms, although the term “cycloalkenyl” also includes instances where no numerical range of carbon atoms is designated).
  • a cycloalkenyl may be designated as "C 3 -C 7 cycloalkenyl" or similar designations.
  • C3-C 6 cycloalkenyl indicates an alkenyl having two, three, four, five or six carbon atoms, e.g., the cycloalkyl is selected from cyclopropenyl, cyclobutenyl, cyclopentenyl, and cyclohexenyl.
  • haloalkyl refers to an alkyl in which at least one hydrogen atom is replaced with a halogen atom. In certain of the embodiments in which two or more hydrogen atom are replaced with halogen atoms, the halogen atoms are all the same as one another. In certain of such embodiments, the halogen atoms are not all the same as one another.
  • alkoxy refers to straight or branched chain alkyl radical covalently bonded to the parent molecule through an — O— linkage.
  • alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, n-butoxy, sec-butoxy, t-butoxy and the like.
  • An alkoxy may be designated as "Ci-C 6 alkoxy” or similar designations.
  • C 1 -C 4 alkoxy indicates an alkyl having one, two, three, or four carbon atoms, e.g., the alkoxy is selected from methoxy, ethoxy, propoxy, zso-propoxy, butoxy, zso-butoxy, sec-butoxy, and tert-butoxy.
  • alkylideneamino refers to a moiety of from one to twenty carbon atoms containing at least one carbon-nitrogen double bond where the moiety is connected to the main group through the nitrogen, including, but not limited to, methylideneamino, ethylideneamino, methylethylideneamino, propylideneamino, 1- methylpropylideneaminyl, 2-methylpropylideneamino, butylideneamino, 1- methylbutylideneamino , 2-methylbutylideneamino , cyclopropylideneamino , cyclobutylideneamino, cyclopentylideneamino, cyclohexylideneamino and the like.
  • the term "carbocycle” refers to a group comprising a covalently closed ring, wherein each of the atoms forming the ring is a carbon atom.
  • Carbocylic rings may be formed by three, four, five, six, seven, eight, nine, or more than nine carbon atoms.
  • Carbocycles may be optionally substituted.
  • heterocycle refers to a group comprising a covalently closed ring wherein at least one atom forming the ring is a heteroatom. Heterocyclic rings may be formed by three, four, five, six, seven, eight, nine, or more than nine atoms.
  • heterocyclic rings may comprise one, two, three, four, five, six, seven, eight, nine, or more than nine heteroatoms.
  • those two or more heteroatoms may be the same or different from one another.
  • Heterocycles may be optionally substituted. Binding to a heterocycle can be at a heteroatom or via a carbon atom. For example, binding for benzo-fused derivatives, may be via a carbon of the benzenoid ring.
  • heterocycles include, but are not limited to the following:
  • D, E, F, and G independently represent a heteroatom.
  • Each of D, E, F, and G may be the same or different from one another.
  • Heterocycles may be aromatic heterocycles (i.e., heteroaryls) or non-aromatic heterocycles.
  • a non-aromatic heterocycle is a fully statured covalently closed ring (for example, piperidine, pyrrolidine, morpholine, piperazine, and the like).
  • heteroatom refers to an atom other than carbon or hydrogen. Heteroatoms are typically independently selected from oxygen, sulfur, nitrogen, and phosphorus, but are not limited to those atoms. In embodiments in which two or more heteroatoms are present, the two or more heteroatoms may all be the same as one another, or some or all of the two or more heteroatoms may each be different from the others.
  • aromatic refers to a group comprising a covalently closed ring having a delocalized ⁇ -electron system.
  • Aromatic rings may be formed by five, six, seven, eight, nine, or more than nine atoms.
  • Aromatics may be optionally substituted. Examples of aromatic groups include, but are not limited to phenyl, naphthalenyl, phenanthrenyl, anthracenyl, tetralinyl, fluorenyl, indenyl, and indanyl.
  • aromatic includes, for example, benzenoid groups, connected via one of the ring-forming carbon atoms, and optionally carrying one or more substituents selected from an aryl, a heteroaryl, a cycloalkyl, a non-aromatic heterocycle, a halo, a hydroxy, an amino, a cyano, a nitro, an alkylamido, an acyl, a Ci_ 6 alkoxy, a Ci_ 6 alkyl, a Ci_ 6 hydroxyalkyl, a Ci_ 6 aminoalkyl, a C 1-6 alkylamino, an alkylsulfenyl, an alkylsulfinyl, an alkylsulfonyl, an sulfamoyl, or a trifluoromethyl.
  • an aromatic group is substituted at one or more of the para, meta, and/or ortho positions.
  • aromatic groups comprising substitutions include, but are not limited to, phenyl, 3-halophenyl, 4- halophenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 3-aminophenyl, 4-aminophenyl, 3- methylphenyl, 4-methylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4- trifluoromethoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, dimethylphenyl, naphthyl, hydroxynaphthyl, hydroxymethylphenyl, (trifluoromethyl)phenyl, alkoxyphenyl, 4- morpholin-4-ylphenyl, 4-pyrrolidin-l-ylphenyl, 4-pyrazolylphenyl, 4-triazolylphenyl, and 4-(2-oxopyrrolidin- 1 -yl)phen
  • aryl refers to an aromatic group wherein each of the atoms forming the ring is a carbon atom.
  • Aryl rings may be formed by five, six, seven, eight, nine, or more than nine carbon atoms.
  • Aryl groups may be optionally substituted.
  • heteroaryl refers to an aromatic mono-, bi- or tricyclic ring system wherein at least one atom forming the aromatic ring system is a heteroatom. Heteroaryl rings may be formed by three, four, five, six, seven, eight, nine, or more than nine atoms. Heteroaryl groups may be optionally substituted.
  • heteroaryl groups include, but are not limited to, aromatic C 3 _ 8 heterocyclic groups comprising one oxygen or sulfur atom or up to four nitrogen atoms, or a combination of one oxygen or sulfur atom and up to two nitrogen atoms, and their substituted as well as benzo- and pyrido-fused derivatives, for example, connected via one of the ring-forming carbon atoms.
  • heteroaryl groups are optionally substituted with one or more substituents, independently selected from halo, hydroxy, amino, cyano, nitro, alkylamido, acyl, Ci_6-alkoxy, Ci_6-alkyl, Ci_6-hydroxyalkyl, Ci_6-aminoalkyl, Ci_ 6 - alkylamino, alkylsulfenyl, alkylsulfinyl, alkylsulfonyl, sulfamoyl, or trifluoromethyl.
  • the substituents are halo, hydroxy, cyano, 0-Ci_6-alkyl, Ci_6-alkyl, hydroxy-Ci-6-alkyl, and amino-Ci-6-alkyl.
  • heteroaryl groups include, but are not limited to, unsubstituted and mono- or di-substituted derivatives of furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, indole, oxazole, benzoxazole, isoxazole, benzisoxazole, thiazole, benzothiazole, isothiazole, imidazole, benzimidazole, pyrazole, indazole, tetrazole, quinoline, isoquinoline, pyridazine, pyrimidine, purine and pyrazine, furazan, 1,2,3-oxadiazole, 1,2,3-thiadiazol
  • non-aromatic ring refers to a group comprising a covalently closed ring that does not have a delocalized ⁇ -electron system.
  • non-aromatic heterocycle refers to a group comprising a non-aromatic ring wherein one or more atoms forming the ring is a heteroatom.
  • Non- aromatic heterocyclic rings may be formed by three, four, five, six, seven, eight, nine, or more than nine atoms.
  • Non-aromatic heterocycles may be optionally substituted.
  • non-aromatic heterocycles comprise one or more carbonyl or thiocarbonyl groups such as, for example, oxo- and thio-containing groups.
  • non-aromatic heterocycles include, but are not limited to, lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, tetrahydrothiopyran, 4H-pyran, tetrahydropyran, piperidine, 1,3-dioxin, 1,3-dioxane, 1,4-dioxin, 1,4-dioxane, piperazine, 1,3-oxathiane, 1,4-oxathiin, 1,4-oxathiane, tetrahydro-l,4-thiazine, 2H-l,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, morpholine, trioxane, hexahydro-l,3,5-triazine, tetrahydrothiophen
  • polycyclic heterocyclyl refers a bicyclic moiety or tricyclic moiety optionally containing one or more heteroatoms wherein at least one of the rings is an aryl or heteroaryl ring and at least one of the rings is non-aromatic.
  • the bicyclic moiety contains two rings wherein the rings are fused.
  • the bicyclic moiety can be appended at any position of the tw a
  • tricyclic moiety contains a bicyclic moiety with an additional fused ring.
  • the tricyclic moiety can be appended at any position of the three rings.
  • tricyclic moiety may refer to a radical
  • arylalkyl refers to a group comprising an aryl group bound to an alkyl group.
  • Carbocycloalkyl refers to a group comprising a carbocyclic cycloalkyl ring. Carbocycloalkyl rings may be formed by three, four, five, six, seven, eight, nine, or more than nine carbon atoms. Carbocycloalkyl groups may be optionally substituted.
  • Rings refers to any covalently closed structure. Rings include, for example, carbocycles (e.g. , aryls and cycloalkyls), heterocycles (e.g. , heteroaryls and non-aromatic heterocycles), aromatics (e.g. , aryls and heteroaryls), and non-aromatics (e.g. , cycloalkyls and non-aromatic heterocycles). Rings may be optionally substituted. Rings may form part of a ring system.
  • carbocycles e.g. , aryls and cycloalkyls
  • heterocycles e.g. , heteroaryls and non-aromatic heterocycles
  • aromatics e.g. , aryls and heteroaryls
  • non-aromatics e.g. , cycloalkyls and non-aromatic heterocycles
  • Rings may be optionally substituted. Rings may form
  • ring system refers to a either a single ring or two or more rings, wherein, if two or more rings are present, the two or more of the rings are fused.
  • fused refers to structures in which two or more rings share one or more bonds.
  • spacer refers to an atom or group of atoms that separate two or more groups from one another by a desired number of atoms. For example, in certain embodiments, it may be desirable to separate two or more groups by one, two, three, four, five, six, or more than six atoms. In such embodiments, any atom or group of atoms may be used to separate those groups by the desired number of atoms. Spacers are optionally substituted. In certain embodiments, a spacer comprises saturated or unsaturated alkyls, heteroalkyls and/or haloalkyls. In certain embodiments, a spacer comprises atoms that are part of a ring.
  • spacers are provided.
  • 1 atom spacers include, but are not limited to, the following:
  • a and E represent groups which are separated by the desired number of atoms.
  • 2 atom spacers include, but are not limited to, the following:
  • a and E represent groups which are separated by the desired number of atoms.
  • Examples of 3 atom spacers include, but are not limited to, the following:
  • a and E represent groups which are separated by the desired number of atoms.
  • the atoms that create the desired separation may themselves be part of a group. That group may be, for example, an alkyl, heteroalkyl, haloalkyl, heterohaloalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, non-aromatic heterocycle, or substituted alkyl all of which are optionally substituted.
  • the term "1- 5 atom spacer” refers to a spacer that separates two groups by 1, 2, 3, 4, or 5 atoms and does not indicate the total size of the group that constitutes the spacer.
  • the term "linked to form a ring” refers to instances where two atoms that are bound either to a single atom or to atoms that are themselves ultimately bound, are each bound to a linking group, such that the resulting structure forms a ring. That resulting ring comprises the two atoms that are linked to form a ring, the atom (or atoms) that previously linked those atoms, and the linker. For example, if A and E below are "linked to form a ring"
  • the resulting ring includes A, E, the C (carbon) or N (nitrogen) to which they are attached, and a linking group. Unless otherwise indicated, that linking group may be of any length and may be optionally substituted.
  • resulting structures include, but are not limited to:
  • the two substituents that together form a ring are not immediately bound to the same atom. For example, if A and E, below, are linked to form a ring:
  • resulting ring comprises A, E, the two atoms that already link A and E and a linking group.
  • resulting structures include, but are not limited to:
  • the atoms that together form a ring are separated by three or more atoms.
  • the resulting ring comprises A, E, the 3 atoms that already link A and E, and a linking group.
  • Examples of resulting structures include, but are not limited to:
  • R x the resulting structure is: FRL , R y
  • null refers to a group being absent from a structure.
  • X is N (nitrogen)
  • R' or R" is null, meaning that only three groups are bound to the N (nitrogen).
  • R refers to a substituent selected from alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and non-aromatic heterocycle (bonded through a ring carbon).
  • cyano refers to the group consisting of formula -CN.
  • isocyanato refers to the group consisting of formula -NCO.
  • thiocyanato refers to the group consisting of formula -CNS.
  • an amide may be an amino acid or a peptide.
  • amino refers to a chemical moiety with formula - NHR'R", where R' and R" are each independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon).
  • amine include such groups that have been esterified or amidified. Procedures and specific groups used to achieve esterification and amidification are known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3 Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein in its entirety.
  • an oxo as a substituent also includes oxides, for example pyridine-N-oxide, thiopyran sulfoxide and thiopyran-S,S- dioxide.
  • the substituent groups may together form a ring.
  • a substituent as depicted as a di-radical i.e., has two points of attachment to the rest of the molecule
  • the substituent can be attached in any directional configuration unless otherwise indicated.
  • a substituent depicted as -AE- or Y 3 ⁇ 4 A ⁇ P tA includes the substituent being oriented such that the A is attached at the leftmost attachment point of the molecule as well as attached at the rightmost attachment point of the molecule.
  • radical naming conventions can include either a mono-radical or a di-radical, depending on the context. For example, where a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a di-radical.
  • attachment includes di-radicals such as
  • carrier refers to a compound that facilitates the incorporation of another compound into cells or tissues.
  • DMSO dimethyl sulfoxide
  • a pharmaceutical agent refers to a chemical compound or composition capable of inducing a desired therapeutic effect in a patient.
  • a pharmaceutical agent comprises an active agent, which is the agent that induces the desired therapeutic effect.
  • a pharmaceutical agent comprises a prodrug.
  • a pharmaceutical agent comprises inactive ingredients such as carriers, excipients, and the like.
  • terapéuticaally effective amount refers to an amount of a pharmaceutical agent sufficient to achieve a desired therapeutic effect.
  • prodrug refers to an pharmaceutical agent that is converted from a less active form into a corresponding more active form in vivo.
  • pharmaceutically acceptable refers to a formulation of a compound that does not significantly abrogate the biological activity, a pharmacological activity and/or other properties of the compound when the formulated compound is administered to a patient. In certain embodiments, a pharmaceutically acceptable formulation does not cause significant irritation to a patient.
  • co-administer refers to administering more than one pharmaceutical agent to a patient.
  • co-administered pharmaceutical agents are administered together in a single dosage unit.
  • co-administered pharmaceutical agents are administered separately.
  • co-administered pharmaceutical agents are administered at the same time.
  • co-administered pharmaceutical agents are administered at different times.
  • patient includes human and animal subjects.
  • substantially pure means an object species (e.g., compound) is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition).
  • a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all species present.
  • a substantially pure composition will comprise more than about 80%, 85%, 90%, 95%, or 99% of all species present in the composition.
  • the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single species.
  • tissue-selective refers to the ability of a compound to modulate a biological activity in one tissue to a greater or lesser degree than it modulates a biological activity in another tissue.
  • the biological activities in the different tissues may be the same or they may be different.
  • the biological activities in the different tissues may be mediated by the same type of target receptor.
  • a tissue-selective compound may modulate receptor mediated biological activity in one tissue and fail to modulate, or modulate to a lesser degree, receptor mediated biological activity in another tissue type.
  • the term "monitoring” refers to observing an effect or absence of any effect. In certain embodiments, one monitors cells after contacting those cells with a compound of the present embodiments. Examples of effects that may be monitored include, but are not limited to, changes in cell phenotype, cell proliferation, receptor activity, or the interaction between a receptor and a compound known to bind to the receptor.
  • cell phenotype refers to physical or biological characteristics. Examples of characteristics that constitute phenotype included, but are not limited to, cell size, cell proliferation, cell differentiation, cell survival, apoptosis (cell death), or the utilization of a metabolic nutrient (e.g., glucose uptake). Certain changes or the absence of changes in cell phenotype are readily monitored using techniques known in the art.
  • cell proliferation refers to the rate at which cells divide.
  • cells are in situ in an organism.
  • cell are grown in vitro in a vessel.
  • the number of cells growing in a vessel can be quantified by a person skilled in the art (e.g., by counting cells in a defined area using a microscope or by using laboratory apparatus that measure the density of cells in an appropriate medium).
  • One skilled in that art can calculate cell proliferation by determining the number of cells at two or more times.
  • contacting refers to bringing two or more materials into close enough proximity that they may interact. In certain embodiments, contacting can be accomplished in a vessel such as a test tube, a petri dish, or the like. In certain embodiments, contacting may be performed in the presence of additional materials. In certain embodiments, contacting may be performed in the presence of cells. In certain of such embodiments, one or more of the materials that are being contacted may be inside a cell. Cells may be alive or may dead. Cells may or may not be intact. Certain compounds
  • Certain compounds that modulate one or more HGF activity and/or bind to HGF receptors play a role in health.
  • compounds are useful for treating any of a variety of diseases or conditions.
  • Certain embodiments provide selective HGF modulators. Certain embodiments provide selective HGF receptor binding agents. Certain embodiments provide methods of making and methods of using selective HGF modulators and/or selective HGF receptor binding agents. In certain embodiments, selective HGF modulators are agonists, partial agonists, and/or antagonists for the HGF receptor.
  • the compounds disclosed herein can be used alone or in combination with other agents, for example, to modulate hematopoiesis, erythropoiesis, granulopoiesis, thrombopoiesis, and myelopoiesis.
  • the instant compounds can also be used alone or in combination with other agents in treatment or prevention of a disease or condition caused by abnormal function of hematopoiesis, erythropoiesis, granulopoiesis, thrombopoiesis, and myelopoiesis.
  • diseases include anemia, neutropenia, thrombocytopenia, cardiovascular disorders, immune/autoimmune disorders, cancers, infectious disorders or diseases, and neurologic disorders.
  • a salt corresponding to a selective HGF modulator is provided.
  • a salt corresponding to a selective HGF receptor binding agent is provided.
  • a salt is obtained by reacting a compound with an acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
  • a salt is obtained by reacting a compound with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as choline, dicyclohexylamine, N-methyl-D- glucamine, tris(hydroxymethyl)methylamine, 4-(2-hydroxyethyl)-morpholine, l-(2- hydroxyethyl)-pyrrolidine, ethanolamine and salts with amino acids such as arginine, lysine, and the like.
  • a salt is obtained by reacting a free acid form of a selective HGF modulator or selective HGF binding agent with multiple molar equivalents of a base, such as bis-sodium, bis-ethanolamine, and the like.
  • a salt corresponding to a compound of the present embodiments is selected from acetate, ammonium, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, cholinate, clavulanate, citrate, dihydrochloride, diphosphate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabanine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mucate, napsylate, nitrate, N-methylglucamine, oxalate
  • one or more carbon atoms of a compound of the present embodiments are replaced with silicon. See e.g., WO 03/037905A1; Tacke and Zilch, Endeavour, New Series, 10, 191-197 (1986); Bains and Tacke, Curr. Opin. Drug Discov Devel. Jul:6(4):526-43(2003), all of which are incorporated herein by reference in their entirety.
  • compounds comprising one or more silicon atoms possess certain desired properties, including, but not limited to, greater stability and/or longer half-life in a patient, when compared to the same compound in which none of the carbon atoms have been replaced with a silicon atom.
  • A-J is O n i and Q-G is ! N Y O ; NR C R D
  • A-J is ;
  • A-J is Y O and Q-G is Y O ;
  • A-J is R H B and Q-G is f Y O ;
  • a 1 is selected from the group consisting of C 3 -C 7 cycloalkenyl, C 3 -C 7 cycloalkyl, C r C 6 alkyl, C 2 -C 6 alkenyl, C r C 6 alkoxy, -(CH 2 ) m NR P R L , heterocycle, aryl, and heteroaryl, said C 3 -C 7 cycloalkenyl, C 3 -C 7 cycloalkyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R , R , and R , said aryl and heteroaryl in the definition of A are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • G 1 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition of G 1 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • A is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of
  • R , R , and R said aryl and heteroaryl in the definition of A are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • G is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition of G 2 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • a 4 is selected from the group consisting of C 3 -C 7 cycloalkenyl, C 3 -C 7 cycloalkyl, Ci-C 6 alkyl, Ci-C 6 heteroalkyl, C 2 -C 6 alkenyl, Ci-C 6 alkoxy, -(CH 2 ) m NR P R L , heterocycle, aryl, and heteroaryl, said C 3 -C 7 cycloalkenyl, C 3 -C 7 cycloalkyl, Ci-C 6 alkyl, Ci-C 6 heteroalkyl, C 2 -C 6 alkenyl, heterocycle, aryl, and heteroaryl, each optionally
  • aryl and heteroaryl in the definition of A 4 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • G 4 is selected from the group consisting of C3-C7 cycloalkenyl, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition of G 4 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • a 5 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R , R , and R , said aryl and heteroaryl in the definition of A are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • each R is separately selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted C 2 -C 6 alkenyl, and an optionally substituted C 3 -C 7 cycloalkyl;
  • -NR R is selected from the group consisting of Ci-C 6 alkyl, C 3 -C6 cycloalkyl, C 3 -C8 cycloalkenyl, Ci-C 6 heteroalkyl, Ci-C 6 heteroalkenyl, Ci-C 6 heteroalkynyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition of R G are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle, or R G is -OR L or -NR P R L ;
  • R H within the definition of -NR G R H is selected from the group consisting of hydrogen, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 7 cycloalkyl, and C 1 -C 3 haloalkyl, NR G R H
  • each R 1 is separately selected from the group consisting of halogen, cyano, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 alkoxy, an optionally substituted C 2 -C 6 alkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, optionally substituted C 3 -C 7 cycloalkenyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • each R is separately selected from the group consisting of halogen, -CKCH.
  • each R 4 is separately selected from the group consisting of halogen, cyano, an optionally substituted CrC 6 alkyl, an optionally substituted CrC 6 alkoxy, an optionally substituted C 2 -C6 alkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted CrC 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • each R 1 is separately selected from the group consisting of hydrogen, Ci-C 6 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 7 cycloalkyl, C C 6 haloalkyl, C C 6 heteroalkyl, and Ci-C 6 heterohaloalkyl;
  • each -NR J R K is separately selected, wherein R J and R K are each independently selected from the group consisting of hydrogen, Ci-C 6 alkyl optionally substituted with up to 5 fluoro, -(CH 2 ) m OR JA , -(CH 2 ) m NR JB R JC , -(CH 2 ) m R R , C 3 -C 7 cycloalkyl, heterocycle, aryl and heteroaryl, said C 3 -C 7 cycloalkyl, heterocycle, aryl and heteroaryl in the definition of R T and R K are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off
  • R J and ⁇ are each optionally substituted with one or more halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C C 6 alkoxy, or -(CH 2 ) m NR KA R KB ; or -NR J R K is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -NR R is an optionally substituted CrC 6 alkylideneamino;
  • each R JA is independently selected from the group consisting of hydrogen, CrC 6 alkyl, and CrC 6 haloalkyl;
  • each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, CrC 6 alkyl, and CrC 6 haloalkyl;
  • each -NR ⁇ RTM is separately selected, wherein R 1 ⁇ and R KB are each independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • each R M is independently selected from the group consisting of hydrogen, an optionally substituted CrC 6 alkyl, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted C 3 -C 7 cycloalkenyl, and -(CH 2 ) m R P ;
  • each -NR N R° is separately selected, wherein R N and R° are each independently selected from the group consisting of hydrogen, -(CH 2 ) m NR NA R NB , aryl and heteroaryl, said aryl and heteroaryl in the definition of R N and R° are each independently optionally substituted with one or more substituents selected from the group consisting of -(CH 2 ) m NR OA R OB , halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off of R N and R° are each optionally substituted with one or more halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, or -NR NA R NB ,
  • each -NR NA R NB is separately selected, wherein R NA and R NB are each independently selected from the group consisting of hydrogen, CrC 6 alkyl, and CrC 6 haloalkyl;
  • each -NR OA R OB is separately selected, wherein R OA and R OB are each independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • R p is selected from the group consisting of hydrogen and Ci-C 6 alkyl
  • R L is selected from the group consisting of C 3 -C 7 cycloalkyl, optionally substituted Ci-C 6 alkyl, optionally substituted Ci-C 6 alkoxy, -(CH 2 ) m OR LA , -
  • (CH 2 ) m NR LB R LC , aryl and heteroaryl said aryl and heteroaryl in the definition of R L are each independently optionally substituted with one or more substituents selected from the group consisting of halo, C C 6 alkyl, C C 6 haloalkyl, C C 6 alkoxy, -(CH 2 ) M NR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of R L are each optionally substituted with one or more halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, or -(CH 2 ) M NR LF R LG ;
  • R LA is selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • R LB and R LC are each independently selected from the group consisting of
  • Ci-C 6 alkyl Ci-C 6 haloalkyl, and Ci-C 6 heteroalkenyl
  • -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom
  • each -NR LD R LE is separately selected, wherein R LD and R LE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted Ci-C 6 alkyl, said aryl and heteroaryl in the definition of R LD and
  • R are each optionally substituted with Ci-C 6 alkyl or Ci-C 6 alkoxy; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and Ci-C 6 alkyl; or
  • R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom
  • L 1 is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
  • L is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
  • L is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
  • L 4 is an optionally substituted aryl
  • R R is selected from the group consisting of CrC 6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • R 7 and R 8 are each independently selected from the group consisting of
  • Ci-C 6 alkyl Ci-C 6 heteroalkyl, and -OH
  • CR R is a three - to eight- membered optionally substituted carbocycle, which optionally has one to three additional hetero atoms incorporated in the ring;
  • R 9 is selected from the group consisting of hydrogen, CrC 6 alkyl, Cp C 6 haloalkyl, Ci-C 6 heteroalkyl, C 3 -C 7 cycloalkylC(0)- and Ci-C 6 alkylC(O)-;
  • each m is independently 0, 1, 2, or 3;
  • each p is independently 0, 1, 2, 3, 4, 5, or 6;
  • each q is independently 1, 2, 3, 4, 5, or 6;
  • each r is independently 1, 2, 3, or 4;
  • any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
  • R 1 can be selected from the group consisting of fluorine, chlorine, and methyl
  • R 2 can be selected from the group consisting of -(CH 2 ) m OR I , -NR J R K , and -(CH 2 ) m SR I
  • R 3 can be selected from the group consisting of -(CH 2 ) m R p , -(CH 2 ) m OR M , and -NR N R°
  • R 4 can be selected from the group consisting of fluorine, chlorine, and methyl
  • R 5 can be selected from the group consisting of -(CH 2 ) m OR I , -NR J R K , and -(CH 2 ) m SR I
  • R 6 can be selected from the group consisting of -(CH 2 ) m R p , -(CH 2 ) m OR M , and -NR N R°
  • R 1 can be selected from the group consisting of fluorine, chlorine, and methyl
  • G 1 can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition of G 1 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle;
  • A can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 , said aryl and heteroaryl in the definition of A can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle;
  • G can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition
  • L can be selected from the group consisting of an optionally substituted ally subs , an optionally substituted
  • L can be selected from the group consisting of an optionally
  • each R 1 can be separately selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl; each R can be separately selected from the group consisting of halogen, -(CH 2 ) m OR I , and -NR B R C , where R I in the definition of can be R 2 selected from the group consisting of hydrogen, and Ci-C 6 alkyl; each R can be fluoro; each -NR T R K canbe separately selected, wherein R T and R K can each be independently selected from the group consisting of hydrogen and Ci-C 6 alkyl; or -NR T R K can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; each R 4 can be separately selected selected from the group consisting of chloro, fluoro, and an optionally substituted Ci-C 6 alkyl; each R 5 can be separately selected from the group consisting of -OCH 2 CH 2 OR 1 , -(CH 2 ) m
  • a 1 , A 2 , A 4 , and A 5 can each be selected from the group consisting of phenyl, naphthyl, benzo[ ⁇ i][l,3]dioxolyl, indolyl, and benzo[d]imidazolyl, each substituted with one or more substituents selected from the group consisting of R 1 and R2 ; each R 1 can be separately selected from the group consisting of phenyl, pyrrolyl, and imidazolyl, each optionally substituted with a substituent selected from Ci-C 6 alkyl, Ci-C 6 alkoxy, Ci-C 6 alkylHN- and (Ci-C 6 alkyl) 2 N-; each R can be separately selected from the group consisting of bromo, chloro, fluoro, -(CH 2 ) m OR I , -(CH 2 ) m R L , and -NR T
  • R I in the definition of R 2 can be separately selected from the group consisting of hydrogen and Ci-C 6 alkyl; each -NR T R K can be separately selected, wherein R T and R K can each be independently selected from the group consisting of hydrogen, and Ci-C 6 alkyl optionally substituted with up to 3 fluoro; or -NR T R K can be a morpholinyl, piperazinyl, pyrrolidinyl, and piperidinyl, each optionally substituted with one or more oxo; each R L can be separately selected from the group consisting aryl and heteroaryl, each optionally substituted with one or more substituents each separately selected from the group consisting of halogen, Ci-C 6 alkyl optionally substituted with up to 5 fluoro, and Ci-C 6 alkoxy optionally substituted with up to 5 fluoro; G 1 , G2 , and G 4 can each be selected from the group consisting of: phenyl, naphthyl, benzo[ ⁇ i
  • Some embodiments disclosed herein provide a compound of Formula I, wherein A can be selected from the group consisting of phenyl, naphthyl, and, indolyl, each substituted with one or more substituents selected from the group consisting of R 1 and R 2 ; each R 1 can be separately selected from the group consisting of phenyl, pyrrolyl, and imidazolyl, each optionally substituted with a substituent selected from Ci-C 6 alkyl, 2
  • each R can be separately selected from the group consisting of bromo, chloro, fluoro, -(CH 2 ) m OR I , -(CH 2 ) m R L , and
  • each R I in the definition of R 2 can be separately selected from the group consisting of hydrogen and Ci-C 6 alkyl; each -NR T R K can be separately selected, wherein
  • R J T and ⁇ K can each be independently selected from the group consisting of hydrogen, and
  • a 1 , A 2 , A 4 , and A 5 can each be selected from the group consisting of selected from the group consisting of a phenyl, naphthyl, benzo[d][l,3]dioxolyl, each substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 ; and
  • G 1 , G2 , and G 4 can each be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 and each optionally fused with a nonaromatic heterocycle or carbocycle.
  • Some embodiments disclosed herein provide a compound of Formula I, having the proviso that a compound for Formula I is not selected from the group consisting of:
  • Some embodiments disclosed herein provide a compound of Formula la, lb, Ic, or Id, wherein L can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl.
  • L can be selected from the group consisting of -0(CH 2 ) p O-, an optionally substituted aryl, and an optionally substituted heteroaryl, or L is L 1 -L2 ;
  • L 1 can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl; and L can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted
  • R E R F N ⁇ / L N ⁇ NR E R F having the structure of Formula If : T O Y O (if) 5 and pharmaceutically acceptable salts thereof.
  • L can be selected from the group consisting of C4-C6 cycloalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl, or L is L 1 -L2 ;
  • L 1 can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl; and
  • L can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl.
  • Some embodiments disclosed herein provide a compound of Formula I and pharmaceutically acceptable salts thereof.
  • L 1 -CR 7'R 8 -I 2 L 1 can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl; L can be selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle; L can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl; and L 4 is an optionally substituted aryl.
  • L can be selected from the group consisting of an optionally substituted aryl or L can be selected from the group consisting of L 1 -L2 , and L 1 -L2 -L 3 ;
  • L 1 can be an optionally substituted heteroaryl;
  • L can be selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle; and
  • L can be an optionally substituted heterocycle.
  • a 6 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 11 , R 12 , and R 13 , said aryl and heteroaryl in the definition of A 6 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • G 6 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 14 , R 15 , and R 16 , said aryl and heteroaryl in the definition of G 6 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • L 6 is an optionally substituted aryl, or an optionally substituted heteroaryl; where the aryl and heteroaryl in the definition of L 6 are optionally fused with a nonaromatic heterocycle or a nonaromatic ected from the group
  • E is O (oxygen) or N-OR where R in the definition of E is selected from the group consisting of hydrogen and an optionally substituted CrC 6 alkyl;
  • each R 11 is separately selected from the group consisting of halogen, an optionally substituted CrC 6 alkyl, an optionally substituted CrC 6 alkoxy, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted CrC 6 haloalkyl, and an optionally substituted Ci-C 6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • each R 12 is separately selected from the group consisting of -0(CH 2 ) m OR A , -(CH 2 ) m OR A , -NR B R C , and -(CH 2 ) m SR A ;
  • each R 13 is separately selected from the group consisting of - (CH 2 ) m OR D , -NR E R F , -S(0)o- 2 R D , -(CH 2 ) m N0 2 , -(CH 2 ) m CN, and -(CH 2 ) m R G ;
  • each R 14 is separately selected from the group consisting of halogen, an optionally substituted CrC 6 alkyl, an optionally substituted CrC 6 alkoxy, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted CrC 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • each R 15 is separately selected from the group consisting of -0(CH 2 ) m OR A , -(CH 2 ) m OR A , -NR B R C , and -(CH 2 ) m SR A ;
  • each R is separately selected from the group consisting of - (CH 2 ) m OR D , -NR E R F , -(CH 2 ) m S(0)o_ 2 R D , -(CH 2 ) m N0 2 , -(CH 2 ) m CN, and -(CH 2 ) m R G ;
  • E 6 is CR 17 when the dashed line between E 6 and X represents a double bond; or E 6 is CR 17 R 17 when the dashed line between E 6 and X represents a single bond;
  • F 6 is CR 18 when the dashed line between F 6 and Y represents a double bond; or F 6 is CR 18 R 18 when the dashed line between F 6 and Y represents a single bond;
  • each R is independently selected from the group consisting of hydrogen, halogen, an optionally substituted CrC 4 alkoxy, an optionally substituted C 3 - C 7 cycloalkyl, and an optionally substituted Q-C 4 alkyl;
  • each R is independently selected from the group consisting of hydrogen, halogen, an optionally substituted C 1 -C 4 alkoxy, an optionally substituted C 3 - C 7 cycloalkyl, and an optionally substituted C 1 -C 4 alkyl;
  • R A is selected from the group consisting of hydrogen, Ci-C 6 alkyl, C 2 - C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 7 cycloalkyl, CrC 6 haloalkyl, CrC 6 heteroalkyl, and Cp C 6 heterohaloalkyl;
  • each -NR R is separately selected, wherein R and R are each
  • heterocycle CrC 6 alkyl, C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, C 3 -C 7 cycloalkyl, Ci-C 6 haloalkyl, Ci-C 6 heteroalkyl, and Ci-C 6 heterohaloalkyl,
  • -NR R is an optionally substituted non-aromatic heterocycle
  • each R D is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl, and - (CH 2 ) m R G ;
  • each -NR R is separately selected, wherein R and are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted CrC 6
  • haloalkyl an optionally substituted Ci-C 6 heteroalkyl, and -(CH 2 ) m R ; or -NR R is an
  • R is selected from optionally substituted aryl and an optionally substituted heteroaryl;
  • R H is selected from the group consisting of hydrogen, C 1 -C 3 alkyl, optionally substituted C 1 -C 3 alkoxy, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, C 2 -C 4 alkenyl, C 2 - C 4 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 3 haloalkyl, and an optionally substituted aryl or heteroaryl;
  • X and Y are independently selected from N (nitrogen), NH, CR 19 , and CR 19 R 20 ;
  • each R 19 and R 20 are independently selected from the group consisting of hydrogen and an optionally substituted C 1 -C 4 alkyl;
  • each m is independently 0, 1, or 2;
  • any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
  • a 6 can be selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 11 , R 12 , and R 13 , said aryl and heteroaryl in the definition of A 6 can each be further optionally f selected from
  • E can be O (oxygen) or N-OR D where R D in the definition of E 2 can be selected from the group consisting of hydrogen and an optionally substituted Ci-C 6 alkyl;
  • G 6 can be selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 14 , R 15 , and R 16 , said aryl and heteroaryl in the definition of G 6 can each be further optionally fused with a nonaromatic heterocycle or carbocycle; each R 11 can be separately selected from the group consisting of fluoro, an optionally substituted aryl and an optionally substituted heteroaryl; each 12
  • R in the definition of can be R selected from the group consisting of hydrogen, and 13
  • Ci-C 6 alkyl each R can be separately selected from the group consisting of -OR D , -NR E R F , -S(0) 2 R D , -CN, and -R G ; each -NR B R C can be separately selected, wherein B nd C
  • R a R can each be independently selected from the group consisting of hydrogen, C3-C7 cycloalkyl, CrC 6 alkyl, and CrC 6 haloalkyl, where the CrC 6 alkyl in the definition of B C
  • R and R can be optionally substituted with an optionally substituted aryl or an optionally substituted heteroaryl, and where the C3-C7 cycloalkyl in the definition of B C
  • R and R can be optionally fused with an optionally substituted aryl
  • -NR R can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • R can be selected from the group consisting of hydrogen, C1-C3 alkyl, an optionally substituted aryl and an optionally substituted heteroaryl;
  • each R 14 can be separately selected selected from the group consisting of chloro, fluoro, an optionally substituted CrC 6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • each R 15 can be separately selected from the group consisting of-0(CH 2 ) m OR A , -(CH 2 ) m OR A , and -NR B R C , where R A in the definition of R 15 can be selected from the group consisting of hydrogen, and Ci-C 6 alkyl; and each R 16 can be separately selected from the group consisting of -OR , -NR R , -S(0) 2 R , -CN, and -R G .
  • A can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 11 , R 12 , and R 13 , said aryl in the definition of A 6 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle;
  • G 6 can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 14 , R 15 , and R 16 , said aryl and heteroaryl in the definition of G 6 can each be further optionally fused with a nonaromatic heterocycle or carbocycle;
  • each R 11 can be separately selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl;
  • each R 12 can be separately selected from the group consisting of -(CH 2 ) m OR A , and -NR B R C , where R A in the definition of R 12 can be selected from
  • a 6 can be selected from the group consisting of phenyl, naphthyl, benzo[ ⁇ i][l,3]dioxolyl, indolyl, and benzo[d] imidazolyl, each optionally substituted with one or more substituents selected from the group consisting of R 11 and R 12 ; each R 11 can be separately selected from the group consisting of phenyl, pyrrolyl, and imidazolyl, each optionally substituted with a substituent selected from CrC 6 alkyl, CrC 6 alkoxy, CrC 6
  • each R can be separately selected from the group consisting of bromo, chloro, fluoro, -(CH 2 ) m OR A , and -NR B R C , where each R A in the definition of R 12 can be separately selected from the group consisting of hydrogen and Ci-
  • A is selected from the group consisting of aryl, heteroaryl, isoindolinyl, indenyl, dihydroindenyl, tetrahydroisoquinolinyl, and tetrahydronaphthalenyl, each optionally substituted with one or more substituents selected
  • A are each further optionally fused with an optionally substituted nonaromatic y
  • A is C 3 -C 7 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of
  • each R is independently selected from the group consisting of halogen, cyano, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 alkoxy, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
  • phenyl in the definition of R is substituted with one or more substituents selected from the group consisting of halogen, cyano, C 1 -C 3 alkyl, an optionally substituted C 1 -C 3 alkoxy, -0(CH 2 ) m OR A , -(CH 2 ) m NR B R c ;
  • Q is O (ox -NR -, aryl, and arylamido; or Q is null;
  • R is independently selected from the group consisting of hydrogen and an optionally substituted C 1 -C4 alkyl
  • G is selected from the group consisting aryl, heteroaryl, and heterocycle, each optionally substituted with one or more substituents selected from the group consisting of 24 25 26 heteroaryl in the definition of 7
  • R , R , and R said aryl and G are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • R is independently selected from the group consisting of halogen, cyano, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 alkoxy, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C3-C 7 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
  • X , X , and X are each independently selected from N (nitrogen) and
  • R is selected from the group consisting of hydrogen, halogen, and an optionally substituted C 1 -C4 alkyl
  • R A is selected from the group consisting of hydrogen, Ci-C 6 alkyl, C 2 - C 4 alkenyl, C 2 -C 4 alkynyl, C3-C 7 cycloalkyl, and Ci-C 6 haloalkyl; [0293] each -NR B R C is separately selected, wherein R B and R C are each independently selected from the group consisting of hydrogen, -S0 2 R H , H
  • each R D is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl, and -(CH 2 ) m R I ;
  • each -NR E R F is separately selected, wherein R E and R F are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl, an optionally substituted C3-C 7 cycloalkyl, an optionally substituted heterocycle, and G E F
  • -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -NR E R F is Ci-C 6 alkylideneamino substituted with an optionally substituted aryl;
  • each R is independently selected from an optionally substituted aryl and an optionally substituted heteroaryl
  • each R H is independently selected from the group consisting of hydrogen, C 1 -C3 alkoxy, C 1 -C3 alkyl, C 1 -C3 haloalkyl, an optionally substituted aryl and an optionally substituted heteroaryl;
  • each R 1 is independently selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl;
  • each R J is independently selected from the group consisting of aryl and heteroaryl, each substituted with one or more -NR E R F ;
  • each R L is independently selected from the group consisting of C3-C7 cycloalkyl, optionally substituted Ci-C 6 alkyl, optionally substituted Ci-C 6 alkoxy, -(CH 2 ) m OR LA , -(CH 2 ) m NR LB R LC , aryl and heteroaryl, said aryl and heteroaryl in the definition of R L are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-
  • C 6 alkoxy, -(CH 2 ) m NR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of R L are each optionally substituted with one or more halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, or -(CH 2 ) m NR LF R LG ;
  • each R LA is independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • R LB and R LC are each independently selected from the group consisting of
  • Ci-C 6 alkyl Ci-C 6 haloalkyl, and Ci-C 6 heteroalkenyl
  • -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom
  • each -NR LD R LE is separately selected, wherein R LD and R LE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted Ci-C 6 alkyl, said aryl and heteroaryl in the definition of R LD and
  • R are each optionally substituted with Ci-C 6 alkyl or Ci-C 6 alkoxy; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and Ci-C 6 alkyl; or
  • R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom
  • each m is independently 0, 1, or 2;
  • each n is independently 0, 1, 2, 3, or 4;
  • each o is independently 1, 2, or 3;
  • each p is independently 0, 1, 2, or 3;
  • each q is independently 0 or 1 ;
  • any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
  • A can be selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl, thienyl, indolyl, and benzimidazolyl, each substituted with one or more substituents selected from the group consisting of R 21 , R 22 , and R 23 , y
  • aryl and heteroaryl in the definition of A can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic
  • G can be selected from the group consisting aryl, heteroaryl, and heterocycle, each substituted with one or more substituents selected from the group consisting of R , R 25 , and R 26 , said aryl and heteroaryl in the definition of G 7 can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted
  • R can be selected from the group consisting of fluorine and
  • each -NR R can be separately selected, wherein R and R can each be independently selected from the group consisting of Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 heteroalkyl, and
  • Ci-C 6 heterohaloalkyl; or -NR R can be an optionally substituted non-aromatic
  • Ci-C 6 alkylideneamino; J can be independently selected from the group consisting of hydrogen and an optionally substituted C 1 -C3 alkyl, with the
  • A can be selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl, thienyl, indolyl, and benzimidazolyl, each substituted
  • aryl and heteroaryl in the definition of A can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic y
  • G can be selected from the group consisting aryl, heteroaryl, and heterocycle,
  • aryl and heteroaryl in the definition of G 7 can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted
  • R can be selected from the group consisting of Ci-C 6 alkyl,
  • R 22 E F fluorine, and chlorine;
  • R A can be selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl; each -NR B R C can be separately selected, wherein R B and R C can each be independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 heteroalkyl, and Ci-C 6 heterohaloalkyl; or
  • -NR B R C can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -NR B R C can be an optionally substituted Ci-C 6 alkylideneaminyl; and
  • J can be , with the proviso when A and G are a phenyl then at least one
  • A can be aryl substituted with one or more substituents selected from the group consisting of R 21 , R 22 , and R 23 ; each R 21 canbe independently selected from the group consisting of halogen, cyano, Ci-C 6 alkyl, and Ci-C 6 alkoxy; each R 22 can be independently selected from the group consisting of -(CH 2 ) m OR A , -0(CH 2 ) m OR A and -(CH 2 ) m NR B R c ; each R 23 can be phenyl substituted with - (CH 2 ) m NR R ; G ; can be heterocycle substituted with one or more
  • each R can be independently selected from the group consisting of halogen, cyano, CrC 6 alkyl, and Cp
  • Some embodiments disclosed herein provide a compound of Formula Illabb, wherein A can be phenyl substituted with one or more substituents selected from
  • each R can be independently selected from the group consisting of -(CH 2 ) m OR A , and -0(CH 2 ) m OR A ; each R A can be independently selected from the group consisting of hydrogen, C 1 -C 3 alkyl, and C 1 -C 3 haloalkyl; G can be piperidinyl substituted with one or more substituents selected from the group consisting of
  • R can be selected from
  • A can each be further optionally fused with an optionally substituted nonaromatic y
  • A can be C 3 -C 7 cycloalkyl optionally substituted with one or more substituents selected from the group
  • C 3 -C 7 cycloalkyl in the definition of A can be fused with an optionally substituted aryl or optionally substituted heteroaryl;
  • G can be selected from the group consisting of a aryl and heteroaryl, each substituted with one or more substituents
  • G can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle.
  • A can be selected from the group consisting of phenyl, indolyl, pyridinyl, pyrimidinyl, thienyl, benzothiofuranyl, naphthalenyl, and tetrahydronaphthalenyl, each substituted with one or
  • said aryl and heteroaryl in the definition of G can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle.
  • Hid having the structure of Formula Illdb: (Illdb), and pharmaceutically acceptable salts, esters, or prodrugs thereof, wherein A can be selected from the group consisting of phenyl, indolyl, pyridinyl, pyrimidinyl, thienyl, benzothiofuranyl, naphthalenyl, and tetrahydronaphthalenyl, each substituted with one or more substituents selected from the group consisting of R 21 , R 22 , and R 23 ; and G 7 can be selected from the group consisting of a aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 24 , R 25 , and R 26 ,
  • said aryl and heteroaryl in the definition of G can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle.
  • G can be selected from the group consisting of phenyl, naphthyl, indolyl, dihydrobenzofuranyl, 1,4-benzodioxanyl, benzotriazolyl, benzimidazolyl, benzofuranyl, and 2,1,3-benzoxadiazolyl, each optionally substituted with one or more substituents selected from the group consisting of R 24 , R 25 , and R 26.
  • R 21 can be selected from the group consisting of halogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 alkoxy, and an optionally substituted 22
  • R can be selected from the group consisting of -(CH 2 ) m OR A , -0(CH 2 ) m OR A , and -NR B R C ;
  • R 23 can be selected from the group consisting of -(CH 2 ) m OR D , -(CH 2 ) m S(0)o- 2 R D , and -(CH 2 ) m R G ;
  • R 24 can be selected from the group consisting of halogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-
  • R 26 can be selected from the group consisting of -(CH 2 ) m OR D , -(CH 2 ) m R G ;
  • each R G can be independently selected from from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl
  • each R can be independently selected from the group consisting of hydrogen, Ci-C 3 alkoxy, Ci-C 3 alkyl, Ci-C 3 haloalkyl, an optionally substituted aryl and optionally substituted heteroaryl
  • each R 1 can be independently selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl
  • each R J can be independently selected from the group consisting of aryl and heteroaryl, each substituted with one or more -NR E R F
  • each m can be independently 0, 1, or 2
  • each n can be independently 0, 1, 2, 3, or 4.
  • Some embodiments disclosed herein provide a compound of Formula III having the proviso that a compound of Formula III is not selected from the group consisting of:
  • A is selected from the group consisting of heterocycle, aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 31 , R 32 , and R 33 , said aryl and heteroaryl in the definition of A 8 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • G is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of
  • R 34 , R 35 , and R 36 , said aryl and heteroaryl in the definition of G 8 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • X is selected from the group consisting of N (nitrogen) and CR ;
  • Y 5 is selected from the group consisting of N (nitrogen) and CR 40 ;
  • each R is independently selected from the group consisting of hydrogen, halogen, and an optionally substituted CrC 4 alkyl; [0332] each R is independently selected from the group consisting of hydrogen and an optionally substituted C 1 -C 4 alkyl;
  • each R is independently selected from the group consisting of halogen, cyano, an optionally substituted CrC 6 alkyl, an optionally substituted CrC 6 alkoxy, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted CrC 6 haloalkyl, and an optionally substituted Ci-C 6 heteroalkyl;
  • each R is independently selected from the group consisting of halogen, -(CH 2 ) m OR A , -NR B R C , and -(CH 2 ) m SR A ;
  • each R 34 is independently selected from the group consisting of halogen, cyano, an optionally substituted CrC 6 alkyl, an optionally substituted CrC 6 alkoxy, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted CrC 6 haloalkyl, and an optionally substituted Ci-C 6 heteroalkyl;
  • each R 39 and R 40 are independently selected from the group consisting of hydrogen, halogen, -OH, -NHR , and an optionally substituted C 1 -C4 alkyl;
  • each R A is independently selected from the group consisting of hydrogen, CrC 6 alkyl, CrC 6 haloalkyl, CrC 6 heteroalkyl, and CrC 6 heterohaloalkyl;
  • each -NR R is separately selected, wherein R and R are each
  • each R D is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl, and -(CH 2 ) m R
  • each -NR E R F is separately selected, wherein R E and R F are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted Ci-C 6
  • heteroalkyl and -(CH 2 ) m R"; or -NR R is an optionally substituted Ci-C 6 alkylideneaminyl; or -NR E R F is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • each R is independently selected from an optionally substituted aryl and an optionally substituted heteroaryl
  • R H is selected from the group consisting of hydrogen, C 1 -C 3 alkyl, Ci- C 3 haloalkyl, C 3 -C 7 cycloalkyl, and an optionally substituted aryl or an optionally substituted heteroaryl;
  • each R L is independently selected from the group consisting of C 3 -C 7 cycloalkyl, optionally substituted Ci-C 6 alkyl, optionally substituted Ci-C 6 alkoxy, -(CH 2 ) m OR LA , -(CH 2 ) m NR LB R LC , aryl and heteroaryl, said aryl and heteroaryl in the definition of R L are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Cp
  • C 6 alkoxy, -(CH 2 ) m NR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of R L are each optionally substituted with one or more halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, or -(CH 2 ) m NR LF R LG ;
  • each R LA is independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • R LB and R LC are each independently selected from the group consisting of
  • Ci-C 6 alkyl Ci-C 6 haloalkyl, and Ci-C 6 heteroalkenyl
  • -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom
  • each -NR LD R LE is separately selected, wherein R LD and R LE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted Ci-C 6 alkyl, said aryl and heteroaryl in the definition of R and
  • R LE are each optionally substituted with CrC 6 alkyl or CrC 6 alkoxy; or -NR LD R LE is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • each -NR LF R LG is separately selected, wherein R L"F r and R L"G are each independently selected from the group consisting of hydrogen, and Ci-C 6 alkyl; or
  • R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom
  • each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and Ci-C 6 alkyl; or
  • R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom
  • each m is independently 0, 1, or 2;
  • each n is independently 0, 1, 2, 3, or 4;
  • each o is independently 1, 2, or 3;
  • each p is independently 0, 1, 2, or 3;
  • each q is independently 0 or 1 ;
  • any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
  • J 8 and Q 8 can each be null.
  • Some embodiments disclosed herein provide a compound of Formula IV, wherein A can be aryl substituted with one or more substituents selected from the group consisting of R 31 , R 32 , and R 33 ; J 8 can be
  • Some embodiments disclosed herein provide a compound of Formula IV, wherein A can be heteroaryl substituted with one or more substituents selected from the group consisting of
  • R 31 , R 32 , and R 3 J 3 J ; G 8° can be heteroaryl substituted with one or more substituents selected
  • A can aryl substituted with R 32 ; G 8 can be aryl substituted with R 35 ; R 32 can be -NR B R C , and R 35 can be -NR B R C .
  • IV having the structure of Formula IVa: (IVa), and pharmaceutically acceptable salts thereof, wherein J can be selected from the group
  • IVc having the structure of Formula IVca: (IVca), and pharmaceutically acceptable salts thereof, or having the structure of Formula IVcb:
  • IVd having the structure of Formula IVda: (IVda), and harmaceutically acceptable salts thereof, or having the structure of Formula IVdb:
  • IVe having the structure of Formula IVea: (IVea), and pharmaceutically acceptable salts thereof, or having the structure of Formula IVeb: (IVeb), and pharmaceutically acceptable salts thereof, or
  • IV having the structure of Formula IVf: (IVf), and pharmaceutically acceptable salts thereof.
  • IV having the structure of Formula IVi: (IVi), and pharmaceutically acceptable salts thereof, wherein R 80 can be selected from the group consisting of hydrogen, R 31 , R 32 , and R 33.
  • R 80 can be selected from the group consisting of hydrogen, R 31 , R 32 , and R 33.
  • G can be phenyl optionally substituted with one or more substituents selected from the group consisting of R 34 , R 35 , and R 36 .
  • Some embodiments disclosed herein provide a compound of Formula IV having the proviso that a compound of Formula IV is not selected from the group consisting of:
  • G 4 is selected from the group consisting of is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 43 and R 44 , said aryl and heteroaryl in the definition of G 4 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • Q 4 is selected from the group consisting of of NR 48 , and O (oxygen); or Q 4 is null;
  • a 4 is selected from the group consisting of CrC 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, a Ci-C 6 heteroalkyl, phenyl, pyridinyl, imidazolyl, and thienyl, each optionally substituted with one or more substituents selected from the group consisting of R 41 and R 42 ;
  • R 41 is independently selected from the group consisting of halogen, cyano, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 alkoxy, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted CrC 6 heteroalkyl;
  • R 41 and R 42 are linked to form an optionally substituted ring
  • each R 43 is independently selected from the group consisting of halogen, cyano, an optionally substituted CrC 6 alkyl, an optionally substituted CrC 6 alkoxy, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted CrC 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl;
  • each R 46 and R 47 is independently selected from the group consisting of hydrogen, halogen, an optionally substituted Ci-C 6 alkyl, and an optionally substituted CrC 6 heteroalkyl;
  • R 48 is selected from the group consisting of hydrogen, an optionally substituted CrC 6 alkyl, an optionally substituted CrC 6 alkoxy, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted C 3 -C 7 cycloalkenyl, and an optionally substituted Ci-C 6 heteroalkyl;
  • each R A is independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 heteroalkyl, and Ci-C 6 heterohaloalkyl;
  • -NR B R C is an optionally substituted Ci-C 6 alkylideneamino
  • each -NR D R E is separately selected, wherein R D and R E are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted C 3 -C 7 cycloalkenyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl, and -(CH 2 ) m R G"; or -NR D R E is an optionally substituted Ci-C 6 alkylideneaminyl; or -NR D R E is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • each R K is independently selected from the group consisting of
  • each m is independently 0, 1, or 2;
  • each dashed line represents an optional double bond.
  • G 4 can be selected from the group consisting of hydrogen, halogen, -(CH 2 ) m OR A , -0(CH 2 ) m OR A , -NR B R C , an optionally substituted CrC 6 alkyl, an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted tetrazolyl, and an optionally substituted imidazolyl;
  • Ci-C 6 alkylideneaminyl, and ; or Q 3 can be null;
  • a 4 can be selected from the group consisting of a aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 41 and R 42 , said aryl and heteroaryl in the definition of A 4 can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • -NR R can be separately se R and R can each be independently selected from the group consisting of hydrogen, -S0 F F F
  • -NR R can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom
  • each D E can be separately selected, wherein D E
  • -NR R R and R can each be independently selected from the group consisting of hydrogen, an optionally substituted CrC 6 alkyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted C 3 -C 7 cycloalkenyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted roalkyl, and G D E
  • Ci-C 6 alkylideneam -NR R can be an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom; each R can be independently selected from the group consisting of hydrogen, an optionally substituted C 1 -C 3 alkyl, an optionally substituted C 1 -C 3 haloalkyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted C 3 -C 7 cycloalkenyl, aryl and heteroaryl, where the aryl and heteroaryl in the definition of F D E
  • each R" can be independently selected from an optionally substituted aryl and an optionally substituted heteroaryl; each R can be independently selected from the group consisting of D E D E
  • each m can be independently 0, 1, or 2; and each dashed line represents an optionally double bond.
  • G 4 can be selected from the group consisting of hydrogen, halogen, -(CH 2 ) m OR A , -0(CH 2 ) m OR A , -NR B R C , an optionally substituted Ci-C 6 alkyl, an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted tetrazolyl, and an optionally substituted imidazol l;
  • Q can be selected from the group consisting of hydrogen, halogen, -(CH 2 ) m OR A , -0(CH 2 ) m OR A , -NR B R C , an optionally substituted Ci-C 6 alkyl, an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted tetrazolyl, and an optionally substituted imidazol l;
  • Q can be selected from the group consisting of hydrogen, halogen, -(CH 2 ) m
  • A can be selected from the group consisting of phenyl, naphthyl, dihydrobenzofuranyl, 1,4- benzodioxanyl, benzotriazolyl, benzimidazolyl, benzofuranyl, and 2,1,3-benzoxadiazolyl, each optionally substituted with one or more substituents selected from the group consisting of, each optionally substituted with one or more substituents selected from the group consisting of R 41 and R 42 ;
  • B C can be separately selected, wherein B C
  • each -NR R R and R can each be independently selected from the group consisting of hydrogen, F F
  • Ci-C 6 haloal -NR R can be an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom; or B C
  • -NR R can be an optionally substituted Ci-C 6 alkylideneamino; each -NR R can be separately selected, wherein R and R can each be independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted C3-C 7 cycloalkyl, an optionally substituted C3-C 7 cycloalkenyl, an optionally substituted Ci-C 6 haloalkyl, and G D E
  • -(CH 2 ) m R"; or -NR R can be an optionally substituted Ci-C 6 alkylideneaminyl; or D E
  • each R can be independently selected from the group consisting of hydrogen, an optionally substituted C 1 -C 3 alkyl, an optionally substituted C 3 -C 6 cycloalkyl, an optionally substituted C 3 -C 6 cycloalkenyl, an optionally substituted C 1 -C 3 haloalkyl, aryl and heteroaryl, where the aryl and heteroaryl in the
  • G 4 can be selected from the group consisting of hydrogen, halogen, - (CH 2 ) m OR A , -0(CH 2 ) m OR A , -NR B R C , an optionally substituted Ci-C 6 alkyl, an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted tetrazolyl, and an optionally substituted imidazolyl;
  • A can be selected from the group consisting of a aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 41 and R 42 , said aryl and heteroaryl in the definition of A 4 can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • NR R can be R and R can each be independently
  • -NR R can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -
  • NR R can be an optionally substituted Ci-C 6 alkylideneamino; each -NR R can be separately selected, wherein R and R can each be independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl, and -(CH 2 ) m R ; or D E be an optionally substituted D E
  • G 4 can be selected from the group consisting of hydrogen, halogen, fluoro, chloro, bromo, -OR A , -0(CH 2 ) m OR A , -NR B R C , an optionally substituted Ci-C 6 alkyl, an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted tetrazolyl, and an optionally substituted imidazolyl;
  • a 4 can be phenyl optionally substituted with one or more substituents selected from the group consisting of R 41 and R 42 , where the phenyl in the definition of A 4 can be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • G 4 can be selected from the group consisting of hydrogen, fluoro, chloro, bromo, imidazolyl, tetrazolyl, N-methyl-N-(2-hydroxyethyl)aminyl, methylaminosulfonamido, 2-hydroxyethyloxy, -(CH 2 ) m OR A , -0(CH 2 ) m OR A , and
  • a 4" can be phenyl optionally substituted with one or more substituents selected from the group consisting of R 41 and R 42 , where the phenyl in the definition of G 4 can be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • each R can be independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 3 alkyl, an optionally substituted C 3 -C 6 cycloalkyl, aryl and heteroaryl, where the aryl and heteroaryl in the definition of R can each be optionally substituted with -NR D R E ;
  • each R G" can be independently selected from an optionally substituted aryl and an optionally substituted heteroaryl;
  • each R can be independently selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl;
  • each m can be independently 0, 1,
  • E is selected from the group consisting of O (oxygen), S (sulfur), NR ' 41 and CR 42 R 43 ;
  • R is selected from the group consisting of hydrogen, halogen, cyano, c
  • Ci-C 6 haloalkyl Ci-C 6 heteroalkyl, and an optionally substituted Ci-C 6 alkyl;
  • R 42 and R 43 are each independently selected from the group consisting of hydrogen, halogen, -OR , -OR ,cc
  • CR 42 R 43 is an optionally substituted C 3 -C7 cycloalkyl
  • X , X , and X are each independently selected from the group consisting of N (nitrogen) and CR 41 ;
  • G 9 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 44 and R 45 , said aryl and heteroaryl in the definition of G 9 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • each R 44 is separately selected from the group consisting of halogen, cyano, an optionally substituted CrC 6 alkyl, an optionally substituted CrC 6 alkoxy, an optionally substituted C 2 -C6 alkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC 6 haloalkyl, and an optionally substituted Ci-C 6 heteroalkyl;
  • each R 45 is separately selected from the group consisting of hydrogen, halogen, -OR AA , -OR cc , -NR A R B , -NR C R D , -SR AA , -(CH 2 ) m R E , Ci-C 6 haloalkyl, Ci-C 6 heteroalkyl, and an optionally substituted CrC 6 alkyl;
  • each R is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 8 alkyl, an optionally substituted Ci-C 8 alkoxy, an optionally substituted C 2 -C 8 alkenyl, an optionally substituted C 2 -C 8 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, and (CH 2 ) m R ;
  • C 7 cycloalkyl is optionally fused with an aryl or heteroaryl; or -NR A R B is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom optionally fused with an aryl or heteroaryl; or -NR A R B is an optionally substituted Ci-C 6 alkylideneamino;
  • each -NR C RD is separately selected, wherein R C and RD are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 8 alkyl, an optionally substituted Ci-C 8 alkoxy, an optionally substituted C 2 -C 8 alkenyl, an optionally substituted C 2 -C 8 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, and (CH 2 ) m R E"; or -NR C RD is an optionally substituted Ci-C 8 alkylideneamino; or -NR C R D is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • each R is separately selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl;
  • each R is separately selected from the group consisting of hydrogen, a an optionally substituted CrC 6 alkyl, an optionally substituted CrC 6 alkoxy, an optionally substituted C 2 -C 6 alkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted aryl and an optionally substituted heteroaryl;
  • each R 46 is independently selected from the group consisting of hydrogen, Ci-C 6 haloalkyl, and an optionally substituted Ci-C 6 alkyl;
  • each m is independently 0, 1, or 2;
  • each q is independently 1, 2, 3, 4, 5, or 6;
  • any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
  • G is selected from the group consisting of Ci-C 6 alkyl, Ci-C 6 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, Ci-C 6 haloalkyl, Cp C 6 heteroalkyl, heterocycle, aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 51 , R 52 , and R 53 , said aryl and heteroaryl in the definition of G 10 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • Q 10 is selected from the group consisting of Q 11 , Q n -Q 12 , and Q 11 -
  • Q is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocycle;
  • each R 51 is separately selected from the group consisting of hydrogen, halogen, cyano, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 alkoxy, an optionally substituted C 2 -C 6 alkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted C 3 -C 7 cycloalkenyl, an optionally substituted Ci-C 6 haloalkyl, and an optionally substituted Ci-C 6 heteroalkyl;
  • each R is separately selected from the group consisting of - (CH 2 ) m OR A , -(CH 2 ) m NR B R c , -(CH 2 ) m S0 2 NR B R c , and -(CH 2 ) m SR A ;
  • each R is separately selected from the group consisting of - (CH 2 ) m OR D , - (CH 2 ) m NR E R F , -(CH 2 ) m S(O) 0 - 2 R D , -(CH 2 ) m N0 2 , -(CH 2 ) m CN, and - (CH 2 ) m R G ;
  • each -NR B R C is separately selected, wherein R B and R C are each independently selected from the group consisting of hydrogen, -(CH 2 ) m S0 2 R , - (CH 2 ) m COR H , -(CH 2 ) m CONR E R F , an optionally substituted C C 8 alkyl, an optionally substituted Ci-C 8 alkoxy, an optionally substituted C 2 -C 8 alkenyl, an optionally substituted C 2 -C 8 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, and -(CH 2 ) m R , where said C 3 -C 7 cycloalkyl is optionally fused with an aryl or heteroaryl; or -NR B R C or is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom optionally fused with an aryl or heteroaryl; or -NR B R C is an optionally substituted Ci
  • each R D is separately selected from the group consisting of hydrogen, an optionally substituted Ci-C 8 alkyl, an optionally substituted C 2 -C 8 alkenyl, an optionally substituted C 2 -C 8 alkynyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted C 3 -C 8 cycloalkenyl, an optionally substituted Ci-C 8 haloalkyl, and an optionally substituted Ci-C 8 heteroalkyl;
  • each -NR E R F is separately selected, wherein R E and R F are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 8 alkyl, an optionally substituted Ci-C 8 alkoxy, an optionally substituted C 2 -C 8 alkenyl, an optionally substituted C 2 -C 8 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, and (CH 2 ) m R G"; or -NR E R F or is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -NR R is an optionally substituted Ci-C 8 alkylideneamino;
  • each R is separately selected from a substituted or unsubstituted aryl and a substituted or unsubstituted heteroaryl;
  • each R H is separately selected from the group consisting of hydrogen, a Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, Ci-C 6 haloalkyl, Ci-C 6 heteroalkyl, an optionally substituted heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • X 1 , X2 , and X 3 are each independently selected from the group consisting of N (nitrogen) and CR 47 ;
  • each R 47 is separately selected from the group consisting of hydrogen, halogen, an optionally substituted CrC 6 alkyl, and an optionally substituted CrC 6 heteroalkyl
  • each m is independently 0, 1, 2, or 3;
  • any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
  • Some embodiments disclosed herein provide a compound of Formula VII, having the proviso that a compound of Formula VII is not selected from the group consisting of:
  • A-J is Y O and Q-G is Y O ;
  • each E is separately selected from the group consisting of -CR 10a - and N (nitrogen);
  • each R 10a is separately selected from the group consisting of H (hydrogen), halogen, cyano, CrC 6 alkyl optionally substituted with up to five fluoro, Cp C 6 alkoxy optionally substituted with up to five fluoro, C 2 -C6 alkenyl optionally substituted with up to five fluoro, C 2 -C 6 alkynyl optionally substituted with up to five fluoro, C3-C 7 cycloalkyl optionally substituted with up to five fluoro, and C3-C 7 cycloalkenyl optionally substituted with up to five fluoro;
  • a 4 is selected from the group consisting of C 3 -C 7 cycloalkenyl, C 3 -C 7 cycloalkyl, C C 6 alkyl, C C 6 heteroalkyl, C 2 -C 6 alkenyl, C C 6 alkoxy, -(CH 2 ) m NR P R L , heterocycle, polycyclic heterocyclyl, aryl, and heteroaryl, said C 3 -C 7 cycloalkenyl, C 3 -C 7 cycloalkyl, Ci-C 6 alkyl, Ci-C 6 heteroalkyl, C 2 -C 6 alkenyl, heterocycle, polycyclic heterocyclyl, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 ;
  • G 4 is selected from the group consisting of polycyclic heterocyclyl, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 ;
  • a 5 is selected from the group consisting of polycyclic heterocyclyl, aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 ;
  • each R is separately selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted C 2 -C 6 alkenyl, and an optionally substituted C 3 -C 7 cycloalkyl;
  • R is selected from the group consisting of Ci-C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C8 cycloalkenyl, CrC 6 heteroalkyl, CrC 6 heteroalkenyl, CrC 6 heteroalkynyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition of R are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle, or R G is -OR L or -NR P R L ;
  • R H is selected from the group consisting of hydrogen, CrC 6 alkyl, C 2 -
  • alkenyl, C 3 -C 7 cycloalkyl, and C 1 -C 3 haloalkyl, or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • each R 1 is separately selected from the group consisting of halogen, cyano, an optionally substituted CrC 6 alkyl, an optionally substituted CrC 6 alkoxy, an optionally substituted C 2 -C 6 alkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, optionally substituted C 3 -C 7 cycloalkenyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • each R 1 is separately selected from the group consisting of hydrogen, Ci-C 6 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 7 cycloalkyl, Ci-C 6 haloalkyl, Ci-C 6 heteroalkyl, and Ci-C 6 heterohaloalkyl;
  • each -NR J R K is separately selected, wherein R J and R K are each independently selected from the group consisting of hydrogen, Ci-C 6 alkyl optionally substituted with up to 5 fluoro, -(CH 2 ) m OR JA , -(CH 2 ) m NR JB R JC , -(CH 2 ) m R R , C 3 -C 7 cycloalkyl, heterocycle, aryl and heteroaryl, said C 3 -C 7 cycloalkyl, heterocycle, aryl and heteroaryl in the definition of R T and R K are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off
  • R J and ⁇ are each optionally substituted with one or more halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, or -(CH 2 ) m NR KA R KB ; or -NR J R K is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; [0474] each R is independently selected from the group consisting of hydrogen, CrC 6 alkyl, and CrC 6 haloalkyl;
  • each -NR JB R JC is separately selected, wherein R JB and R JC are each independently selected from the group consisting of hydrogen, CrC 6 alkyl, and CrC 6 haloalkyl;
  • each -NR ⁇ RTM is separately selected, wherein R 1 ⁇ and R KB are each independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • each R M is independently selected from the group consisting of hydrogen, an optionally substituted CrC 6 alkyl, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted C 3 -C 7 cycloalkenyl, and -(CH 2 ) m R P ;
  • each -NR N R° is separately selected, wherein R N and R° are each independently selected from the group consisting of hydrogen, -(CH 2 ) m NR NA R NB , aryl and heteroaryl, said aryl and heteroaryl in the definition of R N and R° are each independently optionally substituted with one or more substituents selected from the group consisting of -(CH 2 ) m NR OA R OB , halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off of R N and R° are each optionally substituted with one or more halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, or -NR NA R NB ,
  • each -NR NA R NB is separately selected, wherein R NA and R NB are each independently selected from the group consisting of hydrogen, CrC 6 alkyl, and CrC 6 haloalkyl;
  • each -NR OA R OB is separately selected, wherein R OA and R OB are each independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • each R p is independently selected from the group consisting of hydrogen and CrC 6 alkyl
  • eeaacchh RR ]L is independently selected from the group consisting of C 3 -C 7 cycloalkyl, optionally substituted CrC 6 alkyl, optionally substituted CrC 6 alkoxy, - (CH 2 ) m OR LA , -(CH 2 ) m NR LB R LC , aryl and heteroaryl, said aryl and heteroaryl in the definition of R L are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-
  • C 6 alkoxy, -(CH 2 ) m NR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of R L are each optionally substituted with one or more halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl,
  • Ci-C 6 alkoxy or -(CH ⁇ NR ⁇ R 1 ⁇ ;
  • each R LA is independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • each -NR LD R LE is separately selected, wherein R LD and R LE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted Ci-C 6 alkyl, said aryl and heteroaryl in the definition of R LD and
  • R are each optionally substituted with Ci-C 6 alkyl or Ci-C 6 alkoxy; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and Ci-C 6 alkyl; or
  • R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom
  • R R is selected from the group consisting of Ci-C 6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • R u is selected from the group consisting of C3-C7 cycloalkyl Ci-C 6 alkyl optionally substituted with up to 5 fluoro, and an optionally substituted heteroaryl;
  • each m is independently 0, 1, 2, or 3;
  • each p is independently 0, 1, 2, 3, 4, 5, or 6;
  • each q is independently 1, 2, 3, 4, 5, or 6.
  • aryl and heteroaryl where at least one atom forming the heteroaryl aromatic ring is a N (nitrogen), and said aryl and heteroaryl are each optionally substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 , and G 4 is selected from the group consisting of aryl and heteroaryl, where at least one atom forming the heteroaryl aromatic ring is a N (nitrogen), and said aryl and heteroaryl are each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 .
  • VHIb having the formula VHIbb: (VHIbb),
  • E is N (nitrogen) and E is -CH-, or E 1A is -CH- and E 1B is -CH-, or E 1A is -CH- and E 1B is N (nitrogen); and A-J is
  • Vlllbb having the formula VHIbbb: (VHIbbb), and
  • Q-G i A is selected from the group consisting of C 5 -C 7 cycloalkenyl
  • each R 1 is separately selected from the group consisting of halogen, cyano, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 alkoxy, an optionally substituted Ci-C 6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl
  • each R 2 is separately selected from the group consisting of -0(
  • each R 10a is separately selected from the group consisting of H (hydrogen), halogen, CrC 6 alkyl optionally substituted with up to five fluoro, and CrC 6 alkoxy optionally substituted with up to five fluoro;
  • R 1 ⁇ is selected from the group consisting of Ci-C 6 alkyl, aryl, and heteroaryl;
  • a 9 is hydrogen or Ci-C 6 alkyl
  • R A is selected from the group consisting of CrC 6 alkyl, C 3 -C 7 cycloalkyl, heterocycle, polycyclic heterocyclyl, aryl and heteroaryl, each optionally
  • R is selected from the group consisting of hydrogen, CrC 6 alkyl, Ci-C 6 alkoxy, C 2 -C 6 alkenyl, C 3 -C 7 cycloalkyl, and heteroaryl;
  • G 4 is selected from the group consisting of polycyclic heterocyclyl, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 ;
  • each R 1 is separately selected from the group consisting of halogen, cyano, CrC 6 heteroalkyl, an optionally substituted CrC 6 alkyl, an optionally substituted Ci-C 6 alkoxy, an optionally substituted C 2 -C 6 alkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, optionally substituted C 3 -C 7 cycloalkenyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • each R 4 is separately selected from the group consisting of halogen, cyano, Ci-C 6 heteroalkyl, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 alkoxy, an optionally substituted C 2 -C 6 alkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • R is selected from the group consisting of Ci-C 6 alkyl, C 3 -C6 cycloalkyl, C 3 -C 8 cycloalkenyl, Ci-C 6 heteroalkyl, Ci-C 6 heteroalkenyl, Ci-C 6 heteroalkynyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition of R are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle, or R G is -OR L or -NR P R L ;
  • each R 1 is separately selected from the group consisting of hydrogen, Ci-C 6 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 7 cycloalkyl, C C 6 haloalkyl, C C 6 heteroalkyl, and Ci-C 6 heterohaloalkyl;
  • each -NR J R K is separately selected, wherein R J and R K are each independently selected from the group consisting of hydrogen, Ci-C 6 alkyl optionally substituted with up to 5 fluoro, -(CH 2 ) m OR JA , -(CH 2 ) m NR JB R JC , -(CH 2 ) m R R , C 3 -C 7 cycloalkyl, heterocycle, aryl and heteroaryl, said C 3 -C 7 cycloalkyl, heterocycle, aryl and heteroaryl in the definition of R T and R K are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off
  • R J and ⁇ are each optionally substituted with one or more halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C C 6 alkoxy, or -(CH 2 ) m NR KA R KB ; or -NR J R K is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • each R JA is independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • each -NR ⁇ RTM is separately selected, wherein R 1 ⁇ and R KB are each independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • each R M is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C 6 alkyl, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted C 3 -C 7 cycloalkenyl, and -(CH 2 ) m R p ;
  • each -NR N R° is separately selected, wherein R N and R° are each independently selected from the group consisting of hydrogen, -(CH 2 ) m NR NA R NB , aryl and heteroaryl, said aryl and heteroaryl in the definition of R N and R° are each independently optionally substituted with one or more substituents selected from the group consisting of -(CH 2 ) m NR OA R OB , halo, C C 6 alkyl, C C 6 haloalkyl, C C 6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off of R N and R° are each optionally substituted with one or more halo, CrC 6 alkyl, CrC 6 haloalkyl, CrC 6 alkoxy, or -NR NA R NB ,
  • each -NR NA R NB is separately selected, wherein R NA and R NB are each independently selected from the group consisting of hydrogen, Ci-C 6 alkyl, and Ci-C 6 haloalkyl;
  • each -NR OA R OB is separately selected, wherein R OA and R OB are each independently selected from the group consisting of hydrogen, CrC 6 alkyl, and CrC 6 haloalkyl;
  • R p is selected from the group consisting of hydrogen and CrC 6 alkyl
  • each R L is independently selected from the group consisting of C3-C7 cycloalkyl, optionally substituted CrC 6 alkyl, optionally substituted CrC 6 alkoxy, - (CH 2 ) m OR LA , -(CH 2 ) m NR LB R LC , aryl and heteroaryl, said aryl and heteroaryl in the definition of R L are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-
  • C 6 alkoxy, -(CH 2 ) m NR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of R L are each optionally substituted with one or more halo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, or -(CH 2 ) m NR LF R LG ;
  • each R LA is independently selected from the group consisting of hydrogen, CrC 6 alkyl, and CrC 6 haloalkyl;
  • each -NR LD R LE is separately selected, wherein R LD and R LE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted CrC 6 alkyl, said aryl and heteroaryl in the definition of R LD and
  • R are each optionally substituted with Ci-C 6 alkyl or Ci-C 6 alkoxy; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and CrC 6 alkyl; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • R R is selected from the group consisting of Ci-C 6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
  • each m is independently 0, 1, 2, or 3.
  • a compound of Formula IX is not selected from the group consisting of:
  • IX having the fo (IXa), and pharmaceutically wjr
  • R is selected from the group consisting of heterocycle, polycyclic heterocyclyl, aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 1 , R 2 , and R 3
  • each R 1 is separately selected from the group consisting of chloro, cyano, CrC 6 alkyl, Ci-C 6 alkoxy, C 2 -C6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, and CrC 6 haloalkyl
  • IXa having the formula IXaa: (IXaa), and pharmaceutically acceptable salts thereof, wherein G is selected from the group consisting of polycyclic heterocyclyl, aryl, and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , each R 4 is separately selected from the group consisting of chloro, cyano, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 alkoxy, an optionally substituted C 2 -C 6 alkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted Ci-C 6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl, each R 5 is separately selected from the group consisting of -0(CH 2 ) m OR I ,
  • each R 1 is separately selected from the group consisting of cyano, an optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 alkoxy, an optionally substituted Ci-C 6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl
  • Some embodiments disclosed herein provide a method of treating a patient, comprising administering to the patient a therapeutically effective amount of a compound having Formula X:
  • a 10 is selected from the group consisting of CrC 6 alkyl, CrC 6 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, Ci-C 6 haloalkyl, Ci- C 6 heteroalkyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R , R , and R , said aryl and heteroaryl in the definition of A 10 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • G 10 is selected from the group consisting of CrC 6 alkyl, CrC 6 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, Ci-C 6 haloalkyl, Ci- C 6 heteroalkyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition of G 10 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
  • J 10 is a 1-8 atom long spacer containing at least 2 heteroatoms separated by 2 bonds and comprising one or more groups selected from -S(0) 2 NR A -, an optionally substituted CrC 6 heteroalkyl, an optionally substituted heterocycle, and an optionally substituted heteroalkylheterocycle; including the proviso that J 10 is not a 1-8 atom spacer containing at least 2 heteroatoms separated by 3 or 4 bonds and comprising one or more groups selected from an optionally substituted Ci-C 6 heteroalkyl, an optionally substituted heterocycle, and an optionally substituted heteroalkylheterocycle;
  • Q 10 is a 1-8 atom long spacer containing at least 2 heteroatoms separated by 2 bonds and comprising one or more groups selected from -S(0) 2 NR A -, an optionally substituted Ci-C 6 heteroalkyl, an optionally substituted heterocycle, and an optionally substituted heteroalkylheterocycle;
  • R 1 is selected from the group consisting of halogen, optionally substituted CrC 6 alkyl, an optionally substituted CrC 6 alkoxy, an optionally substituted C 2 -C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, and an optionally substituted CrC 6 heteroalkyl;
  • R is selected from the group consisting of halogen, -OR , -NR R , -
  • R 3 is selected from the group consisting of -OR D , -NR E R F , -S(0)o- 2 R D , -NO2, -CN, and -(CH 2 ) m R G , ;
  • R 4 is selected from the group consisting of halogen, optionally substituted Ci-C 6 alkyl, an optionally substituted Ci-C 6 alkoxy, an optionally substituted C 2 -C 6 alkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, , an optionally substituted Ci-C 6 heteroalkyl;
  • R 5 is selected from the group consisting of -OR A , -NR B R C , -SR A ;
  • R is selected from the group consisting of -OR , -NR R , -S(0)o- 2 R D , -NO2, -CN, and -(CH 2 ) m R G ;
  • -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, -S0 H H
  • Ci-C 6 alkyl C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, C3-C7 cycloalkyl, CrC 6 haloalkyl, CrC 6 heteroalkyl, heterocycle, and CrC 6 heterohaloalkyl where the cycloalkyl and the heterocycle are optionally fused with an aryl or heteroaryl; or
  • — NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom
  • each R D is independently selected from the group consisting of hydrogen, an optionally substituted CrC 6 alkyl, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted CrC 6 haloalkyl, an optionally substituted CrC 6 heteroalkyl, an optionally substituted heterocyle, and -(CH 2 ) m R ;
  • each -NR E R F is separately selected, wherein R E and R F are each independently selected from the group consisting of hydrogen, an optionally substituted CrC 6 alkyl, an optionally substituted C 2 -C 4 alkenyl, an optionally substituted C 2 -C 4 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, an optionally substituted Ci-C 6 haloalkyl, an optionally substituted CrC 6 heteroalkyl, an optionally substituted heterocycle, and G E F
  • -(CH 2 ) m R or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
  • each R is separately selected from an optionally substituted aryl and an optionally substituted heteroaryl;
  • each R H is separately selected from the group consisting of hydrogen, a CrC 6 alkyl, a CrC 6 haloalkyl, a CrC 6 heteroalkyl, a C 3 -C 6 cycloalkyl, an optionally substituted heterocycle, and an optionally substituted aryl or an optionally substituted heteroaryl; and
  • each m is independently 0, 1, or 2.
  • Some embodiments disclosed herein provide a method of treating a patient, comprising administering to the patient a therapeutically effective amount of a compound having Formula X having the structure of Formula Xa: (Xa), and pharmaceutically acceptable salts thereof, wherein A 10 can be selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 1 , R 2 , and R 3 , said aryl and heteroaryl in the definition of A 10 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; and G 10 can be selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition of G 10 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle.
  • Some embodiments disclosed herein provide a method of treating a patient, comprising administering to the patient a therapeutically effective amount of a compound having Formula X having the structure of Formula Xb:
  • a 10 can be selected from the group consisting of aryl and heteroaryl, each optionally
  • said aryl and heteroaryl in the definition of A can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; and G 10 can be selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition of G 10 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle.
  • Some embodiments disclosed herein provide a method of treating a patient, comprising administering to the patient a therapeutically effective amount of a compound having Formula X, wherein A 10 can be selected from the group consisting of Ci-C 6 alkyl, C 3 -C 7 cycloalkyl, Ci-C 6 heteroalkyl, heterocycle, aryl, and heteroaryl, each
  • G 10 can be selected from the group consisting of Ci-C 6 alkyl, C 3 -C 7 cycloalkyl, Ci-C 6 heteroalkyl, heterocycle, aryl, and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 4 , R 5 , and R 6 , said aryl and heteroaryl in the definition of G 10 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle;
  • R 1 can be selected from the group consisting of fluorine, chlorine, and methyl;
  • R 2 can be selected from the group consisting of -OR A , -NR B R C , and -SR A ;
  • R 3 can be selected from the group consisting of -(CH 2 ) m R , -OR , and -NR R ;
  • R 1 can be selected from the group consisting of fluorine, chlorine, and methyl
  • R 2 can be selected from the group consisting of -
  • Some embodiments disclosed herein provide a method of treating a patient, comprising administering to the patient a therapeutically effective amount of a compound having Formula X, wherein A 10 can be selected from the group consisting of a C 2 -C 6 alkyl, a C 2 -C 7 cycloalkyl, a CrC 6 heteroalkyl, a heterocycle, phenyl, pyridinyl, pyrrolyl, pyrimidinyl, imidazolyl, isoxazolyl, thiazolyl, thienyl, indolyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, and purinyl, each substituted with one or more substituents selected from the group consisting of R 1 , R 2 , and R 3 ; G 10 can be selected from the group consisting of a C 2 -C 6 alkyl, a C 2 -C 7 cycloalkyl, a CrC 6 hetero
  • reducing agents such sodium borohydride, lithium borohydride, sodium cyanoborohydride, potassium trisiamylborohydride, potassium tri-sec-butylborohydride, lithium trisiamylborohydride, lithium tri-sec-butylborohydride, diisobutylaluminum hydride, lithium triethoxyaluminum hydride and the like can be used in the reduction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to uses of small molecule mimetics of hematopoietic growth factors. In particular the present invention relates to uses of small molecule mimetics of erythropoietin.

Description

USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS
RELATED APPLICATIONS
[0001] This is a non-provisional application claiming the benefit of U.S. Provisional App. No. 61/415,270 filed on November 18, 2010 entitled "USES OF SELECTIVE ERYTHROPOIETIN AGONISTS," the contents of which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to uses of small molecule mimetics of hematopoietic growth factors. In particular, the present invention relates to uses of small molecule mimetics of erythropoietin.
BACKGROUND
[0003] Hematopoietic growth factors (HGFs) include a family of biological molecules such as glycoproteins with important regulatory functions in the processes of proliferation, differentiation, and functional activation of hematopoietic progenitors and mature blood cells. HGF compounds can be potent regulators of blood cell proliferation and development in the bone marrow. They are able to augment hematopoiesis when bone marrow dysfunction exists. Recombinant DNA technology has made it possible to clone the genes responsible for many of these factors.
[0004] One example of an HGF is the glycoprotein hormone erythropoietin (EPO). EPO is an essential viability and growth factor for the erythrocytic progenitors. EPO acts primarily to rescue differentiating erythroid cells from cell death, i.e., apoptosis, to increase their survival. EPO is a member of the family of class I cytokines which fold into a compact globular structure consisting of 4 oc-helical bundles, thus while its molecular mass is 30.4 kDa, EPO migrates with an apparent size of 34-38 kDa on SDS- polyacrylamide gels. The peptide core of 165 amino acids suffices for receptor-binding and in vitro stimulation of erythropoiesis, while the carbohydrate portion (40% of the total molecule) is required for the in vivo survival of the hormone. The 4 carbohydrate chains of EPO have been analyzed in detail. The 3 complex-type N-linked oligosaccharides at asparagines 24, 38 and 83 appear involved in stabilizing EPO in circulation. [0005] During the fetal stage of mammalian development, EPO is mainly produced by hepatocytes. After birth, almost all circulating EPO originates from peritubular fibroblast-like cells located in the cortex of the kidneys. Transcription factors of the GATA-family may be important in the control of the time-specific and tissue- specific expression of the EPO gene. In adults, minor amounts of EPO mRNA are expressed in liver parenchyma, spleen, lung, testis and brain. In brain, EPO exerts neurotrophic and neuroprotective effects, which are separate from the action of circulating EPO on erythropoietic tissues. See e.g., Jelkmann, W., Internal Medicine Vol. 43, No.8 (August 2004).
[0006] EPO binds to the homodimeric EPO receptor to act synergistically with several growth factors (e.g., SCF, GM-CSF, 1L-3, and IGF-1) to cause the maturation and proliferation of erythroid progenitor cells and their subsequent differentiation into red blood cells (RBCs). This process is mediated by a number of intracellular signaling pathways, for example, STAT5, Ras/MAPK and PI3K-GATA 1. Binding of EPO to the EPO receptor induces a conformational change in the homodimer leading to the phosphorylation and activation of EPO receptor-associated JAK2 kinase, which results in tyrosine phosphorylation of the EPO receptor as well as the activation of several downstream signaling pathways, including STAT5, STAT3, STAT1, Ras/MAPK, P13K1AKT and GATA1.
[0007] Four forms of EPO have been approved for use in humans as erythropoiesis stimulating agents, and are currently marketed as treatments for varying types of anemia. All four forms of EPO are synthetic proteins produced by recombinant DNA technology in mammalian cells into which the human erythropoietin gene has been introduced, and include Epoetin alfa (marketed as Epogen® and Procrit® and identical to endogenous EPO), Epoetin beta (marketed only in Europe as NeoRecormon®), Darbepoetin Alfa (marketed as Aranesp®) and a methoxy polyethylene glycol-conjugated form of epoetin beta (marketed as Micera®). All are 165 amino acid glycoproteins and have the same biological effects and identical amino acid sequence as endogenous erythropoietin. Darbepoetin Alfa differs from endogenous EPO by containing two more N-linked oligosaccharide chains.
[0008] In addition to the aforementioned erythropoiesis stimulating agents, there are several other agents begin developed that represent reformulations or alternative chemical modifications, but which are still based on full-length EPO. Hematide™ is a synthetic dimeric PEG-modified peptide-based erythropoiesis stimulating agent immunologically distinct from EPO but which is believed to bind and activate EPO receptor signaling in a manner indistinguishable from EPO. CNTO-530 is a 58 kD EPO receptor agonist that links two EMP-1 (erythropoietin mimetic peptide- 1) peptides to a proprietary MIMETIBODY (Ig Fc domain fusion protein) scaffold. It bears no homology to EPO, yet activates EPO receptor signaling in a manner similar to EPO.
SUMMARY OF THE INVENTION
[0009] Some embodiments provided herein include use of a non-peptidyl small molecule mimetic of EPO in the preparation of a medicament for the treatment of a disorder associated with erythropoiesis by administering an initial effective amount of the mimetic of EPO, and a second effective amount of the mimetic of EPO, wherein the initial and the second effective amounts are substantially the same.
[0010] In some embodiements, the medicament is for the treatment of a disorder associated with erythropoiesis by further administering a third effective amount of the mimetic of EPO that is substantially the same as the initial and second effective amounts.
[0011] In some embodiements, the medicament is for the treatment of a disorder associated with erythropoiesis by further administering one or more subsequent effective amounts of the mimetic of EPO that is substantially the same as the initial, second, and third effective amounts.
[0012] In some embodiements, the initial and the second effective amounts are the same.
[0013] In some embodiements, the medicament is for the treatment of a disorder associated with erythropoiesis by administering a series of effective amounts that are substantially the same at least daily, at least weekly, or at least monthly.
[0014] Some embodiemtns include use of a non-peptidyl small molecule mimetic of EPO in the preparation of a medicament for the treatment of a disorder associated with erythropoiesis without titration of the amount of the mimetic of EPO administered.
[0015] In some embodiements, the medicament is for the treatment of a disorder associated with erythropoiesis by administering at least two successive effective amounts of the mimetic of EPO. [0016] In some embodiements, the medicament is for the treatment of a disorder associated with erythropoiesis without titration over a period of time for administration that is daily, weekly, or monthly.
[0017] In some embodiements, the disorder associated with erythropoiesis comprises anemia.
[0018] In some embodiements, the anemia is associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, anemia of chronic disease, congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or ΗΓ infection.
[0019] In some embodiements, the mimetic of EPO is an EPO receptor partial agonist.
[0020] In some embodiements, the mimetic of EPO activates EPO receptor signaling through the PI3K-GATA1 pathway.
[0021] Some embodiments include a non-peptidyl small molecule mimetic of EPO for use in the treatment of a disorder associated with erythropoiesis by administering an initial effective amount of the mimetic of EPO, and a second effective amount of the mimetic of EPO, wherein the initial and the second effective amounts are substantially the same.
[0022] Some embodiments include use of a mimetic of EPO in the treatment of a disorder associated with erythropoiesis by further administering one or more subsequent effective amounts of the mimetic of EPO that is substantially the same as the initial and second effective amounts.
[0023] In some embodiements, the initial and the second effective amounts are the same.
[0024] Some embodiments include use of a mimetic of EPO in the treatment of a disorder associated with erythropoiesis by administering a series of effective amounts that are substantially the same at least daily, at least weekly, or at least monthly.
[0025] Some embodiments include a non-peptidyl small molecule mimetic of EPO for use in the treatment of a disorder associated with erythropoiesis without titration of the amount of the mimetic of EPO administered.
[0026] Some embodiments include use of a mimetic of EPO for use in the treatment of a disorder associated with erythropoiesis by administering at least two successive effective amounts of the mimetic of EPO. [0027] Some embodiments include use of a mimetic of EPO for use in the treatment of a disorder associated with erythropoiesis without titration over a period of time for administration that is daily, weekly, or monthly.
[0028] In some embodiments, the disorder associated with erythropoiesis comprises anemia. In some embodiments, the anemia is associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, anemia of chronic disease, congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or ΗΓ infection.
[0029] In some embodiments, the mimetic of EPO is an EPO receptor partial agonist.
[0030] In some embodiments, the mimetic of EPO activates EPO receptor signaling through the PI3K-GATA1 pathway.
[0031] Some embodiments include a method of treating a disorder associated with erythropoiesis in a patient in need of such treatment, said method comprising: administering an initial effective amount of a non-peptidyl small molecule mimetic of EPO to the patient; and administering a second effective amount of the mimetic of EPO to the patient, wherein the initial and the second effective amounts are substantially the same.
[0032] Some embodiments include comprising administering a third effective amount of the mimetic of EPO to the patient that is substantially the same as the initial and second effective amounts.
[0033] Some embodiments include administering one or more subsequent effective amounts of the mimetic of EPO to the patient that is substantially the same as the initial, second, and third effective amounts.
[0034] In some embodiments, the initial and the second effective amounts are the same.
[0035] Some embodiments include administering a series of effective amounts that are substantially the same to the patient at least daily, at least weekly, or at least monthly.
[0036] Some embodiments include a method of treating a disorder associated with erythropoiesis to a patient in need of such treatment, said method comprising: administering an effective amount of a non-peptidyl small molecule mimetic of EPO to the patient, wherein the amount administered to the patient is not titrated over the period of time for administration.
[0037] In some embodiments, one or more subsequent effective amounts of the mimetic of EPO are administered to said patient.
[0038] In some embodiments, the period of time for administration includes administration daily, weekly, or monthly.
[0039] In some embodiments, the disorder associated with erythropoiesis comprises anemia. In some embodiments, the anemia is associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, anemia of chronic disease, congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or ΗΓ infection.
[0040] In some embodiments, the mimetic of EPO is an EPO receptor partial agonist.
[0041] In some embodiments, the mimetic of EPO activates EPO receptor signaling through the PI3K-GATA1 pathway.
[0042] In some of the foregoing methods and uses, the EPO mimetic comprises a compound of Formula I) having the structure:
Figure imgf000007_0001
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof.
[0043] In some of the foregoing methods and uses, the mimetic of EPO comprises a compound of Formula II) having the structure:
Figure imgf000007_0002
(ID
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof.
[0044] In some of the foregoing methods and uses, the mimetic of EPO comprises a compound of Formula (III) having the structure:
Figure imgf000008_0001
(III)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof.
[0045] In some of the foregoing methods and uses, the mimetic of EPO comprises a compound of Formula (IV) having the structure:
|8 (-)8
A8-J L8-Q\G8
(IV)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof.
[0046] In some of the foregoing methods and uses, the mimetic of EPO comprises a compound of Formula V) having the structure:
Figure imgf000008_0002
(V)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof.
[0047] In some of the foregoing methods and uses, the mimetic of EPO comprises a compound of Formula VI) having the structure:
Figure imgf000008_0003
(VI)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof.
[0048] In some of the foregoing methods and uses, the mimetic of EPO comprises a compound of Formula (VII) having the structure:
Figure imgf000009_0001
(VII)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof.
[0049] In some of the foregoing methods and uses, the mimetic of EPO comprises a compound of Formula (IX) having the structure:
Figure imgf000009_0002
(IX)
or a pharmaceutically acceptable salt thereof.
[0050] In some of the foregoing methods and uses, the mimetic of EPO comprises a compound of Formula (X) having the structure:
. J 1 ° ^Q 1 °
A1 0 L10 G10
(X)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0051] FIG. 1 shows a schematic diagram of pathways related to the EPO receptor. Such pathways include the proteins JAK2, NFKB, IKB, MAPK, ERK, STAT5,
P13K, AKT, GATA1, and phosphorylated forms of such proteins.
[0052] FIG. 2 shows a diagram of changes in GATA1 and GATA2 activity as erythroid development progresses and cell proliferation decreases as cell differentiation increases. The erythroid development pathway includes the cells: EMP, BFU-E, CFU-E,
Pro erythroblast, Basophilic erythroblast, Polychromatic erythroblast, Orthochromatic erythroblast, Reticulocyte, and Erythrocyte.
[0053] FIG. 3 shows a graph of percentage efficacy of experimental compounds relative to EPO vs. concentration of experimental compounds. (· : recombinant human EPO (rHuEPO); A : compound 101;■: compound 102). Normal serum EPO concentration is about 0.01 U/ml (range: 0.006 - 0.032 U/ml).
[0054] FIG. 4 shows a graph of percentage differentiation of CD235a+ cells relative to number of cells treated with 2.0 U/ml recombinant human EPO (rHuEPO) for cells treated with various experimental compounds.
[0055] [0013] FIG. 5A shows a graph of phosphorylation of the EPO receptor after 15 minutes or 45 minutes treatment with 10 nM Compound 102, 100 nM Compound 102, or control (vehicle). FIG. 5B shows a graph of fold- stimulation of P13K after 60 minutes treatment with EPO, Compound 101, or control (vehicle). FIG. 5C shows fold stimulation of GATA1 after 60 minutes treatment with EPO, Compound 101, or control (vehicle).
[0056] FIG. 6A shows the results of an electrophoretic mobility shift assay for GATA1 in UT7 cells after 30 minute treatments with test compounds. FIG. 6B shows a graph of binding intensity for GATA1 in UT7 cells after 30 minute treatments with test compounds.
[0057] FIG. 7 shows a graph of relative cell viability of an EPO dependent cell line treated with EPO receptor siRNA, GATA1 siRNA, or no siRNA. Cells were further treated with 1 U/ml EPO, 30 nM Compound 101, or control (vehicle).
DETAILED DESCRIPTION
[0058] The present invention relates to methods and uses of certain compounds and compositions with activity that modulate activity of the EPO receptor. In some embodiments, certain compounds and compositions that modulate activity of the EPO also include erythropoiesis stimulating activity. In some embodiments, compounds and compositions that modulate activity of the EPO receptor can include non-peptidyl small molecule mimetic s of EPO.
[0059] EPO acts on the homodimeric EPO receptor to stimulate proliferation of erythroid progenitor cells and induce their survival and differentiation into red blood cells. Various recombinant human EPO derivatives, also known as erythropoiesis- stimulating agents, are marketed or in clinical development for the treatment of anemia due to renal failure or cancer chemotherapy. However, treatment with erythropoiesis- stimulating agent is associated with an increased risk of adverse cardiovascular complications in patients with kidney disease, and may be related to an increase in mortality in cancer patients, when it is used to increase hemoglobin levels above 13.0 g/dl (Rizzo JD, et al. 2008 Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/ American Society of Hematology clinical practice guidelines update. J Clin Oncol 26:132-149). Moreover, such undesirable effects are known to increase the risk of heart attack, heart failure, stroke, or blood clots in patients. Further shortcomings related to treatment with erythropoiesis- stimulating agents include relatively high cost of manufacture, administration though parenteral route, i.e. injection, and potential immunogenicity of erythropoiesis-stimulating agents.
[0060] Some embodiments of the present invention relate to the use of a non- peptidyl small molecules that selectively activate EPO receptor function. It has been discovered that some selective agonists display an efficacy partial to the maximal effect induced by EPO. Accordingly, some compounds and compositions provided herein are most advantageous in at least the lack excessive erythropoietic stimulation that may contribute to the adverse effects of erythropoiesis-stimulating agents. In addition, some compounds and compositions provided herein include further advantages over conventional erythropoiesis-stimulating agents. For example, some compounds and compositions provided herein are less likely to stimulate the production of neutralizing antibodies, can be orally administrable, thus eliminating the need for injections, have longer serum half-life, have an increased bioavailability, and/or can be produced at a lower cost than erythropoiesis-stimulating agents.
[0061] The EPO receptor is a 59 kDa homodimeric protein and is a member of the cytokine receptor family. Binding of EPO to the EPO receptor induces a conformational change resulting in the autophosphorylation of kinases such as Jak2, and activation of several intracellular signaling pathways (FIG. 1). The intracellular signaling pathways include Ικβ/ΝΡκβ, Ras/MAPK/ERK, STAT5, P 13/AKT/G ATA 1 pathways associated with cellular functions such as anti-apoptosis, proliferation, and differentiation of erythroid progenitor cells into red blood cells (Richmond TD, et al. 2005 Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 15:146-155).
[0062] In some embodiments, the compositions and methods provided herein can be used to treat disorders associated with anemia, such as chronic kidney disease, congestive heart failure, rheumatoid arthritis, and other chronic inflammatory diseases. In addition, anemia is a frequent complication in patients with cancer, oftentimes due to impaired EPO production, bone marrow response, iron availability, and red blood cell survival (Adamson JW. 2008 The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2008:159-65). Anemia may also be associated with chemotherapy, especially when platinum-based therapy is used. However, despite evidence that some patients benefit from treatment with erythropoiesis- stimulating agent, some studies have also shown that erythropoiesis-stimulating agent can increase the risk of tumor growth and shorten survival in anemic cancer patients (Rizzo JD, et al. 2008 Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guidelines update. J Clin Oncol 26:132-149)
[0063] Additional advantages associated with some of the compounds and compositions provided herein relate to the selective activation of particular pathways. Some of the compounds and compositions provided herein selectively signal through one or more of the intracellular signaling pathways modulated by the EPO receptor. For example, some of the compounds and compositions provided herein selectively signal through the P13/AKT/GATA1 that is associated with differentiation of bone marrow hematopoietic cells (BM-HCs) into erythrocytes. The survival of erythroid progenitor cells and their terminal differentiation into RBCs is associated with EPO/EPO receptor interactions and GATAl transcription factor activity (FIG. 2). The erythroid development pathway includes cells at various stages such as: EMP, BFU-E, CFU-E, pro-erythroblast, basophilic erythroblast, polychromatic erythroblast, orthochromatic erythroblast, reticulocyte, and erythrocyte. An increase in GATAl cellular levels causes erythroid cells to develop the erythrocyte phenotype (e.g., expression of hemoglobin), and triggers the transition of rapidly proliferating erythroid progenitor cells to mature erythroid cells (Ferreira R, et al. 2005 GATAl function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol 25:1215-27). The selective activation of particular pathways and not other pathways may reduce the risk of tumor growth in cancer patients The risk of tumor growth may be increased and survival may be shortened in cancer patients when particular pathways are stimulated.
[0064] Data provided herein demonstrate certain compounds disclosed herein include selective EPOR agonists that unlike erythropoiesis-stimulating agents, selectively activates the EPO receptor/PI3K/GATAl signal transduction pathway resulting in survival and differentiation of BM-HCs into erythrocytes. The selective agonists display an efficacy partial to the maximal effect induced by EPO, and lack excessive erythropoietic stimulation that may possibly contribute to the adverse effects of erythropoiesis- stimulating agents.
[0065] Administration of erythropoiesis- stimulating agents generally require a patient to undergo a drug titration procedure in order to balance therapeutic effects with undesirable side effects. Drug titration can include administering an initial dose of a drug comprising relatively small dosage, then monitoring the patient's side effects, and subsequently increasing the dosage of the drug until the targeted benefits are achieved or until the patient's side effects meet or exceed a desired threshold. The dosage is increased until the patient's side effects increase to the point that they are judged to warrant no further increase in dosage or that the patient reaches a maximum recommended dosage. Drug titration techniques require face-to-face interaction with medical personnel, which consumes resources and is inconvenient for the patient. It will be understood that certain compounds and compositions provided herein with partial EPO receptor modulatory activity may not require a drug titration procedure. Accordingly, some embodiments of the present invention include administering certain compounds and compositions provided herein without a drug titration procedure.
Definitions
[0066] Unless specific definitions are provided, the nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those known in the art. Standard chemical symbols are used interchangeably with the full names represented by such symbols. Thus, for example, the terms "hydrogen" and "H" are understood to have identical meaning. Standard techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Reactions and purification techniques may be performed e.g., using kits according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al. Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference in its entirety for any purpose.
[0067] As used herein, the following terms are defined with the following meanings, unless expressly stated otherwise.
[0068] The term "selective binding compound" refers to a compound that selectively binds to any portion of one or more target.
[0069] The term "selective HGF receptor binding compound" refers to a compound that selectively binds to any portion of a HGF receptor.
[0070] The term "selective EPO receptor binding compound" refers to a compound that selectively binds to any portion of a EPO receptor.
[0071] The term "selectively binds" refers to the ability of a selective binding compound to bind to a target receptor with greater affinity than it binds to a non-target receptor. In certain embodiments, selective binding refers to binding to a target with an affinity that is at least 10, 50, 100, 250, 500, or 1000 times greater than the affinity for a non-target.
[0072] The term "target receptor" refers to a receptor or a portion of a receptor capable of being bound by a selective binding compound. In certain embodiments, a target receptor is a HGF receptor. In some embodiments, a target receptor is an EPO receptor.
[0073] The term "modulator" refers to a compound that alters an activity. For example, a modulator may cause an increase or decrease in the magnitude of a certain activity compared to the magnitude of the activity in the absence of the modulator. In certain embodiments, a modulator is an inhibitor, which decreases the magnitude of one or more activities. In certain embodiments, an inhibitor completely prevents one or more biological activities. In certain embodiments, a modulator is an activator, which increases the magnitude of at least one activity. In certain embodiments the presence of a modulator results in an activity that does not occur in the absence of the modulator.
[0074] The term "selective modulator" refers to a compound that selectively modulates a target activity.
[0075] The term "selective HGF modulator" refers to a compound that selectively modulates at least one HGF activity. The term selective HGF modulator includes, but is not limited to "HGF mimic" which refers to a compound, the presence of which results in at least one HGF activity. [0076] The term "selective EPO receptor modulator" refers to a compound that selectively modulates at least one EPO receptor activity. The term "selective EPO receptor modulator" includes, but is not limited to "EPO mimic" which refers to a compound, the presence of which results in at least one EPO receptor activity.
[0077] The term "selectively modulates" refers to the ability of a selective modulator to modulate a target activity to a greater extent than it modulates a non-target activity.
[0078] The term "target activity" refers to a biological activity capable of being modulated by a selective modulator. Certain exemplary target activities include, but are not limited to, binding affinity, signal transduction, enzymatic activity, the proliferation and/or differentiation of progenitor cells, generation of platelets, and alleviation of symptoms of a disease or condition.
[0079] The term "HGF activity" refers to a biological activity that results, either directly or indirectly from the presence of HGF. Exemplary HGF activities include, but are not limited to, proliferation and or differentiation of progenitor cells to produce platelets; hematopoiesis; growth and/or development of glial cells; repair of nerve cells; and alleviation of thrombocytopenia. In some embodiments, an example of HGF activity is EPO receptor activity.
[0080] The term "receptor mediated activity" refers to any biological activity that results, either directly or indirectly, from binding of a ligand to a receptor.
[0081] The term "agonist" refers to a compound, the presence of which results in a biological activity of a receptor that is the same as the biological activity resulting from the presence of a naturally occurring ligand for the receptor.
[0082] The term "partial agonist" refers to a compound, the presence of which results in a biological activity of a receptor that is of the same type as that resulting from the presence of a naturally occurring ligand for the receptor, but of a lower magnitude.
[0083] The term "partial EPO receptor agonist" refers to a compound, the presence of which results in a biological activity of EPO receptor that is of the same type as that resulting from the presence of naturally occurring EPO, but which is less than the maximum effect induced by EPO.
[0084] The term "antagonist" refers to a compound, the presence of which results in a decrease in the magnitude of a biological activity of a receptor. In certain embodiments, the presence of an antagonist results in complete inhibition of a biological activity of a receptor.
[0085] The term "alkyl" refers to a branched or unbranched fully saturated acyclic aliphatic hydrocarbon group. An alkyl may be branched or straight chain. Alkyls may be substituted or unsubstituted. Alkyls include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, and the like, each of which may be optionally substituted.
[0086] In certain embodiments, an alkyl comprises 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as "1 to 20" refers to each integer in the given range; e.g., "1 to 20 carbon atoms" means that an alkyl group may comprise only 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the term "alkyl" also includes instances where no numerical range of carbon atoms is designated). An alkyl may be designated as "Ci-C6 alkyl" or similar designations. By way of example only, "CrC4 alkyl" indicates an alkyl having one, two, three, or four carbon atoms, e.g., the alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, zso-butyl, sec-butyl, and tert-butyl.
[0087] The term "alkenyl" used herein refers to a monovalent straight or branched chain aliphatic hydrocarbon radical of from two to twenty carbon atoms containing at least one carbon-carbon double bond including, but not limited to, 1- propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl, and the like. In certain embodiments, an alkenyl comprises 2 to 20 carbon atoms (whenever it appears herein, a numerical range such as "2 to 20" refers to each integer in the given range; e.g., "2 to 20 carbon atoms" means that an alkenyl group may comprise only 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the term "alkenyl" also includes instances where no numerical range of carbon atoms is designated). An alkenyl may be designated as "C2-C6 alkenyl" or similar designations. By way of example only, "C2-C4 alkenyl" indicates an alkenyl having two, three, or four carbon atoms, e.g., the alkenyl is selected from ethenyl, propenyl, and butenyl.
[0088] The term "alkynyl" used herein refers to a monovalent straight or branched chain aliphatic hydrocarbon radical of from two to twenty carbon atoms containing at least one carbon-carbon triple bond including, but not limited to, 1- propynyl, 1-butynyl, 2-butynyl, and the like. In certain embodiments, an alkynyl comprises 2 to 20 carbon atoms (whenever it appears herein, a numerical range such as "2 to 20" refers to each integer in the given range; e.g., "2 to 20 carbon atoms" means that an alkynyl group may comprise only 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the term "alkynyl" also includes instances where no numerical range of carbon atoms is designated). An alkynyl may be designated as "C2-C6 alkynyl" or similar designations. By way of example only, "C2-C4 alkynyl" indicates an alkenyl having two, three, or four carbon atoms, e.g., the alkenyl is selected from ethynyl, propynyl, and butynyl.
[0089] The term "cycloalkyl" used herein refers to saturated aliphatic ring system radical having three to twenty carbon atoms. A cycloalkyl refers to monocyclic and polycyclic saturated aliphatic ring system including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[4.4.0]decanyl, bicyclo[2.2.1]heptanyl, adamantyl, norbornyl, and the like. In certain embodiments, a cycloalkyl comprises 3 to 20 carbon atoms (whenever it appears herein, a numerical range such as "3 to 20" refers to each integer in the given range; e.g., "3 to 20 carbon atoms" means that a cycloalkyl group may comprise only 3 carbon atoms, etc., up to and including 20 carbon atoms, although the term "cycloalkyl" also includes instances where no numerical range of carbon atoms is designated). A cycloalkyl may be designated as "C3-C7 cycloalkyl" or similar designations. By way of example only, "C3-C6 cycloalkyl" indicates an alkenyl having two, three, four, five or six carbon atoms, e.g., the cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0090] The term "cycloalkenyl" used herein refers to aliphatic ring system radical having three to twenty carbon atoms having at least one carbon-carbon double bond in the ring. A cycloalkenyl refers to monocyclic and polycyclic unsaturated aliphatic ring system including, but are not limited to, cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, bicyclo[3.1.0]hexyl, norbornylenyl, Ι, -bicyclopentenyl, and the like. In certain embodiments, a cycloalkenyl comprises 3 to 20 carbon atoms (whenever it appears herein, a numerical range such as "3 to 20" refers to each integer in the given range; e.g., "3 to 20 carbon atoms" means that a cycloalkenyl group may comprise only 3 carbon atoms, etc., up to and including 20 carbon atoms, although the term "cycloalkenyl" also includes instances where no numerical range of carbon atoms is designated). A cycloalkenyl may be designated as "C3-C7 cycloalkenyl" or similar designations. By way of example only, "C3-C6 cycloalkenyl" indicates an alkenyl having two, three, four, five or six carbon atoms, e.g., the cycloalkyl is selected from cyclopropenyl, cyclobutenyl, cyclopentenyl, and cyclohexenyl.
[0091] The term "haloalkyl" refers to an alkyl in which at least one hydrogen atom is replaced with a halogen atom. In certain of the embodiments in which two or more hydrogen atom are replaced with halogen atoms, the halogen atoms are all the same as one another. In certain of such embodiments, the halogen atoms are not all the same as one another.
[0092] The term "heteroalkyl" refers to a group comprising an alkyl and one or more heteroatoms. Certain heteroalkyls are acylalkyls, in which the one or more heteroatoms are within an alkyl chain. Examples of heteroalkyls include, but are not limited to, CH3C(=0)CH2-, CH3C(=0)CH2CH2-, CH3CH2C(=0)CH2CH2-, CH3C(=0)CH2CH2CH2-, CH3OCH2CH2-, CH3NHCH2-, CH3NHC(=0)CH2-, and the like.
[0093] The term "alkoxy" used herein refers to straight or branched chain alkyl radical covalently bonded to the parent molecule through an — O— linkage. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, n-butoxy, sec-butoxy, t-butoxy and the like. An alkoxy may be designated as "Ci-C6 alkoxy" or similar designations. By way of example only, "C1-C4 alkoxy" indicates an alkyl having one, two, three, or four carbon atoms, e.g., the alkoxy is selected from methoxy, ethoxy, propoxy, zso-propoxy, butoxy, zso-butoxy, sec-butoxy, and tert-butoxy.
[0094] The term "olefin" refers to a C=C bond.
[0095] The term "alkylideneamino" used herein refers to a moiety of from one to twenty carbon atoms containing at least one carbon-nitrogen double bond where the moiety is connected to the main group through the nitrogen, including, but not limited to, methylideneamino, ethylideneamino, methylethylideneamino, propylideneamino, 1- methylpropylideneaminyl, 2-methylpropylideneamino, butylideneamino, 1- methylbutylideneamino , 2-methylbutylideneamino , cyclopropylideneamino , cyclobutylideneamino, cyclopentylideneamino, cyclohexylideneamino and the like.
[0096] The term "carbocycle" refers to a group comprising a covalently closed ring, wherein each of the atoms forming the ring is a carbon atom. Carbocylic rings may be formed by three, four, five, six, seven, eight, nine, or more than nine carbon atoms. Carbocycles may be optionally substituted. [0097] The term "heterocycle" refers to a group comprising a covalently closed ring wherein at least one atom forming the ring is a heteroatom. Heterocyclic rings may be formed by three, four, five, six, seven, eight, nine, or more than nine atoms. Any number of those atoms may be heteroatoms (i.e., a heterocyclic ring may comprise one, two, three, four, five, six, seven, eight, nine, or more than nine heteroatoms). In heterocyclic rings comprising two or more heteroatoms, those two or more heteroatoms may be the same or different from one another. Heterocycles may be optionally substituted. Binding to a heterocycle can be at a heteroatom or via a carbon atom. For example, binding for benzo-fused derivatives, may be via a carbon of the benzenoid ring. Examples of heterocycles include, but are not limited to the following:
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000020_0002
wherein D, E, F, and G independently represent a heteroatom. Each of D, E, F, and G may be the same or different from one another. Heterocycles may be aromatic heterocycles (i.e., heteroaryls) or non-aromatic heterocycles. In some embodiments, a non-aromatic heterocycle is a fully statured covalently closed ring (for example, piperidine, pyrrolidine, morpholine, piperazine, and the like).
[0098] The term "heteroatom" refers to an atom other than carbon or hydrogen. Heteroatoms are typically independently selected from oxygen, sulfur, nitrogen, and phosphorus, but are not limited to those atoms. In embodiments in which two or more heteroatoms are present, the two or more heteroatoms may all be the same as one another, or some or all of the two or more heteroatoms may each be different from the others.
[0099] The term "aromatic" refers to a group comprising a covalently closed ring having a delocalized π-electron system. Aromatic rings may be formed by five, six, seven, eight, nine, or more than nine atoms. Aromatics may be optionally substituted. Examples of aromatic groups include, but are not limited to phenyl, naphthalenyl, phenanthrenyl, anthracenyl, tetralinyl, fluorenyl, indenyl, and indanyl. The term aromatic includes, for example, benzenoid groups, connected via one of the ring-forming carbon atoms, and optionally carrying one or more substituents selected from an aryl, a heteroaryl, a cycloalkyl, a non-aromatic heterocycle, a halo, a hydroxy, an amino, a cyano, a nitro, an alkylamido, an acyl, a Ci_6 alkoxy, a Ci_6 alkyl, a Ci_6 hydroxyalkyl, a Ci_6 aminoalkyl, a C1-6 alkylamino, an alkylsulfenyl, an alkylsulfinyl, an alkylsulfonyl, an sulfamoyl, or a trifluoromethyl. In certain embodiments, an aromatic group is substituted at one or more of the para, meta, and/or ortho positions. Examples of aromatic groups comprising substitutions include, but are not limited to, phenyl, 3-halophenyl, 4- halophenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 3-aminophenyl, 4-aminophenyl, 3- methylphenyl, 4-methylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4- trifluoromethoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, dimethylphenyl, naphthyl, hydroxynaphthyl, hydroxymethylphenyl, (trifluoromethyl)phenyl, alkoxyphenyl, 4- morpholin-4-ylphenyl, 4-pyrrolidin-l-ylphenyl, 4-pyrazolylphenyl, 4-triazolylphenyl, and 4-(2-oxopyrrolidin- 1 -yl)phenyl.
[0100] The term "aryl" refers to an aromatic group wherein each of the atoms forming the ring is a carbon atom. Aryl rings may be formed by five, six, seven, eight, nine, or more than nine carbon atoms. Aryl groups may be optionally substituted.
[0101] The term "heteroaryl" refers to an aromatic mono-, bi- or tricyclic ring system wherein at least one atom forming the aromatic ring system is a heteroatom. Heteroaryl rings may be formed by three, four, five, six, seven, eight, nine, or more than nine atoms. Heteroaryl groups may be optionally substituted. Examples of heteroaryl groups include, but are not limited to, aromatic C3_8 heterocyclic groups comprising one oxygen or sulfur atom or up to four nitrogen atoms, or a combination of one oxygen or sulfur atom and up to two nitrogen atoms, and their substituted as well as benzo- and pyrido-fused derivatives, for example, connected via one of the ring-forming carbon atoms. In certain embodiments, heteroaryl groups are optionally substituted with one or more substituents, independently selected from halo, hydroxy, amino, cyano, nitro, alkylamido, acyl, Ci_6-alkoxy, Ci_6-alkyl, Ci_6-hydroxyalkyl, Ci_6-aminoalkyl, Ci_6- alkylamino, alkylsulfenyl, alkylsulfinyl, alkylsulfonyl, sulfamoyl, or trifluoromethyl. In some embodiments, the substituents are halo, hydroxy, cyano, 0-Ci_6-alkyl, Ci_6-alkyl, hydroxy-Ci-6-alkyl, and amino-Ci-6-alkyl. Examples of heteroaryl groups include, but are not limited to, unsubstituted and mono- or di-substituted derivatives of furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, indole, oxazole, benzoxazole, isoxazole, benzisoxazole, thiazole, benzothiazole, isothiazole, imidazole, benzimidazole, pyrazole, indazole, tetrazole, quinoline, isoquinoline, pyridazine, pyrimidine, purine and pyrazine, furazan, 1,2,3-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, triazole, benzotriazole, pteridine, phenoxazole, oxadiazole, benzopyrazole, quinolizine, cinnoline, phthalazine, quinazoline, and quinoxaline.
[0102] The term "non-aromatic ring" refers to a group comprising a covalently closed ring that does not have a delocalized π-electron system.
[0103] The term "non-aromatic heterocycle" refers to a group comprising a non-aromatic ring wherein one or more atoms forming the ring is a heteroatom. Non- aromatic heterocyclic rings may be formed by three, four, five, six, seven, eight, nine, or more than nine atoms. Non-aromatic heterocycles may be optionally substituted. In certain embodiments, non-aromatic heterocycles comprise one or more carbonyl or thiocarbonyl groups such as, for example, oxo- and thio-containing groups. Examples of non-aromatic heterocycles include, but are not limited to, lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, tetrahydrothiopyran, 4H-pyran, tetrahydropyran, piperidine, 1,3-dioxin, 1,3-dioxane, 1,4-dioxin, 1,4-dioxane, piperazine, 1,3-oxathiane, 1,4-oxathiin, 1,4-oxathiane, tetrahydro-l,4-thiazine, 2H-l,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, morpholine, trioxane, hexahydro-l,3,5-triazine, tetrahydrothiophene, tetrahydrofuran, pyrroline, pyrrolidine, pyrrolidone, pyrrolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, 1,3-dioxole, 1,3-dioxolane, 1,3-dithiole, 1,3- dithiolane, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine, and 1,3-oxathiolane.
[0104] The term "polycyclic heterocyclyl" used herein refers a bicyclic moiety or tricyclic moiety optionally containing one or more heteroatoms wherein at least one of the rings is an aryl or heteroaryl ring and at least one of the rings is non-aromatic. The bicyclic moiety contains two rings wherein the rings are fused. The bicyclic moiety can be appended at any position of the tw a
radical including but not limited to:
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000023_0002
The tricyclic moiety contains a bicyclic moiety with an additional fused ring. The tricyclic moiety can be appended at any position of the three rings. For example, tricyclic moiety may refer to a radical
including but not limited to:
Figure imgf000023_0003
[0105] The term "arylalkyl" refers to a group comprising an aryl group bound to an alkyl group.
[0106] The term "carbocycloalkyl" refers to a group comprising a carbocyclic cycloalkyl ring. Carbocycloalkyl rings may be formed by three, four, five, six, seven, eight, nine, or more than nine carbon atoms. Carbocycloalkyl groups may be optionally substituted.
[0107] The term "ring" refers to any covalently closed structure. Rings include, for example, carbocycles (e.g. , aryls and cycloalkyls), heterocycles (e.g. , heteroaryls and non-aromatic heterocycles), aromatics (e.g. , aryls and heteroaryls), and non-aromatics (e.g. , cycloalkyls and non-aromatic heterocycles). Rings may be optionally substituted. Rings may form part of a ring system.
[0108] The term "ring system" refers to a either a single ring or two or more rings, wherein, if two or more rings are present, the two or more of the rings are fused. The term "fused" refers to structures in which two or more rings share one or more bonds.
[0109] The term "spacer" refers to an atom or group of atoms that separate two or more groups from one another by a desired number of atoms. For example, in certain embodiments, it may be desirable to separate two or more groups by one, two, three, four, five, six, or more than six atoms. In such embodiments, any atom or group of atoms may be used to separate those groups by the desired number of atoms. Spacers are optionally substituted. In certain embodiments, a spacer comprises saturated or unsaturated alkyls, heteroalkyls and/or haloalkyls. In certain embodiments, a spacer comprises atoms that are part of a ring.
[0110] Solely for the purposes of illustration, and without limiting the above definition, some examples of spacers are provided. Examples of 1 atom spacers include, but are not limited to, the following:
Figure imgf000024_0001
where A and E represent groups which are separated by the desired number of atoms. Examples of 2 atom spacers include, but are not limited to, the following:
Figure imgf000024_0002
where A and E represent groups which are separated by the desired number of atoms.
[0111] Examples of 3 atom spacers include, but are not limited to, the following:
Figure imgf000024_0003
Figure imgf000025_0001
where A and E represent groups which are separated by the desired number of atoms. As is evident from the above examples, the atoms that create the desired separation may themselves be part of a group. That group may be, for example, an alkyl, heteroalkyl, haloalkyl, heterohaloalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, non-aromatic heterocycle, or substituted alkyl all of which are optionally substituted. Thus the term "1- 5 atom spacer" refers to a spacer that separates two groups by 1, 2, 3, 4, or 5 atoms and does not indicate the total size of the group that constitutes the spacer.
[0112] As used herein, the term "linked to form a ring" refers to instances where two atoms that are bound either to a single atom or to atoms that are themselves ultimately bound, are each bound to a linking group, such that the resulting structure forms a ring. That resulting ring comprises the two atoms that are linked to form a ring, the atom (or atoms) that previously linked those atoms, and the linker. For example, if A and E below are "linked to form a ring"
£( N
3_J^Q A /
the resulting ring includes A, E, the C (carbon) or N (nitrogen) to which they are attached, and a linking group. Unless otherwise indicated, that linking group may be of any length and may be optionally substituted. Referring to the above example, resulting structures include, but are not limited to:
Figure imgf000026_0001
[0113] In certain embodiments, the two substituents that together form a ring are not immediately bound to the same atom. For example, if A and E, below, are linked to form a ring:
A E
,/ w s the resulting ring comprises A, E, the two atoms that already link A and E and a linking group. Examples of resulting structures include, but are not limited to:
A E A E
. vw ; , j»w ; and the like.
[0114] In certain embodiments, the atoms that together form a ring are separated by three or more atoms. For example, if A and E, below, are linked to form a ring:
Figure imgf000027_0001
, the resulting ring comprises A, E, the 3 atoms that already link A and E, and a linking group. Examples of resulting structures include, but are not limited to:
A^^E
,Λ/w "w s and the like.
[0115] As used herein, the term "together form a bond" refers to the instance in which two substituents to neighboring atoms are null the bond between the neighboring atoms becomes a double bond. For example, if A and E below "together form a bond"
A E
Rx the resulting structure is: FRL , Ry
[0116] The term "null" refers to a group being absent from a structure. For example, in the structure
Figure imgf000027_0002
, where in certain instances X is N (nitrogen), if X is N (nitrogen), one of R' or R" is null, meaning that only three groups are bound to the N (nitrogen).
[0117] The substituent "R" appearing by itself and without a number designation refers to a substituent selected from alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and non-aromatic heterocycle (bonded through a ring carbon).
[0118] The term "O-carboxy" refers to the group consisting of formula RC(=0)0-.
[0119] The term "C-carboxy" refers to the group consisting of formula -C(=0)OR.
[0120] The term "acetyl" refers to the group consisting of formula -C(=0)CH3.
[0121] The term "trihalomethanesulfonyl" refers to the group consisting of formula X3CS(=0)2- where X is a halogen.
[0122] The term "cyano" refers to the group consisting of formula -CN.
[0123] The term "isocyanato" refers to the group consisting of formula -NCO. [0124] The term "thiocyanato" refers to the group consisting of formula -CNS.
[0125] The term "isothiocyanato" refers to the group consisting of formula
-NCS.
[0126] The term "sulfonyl" refers to the group consisting of formula -S(=0)-R.
[0127] The term "S-sulfonamido" refers to the group consisting of formula -S(=0)2NR.
[0128] The term "N-sulfonamido" refers to the group consisting of formula RS(=0)2NH-.
[0129] The term "trihalomethanesulfonamido" refers to the group consisting of formula X3CS(=0)2NR-.
[0130] The term "O-carbamyl" refers to the group consisting of formula -OC(=0)-NR.
[0131] The term "N-carbamyl" refers to the group consisting of formula ROC(=0)NH-.
[0132] The term "O-thiocarbamyl" refers to the group consisting of formula -OC(=S)-NR.
[0133] The term "N-thiocarbamyl" refers to the group consisting of formula ROC(=S)NH-.
[0134] The term "C-amido" refers to the group consisting of formula -C(=0)-NR2.
[0135] The term "N-amido" refers to the group consisting of formula RC(=0)NH-.
[0136] The term "oxo" refers to the group consisting of formula =0.
[0137] The term "keto" and "carbonyl" used herein refers to C=0.
[0138] The term "thiocarbonyl" used herein refers to C=S.
[0139] The term "ester" refers to a chemical moiety with formula -(R)n-C(=0)OR', where R and R' are independently selected from alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and non-aromatic heterocycle (bonded through a ring carbon), where n is 0 or 1.
[0140] The term "amide" refers to a chemical moiety with formula -(R)n-C(=0)NHR' or -(R)n-NHC(=0)R', where R is selected from alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), where n is 0 or 1 and R' is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), where n is 0 or 1. In certain embodiments, an amide may be an amino acid or a peptide.
[0141] The term "amino" refers to a chemical moiety with formula - NHR'R", where R' and R" are each independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon).
[0142] The terms "amine," "hydroxy," and "carboxyl" include such groups that have been esterified or amidified. Procedures and specific groups used to achieve esterification and amidification are known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3 Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein in its entirety.
[0143] Unless otherwise indicated, the term "optionally substituted," refers to a group in which none, one, or more than one of the hydrogen atoms has been replaced with one or more group(s) individually and independently selected from: alkyl, alkenyl, cycloalkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, aryl, arylalkyl, alkenylO-, arylalkylO- arylalkylNH- alkenylO-, cycloalkylC(=0)-, arylC(=0)-, arylC(=0)NH- arylNHC(=0)-, aryl(CH2)0-3O(CH2)0-3-, HO(CH2)i_3NH- HO(CH2)i_30- HO(CH2)i-3- HO(CH2)i_30(CH2)i_3-, -C(=0)NHNH2, heteroaryl, heterocycle, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, oxo, thiocarbonyl, O- carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S- sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and amino, including mono- and di-substituted amino groups, and the protected derivatives of amino groups. Such protective derivatives (and protecting groups that may form such protective derivatives) are known to those of skill in the art and may be found in references such as Greene and Wuts, above. When the group contains a nitrogen, or a sulfur, an oxo as a substituent also includes oxides, for example pyridine-N-oxide, thiopyran sulfoxide and thiopyran-S,S- dioxide. In embodiments in which two or more hydrogen atoms have been substituted, the substituent groups may together form a ring. [0144] The term "stereoisomers" as used herein means isomers that possess identical constitution, but which differ in the arrangement of their atoms in space. Including, for example, all enantiomers, diastereomers, geometric isomers, and atropisomers.
[0145] Wherever a substituent as depicted as a di-radical (i.e., has two points of attachment to the rest of the molecule), it is to be understood that the substituent can be attached in any directional configuration unless otherwise indicated. Thus, for example, a substituent depicted as -AE- or Y ¾ A\P tA includes the substituent being oriented such that the A is attached at the leftmost attachment point of the molecule as well as attached at the rightmost attachment point of the molecule.
[0146] It is to be understood that certain radical naming conventions can include either a mono-radical or a di-radical, depending on the context. For example, where a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a di-radical. A substituent identified as alkyl, that requires two points of attachment, includes di-radicals such as -CH2-, -CH2CH2-, - CH2CH(CH3)CH2-, and the like; a substituent depicted as alkoxy that requires two points of attachment, includes di-radicals such as -OCH2- -OCH2CH2- -OCH2CH(CH3)CH2- and the like: and a substituent depicted as ar lC(=0)- that requires two points of
attachment, includes di-radicals such as
Figure imgf000030_0001
and the like.
[0147] Throughout the specification, groups and substituents thereof can be chosen by one skilled in the field to provide stable moieties and compounds.
[0148] The term "carrier" refers to a compound that facilitates the incorporation of another compound into cells or tissues. For example, dimethyl sulfoxide (DMSO) is a commonly used carrier for improving incorporation of certain organic compounds into cells or tissues.
[0149] The term "pharmaceutical agent" refers to a chemical compound or composition capable of inducing a desired therapeutic effect in a patient. In certain embodiments, a pharmaceutical agent comprises an active agent, which is the agent that induces the desired therapeutic effect. In certain embodiments, a pharmaceutical agent comprises a prodrug. In certain embodiments, a pharmaceutical agent comprises inactive ingredients such as carriers, excipients, and the like.
[0150] The term "therapeutically effective amount" refers to an amount of a pharmaceutical agent sufficient to achieve a desired therapeutic effect.
[0151] The term "prodrug" refers to an pharmaceutical agent that is converted from a less active form into a corresponding more active form in vivo.
[0152] The term "pharmaceutically acceptable" refers to a formulation of a compound that does not significantly abrogate the biological activity, a pharmacological activity and/or other properties of the compound when the formulated compound is administered to a patient. In certain embodiments, a pharmaceutically acceptable formulation does not cause significant irritation to a patient.
[0153] The term "co-administer" refers to administering more than one pharmaceutical agent to a patient. In certain embodiments, co-administered pharmaceutical agents are administered together in a single dosage unit. In certain embodiments, co-administered pharmaceutical agents are administered separately. In certain embodiments, co-administered pharmaceutical agents are administered at the same time. In certain embodiments, co-administered pharmaceutical agents are administered at different times.
[0154] The term "patient" includes human and animal subjects.
[0155] The term "substantially pure" means an object species (e.g., compound) is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition). In certain embodiments, a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all species present. In certain embodiments, a substantially pure composition will comprise more than about 80%, 85%, 90%, 95%, or 99% of all species present in the composition. In certain embodiments, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single species.
[0156] The term "tissue-selective" refers to the ability of a compound to modulate a biological activity in one tissue to a greater or lesser degree than it modulates a biological activity in another tissue. The biological activities in the different tissues may be the same or they may be different. The biological activities in the different tissues may be mediated by the same type of target receptor. For example, in certain embodiments, a tissue-selective compound may modulate receptor mediated biological activity in one tissue and fail to modulate, or modulate to a lesser degree, receptor mediated biological activity in another tissue type.
[0157] The term "monitoring" refers to observing an effect or absence of any effect. In certain embodiments, one monitors cells after contacting those cells with a compound of the present embodiments. Examples of effects that may be monitored include, but are not limited to, changes in cell phenotype, cell proliferation, receptor activity, or the interaction between a receptor and a compound known to bind to the receptor.
[0158] The term "cell phenotype" refers to physical or biological characteristics. Examples of characteristics that constitute phenotype included, but are not limited to, cell size, cell proliferation, cell differentiation, cell survival, apoptosis (cell death), or the utilization of a metabolic nutrient (e.g., glucose uptake). Certain changes or the absence of changes in cell phenotype are readily monitored using techniques known in the art.
[0159] The term "cell proliferation" refers to the rate at which cells divide. In certain embodiments, cells are in situ in an organism. In certain embodiments, cell are grown in vitro in a vessel. The number of cells growing in a vessel can be quantified by a person skilled in the art (e.g., by counting cells in a defined area using a microscope or by using laboratory apparatus that measure the density of cells in an appropriate medium). One skilled in that art can calculate cell proliferation by determining the number of cells at two or more times.
[0160] The term "contacting" refers to bringing two or more materials into close enough proximity that they may interact. In certain embodiments, contacting can be accomplished in a vessel such as a test tube, a petri dish, or the like. In certain embodiments, contacting may be performed in the presence of additional materials. In certain embodiments, contacting may be performed in the presence of cells. In certain of such embodiments, one or more of the materials that are being contacted may be inside a cell. Cells may be alive or may dead. Cells may or may not be intact. Certain compounds
[0161] Certain compounds that modulate one or more HGF activity and/or bind to HGF receptors play a role in health. In certain embodiments, compounds are useful for treating any of a variety of diseases or conditions.
[0162] Certain embodiments provide selective HGF modulators. Certain embodiments provide selective HGF receptor binding agents. Certain embodiments provide methods of making and methods of using selective HGF modulators and/or selective HGF receptor binding agents. In certain embodiments, selective HGF modulators are agonists, partial agonists, and/or antagonists for the HGF receptor.
[0163] The compounds disclosed herein can be used alone or in combination with other agents, for example, to modulate hematopoiesis, erythropoiesis, granulopoiesis, thrombopoiesis, and myelopoiesis. The instant compounds can also be used alone or in combination with other agents in treatment or prevention of a disease or condition caused by abnormal function of hematopoiesis, erythropoiesis, granulopoiesis, thrombopoiesis, and myelopoiesis. Some non-limiting examples of diseases include anemia, neutropenia, thrombocytopenia, cardiovascular disorders, immune/autoimmune disorders, cancers, infectious disorders or diseases, and neurologic disorders.
[0164] One of skill in the art will recognize that analogous synthesis schemes may be used to synthesize similar compounds. One of skill will recognize that compounds of the present embodiments may be synthesized using other synthesis schemes. In certain embodiments, a salt corresponding to any of the compounds provided herein is provided.
[0165] In certain embodiments, a salt corresponding to a selective HGF modulator is provided. In certain embodiments, a salt corresponding to a selective HGF receptor binding agent is provided. In certain embodiments, a salt is obtained by reacting a compound with an acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. In certain embodiments, a salt is obtained by reacting a compound with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as choline, dicyclohexylamine, N-methyl-D- glucamine, tris(hydroxymethyl)methylamine, 4-(2-hydroxyethyl)-morpholine, l-(2- hydroxyethyl)-pyrrolidine, ethanolamine and salts with amino acids such as arginine, lysine, and the like. In certain embodiments, a salt is obtained by reacting a free acid form of a selective HGF modulator or selective HGF binding agent with multiple molar equivalents of a base, such as bis-sodium, bis-ethanolamine, and the like.
[0166] In certain embodiments, a salt corresponding to a compound of the present embodiments is selected from acetate, ammonium, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, cholinate, clavulanate, citrate, dihydrochloride, diphosphate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabanine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, pamoate (embonate), palmitate, pantothenate, phosphate, polygalacturonate, potassium, salicylate, sodium, stearate, subaceatate, succinate, sulfate, tannate, tartrate, teoclate, tosylate, triethiodide, tromethamine, trimethylammonium, and valerate salts.
[0167] In certain embodiments, one or more carbon atoms of a compound of the present embodiments are replaced with silicon. See e.g., WO 03/037905A1; Tacke and Zilch, Endeavour, New Series, 10, 191-197 (1986); Bains and Tacke, Curr. Opin. Drug Discov Devel. Jul:6(4):526-43(2003), all of which are incorporated herein by reference in their entirety. In certain embodiments, compounds comprising one or more silicon atoms possess certain desired properties, including, but not limited to, greater stability and/or longer half-life in a patient, when compared to the same compound in which none of the carbon atoms have been replaced with a silicon atom.
[0168] Some embodiments disclosed herein provide a compound of Formula
I:
Figure imgf000034_0001
and pharmaceutically acceptable salts, esters, stereoisomers, tautomers or prodrugs thereof;
[0169] wherein: [0170] A-J is
Figure imgf000035_0001
or and Q-G is
Figure imgf000035_0002
RB RB
[0171] or A-J is O n i and Q-G is ! N Y O ; NRCRD
[0172] or A-J is
Figure imgf000035_0003
;
RERFN^ J L ^ NRERF
[0173] or A-J is Y O and Q-G is Y O ;
Figure imgf000035_0004
O
L , NRGRH
[0175] or A-J is R HB and Q-G is fY O ;
[0176] A1 is selected from the group consisting of C3-C7 cycloalkenyl, C3-C7 cycloalkyl, CrC6 alkyl, C2-C6 alkenyl, CrC6 alkoxy, -(CH2)mNRPRL, heterocycle, aryl, and heteroaryl, said C3-C7 cycloalkenyl, C3-C7 cycloalkyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R , R , and R , said aryl and heteroaryl in the definition of A are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0177] J1 is selected from the group consisting of -(CH2)rNRBC(=0)(CH2)m- and -(CH2)rNRB(CH2)m_ and -(CH2)r-;
[0178] G1 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G1 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0179] A is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of
1 2 3 2
R , R , and R , said aryl and heteroaryl in the definition of A are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0180] G is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G2 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0181] J is selected from the group consisting of an optionally substituted aryl, -(CH2)mNRBC(=0)(CH2)m-, -(CH2)rO(CH2)m-, -(CH2)rNRB(CH2)m-, and - (CH=CH)m-;
[0182] Q is selected from the group consisting of an optionally substituted aryl, -(CH2)rNRBC(=0)(CH2)m-, -(CH2)rO(CH2)m-, -(CH2)rNRB(CH2)m-, and - (CH=CH)r-;
[0183] A4 is selected from the group consisting of C3-C7 cycloalkenyl, C3-C7 cycloalkyl, Ci-C6 alkyl, Ci-C6 heteroalkyl, C2-C6 alkenyl, Ci-C6 alkoxy, -(CH2)mNRPRL, heterocycle, aryl, and heteroaryl, said C3-C7 cycloalkenyl, C3-C7 cycloalkyl, Ci-C6 alkyl, Ci-C6 heteroalkyl, C2-C6 alkenyl, heterocycle, aryl, and heteroaryl, each optionally
1 2 substituted with one or more substituents selected from the group consisting of R , R , and R3, and said aryl and heteroaryl in the definition of A4 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0184] G4 is selected from the group consisting of C3-C7 cycloalkenyl, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G4 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle; [0185] A5 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R , R , and R , said aryl and heteroaryl in the definition of A are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0186] RA is selected from the group consisting of -(CH2)PRL, -(CH2)pORL, -S02RL, -C(=0)RL, -C(=0)NRNR°, -(CH2)PNRNR° , an aryl and an heteroaryl, said aryl and heteroaryl in the definition of RA are each optionally substituted with halogen, cyano, Ci-C6 haloalkyl, Ci-C6 alkyl, Ci-C6 alkoxy, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, - C(=0)NRNR°, -OC(=0)NRNR°, -NHC(=0)NRNR°, -0(CH2)qNRNR°, -NH(CH2)qNRNR°, -(CH2)pNRNR°, an optionally substituted aryl and an optionally substituted heteroaryl, and said aryl and heteroaryl in the definition of RA are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0187] each R is separately selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C6 alkenyl, and an optionally substituted C3-C7 cycloalkyl;
[0188] each -NR C RD is separately selected, wherein each R C is independently selected from the group consisting of hydrogen and an optionally Ci-C6 alkyl, and each RD is independently selected from the group consisting of aryl and heteroaryl, said aryl and heteroaryl in the definition of RD are each optionally substituted with halogen, cyano, Ci-C6 alkyl, C C6 alkoxy, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, -C(=0)NRNR°, -OC(=0)NRNR°, -NHC(=0)NRNR°, -0(CH2)qNRNR°, -NH(CH2)qNRNR° -(CH2)pNRNR°, an optionally substituted aryl and an optionally substituted heteroaryl, and said aryl and heteroaryl in the definition of RD are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0189] each -NRERF is separately selected, wherein each RE is independently selected from the group consisting of hydrogen and an optionally Ci-C6 alkyl, and each R is independently selected from the group consisting of aryl and heteroaryl, said aryl and heteroaryl in the definition of R are each optionally substituted with halogen, cyano, Ci-C6 alkyl, C C6 alkoxy, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, -C(=0)NRNR°, -OC(=0)NRNR°, -NHC(=0)NRNR°, -0(CH2)qNRNR°, -NH(CH2)qNRNR° -(CH2)pNRNR°, an optionally substituted aryl and an optionally substituted heteroaryl, and said aryl and heteroaryl in the definition of R are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0190] R G G H
within the definition of -NR R is selected from the group consisting of Ci-C6 alkyl, C3-C6 cycloalkyl, C3-C8 cycloalkenyl, Ci-C6 heteroalkyl, Ci-C6 heteroalkenyl, Ci-C6 heteroalkynyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of RG are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle, or RG is -ORL or -NRPRL;
[0191] RH within the definition of -NRGRH is selected from the group consisting of hydrogen, Ci-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, and C1-C3 haloalkyl, NR G R H
or - is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0192] each R1 is separately selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
[0193] each R is separately selected from the group consisting of halogen, -CKCH. OR1, -(CH^OR1, -NRJRK, -(CH^SR1, -C(=0)RL, -(CH2)mRL, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and an optionally substituted C3-C7 cycloalkyl where said C3-C7 cycloalkyl is further optionally fused with aryl or heteroaryl;
[0194] each R is separately selected from the group consisting of halogen, -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mS(O)0-2RM, -(CH2)mNHS(O)0-2RM, -(CH2)mN02, -(CH2)mCN, -(CH2)mRp, Ci-C6 alkyl Ci-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, Ci-C6 haloalkyl, heterocycle, aryl, and heteroaryl, said heterocycle, aryl and heteroaryl in the definition of R are each optionally substituted with halogen, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci- C6 alkoxy, or -NRJRK;
[0195] each R4 is separately selected from the group consisting of halogen, cyano, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
[0196] each R5 is separately selected from the group consisting of halogen, -OCCH^OR1, -(CH^OR1, -NRJRK, -(CH^SR1, -C(=0)RL, -(CH2)mRL, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
[0197] each R6 is separately selected from the group consisting of halogen, -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mS(0)o_2RM, -(CH2)mNHS(0)o_2RM, -(CH2)mN02, -(CH2)mCN, -(CH2)mRp, C C6 alkyl, Ci-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, Ci-C6 haloalkyl, Ci- C6 heteroalkyl, heterocycle, aryl, and heteroaryl, said heterocycle, aryl and heteroaryl in the definition of R6 are each optionally substituted with halogen, cyano, Ci-C6 alkyl, Ci- C6 haloalkyl, C C6 alkoxy, or -NRJRK;
[0198] each R1 is separately selected from the group consisting of hydrogen, Ci-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C7 cycloalkyl, C C6 haloalkyl, C C6 heteroalkyl, and Ci-C6 heterohaloalkyl;
[0199] each -NRJRK is separately selected, wherein RJ and RK are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl optionally substituted with up to 5 fluoro, -(CH2)mORJA, -(CH2)mNRJBRJC, -(CH2)mRR, C3-C7 cycloalkyl, heterocycle, aryl and heteroaryl, said C3-C7 cycloalkyl, heterocycle, aryl and heteroaryl in the definition of R T and R K are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off
T K
of RJ and Γ are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, C C6 alkoxy, or -(CH2)mNRKARKB; or -NRJRK is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -NR R is an optionally substituted CrC6 alkylideneamino;
[0200] each RJA is independently selected from the group consisting of hydrogen, CrC6 alkyl, and CrC6 haloalkyl;
TR Ti"1 TR Ti"1
[0201] each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, CrC6 alkyl, and CrC6 haloalkyl;
[0202] each -NR^R™ is separately selected, wherein R1^ and RKB are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
[0203] each RM is independently selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, and -(CH2)mRP;
[0204] each -NRNR° is separately selected, wherein RN and R° are each independently selected from the group consisting of hydrogen, -(CH2)mNRNARNB, aryl and heteroaryl, said aryl and heteroaryl in the definition of RN and R° are each independently optionally substituted with one or more substituents selected from the group consisting of -(CH2)mNROAROB, halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off of RN and R° are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -NRNARNB,
[0205] each -NRNARNB is separately selected, wherein RNA and RNB are each independently selected from the group consisting of hydrogen, CrC6 alkyl, and CrC6 haloalkyl;
[0206] each -NROAROB is separately selected, wherein ROA and ROB are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
[0207] Rp is selected from the group consisting of hydrogen and Ci-C6 alkyl;
[0208] RL is selected from the group consisting of C3-C7 cycloalkyl, optionally substituted Ci-C6 alkyl, optionally substituted Ci-C6 alkoxy, -(CH2)mORLA, -
(CH2)mNR LB R LC , aryl and heteroaryl, said aryl and heteroaryl in the definition of R L are each independently optionally substituted with one or more substituents selected from the group consisting of halo, C C6 alkyl, C C6 haloalkyl, C C6 alkoxy, -(CH2)MNRLDRLE, aryl and heteroaryl, said aryl and heteroaryl substituent off of RL are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -(CH2)MNRLFRLG;
[0209] RLA is selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
[0210] R LB and R LC are each independently selected from the group consisting
LB LC
of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, and Ci-C6 heteroalkenyl; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0211] each -NRLDRLE is separately selected, wherein RLD and RLE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted Ci-C6 alkyl, said aryl and heteroaryl in the definition of RLD and
LE LD LE
R are each optionally substituted with Ci-C6 alkyl or Ci-C6 alkoxy; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0212] each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and Ci-C6 alkyl; or
-NR LF R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0213] L is selected from the group consisting of -0(CH2)PO-, C1-C7 alkyl, C1-C7 heteroalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, an optionally substituted heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl, or L is selected from the group consisting of LX-L2, ΐ θ-L2, i S-L2, LX-NR9-L2, LX-L2-L3, LX-L2-L3-L4, L1-C(=E)-L2, and I CR L2;
[0214] L1 is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
[0215] L is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
[0216] L is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
[0217] L4 is an optionally substituted aryl; [0218] E is O (oxygen), N-NHRU or N-ORu where Ru in the definition of E is selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted C2-C6 alkenyl, -(CH2)mRR, and -C(=0)(CH2)mRR;
[0219] RR is selected from the group consisting of CrC6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
[0220] R 7 and R 8 are each independently selected from the group consisting of
7 8
hydrogen, Ci-C6 alkyl, Ci-C6 heteroalkyl, and -OH; or CR R is a three - to eight- membered optionally substituted carbocycle, which optionally has one to three additional hetero atoms incorporated in the ring;
[0221] R9 is selected from the group consisting of hydrogen, CrC6 alkyl, Cp C6 haloalkyl, Ci-C6 heteroalkyl, C3-C7cycloalkylC(0)- and Ci-C6 alkylC(O)-;
[0222] each m is independently 0, 1, 2, or 3;
[0223] each p is independently 0, 1, 2, 3, 4, 5, or 6;
[0224] each q is independently 1, 2, 3, 4, 5, or 6;
[0225] each r is independently 1, 2, 3, or 4; and
[0226] any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
[0227] Some embodiments disclosed herein provide a compound of Formula I, wherein R1 can be selected from the group consisting of fluorine, chlorine, and methyl; R2 can be selected from the group consisting of -(CH2)mORI, -NRJRK, and -(CH2)mSRI; R3 can be selected from the group consisting of -(CH2)mRp, -(CH2)mORM, and -NRNR°; R4 can be selected from the group consisting of fluorine, chlorine, and methyl; R5 can be selected from the group consisting of -(CH2)mORI, -NRJRK, and -(CH2)mSRI; R6 can be selected from the group consisting of -(CH2)mRp, -(CH2)mORM, and -NRNR°; R1 can be selected from the group consisting of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, and Ci-C6 heteroalkyl; each -NR T R K can be separately selected, wherein R T and R K can each be independently selected from the group consisting of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, and Ci-C6 heteroalkyl; or -NR T R K can be an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom; or -NR T R K can be an optionally substituted Ci-C6 alkylideneamino; each RM can be independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and -(CH2)mRP; RL canbe selected from the group consisting of hydrogen, C1-C3 alkyl, C1-C3 haloalkyl, and an optionally substituted aryl or an optionally substituted heteroaryl; and m can be 0, 1, or 2.
[0228] Some embodiments disclosed herein provide a compound of Formula I, wherein G1 can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G1 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; A can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 , said aryl and heteroaryl in the definition of A can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; G can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G2 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; A4 can be selected from the group consisting of C3-C7 cycloalkenyl, C3-C7 cycloalkyl, Ci-C6 alkyl, Ci-C6 heteroalkyl, C2-C6 alkenyl, Ci-C6 alkoxy, -(CH2)mNRPRL, heterocycle, aryl, and heteroaryl, said C3-C7 cycloalkenyl, C3-C7 cycloalkyl, Ci-C6 alkyl, Ci-C6 heteroalkyl, C2-C6 alkenyl, heterocycle, aryl, and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 , said aryl and heteroaryl in the definition of A4 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; G4 can be selected from the group consisting of C3-C7 cycloalkenyl, aryl, and heteroaryl, each substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G4 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; A5 canbe selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 1 , R 2 , and R 3 , said aryl and heteroaryl in the definition of A 5 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; R1 can be selected from the group consisting of fluorine, chlorine, and methyl; R can be selected from the group consisting of -(CH2)mORI and -NRJRK; R3 can be -Rp; R4 can be selected from the group consisting of fluorine, chlorine, and methyl; R5 can be selected from the group consisting of -(CH2)mORI and -NRJRK; R6 can be -Rp; and RL can be selected from the group consisting of Q-Q alkyl, C1-C3 haloalkyl, an optionally substituted aryl and an optionally substituted heteroaryl.
[0229] Some embodiments disclosed herein provide a compound of Formula I, wherein L can be selected from the group consisting of an optionally substituted ally subs , an optionally substituted
lly substituted
Figure imgf000044_0001
; and E can be O (oxygen), N-NHRQ or N-ORQ where RQ in the definition of E can be selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C4 alkenyl, -R R , and -C(=0)R R . In some embodiments, L can be selected from the group consisting of an optionally
substituted
Figure imgf000044_0002
and an optionally substituted ; each R1 can be separately selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl; each R can be separately selected from the group consisting of halogen, -(CH2)mOR I , and -NR B R C , where R I in the definition of can be R 2 selected from the group consisting of hydrogen, and Ci-C6 alkyl; each R can be fluoro; each -NR T R K canbe separately selected, wherein R T and R K can each be independently selected from the group consisting of hydrogen and Ci-C6 alkyl; or -NR T R K can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; each R4 can be separately selected selected from the group consisting of chloro, fluoro, and an optionally substituted Ci-C6 alkyl; each R5 can be separately selected from the group consisting of -OCH2CH2OR1, -(CH2)mORI, and -NRJRK, where R1 in the definition of canbe R5 selected from the group consisting of hydrogen, and Ci-C6 alkyl; and each R6 can be separately selected from the group consisting an optionally substituted aryl and an optionally substituted heteroaryl.
[0230] Some embodiments disclosed herein provide a compound of Formula I, wherein A1, A2, A4, and A5 can each be selected from the group consisting of phenyl, naphthyl, benzo[<i][l,3]dioxolyl, indolyl, and benzo[d]imidazolyl, each substituted with one or more substituents selected from the group consisting of R 1 and R2 ; each R 1 can be separately selected from the group consisting of phenyl, pyrrolyl, and imidazolyl, each optionally substituted with a substituent selected from Ci-C6 alkyl, Ci-C6 alkoxy, Ci-C6 alkylHN- and (Ci-C6 alkyl)2N-; each R can be separately selected from the group consisting of bromo, chloro, fluoro, -(CH2)mOR I , -(CH2)mR L , and -NR T R K , where each
R I in the definition of R 2 can be separately selected from the group consisting of hydrogen and Ci-C6 alkyl; each -NR T R K can be separately selected, wherein R T and R K can each be independently selected from the group consisting of hydrogen, and Ci-C6 alkyl optionally substituted with up to 3 fluoro; or -NR T R K can be a morpholinyl, piperazinyl, pyrrolidinyl, and piperidinyl, each optionally substituted with one or more oxo; each RL can be separately selected from the group consisting aryl and heteroaryl, each optionally substituted with one or more substituents each separately selected from the group consisting of halogen, Ci-C6 alkyl optionally substituted with up to 5 fluoro, and Ci-C6 alkoxy optionally substituted with up to 5 fluoro; G 1 , G2 , and G 4 can each be selected from the group consisting of: phenyl, naphthyl, benzo[<i][l,3]dioxolyl, indolyl, and benzo [d] imidazolyl, each substituted with one or more substituents selected from the group consisting of R4 and R5; each R4 can be separately selected from the group consisting of phenyl, pyrrolyl, and imidazolyl, each optionally substituted with a substituent selected from Ci-C6 alkyl, Ci-C6 alkoxy, Ci-C6 alkylHN- and (Ci-C6 alkyl)2N-; and each R5 can be separately selected from the group consisting of bromo, chloro, fluoro, -(CH2)mORI, and -NRJRK, where each R1 in the definition of R5 can be separately selected from the group consisting of hydrogen and Ci-C6 alkyl.
[0231] Some embodiments disclosed herein provide a compound of Formula I, wherein A can be selected from the group consisting of phenyl, naphthyl, and, indolyl, each substituted with one or more substituents selected from the group consisting of R1 and R 2 ; each R 1 can be separately selected from the group consisting of phenyl, pyrrolyl, and imidazolyl, each optionally substituted with a substituent selected from Ci-C6 alkyl, 2
Ci-C6 alkoxy, Ci-C6 alkylHN- and (Ci-C6 alkyl)2N-; each R can be separately selected from the group consisting of bromo, chloro, fluoro, -(CH2)mORI, -(CH2)mRL, and
-NR T R K , where each R I in the definition of R 2 can be separately selected from the group consisting of hydrogen and Ci-C6 alkyl; each -NR T R K can be separately selected, wherein
RJ T and Γ K can each be independently selected from the group consisting of hydrogen, and
Ci-C6 alkyl optionally substituted with up to 3 fluoro; or -NR T R K can be a morpholinyl, piperazinyl, pyrrolidinyl, and piperidinyl, each optionally substituted with one or more oxo; each RL can be separately selected from the group consisting aryl and heteroaryl, each optionally substituted with one or more substituents each separately selected from the group consisting of halogen, Ci-C6 alkyl optionally substituted with up to 5 fluoro, and Ci-C6 alkoxy optionally substituted with up to 5 fluoro; G can be selected from the group consisting of: phenyl, naphthyl, and, indolyl, each substituted with one or more substituents selected from the group consisting of R4 and R5; each R4 can be separately selected from the group consisting of phenyl, pyrrolyl, and imidazolyl, each optionally substituted with a substituent selected from Ci-C6 alkyl, Ci-C6 alkoxy, Ci-C6 alkylHN- and (Ci-C6 alkyl)2N-; and each R5 can be separately selected from the group consisting of bromo, chloro, fluoro, -(CH2)mORI, and -NRJRK, where each R1 in the definition of R5 can be separately selected from the group consisting of hydrogen and Ci-C6 alkyl.
[0232] Some embodiments disclosed herein provide a compound of Formula I, wherein A1, A2, A4, and A5 can each be selected from the group consisting of selected from the group consisting of a phenyl, naphthyl, benzo[d][l,3]dioxolyl, each substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 ; and
G 1 , G2 , and G 4 can each be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R4, R5, and R6 and each optionally fused with a nonaromatic heterocycle or carbocycle.
[0233] Some embodiments disclosed herein provide a compound of Formula I, wherein L can be selected from the group consisting of aryl, and heteroaryl, each substituted with one or more substituents each individually selected from the group consisting of alkyl, cycloalkyl, alkoxy, alkenylO-, arylC(=0)-, arylC(=0)NH-, arylNHC(=0)-, aryl(CH2)0-3O(CH2)0-3-, aryl(CH2)0-3NH(CH2)0-3-, HO(CH2)!_3NH-, HO(CH2)i_30- HO(CH2)i_3- HO(CH2)i_30(CH2)i_3- and amino. [0234] Some embodiments disclosed herein provide a compound of Formula I, wherein L can be Lx-L2, or ΐ θ-L2, or LX-NR9-L2, or Lx-L2-L3, or ΐλ-ΐΑ-ΐΛ-Ι.4, or L1-C(=E)-L2.
[0235] Some embodiments disclosed herein provide a compound of Formula I, wherein L1 can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents each individually selected from the group consisting of alkyl, cycloalkyl, alkoxy, alkenylO-, arylC(=0)-, arylC(=0)NH-, arylNHC(=0)-, aryl(CH2)0-3O(CH2)0-3-, aryl(CH2)0-3NH(CH2)0-3- HO(CH2)!_3NH-, HO(CH2) i_30-, HO(CH2)i_3-, HO(CH2) i_30(CH2)i_3- and amino.
[0236] Some embodiments disclosed herein provide a compound of Formula I, wherein L can be selected from the group consisting of aryl, heteroaryl, and heterocyclyl, each substituted with one or more substituents each individually selected from the group consisting of alkyl, cycloalkyl, alkoxy, alkenylO-, arylC(=0)-, arylC(=0)NH- arylNHC(=0)-, aryl(CH2)0-3O(CH2)0-3-, aryl(CH2)0-3NH(CH2)0-3-, HO(CH2) i_3NH- HO(CH2)i_30- HO(CH2) i_3- HO(CH2)i_30(CH2) i_3- and amino.
[0237] Some embodiments disclosed herein provide a compound of Formula I, wherein L can be selected from the group consisting of aryl, heteroaryl, and heterocyclyl, each substituted with one or more substituents each individually selected from the group consisting of alkyl, cycloalkyl, alkoxy, alkenylO-, arylC(=0)-, arylC(=0)NH- arylNHC(=0)-, aryl(CH2)0-3O(CH2)0-3-, aryl(CH2)0-3NH(CH2)0-3-, HO(CH2) i_3NH- HO(CH2)i_30- HO(CH2) i_3- HO(CH2)i_30(CH2) i_3- and amino.
[0238] Some embodiments disclosed herein provide a compound of Formula I, wherein L4 can be aryl substituted with one or more substituents each individually selected from the group consisting of alkyl, cycloalkyl, alkoxy, alkenylO-, arylC(=0)-, arylC(=0)NH-, arylNHC(=0)-, aryl(CH2)0-3O(CH2)0-3-, aryl(CH2)0-3NH(CH2)0-3-, HO(CH2) i_3NH- HO(CH2)i_30- HO(CH2) i_3- HO(CH2)i_30(CH2) i_3- and amino.
[0239] Some embodiments disclosed herein provide a compound of Formula I, having the proviso that a compound for Formula I is not selected from the group consisting of:
Figure imgf000047_0001
Figure imgf000048_0001
[0240] Some embodiments disclosed herein provide a compound of Formula I
Figure imgf000048_0002
eutically
acceptable salts thereof, having the formula lb:
Figure imgf000048_0003
(lb), and pharmaceutically acceptable salts thereof, or having the formula Ic:
Figure imgf000048_0004
(Ic), and pharmaceutically acceptable salts thereof.
[0241] Some embodiments disclosed herein provide a compound of Formula la, lb, Ic, or Id, wherein L can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl.
[0242] Some embodiments disclosed herein provide a compound of Formula I
H having the formula Id: Ύ O Ν· Y O (Id), and pharmaceutically acceptable salts thereof. [0243] Some embodiments disclosed herein provide a compound of Formula I
having the structure of Formula Ie:
Figure imgf000049_0001
(Ie) and pharmaceutically acceptable salts thereof.
[0244] Some embodiments disclosed herein provide a compound of Formula Ie, wherein L can be selected from the group consisting of -0(CH2)pO-, an optionally substituted aryl, and an optionally substituted heteroaryl, or L is L 1 -L2 ; J 3 can be selected from the group consisting of an optionally substituted aryl, -(CH2)mNR C(=0)-, -(CH2)rO-, and -(CH=CH)m-; Q can be selected from the group consisting of an optionally substituted aryl, -(CH2)rNRBC(=0)-, -(CH2)rO- and -(CH=CH)r-; L1 can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl; and L can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl. In some embodiments, L can be -0(CH2)pO-.
[0245] Some embodiments disclosed herein provide a compound of Formula I
RERFN^ / LN ^NRERF having the structure of Formula If : T O Y O (if)5 and pharmaceutically acceptable salts thereof.
[0246] Some embodiments disclosed herein provide a compound of Formula If, wherein L can be selected from the group consisting of C4-C6 cycloalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl, or L is L 1 -L2 ; L 1 can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl; and L can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl.
[0247] Some embodiments disclosed herein provide a compound of Formula I
Figure imgf000049_0002
and pharmaceutically acceptable salts thereof.
[0248] Some embodiments disclosed herein provide a compound of Formula Ig, wherein L can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl, or L can be selected from the group consisting of Lx-L2, ΐ θ-L2, i S-L2, LX-NR9-L2, iA-lA-L3, ΐΑ-ΐΑ-ΐΛ-Ι.4, L1-C(=E)-L2, and
L 1 -CR 7'R 8 -I 2; L 1 can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl; L can be selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle; L can be selected from the group consisting of an optionally substituted aryl, and an optionally substituted heteroaryl; and L4 is an optionally substituted aryl.
[0249] Some embodiments disclosed herein provide a compound of Formula I
having the structure of Formula Ih:
Figure imgf000050_0001
(Ih), and pharmaceutically acceptable salts thereof.
[0250] Some embodiments disclosed herein provide a compound of Formula Ih, wherein L can be selected from the group consisting of an optionally substituted aryl or L can be selected from the group consisting of L 1 -L2 , and L 1 -L2 -L 3 ; L 1 can be an optionally substituted heteroaryl; L can be selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle; and L can be an optionally substituted heterocycle.
[0251] Some embodiments disclosed herein provide a compound of Formula
II:
Figure imgf000050_0002
and pharmaceutically acceptable salts, esters, stereoisomers, tautomers or prodrugs thereof;
wherein:
[0252] A6 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R11, R12, and R13, said aryl and heteroaryl in the definition of A6 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0253] G6 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R14, R15, and R16, said aryl and heteroaryl in the definition of G6 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0254] L6 is an optionally substituted aryl, or an optionally substituted heteroaryl; where the aryl and heteroaryl in the definition of L6 are optionally fused with a nonaromatic heterocycle or a nonaromatic ected from the group
consisting of an optionally substituted
Figure imgf000051_0001
, and an optionally
substituted
Figure imgf000051_0002
[0255] E is O (oxygen) or N-OR where R in the definition of E is selected from the group consisting of hydrogen and an optionally substituted CrC6 alkyl;
[0256] each R11 is separately selected from the group consisting of halogen, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
[0257] each R 12 is separately selected from the group consisting of -0(CH2)mORA, -(CH2)mORA, -NRBRC, and -(CH2)mSRA;
[0258] each R 13 is separately selected from the group consisting of - (CH2)mORD, -NRERF, -S(0)o-2RD, -(CH2)mN02, -(CH2)mCN, and -(CH2)mRG;
[0259] each R14 is separately selected from the group consisting of halogen, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
[0260] each R15 is separately selected from the group consisting of -0(CH2)mORA, -(CH2)mORA, -NRBRC, and -(CH2)mSRA; [0261] each R is separately selected from the group consisting of - (CH2)mORD, -NRERF, -(CH2)mS(0)o_2RD, -(CH2)mN02, -(CH2)mCN, and -(CH2)mRG;
[0262] E6 is CR17 when the dashed line between E6 and X represents a double bond; or E6 is CR17R17 when the dashed line between E6 and X represents a single bond;
[0263] F6 is CR18 when the dashed line between F6 and Y represents a double bond; or F6 is CR18R18 when the dashed line between F6 and Y represents a single bond;
[0264] 17
each R is independently selected from the group consisting of hydrogen, halogen, an optionally substituted CrC4 alkoxy, an optionally substituted C3- C7 cycloalkyl, and an optionally substituted Q-C4 alkyl;
[0265] 18
each R is independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-C4 alkoxy, an optionally substituted C3- C7 cycloalkyl, and an optionally substituted C1-C4 alkyl;
[0266] RA is selected from the group consisting of hydrogen, Ci-C6 alkyl, C2- C4 alkenyl, C2-C4 alkynyl, C3-C7 cycloalkyl, CrC6 haloalkyl, CrC6 heteroalkyl, and Cp C6 heterohaloalkyl;
[0267] B C B C
each -NR R is separately selected, wherein R and R are each
H H
independently selected from the group consisting of hydrogen, -S02R , -C(=0)R ,
-C(=0)NR E R F
, heterocycle, CrC6 alkyl, C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, C3-C7 cycloalkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl,
R B C
where the CrC6 alkyl in the definition of and R is optionally substituted with an optionally substituted aryl or an optionally substituted heteroaryl and where the C3-C7
B C
cycloalkyl and the heterocycle in the definition of R and R are optionally fused with an
B C
aryl or heteroaryl; or -NR R is an optionally substituted non-aromatic heterocycle
NR B R C
linked through a ring nitrogen atom; or - is an optionally substituted CrC6 alkylideneamino ;
[0268] each RD is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and - (CH2)mRG;
[0269] E F E R F
each -NR R is separately selected, wherein R and are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6
G E F
haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and -(CH2)mR ; or -NR R is an
E F
optionally substituted CrC6 alkylideneamino; or -NR R is an optionally substituted
G
non-aromatic heterocycle linked through a ring nitrogen atom;R is selected from optionally substituted aryl and an optionally substituted heteroaryl;
[0270] RH is selected from the group consisting of hydrogen, C1-C3 alkyl, optionally substituted C1-C3 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, C2-C4 alkenyl, C2- C4 alkynyl, C3-C7 cycloalkyl, C1-C3 haloalkyl, and an optionally substituted aryl or heteroaryl;
[0271] X and Y are independently selected from N (nitrogen), NH, CR19, and CR19R20;
[0272] each R19 and R20 are independently selected from the group consisting of hydrogen and an optionally substituted C1-C4 alkyl;
[0273] each m is independently 0, 1, or 2; and
[0274] any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
[0275] Some embodiments disclosed herein provide a compound of Formula II, wherein A6 can be selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R11, R12, and R13, said aryl and heteroaryl in the definition of A6 can each be further optionally f selected from
the group c an optionally
substituted
Figure imgf000053_0001
, an optionally substituted , an optionally substituted
Figure imgf000054_0001
, and an optionally substituted ; E can be O (oxygen) or N-ORD where RD in the definition of E2 can be selected from the group consisting of hydrogen and an optionally substituted Ci-C6 alkyl; G6 can be selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R14, R15, and R16, said aryl and heteroaryl in the definition of G6 can each be further optionally fused with a nonaromatic heterocycle or carbocycle; each R11 can be separately selected from the group consisting of fluoro, an optionally substituted aryl and an optionally substituted heteroaryl; each 12
R
can be separately selected from the group consisting of -0(CH2)mORA, -(CH2)mORA, and
B C A 12
— NR R , where R" in the definition of can be R selected from the group consisting of hydrogen, and 13
Ci-C6 alkyl; each R can be separately selected from the group consisting of -ORD, -NRERF, -S(0)2RD, -CN, and -RG; each -NRBRC can be separately selected, wherein B nd C
R a R can each be independently selected from the group consisting of hydrogen, C3-C7 cycloalkyl, CrC6 alkyl, and CrC6 haloalkyl, where the CrC6 alkyl in the definition of B C
R and R can be optionally substituted with an optionally substituted aryl or an optionally substituted heteroaryl, and where the C3-C7 cycloalkyl in the definition of B C
R and R can be optionally fused with an optionally substituted aryl; or
B C
-NR R can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; R can be selected from the group consisting of hydrogen, C1-C3 alkyl, an optionally substituted aryl and an optionally substituted heteroaryl; each R14 can be separately selected selected from the group consisting of chloro, fluoro, an optionally substituted CrC6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; each R15 can be separately selected from the group consisting of-0(CH2)mORA, -(CH2)mORA, and -NRBRC, where RA in the definition of R15 can be selected from the group consisting of hydrogen, and Ci-C6 alkyl; and each R16 can be separately selected from the group consisting of -OR , -NR R , -S(0)2R , -CN, and -RG. In some embodiments, A can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R11, R12, and R13, said aryl in the definition of A6 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; G6 can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R14, R15, and R16, said aryl and heteroaryl in the definition of G6 can each be further optionally fused with a nonaromatic heterocycle or carbocycle; each R11 can be separately selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl; each R 12 can be separately selected from the group consisting of -(CH2)mORA, and -NRBRC, where RA in the definition of R 12 can be selected from the group consisting of hydrogen, and Ci-C6 alkyl; each R 13 can be fluoro; each -NR B R C can be separately selected, wherein R B and
R C can each be independently selected from the group consisting of hydrogen, -C(=0)R H , and Ci-C6 alkyl; or -NR B R C can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; each R14 can be separately selected selected from the group consisting of chloro, fluoro, an optionally substituted CrC6 alkyl, an optionally substituted aryl and an optionally substituted heteroaryl; each R15 can be separately selected from the group consisting of -OCH2CH2ORA, -(CH2)mORA, and -NRBRC, where RA in the definition of can be R15 selected from the group consisting of hydrogen, and Ci- C6 alkyl; and each R16 can be fluoro.
0276] Some embodiments disclosed herein provide a compound of Formula
Figure imgf000055_0001
Figure imgf000056_0001
[0277] Some embodiments disclosed herein provide a compound of Formula II, wherein A6 can be selected from the group consisting of phenyl, naphthyl, benzo[<i][l,3]dioxolyl, indolyl, and benzo[d] imidazolyl, each optionally substituted with one or more substituents selected from the group consisting of R11 and R12; each R11 can be separately selected from the group consisting of phenyl, pyrrolyl, and imidazolyl, each optionally substituted with a substituent selected from CrC6 alkyl, CrC6 alkoxy, CrC6
12
alkylHN- and (Ci-C6 alkyl)2N-; each R can be separately selected from the group consisting of bromo, chloro, fluoro, -(CH2)mORA, and -NRBRC, where each RA in the definition of R 12 can be separately selected from the group consisting of hydrogen and Ci-
C6 alkyl; each— NR B R C can be separately selected, wherein R B and R C can each be independently selected from the group consisting of hydrogen, -C(=0)R , Ci-C6 alkyl optionally substituted with up to 5 fluoro, and an optionally substituted C3-C7 cycloalkyl further optionally fused with phenyl; or -NR B R C can be a morpholinyl, piperazinyl, pyrrolidinyl, and piperidinyl, each optionally substituted with one or more oxo; each R can be separately selected from the group consisting aryl and heteroaryl, each optionally substituted with one or more substituents each separately selected from the group consisting of halogen, Ci-C6 alkyl optionally substituted with up to 5 fluoro, and Ci-C6 alkoxy optionally substituted with up to 5 fluoro; G6 canbe selected from the group consisting of: phenyl, naphthyl, benzo[<i][l,3]dioxolyl, indolyl, and benzo[d] imidazolyl, each optionally substituted with one or more substituents selected from the group consisting of R14 and R15; each R14 can be separately selected from the group consisting of phenyl, pyrrolyl, and imidazolyl, each optionally substituted with a substituent selected from Ci-Ce alkyl, Ci-C6 alkoxy, Ci-C6 alkylHN- and (Ci-C6 alkyl)2N-; and each R15 can be separately selected from the group consisting of bromo, chloro, fluoro, -(CH2)mORA, and -NRBRC, where each RA in the definition of R15 can be separately selected from the group consisting of hydrogen and CrC6 alkyl. [0278] Some embodiments disclosed herein provide a compound of Formula
Figure imgf000057_0001
and pharmaceutically acceptable salts, esters stereoisomers, tautomers or prodrugs thereof;
wherein:
[0279] A is selected from the group consisting of aryl, heteroaryl, isoindolinyl, indenyl, dihydroindenyl, tetrahydroisoquinolinyl, and tetrahydronaphthalenyl, each optionally substituted with one or more substituents selected
21 22 23
from the group consisting of R , R , and R , said aryl and heteroaryl in the definition of y
A are each further optionally fused with an optionally substituted nonaromatic y
heterocycle or an optionally substituted nonaromatic carbocycle; or A is C3-C7 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of
21 22 23 7
R , R , and R , said C3-C7 cycloalkyl in the definition of A is fused with an optionally substituted aryl or optionally substituted heteroaryl;
21
[0280] each R is independently selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
22
[0281] each R is independently selected from the group consisting of - (CH2)mORA, -0(CH2)mORA, -C(=0)ORA, -0(CH2)0NRBRc, -(CH2)mNRBRc, -C(=0)NRBRc, and -(CH2)mSRA;
23
[0282] each R is independently selected from the group consisting of phenyl, -NHC(=NH)NH2, -(CH2)mORD, -C(=NNRBRC)H, -NRLC(=0)NRBRc, -C(=0)NRDN(=CHRG), -(CH2)mS(0)o_2RD, -(CH2)mN02, -(CH2)mCN, and -(CH2)mRG,
23
said phenyl in the definition of R is substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-C3 alkyl, an optionally substituted C1-C3 alkoxy, -0(CH2)mORA, -(CH2)mNRBRc; [0283] J is selected from the group consisting of -(CH2)n[NHC(=0)](CH2)0[NHC(=0)](CH2)p-, -(CH2)n[NHC(=0)](CH2)0[NH]q-,
-NH[C(=0)] [C(=0)]NH- and R28 ;
[0284] 7 selected from the group consisting of ygen), 28
Q is O (ox -NR -, aryl, and arylamido; or Q is null;
[0285] each 28
R is independently selected from the group consisting of hydrogen and an optionally substituted C1-C4 alkyl;
[0286] G is selected from the group consisting aryl, heteroaryl, and heterocycle, each optionally substituted with one or more substituents selected from the group consisting of 24 25 26 heteroaryl in the definition of 7
R , R , and R , said aryl and G are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0287] each 24
R is independently selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
[0288] each 25
R is independently selected from the group consisting of - (CH2)mORA, -0(CH2)mORA, -C(=0)ORA, -0(CH2)0NRBRc, -(CH2)mNRBRc, -(CH2)mC(=0)NRBRc, -C(=NNRBRC)H, and -(CH2)mSRA;
[0289] each R26 is independently selected from the group consisting of phenyl, -NHC(=NH)NH2, -(CH2)mORD, -C(=NNRBRC)H, -NRLC(=0)NRBRc, -C(=0)NRDN(=CH)RG, -(CH2)mS(0)o-2RD, -(CH2)mN02, -(CH2)mCN, -(CH2)mRG, said phenyl in the definition of R23 is substituted with -(CH2)mNRBRc;
[0290] 1 2 3
X , X , and X are each independently selected from N (nitrogen) and
CR27;
[0291] 27
R is selected from the group consisting of hydrogen, halogen, and an optionally substituted C1-C4 alkyl;
[0292] RA is selected from the group consisting of hydrogen, Ci-C6 alkyl, C2- C4 alkenyl, C2-C4 alkynyl, C3-C7 cycloalkyl, and Ci-C6 haloalkyl; [0293] each -NR B R C is separately selected, wherein R B and R C are each independently selected from the group consisting of hydrogen, -S02R H , H
-C(=0)R , -(CH2)nORH, -(CH2U1, -(CH2)mRJ, -(CH2)nC(=0)NRERF, -(CH2)nNRERF, - S02NRERF, heterocycle, C C6 alkyl, C C6 haloalkyl, C C6 heteroalkyl, C3-C7 cycloalkyl, and Ci-C6 heterohaloalkyl where the C3-C7 cycloalkyl and the heterocycle are each optionally fused with an optionally substituted aryl or optionally substituted heteroaryl; or -NR B R C is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom, said optionally substituted non-aromatic heterocycle is optionally fused with an optionally substituted aryl or optionally substituted heteroaryl;
[0294] each RD is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and -(CH2)mRI;
[0295] each -NR E R F is separately selected, wherein R E and R F are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted heterocycle, and G E F
-(CH2)mR"; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;or -NR E R F is Ci-C6 alkylideneamino substituted with an optionally substituted aryl;
[0296] each R is independently selected from an optionally substituted aryl and an optionally substituted heteroaryl;
[0297] each RH is independently selected from the group consisting of hydrogen, C1-C3 alkoxy, C1-C3 alkyl, C1-C3 haloalkyl, an optionally substituted aryl and an optionally substituted heteroaryl;
[0298] each R1 is independently selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl;
[0299] each RJ is independently selected from the group consisting of aryl and heteroaryl, each substituted with one or more -NR E R F ;
[0300] each RL is independently selected from the group consisting of C3-C7 cycloalkyl, optionally substituted Ci-C6 alkyl, optionally substituted Ci-C6 alkoxy, -(CH2)mORLA, -(CH2)mNRLBRLC, aryl and heteroaryl, said aryl and heteroaryl in the definition of RL are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-
C6 alkoxy, -(CH2)mNR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of RL are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -(CH2)mNRLFRLG;
[0301] each RLA is independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
[0302] R LB and R LC are each independently selected from the group consisting
LB LC
of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, and Ci-C6 heteroalkenyl; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0303] each -NRLDRLE is separately selected, wherein RLD and RLE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted Ci-C6 alkyl, said aryl and heteroaryl in the definition of RLD and
LE LD LE
R are each optionally substituted with Ci-C6 alkyl or Ci-C6 alkoxy; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0304] each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and Ci-C6 alkyl; or
-NR LF R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0305] each m is independently 0, 1, or 2;
[0306] each n is independently 0, 1, 2, 3, or 4;
[0307] each o is independently 1, 2, or 3;
[0308] each p is independently 0, 1, 2, or 3;
[0309] each q is independently 0 or 1 ; and
[0310] any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
[0311] Some embodiments disclosed herein provide a compound of Formula
III, wherein A can be selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl, thienyl, indolyl, and benzimidazolyl, each substituted with one or more substituents selected from the group consisting of R 21 , R 22 , and R 23 , y
said aryl and heteroaryl in the definition of A can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic
y
carbocycle; G can be selected from the group consisting aryl, heteroaryl, and heterocycle, each substituted with one or more substituents selected from the group consisting of R , R25, and R26, said aryl and heteroaryl in the definition of G7 can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted
21
nonaromatic carbocycle; R can be selected from the group consisting of fluorine and
22 A B C chlorine; R can be selected from the group consisting of -(CH2)mOR , -C(=0)NR R ,
B C A 23
-NR R , and -(CH2)mSR ; R can be selected from the group consisting of -(CH2)mORD, and -C(=0)NRDN(=CHRG); R25 can be selected from the group consisting of -(CH2)mORA, -C(=0)NRBRc, -NRBRC; each RA can be independently selected from the group consisting of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, and Ci-C6 heteroalkyl;
B C B C
each -NR R can be separately selected, wherein R and R can each be independently selected from the group consisting of Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and
B C
Ci-C6 heterohaloalkyl; or -NR R can be an optionally substituted non-aromatic
B C
heterocycle linked through a ring nitrogen atom; or -NR R is an optionally substituted
Figure imgf000061_0001
Ci-C6 alkylideneamino; J can be independently selected from the group consisting of hydrogen and an optionally substituted C1-C3 alkyl, with the
7 7 22 23 25 26 proviso when A and G are a phenyl then at least one of R , R , R , and R can be selected from the group consisting of -(CH2)mORA, -(CH2)mORD, -NRBRC, -C(=0)NRDN(=CHRG), -NRERF, -C(=0)NRBRc, and an optionally substituted phenyl.
[0312] Some embodiments disclosed herein provide a compound of Formula
III, wherein A can be selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl, thienyl, indolyl, and benzimidazolyl, each substituted
21 22 23 with one or more substituents selected from the group consisting of R , R , and R , y
said aryl and heteroaryl in the definition of A can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic y
carbocycle; G can be selected from the group consisting aryl, heteroaryl, and heterocycle,
24 each substituted with one or more substituents selected from the group consisting of R , R25, and R26, said aryl and heteroaryl in the definition of G7 can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted
21
nonaromatic carbocycle; R can be selected from the group consisting of Ci-C6 alkyl,
22 E F fluorine, and chlorine; R can be selected from the group consisting of -NHC(=0)R R , -(CH2)mOR A , and -NR B R C ; R 23 can be selected from the group consisting of -(CH2)mORD, and -C(=0)NRDN(=CHRG); RA can be selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl; each -NR B R C can be separately selected, wherein R B and R C can each be independently selected from the group consisting of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl; or
-NR B R C can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -NR B R C can be an optionally substituted Ci-C6 alkylideneaminyl; and
J can be
Figure imgf000062_0001
, with the proviso when A and G are a phenyl then at least one
22 23 25 26 A. of R , R , R , and R can be selected from the group consisting of -(CH2)mOR , -(CH2)mORD, -NRBRC, -NHC(=0)RERF, -C(=0)NRDN(=CHRG), and an optionally substituted phenyl.
[0313] Some embodiments disclosed herein provide a compound of Formula
III having the structure of Formula Illaa:
Figure imgf000062_0002
(Illaa), and pharmaceutically acceptable salts, esters, stereoisomers, tautomers or prodrugs
thereof, or having the formula 11 lab:
Figure imgf000062_0003
(lb), and pharmaceutically acceptable salts, esters, stereoisomers, tautomers or prodrugs thereof.
[0314] Some embodiments disclosed herein provide a compound of Formula Illab having the structure of Formula Illabb:
Figure imgf000062_0004
(Illabb), and pharmaceutically acceptable salts, esters, stereoisomers, tautomers or prodrugs thereof, wherein A can be aryl substituted with one or more substituents selected from the group consisting of R 21 , R 22 , and R 23 ; each R 21 canbe independently selected from the group consisting of halogen, cyano, Ci-C6 alkyl, and Ci-C6 alkoxy; each R 22 can be independently selected from the group consisting of -(CH2)mORA, -0(CH2)mORA and -(CH2)mNRBRc; each R23 can be phenyl substituted with - (CH2)mNR R ; G; can be heterocycle substituted with one or more
24 25 26 24 substituents selected from the group consisting of R , R , and R ; each R can be independently selected from the group consisting of halogen, cyano, CrC6 alkyl, and Cp
25
C6 alkoxy; each R can be independently selected from the group consisting of - (CH2)mORA, -0(CH2)mORA; each R26 can be phenyl substituted with one or more -(CH2)mNRBRc; RB can be hydrogen; Rc can be -C(=0)RH; and RH can be an optionally substituted aryl.
[0315] Some embodiments disclosed herein provide a compound of Formula Illabb, wherein A can be phenyl substituted with one or more substituents selected from
22 22
the group consisting of R ; each R can be independently selected from the group consisting of -(CH2)mORA, and -0(CH2)mORA; each RA can be independently selected from the group consisting of hydrogen, C1-C3 alkyl, and C1-C3 haloalkyl; G can be piperidinyl substituted with one or more substituents selected from the group consisting of
26 26 H H
R ; each R can be phenyl substituted with -NHC(=0)R ; and R can be an optionally substituted phenyl.
[0316] Some embodiments disclosed herein provide a compound of Formula
III having the structure of Formula Illb:
Figure imgf000063_0001
(Illb), 80
and pharmaceutically acceptable salts thereof, wherein R can be selected from
21 22 23
the group consisting of hydrogen, R , R , and R .
[0317] Some embodiments disclosed herein rovide a compound of Formula
III having the structure of Formula IIIc:
Figure imgf000063_0002
(IIIc), and pharmaceutically acceptable salts thereof. [0318] Some embodiments disclosed herein rovide a compound of Formula
III having the structure of Formula Hid:
Figure imgf000064_0001
(Hid), and pharmaceutically acceptable salts thereof, wherein A can be selected from the group consisting of aryl and heteroaryl, each substituted with one or more substituents selected
21 22 23
from the group consisting of R , R , and R , said aryl and heteroaryl in the definition of y
A can each be further optionally fused with an optionally substituted nonaromatic y
heterocycle or an optionally substituted nonaromatic carbocycle; or A can be C3-C7 cycloalkyl optionally substituted with one or more substituents selected from the group
21 22 23 7 consisting of R , R , and R , said C3-C7 cycloalkyl in the definition of A can be fused with an optionally substituted aryl or optionally substituted heteroaryl; J can be selected from the group consisting of -(CH2)„[NHC(=0)](CH2)oNHC(=0)(CH2)p-,
Figure imgf000064_0002
; and G can be selected from the group consisting of a aryl and heteroaryl, each substituted with one or more substituents
24 25 26
selected from the group consisting of R , R , and R , said aryl and heteroaryl in the y
definition of G can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle.
[0319] Some embodiments disclosed herein rovide a compound of Formula
Hid having the structure of Formula 11 Ida:
Figure imgf000064_0003
(Illda), and y
pharmaceutically acceptable salts, esters, or prodrugs thereof, wherein A can be selected from the group consisting of phenyl, indolyl, pyridinyl, pyrimidinyl, thienyl, benzothiofuranyl, naphthalenyl, and tetrahydronaphthalenyl, each substituted with one or
21 22 23 7 more substituents selected from the group consisting of R , R , and R ; and G can be selected from the group consisting of a aryl and heteroaryl, each optionally substituted
24 25 26 with one or more substituents selected from the group consisting of R , R , and R ,
y
said aryl and heteroaryl in the definition of G can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle.
[0320] Some embodiments disclosed herein provide a compound of Formula
Hid having the structure of Formula Illdb:
Figure imgf000065_0001
(Illdb), and pharmaceutically acceptable salts, esters, or prodrugs thereof, wherein A can be selected from the group consisting of phenyl, indolyl, pyridinyl, pyrimidinyl, thienyl, benzothiofuranyl, naphthalenyl, and tetrahydronaphthalenyl, each substituted with one or more substituents selected from the group consisting of R 21 , R 22 , and R 23 ; and G 7 can be selected from the group consisting of a aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 24 , R 25 , and R 26 ,
y
said aryl and heteroaryl in the definition of G can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle.
[0321] Some embodiments disclosed herein provide a compound of Formula
y
Illda or Formula Illdb, wherein G can be selected from the group consisting of phenyl, naphthyl, indolyl, dihydrobenzofuranyl, 1,4-benzodioxanyl, benzotriazolyl, benzimidazolyl, benzofuranyl, and 2,1,3-benzoxadiazolyl, each optionally substituted with one or more substituents selected from the group consisting of R 24 , R 25 , and R 26. In some embodiments, R 21 can be selected from the group consisting of halogen, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, and an optionally substituted 22
C3-C7 cycloalkyl; R can be selected from the group consisting of -(CH2)mORA, -0(CH2)mORA, and -NRBRC; R23 can be selected from the group consisting of -(CH2)mORD, -(CH2)mS(0)o-2RD, and -(CH2)mRG; R24 can be selected from the group consisting of halogen, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-
C6 alkoxy, an optionally substituted cloalkyl; R 25
C3-C7 cy can be selected from the group consisting of -(CH2)mORA, -0(CH2)mORA, -C(=0)NRBRc, -C(=NNRBRC)H, -NRBRC; R26 can be selected from the group consisting of -(CH2)mORD, -(CH2)mRG; RA can be selected from the group consisting of hydrogen, Ci-C6 alkyl, C3-C7 cycloalkyl, and Ci-C6 haloalkyl; each -NR B R C can be separately selected, wherein R B and R C can each be independently selected from the group consisting of hydrogen, -S02R H , -C(=0)R H , - (CH2)nORH, -(CHiU1, -(CH2)mRJ, -(CH2)nC(=0)NRERF, -(CH2)nNRERF, - S02NRERF, Ci-C6 alkyl, C C6 haloalkyl, C C6 heteroalkyl, C3-C7 cycloalkyl, and C C6 heterohaloalkyl where the alkyl and the heteroalkyl are optionally fused with an aryl or heteroaryl; or -NR R can be an optionally substituted heterocyle; each R can be independently selected from the group consisting of hydrogen, an optionally substituted
Ci-C6 alkyl, and -(CH^R I1; each -NR E R F can be separately selected, wherein R E and R F can each be independently selected from the group consisting of hydrogen, an optionally substituted C C6 alkyl, and -(CH2)mR G"; or -NR E R F can be an optionally substituted Cp
C6 alkylideneamino; or -NR E R F can be an optionally substituted heterocyle; each R G can be independently selected from from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl; each R can be independently selected from the group consisting of hydrogen, Ci-C3 alkoxy, Ci-C3 alkyl, Ci-C3 haloalkyl, an optionally substituted aryl and optionally substituted heteroaryl; each R1 can be independently selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl; each RJ can be independently selected from the group consisting of aryl and heteroaryl, each substituted with one or more -NR E R F ; each m can be independently 0, 1, or 2; and each n can be independently 0, 1, 2, 3, or 4.
[0322] Some embodiments disclosed herein provide a compound of Formula III having the proviso that a compound of Formula III is not selected from the group consisting of:
Figure imgf000066_0001
Figure imgf000067_0001
66
Figure imgf000068_0001
[0323] Some embodiments disclosed herein provide a compound of Formula
Figure imgf000068_0002
and pharmaceutically acceptable salts, esters stereoisomers, tautomers or prodrugs thereof;
wherein:
[0324] A is selected from the group consisting of heterocycle, aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 31 , R 32 , and R 33 , said aryl and heteroaryl in the definition of A 8 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0325] G is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of
R 34 , R 35 , and R 36 , said aryl and heteroaryl in the definition of G 8 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0326] J is selected from the group consisting of aryl, heteroaryl, heterocycle, -C(=0)-, -(CH=CH)_ -OC(=0)-, -NHC(=0)NH- -NHC(=S)NH- -S(=0)2-NH2- -OC(=S)-, -NHC(=S)-, -(CH2)„NH-, -(CH2)n[NHC(=0)](CH2)0NHC(=0)(CH2)p-,
Figure imgf000069_0001
null;
[0327] Q is selected from the group consisting of aryl, heteroaryl, heterocycle, -C(=0)-, -(CH=CH)- -OC(=0)-, -NHC(=0)NH- -NHC(=S)NH- -
S(=0)2-NH2- -OC(=S)-, -NHC(=S)-, -(CH2)„NH-
- =0)](CH2)0NHC(=0)(CH2)p-, -(CH2)n[NHC(=0)](CH2)0[NH]q_
; or Q8 i
Figure imgf000069_0002
5 39
[0329] X is selected from the group consisting of N (nitrogen) and CR ;
[0330] Y5 is selected from the group consisting of N (nitrogen) and CR40;
27
[0331] each R is independently selected from the group consisting of hydrogen, halogen, and an optionally substituted CrC4 alkyl; [0332] each R is independently selected from the group consisting of hydrogen and an optionally substituted C1-C4 alkyl;
[0333] 31
each R is independently selected from the group consisting of halogen, cyano, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
[0334] 32
each R is independently selected from the group consisting of halogen, -(CH2)mORA, -NRBRC, and -(CH2)mSRA;
[0335] 33
each R is independently selected from the group consisting of halogen, -C(=0)OH, -(CH2)mORD, -NRERF, -NRLC(=0)NRBRc, -(CH2)mS(O)0-2RD, - (CH2)mN02, -(CH2)mCN, and -(CH2)mRG;
[0336] each R34 is independently selected from the group consisting of halogen, cyano, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
[0337] 35
each R is independently selected from the group consisting of halogen, C(=0)OH, -(CH2)mORA, -NRBRC, -C(=0)NRBRc, and -(CH2)mSRA;
[0338] each R36 is independently selected from the group consisting of halogen, -(CH2)mORD, -NRERF, -NRLC(=0)NRBRc, -(CH2)mS(O)0-2RD, -(CH2)mN02, - (CH2)mCN, and -(CH2)mRG;
[0339] each R39 and R40 are independently selected from the group consisting of hydrogen, halogen, -OH, -NHR , and an optionally substituted C1-C4 alkyl;
[0340] each RA is independently selected from the group consisting of hydrogen, CrC6 alkyl, CrC6 haloalkyl, CrC6 heteroalkyl, and CrC6 heterohaloalkyl;
[0341] B C B C
each -NR R is separately selected, wherein R and R are each
H H
independently selected from the group consisting of hydrogen, -S02R , -C(=0)R , -C(=0)C(=0)RH, -(CH2)mC(=0)ORH, -C(=0)NRERF, -(CH2)mRG, -(CH2)mORH, -
(CH2)mR , CrC6 alkyl, C3-C7 cycloalkyl, C2-C6 alkenyl, non-aromatic heterocycle, CrC6 haloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl where the C3-C7 cycloalkyl and the non-aromatic heterocycle are optionally fused with an an optionally substituted aryl or an optionally substituted heteroaryl; or -NR B R C is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -NR B R C is an optionally substituted Ci-C6 alkylideneamino;
[0342] each RD is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and -(CH2)mR
[0343] each -NR E R F is separately selected, wherein R E and R F are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6
G E F
heteroalkyl, and -(CH2)mR"; or -NR R is an optionally substituted Ci-C6 alkylideneaminyl; or -NR E R F is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0344] each R is independently selected from an optionally substituted aryl and an optionally substituted heteroaryl;
[0345] RH is selected from the group consisting of hydrogen, C1-C3 alkyl, Ci- C3 haloalkyl, C3-C7 cycloalkyl, and an optionally substituted aryl or an optionally substituted heteroaryl;
[0346] each RL is independently selected from the group consisting of C3-C7 cycloalkyl, optionally substituted Ci-C6 alkyl, optionally substituted Ci-C6 alkoxy, -(CH2)mORLA, -(CH2)mNRLBRLC, aryl and heteroaryl, said aryl and heteroaryl in the definition of RL are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Cp
C6 alkoxy, -(CH2)mNR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of RL are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -(CH2)mNRLFRLG;
[0347] each RLA is independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
[0348] R LB and R LC are each independently selected from the group consisting
LB LC
of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, and Ci-C6 heteroalkenyl; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0349] each -NRLDRLE is separately selected, wherein RLD and RLE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted Ci-C6 alkyl, said aryl and heteroaryl in the definition of R and
R LE are each optionally substituted with CrC6 alkyl or CrC6 alkoxy; or -NR LD R LE is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0350] each -NR LF R LG is separately selected, wherein R L"Fr and R L"G are each independently selected from the group consisting of hydrogen, and Ci-C6 alkyl; or
-NR LF R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0351] each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and Ci-C6 alkyl; or
-NR LF R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0352] each m is independently 0, 1, or 2;
[0353] each n is independently 0, 1, 2, 3, or 4;
[0354] each o is independently 1, 2, or 3;
[0355] each p is independently 0, 1, 2, or 3;
[0356] each q is independently 0 or 1 ; and
[0357] any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
[0358] Some embodiments disclosed herein provide a compound of Formula
IV, wherein J 8 and Q 8 can each be null. Some embodiments disclosed herein provide a compound of Formula IV, wherein A can be aryl substituted with one or more substituents selected from the group consisting of R 31 , R 32 , and R 33 ; J 8 can be
-NHC(=0)-; L can b
Figure imgf000072_0001
can be null; and G can be aryl substituted with one or more substituents selected from the group consisting of R , R , and R . Some embodiments disclosed herein provide
be aryl substituted with one or more R ; J c
Figure imgf000072_0002
Q can be
Figure imgf000073_0001
; and G can be aryl substituted with one or more R . Some embodiments disclosed herein provide a compound of Formula IV, wherein A can be heteroaryl substituted with one or more substituents selected from the group consisting of
R 31 , R 32 , and R 3J3J; G 8° can be heteroaryl substituted with one or more substituents selected
from the group consisting of R , R , and R ; J can be
Figure imgf000073_0002
; and Q can be s disclosed herein provide a compound of Formula IV,
Figure imgf000073_0003
can be -C(=0)-; Q8 can be -C(=0)NH-; A can aryl substituted with R32; G8 can be aryl substituted with R35; R32 can be -NRBRC, and R35 can be -NRBRC.
[0359] Some embodiments disclosed herein rovide a compound of Formula
IV having the structure of Formula IVa:
Figure imgf000073_0004
(IVa), and pharmaceutically acceptable salts thereof, wherein J can be selected from the group
consisting -OC(=0)-, -S(=0)2-NH2-, -(CH2)„NH-, and
Figure imgf000073_0005
can be selected from the group consisting -OC(=0)-, -S(=0)2-NH2-, -(CH2)nNH-, and
Figure imgf000073_0006
Some embodiments disclosed herein provide a compound of Formula
IVa, wherein J can be selected from the group consisting of -S(=0)2-NH2- and ; and Q can be selected from the group consisting -S(=0)2-NH2-,and
Figure imgf000074_0001
[0360] Some embodiments disclosed herein provide a compound of Formula
IV having the structure of Formula IVb:
Figure imgf000074_0002
(IVb), and pharmaceutically acceptable salts thereof, wherein Je can be -CH=CH-; or Je can be null; and Q 8 can be -CH=CH-; or Q 8 can be null.
[0361] Some embodiments disclosed herein provide a compound of Formula
IVb having the structure of Formula IVba:
Figure imgf000074_0003
(IVba), and pharmaceutically acceptable salts thereof.
[0362] Some embodiments disclosed herein provide a compound of Formula of Formula IVbc:
Figure imgf000074_0004
(IVba), and pharmaceutically acceptable salts thereof.
[0363] Some embodiments disclosed herein provide a compound of Formula
IV having the structure of Formula IVc:
Figure imgf000074_0005
(IVc), and pharmaceutically acceptable salts thereof, wherein J can be selected from the group consisting of -OC(=0)-, -NHC(=0)NH- -S(=0)2
Figure imgf000075_0001
; or J can be null; Q can be selected from the group consisting of -OC(=0)-, -NHC(=0)NH-,
0)2-NH2- and
Figure imgf000075_0002
or Qe can be null.
[0364] Some embodiments disclosed herein rovide a compound of Formula
IVc having the structure of Formula IVca:
Figure imgf000075_0003
(IVca), and pharmaceutically acceptable salts thereof, or having the structure of Formula IVcb:
Figure imgf000075_0004
(IVcb), and pharmaceuticall acceptable salts thereof, or
having the structure of Formula IVcc:
Figure imgf000075_0005
(IVcc), and pharmaceutically acceptable salts thereof.
[0365] Some embodiments disclosed herein rovide a compound of Formula
having the structure of Formula IVd:
Figure imgf000075_0006
(IVd), and pharmaceutically acceptable salts thereof, wherein J can be selected from the group
consisting of -C(=0)-, -(CH2)„NH- -NHC(=S)NH-, and
Figure imgf000075_0007
; or J can be null;
Qe 8 can be selected from the group consisting of -C(=0)-, -NHC(=S)NH-, and
O
R28 [0366] Some embodiments disclosed herein rovide a compound of Formula
IVd having the structure of Formula IVda:
Figure imgf000076_0001
(IVda), and harmaceutically acceptable salts thereof, or having the structure of Formula IVdb:
Figure imgf000076_0002
(IVdb), and pharmaceuticall acceptable salts thereof, or
having the structure of Formula IVdc:
Figure imgf000076_0003
(IVdc), and pharmaceutically acceptable salts thereof, or having the structure of Formula IVde:
Figure imgf000076_0004
(IVde), and pharmaceutically acceptable salts thereof.
[0367] Some embodiments disclosed herein rovide a compound of Formula
having the structure of Formula IVe:
Figure imgf000076_0005
(IVe), and pharmaceutically acceptable salts thereof, wherein J can be null; and Q can be
Figure imgf000076_0006
[0368] Some embodiments disclosed herein provide a compound of Formula
IVe having the structure of Formula IVea:
Figure imgf000076_0007
(IVea), and pharmaceutically acceptable salts thereof, or having the structure of Formula IVeb:
Figure imgf000077_0001
(IVeb), and pharmaceutically acceptable salts thereof, or
having the structure of Formula IVec:
Figure imgf000077_0002
(IVec), and pharmaceutically acceptable salts thereof.
[0369] Some embodiments disclosed herein rovide a compound of Formula
IV having the structure of Formula IVf:
Figure imgf000077_0003
(IVf), and pharmaceutically acceptable salts thereof.
[0370] Some embodiments disclosed herein provide a compound of Formula
IV having the structure of Formula IVg:
Figure imgf000077_0004
(IVg), and pharmaceutically acceptable salts thereof, wherein J can be selected from the group consisting of -(CH2)„[NHC(=0)](CH2)oNHC(=0)(CH2)p- and
-(CH2)n[NHC(=0)](CH2)0[NH]q-.
[0371] Some embodiments disclosed herein provide a compound of Formula
IV havin the structure of Formula IVh:
Figure imgf000077_0005
(IVh), and pharmaceutically acceptable salts thereof, wherein R can be selected from the group consisting hydrogen, R31, R32, and R33. [0372] Some embodiments disclosed herein rovide a compound of Formula
IV having the structure of Formula IVi:
Figure imgf000078_0001
(IVi), and pharmaceutically acceptable salts thereof, wherein R 80 can be selected from the group consisting of hydrogen, R 31 , R 32 , and R 33. Some embodiments disclosed herein provide a compound of Formula IVi, wherein G can be phenyl optionally substituted with one or more substituents selected from the group consisting of R34, R35, and R36.
[0373] Some embodiments disclosed herein provide a compound of Formula IV having the proviso that a compound of Formula IV is not selected from the group consisting of:
Figure imgf000078_0002
Figure imgf000078_0003
Figure imgf000079_0001
Figure imgf000080_0001
[0374] Some embodiments disclosed herein provide a compound of Formula
Figure imgf000080_0002
and pharmaceutically acceptable salts, esters, stereoisomers, tautomers or prodrugs thereof;
wherein:
[0375] G4 is selected from the group consisting of is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R43 and R44, said aryl and heteroaryl in the definition of G4 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0376] Q is selected from the group consisting of an ester, an amide, a urea, a carbamide, a thioamide, a sulfonamide; or Q is selected from the group consisting of -C(=0)0- -C(=0)NR45-, -C(=0)NHN=CH- -NR45C(=0)NR45-,
-NR45C(=0)(CH2)mO- -OC(=0)NR45-, -C(=S)NR45-, -NR45S(0)i_2- C C6
alkylideneamino, and
Figure imgf000080_0003
; or when Y3 is C (carbon) substituted with - Q3- G4 then Q3 is optionally fused with Z1 to form a five-member ring heterocycle; [0377] L3 is selected from the group consiting of -C(=0)NR45-, -0-Ci-C8- alkyl, -C(=NR45)-, -NR45C(=0)-(CH2)mC(=0)NR45-, and -NR45C(=0)- (CH2)mNR45C(=0)-;
[0378] Q4 is selected from the group consisting of of NR48, and O (oxygen); or Q4 is null;
[0379] A4 is selected from the group consisting of CrC6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, a Ci-C6 heteroalkyl, phenyl, pyridinyl, imidazolyl, and thienyl, each optionally substituted with one or more substituents selected from the group consisting of R41 and R42;
Figure imgf000081_0001
are each independently selected from N (nitrogen) and
CR46;
Figure imgf000081_0002
are each independently selected from N (nitrogen) and
CR47;
[0382] Z, Z 1 2
, and Z are each independently selected from C (carbon), CH, and N (nitrogen);
[0383] R41 is independently selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted CrC6 heteroalkyl;
[0384] 42
each R is independently selected from the group consisting of - (CH2)mORA, -0(CH2)mORA, -NRBRC, -C(=0)NRBRc, -C(=NNRBRC)H, -(CH2)mSRA, - (CH2)mRK, -0(CH2)mRK;
[0385] or R41 and R42 are linked to form an optionally substituted ring;
[0386] each R43 is independently selected from the group consisting of halogen, cyano, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl;
[0387] each R44 is independently selected from the group consisting of - (CH2)mORA, -0(CH2)mORA, -NRBRC, -C(=0)NRBRc, -C(=NNRBRC)H, -(CH2)mSRA, - (CH2)mRK, -0(CH2)mRK; [0388] each R is independently selected from the group consisting of hydrogen, an optionally substituted C1-C4 alkyl, and an optionally substituted CrC6 heteroalkyl;
[0389] each R46 and R47 is independently selected from the group consisting of hydrogen, halogen, an optionally substituted Ci-C6 alkyl, and an optionally substituted CrC6 heteroalkyl;
[0390] R 48 is selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, and an optionally substituted Ci-C6 heteroalkyl;
[0391] each RA is independently selected from the group consisting of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl;
[0392] each -NR B R C is separately selected, wherein R B and R C are each independently selected from the group consisting of hydrogen, -SO2R F , -C(=0)R F , -(CH2)mRF, -S02NRDRE, -C(=0)NRDRE, -(CH2)mNRDRE, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl where the alkyl and the heteroalkyl are optionally fused with an aryl or heteroaryl; or -NR B R C is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or
-NR B R C is an optionally substituted Ci-C6 alkylideneamino;
[0393] each -NR D R E is separately selected, wherein R D and R E are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and -(CH2)mR G"; or -NR D R E is an optionally substituted Ci-C6 alkylideneaminyl; or -NR D R E is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0394] each R is independently selected from the group consisting of hydrogen, an optionally substituted C1-C4 alkyl, an optionally substituted C1-C4 haloalkyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, aryl and heteroaryl, where the aryl and heteroaryl in the definition of R are each optionally substituted with -C(=0)NRDRE or -NRDRE; [0395] each R is independently selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl;
[0396] each RK is independently selected from the group consisting of
D E D E
-C(=0)NR R , -NR R , an optionally substituted aryl and an optionally substituted heteroaryl;
[0397] each m is independently 0, 1, or 2; and
[0398] each dashed line represents an optional double bond.
[0399] Some embodiments disclosed herein rovide a compound of Formula
V having the structure of Formula Va:
Figure imgf000083_0001
pharmaceutically acceptable salts, esters, or prodrugs thereof, wherein G4 can be selected from the group consisting of hydrogen, halogen, -(CH2)mORA, -0(CH2)mORA, -NRBRC, an optionally substituted CrC6 alkyl, an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted tetrazolyl, and an optionally substituted imidazolyl; Q can be selected from the group consisting of -C(=0)0-, -C(=0)NH- -C(=0)NHNH- -NR45C(=0)N 45-, -OC(=0)NR45-, -C(=S)NR45-, -NR45S(0)i_2-
Ci-C6 alkylideneaminyl, and
Figure imgf000083_0002
; or Q3 can be null; A4 can be selected from the group consisting of a aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R41 and R42, said aryl and heteroaryl in the definition of A4 can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle; L3 can be selected from -O- (oxygen), -S(O)0-2- -NR45S(0)i_2- -NR45C(=0)-(CH2)mC(=0)NR45-, -NR45C(=0)-(CH2)mNR45C(=0)-, -NR45-, -C(=0)-, -C(=S)-, -C(=0)NR45-, -C(=NR45)-, an optionally substituted C C8 alkyl, an optionally substituted Ci-C8 heteroalkyl, an optionally substituted heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl; or L3 can be null; each R41 can be independently selected from the group consisting of hydrogen, halogen, and an
42
optionally substituted C1-C3 alkyl; each R can be independently selected from the group consisting of hydrogen and an optionally substituted C1-C3 alkyl; each R43 can be independently selected from the group consisting of halogen, an optionally substituted Cp C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted CrC6 heteroalkyl; each R44 can be independently selected from the group consisting of halogen, -(CH2)mORA, -0(CH2)mORA, -NRBRC, -C(=0)NRBRc, -C(=NNRBRC)H, -(CH2)mRK, -0(CH2)mR , an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted CrC6 heteroalkyl; each R45 can be independently selected from the group consisting of hydrogen, and an optionally substituted C1-C4 alkyl; each RA can be independently selected from the group consisting of hydrogen, CrC6 alkyl, and CrC6 haloalkyl; each
B C lected, wherein B C
-NR R can be separately se R and R can each be independently selected from the group consisting of hydrogen, -S0 F F F
2R , -C(=0)R , -(CH2)mR , -(CH2)mORF, -S02NRDRE, -C(=0)NRDRE, -C(=NH)NRDRE, -(CH2)mNRDRE, Ci-C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, CrC6 haloalkyl, CrC6 heteroalkyl, and Cp C6 heterohaloalkyl where the alkyl and the heteroalkyl are optionally fused with an aryl or heteroaryl; or B C
-NR R can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or B C
-NR R can be an optionally substituted Ci-C6 alkylideneamino; each D E can be separately selected, wherein D E
-NR R R and R can each be independently selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted roalkyl, and G D E
C C6 hete -(CH2)mR"; or -NR R can be an optionally substituted ino; or D E
Ci-C6 alkylideneam -NR R can be an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom; each R can be independently selected from the group consisting of hydrogen, an optionally substituted C1-C3 alkyl, an optionally substituted C1-C3 haloalkyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, aryl and heteroaryl, where the aryl and heteroaryl in the definition of F D E
R can each be optionally substituted with -C(=0)NR R or D E G
-NR R ; each R" can be independently selected from an optionally substituted aryl and an optionally substituted heteroaryl; each R can be independently selected from the group consisting of D E D E
-C(=0)NR R , -NR R , an optionally substituted aryl and an optionally substituted heteroaryl; each m can be independently 0, 1, or 2; and each dashed line represents an optionally double bond.
[0400] Some embodiments disclosed herein provide a compound of Formula Va, wherein G4 can be selected from the group consisting of hydrogen, halogen, -(CH2)mORA, -0(CH2)mORA, -NRBRC, an optionally substituted Ci-C6 alkyl, an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted tetrazolyl, and an optionally substituted imidazol l; Q can be selected from the group
consisting of -C(=0)NH-, and
Figure imgf000085_0001
; or Q can be null: A can be selected from the group consisting of phenyl, naphthyl, dihydrobenzofuranyl, 1,4- benzodioxanyl, benzotriazolyl, benzimidazolyl, benzofuranyl, and 2,1,3-benzoxadiazolyl, each optionally substituted with one or more substituents selected from the group consisting of, each optionally substituted with one or more substituents selected from the group consisting of R41 and R42; L3 can be a 1-6 atom long linker comprising one or more groups selected from-NR45-, -C(=0)-, -C(=S)-, and -C(=0)NR45— ; or L3 can be null; each R41 can be independently selected from the group consisting of halogen, an optionally substituted ptionally substituted 42
Ci-C6 alkyl, and an o Ci-C6 alkoxy; each R can be independently selected from the group consisting of -(CH2)mORA, -0(CH2)mORA, -NRBRC, -C(=0)NRBRc, -C(=NNRBRC)H, -(CH2)mRK and -0(CH2)mRK ; each R45 can be independently selected from the group consisting of hydrogen, and methyl; each RA can be independently selected from the group consisting of hydrogen, C1-C4 alkyl, and Ci-
B C can be separately selected, wherein B C
C4 haloalkyl; each -NR R R and R can each be independently selected from the group consisting of hydrogen, F F
-C(=0)R , -(CH2)mR , -S02NRDRE, -C(=0)NRDRE, -C(=NH)NRDRE, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, and kyl; or B C
Ci-C6 haloal -NR R can be an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom; or B C
-NR R can be an optionally substituted Ci-C6 alkylideneamino; each -NR R can be separately selected, wherein R and R can each be independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, and G D E
-(CH2)mR"; or -NR R can be an optionally substituted Ci-C6 alkylideneaminyl; or D E
-NR R can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; each R can be independently selected from the group consisting of hydrogen, an optionally substituted C1-C3 alkyl, an optionally substituted C3-C6 cycloalkyl, an optionally substituted C3-C6 cycloalkenyl, an optionally substituted C1-C3 haloalkyl, aryl and heteroaryl, where the aryl and heteroaryl in the
F D E D E
definition of R can each be optionally substituted with -C(=0)NR"R" or -NR R ; each R can be independently selected from an optionally substituted aryl and an optionally substituted heteroaryl; each m can be independently 0, 1, or 2; and each dashed line represents an optional double bond.
[0401] Some embodiments disclosed herein provide a compound of Formula V, wherein G4 can be selected from the group consisting of hydrogen, halogen, - (CH2)mORA, -0(CH2)mORA, -NRBRC, an optionally substituted Ci-C6 alkyl, an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted tetrazolyl, and an optionally substituted imidazolyl; Q can be selected from the group consisting of an ester, an amide, a urea, a carbamide, a thioamide, an imidamide, a sulfonamide, and a hydrazide derivative; or Q is selected from the group consisting of -C(=0)0-, -C(=0)NH- -NR45C(= 45-, -OC(=0)NR45-, -C(=S)NR45-, -NR45S(0)i_2- C C6
alkylideneaminyl, and
Figure imgf000086_0001
; or Q can be null; A can be selected from the group consisting of a aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R41 and R42, said aryl and heteroaryl in the definition of A4 can each be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle; L can be selected from -O- (oxygen), -S(O)0-2- -NR45S(0)i_2- -NR45-, -C(=0)-, -C(=S)-, -C(=0)NR45-, -C(=NR45)-, -NR45C(=0)-(CH2)mC(=0)NR45-, -NR45C(=0)- (CH2)mNR45C(=0)-, an optionally substituted Ci-C8 alkyl, an optionally substituted Ci- C8 heteroalkyl, an optionally substituted heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl; or L3 can be null; each R41 can be independently selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted Ci-C6 haloalkyl, an
42
optionally substituted Ci-C6 heteroalkyl, and null; each R can be independently selected from the group consisting of -(CH2)mORA, -NRBRC, -C(=0)NRBRc, -C(=NNRBRC)H, - (CH2)mR , -0(CH2)mR , an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted Ci- C6 heteroalkyl; each R45 can be independently selected from the group consisting of hydrogen, and an optionally substituted C1-C4 alkyl; each RA can be independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl; each -
B C separately selected, wherein B C
NR R can be R and R can each be independently
F F F
selected from the group consisting of hydrogen, -S02R , -C(=0)R , -(CH2)mR , -(CH2)mORF, -S02NRDRE, -C(=0)NRDRE, -C(=NH)NRDRE, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl where the alkyl and the heteroalkyl are optionally fused with an aryl or heteroaryl; or B C
-NR R can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -
B C D E
NR R can be an optionally substituted Ci-C6 alkylideneamino; each -NR R can be separately selected, wherein R and R can each be independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and -(CH2)mR ; or D E be an optionally substituted D E
-NR R can Ci-C6 alkylideneaminyl; or -NR R can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; each R can be independently selected from the group consisting of hydrogen, C1-C3 alkyl, C1-C3 haloalkyl, aryl and heteroaryl, where the aryl and heteroaryl in the definition of RF can each be optionally substituted with -C(=0)NRDRE or -NRDRE; each RG can be independently selected from an optionally substituted aryl and an optionally substituted heteroaryl; each m can be independently 0, 1, or 2; and one dashed line represents a double bond.
[0402] Some embodiments disclosed herein rovide a compound of Formula
Va having the structure of Formula Vb:
Figure imgf000087_0001
pharmaceutically acceptable salts, wherein G4 can be selected from the group consisting of hydrogen, halogen, fluoro, chloro, bromo, -ORA, -0(CH2)mORA, -NRBRC, an optionally substituted Ci-C6 alkyl, an optionally substituted phenyl, an optionally substituted pyridinyl, an optionally substituted tetrazolyl, and an optionally substituted imidazolyl; A4 can be phenyl optionally substituted with one or more substituents selected from the group consisting of R41 and R42, where the phenyl in the definition of A4 can be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle; L3 can be selected from -C(=0)NR45-, -NR45C(=0)-(CH2)mC(=0)NR45-, -NR45C(=0)-(CH2)mNR45C(=0)-, and an optionally substituted heteroaryl; or L3 can be null; each R41 can be independently selected from the group consisting of halogen, an optionally substituted CrC6 alkyl, an optionally substituted Ci-C6 alkoxy; each R 42 can be independently selected from the group consisting of -(CH2)mORA, -0(CH2)mORA, -NRBRC, -C(=0)NRBRc, -C(=NNRBRC)H, -
(CH2)mR K , -0(CH2)mR K ; each R 45 can be independently selected from the group consisting of hydrogen, and an optionally substituted CrC4 alkyl; each RA is independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl; each -NR B R C can be separately selected, wherein R B and R C can each be independently selected from the group consisting of hydrogen, -S02R F , -C(=0)R F , -(CH2)mRF, -(CH2)mORF, -S02NRDRE, -C(=0)NRDRE, -C(=NH)NRDRE, - (CH2)mNRDRE , Ci-C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ci-C6 haloalkyl, d- C6 heteroalkyl, and Ci-C6 heterohaloalkyl where the alkyl and the heteroalkyl are optionally fused with an aryl or heteroaryl; or -NR B R C can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; each -NR R can be separately selected, wherein R and R can each be independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and -(CH2)mR ; or -NR D R E can be an optionally substituted Ci-C6 alkylideneaminyl; or -NR D R E can be an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; each R can be independently selected from the group consisting of hydrogen, an optionally substituted Ci-C3 alkyl, an optionally substituted C3-C7 cycloalkyl, aryl and heteroaryl, where the aryl and heteroaryl in the definition of R can each be optionally substituted with -C(=0)NR D"R E" or -NR D R E ; each R G" can be independently selected from an optionally substituted aryl and an optionally substituted heteroaryl; each R can be independently selected from the group consisting of -C(=0)NR D R E , -NR D R E , an optionally substituted aryl and an optionally substituted heteroaryl; each m can be independently 0, 1, or 2; and, each dashed line represents an optionally double bond.
[0403] Some embodiments disclosed herein provide a compound of Formula Vb, wherein G4 can be selected from the group consisting of hydrogen, fluoro, chloro, bromo, imidazolyl, tetrazolyl, N-methyl-N-(2-hydroxyethyl)aminyl, methylaminosulfonamido, 2-hydroxyethyloxy, -(CH2)mORA, -0(CH2)mORA, and
-NR B R C ; A 4" can be phenyl optionally substituted with one or more substituents selected from the group consisting of R41 and R42, where the phenyl in the definition of G4 can be further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle; L can be selected from the group consisting of -C(=0)NH- -NHC(=0)-C(=0)NH- and an optionally substituted heteroaryl; or L3 can be null; each R41 can be an optionally substituted CrC6 alkoxy; each R42 can be independently selected from the group consisting of -(CH2)mORA, -0(CH2)mORA, -NRBRC, -C(=0)NRBRc, -C(=NNRBRC)H, -(CH2)mRK, and
K A
-0(CH2)mir; each Ra can be independently selected from the group consisting of hydrogen, and CrC6 alkyl; each -NR B R C can be separately selected, wherein R B and R C can each be independently selected from the group consisting of hydrogen, -S02R , - C(=0)RF, -(CH2)mRF, -ORF, -S02NRDRE, - (CH2)mNRDRE , C C6 alkyl, and C3-C7 cycloalkyl; or -NR B R C can be selected from the group consisting of pyrrolidinyl, morpholinyl, 4-methylpiperazinyl, piperazinyl, piperidinyl, 3-hydroxypyrrolidinyl, and 4- hydroxypiperidinyl, each optionally substituted with oxo; each -NR R can be separately selected, wherein R and R can each be independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted
C3-C6 cycloalkyl, and -(CH2)mR G"; or -NR D R E can be selected from the group consisting of pyrrolidinyl, morpholinyl, 4-methylpiperazinyl, piperazinyl, piperidinyl, 3- hydroxypyrrolidinyl, and 4-hydroxypiperidinyl, each optionally substituted with oxo; each R can be independently selected from the group consisting of hydrogen, an optionally substituted Ci-C3 alkyl, an optionally substituted C3-C6 cycloalkyl, aryl and heteroaryl, where the aryl and heteroaryl in the definition of R can each be optionally substituted with -NR D R E ; each R G" can be independently selected from an optionally substituted aryl and an optionally substituted heteroaryl; each R can be independently selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl; each m can be independently 0, 1, or 2; and each dashed line represents an optionally double bond. [0404] Some embodiments disclosed herein provide a compound of Formula V, having the proviso that a compound of Formula V is not selected from the group consisting of:
Figure imgf000090_0001
[0405] Some embodiments disclosed herein provide a compound of Formula
VI:
Figure imgf000090_0002
and pharmaceutically acceptable salts, esters, stereoisomers, tautomers or prodrugs thereof;
wherein:
[0406] E is selected from the group consisting of O (oxygen), S (sulfur), NR' 41 and CR42R43;
[0407] R is selected from the group consisting of hydrogen, halogen, cyano, c
-C(=0)R , Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and an optionally substituted Ci-C6 alkyl;
[0408] R42 and R43 are each independently selected from the group consisting of hydrogen, halogen, -OR , -OR ,cc
-NRARB, -NRCRD, SR , -(CH^R*, -CONR R , an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl; or CR42R43 is an optionally substituted C3-C7 cycloalkyl;
[0409] X , X , and X are each independently selected from the group consisting of N (nitrogen) and CR41;
[0410] G9 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R44 and R45, said aryl and heteroaryl in the definition of G9 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0411] each R44 is separately selected from the group consisting of halogen, cyano, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
[0412] each R45 is separately selected from the group consisting of hydrogen, halogen, -ORAA, -ORcc, -NRARB, -NRCRD, -SRAA, -(CH2)mRE, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and an optionally substituted CrC6 alkyl;
[0413] each RAA is independently selected from the group consisting of hydrogen, -(CH2)mS02RF, -(CH2)mC(=0)RF, -(CH2)mC(=0)NRcRD, an optionally substituted Ci-C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, and an optionally substituted C3- C7 cycloalkyl, where said C3-C7 cycloalkyl is optionally fused with an aryl or heteroaryl;
[0414] each R is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, an optionally substituted C3-C7 cycloalkyl, and (CH2)mR ;
[0415] each -NR A R B is separately selected, wherein R A and R B are each independently selected from the group consisting of hydrogen, -(CH2)mS02R , -(CH2)mC(=0)RF, -(CH2)mC(=0)NRcRD , an optionally substituted C C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, and an optionally substituted C3-C7 cycloalkyl, where said C3-
C7 cycloalkyl is optionally fused with an aryl or heteroaryl; or -NR A R B is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom optionally fused with an aryl or heteroaryl; or -NR A R B is an optionally substituted Ci-C6 alkylideneamino;
[0416] each -NR C RD is separately selected, wherein R C and RD are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, an optionally substituted C3-C7 cycloalkyl, and (CH2)mR E"; or -NR C RD is an optionally substituted Ci-C8 alkylideneamino; or -NR C R D is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0417] each R is separately selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl;
[0418] each R is separately selected from the group consisting of hydrogen, a an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted aryl and an optionally substituted heteroaryl;
[0419] L9 is selected from the group consisting of -(CH2)mC(=0)NR46(CH2)q-, -(CH2)mC(=0)NR46(CH2)qC(=0)NR46-, -S(0)2NH-, O (oxygen), -NR46-, -OC(=0)0-, -OC(=0)NH-, -NHC(=0)NH-, -NHC=SNH-, -C(=NR46)-, -C(=0)NR46-, -C(=S)NR46-; or L9 is null;
[0420] each R46 is independently selected from the group consisting of hydrogen, Ci-C6 haloalkyl, and an optionally substituted Ci-C6 alkyl;
[0421] each m is independently 0, 1, or 2;
[0422] each q is independently 1, 2, 3, 4, 5, or 6; and
[0423] any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
[0424] Some embodiments disclosed herein provide a compound of Formula
VI having the structure of Formula Via:
(Via), and pharmaceutically acceptable salts.
[0425] Some embodiments disclosed herein provide a compound of Formula
VII:
Figure imgf000092_0002
[0426] and pharmaceutically acceptable salts, esters, stereoisomers, tautomers or prodrugs thereof;
wherein: [0427] G is selected from the group consisting of Ci-C6 alkyl, Ci-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ci-C6 haloalkyl, Cp C6 heteroalkyl, heterocycle, aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R51, R52, and R53, said aryl and heteroaryl in the definition of G10 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0428] Q10 is selected from the group consisting of Q11, Qn-Q12, and Q11-
Q12-Q13;
11 13
[0429] Q and Q are each independently selected from the group consisting of piperazinyl, -C(=0)0- -C(=0)NR51-, -NR51C(=0)NR51-, -OC(=0)NR51-, -C(=S)NR51-, -NR51S(0)i-2- -(CH2)mC(=0)NR51(CH2)q-, and
-(CH2)mC(=0)NR51(CH2)qC(=0)NR51-;
12
[0430] Q is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocycle;
[0431] each R51 is separately selected from the group consisting of hydrogen, halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
52
[0432] each R is separately selected from the group consisting of - (CH2)mORA, -(CH2)mNRBRc, -(CH2)mS02NRBRc , and -(CH2)mSRA;
53
[0433] each R is separately selected from the group consisting of - (CH2)mORD, - (CH2)mNRERF, -(CH2)mS(O)0-2RD, -(CH2)mN02, -(CH2)mCN, and - (CH2)mRG;
[0434] each R54 is separately selected from the group consisting of hydrogen, -(CH2)mORA, -(CH2)mNRBRc, -0(CH2)mNRBRc, -C(=0)NRBRc, -(CH2)mSRA, -(CH2)mRG, -0(CH2)mRG, -(CH2)mS02NRBRc -(CH2)mCN, an optionally substituted d- C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl; [0435] each RA is separately selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted CrC6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
[0436] each -NR B R C is separately selected, wherein R B and R C are each independently selected from the group consisting of hydrogen, -(CH2)mS02R , - (CH2)mCORH, -(CH2)mCONRERF, an optionally substituted C C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, an optionally substituted C3-C7 cycloalkyl, and -(CH2)mR , where said C3-C7 cycloalkyl is optionally fused with an aryl or heteroaryl; or -NR B R C or is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom optionally fused with an aryl or heteroaryl; or -NR B R C is an optionally substituted Ci-C8 alkylideneamino ;
[0437] each RD is separately selected from the group consisting of hydrogen, an optionally substituted Ci-C8 alkyl, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted C3-C8 cycloalkenyl, an optionally substituted Ci-C8 haloalkyl, and an optionally substituted Ci-C8 heteroalkyl;
[0438] each -NR E R F is separately selected, wherein R E and R F are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, an optionally substituted C3-C7 cycloalkyl, and (CH2)mR G"; or -NR E R F or is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -NR R is an optionally substituted Ci-C8 alkylideneamino;
[0439] each R is separately selected from a substituted or unsubstituted aryl and a substituted or unsubstituted heteroaryl;
[0440] each RH is separately selected from the group consisting of hydrogen, a Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, an optionally substituted heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl; [0441] X 1 , X2 , and X 3 are each independently selected from the group consisting of N (nitrogen) and CR 47 ;
[0442] each R 47 is separately selected from the group consisting of hydrogen, halogen, an optionally substituted CrC6 alkyl, and an optionally substituted CrC6 heteroalkyl
[0443] each m is independently 0, 1, 2, or 3; and
[0444] any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
[0445] Some embodiments disclosed herein provide a compound of Formula
VII having the structure of Formula Vila:
Figure imgf000095_0001
(Vila), and pharmaceutically acceptable salts.
[0446] Some embodiments disclosed herein provide a compound of Formula VII, having the proviso that a compound of Formula VII is not selected from the group consisting of:
Figure imgf000095_0002
[0447] Some embodiments disclosed herein provide a compound of
R10c R10b (VIII)
[0448] and pharmaceutically acceptable salts thereof;
[0449] wherein:
RERFN^ J L . NRERF
[0450] A-J is Y O and Q-G is Y O ;
Figure imgf000096_0001
[0454] each E is separately selected from the group consisting of -CR10a- and N (nitrogen);
[0455] each R10a is separately selected from the group consisting of H (hydrogen), halogen, cyano, CrC6 alkyl optionally substituted with up to five fluoro, Cp C6 alkoxy optionally substituted with up to five fluoro, C2-C6 alkenyl optionally substituted with up to five fluoro, C2-C6 alkynyl optionally substituted with up to five fluoro, C3-C7 cycloalkyl optionally substituted with up to five fluoro, and C3-C7 cycloalkenyl optionally substituted with up to five fluoro;
[0456] R10b is selected from the group consisting of R10bb, H (hydrogen), halogen, cyano, CrC6 alkyl optionally substituted with up to five fluoro, CrC6 alkoxy optionally substituted with up to five fluoro, C2-C6 alkenyl optionally substituted with up to five fluoro, C2-C6 alkynyl optionally substituted with up to five fluoro, C3-C7 cycloalkyl optionally substituted with up to five fluoro, and C3-C7 cycloalkenyl optionally substituted with up to five fluoro; [0457] R c is selected from the group consisting of H (hydrogen), R S02-, RuC(=0)-, CrC6 alkyl optionally substituted with up to five fluoro, and C3-C7 cycloalkyl optionally substituted with up to five fluoro, or R10c is R10cc when R10b is R10bb;
[0458] R10cc and R10bb together with the atoms to which they are attached is a five-membered heteroaryl optionally substituted with one or more substituents each separately selected from the group consisting of halogen, cyano, CrC6 alkyl optionally substituted with up to five fluoro, Ci-C6 alkoxy optionally substituted with up to five fluoro, Ci-C6 alkylC(=0)- and C3-C7 cycloalkylC(=0)-;
[0459] A4 is selected from the group consisting of C3-C7 cycloalkenyl, C3-C7 cycloalkyl, C C6 alkyl, C C6 heteroalkyl, C2-C6 alkenyl, C C6 alkoxy, -(CH2)mNRPRL, heterocycle, polycyclic heterocyclyl, aryl, and heteroaryl, said C3-C7 cycloalkenyl, C3-C7 cycloalkyl, Ci-C6 alkyl, Ci-C6 heteroalkyl, C2-C6 alkenyl, heterocycle, polycyclic heterocyclyl, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 ;
[0460] G4 is selected from the group consisting of polycyclic heterocyclyl, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6;
[0461] A5 is selected from the group consisting of polycyclic heterocyclyl, aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 ;
[0462] each R is separately selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C6 alkenyl, and an optionally substituted C3-C7 cycloalkyl;
[0463] each -NRERF is separately selected, wherein each RE is independently selected from the group consisting of hydrogen and an optionally Ci-C6 alkyl, and each R is independently selected from the group consisting of aryl and heteroaryl, said aryl and heteroaryl in the definition of R are each optionally substituted with halogen, cyano, Ci-C6 alkyl, C C6 alkoxy, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, -C(=0)NRNR°, -OC(=0)NRNR°, -NHC(=0)NRNR°, -0(CH2)qNRNR°, -NH(CH2)qNRNR° -(CH2)pNRNR°, an optionally substituted aryl and an optionally substituted heteroaryl, and said aryl and heteroaryl in the definition of R are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0464] R is selected from the group consisting of Ci-C6 alkyl, C3-C6 cycloalkyl, C3-C8 cycloalkenyl, CrC6 heteroalkyl, CrC6 heteroalkenyl, CrC6 heteroalkynyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of R are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle, or RG is -ORL or -NRPRL;
[0465] RH is selected from the group consisting of hydrogen, CrC6 alkyl, C2-
C6 G H
alkenyl, C3-C7 cycloalkyl, and C1-C3 haloalkyl, or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0466] each R1 is separately selected from the group consisting of halogen, cyano, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
[0467] each R is separately selected from the group consisting of halogen, -OCCHa OR1, -(CH^OR1, -NRJRK, -(CH^SR1, -C(=0)RL, -(CH2)mRL, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted CrC6 haloalkyl, an optionally substituted CrC6 heteroalkyl, and an optionally substituted C3-C7 cycloalkyl where said C3-C7 cycloalkyl is further optionally fused with aryl or heteroaryl;
[0468] each R is separately selected from the group consisting of halogen, -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mS(0)o-2RM, -(CH2)mNHS(0)o-2RM, -(CH2)mN02, -(CH2)mCN, -(CH2)mRp, Ci-C6 alkyl CrC6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, CrC6 haloalkyl, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl polycyclic heterocyclyl, and heteroaryl in the definition of R are each optionally substituted with halogen, hydroxy, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, -C(=0)ORM, or - NRJRK; [0469] each R is separately selected from the group consisting of halogen, cyano, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
[0470] each R5 is separately selected from the group consisting of halogen, -OCCH^OR1, -(CH^OR1, -NRJRK, -(CH^SR1, -(CH2)mC(=0)RL, -(CH2)mRL, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
[0471] each R6 is separately selected from the group consisting of halogen, -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, - (CH2)mS(0)o_2RM, -(CH2)mNHS(0)o_2RM, -(CH2)mN02, -(CH2)mCN, -(CH2)mRp, C C6 alkyl, Ci-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, Ci-C6 haloalkyl, Ci- C6 heteroalkyl, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl in the definition of R6 are each optionally substituted with halogen, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, -C(=0)ORM, or -NRJRK;
[0472] each R1 is separately selected from the group consisting of hydrogen, Ci-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C7 cycloalkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl;
[0473] each -NRJRK is separately selected, wherein RJ and RK are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl optionally substituted with up to 5 fluoro, -(CH2)mORJA, -(CH2)mNRJBRJC, -(CH2)mRR, C3-C7 cycloalkyl, heterocycle, aryl and heteroaryl, said C3-C7 cycloalkyl, heterocycle, aryl and heteroaryl in the definition of R T and R K are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off
T K
of RJ and Γ are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -(CH2)mNRKARKB; or -NRJRK is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; [0474] each R is independently selected from the group consisting of hydrogen, CrC6 alkyl, and CrC6 haloalkyl;
[0475] each -NRJBRJC is separately selected, wherein RJB and RJC are each independently selected from the group consisting of hydrogen, CrC6 alkyl, and CrC6 haloalkyl;
[0476] each -NR^R™ is separately selected, wherein R1^ and RKB are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
[0477] each RM is independently selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, and -(CH2)mRP;
[0478] each -NRNR° is separately selected, wherein RN and R° are each independently selected from the group consisting of hydrogen, -(CH2)mNRNARNB, aryl and heteroaryl, said aryl and heteroaryl in the definition of RN and R° are each independently optionally substituted with one or more substituents selected from the group consisting of -(CH2)mNROAROB, halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off of RN and R° are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -NRNARNB,
[0479] each -NRNARNB is separately selected, wherein RNA and RNB are each independently selected from the group consisting of hydrogen, CrC6 alkyl, and CrC6 haloalkyl;
[0480] each -NROAROB is separately selected, wherein ROA and ROB are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
[0481] each Rp is independently selected from the group consisting of hydrogen and CrC6 alkyl;
[[00448822]] eeaacchh RR]L is independently selected from the group consisting of C3-C7 cycloalkyl, optionally substituted CrC6 alkyl, optionally substituted CrC6 alkoxy, - (CH2)mORLA, -(CH2)mNRLBRLC, aryl and heteroaryl, said aryl and heteroaryl in the definition of RL are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-
C6 alkoxy, -(CH2)mNR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of RL are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl,
Ci-C6 alkoxy, or -(CH^NR^R1^;
[0483] each RLA is independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
[0484] R LB and R LC are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, and Ci-C6 heteroalkenyl, said Ci-C6 alkyl, Cp C6 haloalkyl, and Ci-C6 heteroalkenyl each optionally substituted with one or more halogen, cyano, or -(CH2)mC(=0)OH; or -NR LB R LC is an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom;
[0485] each -NRLDRLE is separately selected, wherein RLD and RLE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted Ci-C6 alkyl, said aryl and heteroaryl in the definition of RLD and
LE LD LE
R are each optionally substituted with Ci-C6 alkyl or Ci-C6 alkoxy; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0486] each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and Ci-C6 alkyl; or
-NR LF R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0487] RR is selected from the group consisting of Ci-C6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
[0488] Ru is selected from the group consisting of C3-C7 cycloalkyl Ci-C6 alkyl optionally substituted with up to 5 fluoro, and an optionally substituted heteroaryl;
[0489] each m is independently 0, 1, 2, or 3;
[0490] each p is independently 0, 1, 2, 3, 4, 5, or 6; and
[0491] each q is independently 1, 2, 3, 4, 5, or 6.
[0492] Some embodiments disclosed herein rovide a compound of Formula
VIII having the formula Villa:
Figure imgf000101_0001
(Villa), and pharmaceutically acceptable salts thereof. [0493] Some embodiments disclosed herein provide a compound of Formula
Villa having the formula Vlllaa:
Figure imgf000102_0001
(Vlllaa), and pharmaceutically acceptable salts thereof, and having the formula Vlllab:
Figure imgf000102_0002
(Vlllab), and pharmaceutically acceptable salts thereof.
[0494] Some embodiments disclosed herein provide a compound of Formula
Vlllaa, wherein A-J is
Figure imgf000102_0003
group consisting of aryl and heteroaryl, where at least one atom forming the heteroaryl aromatic ring is a N (nitrogen), and said aryl and heteroaryl are each optionally substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 , and G4 is selected from the group consisting of aryl and heteroaryl, where at least one atom forming the heteroaryl aromatic ring is a N (nitrogen), and said aryl and heteroaryl are each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6.
[0495] Some embodiments disclosed herein provide a compound of Formula
VIII having the formula Vlllb:
Figure imgf000102_0004
(Vlllb), and pharmaceutically acceptable salts thereof, wherein L 5 is E 1 =E1 or E 2 -E 2 , each E 1 is separately selected from the group consisting of -CR10dd- and N (nitrogen), each 10dd is separately selected from the group consisting of H (hydrogen), halogen, cyano, CrC6 alkyl optionally substituted with up to five fluoro, Ci-C6 alkoxy optionally substituted with up to five fluoro, C C6 alkylC(=0)- and C3-C7 cycloalkylC(=0)-, each E2 is separately selected from the group consisting of -CR 7 R 8 - and NR 9 , R 7 and R 8 are each independently selected from the group consisting of hydrogen, -OH, and CrC6 alkyl optionally substituted with up to five fluoro, or optionally CR 7 R 8 is -C(=0)-, and, R 9 is selected from the group consisting of hydrogen, C3-C7cycloalkylC(0)- and CrC6 alkylC(O)-, and CrC6 alkyl optionally substituted with up to five fluoro.
[0496] Some embodiments disclosed herein rovide a compound of Formula
VHIb having the formula VHIbb:
Figure imgf000103_0001
(VHIbb),
pharmaceutically acceptable salts thereof, wherein E is N (nitrogen) and E is -CH-, or E1A is -CH- and E1B is -CH-, or E1A is -CH- and E1B is N (nitrogen); and A-J is
and Q-G is
Figure imgf000103_0002
[0497] Some embodiments disclosed herein provide a compound of Formula
Vlllbb having the formula VHIbbb:
Figure imgf000103_0003
(VHIbbb), and
O pharmaceutically acceptable salts thereof, wherein A-J is H ? and Q-G is
? f L . NRGRH L . NRGRH H , or A-J is H ? and Q_G is O 5 or A-J is O
and Q-G i
Figure imgf000103_0004
A is selected from the group consisting of C5-C7 cycloalkenyl,
C3-C6 cycloalkyl, CrC6 alkyl, CrC6 heteroalkyl, C2-C6 alkenyl, -NRPRL, heterocycle, aryl, and heteroaryl, said C5-C7 cycloalkenyl, C3-C6 cycloalkyl, Ci-C6 alkyl, Ci-C6 heteroalkyl, C2-C6 alkenyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R , R , and R , each R1 is separately selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl, each R 2 is separately selected from the group consisting of -0(CH2)mOR I , -(CH2)mORI , - NRJRK, -(CH2)mSRI, -C(=0)RL, and -(CH2)mRL, each R3 is separately selected from the group consisting of -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mS(0)o-2RM, -(CH2)mNHS(0)o-2RM, -(CH2)mN02, -(CH2)mCN, - (CH2)mRp, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl polycyclic heterocyclyl, and heteroaryl in the definition of R are each optionally substituted with halogen, hydroxy, cyano, CrC6 alkyl, CrC6 haloalkyl, CrC6 alkoxy, - C(=0)ORM, or -NRJRK, G4 is selected from the group consisting of aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, each R4 is separately selected from the group consisting of halogen, cyano, an optionally substituted CrC6 alkyl, and an optionally substituted CrC6 heteroalkyl, each R5 is separately selected from the group consisting of halogen, -(CH2)mOH, -NRJRK, and -(CH2)mC(=0)RL, each RL is independently selected from the group consisting of -OH, Ci-C6 alkyl, and Ci-C6 alkoxy, each R6 is separately selected from the group consisting of -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mRp, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl in the definition of R6 are each optionally substituted with halogen, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, -C(=0)ORM, or -NRJRK, RG within the definition of -NRGRH is heteroaryl optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R 6 , and R H within the definition of -NR G R H is hydrogen.
[0498] Some embodiments disclosed herein provide a compound of Formula
IX:
Figure imgf000104_0001
[0499] and pharmaceutically acceptable salts thereof;
[0500] wherein: [0501] Z is
Figure imgf000104_0002
, or -C(=E3)-; [0502] each E is separately selected from the group consisting of -CR a- and N (nitrogen);
[0503] each R10a is separately selected from the group consisting of H (hydrogen), halogen, CrC6 alkyl optionally substituted with up to five fluoro, and CrC6 alkoxy optionally substituted with up to five fluoro;
[0504] E3 is O (oxygen), N-NHRQ or N-ORQ where RQ in the definition of E3 is selected from the group consisting of hydrogen, Ci-C6 alkyl, C2-C6 alkenyl, -(CH^R1^, and -C(=0)(CH2)mRRA;
[0505] R1^ is selected from the group consisting of Ci-C6 alkyl, aryl, and heteroaryl;
[0506] A9 is hydrogen or Ci-C6 alkyl;
[0507] A10 is selected from the group consisting of CrC6 alkyl, C2-C6 alkenyl, -C(=0)RA, -C(=0)C(=0)RA ,-(CH2)RB, -(CH2)ORB;
[0508] RA is selected from the group consisting of CrC6 alkyl, C3-C7 cycloalkyl, heterocycle, polycyclic heterocyclyl, aryl and heteroaryl, each optionally
1 2 substituted with one or more substituents selected from the group consisting of R , R , and R3;
[0509] R is selected from the group consisting of hydrogen, CrC6 alkyl, Ci-C6 alkoxy, C2-C6 alkenyl, C3-C7 cycloalkyl, and heteroaryl;
[0510] G4 is selected from the group consisting of polycyclic heterocyclyl, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6;
[0511] each R1 is separately selected from the group consisting of halogen, cyano, CrC6 heteroalkyl, an optionally substituted CrC6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
[0512] each R is separately selected from the group consisting of halogen, -C CH^OR1, -(CH. OR1, -NRJRK, -(CH^SR1, -C(=0)RL, -(CH2)mRL, C C6 heteroalkyl, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted CrC6 haloalkyl, and an optionally substituted C3-C7 cycloalkyl where said C3-C7 cycloalkyl is further optionally fused with aryl or heteroaryl;
[0513] each R is separately selected from the group consisting of halogen, -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mS(0)o_2RM, -(CH2)mNHS(O)0-2RM,-(CH2)mCN, -(CH2)mRp, Ci-C6 alkyl Ci-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, Ci-C6 haloalkyl, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl polycyclic heterocyclyl, and heteroaryl in the definition of R are each optionally substituted with halogen, hydroxy, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, -C(=0)ORM, or -NRJRK;
[0514] each R4 is separately selected from the group consisting of halogen, cyano, Ci-C6 heteroalkyl, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
[0515] each R5 is separately selected from the group consisting of halogen, -C CH^OR1, -(CH^OR1, -NRJRK, -(CH^SR1, -(CH2)mC(=0)RL, -(CH2)mRL, C C6 heteroalkyl, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C3-C7 cycloalkyl, and an optionally substituted Ci-C6 haloalkyl;
[0516] each R6 is separately selected from the group consisting of halogen, -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, - (CH2)mS(0)o_2RM, -(CH2)mNHS(0)o_2RM,-(CH2)mCN, -(CH2)mRp, C C6 alkyl, C C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl in the definition of R6 are each optionally substituted with halogen, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, -C(=0)ORM, or -NRJRK;
[0517] R is selected from the group consisting of Ci-C6 alkyl, C3-C6 cycloalkyl, C3-C8 cycloalkenyl, Ci-C6 heteroalkyl, Ci-C6 heteroalkenyl, Ci-C6 heteroalkynyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of R are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle, or RG is -ORL or -NRPRL;
[0518] each R1 is separately selected from the group consisting of hydrogen, Ci-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C7 cycloalkyl, C C6 haloalkyl, C C6 heteroalkyl, and Ci-C6 heterohaloalkyl;
[0519] each -NRJRK is separately selected, wherein RJ and RK are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl optionally substituted with up to 5 fluoro, -(CH2)mORJA, -(CH2)mNRJBRJC, -(CH2)mRR, C3-C7 cycloalkyl, heterocycle, aryl and heteroaryl, said C3-C7 cycloalkyl, heterocycle, aryl and heteroaryl in the definition of R T and R K are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off
T K
of RJ and Γ are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, C C6 alkoxy, or -(CH2)mNRKARKB; or -NRJRK is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0520] each RJA is independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
TR Ti"1 TR Ti"1
[0521] each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
[0522] each -NR^R™ is separately selected, wherein R1^ and RKB are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
[0523] each RM is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, and -(CH2)mRp;
[0524] each -NRNR° is separately selected, wherein RN and R° are each independently selected from the group consisting of hydrogen, -(CH2)mNRNARNB, aryl and heteroaryl, said aryl and heteroaryl in the definition of RN and R° are each independently optionally substituted with one or more substituents selected from the group consisting of -(CH2)mNROAROB, halo, C C6 alkyl, C C6 haloalkyl, C C6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off of RN and R° are each optionally substituted with one or more halo, CrC6 alkyl, CrC6 haloalkyl, CrC6 alkoxy, or -NRNARNB,
[0525] each -NRNARNB is separately selected, wherein RNA and RNB are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
[0526] each -NROAROB is separately selected, wherein ROA and ROB are each independently selected from the group consisting of hydrogen, CrC6 alkyl, and CrC6 haloalkyl;
[0527] Rp is selected from the group consisting of hydrogen and CrC6 alkyl;
[0528] each RL is independently selected from the group consisting of C3-C7 cycloalkyl, optionally substituted CrC6 alkyl, optionally substituted CrC6 alkoxy, - (CH2)mORLA, -(CH2)mNRLBRLC, aryl and heteroaryl, said aryl and heteroaryl in the definition of RL are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-
C6 alkoxy, -(CH2)mNR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of RL are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -(CH2)mNRLFRLG;
[0529] each RLA is independently selected from the group consisting of hydrogen, CrC6 alkyl, and CrC6 haloalkyl;
[0530] R LB and R LC are each independently selected from the group consisting of hydrogen, CrC6 alkyl, CrC6 haloalkyl, and CrC6 heteroalkenyl, said CrC6 alkyl, Cp C6 haloalkyl, and Ci-C6 heteroalkenyl each optionally substituted with one or more halogen, cyano, or -(CH2)mC(=0)OH; or — NR LB R LC is an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom;
[0531] each -NRLDRLE is separately selected, wherein RLD and RLE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted CrC6 alkyl, said aryl and heteroaryl in the definition of RLD and
LE LD LE
R are each optionally substituted with Ci-C6 alkyl or Ci-C6 alkoxy; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0532] each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and CrC6 alkyl; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0533] RR is selected from the group consisting of Ci-C6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; and
[0534] each m is independently 0, 1, 2, or 3.
[0535] In some embodiments, a compound of Formula IX is not selected from the group consisting of:
Figure imgf000109_0001
[0536] provide a compound of Formula
IX having the fo
Figure imgf000109_0002
(IXa), and pharmaceutically wjr
acceptable salts thereof, wherein Z is N— N 5 or -C(=0)-, R is selected from the group consisting of heterocycle, polycyclic heterocyclyl, aryl and heteroaryl, each substituted with one or more substituents selected from the group consisting of R 1 , R 2 , and R 3 , each R 1 is separately selected from the group consisting of chloro, cyano, CrC6 alkyl, Ci-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, and CrC6 haloalkyl, each R is separately selected from the group consisting of -0(CH2)mORI, -(CH2)mORI, -NRJRK, -(CH2)mSRI, -C(=0)RL, and -(CH2)mRL, and each R3 is separately selected from the group consisting of -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mS(O)0-2RM, -(CH2)mNHS(O)0- 2RM, -(CH2)mCN, -(CH2)mRp, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl polycyclic heterocyclyl, and heteroaryl in the definition of R are each optionally substituted with halogen, hydroxy, cyano, CrC6 alkyl, CrC6 haloalkyl, Ci-C6 alkoxy, -C(=0)ORM, or -NRJRK.
[0537] Some embodiments disclosed herein rovide a compound of Formula
IXa having the formula IXaa:
Figure imgf000110_0001
(IXaa), and pharmaceutically acceptable salts thereof, wherein G is selected from the group consisting of polycyclic heterocyclyl, aryl, and heteroaryl, each substituted with one or more substituents selected from the group consisting of R4, R5, and R6, each R4 is separately selected from the group consisting of chloro, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl, each R5 is separately selected from the group consisting of -0(CH2)mORI, -(CH2)mORI, - NRJRK, -(CH2)mSRI, -(CH2)mC(=0)RL, -(CH2)mRL, an optionally substituted C C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl, each R6 is separately selected from the group consisting of -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mS(O)0-2RM, -(CH2)mNHS(0)o_2RM, -(CH2)mN02, -(CH2)mCN, - (CH2)mRp, Ci-Ce alkyl, C C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C C6 haloalkyl, Ci-C6 heteroalkyl, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl in the definition of R6 are each optionally substituted with halogen, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, -C(=0)ORM, or -NRJRK.
[0538] Some embodiments disclosed herein provide a compound of Formula IXa, wherein each R1 is separately selected from the group consisting of cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl, each R 2 is separately selected from the group consisting of -0(CH2)mOR I , -(CH2)mORI, -NRJRK, -(CH2)mSRI, -C(=0)RL, and -(CH2)mRL, each R3 is separately selected from the group consisting of -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mS(O)0-2RM, -(CH2)mNHS(O)0-2RM, -(CH2)mN02, - (CH2)mCN, -(CH2)mRp, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl polycyclic heterocyclyl, and heteroaryl in the definition of R are each optionally substituted with halogen, hydroxy, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, -C(=0)ORM, or -NRJRK, each R4 is separately selected from the group consisting of cyano, an optionally substituted Ci-C6 alkyl, and an optionally substituted Ci-C6 heteroalkyl, each R5 is separately selected from the group consisting of -(CH2)mOH, -NRJRK, and -(CH2)mC(=0)RL, each RL is independently selected from the group consisting of -OH, Ci-C6 alkyl, and Ci-C6 alkoxy, and each R6 is separately selected from the group consisting of -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mRp, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl in the definition of R6 are each optionally substituted with halogen, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, -C(=0)ORM, or -NRJRK.
[0539] Some embodiments disclosed herein provide a method of treating a patient, comprising administering to the patient a therapeutically effective amount of a compound having Formula X:
J1 0 Q10
A1 0' L1 0" ^G1 0 (x) [0540] and pharmaceutically acceptable salts, esters, stereoisomers, tautomers or prodrugs thereof;
wherein:
[0541] A10 is selected from the group consisting of CrC6 alkyl, CrC6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ci-C6 haloalkyl, Ci- C6 heteroalkyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R , R , and R , said aryl and heteroaryl in the definition of A10 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0542] G10 is selected from the group consisting of CrC6 alkyl, CrC6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ci-C6 haloalkyl, Ci- C6 heteroalkyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G10 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0543] J10 is a 1-8 atom long spacer containing at least 2 heteroatoms separated by 2 bonds and comprising one or more groups selected from -S(0)2NRA-, an optionally substituted CrC6 heteroalkyl, an optionally substituted heterocycle, and an optionally substituted heteroalkylheterocycle; including the proviso that J10 is not a 1-8 atom spacer containing at least 2 heteroatoms separated by 3 or 4 bonds and comprising one or more groups selected from an optionally substituted Ci-C6 heteroalkyl, an optionally substituted heterocycle, and an optionally substituted heteroalkylheterocycle;
[0544] Q10 is a 1-8 atom long spacer containing at least 2 heteroatoms separated by 2 bonds and comprising one or more groups selected from -S(0)2NRA-, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted heterocycle, and an optionally substituted heteroalkylheterocycle;
[0545] L10 is a 2-14 atom long linker comprising one or more groups selected from -O- (oxygen), -C(=0)-, -C(=S)-, -NRA- -S(O)0_2-, -NRAS(0)i_2NRA- and - NRAS(0)i_20-, and one or more groups selected from -O- (oxygen), -C(=0)-, -C(=S)-, - NRA- -S(0)o-2- -NRAS(0)i_2NRA- and -NRAS(0)i_20- an optionally substituted C C10 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; where the an optionally substituted aryl and an optionally substituted heteroaryl in the definition of L are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
[0546] R1 is selected from the group consisting of halogen, optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, and an optionally substituted CrC6 heteroalkyl;
2 A B C
[0547] R is selected from the group consisting of halogen, -OR , -NR R , -
SRA;
[0548] R3 is selected from the group consisting of -ORD, -NRERF, -S(0)o-2RD, -NO2, -CN, and -(CH2)mRG, ;
[0549] R4 is selected from the group consisting of halogen, optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, , an optionally substituted Ci-C6 heteroalkyl;
[0550] R5 is selected from the group consisting of -ORA, -NRBRC, -SRA;
[0551] R is selected from the group consisting of -OR , -NR R , -S(0)o-2RD, -NO2, -CN, and -(CH2)mRG;
[0552] each RA is separately selected from the group consisting of hydrogen, -S02RF, -C(=0)RF, -C(=0)NRcRD, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, CrC6 haloalkyl, CrC6 heteroalkyl, and CrC6 heterohaloalkyl, where the Ci-C6 alkyl, C3-C7 cycloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl in the definition of RA are optionally substituted;
[0553] each B C B C
-NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, -S0 H H
2R , -C(=0)R , -C(=0)NRERF, Ci-C6 alkyl, C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, C3-C7 cycloalkyl, CrC6 haloalkyl, CrC6 heteroalkyl, heterocycle, and CrC6 heterohaloalkyl where the cycloalkyl and the heterocycle are optionally fused with an aryl or heteroaryl; or
B C
— NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or B C
-NR R is an optionally substituted Ci-C6 alkylideneamino; [0554] each RD is independently selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted CrC6 heteroalkyl, an optionally substituted heterocyle, and -(CH2)mR ;
[0555] each -NR E R F is separately selected, wherein R E and R F are each independently selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted CrC6 heteroalkyl, an optionally substituted heterocycle, and G E F
-(CH2)mR ; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
[0556] each R is separately selected from an optionally substituted aryl and an optionally substituted heteroaryl;
[0557] each RH is separately selected from the group consisting of hydrogen, a CrC6 alkyl, a CrC6 haloalkyl, a CrC6 heteroalkyl, a C3-C6 cycloalkyl, an optionally substituted heterocycle, and an optionally substituted aryl or an optionally substituted heteroaryl; and
[0558] each m is independently 0, 1, or 2.
[0559] Some embodiments disclosed herein provide a method of treating a patient, comprising administering to the patient a therapeutically effective amount of a compound having Formula X having the structure of Formula Xa:
Figure imgf000114_0001
(Xa), and pharmaceutically acceptable salts thereof, wherein A10 can be selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R1, R2, and R3, said aryl and heteroaryl in the definition of A10 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; and G10 can be selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G10 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle.
[0560] Some embodiments disclosed herein provide a method of treating a patient, comprising administering to the patient a therapeutically effective amount of a compound having Formula X having the structure of Formula Xb:
O O
A10^N ^ ^N -^G 0
I I
K K (Xb), and pharmaceutically acceptable salts thereof, wherein
A10 can be selected from the group consisting of aryl and heteroaryl, each optionally
1 2 substituted with one or more substituents selected from the group consisting of R , R ,
3 10
and R , said aryl and heteroaryl in the definition of A can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; and G10 can be selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G10 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle.
[0561] Some embodiments disclosed herein provide a method of treating a patient, comprising administering to the patient a therapeutically effective amount of a compound having Formula X, wherein A10 can be selected from the group consisting of Ci-C6 alkyl, C3-C7 cycloalkyl, Ci-C6 heteroalkyl, heterocycle, aryl, and heteroaryl, each
1 2 substituted with one or more substituents selected from the group consisting of R , R ,
3 10
and R , said aryl and heteroaryl in the definition of A can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; G10 can be selected from the group consisting of Ci-C6 alkyl, C3-C7 cycloalkyl, Ci-C6 heteroalkyl, heterocycle, aryl, and heteroaryl, each substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G10 can each be further optionally fused with a nonaromatic heterocycle or nonaromatic carbocycle; R1 can be selected from the group consisting of fluorine, chlorine, and methyl; R2 can be selected from the group consisting of -ORA, -NRBRC, and -SRA; R3 can be selected from the group consisting of -(CH2)mR , -OR , and -NR R ; R can be selected from the group consisting of fluorine, chlorine, and methyl; R5 can be selected from the group consisting of -ORA, -NRBRC, and -SRA; R6 can be selected from the group consisting of -(CH2)mRG, -ORD, and -NRERF; J10 and Q10 can each be independently selected from the group consisting of an ester, an amide, a urea, a carbamide, -S(0)2NRA-, a thioamide, a thioester, and an imidamide; L10 can be a 3-13 atom long linker comprising comprising one or more groups selected from -O- (oxygen), -NRA-, -S(0)o-2-, and -NRAS(0)i_20-, and one or more groups selected from -O- (oxygen), -NRA- -S(O)0-2- and -NRAS(0)i_20- an optionally substituted CrC8 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; where the an optionally substituted aryl and an optionally substituted heteroaryl in the definition of L10 can each be further optionally fused with a nonaromatic heterocycle or a nonaromatic carbocycle; and each m can be independently 0, 1, or 2.
[0562] Some embodiments disclosed herein provide a method of treating a patient, comprising administering to the patient a therapeutically effective amount of a compound having Formula X, wherein A10 can be selected from the group consisting of a C2-C6 alkyl, a C2-C7 cycloalkyl, a CrC6 heteroalkyl, a heterocycle, phenyl, pyridinyl, pyrrolyl, pyrimidinyl, imidazolyl, isoxazolyl, thiazolyl, thienyl, indolyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, and purinyl, each substituted with one or more substituents selected from the group consisting of R1, R2, and R3; G10 can be selected from the group consisting of a C2-C6 alkyl, a C2-C7 cycloalkyl, a CrC6 heteroalkyl, a heterocycle, phenyl, pyridinyl, pyrrolyl, pyrimidinyl, imidazolyl, isoxazolyl, thiazolyl, thienyl, indolyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, and purinyl, each substituted with one or more substituents selected from the group consisting of R4, R5, and R6; R1 can be selected from the group consisting of fluorine, chlorine, and methyl; R can be selected from the group consisting of -OR A and -NR B R C ; R 3 can be R G ; R 4 can be selected from the group consisting of fluorine, chlorine, and methyl; R5 can be selected from the group consisting of -ORA and -NRARB; R6 can be RG; J10 and Q10 can each be independently selected from the group consisting of an amide, a urea, a carbamide, -S(0)2NRA-, a thioamide, and an imidamide; L10 can be a 3-13 atom long linker comprising one or more groups selected from -O- (oxygen), -C(=0)-, -NRA- -S(O)0-2- -NRAS(0)i_2NRA- and one or more groups selected from an optionally substituted aryl, and an optionally substituted heteroaryl; where the an optionally substituted aryl and an optionally substituted heteroaryl in the definition of L10 can each be further optionally fused with a nonaromatic heterocycle or a nonaromatic carbocycle. [0563] In some specific embodiments disclosed herein provide a method of treating a patient, comprising administering to the patient a therapeutically effective amount of a compound having the structure:
Figure imgf000117_0001
Figure imgf000118_0001
117
Figure imgf000119_0001
118 Certain Synthesis Methods
Scheme I
Figure imgf000120_0001
[0564] The process of Scheme I describes the general synthesis of compounds of general structure 4 described in Formula I, wherein R can be Ci_6 alkyl, aryl and the like. Treatment of the ester derivatives of general structure 1 with hydrazine affords hydrazide derivatives of general structure 2. The intermediates of general structure 2 are condensed with an aldehyde of general structure 3 to generate the compounds of general structure 4.
Scheme II
Figure imgf000120_0002
9
[0565] The process of Scheme II describes general synthesis of the compounds of Formula II. Condensation reactions of the biscarbonyl compounds of general structure 7 and substituted hydrazides of general structures 5 or 6 under standard conditions provide the pseudo-symmetric compounds of structure 8. Alternatively, when the hydrazides of general structures 5 and 6 are different, the condensation reactions can be run sequentially to provide compounds of general structure 8. Compounds of general structure 9 can be obtained by a standard reduction of compounds of general structure 8. For example, reducing agents such sodium borohydride, lithium borohydride, sodium cyanoborohydride, potassium trisiamylborohydride, potassium tri-sec-butylborohydride, lithium trisiamylborohydride, lithium tri-sec-butylborohydride, diisobutylaluminum hydride, lithium triethoxyaluminum hydride and the like can be used in the reduction. Scheme ΙΠ
Figure imgf000121_0001
Figure imgf000121_0002
[0566] The process of Scheme III describes general synthesis of the compounds of Formula III. Coupling of an acid derivative of structure 10 with an amino derivative of structure 11 under standard conditions provides the amide intermediate of structure 12. The two nitro groups of structure 12 are reduced under a typical reduction condition such as a metal catalyzed hydrogenation to give the diamino intermediate and then the intermediate is condensed with an aldehyde of structure 13 under an oxidative condition to afford desired compounds of structure 14. Alternatively, compounds of structure 10 can be prepared from diamino derivatives of structure 15. Condensation reaction of compounds of structure 15 with compounds of structure 13 under an oxidative condition provides the intermediate of structure 16. A nitro reduction of intermediates 16 followed by an amide formation reaction under similar conditions described previously generate the compounds of structure 14. Scheme IV
Figure imgf000122_0001
[0567] The process of Scheme IV describes general synthesis of the compounds of Formula IV. Coupling reaction of compounds of structure 17 and compounds of structure 18 under the standard condition based on the nature of substituents L' and L" provides intermediates of structure 19. Amide formation reaction of compounds of structures 20 and 21 and intermediates of structure 19 affords the products of structure 22. Alternatively, especially for compounds of structure 22 that have different rings or side chains, compounds of structure 22 can be prepared with different coupling strategy. Amide coupling reactions between compounds of structures 17 and 21 and between compounds of structures 18 and 20 generate separate intermediates of structures 23 and 24. The intermediates of structures 23 and 24 are then coupled to form final compounds of structure 22. Scheme V
Figure imgf000123_0001
[0568] The process of Scheme V describes general synthesis of the compounds of Formula V. General coupling reaction of compounds of structures 25 and 26 affords the intermediates of structure 27. A reduction of intermediate of structure 27 by a reducing agent such as metal catalyzed hydrogenation followed by an oxidative condensation with compounds of structure 28 give intermediates of structure 29. The acid derivatives of structure 29 are coupled with compounds of structure 30 to provide the final products of structure 31. Alternatively, compounds of structure 25 can be reduced and coupled with aldehydes 28 to provide bicyclic imidazole derivatives of structure 32. Coupling reaction between compounds of structures 32 and 26 affords the same intermediates of structure 29.
Examples
[0569] The following examples are set forth merely to assist in understanding the embodiments and should not be construed as limiting the embodiments described and claimed herein in any way. Variations of the invention, including the substitution of all equivalents now known or later developed, which would be within the purview of those skilled in the art, and changes in formulation or minor changes in experimental design, are to be considered to fall within the scope of the invention incorporated herein.
EXAMPLE 1
[0570] (N',N"'E,N',N"'E)-N',N"'-((Oxybis(4,l- phenylene) )bis (methanylylidene) )bis (4- (dimethylamino)benzohydrazide) (Compound 101)
Figure imgf000124_0001
[0571] Compound 101 was prepared according to the procedure described in Scheme II. To a solution of 4,4' -oxybisbenzaldehyde (Aldrich, 42 mg, 0.186 mmol) and 4-dimethylaminobenzyhydrazide (Alfa Aesar, 73 mg, 0.408 mmol) in 3 mL of ethanol was added 3 drops of acetic acid. The reaction was heated to 60 °C for 12 h, cooled to room temperature and filtered. The white precipitate was washed with water (5 mL) followed by methanol (5 mL) and dried under vacuum to yield 55 mg of compound 101 as a white powder. [M+H]+ calcd for C32H33N6O3: 549.26; found: 549.05.
EXAMPLE 2
[0572] (N',N"'E,N',N"'E)-N',N"'-((oxybis(4, 1 - phenylene))bis(methanylylidene))bis(3-methoxybenzohydrazide) (Compound 102)
Figure imgf000124_0002
[0573] Compound 102 was prepared according to the procedure described in Scheme II from 4,4' -oxybisbenzaldehyde and 3-methoxybenzoate. [M+H]+ calcd for C30H26N4O5: 523.20; found: 513.15.
EXAMPLE 3
[0574] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- (dimethylamino)benzohydrazide) (Compound 103)
Figure imgf000125_0001
[0575] Compound 103 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 4-dimethylaminobenzoate. [M+H]+ calcd for CieHasNeOi: 457.23; found: 457.01.
EXAMPLE 4
[0576] (N',N"'E,N',N"'E)-N',N"'-((5-met oxy-l,3- phenylene)bis(methanylylidene))bis(4-(dimethylamino)benzohydrazide) (Compound 104)
Figure imgf000125_0002
[0577] Compound 104 was prepared according to the procedure described in Scheme II from 5-5-methoxybenzene- 1,3-dicarboxaldehyde and 4- dimethylaminobenzoate. 1H NMR (300MHz, DMSO-d6) δ 11.62 (s, 2H), 8.41 (s, 2H), 7.81 (d, J = 7.5 Hz, 4H), 7.60 (s, 1H), 7.26 (d, J = 3 Hz, 2H), 6.76 (d, J = 7.5 Hz, 4H), 3.84 (s, 3H), 2.99 (s, 12H).
EXAMPLE 5
[0578] (N',N"'E,N',iV'"E)-iV,iV"-((5-methoxy-l,3- phenylene)bis(methan lylidene))bis(4-methoxybenzohydrazide) (Compound 105)
Figure imgf000125_0003
[0579] Compound 105 was prepared according to the procedure described in Scheme II from 5-5-methoxybenzene- 1,3-dicarboxaldehyde and 4-methoxybenzoate. [M+H]+ calcd for C25H24N4O5: 461.18; found: 461.00.
EXAMPLE 6
[0580] (N',N"'E,N',N"'E)-N',N"'-((4-methoxy-l,3- phenylene)bis(methanylylidene))bis(4-(dimethylamino)benzohydrazide) (Compound 106)
Figure imgf000126_0001
[0581] Compound 106 was prepared according to the procedure described in Scheme Π from 4-4-methoxybenzene-l,3-dicarboxaldehyde and 4- dimethylaminobenzoate. 1H NMR (500MHz, DMSO-d6) δ 11.72 (s, 1H), 11.58 (s, 1H), 8.88 (s, 1H), 8.51 (s, 1H), 8.33 (s, 1H), 7.94 (dd, / = 7.5, 15 Hz, 4H), 7.80 (d, / =7.5 Hz, 1H), 7.29 (d, / = 7.5 Hz, 1H), 6.86 (d, / = 7.5 Hz, 4H), 4.10 (s, 3H), 3.10 (s, 12H).
EXAMPLE 7
[0582] (N',N'"E,N',iV'"E)-iV,iV"-((5-(benzyloxy)-l,3- phenylene)bis(methanylylidene))bis(4-(dimethylamino)benzohydrazide) (Compound 107)
Figure imgf000126_0002
[0583] Compound 107 was prepared according to the procedure described in Scheme II from 5-5-benzyloxybenzene-l,3-dicarboxaldehyde and 4- dimethylaminobenzoate. [M+H]+ calcd for C33H35N6O3: 563.28; found: 563.08.
EXAMPLE 8
[0584] 2(N',N'"E,N',iV'"E)-iV,iV"-([l,r-biphenyl]-3,5- diylbis(methanylylidene))bis(4-(dimethylamino)benzohydrazide) (Compound 108)
Figure imgf000126_0003
[0585] Compound 108 was prepared according to the procedure described in Scheme Π from 5-phenylbenzene-l,3-dicarboxaldehyde and 4-dimethylaminobenzoate. [M+H]+ calcd for C32H32N6O2: 533.26; found: 533.08. EXAMPLE 9
[0586] (N^N^^N^N^ l-^^^i^S-phenylenebisimethanylylidene)) bis(benzo[<i] [l,3]dioxole-5- carbohydrazide) (Compound 109)
Figure imgf000127_0001
[0587] Compound 109 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 5-(l,3-dioxolano)benzoate. 1H NMR (500MHz, DMSO-d6) δ 11.88 (s, 2H), 8.58 (s, 2H), 8.19 (s, 1H), 7.85 (d, / = 6.3 Hz, 2H), 7.64 (m, 3H), 7.56 (s, 2H), 7.17 (d, / = 6 Hz, 2H), 6.22 (s, 4H).
EXAMPLE 10
[0588] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- (lH-pyrrol-l-yl)benzoh drazide) (Compound 110)
Figure imgf000127_0002
[0589] Compound 110 was prepared according to the procedure described in Scheme Π from benzene- 1,3-dicarboxaldehyde and 4-pyrrolebenzoate. 1H NMR (500MHz, DMSO-d6) δ 12.15 (s, 2H), 8.63 (s, 2H), 8.24 (s, 1H), 8.13 (d, / = 7.5 Hz, 4H), 7.89 (d, / = 7.5 Hz, 6H), 7.64 (m, 5H), 6.43 (s, 4H).
EXAMPLE 11
[0590] (N',N"'E,N',N"'E)-N',N"'-((5-(dimethylamino)-l,3- phenylene)bis(methanylylidene))bis(4-(dimethylamino)benzohydrazide) (Compound 111)
Figure imgf000127_0003
[0591] Compound 111 was prepared according to the procedure described Scheme Π from 5-dimethylaminobenzene- 1,3-dicarboxaldehyde and dimethylaminobenzoate. [M+H]+ calcd for C28H33N7O2: 500.27; found: 500.07. EXAMPLE 12
[0592] (N',N'''E,N',N','E)-N',N'"-(l,3-phenylenebis(methanylylidene))bis(4- isopropylbenzohydrazide (Compound 112)
Figure imgf000128_0001
[0593] Compound 112 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 4-isopropylbenzoate. 1H NMR (500 MHz, DMSO-d6) δ 11.9 (s, 2H), 8.51 (s, 2H), 8.12 (s, 1H), 7.87 (d, / = 8.1 Hz, 4H), 7.77 (d, / = 7.3 Hz, 2H), 7.56 (dd, / = 7.3, 7.3 Hz, 1H), 7.42 (d, / = 8.1 Hz, 4H), 3.01-2.96 (m, 2H), 1.25 (d, 7 = 6.8 Hz, 12H).
EXAMPLE 13
[0594] (N',N'"E,N',iV'"E)-iV,iV"-((5-(allyloxy)-l,3- phenylene)bis(methanylylidene))bis(4-(dimethylamino)benzohydrazide) (Compound 113)
Figure imgf000128_0002
[0595] Compound 113 was prepared according to the procedure described in Scheme II from 5-allyloxybenzene-l,3-dicarboxaldehydeand 4-dimethylaminobenzoate. [M+H]+ calcd for C29H32N6O3: 513.26; found: 513.10.
EXAMPLE 14
[0596] (N',N'"E,N',iV'"E)-iV,iV"-((5-(benzylamino)-l,3- phenylene)bis(methanylylidene))bis(4-(dimethylamino)benzohydrazide) (Compound 114)
Figure imgf000128_0003
[0597] Compound 114 was prepared according to the procedure described Scheme Π from 5-benzylaminobenzene- 1,3-dicarboxaldehyde and dimethylaminobenzoate. [M+H]+ calcd for C33H35N7O2: 562.29; found: 562.17. EXAMPLE 15
[0598] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- (bis(2,2,2-trifluoroethyl)amino)benzohydrazide) (Compound 115)
Figure imgf000129_0001
[0599] Compound 115 was prepared according to the procedure described in Scheme Π from benzene- 1,3-dicarboxaldehyde and 4-di(2,2,2- trifluoroethyl)aminobenzoate. 1H NMR (500 MHz, DMSO-d6) δ 11.7 (s, 2H), 8.47 (s, 2H), 8.08 (s, 1H), 7.83 (d, / = 8.3 Hz, 4H), 7.72 (m, 2H), 7.53 (t, J = 7.8 Hz, 1H), 7.19 (d, / = 7.8 Hz, 4H), 4.49 (q, JH-F = 8.3 Hz, 8H).
EXAMPLE 16
[0600] N-(3,5-bis((£)-(2-(4- (dimethylamino)benzoyl)hydrazono)methyl)phenyl)benzamide
[0601] (Compound 116)
Figure imgf000129_0002
[0602] Compound 116 was prepared according to the procedure described in Scheme Π from 5-benzoylaminobenzene- 1,3-dicarboxaldehyde and 4- dimethylaminobenzoate. [M+H]+ calcd for CssHssNsCh: 619.31 ; found: 619.16.
EXAMPLE 17
[0603] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- (isopropylamino)benzoh drazide) (Compound 117)
Figure imgf000129_0003
[0604] Compound 117 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 4-isopropylaminobenzoate. 1H NMR (500 MHz, DMSO-d6) δ 11.52 (s, 2H), 8.45 (s, 2H), 8.04 (s, 1H), 7.74-7.69 (m, 6H), 7.52 (t, / = 7.8 Hz, 1H), 6.61 (d, / = 8.8 Hz, 4H), 6.16 (d, / = 7.8 Hz, 2H), 3.68-3.61 (m, 2H), 1.16 (d, 7 = 6.3 Hz, 12H).
EXAMPLE 18
[0605] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- (cyclopentylamino benzohydrazide) (Compound 118)
Figure imgf000130_0001
[0606] Compound 118 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 4-cyclopentylaminobenzoate. 1H NMR (500 MHz, DMSO-d6) δ 11.95 (s, 1H), 7.91 (d, / = 8.9 Hz, 1H), 7.17 (d, / = 8.9 Hz, 1H), 6.70 (s, 1H), 5.28 (q, / = 9.2 Hz, 2H), 3.04 (q, / = 7.3 Hz, 2H), 2.44 (s, 3H), 1.09 (t, 7 = 7.3 Hz, 3H).
EXAMPLE 19
[0607] (N',N'"E,N',iV'"E)-iV,iV"-(l,3- phenylenebis(methanylylidene))bis(([l,l'-biphenyl]-4-carbohydrazide)) (Compound 119)
Figure imgf000130_0002
[0608] Compound 119 was prepared according to the procedure described in Scheme Π from benzene- 1,3-dicarboxaldehyde and 4-phenylbenzoate. 1H NMR (500 MHz, DMSO-i¾) δ 11.95 (s, 1H), 7.91 (d, / = 8.9 Hz, 1H), 7.17 (d, / = 8.9 Hz, 1H), 6.70 (s, 1H), 5.28 (q, / = 9.2 Hz, 2H), 3.04 (q, / = 7.3 Hz, 2H), 2.44 (s, 3H), 1.09 (t, / = 7.3 Hz, 3H).
EXAMPLE 20
[0609] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- (diethylamino) benzohydrazide) (Compound 120)
Figure imgf000131_0001
[0610] Compound 120 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 4-diethylaminobenzoate. 1H NMR (500 MHz, DMSO-d6) δ 11.95 (s, 1H), 7.91 (d, / = 8.9 Hz, 1H), 7.17 (d, / = 8.9 Hz, 1H), 6.70 (s, 1H), 5.28 (q, / = 9.2 Hz, 2H), 3.04 (q, / = 7.3 Hz, 2H), 2.44 (s, 3H), 1.09 (t, / = 7.3 Hz, 3H).
EXAMPLE 21
[0611] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(2- naphthohydrazide) (Compound 121)
Figure imgf000131_0002
[0612] Compound 121 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 4-dimethylaminobenzoate. 1H NMR (500 MHz, DMSO-d6) δ 11.95 (s, 1H), 7.91 (d, / = 8.9 Hz, 1H), 7.17 (d, / = 8.9 Hz, 1H), 6.70 (s, 1H), 5.28 (q, / = 9.2 Hz, 2H), 3.04 (q, / = 7.3 Hz, 2H), 2.44 (s, 3H), 1.09 (t, / = 7.3 Hz, 3H).
EXAMPLE 22
[0613] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- (lH-imidazol-l- l)benzohydrazide) (Compound 122)
Figure imgf000131_0003
[0614] Compound 122 was prepared according to the procedure described in Scheme Π from benzene- 1,3-dicarboxaldehyde and 4-imidazolebenzoate. 1H NMR (500 MHz, DMSO-d6) δ 12.0 (s, 2H), 8.55 (s, 2H), 8.49 (s, 2H), 8.16 (s, 1H), 8.09 (d, / = 8.3 Hz, 4H), 7.93 (s, 2H), 7.89 (d, / = 7.5 Hz, 4H), 7.81 (d, / = 7.5 Hz, 2H), 7.58 (t, / = 7.6 Hz, 1H), 7.21 (bs, 2H). EXAMPLE 23
[0615] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- ((4-fluorobenz l)amino) benzohydrazide) (Compound 123)
Figure imgf000132_0001
[0616] Compound 123 was prepared according to the procedure described in Scheme Π from benzene- 1,3-dicarboxaldehyde and 4-(4-fluorobenzylamino)benzoate. 1H NMR (500 MHz, DMSO-d6) δ 11.95 (s, 1H), 7.91 (d, / = 8.9 Hz, 1H), 7.17 (d, / = 8.9 Hz, 1H), 6.70 (s, 1H), 5.28 (q, / = 9.2 Hz, 2H), 3.04 (q, / = 7.3 Hz, 2H), 2.44 (s, 3H), 1.09 (t, 7 = 7.3 Hz, 3H).
EXAMPLE 24
[0617] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- ((2,3-dihydro- lH-inden-2- l)amino)benzohydrazide) (Compound 124)
Figure imgf000132_0002
[0618] Compound 124 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 4-(2-indanylamino)benzoate. 1H NMR (500 MHz, DMSO-d6) δ 11.95 (s, 1H), 7.91 (d, / = 8.9 Hz, 1H), 7.17 (d, / = 8.9 Hz, 1H), 6.70 (s, 1H), 5.28 (q, / = 9.2 Hz, 2H), 3.04 (q, / = 7.3 Hz, 2H), 2.44 (s, 3H), 1.09 (t, 7 = 7.3 Hz, 3H).
EXAMPLE 25
[0619] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(l- methyl-lH-indole-5-carboh drazide) (Compound 125)
Figure imgf000132_0003
[0620] Compound 125 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and l-methyl-5-indolecarboxylate. [M+H]+ calcd for
Figure imgf000133_0001
477.20; found: 477.06.
EXAMPLE 26
[0621] (N N'' N N'"E)-NJV"-((5-(me&ylwano)-l,3- phenylene)bis(methanylylidene))bis(4-(dimethylamino)benzohydrazide) (Compound 126)
Figure imgf000133_0002
[0622] Compound 126 was prepared according to the procedure described in Scheme II from 5-methylaminobenzene- 1,3-dicarboxaldehyde and 4- dimethylaminobenzoate. [M+H]+ calcd for C27H31N7O2: 486.26; found: 486.03.
EXAMPLE 27
[0623] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- (pyrrolidin-l-yl)benzoh drazide) (Compound 127)
Figure imgf000133_0003
[0624] Compound 127 was prepared according to the procedure described in Scheme Π from benzene- 1,3-dicarboxaldehyde and 4-pyrrolidinebenzoate. 1H NMR (500 MHz, DMSO-i¾) δ 11.95 (s, 1H), 7.91 (d, / = 8.9 Hz, 1H), 7.17 (d, / = 8.9 Hz, 1H), 6.70 (s, 1H), 5.28 (q, / = 9.2 Hz, 2H), 3.04 (q, / = 7.3 Hz, 2H), 2.44 (s, 3H), 1.09 (t, / = 7.3 Hz, 3H).
EXAMPLE 28
[0625] (N',N'"E,N',iV'"E)-iV,iV"-((5-((benzyloxy)methyl)-l,3- phenylene)bis(methanylylidene))bis(4-(dimethylamino)benzohydrazide) (Compound 128)
Figure imgf000134_0001
[0626] Compound 128 was prepared according to the procedure described in Scheme II from 5-benzyloxymethylbenzene- 1,3-dicarboxaldehyde and 4- dimethylaminobenzoate. [M+H]+ calcd for C34H36N6O3: 577.26; found: 577.10.
EXAMPLE 29
[0627] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- (methylamino)benzohydrazide) (Compound 129)
Figure imgf000134_0002
[0628] Compound 129 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 4-methylaminobenzoate. 1H NMR (500 MHz, DMSO-d6) δ 11.95 (s, 1H), 7.91 (d, / = 8.9 Hz, 1H), 7.17 (d, J = 8.9 Hz, 1H), 6.70 (s, 1H), 5.28 (q, J = 9.2 Hz, 2H), 3.04 (q, J = 7.3 Hz, 2H), 2.44 (s, 3H), 1.09 (t, J = 7.3 Hz, 3H).
EXAMPLE 30
[0629] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- ((2-hydroxyeth l)amino)benzohydrazide) (Compound 130)
Figure imgf000134_0003
[0630] Compound 130 was prepared according to the procedure described in Scheme Π from benzene- 1,3-dicarboxaldehyde and 4-(2-hydroxyethylamino)benzoate. 1H NMR (500 MHz, DMSO-d6) δ 11.95 (s, 1H), 7.91 (d, / = 8.9 Hz, 1H), 7.17 (d, / = 8.9 Hz, 1H), 6.70 (s, 1H), 5.28 (q, / = 9.2 Hz, 2H), 3.04 (q, / = 7.3 Hz, 2H), 2.44 (s, 3H), 1.09 (t, 7 = 7.3 Hz, 3H). EXAMPLE 31
[0631] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(3- (dimethylamino)benzoh drazide) (Compound 131)
Figure imgf000135_0001
[0632] Compound 131 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 3-dimethylaminobenzoate. 1H NMR
(500 MHz, DMSO-d6) δ 11.82 (s, 2H), 8.52 (s, 2H), 8.11 (s, 1H), 7.76 (d, / = 7.5 Hz, 2H), 7.56 (t, / = 7.5 Hz, 1H), 7.33 (t, / = 8.0 Hz, 2H), 7.19 (d, / = 7.0 Hz, 4H), 6.94 (d, / = 2.2 Hz, 2H), 2.97 (s, 12H).
EXAMPLE 32
[0633] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4- morpholinobenzohydrazide) (Compound 132)
Figure imgf000135_0002
[0634] Compound 132 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 4-morpholinobenzoate. [M+H]+ calcd for C30H33N6O4: 541.26; found: 541.05
EXAMPLE 33
[0635] (N',N"'E,N',N"'E)-N',N"'-(l,3-phenylenebis(methanylylidene))bis(4-(2- oxopyrrolidin-l-yl benzohydrazide) (Compound 133)
Figure imgf000135_0003
[0636] Compound 133 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 4-pyrrolidonobenzoate. 1H NMR
(500MHz, DMSO-d6) δ 11.93 (s, 2H), 8.47 (s, 2H), 8.17 (s, 1H), 7.95 (d, / = 13.7 Hz, 4H), 7.81 (d, / = 10 Hz, 4H), 7.77 (d, / = 10 Hz, 2H), 7.55 (t, / = 10, 12.5 Hz, 1H), 4.28 (m, 4H), 2.53 (m, 4H), 2.07 (m, 4H).
EXAMPLE 34
[0637] (N;N'''E,N',N'''E)-N',N'"-(l,3-phenylenebis(methanylylidene))bis(4- (piperazin-l-yl)benzohydrazide) (Compound 134)
Figure imgf000136_0001
[0638] Compound 134 was prepared according to the procedure described in Scheme II from benzene- 1,3-dicarboxaldehyde and 4-piperizinylbenzoate. 1H NMR (500MHz, DMSO-d6) δ 11.54 (s, 2H), 10.15 (s, 2H), 8.47 (s, 2H), 8.25 (s, 1H), 7.86 (d, / = 12 Hz, 4H), 7.71 (m, 3H), 7.02 (d, / = 12 Hz, 4H), 3.17 (m, 8H), 2.86 (m, 8H).
EXAMPLE 35
[0639] (N',N'"E,N',iV'"E)-iV,iV"-((5-((2-hydroxyethyl)amino)-l,3- phenylene)bis(methanylylidene))bis(4-(dimethylamino)benzohydrazide) (Compound 135)
Figure imgf000136_0002
[0640] Compound 135 was prepared according to the procedure described in Scheme Π from 5-(2-hydroxyethyl)aminobenzene- 1,3-dicarboxaldehyde and 4- dimethylaminobenzoate. [M+H]+ calcd for C28H33N7O3: 516.27; found: 516.00.
EXAMPLE 36
[0641] (N;N'''E,N;N'''E)-N,,N'"-(pyridine-3,5-diylbis(methanylylidene))bis(4- morpholinobenzohydrazide) (Compound 136)
Figure imgf000136_0003
[0642] Compound 136 was prepared according to the procedure described in Scheme II from pyridine-3,5-dicarboxaldehyde and 4-morpholinobenzoate. [M+H]+ calcd for C29H31N7O4: 542.25; found: 541.99. EXAMPLE 37
[0643] (N;N'''E,N;N'''E)-^,A^"-(pyridine-3,5-diylbis(methanylylidene))bis(4- (dimethylamino)benzohydrazide) (Compound 137)
Figure imgf000137_0001
[0644] Compound 137 was prepared according to the procedure described in Scheme II from pyridine-3,5-dicarboxaldehyde and 4-dimethylaminobenzoate. 1H NMR (500MHz, DMSO-d6) δ 11.79 (s, 2H), 8.81 (d, / = 3.75 Hz, 2H), 8.51 (s, 2H), 8.45 (s, 1H), 7.83 (d, / = 15 Hz, 4H), 6.77 (d, / = 11.2 Hz, 4H), 3.01 (s, 12H).
EXAMPLE 38
[0645] jV,iV"-((5-(benzyloxy)- 1 ,3-phenylene)bis(methylene))bis(4- (dimethylamino)benzoh drazide) (Compound 138)
Figure imgf000137_0002
[0646] Compound 138 was prepared according to the procedure described in Scheme II from 5-5-benzyloxybenzene-l,3-dicarboxaldehyde and 4- dimethylaminobenzoate. [M+H]+ calcd for C33H28N6O3: 567.30; found: 567.17.
EXAMPLE 39
[0647] (E)-4-(2-(3-Methoxybenzylidene)hydrazinecarbonyl)-N-(3-((3- methoxyphenethyl)amino)-3-oxopropyl)benzamide (Compound 139)
Figure imgf000137_0003
[0648] Compound 139 was prepared according to the general procedure described in Scheme I. Preparation of 3-((tert-butoxycarbonyl)amino)propanoic acid: β- Alanine (Sigma- Aldrich, 1.0 g, 11.2 mmol) and K2CO3 (3.1 g, 22.4 mmol) were dissolved in a mixture of dioxane (25 mL) and water (12.5 mL) then the solution was cooled to 0 °C in an ice bath. Di-te/t-butyl dicarbonate (2.7 g, 12.3 mmol) was added then the solution was warmed slowly to room temperature and allowed to stir overnight. Upon completion, the solution was acidified with KHSO4 until pH 3 then extracted with ethyl acetate. The organic layer was washed with brine, dried over Na2S04 then the solvent was removed under reduced pressure to give crude product which was taken forward without further purification.
[0649] Preparation of tert-butyl (3-((3-methoxyphenethyl)amino)-3- oxopropyl)carbamate: 3-methoxyphenethylamine (Aldrich, 100 mg, 0.66 mmol), 3-((tert- butoxycarbonyl)amino)-propanoic acid (125 mg, 0.66 mmol), hydroxybenzotriazole (8.9 mg, 0.066 mmol), triethylamine (102 μί, 0.73 mmol) and dimethyformamide (6.6 mL) were combined, then l-ethyl-3-(3-dimethylaminopropyl) carbodiimide (139 mg, 0.73 mmol) was added. The solution was allowed to stir at room temperature overnight. Upon completion, ethyl acetate and water were added and the layers were separated. The aqueous phase was extracted with ethyl acetate then the combined organic layers were washed with brine and dried over Na2S04. Solvent was removed under reduced pressure to give crude product which was purified by flash chromatography using 0 - 80% ethyl acetate/hexane as the eluent to give the product as a pure white solid (140 mg, 66 %).
[0650] Preparation of 3-amino-N-(3-methoxyphenethyl)propanamide: tert- butyl (3-((3-methoxyphenethyl)amino)-3-oxopropyl)carbamate was dissolved in dichloromethane (0.5 mL) then the solution was cooled to 0 °C in an ice bath. Trifluoroacetic acid (300
Figure imgf000138_0001
was added then the solution was allowed to warm slowly to room temperature with stirring. Upon completion of the reaction the solvent is removed under reduced pressure to give crude product which is used without further purification.
[0651] Preparation of methyl 4-((3-((3-methoxyphenethyl)amino)-3- oxopropyl)carbamoyl)benzoate: To 3-amino-N-(3-methoxyphenethyl)propanamide (60 mg, 0.27 mmol) was added 4-(methoxycarbonyl)benzoic acid (49 mg, 0.27 mmol), hydroxybenzotriazole (3.7 mg, 0.027 mmol), triethylamine (42 \L, 0.30 mmol) and dimethyformamide (2.7 mL). Lastly, l-ethyl-3-(3-dimethylaminopropyl) carbodiimide (57 mg, 0.30 mmol) was added and the solution was allowed to stir overnight at room temperature in a capped vial. Upon completion of the reaction an aqueous workup is performed to give the crude product which was purified using flash chromatography.
[0652] Preparation of 4-(hydrazinecarbonyl)-iV-(3-((3- methoxyphenethyl)amino)-3-oxopropyl)benzamide: Methyl 4-((3-((3- methoxyphenethyl)amino)-3-oxopropyl)carbamoyl)benzoate was treated with methanol (3 mL) and hydrazine hydrate (300 μί), heated to 65 °C, then allowed to stir overnight. The reaction is monitored by TLC and upon completion the solvent is removed under reduced pressure to give crude product which is used without purification.
[0653] Preparation of Compound 139: To the above crude product (15.0 mg, 0.039 mmol) was added 3-anisaldehyde (9.5 μί, 0.078 mmol), acetic acid (several drops) and ethanol (1 mL). The reaction was allowed to stir overnight at room temperature. The solid product that has formed is isolated by centrifugation then analyzed by LCMS. MS [M+H]+ calcd for C28H30N4O5: 503.22; found: 503.04.
EXAMPLE 40
[0654] (E)-N-(3-((2-(lH-indol-3-yl)ethyl)amino)-3-oxopropyl)-4-(2-(3- methoxybenzylidene hydrazinecarbonyl)benzamide (Compound 140)
Figure imgf000139_0001
[0655] Compound 140 was prepared according to the procedure described in Scheme I from 4-(2-(3-indolylethyl)aminocarbonyl)ethylaminocarbonyl)benzoate and 3- methoxybenzaldehyde. [M+H]+ calcd for C29H29N5O4: 512.22; found: 512.03.
EXAMPLE 41
[0656] (E)-N-(3-((2-hydroxyethyl)amino)-3-oxopropyl)-4-(2-(3- methoxybenzylidene)hydrazinecarbonyl)benzamide (Compound 141)
Figure imgf000139_0002
[0657] Compound 141 was prepared according to the procedure described in Scheme I from 4-(2-(2-hydroxyethylaminocarbonyl)ethylaminocarbonyl)benzoate and 3- methoxybenzaldehyde. [M+H]+ calcd for C21H24N4O5: 413.17; found: 413.00.
EXAMPLE 42
[0658] 4-((E)-2-(3-((E)-2-chlorostyryl)benzylidene)hydrazinecarbonyl)-N-(3- ((2-hydroxyethyl)amino)-3-oxopropyl)benzamide (Compound 142)
Figure imgf000140_0001
[0659] Compound 142 was prepared according to the procedure described in Scheme I from 4-(2-(2-hydroxyethylaminocarbonyl)ethylaminocarbonyl)benzoate and 3- (2E-(2-chlorophenyl)ethenyl)benzaldehyde. [M+H]+ calcd for C28H27CIN4O4: 519.17; found: 519.00.
EXAMPLE 43
[0660] (E)-4-(2-(4-fluoro-3-methoxybenzylidene)hydrazinecarbonyl)-N-(3- ((2-hydroxyethyl)amino)-3-oxopropyl)benzamide (Compound 143)
Figure imgf000140_0002
[0661] Compound 143 was prepared according to the procedure described in Scheme I from 4-(2-(2-hydroxyethylaminocarbonyl)ethylaminocarbonyl)benzoate and 4- fluoro-3-methoxybenzaldehyde. [M+H]+ calcd for C21H23FN4O5: 431.17; found: 431.00.
EXAMPLE 44
[0662] (E) -4- (2- (2-hydroxy-5 -methoxybenzylidene)hydrazinecarbonyl)-iV- (3 - ((2-hydroxyethyl)amino)-3-oxopropyl)benzamide (Compound 144)
Figure imgf000140_0003
[0663] Compound 144 was prepared according to the procedure described in Scheme I from 4-(2-(2-hydroxyethylaminocarbonyl)ethylaminocarbonyl)benzoate and 2- hydroxy-5-methoxybenzaldehyde. [M+H]+ calcd for C21H24N4O6: 429.17; found: 429.00
EXAMPLE 45
[0664] (E)-4-(2-(3,5-dimethoxybenzylidene)hydrazinecarbonyl)-N-(3-((2- hydroxyethyl)amino)-3-oxopropyl)benzamide (Compound 145)
Figure imgf000141_0001
[0665] Compound 145 was prepared according to the procedure described in Scheme I from 4-(2-(2-hydroxyethylaminocarbonyl)ethylaminocarbonyl)benzoate and 3,5-dimethoxybenzaldehyde. [M+H]+ calcd for C22H26N4O6: 443.19; found: 442.91.
EXAMPLE 46
[0666] (E)-4-(2-(4-hydroxy-3-methoxybenzylidene)hydrazinecarbonyl)-N-(3- ((2-hydroxyethyl)amino)-3-oxopropyl)benzamide (Compound 146)
Figure imgf000141_0002
[0667] Compound 146 was prepared according to the procedure described in Scheme I from 4-(2-(2-hydroxyethylaminocarbonyl)ethylaminocarbonyl)benzoate and 4- hydroxy-5-methoxybenzaldehyde. [M+H]+ calcd for C21H24N4O6: 429.17; found: 428.88.
EXAMPLE 47
[0668] (E)-N-(3-((2-hydroxyethyl)amino)-3-oxopropyl)-4-(2-(3-methoxy-4- methylbenzylidene)hydrazinecarbonyl)benzamide (Compound 147)
Figure imgf000141_0003
[0669] Compound 147 was prepared according to the procedure described in Scheme I from 4-(2-(2-hydroxyethylaminocarbonyl)ethylaminocarbonyl)benzoate and 3- methoxy-4-methylbenzaldehyde. [M+H]+ calcd for C22H26N4O5: 427.19; found: 426.92.
EXAMPLE 48
[0670] (E)-N-(2-hydroxyethyl)-4-((4-(2-(3- methoxybenzylidene)hydrazinecarbonyl)phenyl)amino)butanamide (Compound 148)
Figure imgf000142_0001
[0671] Compound 148 was prepared according to the procedure described in Scheme I from 4-(3-(2-hydroxyethylaminocarbonyl)propylamino)benzoate and 3- methoxybenzaldehyde. [M+H]+ calcd for C21H26N4O4: 399.20; found: 399.47.
EXAMPLE 49
[0672] (E)-4-(2-(3-(dimethylamino)benzylidene)hydrazinecarbonyl)-N-(3-((2- hydroxyethyl)amino)-3-oxopropyl)benzamide (Compound 149)
Figure imgf000142_0002
[0673] Compound 149 was prepared according to the procedure described in Scheme I from 4-(2-(2-hydroxyethylaminocarbonyl)ethylaminocarbonyl)benzoate and 3- dimethylaminobenzaldehyde. [M+H]+ calcd for C22H27N5O4: 426.21 ; found: 426.53.
EXAMPLE 50
[0674] (E)-4-((4-(2-(2-hydroxy-5- methoxybenzylidene)hydrazinecarbonyl)phenyl)amino)-N-(2-hydroxyethyl)butanamide (Compound 1
Figure imgf000142_0003
[0675] Compound 150 was prepared according to the procedure described in Scheme I from 4-(3-(2-hydroxyethylaminocarbonyl)propylamino)benzoate and 2- hydroxy-5-methoxybenzaldehyde. [M+H]+ calcd for C21H26N4O5: 415.19; found: 415.53.
EXAMPLE 51
[0676] (E)-4-((4-(2-(3-
(dimethylamino)benzylidene)hydrazinecarbonyl)phenyl)amino)-iV-(2- hydroxyethyl)butanamide (Compound 151)
Figure imgf000143_0001
[0677] Compound 151 was prepared according to the procedure described in Scheme I from 4-(3-(2-hydroxyethylaminocarbonyl)propylamino)benzoate and 3- dimethylaminobenzaldehyde. [M+H]+ calcd for C22H29N5O3: 412.23; found: 412.56.
EXAMPLE 52
[0678] (£)-4-((4-(2-(3-(2- hydroxyethoxy)benzylidene)hydrazinecarbonyl)phenyl)amino)-iV-(2- hydroxyethyl)butanamide Compound 152)
Figure imgf000143_0002
[0679] Compound 152 was prepared according to the procedure described in Scheme I from 4-(3-(2-hydroxyethylaminocarbonyl)propylamino)benzoate and 3-(2- hydroxyethoxy)benzaldehyde. [M+H]+ calcd for C22H28N4O5: 429.21 ; found: 429.50.
EXAMPLE 53
[0680] (E)-4-((4-(2-(3,5- dimethoxybenzylidene)hydrazinecarbonyl)phenyl)amino)-N-(2-hydroxyethyl)butanamide (Compound 1
Figure imgf000143_0003
[0681] Compound 153 was prepared according to the procedure described in Scheme I from 4-(3-(2-hydroxyethylaminocarbonyl)propylamino)benzoate and 3,5- dimethoxybenzaldehyde. [M+H]+ calcd for C22H28N4O5: 429.21 ; found: 429.50.
EXAMPLE 54
[0682] (E)-4-((4-(2-((lH-indol-6- yl)methylene)hydrazinecarbonyl)phenyl)amino)-N-(2-hydroxyethyl)butanamide
(Compound 154)
Figure imgf000144_0001
[0683] Compound 154 was prepared according to the procedure described in Scheme I from 4-(3-(2-hydroxyethylaminocarbonyl)propylamino)benzoate and 6- indolecarboxaldehyde. [M+H]+ calcd for C22H25N5O3: 408.20; found: 408.51.
EXAMPLE 55
[0684] (E)-4-(5-(2-(3-methoxybenzylidene)hydrazinecarbonyl)-lH-indol-l- yl)-N-(2-methox ethyl)butanamide (Compound 155)
Figure imgf000144_0002
[0685] Compound 155 was prepared according to the procedure described in Scheme I from l-(3-(2-methoxyethyl)aminocarbonylpropyl)indole-5-carboxylate and 3- methoxybenzaldehyde. 1H NMR (500MHz, DMSO-d6) δ 11.77 (s, 1H), 8.43 (s, 1H), 8.20 (d, / = 1.5 Hz, 1H), 7.89 (t, / = 5.5 Hz, 1H), 7.72 (dd, / = 2, 9 Hz, 1H), 7.57 (d, / = 9 Hz, 1H), 7.46 (d, / = 3Hz, 1H), 7.36 (t, / = 8 Hz, 1H), 7.27 (s, 2H), 6.99 (d, / = 8Hz, 1H), 6.58 (d, / = 2.5 Hz, 1H), 4.20 (t, / = 6.5 Hz, 2H), 3.80 (s, 3H), 3.32-3.29 (m, 2H), 3.20- 3.14 (m, 5H), 2.05 (t, / = 8 Hz, 2H), 1.96 (p, / = 7 Hz, 2H).
EXAMPLE 56
[0686] (E)-N-(3-(dimethylamino)phenyl)-4-(5-(2-(3- methoxybenzylidene)hydrazinecarbonyl)- lH-indol- 1 -yl)butanamide (Compound 156)
Figure imgf000144_0003
[0687] Compound 156 was prepared according to the procedure described in Scheme I from l-(3-(3-dimethylaminophenyl)aminocarbonylpropyl)indole-5-carboxylate and 3-methoxybenzaldehyde. [M+H]+ calcd for C29H31N5O3: 498.24; found: 497.98. EXAMPLE 57
[0688] (E)-N-(4-(dimethylamino)phenyl)-4-(5-(2-(3- methoxybenzylidene)hydrazinecarbonyl)- lH-indol- 1 -yl)butanamide (Compound 157)
Figure imgf000145_0001
[0689] Compound 157 was prepared according to the procedure described in Scheme I from l-(3-(4-dimethylaminophenyl)aminocarbonylpropyl)indole-5-carboxylate and 3-methoxybenzaldehyde. 1H NMR (500MHz, DMSO-d6) δ 11.77 (s, 1H), 9.58 (s, 1H), 8.43 (bs, 1H), 8.21 (d, / = 1.0 Hz, 1H), 7.73 (dd, / = 1.5, 8.5 Hz, 1H), 7.60 (d, / = 8.5 Hz, 1H), 7.50 (d, / = 2.5Hz, 1H), 7.44 (m, 1H), 7.36 (d, / = 9 Hz, 2H), 7.26 (m, 2H), 6.99 (d, / = 8 Hz, 1H), 6.75 (d, / = 9 Hz, 1H), 6.65 (d, / = 9 Hz, 2H), 6.60 ( d, / = 2.5 Hz, 1H), 4.27 (t, / = 7 Hz, 2H), 3.80 (s, 3H), 2.81 (s, 6H), 2.23 (t, J = 7.5 Hz, 2H), 2.06 (p, / = 7.5 Hz, 2H).
EXAMPLE 58
[0690] (E) -4- (5 - (2- (3 - ( 1 H-pyrazol- 1 -yl)benzylidene)hydrazinecarbonyl) - 1 H- indol- 1 -yl)-N- -(dimethylamino)phenyl)butanamide (Compound 158)
Figure imgf000145_0002
[0691] Compound 158 was prepared according to the procedure described in Scheme I from l-(3-(3-dimethylaminophenyl)aminocarbonylpropyl)indole-5-carboxylate and 3-(pyrazol-l-yl)benzaldehyde. [M+H]+ calcd for C31H31N7O2: 534.25; found: 534.00.
EXAMPLE 59
[0692] (E) -4- (5 - (2- (3 - ( 1 H-pyrazol- 1 -yl)benzylidene)hydrazinecarbonyl) - 1 H- indol- 1 -yl)-N- -(dimethylamino)phenyl)butanamide (Compound 159)
Figure imgf000145_0003
[0693] Compound 159 was prepared according to the procedure described in Scheme I from l-(3-(4-dimethylaminophenyl)aminocarbonylpropyl)indole-5-carboxylate and 3-(pyrazol-l-yl)benzaldehyde. [M+H]+ calcd for C31H31N7O2: 534.25; found: 533.97.
EXAMPLE 60
[0694] (E) -4- (5 - (2- (3 - ( 1 H-pyrazol- 1 -yl)benzylidene)hydrazinecarbonyl) - 1 H- indol-l-yl)-N-(2-methoxyethyl)butanamide (Compound 160)
Figure imgf000146_0001
[0695] Compound 160 was prepared according to the procedure described in Scheme I from l-(3-(2-methoxyethyl)aminocarbonylpropyl)indole-5-carboxylate and 3- (pyrazol-l-yl)benzaldehyde. [M+H]+ calcd for CieftsNeCh: 473.22; found: 472.94.
EXAMPLE 61
[0696] (E)-4-(5-(2-(3-(lH-pyrazol-l-yl)benzylidene)hydrazinecarbonyl)-lH- indol-l-yl)-N-(2-acetamidoethyl)butanamide (Compound 161)
Figure imgf000146_0002
[0697] Compound 161 was prepared according to the procedure described in Scheme I from l-(3-(2-acetylamidoethyl)aminocarbonylpropyl)indole-5-carboxylate and 3-(pyrazol-l-yl)benzaldehyde. [M+H]+ calcd for C27H29N7O3: 500.23; found: 499.94.
EXAMPLE 62
[0698] (E)-N-(2-acetamidoethyl)-4-(5-(2-(3- methoxybenzylidene)hydrazinecarbonyl)- lH-indol- 1 -yl)butanamide (Compound 162)
Figure imgf000146_0003
[0699] Compound 162 was prepared according to the procedure described in Scheme I from l-(3-(2-acetylamidoethyl)aminocarbonylpropyl)indole-5-carboxylate and 3-methoxybenzaldehyde. [M+H]+ calcd for C25H29N5O4: 464.22; found: 463.93. EXAMPLE 63
[0700] (E)-4-(5-(2-(3-methoxybenzylidene)hydrazinecarbonyl)-lH-indol-l- yl)-N-(2,2,2-trifluoroeth l)butanamide (Compound 163)
Figure imgf000147_0001
[0701] Compound 163 was prepared according to the procedure described in Scheme I from l-(3-(2,2,2-trifluoroethyl)aminocarbonylpropyl)indole-5-carboxylate and 3-methoxybenzaldehyde. [M+H]+ calcd for C23H23F3N4O3: 461.17; found: 460.92.
EXAMPLE 64
[0702] (E)-N-(2-hydroxyethyl)-4-(5-(2-(3- methoxybenzylidene)hydrazinecarbonyl)- lH-indol- 1 -yl)butanamide (Compound 164)
Figure imgf000147_0002
[0703] Compound 164 was prepared according to the procedure described in Scheme I from l-(3-(2-hydroxyethyl)aminocarbonylpropyl)indole-5-carboxylate and 3- methoxybenzaldehyde. [M+H]+ calcd for C23H26N4O4: 423.20; found: 422.88.
EXAMPLE 65
[0704] (E)-N-(3-((4-hydroxybutyl)amino)-3-oxopropyl)-4-(2-(3- methoxybenzylidene)hydrazinecarbonyl)benzamide (Compound 165)
Figure imgf000147_0003
[0705] Compound 165 was prepared according to the procedure described in Scheme I from 4-(2-(4-hydroxybutylaminocarbonyl)ethylaminocarbonyl)benzoate and 3- methoxybenzaldehyde. [M+H]+ calcd for C23H28N4O5: 441.21 ; found: 441.01.
EXAMPLE 66
[0706] (E)-N-(2-(dimethylamino)ethyl)-4-(5-(2-(3- methoxybenzylidene)hydrazinecarbonyl)- lH-indol- 1 -yl)butanamide (Compound 166)
Figure imgf000148_0001
[0707] Compound 166 was prepared according to the procedure described in Scheme I from l-(3-(2-dimethylaminoethyl)aminocarbonylpropyl)indole-5-carboxylate and 3-methoxybenzaldehyde. 1H NMR (500MHz, Acetone-J6) δ 11.09 (bs, 1H), 8.51 (bs, 1H), 8.26 (d, / = 19 Hz, 2H), 7.83 (dd, / = 1.5, 8.5 Hz, 1H), 7.39 (bs, 1H), 7.35 (t, / = 7.5 Hz, 1H), 7.30 (m, 1H), 7.08 (s, 1H), 6.99-6.97 (m, 1H), 6.58 (d, / = 3 Hz, 1H), 4.31 (t, / = 7 Hz, 2H), 3.85 (s, 3H), 3.39 (q, / = 6 Hz, 2H), 2.67 (t, / = 6 Hz, 2H), 2.41 (s, 6H), 2.18-2.11 (m, 4H).
EXAMPLE 67
[0708] Methyl 4-(2-(4-morpholinophenyl)-lH-benzo[J]imidazole-5- carboxamido)benzoate (Compound 167)
Figure imgf000148_0002
[0709] Compound 167 was prepared according to the general procedure similar to that described in Scheme ΠΙ. Preparation of 2-(4-morpholinophenyl)-lH- benzo[d]imidazole-5-carboxylic acid: 4-Morpholinobenzaldehyde (475 mg, 2.5 mmole), sodium metabisulfite (85 mg) and 3,4-diaminobenzoic acid (152 mg, 2.7 mmole) were placed in a 10-mL microwave tube and 5.0 mL HPLC grade 2-propanol added. The reaction mixture was microwaved at 170 °C for 55 minutes. The reaction mixture was added dropwise to 25 mL water and stirred at room temperature for 30 min. then it was filtered and washed with plenty of water, ethyl acetate and hexanes and dried to provide the pure intermediate acid (323 mg, 40% yield). This compound was used for next step without any further purification.
[0710] Preparation of Compound 167: 2-(4-Morpholinophenyl)-lH- benzo[d]imidazole-5-carboxylic acid (32 mg, 0.1 mmol) and N-(3-dimethylaminopropyl)- N'-ethylcarbodiimide hydrochloride (EDC) (40 mg, 0.2 mmole) were place in a 20 mL vial and pyridine (1.0 mL) added and capped tightly. The reaction mixture was stirred at room temperature for overnight. The reaction mixture was evaporated to dryness and the residue was washed thoroughly with plenty of water, hexanes and EtOAc then dried. Crystallization out of methanol/water provided compound 167 in 25% yield (11.4 mg). [M+H]+ calcd for C26H24N4O4: 457.18; found: 456.94.
EXAMPLE 68
[0711] 2-(4-Morpholinophenyl)-N-(3-((4-morpholinophenyl)amino)-3- oxopropyl)-l -benzo[d]imidazole-5-carboxamide (Compound 168)
Figure imgf000149_0001
[0712] Compound 168 was prepared according to the procedure similar to that described in Scheme ΙΠ from the 3,4-dinitrobenzamide and 4-morpholinobenzaldehyde. [M+H]+ calcd for C31H34N6O4: 555.26; found: 555.03.
EXAMPLE 69
[0713] N-(2-(4-Methyl-3,4-dihydro-2H-benzo[b][l,4]oxazin-7-yl)-lH- benzimidazol-5-yl)-4-morpholinobenzamide (Compound 169)
Figure imgf000149_0002
[0714] Compound 169 was prepared according to the procedure similar to that described in Scheme ΙΠ from 5-amino-2-(4-methyl-3,4-dihydrobenzoxazin-7- yl)benzimidazole and 4-morpholinobenzoic acid. [M+H]+ calcd for C27H27N5O3: 470.21; found: 496.96.
EXAMPLE 70
[0715] N-(2-(4-Phenoxyphenyl)-lH-benzo[d]imidazol-5-yl)benzamide (Compound 170)
Figure imgf000149_0003
[0716] Compound 170 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-benzoaniline and 4-phenoxybenzaldehyde. [M+H]+ calcd for C26H19N3O2: 406.16; found: 406.08.
EXAMPLE 71
[0717] N-(2-(6-Methoxynaphthalen-2-yl)- lH-benzo[ d]imidazol-5- yl)benzamide (Compound 171
Figure imgf000150_0001
[0718] Compound 171 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-iV-benzoaniline and 6-methoxynaphthalene-2- carboxaldehyde. [M+H]+ calcd for C25H19N3O2: 394.15; found: 394.10.
EXAMPLE 72
[0719] N-(2-Phenyl-lH-benzo[J]imidazol-5-yl)-[l,r-biphenyl]-4- carboxamide (Compound 172
Figure imgf000150_0002
[0720] Compound 172 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-phenylbenzo)aniline and benzaldehyde. 1H NMR (500MHz, DMSO-d6) δ 10.62 (s, 1H), 8.83 (m, 1H), 8.52 (d, / = 1.5 Hz, 1H), 8.23 (m, 2H), 8.13 (d, / = 8.5 Hz, 2H), 7.82 (d, / = 9 Hz, 3H), 7.79 (dd, " = 1.5, 9 Hz, 1H), 7.70 (dd, / = 1.5, 9 Hz, 2H), 7.73 (m, 3H), 7.53 (t, / = 7.5 Hz, 2H), 7.44 (dt, / = 1, 7.5 Hz, 1H).
EXAMPLE 73
[0721 ] N- (2- (4- (pyrimidin- 5 -yl)phenyl)- 1 H-benzo [d] imidazol- 5 -yl)benzamide (Compound 173)
Figure imgf000150_0003
[0722] Compound 173 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-benzoaniline and 4-(pyrimidin-5- yl)benzaldehyde. [M+H]+ calcd for C24H17N5O: 392.15; found: 391.91.
EXAMPLE 74
[0723] N- (2- (4- (pyridin- 3 -yl)phenyl)- 1 H-benzo [d] imidazol- 5 -yl)benzamide (Compound 174)
Figure imgf000151_0001
[0724] Compound 174 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-benzoaniline and 4-(pyridyl-3-)benzaldehyde. [M+H]+ calcd for C25H18N4O: 391.16; found: 390.90.
EXAMPLE 75
[0725] 2'-(4-Ethoxyphenyl)-5-(4-methylpiperazin-l-yl)-lH,rH-2,5'- bibenzo [d] imidazole (Compound 175)
Figure imgf000151_0002
[0726] Compound 175 was prepared according to the procedure similar to that described in Scheme ΠΙ from 5-(iV-methylpiperizinyl)-2-(3,4- diaminophenyl)benzimidazole and 4-ethoxybenzaldehyde.
EXAMPLE 76
[0727] 3-Bromo-iV-(2-phenyl- lH-benzo[d]imidazol-5-yl)benzamide
(Compound 176)
Figure imgf000151_0003
[0728] Compound 176 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(3-bromobenzo)aniline and benzaldehyde. 1H NMR (300MHz, Acetone-J6) δ 9.77 (bs, 1H), 8.37 (s, 1H), 8.23 (d, / = 7 Hz, 2H), 8.18 (s, 1H), 8.04 (m, 1H), 7.75 (d, / = 8.5 Hz, 1H), 7.62-7.46 (m, 7H).
EXAMPLE 77
[0729] 4-Methoxy-N-(2-(4-(pyrrolidin-l-yl)phenyl)-lH-benzo[J]imidazol-5- yl)benzamide (Compound 177
Figure imgf000152_0001
[0730] Compound 177 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-methoxybenzo)aniline and 4-(pyrrolidin-l- yl)benzaldehyde. [M+H]+ calcd for C25H24N4O2: 413.20; found: 413.51.
EXAMPLE 78
[0731] 4-Guanidino-N-(2-(4-(pyrrolidin-l-yl)phenyl)-lH-benzo[J]imidazol-5- yl)benzamide (Compound 178
Figure imgf000152_0002
[0732] Compound 178 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-amidinoaminobenzo)aniline and 4- (pyrrolidin-l-yl)benzaldehyde. [M+H]+ calcd for C25H25N7O: 440.22; found: 440.57.
EXAMPLE 79
[0733] 4-(Dimethylamino)-N-(2-(4-(2-oxopyrrolidin-l-yl)phenyl)-lH- benzo[d]imidazol-5-yl)benzamide (Compound 179)
Figure imgf000152_0003
[0734] Compound 179 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-dimethylaminobenzo)aniline and 4- (pyrrolidon-l-yl)benzaldehyde. [M+H]+ calcd for C26H25N5O2: 440.20; found: 440.50. EXAMPLE 80
[0735] 4-(Dimethylamino)-N-(2-(phenylamino)-lH-benzo[(i]imidazol-5- yl)benzamide (Compound 180)
Figure imgf000153_0001
[0736] Compound 180 was prepared according to the procedure similar to that described in Scheme ΙΠ from 4-dimethylaminobenzoic acid and 5-amino-2- phenylaminobenzimidazole. [M+H]+ calcd for C22H22N5O: 372.18; found: 371.95.
EXAMPLE 81
[0737] 4-(Dimethylamino)-N-(2-(4-methyl-3,4-dihydro-2H- benzo[b] [l,4]oxazin- -yl)-lH-benzo[(i]imidazol-5-yl)benzamide (Compound 181)
Figure imgf000153_0002
[0738] Compound 181 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and 1- methyl-2,3-dihydrobenzo[l,4]oxazine-6-carboxaldehyde. [M+H]+ calcd for C25H25N5O2: 428.20; found: 428.49.
EXAMPLE 82
[0739] N-(4-(5-(cyclopent-l-enecarboxamido)-lH-benzo[(i]imidazol-2- yl)phenyl)cyclopent- -enecarboxamide (Compound 182)
Figure imgf000153_0003
[0740] Compound 182 was prepared according to the procedure similar to that described in Scheme ΠΙ from 5-amino-2-(4-aminophenyl)benzimidazole and 1- cyclohexenecarboxylic acid. [M+H]+ calcd for C25H24N4O2: 413.20; found: 412.96. EXAMPLE 83
[0741] N-(2-(2,3-dihydrobenzofuran-5-yl)-lH-benzo[J]imidazol-5-yl)-4- (dimethylamino)benzamide (Compound 183)
Figure imgf000154_0001
[0742] Compound 183 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and 2,3- dihydrobenzofuran-5-carboxaldehyde. [M+H]+ calcd for C24H24N4O2: 399.18; found: 399.47.
EXAMPLE 84
[0743] N-(2-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-lH-benzo[J]imidazol-5- yl)-4-(dimethylamino)benzamide (Compound 184)
Figure imgf000154_0002
[0744] Compound 184 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and benzo[l,4]dioxane-6-carboxaldehyde. [M+H]+ calcd for C24H22N4O3: 415.17; found: 415.47.
EXAMPLE 85
[0745] 4-(dimethylamino)-N-(2-(l-methyl-lH-benzoM[l,2,3]triazol-5-yl)- lH-benzo[d]imidazo -5-yl)benzamide (Compound 185)
Figure imgf000154_0003
[0746] Compound 185 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and 1- methylbenzotriazole-5-carboxaldehyde. [M+H]+ calcd for C23H21N7O: 412.18; found: 412.50. EXAMPLE 86
[0747] N-(2-(benzo[c][l,2,5]oxadiazol-5-yl)-lH-benzo[J]imidazol-5-yl)-4- (dimethylamino)benzamide (Compound 186)
Figure imgf000155_0001
[0748] Compound 186 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and benzofurazan-5-carboxaldehyde. [M+H]+ calcd for C22Hi8N602: 399.15; found: 399.47.
EXAMPLE 87
[0749] N-(lH,rH-[2,5'-bibenzo[J]imidazol]-5-yl)-4- (dimethylamino)benzamide (Compound 187)
Figure imgf000155_0002
[0750] Compound 187 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and benzimidazole-5-carboxaldehyde. [M+H]+ calcd for C23H2oN60: 397.17; found: 397.52.
EXAMPLE 88
[0751] N-(2-(benzofuran-5-yl)-lH-benzo[J]imidazol-5-yl)-4- (dimethylamino)benzamide (Compound 188)
Figure imgf000155_0003
[0752] Compound 188 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and benzofuran-5-carboxaldehyde. [M+H]+ calcd for C24H2oN402: 397.16; found: 397.52.
EXAMPLE 89
[0753] 2N-(2-(4-(l^-imidazol-l-yl)phenyl)-lH-benzo[J]imidazol-5-yl)-4- (pyrrolidin-l-yl)benzamide (Compound 189)
Figure imgf000156_0001
[0754] Compound 189 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-pyrrolidin-l-ylbenzoyl)aniline and 4- imidazolylbenzaldehyde. [M+H]+ calcd for C27H24N6O: 449.21 ; found: 449.48.
EXAMPLE 90
[0755] N-(2-(4-(dimethylamino)phenyl)-lH-benzo[J]imidazol-5-yl)-l-methyl- lH-benzo[d] [l,2,3]triazole-6-carboxamide (Compound 190)
Figure imgf000156_0002
[0756] Compound 190 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(l-methyl-6-benzotriazolylcarbonyl)aniline and 4-dimethylaminobenzaldehyde. 1H NMR (500MHz, DMSO-d6) δ 10.74 (s, 1H), 8.78 (s, 1H), 8.43 (d, / = 1.5 Hz, 1H), 8.16 (dd, / = 1, 8.5 Hz, 1H), 8.10 (d, / = 9 Hz, 2H), 8.01 (d, / = 8.5 Hz, 2H), 7.84 (dd, / = 2, 9 Hz, 1H), 7.72 (d, / = 9 Hz, 1H), 6.96 (d, / = 9 Hz, 2H), 4.39 (s, 3H), 3.10 (s, 6H).
EXAMPLE 91
[0757] 4-(5-benzamido-lH-benzo[J]imidazol-2-yl)-N-(4- (dimethylamino)phenyl)benzamide (Compound 191)
Figure imgf000156_0003
[0758] Compound 191 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and 4- phenylaminocarbonylbenzaldehyde. [M+H]+ calcd for C29H25N5O2: 476.20; found: 475.98. EXAMPLE 92
[0759] 4-(dimethylamino)-N-(2-(4-(phenylcarbamoyl)phenyl)- 1H- benzo[d]imidazol-5-yl)benzamide (Compound 192)
Figure imgf000157_0001
[0760] Compound 192 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-benzoylaniline and 4-(4- dimethylaminophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C29H25N5O2: 476.20; found: 475.91.
EXAMPLE 93
[0761] 4-(dimethylamino)-N-(2-(4-((4- (dimethylamino)phenyl)carbamoyl)phenyl)-lH-benzo[(i]imidazol-5-yl)benzamide (Compound 19
Figure imgf000157_0002
[0762] Compound 193 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and 4-(4- dimethylaminophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C31H30N6O2: 519.24; found: 519.04.
EXAMPLE 94
[0763] 3-chloro-N-(2-(4-(phenylcarbamoyl)phenyl)-lH-benzo[(i]imidazol-5- yl)benzamide (Compound 194)
Figure imgf000157_0003
[0764] Compound 194 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-chlorobenzoyl)aniline and 4- phenylaminocarbonylbenzaldehyde. [M+H]+ calcd for C27H19CIN4O2: 467.12; found: 466.93.
EXAMPLE 95
[0765] 4-morpholino-N-(2-(4-((4-morpholinophenyl)carbamoyl)phenyl)-lH- benzo[d]imidazol-5-yl)benzamide (Compound 195)
Figure imgf000158_0001
[0766] Compound 195 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-morpholin-4-ylbenzoyl)aniline and 4-(4- morpholinylphenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C35H34N6O4: 603.26; found: 603.36.
EXAMPLE 96
[0767] 4-(4-methylpiperazin- 1 -yl)-N-(2-(4-((4-(4-methylpiperazin- 1 - yl)phenyl)carbamoyl)phenyl)- lH-benzo[d]imidazol-5-yl)benzamide (Compound 196)
Figure imgf000158_0002
[0768] Compound 196 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-(4-methylpiperazin-l-yl)benzoyl)aniline and 4-(4-(4-methylpiperazin-l-yl)phenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C37H4oN802: 629.33; found: 629.16.
EXAMPLE 97
[0769] N-(4-(dimethylamino)phenyl)-2-(4-((4- (dimethylamino)phenyl)carbamoyl)phenyl)-lH-benzo[(i]imidazole-5-carboxamide (Compound 19
Figure imgf000158_0003
[0770] Compound 197 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(4-dimethylaminophenyl)-3,4-dinitrobenzamide and 4-(4- dimethylaminophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C31H30N6O2: 519.24; found: 519.04.
EXAMPLE 98
[0771] 2-(4-(4-(dimethylamino)benzamido)phenyl)-N-(4- (dimethylamino)phenyl)- lH-benzo[d]imidazole-5-carboxamide (Compound 198)
Figure imgf000159_0001
[0772] Compound 198 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(4-dimethylaminophenyl)-3,4-dinitrobenzamide and 4-(4- dimethylaminobenz)amidobenzaldehyde. [M+H]+ calcd for C31H30N6O2: 519.24; found: 518.97.
EXAMPLE 99
[0773] N-(2-(4-(l^-pyrazol-l-yl)phenyl)-lH-benzo[J]imidazol-6-yl)-4- (dimethylamino)benzamide (Compound 199)
Figure imgf000159_0002
[0774] Compound 199 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and 4- imidazolylbenzaldehyde. [M+H]+ calcd for C25H22N6O: 423.20; found: 423.01.
EXAMPLE 100
[0775] N-(2-(4-(l^-l,2,4-triazol-l-yl)phenyl)-lH-benzo[J]imidazol-5-yl)-4- (dimethylamino)benzamide (Compound 200)
Figure imgf000159_0003
[0776] Compound 200 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and 4-(l,2,4-triazolyl-l-)benzaldehyde. [M+H]+ calcd for C24H21N7O: 424.19; found: 424.02.
EXAMPLE 101
[0777] N-(2-phenyl- lH-benzo [d] imidazol-5-yl)benzo [b] thiophene-2- carboxamide (Compound 201)
Figure imgf000160_0001
[0778] Compound 201 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(3,4-dinitrophenyl)benzo[b]thiophene-2-carboxamide and benzaldehyde. 1H NMR (500MHz, CD3OD) δ 8.18 (d, / = 2 Hz, 1H), 8.14 (s, 1H), 8.06 (d, / = 8 Hz, 2H), 7.91 (m, 2H), 7.85 (d, / = 8.5 Hz, 1H), 7.73 (d, / = 8.5 Hz, 1H), 7.60 (d, / = 8.5 Hz, 1H), 7.53 (m, 3H), 7.44 (m, 3H).
EXAMPLE 102
[0779] N-(2-(4-(2H-tetrazol-5-yl)phenyl)-lH-benzo[J]imidazol-5-yl)-4- (dimethylamino)benzamide (Compound 202)
Figure imgf000160_0002
[0780] Compound 202 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and 4-(l,2,3,5-tetrazolyl-5-)benzaldehyde. [M+H]+ calcd for C23H20N8O: 415.19; found: 424.97.
EXAMPLE 103
[0781] N-(2-phenyl-lH-benzo[<i]imidazol-5-yl)-lH-indole-2-carboxamide (Compound 203)
Figure imgf000160_0003
[0782] Compound 203 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(indol-2-oyl)aniline and benzaldehyde. 1H NMR (500MHz, CD3OD) δ 8.20 (d, / = 1.5 Hz, 1H), 8.09 (dd, / = 1.5, 8 Hz, 2H). 7.66 (d, / = 8 Hz, 1H), 7.61 (d, / = 8.5 Hz, 1H), 7.57 - 7.52 (m, 4H), 7.48 (dd, / = 0.5, 8 Hz, 1H), 7.34 (s, 1H), 7.25 (dt, / = 1, 7 Hz, 1H), 7.09 (dt, / = 0.5, 8 Hz, 1H).
EXAMPLE 104
[0783] N-(2-phenyl-lH-benzo[J]imidazol-5-yl)- 1,2,3,4- tetrahydronaphthalene-2-carboxamide (Compound 204)
Figure imgf000161_0001
[0784] Compound 204 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(l,2,3,4-tetrahydronaphthalen-2-oyl)aniline and benzaldehyde. [M+H]+ calcd for C24H2iN30: 368.17; found: 368.00.
EXAMPLE 105
[0785] N-(2-(4-methoxyphenyl)-lH-benzo[(i]imidazol-5-yl)isonicotinamide (Compound 205)
Figure imgf000161_0002
[0786] Compound 205 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(pyridin-4-oyl)aniline and 4- methoxybenzaldehyde. [M+H]+ calcd for C20Hi6N4O2: 345.13; found: 345.00.
EXAMPLE 106
[0787] 4-(dimethylamino)-N-(2-(4-(dimethylamino)phenyl)- 1H- benzo[d]imidazol-5-yl)benzamide (Compound 206)
Figure imgf000161_0003
[0788] Compound 206 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-dimethylaminobenzoyl)aniline and 4- dimethylaminobenzaldehyde. 1H NMR (300MHz, DMSO-d6) δ 10.20 (s, 1H), 8.39 (s, 1H), 8.11 (d, / = 8 Hz, 2H), 7.90 (d, / = 9 Hz, 2H), 7.81 (d, / = 9 Hz, 2H), 7.68 (d, / = 9 Hz, 2H), 6.95 (d, / = 9 Hz, 2H), 6.78 (d, / = 9 Hz, 2H), 3.07 (s, 6H), 2.99 (s, 6H).
EXAMPLE 107
[0789] N-(2-(4-(dimethylamino)phenyl)-lH-benzo[J]imidazol-5- yl)isonicotinamide (Compound 207)
Figure imgf000162_0001
[0790] Compound 207 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(pyridin-4-oyl)aniline and 4- dimethylaminobenzaldehyde. 1H NMR (500MHz, DMSO-d6) δ 10.90 (s, 1H), 8.83 (d, / = 6 Hz, 2H), 8.40 (s, 1H), 8.10 (d, / = 9 Hz, 2H), 7.98 (d, / = 6 Hz, 2H), 7.81 (dd, / = 2, 9 Hz, 1H), 7.75 (d, / = 9 Hz, 1H), 6.97 (d, / = 9 Hz, 2H), 3.09 (s, 6H).
EXAMPLE 108
[0791] N-(2-(4-(dimethylamino)phenyl)-lH-benzo[J]imidazol-5-yl)-4- methoxybenzamide
[0792] (Compound 208)
Figure imgf000162_0002
[0793] Compound 208 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-methoxybenzoyl)aniline and 4- dimethylaminobenzaldehyde. 1H NMR (500MHz, DMSO-d6) δ 10.41 (s, 1H), 8.39 (d, / = 1.5 Hz, 1H), 8.08 (d, / = 9.5 Hz, 2H), 8.01 (d, / = 7 Hz, 2H), 7.79 (dd, / = 2, 9 Hz, 1H), 7.67 (d, / = 9 Hz, 1H), 7.09 (d, / = 9 Hz, 2H), 6.96 (d, / = 9 Hz, 2H), 3.82 (s, 3H), 3.08 (s, 6H). EXAMPLE 109
[0794] 4-(lH-imidazol-l-yl)-N-(2-(4-methoxyphenyl)-lH-benzo[J]imidazol- 5-yl)benzamide (Compound 209)
Figure imgf000163_0001
[0795] Compound 209 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-imidazol-l-ylbenzoyl)aniline and 4- methoxybenzaldehyde. [M+H]+ calcd for C24H19N5O2: 410.05; found: 410.00.
EXAMPLE 110
[0796] N-(2-(4-methoxyphenyl)-lH-benzo[(i]imidazol-5-yl)thiophene-2- carboxamide (Compound 210)
Figure imgf000163_0002
[0797] Compound 210 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(thien-2-oyl)aniline and 4- methoxybenzaldehyde. [M+H]+ calcd for C19H15N3O2S: 350.09; found: 349.89.
EXAMPLE 111
[0798] N,2-bis(4-morpholinophenyl)-lH-benzo[(i]imidazole-5-carboxamide (Compound 211
Figure imgf000163_0003
[0799] Compound 211 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(4-morpholinylphenyl)-3,4-dinitrobenzamide and 4- morpholinylbenzaldehyde. [M+H]+ calcd for C28H29N5O3: 484.23; found: 483.92. EXAMPLE 112
[0800] 4-morpholino-N-(2-(4-morpholinophenyl)-lH-benzo[(i]imidazol-5- yl)benzamide (Compound 212)
Figure imgf000164_0001
[0801] Compound 212 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-morpholin-4-ylbenzoyl)aniline and 4- morpholinylbenzaldehyde. [M+H]+ calcd for C28H29N5O3: 484.23; found: 483.94.
EXAMPLE 113
[0802] iV-phenyl-4- (5 - (4- (pyrrolidin- 1 -yl)benzamido) - 1 H-benzo [d] imidazol-2- yl)benzamide (Compound 213)
Figure imgf000164_0002
[0803] Compound 213 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-pyrrolidinylbenzamide and 4- phenylaminocarbonylbenzaldehyde. [M+H]+ calcd for C31H27N5O2: 502.23; found: 502.03.
EXAMPLE 114
[0804] 4-((2-hydroxyethyl)(methyl)amino)-N-(2-(4- (phenylcarbamoyl)phenyl)-lH-benzo[<i]imidazol-5-yl)benzamide (Compound 214)
Η
Figure imgf000164_0003
[0805] Compound 214 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(3,4-dinitrophenyl)-4-(N-methyl-iV-2- hydroxyethylamino)benzamide and 4-phenylaminocarbonylbenzaldehyde. [M+H]+ calcd for C30H27N5O3: 506.22; found: 506.01 EXAMPLE 115
[0806] N-phenyl-4- (5 - (4- (piperidin- 1 -yl)benzamido) - 1 H-benzo [d] imidazol-2- yl)benzamide (Compound 215)
Figure imgf000165_0001
[0807] Compound 215 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-piperidinylbenzamide and 4- phenylaminocarbonylbenzaldehyde. [M+H]+ calcd for C32H29N5O2: 516.24; found: 516.07.
EXAMPLE 116
[0808] 4-(4-methylpiperazin- 1 -yl)-N-(2-(4-(phenylcarbamoyl)phenyl)- 1H- benzo[d]imidaz -5-yl)benzamide (Compound 216)
Figure imgf000165_0002
[0809] Compound 216 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-(l-methyl-4-piperazinyl)benzamide and 4-phenylaminocarbonylbenzaldehyde. [M+H]+ calcd for C32H30N6O2: 531.25; found: 531.05.
EXAMPLE 117
[0810] 4-morpholino-N-(2-(4-(phenylcarbamoyl)phenyl)- 1H- benzo[d]imidaz -5-yl)benzamide (Compound 217)
Figure imgf000165_0003
[0811] Compound 217 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-morpholinylbenzamide and 4- phenylaminocarbonylbenzaldehyde. [M+H]+ calcd for C31H27N5O3: 518.22; found: 518.03.
EXAMPLE 118
[0812] 4-(dimethylamino)-N-(2-(4-(2-hydroxyethoxy)phenyl)- 1H- benzo[d]imidaz -5-yl)benzamide (Compound 218)
Figure imgf000166_0001
[0813] Compound 218 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(3,4-dinitrophenyl)-4-dimethylaminobenzamide and 4-(2- hydroxyethyloxy)benzaldehyde. [M+H]+ calcd for C24H24N4O3: 417.19; found: 417.00.
EXAMPLE 119
[0814] 4-(dimethylamino)-N-(2-(3-(2-hydroxyethoxy)phenyl)- 1H- benzo[d]imidazol-5- l)benzamide (Compound 219)
Figure imgf000166_0002
[0815] Compound 219 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(3,4-dinitrophenyl)-4-dimethylaminobenzamide and 3-(2- hydroxyethyloxy)benzaldehyde. [M+H]+ calcd for C24H24N4O3: 417.19; found: 416.94.
EXAMPLE 120
[0816] 4-(dimethylamino)-N-(2-(4'-(dimethylamino)-[l,r-biphenyl]-4-yl)-lH- benzo[d]imidazol-5-yl)benzamide (Compound 220)
Figure imgf000166_0003
[0817] Compound 220 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(3,4-dinitrophenyl)-4-dimethylaminobenzamide and 4-(4- dimethylaminophenyl)benzaldehyde. [M+H]+ calcd for C30H29N5O: 476.24; found: 475.98. EXAMPLE 121
[0818] N-(2-(4-(phenylcarbamoyl)phenyl)-lH-benzo[J]imidazol-5-yl)-2- (pyrrolidin-l-yl)pyrimidine-5-carboxamide (Compound 221)
Figure imgf000167_0001
[0819] Compound 221 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-2-(pyrrolidin-l-yl)pyrimidine-5- carboxamide and 4-phenylaminocarbonylbenzaldehyde. [M+H]+ calcd for C29H25N7O2: 504.22; found: 503.92.
EXAMPLE 122
[0820] 4-(5-(4-(lH-tetrazol-l-yl)benzamido)-lH-benzo[J]imidazol-2-yl)-N- phenylbenzamide (Compound 222)
Figure imgf000167_0002
[0821] Compound 222 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-tetrazolylbenzamide and 4- phenylaminocarbonylbenzaldehyde. [M+H]+ calcd for C28H20N8O2: 501.18; found: 500.88.
EXAMPLE 123
[0822] N-(2-(4-(2-hydroxyethoxy)phenyl)-lH-benzo[J]imidazol-5-yl)-4-((2- hydroxyethyl)(methyl)amino)benzamide (Compound 223)
Figure imgf000167_0003
[0823] Compound 223 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(3,4-dinitrophenyl)-4-(N-methyl-iV-2- hydroxyethylamino)benzamide and 4-(2-hydroxyethyloxy)benzaldehyde. [M+H]+ calcd for C25H26N4O4: 447.21 ; found: 446.89.
EXAMPLE 124
[0824] 3-(5-(4-(dimethylamino)benzamido)-lH-benzo[J]imidazol-2-yl)-N-(4- (dimethylamino)phenyl)benzamide (Compound 224)
Figure imgf000168_0001
[0825] Compound 224 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-dimethylaminobenzo)aniline and 3-(4- dimethylaminophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C31H30N6O2: 519.25; found: 519.04.
EXAMPLE 125
[0826] 4-(pyrrolidin- 1 -yl)-N-(2-(4-(pynolidin- 1 -yl)phenyl)- 1H- benzo[d]imidazol-5-yl)benzamide (Compound 225)
Figure imgf000168_0002
[0827] Compound 225 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-pyrrolidinylbenzamide and 4- pyrrolidinylbenzaldehyde. [M+H]+ calcd for C28H29N5O: 452.25; found: 451.95.
EXAMPLE 126
[0828] N-(2-(4-(P rolidin-l-yl)phenyl)-lH-benzo[J]imidazol-5-yl)-4-(lH- tetrazol-l-yl)benzamide Compound 226)
Figure imgf000168_0003
[0829] Compound 226 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-tetrazolylbenzamide and 4- pyrrolidinylbenzaldehyde. [M+H]+ calcd for C25H22N8O: 451.20; found: 451.50. EXAMPLE 127
[0830] N-(2-hydroxyethyl)-4-(5-(4-(P rolidm-l-y1)benzamido)-lH- benzo[d]imidaz -2-yl)benzamide (Compound 227)
Figure imgf000169_0001
[0831] Compound 227 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-pyrrolidinylbenzamide and 4-(2- hydroxyethyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C27H27N5O3: 470.22; found: 469.58.
EXAMPLE 128
[0832] iV-cyclopropyl-4- (5 - (4- (pyrrolidin- 1 -yl)benzamido) - 1 H- benzo[d]imidaz -2-yl)benzamide (Compound 228)
Figure imgf000169_0002
[0833] Compound 228 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-pyrrolidinylbenzamide and 4- cyclopropylaminocarbonylbenzaldehyde. [M+H]+ calcd for C28H27N5O2: 466.23; found: 466.55.
EXAMPLE 129
[0834] N-(2,3-dihydroxypropyl)-4-(5 4 P rolidm-l-y^benzamido)-l^- benzo[d]imidaz -2-yl)benzamide (Compound 229)
Figure imgf000169_0003
[0835] Compound 229 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(3,4-dinitrophenyl)-4-pyrrolidinylbenzamide and 4-(2,3- dihydroxypropyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C28H29N5O4: 500.23; found: 500.56.
EXAMPLE 130
[0836] N-(2-(4-(hydrazinecarbonyl)phenyl)-lH-benzo[(i]imidazol-5-yl)-4- (pyrrolidin-l-yl)benzamide (Compound 230)
Figure imgf000170_0001
[0837] Compound 230 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-pyrrolidinylbenzamide and 4- hydrazinylcarbonylbenzaldehyde. [M+H]+ calcd for C25H24N6O2: 441.21; found: 441.51.
EXAMPLE 131
[0838] N-(2-morpholinoethyl)-4-(5-(4-(pyrrolidin-l-yl)benzamido)-lH- benzo[d]imidaz -2-yl)benzamide (Compound 231)
Figure imgf000170_0002
[0839] Compound 231 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-pyrrolidinylbenzamide and 4-(2- morpholinylethyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C31H34N6O3: 539.28; found: 539.63.
EXAMPLE 132
[0840] N-(3-methyl-lH-pyrazol-4-yl)-4-(5-(4-(P rolidm-l-y1)benzamido)-lH- benzo[d]imidaz -2-yl)benzamide (Compound 232)
Figure imgf000170_0003
[0841] Compound 232 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-pyrrolidinylbenzamide and 4-(3- methyl-4-pyrazolyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C29H27N7O2: 506.23; found: 506.25.
EXAMPLE 133
[0842] N-(2-(diethylamino)ethyl)-2-(4-((4- (dimethylamino)phenyl)carbamoyl)phenyl)-lH-benzo[(i]imidazole-5-carboxamide (Compound 233)
Figure imgf000171_0001
[0843] Compound 233 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(2-N,N-diethylaminoethyl)-dinitrophenyl)-3,4- dinitrobenzamide and 4-(4-dimethylaminophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C29H34N6O2: 499.27; found: 499.61.
EXAMPLE 134
[0844] iV-cyclopropyl-4- (5 - (4-fluorobenzamido) - 1 H-benzo [d] imidazol-2- yl)benzamide (Compound 234)
Figure imgf000171_0002
Η
[0845] Compound 234 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-fluorobenzamide and 4- cyclopropylaminocarbonylbenzaldehyde. [M+H]+ calcd for C24H19FN4O2: 415.16; found: 415.53.
EXAMPLE 135
[0846] N-cyclopropyl-4-(5-(4-((2-hydroxyethyl)(methyl)amino)benzamido)- lH-benzo[d]imidazol-2- l benzamide om ound 2 5
Figure imgf000171_0003
[0847] Compound 235 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-(N-2-hydroxyethyl-N- methylamino)benzamide and 4-cyclopropylaminocarbonylbenzaldehyde. [M+H]+ calcd for C27H27N5O3: 470.22; found: 470.60.
EXAMPLE 136
[0848] N-cyclopropyl-4-(5-(4-((N-methylsulfamoyl)amino)benzamido)-lH- benzo[d]imidazol-2-yl)benzamide (Compound 236)
Figure imgf000172_0001
[0849] Compound 236 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4- methylaminosulfonamido)benzamide and 4-cyclopropylaminocarbonylbenzaldehyde. [M+H]+ calcd for C25H24N6O4S: 505.17; found: 504.47.
EXAMPLE 137
[0850] N-cyclopropyl-4-(5-(4-(2-hydroxyethoxy)benzamido)- 1H- benzo[d]imidazol-2-yl)benzamide (Compound 237)
Figure imgf000172_0002
[0851] Compound 237 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(3,4-dinitrophenyl)-4-(2-hydroxyethoxy)benzamide and 4-cyclopropylaminocarbonylbenzaldehyde. [M+H]+ calcd for C26H24N4O4: 457.19; found: 457.51.
EXAMPLE 138
[0852] (E)-4-(dimethylamino)-N-(2-(3-((2-(4- (dimethylamino)benzoyl)hydrazono)methyl)phenyl)-lH-benzo[(i]imidazol-5- yl)benzamide (Compound 238)
Figure imgf000173_0001
[0853] Compound 238 was prepared according to the procedure described in Scheme I from 4-dimethylaminobenzohydrazide and 3-(5-(4- dimethylaminobenzamido)benzimidazolyl-2-)benzaldehyde. [M+H]+ calcd for
C32H31N7O2: 546.26; found: 546.65.
EXAMPLE 139
[0854] N-(2-(4-(morpholine-4-carbonyl)phenyl)-lH-benzo[J]imidazol-5-yl)-4- (pyrrolidin-l-yl)benzamide (Compound 239)
Figure imgf000173_0002
[0855] Compound 239 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-pyrrolidinylbenzamide and 4- morpholinylcarbonylbenzaldehyde. [M+H]+ calcd for C29H29N5O3: 496.24; found: 496.25.
EXAMPLE 140
[0856] iV-cyclopropyl-4- (5 - (4- (3 -hydroxypyrrolidin- 1 -yl)benzamido)- 1 H- benzo[d]imidazo -2-yl)benzamide (Compound 240)
Figure imgf000173_0003
[0857] Compound 240 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-(3-hydroxypyrrolidinyl)benzamide and 4-cyclopropyl aminocarbonylbenzaldehyde. [M+H]+ calcd for C28H27N5O3: 482.22; found: 481.93. EXAMPLE 141
[0858] N-(P idin-3-yl)-4-(5-(4-(pyrrolidin-l-yl)benzamido)-lH- benzo[d]imidaz -2-yl)benzamide (Compound 241)
Figure imgf000174_0001
[0859] Compound 241 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-pyrrolidinylbenzamide and 4-(3- pyridinylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C30H26N6O2: 503.22; found: 502.97.
EXAMPLE 142
[0860] N-cyclopropyl-4-(5-(4-(4-hydroxypiperidin- 1 -yl)benzamido)- 1H- benzo[d]imidazol-2-yl)benzamide (Compound 242)
Figure imgf000174_0002
[0861] Compound 242 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-(2-hydroxypiperidinyl)benzamide and 4-cyclopropyl aminocarbonylbenzaldehyde. [M+H]+ calcd for C29H29N5O3: 496.24; found: 495.95.
EXAMPLE 143
[0862] N-(2-(4-(2-hydroxyethoxy)phenyl)-lH-benzo[J]imidazol-5-yl)-2- (pyrrolidin-l-yl)pyrimidine-5-carboxamide (Compound 243)
Figure imgf000174_0003
[0863] Compound 243 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-2-(pyrrolidin-l-yl)pyrimidine-5- carboxamide and 4-(2-hydroxyethoxy)benzaldehyde. [M+H]+ calcd for C24H24N6O3: 445.20; found: 444.87.
EXAMPLE 144
[0864] 4-(dimethylamino)-N-(4-(6-(4- (dimethylamino)benzamido)benzo [d] oxazol-2- l) hen l)benzamide (Compound 244)
Figure imgf000175_0001
[0865] Compound 244 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(3-hydoxy-4-nitro)phenyl-4-dimethylaminobenzamide and 4-(4-dimethylaminobenz)amidobenzaldehyde. [M+H]+ calcd for C31H29N5O3: 520.23; found: 520.60.
EXAMPLE 145
[0866] 4-(dimethylamino)-N-(4-(5-(4- (dimethylamino)benzamido)benzo [d] oxazol-2- l) hen l)benzamide (Compound 245)
Figure imgf000175_0002
[0867] Compound 245 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(4-hydoxy-3-nitro)phenyl-4-dimethylaminobenzamide and 4-(4-dimethylaminobenz)amidobenzaldehyde. [M+H]+ calcd for C31H29N5O3: 520.23; found: 520.60.
EXAMPLE 146
[0868] 4-(dimethylamino)-N-(2-(4-((4- (dimethylamino)phenyl)carbamoyl)phenyl)- lH-indol-5-yl)benzamide (Compound 246)
Figure imgf000175_0003
[0869] Compound 246 was prepared according to the procedure similar to that described in Scheme ΠΙ from 5-nitro-2-(4-methoxycarbonylphenyl)indole, 4- dimethylaminoaniline, and 4-dimethylaminobenzoic acid. [M+H]+ calcd for C31H30N6O2: 519.25; found: 519.59.
EXAMPLE 147
[0870] Methyl 4-(6-(4-(dimethylamino)benzamido)-lH-indol-2-yl)benzoate (Compound 247)
Figure imgf000176_0001
[0871] Compound 247 was prepared according to the procedure similar to that described in Scheme ΠΙ from 5-nitro-2-(4-methoxycarbonylphenyl)indole and 4- dimethylaminobenzoic acid. [M+H]+ calcd for C24H22N4O3: 415.17; found: 415.60.
EXAMPLE 148
[0872] 4-((E)-2-(3-methoxybenzylidene)hydrazinecarbonyl)-N-(4-(6-(4-((E)- 2-(3-methoxybenzylidene)hydrazinecarbonyl)benzamido)benzo[<i]oxazol-2- yl)phenyl)benzamide (Compound 248)
Figure imgf000176_0002
[0873] Compound 248 was prepared according to the procedure similar to that described in Scheme Π from the 2-phenylbenzoxazole-bis-hydrazide and 3- methoxybenzaldehyde. [M+H]+ calcd for C45H35N7O7: 786.26; found: 786.23.
EXAMPLE 149
[0874] 4-(4-methylpiperazin-l-yl)-N-(2-(4-((4- morpholinophenyl)carbamoyl)phenyl)-lH-benzo[(i]imidazol-5-yl)benzamide (Compound 249)
Figure imgf000176_0003
[0875] Compound 249 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-(4-methylpiperazinyl)benzamide and 4-(4-morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C36H37N7O3: 616.30; found: 616.09.
EXAMPLE 150
[0876] N-(4-(4-methylpiperazin-l-yl)phenyl)-4-(5-(4-morpholinobenzamido)- lH-benzo[d]imidazol-2-yl)benzamide (Compound 250)
Figure imgf000177_0001
[0877] Compound 250 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-morpholinobenzamide and 4-(4-(4- methylpiperazinyl)phenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C36H37N7O3: 616.30; found: 616.13.
EXAMPLE 151
[0878] 4-(piperazin-l-yl)-N-(2-(4-((4-(piperazin-l- yl)phenyl)carbamoyl)phenyl) - 1 H-benzo [d] imidazol- 5 -yl)benzamide (Compound 251 )
Figure imgf000177_0002
[0879] Compound 251 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(3,4-dinitrophenyl)-4-piperazinylbenzamide and 4-(4-(4- methylpiperazinyl)phenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C35H36N8O2: 601.30; found: 601.19.
EXAMPLE 152
[0880] 4-((2-hydroxyethyl)(methyl)amino)-N-(2-(4-((4- morpholinophenyl)carbamoyl)phenyl)-lH-benzo[(i]imidazol-5-yl)benzamide (Compound 252)
Figure imgf000178_0001
[0881] Compound 252 was prepared according to the procedure similar to that described in Scheme ΠΙ from N-(3,4-dinitrophenyl)-4-(N-methyl-N-2- hydroxyethylamino)-benzamide and 4-(4-morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C34H34N6O4: 591.26; found: 591.06.
EXAMPLE 153
[0882] 6-morpholino-N-(2-(4-((4-morpholinophenyl)carbamoyl)phenyl)-lH- benzo[d]imidazol-5-yl)nicotinamide (Compound 253)
Figure imgf000178_0002
[0883] Compound 253 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(2-morpholinyl-5-pyridinecarbonyl)aniline and 4-(4-morpholinylphenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C34H33N7O4: 604.26; found: 604.10.
EXAMPLE 154
[0884] 4-morpholino-N-(2-(4-thiomorpholinophenyl)-lH-benzo[(i]imidazol-5- yl)benzamide (Compound 254)
Figure imgf000178_0003
[0885] Compound 254 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-thiomorpholinylbenzoyl)aniline and 4- morpholinylbenzaldehyde. [M+H]+ calcd for C28H29N5O2S: 500.20; found: 500.00.
EXAMPLE 155
[0886] N-(2-(4-(4-hydroxypiperidin-l-yl)phenyl)-lH-benzo[J]imidazol-5-yl)- 4-morpholinobenzamide (Compound 255)
Figure imgf000179_0001
[0887] Compound 255 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-morpholinylbenz)aniline and 4-(4- hydroxypiperidinyl)benzaldehyde. [M+H]+ calcd for C29H31N5O3: 498.24; found: 497.98.
EXAMPLE 156
[0888] 4-morpholino-N-(2-(6-morpholinopyridin-3-yl)-lH-benzo[(i]imidazol- 5-yl)benzamide (Compound 256)
Figure imgf000179_0002
[0889] Compound 256 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-morpholinylbenz)aniline and 6- morpholinylpyridine-3-carboxaldehyde. [M+H]+ calcd for C27H28N6O3: 485.22; found: 484.99.
EXAMPLE 157
[0890] 4-morpholino-N-(2-(4-(morpholinomethyl)phenyl)- 1H- benzo[d]imidazol-5-yl)benzamide (Compound 257)
Figure imgf000179_0003
[0891] Compound 257 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-morpholinylbenz)aniline and 4- morpholinomethylbenzaldehyde. [M+H]+ calcd for C29H31N5O3: 498.24; found: 498.02.
EXAMPLE 158
[0892] N-(2-(4-(3-(dimethylamino)propoxy)phenyl)-lH-benzo[(i]imidazol-5- yl)-4-morpholinobenzamide (Compound 258)
Figure imgf000180_0001
[0893] Compound 258 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-morpholinylbenz)aniline and 4-(3- dimethylaminopropyloxy)benzaldehyde. [M+H]+ calcd for C29H33N5O3: 500.26; found: 500.01.
EXAMPLE 159
[0894] N-(2-(4-morpholinophenyl)-iH-benzo[d]imidazol-5-yl)benzamide (Compound 259)
Figure imgf000180_0002
[0895] Compound 259 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-benzoylaniline and 4- morpholinylbenzaldehyde. [M+H]+ calcd for C24H22N4O2: 399.18; found: 398.99.
EXAMPLE 160
[0896] 2,2'-((lH,3'H-[5,5'-bibenzo[J]imidazole]-2,2'-diylbis(4,l- phenylene))bis(oxy))diethanol (Compound 260)
Figure imgf000180_0003
[0897] Compound 260 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,3'-diaminobenzidine and 4-(2- hydroxyethoxy)benzaldehyde. [M+H]+ calcd for C30H26N4O4: 507.20; found: 507.00.
EXAMPLE 161
[0898] 4,4'-(lH,3'H-[5,5'-bibenzo[J]imidazole]-2,2'-diyl)bis(N- phenylbenzamide) (Compound 261)
Figure imgf000181_0001
[0899] Compound 261 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,3'-diaminobenzidine and 4- phenylaminocarbonylbenzaldehyde. [M+H]+ calcd for C40H28N6O2: 625.23; found: 625.53.
EXAMPLE 162
[0900] 2,2'-bis((E)-4-methoxystyryl)-lH,3'H-5,5'-bibenzo[J]imidazole (Compound 262)
Figure imgf000181_0002
[0901] Compound 262 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,3'-diaminobenzidine and 3-(4- methoxyphenyl)acrylaldehyde. [M+H]+ calcd for C32H26N4O2: 499.21; found: 499.00.
EXAMPLE 163
[0902] 4,4'-(propane-l,3-diylbis(oxy))bis(N-(2-(4-methoxyphenyl)-lH- benzo[d]imidazol-5- l)benzamide) (Compound 263)
Figure imgf000181_0003
[0903] Compound 263 was prepared according to the procedure similar to that described in Scheme ΙΠ from l,3-propanedioxybis-(4-benzoic acid) and 5-amino-2-(4- methoxyphenyl)benzimidazole. [M+H]+ calcd for C45H38N606: 759.29; found: 759.54.
EXAMPLE 164
[0904] 4,4'-((lE,rE)-lH,3'H-[5,5'-bibenzo[J]imidazole]-2,2'-diylbis(ethene- 2,l-diyl))bis(N,N-dimethylaniline) (Compound 264)
Figure imgf000182_0001
[0905] Compound 264 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,3'-diaminobenzidine and 3-(4- dimethylaminophenyl)acrylaldehyde. [M+H]+ calcd for C34H32N6: 525.27; found: 525.59.
EXAMPLE 165
[0906] N,N'-(1^3'H-[5,5'-bibenzo[J]imidazole]-2,2'-diylbis(4,l- phenylene bis(4-(dimethylamino)benzamide) (Compound 265)
Figure imgf000182_0002
[0907] Compound 265 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,3'-diaminobenzidine and 4-(4- dimethylaminobenzamido)benzaldehyde. [M+H]+ calcd for C44H38N8 02: 711.31 ; found: 711.38.
EXAMPLE 166
[0908] 4,4' -(propane- l,3-diylbis(oxy))bis(N-(2-(trifluoromethyl)-lH- benzo[d]imidazol-5- l)benzamide) (Compound 266)
Figure imgf000182_0003
[0909] Compound 266 was prepared according to the procedure similar to that described in Scheme ΠΙ from l,3-propanedioxybis-(4-benzoic acid) and 5-amino-2- trifluoromethylbenzimidazole. [M+H]+ calcd for C33H24 Ε6Ν604: 683.18; found: 683.04.
EXAMPLE 167
[0910] 4,4'-(lH,3'H-[5,5'-bibenzo[J]imidazole]-2,2'-diyl)bis(N-(4- (dimethylamino)phenyl)benzamide) (Compound 267)
Figure imgf000183_0001
[0911] Compound 267 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,3'-diaminobenzidine and 4-(4- dimethylaminophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C44H38N8O2: 711.31 ; found: 711.38.
EXAMPLE 168
[0912] N,N'-(2,2'-(l,3-phenylene)bis(lH-benzo[J]imidazole-5,2-diyl))bis(4- (pyrrolidin-l- l)benzamide) (Compound 268)
Figure imgf000183_0002
[0913] Compound 268 was prepared according to the procedure similar to that described in Scheme ΙΠ from N-(3,4-dinitrophenyl)-4-pyrrolidinylbenzamide and 1,3- benzbisaldehyde. [M+H]+ calcd for C42H48N8O2: 687.32; found: 687.19.
EXAMPLE 169
[0914] (E)-4-(2-(3-Methoxybenzylidene)hydrazinecarbonyl)-N-(2-(4- methoxyphen l)-lH-benzo[<i]imidazol-6-yl)benzamide (Compound 269)
Figure imgf000183_0003
[0915] Compound 269 was prepared according to the general procedure described in Scheme V. Preparation of methyl 4-((2-(4-methoxyphenyl)-lH- benzo[d]imidazol-6-yl)carbamoyl)benzoate: 2-(4-Methoxyphenyl)-lH-benzo[<i]imidazol- 6-amine (120 mg, 0.5 mmol) and methyl 4-(chlorocarbonyl)benzoate (80 mg, 0.4 mmole) were place in a 20 mL vial and pyridine (2.0 mL) added and capped tightly. The reaction mixture was stirred at room temperature for 2 h till a solid precipitated out. To this mixture, 10 mL EtOAC was added and stirred for further 15 minutes then filtered. The filter cake was washed with plenty of water and then with some EtOAc (10 mL) and dried to provide pure title compound (70 mg, 44% yield).
[0916] Preparation of 4-(hydrazinecarbonyl)-N-(2-(4-methoxyphenyl)-lH- benzo[d]imidazol-6-yl)benzamide: In a 15-mL sealed tube, methyl 4-((2-(4- methoxyphenyl)-lH-benzo[d]imidazol-6-yl)carbamoyl)benzoate (28 mg, 0.07 mmole) was dissolved in 2 mL absolute ethanol and hydrazine (1 mL) was added. The reaction mixture was heated in an oil bath at 70 °C for overnight. In the morning the reaction mixture was evaporated to dryness to provide the title compound (28 mg, 99%, >95% pure by 1H-NMR). This compound was used for next step without any further purification.
[0917] Preparation of Compound 269: In a 20-mL sealed tube, 4- (hydrazinecarbonyl)-N-(2-(4-methoxyphenyl)-lH-benzo[(i]imidazol-6-yl)benzamide (28 mg, 0.07 mmole) was dissolved in 2 mL absolute ethanol then glacial acetic acid (1.0 mL) and sodium acetate (20 mg) was added. The reaction mixture was heated in an oil bath at 72 °C for overnight. In the morning, water (5.0 mL) added and stirred for 15 min. then it was filtered. The filter cake was washed with water, hexanes, ethyl acetate and dried to provide pure compound 269 (10 mg, 27% yield). [M+H]+ calcd for C30H25N5O4: 520.19; found: 519.98.
EXAMPLE 170
[0918] 2,2'-(l,4-phenylenebis(oxy))bis(N-(2-(trifluoromethyl)-lH- benzo[d]imidazol-5-yl)acetamide) (Compound 270)
Figure imgf000184_0001
[0919] Compound 270 was prepared according to the procedure similar to that described in Scheme V from 1,4-phenyldioxybisacetate and 5-amino-2- trifluoromethylbenzimidazole. [M+H]+ calcd for C26Hi8F6N604: 593.13; found: 592.86.
EXAMPLE 171
[0920] methyl 4-((2-(trifluoromethyl)-lH-benzo[J]imidazol-5- yl)carbamoyl)benzoate (Compound 271)
Figure imgf000185_0001
[0921] Compound 271 was prepared according to the procedure similar to that described in Scheme V from terephthalic acid mono-ester and 5-amino-2- trifluoromethylbenzimidazole. [M+H]+ calcd for C17H12F3N3O3: 364.08; found: 363.86.
EXAMPLE 172
[0922] 2-(4-(dimethylamino)phenyl)-N-(2-(4-methoxyphenyl)- 1H- benzo[d]imidazol-5-y - lH-benzo[d]imidazole-6-carboxamide (Compound 272)
Figure imgf000185_0002
[0923] Compound 272 was prepared according to the procedure similar to that described in Scheme V from 2-(4-dimethylaminophenyl)-5-aminobenzimidazole and 2- (4-dimethylaminophenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C30H26N6O2: 503.21 ; found: 503.25.
EXAMPLE 173
[0924] N-(2-(4-(dimethylamino)phenyl)-lH-benzo[J]imidazol-5-yl)-4- (hydrazinecarbonyl)benzamide Compound 273)
Figure imgf000185_0003
[0925] Compound 273 was prepared according to the procedure similar to that described in Scheme V from 2-(4-dimethylaminophenyl)-5-aminobenzimidazole and terephthalic acid. [M+H]+ calcd for C23H22N6O2: 415.18; found: 414.91.
EXAMPLE 174
Nl,N4-bis(2-(4-methoxyphenyl)-lH-benzo[d]imidazol-5-yl)terephthalamide (Compound 274)
Figure imgf000186_0001
[0926] Compound 274 was prepared according to the procedure similar to that described in Scheme V from 2-(4-methoxyphenyl)-5-aminobenzimidazole and terephthalic acid. [M+H]+ calcd for QeHasNeC : 609.22; found: 608.99.
EXAMPLE 175
[0927] 2-(4-(dimethylamino)phenyl)-N-(4-(hydrazinecarbonyl)phenyl)-lH- benzo[d]imidazole-5-carboxamide Compound 275)
Figure imgf000186_0002
[0928] Compound 275 was prepared according to the procedure similar to that described in Scheme V from 2-(4-dimethylaminophenyl)benzimidazole-5-carboxylic acid and 4-aminobenzhydrazide. [M+H]+ calcd for C23H22N6O2: 415.18; found: 414.91.
EXAMPLE 176
[0929] (E) -4- (2- (3 -methoxybenzylidene)hydrazinecarbonyl)-iV- (2- (trifluoromethyl)- lH-benzo[d]imidazol-5-yl)benzamide (Compound 276)
Figure imgf000186_0003
[0930] Compound 276 was prepared according to the procedure similar to that described in Scheme V from terephthalic acid mono-ester, 3-methoxybenzaldehyde and 5- amino-2-trifluoromethylbenzimidazole. [M+H]+ calcd for C24Hi8F3N503: 482.14; found: 481.45. EXAMPLE 177
[0931 ] (E) -4- (2- (4-methoxybenzylidene)hydrazinecarbonyl)-N- (2- (trifluoromethyl)- lH-benzo imidazol-5-yl)benzamide (Compound 277)
Figure imgf000187_0001
[0932] Compound 277 was prepared according to the procedure similar to that described in Scheme V from terephthalic acid mono-ester, 4-methoxybenzaldehyde and 5- amino-2-trifluoromethylbenzimidazole. [M+H]+ calcd for C24H18F3N5O3: 482.14; found:
481.45.
EXAMPLE 178
[0933] (E)-N-(2-(4-(dimethylamino)phenyl)-lH-benzo[J]imidazol-6-yl)-4-(2- (3-methoxybenz lidene)hydrazinecarbonyl)benzamide (Compound 278)
Figure imgf000187_0002
[0934] Compound 278 was prepared according to the procedure described in Scheme V from 5-amino-2-(4-dimethylaminophenyl)benzimidazole, terephthalic acid, and 3-methoxybenzaldehyde. [M+H]+ calcd for CsiHasNeOs: 533.22; found: 532.96.
EXAMPLE 179
[0935] (E)-2-(4-(dimethylamino)phenyl)-N-(4-(2-(3- methoxybenzylidene)hydrazinecarbonyl)phenyl)-lH-benzo[(i]imidazole-6-carboxamide (Compound 279
Figure imgf000187_0003
[0936] Compound 279 was prepared according to the procedure described in Scheme V from 2-(4-dimethylaminophenyl)benzimidazole-5-carboxylic acid, 4- aminobenzoic acid, and 3-methoxybenzaldehyde. [M+H]+ calcd for C31H28N6O3: 533.22; found: 532.95. EXAMPLE 180
[0937] N,iV-(l ,4-phenylene)bis(2-(4-morpholinoph(
benzo[d]imidazole-5-carboxamide) (Compound 280)
Figure imgf000188_0001
[0938] Compound 280 was prepared according to the procedure similar to that described in Scheme V from 2-(4-morpholinylphenyl)benzimidazole-5-carboxylic acid and 1,4-phenylenediamine. [M+H]+ calcd for C42H38N8O4: 719.30; found: 719.12.
EXAMPLE 181
[0939] N,iV-(l ,4-phenylene)bis(2-(4-cyanophenyl)- 1 H-benzo [d] imidazole- 5 - carboxamide) (Compound 281)
Figure imgf000188_0002
[0940] Compound 281 was prepared according to the procedure similar to that described in Scheme V from 2-(4-cyanophenyl)benzimidazole-5-carboxylic acid and 1,4- phenylenediamine. [M+H]+ calcd for CseHaiNgOa: 599.19; found: 598.97.
EXAMPLE 182
[0941] iV,jV-(l ,4-phenylene)bis(2-(4-(bis(2-hydroxyethyl)amino)phenyl)- 1H- benzo[d]imidazole-5-carboxamide) (Compound 282)
Figure imgf000188_0003
[0942] Compound 282 was prepared according to the procedure similar to that described in Scheme V from 2-(4-di(2-hydroxyethyl)aminophenyl)benzimidazole-5- carboxylic acid and 1,4-phenylenediamine. [M+H]+ calcd for C42H42N8O6: 755.32; found: 755.16. EXAMPLE 183
[0943] N,iV-(l ,4-phenylene)bis(2-(4-(dimethylamino)phenyl)- 1H- benzo[d]imidazole-5-carboxamide) (Compound 283)
Figure imgf000189_0001
[0944] Compound 283 was prepared according to the procedure similar to that described in Scheme V from 2-(4-dimethylaminophenyl)benzimidazole-5-carboxylic acid and 1,4-phenylenediamine. [M+H]+ calcd for C38H34N8O2: 635.28; found: 635.05.
EXAMPLE 184
[0945] Methyl 4-((2-(4-(2-hydroxyethoxy)phenyl)- lH-benzo[ d]imidazol-5- yl)carbamoyl)benzoate (Compound 284)
Figure imgf000189_0002
[0946] Compound 284 was prepared according to the procedure similar to that described in Scheme V from 2-(4-(2-hydroxyethoxy)phenyl)-5-aminobenzimidazole and terephthalic acid monoester. [M+H]+ calcd for C24H21N3O5: 432.15; found: 431.86.
EXAMPLE 185
[0947] N4,N4'-bis(2-chloro-lH-benzo[J]imidazol-5-yl)-[l,r-biphenyl]-4,4'- dicarboxamide (Compound 285)
Figure imgf000189_0003
[0948] Compound 285 was prepared according to the procedure similar to that described in Scheme V from 4,4' -bisbenzoic acid and 5-amino-2-chlorobenzimidazole. [M+H]+ calcd for C28Hi8N602: 541.09; found: 541.91. EXAMPLE 186
Figure imgf000190_0001
[0950] Compound 286 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,3 '-diaminobenzidine and 4-morpholinylbenzaldehyde. [M+H]+ calcd for C34H32N6O2: 557.26; found: 557.58.
EXAMPLE 187
[0951 ] (E) -4- (2- (4- (dimethylamino)benzylidene)hydrazinecarbonyl) -iV-(2-(4- methoxyphen -lH-benzo[<i]imidazol-6-yl)benzamide (Compound 287)
Figure imgf000190_0002
[0952] Compound 287 was prepared according to the procedure described in Scheme V from 5-amino-2-(4-methoxyphenyl)benzimidazole, terephthalic acid, and 4- dimethylaminobenzaldehyde. [M+H]+ calcd for C3iH28N6 03: 533.22; found: 532.55.
EXAMPLE 188
[0953] 2-(4-(bis(2-hydroxyethyl)amino)phenyl)-N-(2-(4-morpholinophenyl)- lH-benzo[<i]imidazol-5-yl)-lH-benzo[(i]imidazole-6-carboxamide (Compound 288)
Figure imgf000190_0003
[0954] Compound 288 was prepared according to the procedure similar to that described in Scheme V from 2-(4-morpholinophenyl)-5-aminobenzimidazole and 2-(4- N,N-(2-hydroxyethyl)aminophenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C35H35N704: 618.28; found: 618.03. EXAMPLE 189
[0955] (2-(4-(bis(2-Hydroxyethyl)amino)phenyl)-N-(2-(4-(bis(2- hydroxyethyl)amino)phenyl)-lH-benzimidazol-5-yl)-lH-benzimidazole-6-carboxamide (Compound 289)
Figure imgf000191_0001
[0956] Compound 289 was prepared according to the procedure similar to that described in Scheme V from 2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5- aminobenzimidazole and 2-(4-(bis(2-hydroxyethyl)amino)phenyl)benzimidazole-5- carboxylate. [M+H]+ calcd for C35H37N7O5: 636.29; found: 636.06.
EXAMPLE 190
[0957] (2-(4-(bis(2-Hydroxyethyl)amino)phenyl)-N-(2-(4-cyano)phenyl)-lH- benzimidazol-5-yl)- lH-benzimidazole-6-carboxamide (Compound 290)
Figure imgf000191_0002
[0958] Compound 290 was prepared according to the procedure similar to that described in Scheme V from 2-(4-cyanophenyl)-5-aminobenzimidazole and 2-(4-(bis(2- hydroxyethyl)amino)phenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for
C32H27N7O3: 558.22; found: 557.95.
EXAMPLE 191
[0959] (2-(4-(bis(2-Hydroxyethyl)amino)phenyl)-N-(2-(4-(2- hydroxy)ethoxy)phenyl)-lH-benzimidazol-5-yl)-lH-benzimidazole-6-carboxamide (Compound 291)
Figure imgf000191_0003
[0960] Compound 291 was prepared according to the procedure similar to that described in Scheme V from 2-(4-(2-hydroxy)ethoxyphenyl)-5-aminobenzimidazole and 2-(4-(bis(2-hydroxyethyl)amino)phenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C33H32N6O5: 593.24; found: 593.03.
EXAMPLE 192
[0961] 2-(4-cyanophenyl)-N-(2-(4-morpholinophenyl)-lH-benzo[(i]imidazol- 5-yl)-lH-benzo[<i]imidazole-6-carboxamide (Compound 292)
Figure imgf000192_0001
[0962] Compound 292 was prepared according to the procedure similar to that described in Scheme V from 2-(4-morpholinophenyl)-5-aminobenzimidazole and 2-(4- cyanophenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C32H25N7O2: 540.21 ; found: 539.97.
EXAMPLE 193
[0963] N-(2-(4-(bis(2-hydroxyethyl)amino)phenyl)-lH-benzo[(i]imidazol-5- yl)-2-(4-cyanophenyl)-lH-benzo[(i]imidazole-6-carboxamide (Compound 293)
Figure imgf000192_0002
[0964] Compound 293 was prepared according to the procedure similar to that described in Scheme V from 2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5- aminobenzimidazole and 2-(4-cyanophenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C32H25N7O3: 558.22; found: 557.99.
EXAMPLE 194
[0965] 2-(4-cyanophenyl)-N-(2-(4-(2-hydroxyethoxy)phenyl)- 1H- benzo[d]imidazol-5-yl)- lH-benzo[d]imidazole-6-carboxamide (Compound 294)
Figure imgf000192_0003
[0966] Compound 294 was prepared according to the procedure similar to that described in Scheme V from 2-(4-(2-hydroxyethoxy)amino)phenyl)-5- aminobenzimidazole and 2-(4-cyanophenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C30H22N6O3: 515.18; found: 514.92.
EXAMPLE 195
[0967] 2-(4-cyanophenyl)-N-(2-(4-cyanophenyl)-lH-benzo[<i]imidazol-5-yl)- lH-benzo[d]imidazole-6-carboxamide (Compound 295)
Figure imgf000193_0001
[0968] Compound 295 was prepared according to the procedure similar to that described in Scheme V from 2-(4-cyano)phenyl)-5-aminobenzimidazole and 2-(4- cyanophenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C29H17N7O: 480.15; found: 479.89.
EXAMPLE 196
[0969] N-(2-(4-(bis(2-hydroxyethyl)amino)phenyl)-lH-benzo[(i]imidazol-5- yl)-2-(4-morpholinophenyl)-lH-benzo[(i]imidazole-6-carboxamide (Compound 296)
[0970] Compound 296 was prepared according to the procedure similar to that described in Scheme V from 2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5- aminobenzimidazole and 2-(4-morpholinophenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C35H35N7O4: 618.28; found: 618.03.
EXAMPLE 197
[0971] N-(2-(4-(2-hydroxyethoxy)phenyl)-lH-benzo[J]imidazol-5-yl)-2-(4- morpholinophen l)-lH-benzo[<i]imidazole-6-carboxamide (Compound 297)
Figure imgf000193_0003
[0972] Compound 297 was prepared according to the procedure similar to that described in Scheme V from 2-(4-(2-hydroxyethoxy)amino)phenyl)-5- aminobenzimidazole and 2-(4-morpholinophenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C33H30N6O4: 575.23; found: 575.00. EXAMPLE 198
[0973] N-(2-(4-cyanophenyl)-lH-benzo[J]imidazol-5-yl)-2-(4- morpholinophenyl)-lH-benzo[(i]imidazole-6-carboxamide (Compound 298)
Figure imgf000194_0001
[0974] Compound 298 was prepared according to the procedure similar to that described in Scheme V from 2-(4-cyano)phenyl)-5-aminobenzimidazole and 2-(4- morpholinophenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C32H25N7O2: 540.21; found: 539.97.
EXAMPLE 199
[0975] 2-(4-(2-hydroxyethoxy)phenyl)-N-(2-(4-morpholinophenyl)-lH- benzo[d]imid 99)
Figure imgf000194_0002
[0976] Compound 299 was prepared according to the procedure similar to that described in Scheme V from 2-(4-morpholinophenyl)-5-aminobenzimidazole and 2-(4-(2- hydroxyethoxy)phenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C33H30N6O4: 575.23; found: 575.07.
EXAMPLE 200
[0977] N,N1-(oxybis(4,l-phenylene))bis(4-(dimethylamino)benzamide) (Compound 300)
Figure imgf000194_0003
[0978] Compound 300 was prepared according to the procedure described in Scheme Γ from 4,4'-oxybisphenylamine and 4-dimethylaminobenzoate. [M+H]+ calcd for C30H31N4O3: 495.24; found: 495.01
EXAMPLE 201
[0979] N,iV-(carbonylbis(4, 1 -phenylene))bis(4-(dimethylamino)benzamide) (Compound 301)
Figure imgf000195_0001
[0980] Compound 301 was prepared according to the procedure described in Scheme IV. 4-(Dimethylamino)benzoyl chloride (Aldrich, 151 mg, 0.825 mmol) in 1 mL of methylene chloride was slowly added over 5 min to 4,4'-diaminobenzophenone (Aldrich, 70 mg, 0.330 mmol) in 3 mL of methylene chloride containing 0.3 mL of pyridine. The reaction was allowed to stir at room temperature for 12 h and filtered. The white precipitate was washed with water (5 mL), ethanol (2 mL) and dried under vacuum to yield 165 mg of N,N'-(carbonylbis(4,l-phenylene))bis(4-(dimethylamino)benzamide) as a white powder. 1H NMR (500MHz, DMSO-d6) δ 10.19 (s, 2H), 7.97 (d, / = 8.7 Hz, 4H), 7.89 (d, / = 8.5 Hz, 4H), 7.77 (d, / = 8.5 Hz, 4H), 6.77 (d, / = 8.7 Hz, 4H), 3.00 (s, 12H).
EXAMPLE 202
[0981] N,N1-(carbonylbis(4,l-phenylene))bis(4-morpholinobenzamide) (Compound 3
Figure imgf000195_0002
[0982] Compound 302 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone and 4-morpholinylbenzoate. [M+H]+ calcd for C35H35N4O5: 591.26; found: 591.20
EXAMPLE 203
[0983] N,N'-(((methoxyimino)methylene)bis(4,l-phenylene))bis(4- morpholinobenzamide) (Compound 303)
Figure imgf000195_0003
[0984] Compound 303 was prepared from compound 302 by a standard synthesis procedure. [M+H]+ calcd for C36H37N5O5: 620.24; found: 620.11.
EXAMPLE 204
[0985] N,N'-(((hydroxyimino)methylene)bis(4,l-phenylene))bis(4- morpholinobenzamide) (Compound 304)
Figure imgf000196_0001
[0986] Compound 304 was prepared from compound 302 by a standard synthesis procedure. [M+H]+ calcd for C35H35N5O5: 606.27; found: 606.06.
EXAMPLE 205
[0987] N,N'-((hydroxymethylene)bis(4, 1 -phenylene))bis(4- (dimethylamino)benzamide) (Compound 305)
Figure imgf000196_0002
[0988] Compound 305 was prepared from compound 301 by a standard reduction condition. [M+H]+ calcd for C31H32N4O3: 509.14; found: 508.98.
EXAMPLE 206
[0989] N,N'-(((hydroxyimino)methylene)bis(4, 1 -phenylene))bis(4- (dimethylamino)benzamide) (Compound 306)
Figure imgf000196_0003
[0990] Compound 306 was prepared from compound 301 by a standard synthesis procedure. [M+H]+ calcd for C31H31N5O3: 522.25; found: 522.01. EXAMPLE 207
[0991] N,N'-(((ethoxyimino)methylene)bis(4,l-phenylene))bis(4- (dimethylamino)benzamide) (Compound 307)
Figure imgf000197_0001
[0992] Compound 307 was prepared from compound 301 by a standard synthesis procedure. [M+H]+ calcd for C33H35N5O3: 550.28; found: 550.02.
EXAMPLE 208
[0993] N,N'-((((benzyloxy)imino)methylene)bis(4,l-phenylene))bis(4- (dimethylamino)benzamide) (Compound 308)
Figure imgf000197_0002
[0994] Compound 308 was prepared from compound 301 by a standard synthesis procedure. [M+H]+ calcd for C38H37N5O3: 612.29; found: 612.07.
EXAMPLE 209
[0995] N,N'-((((allyloxy)imino)methylene)bis(4,l-phenylene))bis(4- (dimethylamino)benzamide) (Compound 309)
Figure imgf000197_0003
[0996] Compound 309 was prepared from compound 301 by a standard oxime synthesis procedure. [M+H]+ calcd for C34H35N5O3: 562.28; found: 562.04.
EXAMPLE 210
[0997] N,N'-((((2-phenylacetoxy)imino)methylene)bis(4,l-phenylene))bis(4- (dimethylamino)benzamide) (Compound 310)
Figure imgf000198_0001
[0998] Compound 310 was prepared from compound 301 by a standard synthesis procedure. [M+H]+ calcd for C39H37N5O4: 640.29; found: 640.23.
EXAMPLE 211
[0999] N,N'-(((acetoxyimino)methylene)bis(4,l-phenylene))bis(4- (dimethylamino)benzamide) (Compound 311)
Figure imgf000198_0002
[1000] Compound 311 was prepared from compound 301 by a standard synthesis procedure. [M+H]+ calcd for C33H33N5O4: 564.26; found: 564.00.
EXAMPLE 212
[1001] N,N1-(((((thiophene-2-carbonyl)oxy)imino)methylene)bis(4,l- phenylene))bis( -(dimethylamino)benzamide) (Compound 312)
Figure imgf000198_0003
[1002] Compound 312 was prepared from compound 301 by a standard synthesis procedure. [M+H]+ calcd for C36H33N5O4S: 632.77; found: 631.99.
EXAMPLE 213
[1003] N,N1-((((benzoyloxy)imino)methylene)bis(4,l-phenylene))bis(4- (dimethylamino)benzamide) (Compound 313)
Figure imgf000199_0001
[1004] Compound 313 was prepared from compound 301 by a standard synthesis procedure. [M+Na]+ calcd for C38H35N5O4: 647.74; found: 647.86.
EXAMPLE 214
[1005] N,N1-(carbonylbis(4,l-phenylene))bis(4-(3-hydroxypyrrolidin-l- yl)benzamide) (Compound 314)
Figure imgf000199_0002
[1006] Compound 314 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone and 4-(2-hydroxypyrrolidino)benzoate. [M+H]+ calcd for C35H35N4O5: 591.26; found: 591.03.
EXAMPLE 215
[1007] N,N'-(((methoxyimino)methylene)bis(4,l-phenylene))bis(4-(3- hydroxypyrrolidin-l-yl)benzamide) (Compound 315)
Figure imgf000199_0003
[1008] Compound 315 was prepared from compound 314 by a standard synthesis procedure. [M+H]+ calcd for C36H37N5O5: 620.28; found: 620.11.
EXAMPLE 216
[1009] N,N1-(carbonylbis(4,l-phenylene))bis(4-(4-methylpiperazin-l- yl)benzamide) (Compound 316)
Figure imgf000200_0001
[1010] Compound 316 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-(4-methylpiperazino)benzoate. [M+H]+ calcd for C37H41N6O3: 617.32; found: 617.12.
EXAMPLE 217
[1011] N,N1-(carbonylbis(4,l-phenylene))bis(4-(piperazin-l-yl)benzamide) (Compound 3
Figure imgf000200_0002
[1012] Compound 317 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-piperazinobenzoate. [M+H]+ calcd for C35H37N6O3: 589.29; found: 589.07.
EXAMPLE 218
[1013] N,N1-(carbonylbis(4,l-phenylene))bis(4-(4-(3-hydroxypropyl)piperazin- l-yl)benzamide) (Compound 318)
Figure imgf000200_0003
[1014] Compound 318 was prepared according to the procedure described in Scheme Γ from 4,4' -diaminobenzophenone and 4-(4-(3- hydroxypropyl)piperazino)benzoate. [M+H]+ calcd for C4iH48N605: 705.37; found: 705.19.
EXAMPLE 219
[1015] N,N1-(carbonylbis(4,l-phenylene))bis(4-(3,5-dimethylpiperazin-l- yl)benzamide) (Compound 319)
Figure imgf000201_0001
[1016] Compound 319 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone and 4-(3,5-dimethylpiperazino)benzoate. [M+H]+ calcd for C39H44N6O3: 645.35; found: 645.16.
EXAMPLE 220
[1017] N,N'-(carbonylbis(4,l-phenylene))bis(4-(4-(2-(2- hydroxyethoxy)ethyl)piperazin-l-yl)benzamide) (Compound 320)
Figure imgf000201_0002
[1018] Compound 320 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone and 4-(4-(2- hydroxyethoxy)ethyl)piperazino)benzoate. [M+H]+ calcd for C43H52N6O7: 765.39; found: 765.36.
EXAMPLE 221
[1019] N,N'-(carbonylbis(4,l-phenylene))bis(4-(4- (cyclopropanecarbonyl)piperazin-l-yl)benzamide) (Compound 321)
Figure imgf000201_0003
[1020] Compound 321 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone and 4-(4- cyclopropylcarbonyl)piperazino)benzoate. [M+H]+ calcd for C43H44N6O5: 725.34; found: 725.11. EXAMPLE 222
[1021] N,N1-(carbonylbis(4,l-phenylene))bis(4-(piperidin-l-yl)benzamide) (Compound 32
Figure imgf000202_0001
[1022] Compound 322 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-piperidinobenzoate. [M+H]+ calcd for C37H38N4O3: 587.30; found: 587.02.
EXAMPLE 223
[1023] N,N1-(carbonylbis(4,l-phenylene))bis(4-(4-hydroxypiperidin-l- yl)benzamide (Compound 323)
Figure imgf000202_0002
[1024] Compound 323 was prepared according to the procedure described in Scheme Γ from 4,4' -diaminobenzophenone and 4-(4-hydroxypiperidino)benzoate. [M+H]+ calcd for C37H39N4O5: 619.29; found: 619.10.
EXAMPLE 224
[1025] N,N1-(carbonylbis(4,l-phenylene))bis(4-(pyrrolidin-l-yl)benzamide) (Compound 324)
Figure imgf000202_0003
[1026] Compound 324 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-pyrrolidinobenzoate. [M+H]+ calcd for C35H34N4O3: 559.27; found: 559.00. EXAMPLE 225
[1027] N,N'-(carbonylbis(4,l-phenylene))bis(4-(lH-pyrrol-l-yl)benzamide) (Compound 325)
Figure imgf000203_0001
[1028] Compound 325 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-pyrrolylbenzoate. [M+H]+ calcd for C35H26N4O3: 551.20; found: 551.04.
EXAMPLE 226
[1029] N,N1-(carbonylbis(4,l-phenylene))bis(4-(lH-imidazol-l-yl)benzamide) (Compound 326)
Figure imgf000203_0002
[1030] Compound 326 was prepared according to the procedure described in Scheme Γ from 4,4' -diaminobenzophenone and 4-imidazolylbenzoate. [M+H]+ calcd for C33H24N6O3: 553.19; found: 552.98.
EXAMPLE 227
[1031] N,N'-(carbonylbis(4,l-phenylene))bis(4-(bis(2- hydroxyethyl)amino)benzamide)
[1032] (Compound 327)
Figure imgf000203_0003
[1033] Compound 327 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-bis(2-hydroxylethyl)aminobenzoate. [M+H]+ calcd for C35H38N4O7: 627.28; found: 627.06. EXAMPLE 228
[1034] N,N'-(carbonylbis(4,l-phenylene))bis(l -methyl- lH-indole-5- carboxamide) (Compound 328)
Figure imgf000204_0001
[1035] Compound 328 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 5-(l-methylindole)caboxylate. [M+H]+ calcd for C33H26N4O3: 527.20; found: 527.00.
EXAMPLE 229
[1036] N,N'-(carbonylbis(4,l-phenylene))bis(4-methyl-3,4-dihydro-2H- benzo[b][l,4]oxazin -7-carboxamide) (Compound 329)
Figure imgf000204_0002
[1037] Compound 329 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 6-(l-methyl-l,4- benzoxazine)caboxylate. [M+H]+ calcd for C33H30N4O5: 563.22; found: 562.92.
EXAMPLE 230
[1038] N,N'-(carbonylbis(4,l-phenylene))bis(4-((2- hydroxyethyl)(methyl)amino)benzamide) (Compound 330)
Figure imgf000204_0003
[1039] Compound 330 was prepared according to the procedure described in Scheme Γ from 4,4' -diaminobenzophenone and 4-(N-2-hydroxylethyl-N- methylamino)benzoate. [M+H]+ calcd for C33H35N4O5: 567.26; found: 567.04. EXAMPLE 231
[1040] N,N'-(((2-phenylhydrazono)methylene)bis(4,l-phenylene))bis(4- (dimethylamino)benzamide) (Compound 331)
Figure imgf000205_0001
[1041] Compound 331 was prepared from compound 301 by a standard hydrazone synthesis procedure. [M+H]+ calcd for C37H36N602: 597.29; found: 597.08.
EXAMPLE 232
[1042] N,N'-(((methoxyimino)methylene)bis(4,l-phenylene))bis(4-((2- hydroxyethyl)(methyl)amino)benzamide) (Compound 332)
Figure imgf000205_0002
[1043] Compound 332 was prepared from compound 330 by a standard synthesis procedure. [M+H]+ calcd for C^H^NsOs: 596.28; found: 596.07.
EXAMPLE 233
[1044] N,N'-(((methoxyimino)methylene)bis(4,l-phenylene))bis(4- fluorobenzamide) (Com ound 333)
Figure imgf000205_0003
[1045] Compound 333 was prepared according to the procedure described in Scheme Γ from 4,4' -diaminobenzophenone and 4-fluorobenzoate followed by a standard oxime synthesis procedure. 1H NMR (500MHz, DMSO-d6) δ 11.00 (d, / = 12.5 Hz, 1H), 10.41 (d, / = 12.5 Hz, 1H), 8.03 (m, 4H), 7.85 (d, 7 = 15 Hz, 2H), 7.79 (d, 7 = 15 2H), 7.38 (m, 6H), 7.29 (d, / = 15 Hz, 2H), 3.79 (s, 3H).
EXAMPLE 234
[1046] N,N'-(((methoxyimino)methylene)bis(4,l-phenylene))bis(4-(ethyl(2- hydroxyethyl)amino)benzamide) (Compound 334)
[1047] Compound 334 was prepared from compound 333 and N-2- hydroxyethyl-N-ethylamine by a standard procedure. [M+H]+ calcd for C36H41N5O5: 624.31; found: 624.09.
EXAMPLE 235
[1048] N,N'-(((methoxyimino)methylene)bis(4,l-phenylene))bis(4-((2- hydroxyethyl)amino)benzamide) (Compound 335)
Figure imgf000206_0002
[1049] Compound 335 was prepared from compound 333 and 2- hydroxyethylamine by a standard procedure. [M+H]+ calcd for C32H33N5O5: 568.25; found: 567.98.
EXAMPLE 236
[1050] N,N'-(((methoxyimino)methylene)bis(4,l-phenylene))bis(4-(2- hydroxyethoxy)benzamide) (Compound 336)
Figure imgf000207_0001
[1051] Compound 336 was prepared from compound 333 and ethylenediol by a standard procedure. [M+H]+ calcd for C32H31N3O7: 570.22; found: 570.01.
EXAMPLE 237
[1052] N,N'-(((methoxyimino)methylene)bis(4,l-phenylene))bis(4-(4-(3- hydroxypropyl)piperazin-l-yl)benzamide) (Compound 337)
Figure imgf000207_0002
[1053] Compound 337 was prepared from compound 333 and 3- hydroxypropylpiperazine by a standard procedure. [M+H]+ calcd for C42H51N7O5: 734.93; found: 734.23.
EXAMPLE 238
[1054] N,N'-(((methoxyimino)methylene)bis(4,l-phenylene))bis(4-(4- (cyclopropanecarbonyl)piperazin-l-yl)benzamide) (Compound 338)
Figure imgf000207_0003
[1055] Compound 338 was prepared from compound 333 and 4- cyclopropylcarbonylpiperazine by a standard procedure. [M+H]+ calcd for C44H47N7O5: 754.92; found: 754.29. EXAMPLE 239
[1056] N,A^-(((methoxyimino)methylene)bis(4,l-phenylene))bis(4-(piperidin- l-yl)benzamide) (Compound 339)
Figure imgf000208_0001
[1057] Compound 339 was prepared from compound 333 and piperidine standard procedure. [M+H]+ calcd for C38H41N5O3: 616.79; found: 616.19.
EXAMPLE 240
[1058] N,N'-(4,4'-(Oxazolidine-2,2-diyl)bis(4,l-phenylene))bis(4-(2- hydroxylethylamino)benzamide) (Compound 340)
Figure imgf000208_0002
[1059] Compound 340 was prepared from N,N'-(4,4'-Benzophenone)bis(4- fluorobenzamide) and 2-hydroxyethylamine by a standard procedure. [M+H]+ calcd for C33H36N5O5: 582.27; found: 582.07.
EXAMPLE 241
[1060] 4,4'-Carbonylbis(4,l-phenylene)bis(4-(dimethylamino)benzoate (Compound 341)
Figure imgf000208_0003
[1061] Compound 341 was prepared according to the procedure described in Scheme IV from 4,4'-dihydroxybenzophenone and 4-dimethylaminobenzoic acid. [M+H]+ calcd for C31H28N2O5: 509.20; found: 509.05. EXAMPLE 242
[1062] N,N'-(4,4'-Carbonylbis(4,l-phenylene))bis(4-ethoxybenzamide) (Compound 342)
Figure imgf000209_0001
[1063] Compound 342 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone and 4-ethoxybenzoate. [M+H]+ calcd for C31H28N2O5: 509.20; found: 508.98.
EXAMPLE 243
[1064] N,N'-(4,4'-Carbonylbis(4,l-phenylene))bis(4-methoxybenzamide) (Compound 343)
Figure imgf000209_0002
[1065] Compound 343 was prepared according to the procedure described in Scheme Γ from 4,4'-diaminobenzophenone and 4-methoxybenzoate. [M+H]+ calcd for C29H24N2O5: 481.17; found: 480.90.
EXAMPLE 244
[1066] N,N'-(4,4'-Carbonylbis(4,l-phenylene))dibenzo[l,3]dioxole-5- carboxamide) (Com ound 344)
Figure imgf000209_0003
[1067] Compound 344 was prepared according to the procedure described in Scheme Γ from 4,4'-diaminobenzophenone and benzo[l,3]dioxole-5-carboxylate. [M+H]+ calcd for C29H20N2O7: 509.13; found: 508.91.
EXAMPLE 245
[1068] N,N'-(4,4'-Carbonylbis(4,l-phenylene))bis(lH-indole-5-carboxamide) (Compound 345)
Figure imgf000210_0001
[1069] Compound 345 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and lH-indole-5-carboxylate. [M+H]+ calcd for C31H22N4O3: 499.17; found: 498.92.
EXAMPLE 246
[1070] N-(4-(4-Aminobenzoyl)phenyl)-lH-indole-5-carboxamide (Compound
346)
Figure imgf000210_0002
[1071] Compound 346 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and lH-indole-5-carboxylate. [M+H]+ calcd for C22Hi7N302: 356.14; found: 355.90.
EXAMPLE 247
[1072] N,N'-(4,4'-Carbonylbis(4,l-phenylene))bis(4-(lH-pyrazol-l- yl)benzamide) (Compound 347)
Figure imgf000210_0003
[1073] Compound 347 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-(pyrazol-l-yl)benzoate. [M+H]+ calcd for C33H24N603: 553.19; found: 552.99.
EXAMPLE 248
[1074] N-(4-(4-(2-phenylacetamido)benzoyl)phenyl)-lH-indole-5- carboxamide (Compound 348)
Figure imgf000211_0001
[1075] Compound 348 was prepared from compound 346 and benzylbromide. [M+H]+ calcd for C30H23N3O3: 474.05; found: 474.49.
EXAMPLE 249
[1076] 4-ethoxy-N-(4-(4-(2-(4-ethoxyphenyl)-2- oxoethyl)benzoyl)phenyl)benzamide (Compound 349)
Figure imgf000211_0002
[1077] Compound 349 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and l-methylindole-5-carboxylate. [M+H]+ calcd for C25H21N3O3: 412.07; found: 411.94.
EXAMPLE 250
[1078] N- (4- (4- (4-Methoxyphenylsulf onamido)benzoyl)phenyl) -4- (pyrrolidin- l-yl)benzamide (Compound 350)
Figure imgf000211_0003
[1079] Compound 350 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-pyrrolidinylbenzoate. [M+H]+ calcd for C31H29N3O5S: 556.17; found: 555.99.
EXAMPLE 251
[1080] N,N'-(4,4'-Carbonylbis(4,l-phenylene))dithiophene-2-carboxamide (Compound 351)
Figure imgf000211_0004
[1081] Compound 351 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 2-thiophenecarboxylate. 1H NMR (500MHz, DMSO-d6) δ 10.54 (s, 2H), 8.09 (d, / = 3.75 Hz, 2H), 7.94 (d, / = 12.5 Hz, 4H), 7.91 (d, / = 3.75 Hz, 2H), 7.88 (d, / = 12.5 Hz, 4H), 7.25 (t, / = 3.75 Hz, 2H).
EXAMPLE 252
[1082] N,N'-(4,4'-Carbonylbis(4,l-phenylene))bis(4-(2- hydroxyethox benzamide) (Compound 352)
Figure imgf000212_0001
[1083] Compound 352 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-(2-hydroxyethoxy)benzoate. [M+H]+ calcd for C31H28N2O7: 541.09; found: 541.05.
EXAMPLE 253
[1084] N-(4-Benzoylphenyl)-4-(4-cyclopropanecarbonylpiperazin- 1 - yl)benzamide (Compound 353)
Figure imgf000212_0002
[1085] Compound 353 was prepared according to the procedure described in Scheme Γ from 4-aminobenzophenone and 4-piperazinebenzoate. [M+H]+ calcd for C28H28N3O3: 454.21 ; found: 454.01.
EXAMPLE 254
[1086] 4-(Dimethylamino)-N-(4-(4-(4- fluorobenzamido)benzoyl)phenyl)benzamide (Compound 354)
Figure imgf000212_0003
[1087] Compound 354 was prepared according to the procedure described in Scheme IV from 4,4' -diammobenzophenone and the substituted benzoates. [M+H]+ calcd for C29H25FN3O3: 482.19; found: 482.22.
EXAMPLE 255
[1088] N,N'-(4,4'-Carbonylbis(4,l-phenylene))diisonicotinamide (Compound
355)
Figure imgf000213_0001
[1089] Compound 355 was prepared according to the procedure described in Scheme IV from 4,4' -diammobenzophenone and 4-picolinic acid. [M+H]+ calcd for C25Hi9N403: 423.15; found: 422.87.
EXAMPLE 256
[1090] N,N'-(4,4'-Carbonylbis(4,l-phenylene))bis(6-morpholinonicotinamide) (Compound 356)
Figure imgf000213_0002
[1091] Compound 356 was prepared according to the procedure described in Scheme IV from 4,4' -diammobenzophenone and 6-morpholinonicotinic acid. [M+H]+ calcd for C33H33N605: 593.25; found: 593.03.
EXAMPLE 257
[1092] N,N'-(4,4'-Carbonylbis(4,l-phenylene))bis(4- (morpholinomethyl)benzamide) (Compound 357)
Figure imgf000213_0003
[1093] Compound 357 was prepared according to the procedure described in Scheme IV from 4,4' -diammobenzophenone and 4-morpholinomethylbenzoate. [M+H]+ calcd for C37H39N405: 619.29; found: 619.10. EXAMPLE 258
[1094] N-(4-(4-(4-Dimethylamino)benzoyl)phenyl)isonicotinamide
(Compound 358)
Figure imgf000214_0001
[1095] Compound 358 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-picolinic acid. [M+H]+ calcd for C28H25N4O3: 465.19; found: 464.98.
EXAMPLE 259
[1096] N-(4-(4-Cyclopropanecarboxamido)benzoyl)phenyl)-4- morpholinobenzamide (Compound 359)
Figure imgf000214_0002
[1097] Compound 359 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C28H28N3O4: 470.21; found: 469.97.
EXAMPLE 260
[1098] N-(4-(4-(2-Thienyl)carboxamido)benzoyl)phenyl)-4- morpholinobenzamide (Compound 360)
Figure imgf000214_0003
[1099] Compound 360 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H26N3O4S: 512.16; found: 511.95. EXAMPLE 261
[1100] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4- (dimethylamino)benzamide) (Compound 361)
Figure imgf000215_0001
[1101] Compound 361 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-dimethylaminobenzoate. [M+H]+ calcd for C30H31N5O2: 494.25; found: 494.04.
EXAMPLE 262
[1102] 4-(dimethylamino)-iV-(4-(jV-(4-(4- (dimethylamino)benzamido)phenyl)acetamido)phenyl)benzamide (Compound 362)
Figure imgf000215_0002
[1103] Compound 362 was prepared according to the procedure described in Scheme Γ from 4,4'-diaminodiphenylamine and 4-dimethylaminobenzoate. 1H NMR (500MHz, DMSO-d6) δ 9.99 (bs, 1H), 9.89 (bs, 1H), 7.84 (d, / = 9 Hz, 6H), 7.70 (bs, 2H), 7.36 (bs, 2H), 7.20 (bs, 2H), 6.73 (d, / = 9 Hz, 4H), 2.98 (s, 12H), 1.93 (s, 3H).
EXAMPLE 263
[1104] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-morpholinobenzamide) (Compound 3
Figure imgf000215_0003
[1105] Compound 363 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-morpholinobenzoate. [M+H]+ calcd for C34H35N5O4: 578.27; found: 578.11. EXAMPLE 264
[1106] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-(4- hydroxypiperidino benzamide) (Compound 364)
Figure imgf000216_0001
[1107] Compound 364 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-(4-hydroxypiperidinobenzoate. 1H NMR (500MHz, DMSO-d 6) δ 9.75 (s, 2H), 7.94 (s, 1H), 7.82 (d, / = 9 Hz, 4H), 7.57 (d, / = 9 Hz, 4H), 6.98 (t, / = 9 Hz, 8H), 4.71 (d, / = 4.5 Hz, 2H), 3.67 (m, 8H), 2.98 (dt, / = 3, 10 Hz, 2H), 1.80 (m, 4H), 1.43 (m, 4H).
EXAMPLE 265
[1108] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-piperazinobenzamide) (Compound 3
Figure imgf000216_0002
[1109] Compound 365 was prepared according to the procedure described in Scheme Γ from 4,4'-diaminodiphenylamine and 4-piperazinobenzoate. [M+H]+ calcd for C34H38N7O2: 576.31; found: 576.17.
EXAMPLE 266
[1110] 4-morpholino-N-(4-((4-(4-(piperazin-l- yl)benzamido)phenyl)amino)phenyl)benzamide (Compound 366)
Figure imgf000216_0003
[1111] Compound 366 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-morpholinobenzoate. [M+H]+ calcd for C34H36N6O3: 577.21; found: 577.16. EXAMPLE 267
[1112] 4-Fluoro-N-(4-(4-(4- piperazinobenzamido)phenylamino)phenyl)benzamide (Compound 367)
Figure imgf000217_0001
[1113] Compound 367 was prepared according to the procedure described in Scheme Γ from 4,4'-diaminodiphenylamine and 4-piperazinobenzoate. [M+H]+ calcd for C30H29FN5O2: 510.23; found: 510.06.
EXAMPLE 268
[1114] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-fluorobenzamide) (Compound 368)
Figure imgf000217_0002
[1115] Compound 368 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-fluorobenzoate. [M+H]+ calcd for C26Hi9F2N302: 444.14; found: 443.86.
EXAMPLE 269
[1116] N-(l-(4-Aminophenyl)-lH-indol-5-yl)-4-dimethylaminobenzamide (Compound 369)
Figure imgf000217_0003
[1117] Compound 369 was prepared according to the general procedure described in Scheme IV. Preparation of 4-(dimethylamino)-N-(lH-indol-5-yl)benzamide: lH-indol-5-amine (200 mg, 1.51 mmol), hydroxybenzotriazole (204 mg, 1.51 mmol), triethylamine (0.23 mL, 1.66 mmol), and 4-(dimethylamino)benzoic acid (275 mg, 1.66 mmol) were taken up in DMF (7.5 mL) and stirred. EDC (319 mg, 1.66 mmol) was added to the solution last. After the addition, the solution was stirred at room temperature for 4 h. Water was then added to the solution and stirred for 10 min. The formed precipitate was filtered and washed well with water, followed by hexanes. The grayish solid was dried under vacuum to give 393 mg (93%) of the product.
[1118] Preparation of 4-(dimethylamino)-N-(l-(4-nitrophenyl)-lH-indol-5- yl)benzamide: 4-(Dimethylamino)-N-(lH-indol-5-yl)benzamide (200 mg, 0.71 mmol), 4- fluoronitrobenze (101 mg, 0.71 mmol) and potassium carbonate (99 mg, 0.72 mmol) were taken up in DMSO (7.2 mL). The solution was heated to 100 °C and stirred for 24 h. After the solution was cooled it was diluted with water until a precipitate formed and stirred well for 5 min. Filtration gave a yellow solid, which was then washed well with water, followed by hexanes. The solid was dried under vacuum to give 258 mg (90%) product as a yellow solid.
[1119] Preparation of Compound 369: 4-(Dimethylamino)-N-(l-(4- nitrophenyl)-lH-indol-5-yl)benzamide (330 mg, 0.82 mmol) was taken up in ethanol (28 mL) under nitrogen. The solution was treated with Pd(OH)2 (35 mg, 0.24 mmol) and placed under a balloon of H2 gas. After stirring at RT for 2 h, the catalyst was removed via filtration through celite. Concentration of the filtrate yielded 260 mg (85%) of compound 369. MS [M+H]+ calcd for C23H22N40: 371.18; found: 370.94.
EXAMPLE 270
[1120] N-(l-(4-(4-Dimethylaminobenzamido)phenyl)-lH-indol-5-yl)-4- dimethylaminobenzamide (Compound 370)
Figure imgf000218_0001
[1121] Compound 370 was prepared according to the procedure described in Scheme Γ from 5-amino-l-(4-aminophenyl)indole and 4-dimethylaminobenzoate. [M+H]+ calcd for C32H3iN502: 518.25; found: 517.95.
EXAMPLE 271
[1122] N-(l-(4-Aminophenyl)-lH-indazol-5-yl)-4-dimethylaminobenzamide (Compound 371)
Figure imgf000219_0001
[1123] Compound 371 was prepared according to the general procedure described in Scheme IV. Preparation of 4-(dimethylamino)-iV-(lH-indazol-5- yl)benzamide: lH-Indazol-5-amine (200 mg, 1.50 mmol), hydroxybenzotriazole (20 mg, 0.15 mmol), triethylamine (0.23 mL, 1.65 mmol), and 4-(dimethylamino)benzoic acid (273 mg, 1.65 mmol) were taken up in DMF (7.5 mL) and stirred. EDC (317 mg, 1.65 mmol) was added to the solution last. After the addition, the solution was stirred at room temperature for 4 h. Water was then added to the solution and stirred for 10 min. The formed precipitate was filtered and washed well with water, followed by hexanes. The solid was dried under vacuum to give 410 mg (97%) of the product as a brown solid.
[1124] Preparation of 4-(dimethylamino)-N-(l-(4-nitrophenyl)-lH-indazol-5- yl)benzamide: 4-(dimethylamino)-N-(lH-indazol-5-yl)benzamide (100 mg, 0.35 mmol), 4-fluoronitrobenze (50 mg, 0.35 mmol) and potassium carbonate (49 mg, 0.35 mmol) were taken up in DMSO (3.6 mL). The solution was heated to 100 °C and stirred for 24 h. After the solution was cooled it was diluted with water until a precipitate formed and stirred well for 5 min. Filtration gave a yellow solid, which was then washed well with water, followed by hexanes. The solid was dried under vacuum to give 133 mg (93%) of the product as a yellow solid.
[1125] Preparation of Compound 371: 4-(Dimethylamino)-N-(l-(4- nitrophenyl)-lH-indazol-5-yl)benzamide (400 mg, 0.99 mmol) was taken up in ethanol (33 mL) under nitrogen. The solution was treated with Pd(OH)2 (35 mg, 0.25 mmol) and placed under a balloon of H2 gas. After stirring at RT for 2 h, the catalyst was removed via filtration through celite. The filtrate was concentrated onto silica under reduced pressure. Purification via flash chromatography (0-5% MeOH/ CH2C12) gave 180 mg (48%) of final compound 371 as a light brown solid. 1H NMR (500 MHz, DMSO- d6) 9.95 (s, 1H), 8.29 (s, 1H), 8.18 (s, 1H), 7.89 (d, / = 9 Hz, 2H), 7.69 (dd, / = 2, 9 Hz, 1H), 7.58 (d, / = 9 Hz, 1H), 7.32 (d, / = 9 Hz, 2H), 6.76 (d, / = 9 Hz, 2H), 6.71 (d, / = 9 Hz, 2H), 5.32 (s, 2H), 2.99 (s, 6H). EXAMPLE 272
[1126] N-(2- Acetyl- l-(4-(4-dimethylaminobenzamido)phenyl)-lH-indol-5-yl)- 4-dimethylaminobenzamide (Compound 372)
Figure imgf000220_0001
[1127] Compound 372 was prepared according to the procedure described in Scheme IV from 2-acetyl-5-amino-l-(4-aminophenyl)indole and 4- dimethylaminobenzoate. [M+H]+ calcd for C34H33N5O3: 560.26; found: 560.02.
EXAMPLE 273
[1128] N-(l-(4-(4-Dimethylaminobenzamido)phenyl)-lH-indazol-5-yl)-4- dimethylaminobenzamide (Compound 373)
Figure imgf000220_0002
[1129] Compound 373 was prepared according to the procedure described in Scheme lY from 5-amino-l-(4-aminophenyl)indazole and 4-dimethylaminobenzoate. 1H NMR (500MHz, Acetone- d 6) δ 9.44 (s, 1H), 9.38 (s, 1H), 8.49 (s, 1H), 8.23 (s, 1H), 8.08 (d, / = 9 Hz, 2H), 7.95 (d, / = 9 Hz, 4H), 7.81 (m, 2H), 7.76 (d, / = 9 Hz, 2H), 6.79 (d, / = 9 Hz, 4H), 3.06 (s, 6 H), 3.05 (s, 6H).
EXAMPLE 274
[1130] N-(l-(4-Acetamidophenyl)-lH-indazol-5-yl)-4- dimethylaminobenzamide (Compound 374)
Figure imgf000220_0003
[1131] Compound 374 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-dimethylaminobenzoate. [M+H]+ calcd for C24H23N5O2: 414.19; found: 413.97.
EXAMPLE 275
[1132] N-(l-(4-Benzamidophenyl)-lH-indazol-5-yl)-4- dimethylaminobenzamide (Compound 375)
Figure imgf000221_0001
[1133] Compound 375 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-dimethylaminobenzoate. 1H NMR (500MHz, DMSO-d 6) δ 10.45 (s, 1H), 10.01 (s, 1H), 8.37 (d, / = 1.5 Hz, 1H), 8.33 (d, / = 1 Hz, 1H), 8.01 - 7.78 (m, 11H), 7.55 (t, / = 8 Hz, 2H), 6.77 (d, / = 9 Hz, 2H), 3.00 (s, 6H).
EXAMPLE 276
[1134] 4-(dimethylamino)-N-(l-(4-morpholinophenyl)-lH-indol-5- yl)benzamide (Compound 376)
Figure imgf000221_0002
[1135] Compound 376 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-morpholinophenyl)indole and 4-dimethylaminobenzoate. [M+H]+ calcd for C27H28N4O2: 441.22; found: 441.02.
EXAMPLE 277
[1136] N-(l-(4-Morpholinocarboxamidophenyl)-lH-indazol-5-yl)-4- dimethylaminobenzamide (Compound 377)
Figure imgf000221_0003
[1137] Compound 377 was prepared according to the procedure described Scheme IV from 5-amino-l-(4-morpholinocarboxamidophenyl)indazole and dimethylaminobenzoate. [M+H]+ calcd for C27H28N6O3: 485.22; found: 485.02.
EXAMPLE 278
[1138] N-(l-(4-Cyclopropanecarboxamidophenyl)-lH-indazol-5-yl)-4- dimethylaminobenzamide (Compound 378)
Figure imgf000222_0001
[1139] Compound 378 was prepared according to the procedure described Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-dimethylaminobenzoate.
NMR (500MHz, DMSO- d6) δ 10.38 (s, 1H), 10.00 (s, 1H), 8.35 (t, / = 1 Hz, 1H), 8.30 (d, / = 1 Hz, 1H), 7.89 (d, / = 7 Hz, 2H), 7.80 - 7.76 (m, 4H), 7.68 (d, / = 9 Hz, 2H), 6.76 (d, / = 9 Hz, 2H), 3.00 (s, 6H), 1.80 (m, 1H), 0.82 (m, 4H).
EXAMPLE 279
[1140] N-(2- Acetyl- l-(4-cyclopropanecarboxamidophenyl)-lH-indol-5-yl)-4- dimethylaminobenzamide (Compound 379)
Figure imgf000222_0002
[1141] Compound 379 was prepared according to the procedure described Scheme IV from 2-acetyl-5-amino-l-(4-aminophenyl)indole and dimethylaminobenzoate. [M+H]+ calcd for C29H28N4O3: 481.22; found: 480.97.
EXAMPLE 280
[1142] N-(l-(4-Cyclopropanecarboxamidophenyl)-lH-indazol-5-yl)-4- morpholinobenzamide (Compound 380)
Figure imgf000223_0001
[1143] Compound 380 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C28H27N5O3: 482.21; found: 481.98.
EXAMPLE 281
[1144] N-(l-(4-Aminophenyl)-lH-indazol-5-yl)-4-morpholinobenzamide (Compound 381)
Figure imgf000223_0002
[1145] Compound 381 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C24H23N5O2: 414.19; found: 414.01.
EXAMPLE 282
[1146] N-(l-(4-Pivaloylaminophenyl)-lH-indazol-5-yl)-4- morpholinobenzamide (Compound 382)
Figure imgf000223_0003
[1147] Compound 382 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C29H31N5O3: 498.24; found: 498.05.
EXAMPLE 283
[1148] tert-Butyl 1 -(4-(4-dimethylaminobenzamido)phenyl)- lH-indazol-5- ylcarbamate (Compound 383)
Figure imgf000224_0001
[1149] Compound 383 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-dimethylaminobenzoate. [M+H]+ calcd for C27H29N5O3: 472.23; found: 472.06.
EXAMPLE 284
[1150] N-(4-(5-(cyclopropanecarboxamido)-lH-indazol-l-yl)phenyl)-4- (dimethylamino)benzamide (Compound 384)
Figure imgf000224_0002
[1151] Compound 384 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-dimethylaminobenzoate. 1H NMR (500MHz, DMSO- d6) δ 10.30 (s, 1H), 10.05 (s, 1H), 8.27 (d, / = 1 Hz, 1H), 8.23 (s, 1H), 7.97 (d, / = 9 Hz, 2H), 7.89 (d, / = 9 Hz, 2H), 7.78 (d, / = 9 Hz, 1H), 7.70 (d, / = 9 Hz, 1H), 7.55 (dd, / = 2, 12 Hz, 1H), 6.77 (d, / = 9 Hz, 2H), 3.00 (s, 6H), 1.79 (m, 1H), 0.81 (m, 4H).
EXAMPLE 285
[1152] N-(l-(4-(l-Cyanocyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)- 4-morpholinobenzamide (Compound 385)
Figure imgf000224_0003
[1153] Compound 385 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C29H26N6O3: 507.21 ; found: 507.01. EXAMPLE 286
[1154] N-(l-(4-Isobutyramidophenyl)-lH-indazol-5-yl)-4- morpholinobenzamide (Compound 386)
Figure imgf000225_0001
[1155] Compound 386 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C28H29N5O3: 484.23; found: 484.01.
EXAMPLE 287
[1156] N-( 1 -(4-( 1 -Aminomethylcyclopropanecarboxamido)phenyl)- 1H- indazol-5-yl)-4-morpholinobenzamide (Compound 387)
Figure imgf000225_0002
[1157] Compound 387 was prepared by reduction of compound 385. [M+H]+ calcd for C29H30N6O3: 511.24; found: 511.01.
EXAMPLE 288
[1158] N-(l-(4-Amino-2-fluorophenyl)-lH-indazol-5-yl)-4- dimethylaminobenzamide (Compound 388)
Figure imgf000225_0003
[1159] Compound 388 was prepared according to the procedure described Scheme Γ from 5-amino-l-(4-amino-2-fluorophenyl)indazole and dimethylaminobenzoate. [M+H]+ calcd for C22H20FN5O: 390.17; found: 389.96. EXAMPLE 289
[1160] N-(l-(4-Cyclopropanecarboxamido-2-fluorophenyl)-lH-indazol-5-yl)- 4-dimethylaminobenzamide (Compound 389)
Figure imgf000226_0001
[1161] Compound 389 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-amino-2-fluorophenyl)indazole and 4- dimethylaminobenzoate. [M+H]+ calcd for C26H24FN5O2: 458.19; found: 457.98.
EXAMPLE 290
[1162] N-(l-(4-Acrylamidophenyl)-lH-indazol-5-yl)-4-morpholinobenzamide (Compound 390)
Figure imgf000226_0002
[1163] Compound 390 was prepared according to the procedure described Scheme lY from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate.
NMR (500MHz, Acetone- d6) δ 9.59 (s, 1H), 9.47 (s, 1H), 8.49 (s, 1H), 8.24 (s, 1H), 7.98 (dd, / = 2, 9 Hz, 4 H), 7.81 (m, 2H), 7.77 (d, / = 9 Hz, 1H), 7.05 (d, J = 9 Hz, 2H), 6.52 - 6.38 (m, 2H), 5.75 (dd, / = 2, 10 Hz, 1H), 3.80 (m, 4H), 3.29 (m, 4H).
EXAMPLE 291
[1164] N-(l-(4-(3-Morpholinopropanamido)phenyl)-lH-indazol-5-yl)-4- morpholinobenzamide (Compound 391)
Figure imgf000226_0003
[1165] Compound 391 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C31H34N6O4: 555.26; found: 555.09.
EXAMPLE 292
[1166] N-(l-(4-(4-Dimethylaminobenzamido)-2-fluorophenyl)-lH-indazol-5- yl)-4-dimethylaminobenzamide (Compound 392)
Figure imgf000227_0001
[1167] Compound 392 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-dimethylaminobenzoate. 1H NMR (500MHz, DMSO- d6) δ 9.64 (s, 1H), 9.37 (s, 1H), 8.49 (m, 1H), 8.26 (s, 1H), 8.21 (m, 1H), 7.95 (d, / = 9 Hz, 4H), 7.79 (dt, J = 2, 9Hz, 1H), 7.76 (m, 1H), 7.61 (t, / = 9 Hz, 1H), 7.41 (dd, / = 3, 9 Hz, 1H), 6.80 (m, 4H), 3.07 (s, 6H), 3.05 (s, 6H).
EXAMPLE 293
[1168] N-(l-(4-(2-Thienyl)carboxaminophenyl)-lH-indazol-5-yl)-4- morpholinobenzamide (Compound 393)
Figure imgf000227_0002
[1169] Compound 393 was prepared according to the procedure described in Scheme Γ from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C29H25N5O3S: 524.17; found: 523.97.
EXAMPLE 294
[1170] N-(l-(4-Cyclobutanecarboxaminophenyl)-lH-indazol-5-yl)-4- morpholinobenzamide (Compound 394)
Figure imgf000228_0001
[1171] Compound 394 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C29H29N5O3: 496.23; found: 496.03.
EXAMPLE 295
[1172] (+)-N-(l-(4-(2,2-Difluorocyclopropane)carboxamidophenyl)-lH- indazol-5-yl)-4-morpholinobenzamide (Compound 395)
Figure imgf000228_0002
[1173] Compound 395 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C28H25F2N5O3: 518.19; found: 518.03.
EXAMPLE 296
[1174] N-( 1 -(4-( 1 -Trifluoromethylcyclopropane)carboxaminophenyl)- 1H- indazol-5-yl)-4-morpholinobenzamide (Compound 396)
Figure imgf000228_0003
[1175] Compound 396 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C29H26F3N5O3: 550.21 ; found: 550.16.
EXAMPLE 297
[1176] N-(l-(4-Cyclopropanecarboxamidophenyl)-lH-indazol-5-yl)-4-(4- hydroxypiperidino)benzamide (Compound 397)
Figure imgf000229_0001
[1177] Compound 397 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4- hydroxypiperidino)benzoate. [M+H]+ calcd for C29H29N5O3: 496.23; found: 496.10.
EXAMPLE 298
[1178] N-(l-(4-(3-Methylbut-2-enamido)phenyl)-lH-indazol-5-yl)-4- morpholinobenzamide (Compound 398)
Figure imgf000229_0002
[1179] Compound 398 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. 1H NMR (500MHz, Acetone-J6) δ 9.47 (s, 1H), 9.27 (s, 1H), 8.48 (s, 1H), 8.23 (s, 1H), 7.98 (d, / = 8.5 Hz, 2H), 7.94 (d, / = 8.5 Hz, 2H), 7.80 (s, 2H), 7.73 (d, / = 8.5 Hz, 2H), 7.05 (d, / = 8.5 Hz, 2H), 5.92 (s, 1H), 3.80 (t, / = 5 Hz, 4H), 3.29 (t, / = 5 Hz, 4H), 2.24 (s, 3H), 1.90 (s, 3H).
EXAMPLE 299
[1180] N-(l-(4-Cyclopropanecarboxamidophenyl)-lH-indazol-5-yl)-4- piperazinobenzamide (Compound 399)
Figure imgf000229_0003
[1181] Compound 399 was prepared according to the procedure described in Scheme Γ from 5-amino-l-(4-aminophenyl)indazole and 4-piperazinobenzoate. [M+H]+ calcd for 02»ϋ2»Ν602: 481.23; found: 481.04. EXAMPLE 300
[1182] N-(4-(4-(4-(4-Cyclopropanecarbonyl)piperazin-l- izamido)benzoyl)phenyl)thiophene-2-carboxamide (Compound 400)
Figure imgf000230_0001
[1183] Compound 400 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-piperazinebenzoate. [M+H]+ calcd for C33H30N4O4S: 579.51; found: 579.06.
EXAMPLE 301
[1184] N-(4-(4-(4-(4-Cyclopropanecarbonyl)piperazin-l- yl)benzamido)benzoyl)phenyl)cyclopropanecarboxamide (Compound 401)
Figure imgf000230_0002
[1185] Compound 401 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-piperazinebenzoate. [M+H]+ calcd for C32H32N4O4: 537.15; found: 537.06.
EXAMPLE 302
[1186] N-(4-(4-(4-Morpholinobenzamido)benzoyl)phenyl)-lH-indole-5- carboxamide (Compound 402)
Figure imgf000230_0003
[1187] Compound 402 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-piperazinebenzoate. [M+H]+ calcd for
C33H28N4O4: 545.13; found: 545.03. EXAMPLE 303
[1188] N,N'-(carbonylbis(4,l-phenylene))bis(l -methyl- 1H- benzo[d][l,2,3]triazole-5-carboxamide) (Compound 403)
Figure imgf000231_0001
[1189] Compound 403 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone and 1 -methyl- lH-benzo triazole- 5- carboxylate. [M+H]+ calcd for C29H22N8O3: 531.06; found: 531.05.
EXAMPLE 304
[1190] N-(l-(4-Cyanophenyl)-lH-indazol-5-yl)-4-(4- hydroxypiperidino)benzamide Compound 404)
Figure imgf000231_0002
[1191] Compound 404 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-cyanophenyl)indazole and 4-(4- hydroxypiperidino)benzoate. [M+H]+ calcd for C26H23N5O2: 438.19; found: 437.99.
EXAMPLE 305
[1192] N-(l-(4-Cyanophenyl)-lH-indazol-5-yl)-4-morpholinobenzamide (Compound 405)
Figure imgf000231_0003
[1193] Compound 405 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-cyanophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C25H21N5O2: 424.17; found: 424.09. EXAMPLE 306
[1194] l-(4-(4-Dimethylaminobenzamido)phenyl)-N-(4-morpholinophenyl)- lH-indole-5-carboxamide (Compound 406)
Figure imgf000232_0001
[1195] Compound 406 was prepared according to the procedure described in Scheme IV from l-(4-dimethylaminophenylbenzamido)indole and 4-morpholinoaniline.
1H NMR (500MHz, DMSO- d6) 510.08 (s, 1H), 10.02 (2, 1H), 8.33 (d, / = 2 Hz, 1H), 7.99 (d, / = 9 Hz, 2H), 7.89 (d, / = 9 Hz, 2H), 7.82 (dd, / = 2, 9 Hz, 1H), 7.74 (d, J = 3 Hz, 1H), 7.66 (d, / = 9 Hz, 2H), 7.60 (d, / = 9 Hz, 1H), 7.57 (d, / = 5 Hz, 2H), 6.93 (d, / = 9 Hz, 2H), 6.83 (d, / = 3 Hz, 1H), 6.78 (d, / = 9 Hz, 2H), 3.73 (m, 4H), 3.06 (m, 4H), 3.01 (s, 6H).
EXAMPLE 307
[1196] 4-Dimethylamino-N-( 1 -(4-(4- dimethylaminobenzamido)benzoyl)piperidin-4-yl)benzamide (Compound 407)
Figure imgf000232_0002
[1197] Compound 407 was prepared according to the procedure described in Scheme IV from 4-(4-dimethylaminobenzamido)benzoate and 4-(4- dimethylaminophenyl)piperidine. [M+H]+ calcd for C30H35N5O3: 514.27; found: 513.98.
EXAMPLE 308
[1198] N,N'-(4,4'-Thiobis(4,l-phenylene))bis(4-(dimethylamino)benzamide) (Compound 408)
Figure imgf000232_0003
[1199] Compound 408 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-dimethylaminobenzoate. [M+H]+ calcd for C30H30N4O2S: 511.21; found: 510.94.
EXAMPLE 309
[1200] tert-butyl (4-(4-(4-morpholinobenzamido)piperidine-l- carbonyl)phenyl)carbamate
[1201] (Compound 409)
Figure imgf000233_0001
[1202] Compound 409 was prepared according to the procedure described in Scheme IV from 4-aminobenzoate and 4-(4-dimethylaminophenyl)piperidine. [M+H]+ calcd for C28H36N4O5: 509.27; found: 508.99.
EXAMPLE 310
[1203] N-(4-(4-Morpholinophenylamino)phenyl)-4-dimethylaminobenzamide (Compound 410)
Figure imgf000233_0002
[1204] Compound 410 was prepared according to the procedure described in Scheme Γ from 4,4'-diaminodiphenylamine and 4-dimethylaminobenzoate. [M+H]+ calcd for C25H29N4O2: 417.23; found: 417.01.
EXAMPLE 311
[1205] 4-Dimethylamino-N-(4-(2-(4-(4-hydroxypiperidinyl)phenyl)-lH- benzimidazol-5-ylcarbamoyl)phenyl)benzamide (Compound 411)
Figure imgf000233_0003
[1206] Compound 411 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-aminobenzoyl)aniline and 4-(4- hydroxypiperidinyl)benzaldehyde. [M+H]+ calcd for C34H34N6O3: 575.27; found: 575.07.
EXAMPLE 312
[1207] 4-Dimethylamino-N-(4-(2-(4-(bis(2-hydroxyethyl)amino)phenyl)-lH- benzimidazol- -ylcarbamoyl)phenyl)benzamide (Compound 412)
Figure imgf000234_0001
[1208] Compound 412 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-aminobenzoyl)aniline and 4-bis(2- hydroxyethyl)aminobenzaldehyde. [M+H]+ calcd for C33H34N6O4: 579.26; found: 579.06.
EXAMPLE 313
[1209] N-(2-(4-(l,4-Dioxa-8-azaspiro[4,5]decan-8-yl)phenyl)-lH- benzimidazol- -yl)-4-morpholinobenzamide (Compound 413)
Figure imgf000234_0002
[1210] Compound 413 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 4-(l,4- dioxa-8-azaspiro[4,5]decan-8-yl)benzaldehyde. [M+H]+ calcd for C31H33N5O4: 540.25; found: 540.05.
EXAMPLE 314
[1211] N-(2-(4-(4-(2-Hydroxyethyl)piperidinyl)phenyl)-lH-benzimidazol-5- yl)-4-morpholinobenzamide (Compound 414)
Figure imgf000234_0003
[1212] Compound 414 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 4-(2- hydroxyethyl)piperidinylbenzaldehyde. [M+H]+ calcd for C31H35N5O3: 526.27; found: 526.11.
EXAMPLE 315
[1213] N-(2-(4-(4-Cyclopropanecarbonylpiperazinyl)phenyl)-lH- benzimidazol-5- -4-morpholinobenzamide (Compound 415)
Figure imgf000235_0001
[1214] Compound 415 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 4-(4- cyclopropanecarbonylpiperazinyl)benzaldehyde. [M+H]+ calcd for C32H34N6O3: 551.27; found: 551.10.
EXAMPLE 316
[1215] N-(2-(4-(4-(2-Hydroxymethyl)piperidinyl)phenyl)-lH-benzimidazol-5- yl)-4-morpholinobenzamide (Compound 416)
Figure imgf000235_0002
[1216] Compound 416 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 4-(2- hydroxymethyl)piperidinylbenzaldehyde. [M+H]+ calcd for C30H33N5O3: 512.26; found: 512.09.
EXAMPLE 317
[1217] N-(2-(2-(4-Hydroxypiperidinyl)thien-5-yl)-lH-benzimidazol-5-yl)-4- morpholinobenzamide (Compound 417)
Figure imgf000235_0003
[1218] Compound 417 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 5-(4- hydroxypiperidinyl)thiophene-2-carboxaldehyde. [M+H]+ calcd for C27H29N5O3S: 504.20; found: 503.99.
EXAMPLE 318
[1219] N-(2-(2-Morpholinothien-5-yl)- lH-benzimidazol-5-yl)-4- morpholinobenzamide (Compound 418)
Figure imgf000236_0001
[1220] Compound 418 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 5- morpholinothiophene-2-carboxaldehyde. [M+H]+ calcd for C26H27N5O3S: 490.18; found: 489.95.
EXAMPLE 319
[1221] N-(2-(3-Morpholinomethylphenyl)-lH-benzimidazol-5-yl)-4- morpholinobenzamide (Compound 419)
Figure imgf000236_0002
[1222] Compound 419 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 3- morpholinomethylbenzaldehyde. [M+H]+ calcd for C29H31N5O3: 498.24; found: 497.98.
EXAMPLE 320
[1223] N-(2-(l-Methylpiperidin-4-yl)-lH-benzimidazol-5-yl)-4- morpholinobenzamide (
Figure imgf000236_0003
[1224] Compound 420 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 4-(l- methylpiperidinyl)caboxaldehyde. [M+H]+ calcd for C24H29N5O2: 420.23; found: 420.04.
EXAMPLE 321
[1225] N-(2-(4-(l,l-Dioxo-4-thiomorpholino)phenyl)-lH-benzimidazol-5-yl)- 4-morpholinobenzamide (Compound 421)
Figure imgf000237_0001
[1226] Compound 421 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 4-(l,l- dioxo-4-thiomorpholino)benzaldehyde. [M+H]+ calcd for C28H29N5O4S: 532.19; found: 532.02.
EXAMPLE 322
[1227] N-(2-(4-((4-methylpiperazin- 1 -yl)methyl)phenyl)- 1H- benzo[d]imidazol-5- -4-morpholinobenzamide (Compound 422)
Figure imgf000237_0002
[1228] Compound 422 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 4- piperazinomethylbenzaldehyde. [M+H]+ calcd for C30H34N6O2: 511.27; found: 511.07.
EXAMPLE 323
[1229] N-(2-(4-(4-Methylpiperazino)phenyl)-lH-benzimidazol-5-yl)-4- morpholinobenzamide (Compound 423)
Figure imgf000237_0003
[1230] Compound 423 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 4-(4- methylpiperazino)benzaldehyde. [M+H]+ calcd for C29H32N6O2: 497.26; found: 496.98.
EXAMPLE 324
[1231] N-(2-(2-Methoxy-4-morpholinophenyl)-lH-benzimidazol-5-yl)-4- morpholinobenzamide (Compound 424)
Figure imgf000238_0001
[1232] Compound 424 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-morpholinobenzoyl)aniline and 2-methoxy- 4-morpholinobenzaldehyde. [M+H]+ calcd for C29H31N5O4: 514.25; found: 514.05.
EXAMPLE 325
[1233] N-(2-(4-Morpholinophenyl)-lH-benzimidazol-5-yl)-3,5- dihydroxybenzamide (Compound 425)
Figure imgf000238_0002
[1234] Compound 425 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(3,5-dihydroxybenzoyl)aniline and 4- morpholinobenzaldehyde. [M+H]+ calcd for C24H22N4O4: 431.17; found: 431.18.
EXAMPLE 326
[1235] N-(2-(4-Morpholinophenyl)- lH-benzimidazol-5-yl)-4- hydroxybenzamide (Compound 426)
Figure imgf000238_0003
[1236] Compound 426 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(4-hydroxybenzoyl)aniline and 4- morpholinobenzaldehyde. [M+H]+ calcd for C24H22N4O3: 415.18; found: 415.17. EXAMPLE 327
[1237] N-(2-(4-Morpholinophenyl)- lH-benzimidazol-5-yl)-2- hydroxybenzamide (Compound 427)
Figure imgf000239_0001
[1238] Compound 427 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitro-N-(2-hydroxybenzoyl)aniline and 4- morpholinobenzaldehyde. [M+H]+ calcd for C24H22N4O3: 415.18; found: 414.98.
EXAMPLE 328
[1239] 4-(4-(5-(5-(4-Morpholinophenyl)-l,3,4-oxadiazol-2-yl)-lH- benzimidazol-2-yl) henyl) morpholine (Compound 428)
Figure imgf000239_0002
[1240] Compound 428 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitro-l-(5-(4-morpholinophenyl)-l,3,4-oxadiazol-2- yl)benzene and 4-morpholinobenzaldehyde. [M+H]+ calcd for C29H28N6O3: 590.23; found: 508.98.
EXAMPLE 329
[1241] 4-Dimethylamino-N-(2-(3-methoxyphenylamino)-lH-benzimidazol-5- yl)benzamide (Compoun
Figure imgf000239_0003
[1242] Compound 429 was prepared from 4-dimethylaminobenzoate and 5- amino-2-(3-methoxyphenylamino)benzimidazole by standard conditions. [M+H]+ calcd for C23H23N5O2: 402.19; found: 401.96.
EXAMPLE 330
[1243] N-(2-Dimethylamino)- lH-benzimidazol-5-yl)-2-(4- dimethylaminophenyl)- lH-benzimidazole-5-carbamide (Compound 430)
Figure imgf000240_0001
[1244] Compound 430 was prepared from 2-(4- dimethylaminophenyl)benzimidazole-5-caboxylate and 5-amino-2-
(dimethylamino)benzimidazole by standard conditions. [M+H]+ calcd for C25H25N7O: 440.21 ; found: 440.01.
EXAMPLE 331
[1245] 2-(4-(2-Hydroxyethoxy)phenyl)-N-2-(4-(2-hydroxyethoxy)phenyl)-lH- benzimidazol- -yl)- lH-benzimidazole-6-carboxamide (Compound 431)
Figure imgf000240_0002
[1246] Compound 431 was prepared according to the procedure similar to that described in Scheme V from 2-(4-(2-hydroxyethoxy)phenyl)-5-aminobenzimidazole and 2-(4-(2-hydroxyethoxy)phenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C31H27N5O5: 550.20; found: 549.96.
EXAMPLE 332
[1247] 2-(4-Cyanophenyl)-N-2-(4-(2-hydroxyethoxy)phenyl)- 1H- benzimidazol-5- l)- lH-benzimidazole-6-carboxamide (Compound 432)
Figure imgf000240_0003
[1248] Compound 432 was prepared according to the procedure similar to that described in Scheme V from 2-(4-cyanophenyl)-5-aminobenzimidazole and 2-(4-(2- hydroxyethoxy)phenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C30H22N6O3: 515.18; found: 514.92.
EXAMPLE 333
[1249] 2-(4-bis(2-Hydroxyethyl)aminophenyl)-N-2-(4-(2- hydroxyethoxy)phenyl)-lH-benzimidazol-5-yl)-lH-benzimidazole-6-carboxamide (Compound 433)
Figure imgf000241_0001
[1250] Compound 433 was prepared according to the procedure similar to that described in Scheme V from 2-(4-bis(2-hydroxyethyl)aminophenyl)-5- aminobenzimidazole and 2- (4- (2-hydroxyethoxy)phenyl)benzimidazole- 5 -carboxylate . [M+H]+ calcd for C33H32N6O5: 593.24; found: 593.03.
EXAMPLE 334
[1251] N,N'-bis-(2-(4-Morpholinophenyl)-lH-benzimidazol-5-yl)oxalamide (Compound 434
Figure imgf000241_0002
[1252] Compound 434 was prepared according to the procedure similar to that described in Scheme V from 2-(4-morpholinophenyl)-5-aminobenzimidazole and oxalic acid. [M+H]+ calcd for C36H34N8O4: 643.27; found: 643.09.
EXAMPLE 335
[1253] N,N'-bis(2-Dimethylamino-lH-benzimidazol-5-yl)terephthalamide (Compound 435)
Figure imgf000241_0003
[1254] Compound 435 was prepared according to the procedure similar to that described in Scheme V from 2-dimethylamino-5-aminobenzimidazole and terephthalic acid. [M+H]+ calcd for CaeHaeNgOa: 483.22; found: 483.02.
EXAMPLE 336
[1255] N,N'-bis(2-Dimethylamino-lH-benzimidazol-5-yl)-3(E),3'(E)-(l,4- phenylene)bis(acrylamide) (Compound 436)
Figure imgf000241_0004
[1256] Compound 436 was prepared according to the procedure similar to that described in Scheme V from 2-dimethylamino-5-aminobenzimidazole and 3(E),3'(E)- (l,4-phenylene)bisacrylic acid. [M+H]+ calcd for C30H30N8O2: 535.25; found: 535.09.
EXAMPLE 337
[1257] N-(2-Dimethylamino)- lH-benzimidazol-5-yl)-4-(4- dimethylaminobenzamido)benzamide (Compound 437)
Figure imgf000242_0001
[1258] Compound 437 was prepared from 4-(4- dimethylaminobenzamido)benzoate and 5-amino-2-(dimethylamino)benzimidazole by standard conditions. [M+H]+ calcd for CisfteNeOi: 443.21 ; found: 443.05.
EXAMPLE 338
[1259] N-(2-(3-Methoxyphenyl)amino)-lH-benzimidazol-5-yl)-4-(4- dimethylaminobenzamido) benzamide (Compound 438)
Figure imgf000242_0002
[1260] Compound 438 was prepared from 4-(4- dimethylaminobenzamido)benzoate and 5-amino-2-(3- methoxyphenyl)aminobenzimidazole by standard conditions. [M+H]+ calcd for C30H28N6O3: 521.22; found: 521.06.
EXAMPLE 339
[1261] N-(2-(3-Methoxyphenyl)amino-lH-benzimidazol-5-yl)-2-(4- dimethylaminophenyl)- lH-benzimidazole-5-carbamide (Compound 439)
Figure imgf000242_0003
[1262] Compound 439 was prepared from 2-(4- dimethylaminophenyl)benzimidazole-5-caboxylate and 5-amino-2-(3- methoxyphenyl)aminobenzimidazole by standard conditions. [M+H]+ calcd for C30H27N7O2: 518.22; found: 518.03.
EXAMPLE 340
[1263] N-(2-(2,3-Dihydroxypropyl)amino-lH-benzimidazol-5-yl)-4-(4- dimethylaminobenzamido)benzamide (Compound 440)
Figure imgf000243_0001
[1264] Compound 440 was prepared from 4-(4- dimethylaminobenzamido)benzoate and 5-amino-2-(2,3- dihydroxypropylamino)benzimidazole by standard conditions. [M+H]+ calcd for C26H28N6O4: 489.22; found: 489.01.
EXAMPLE 341
[1265] N,N'-(1 ,4-Cyclohexane)bis(2-(4-dimethylaminophenyl)- 1H- benzimidazo -5-carboxamide) (Compound 441)
Figure imgf000243_0002
[1266] Compound 441 was prepared according to the procedure similar to that described in Scheme V from 1,4-cyclohexanediamine and 2-(4- dimethylaminophenyl)benzimidazole-5-carboxylate. [M+H]+ calcd for C38H40N8O2: 641.33; found: 641.24.
EXAMPLE 342
[1267] N-(2-(4-Dimethylaminophenyl)-lH-benzimidazol-5-yl)-4-(4- dimethylaminobenzamido) benzamide (Compound 442)
Figure imgf000244_0001
[1268] Compound 442 was prepared from 4-(4- dimethylaminobenzamido)benzoate and 5-amino-2-(4- dimethylaminophenyl)benzimidazole by standard conditions [M+H]+ calcd for C31H30N6O2: 519.24; found: 518.99.
EXAMPLE 343
[1269] N-(4-(4-Dimethylaminobenzamido)phenyl)-2-(4- dimethylaminophenyl)- lH-benzimidazole-5-carboxamide (Compound 443)
Figure imgf000244_0002
[1270] Compound 443 was prepared from 4-(4- dimethylaminobenzamido) aniline and 2- (4-dimethylaminophenyl)benzimidazole- 5 - carboxylate by standard conditions. [M+H]+ calcd for C31H30N6O2: 519.24; found: 519.04.
EXAMPLE 344
[1271] 4-(dimethylamino)-N-(4-((2-(4-methoxyphenyl)-lH-benzo[(i]imidazol- 5-yl)carbamoyl) phenyl)benzamide (Compound 444)
Figure imgf000244_0003
[1272] Compound 444 was prepared from 4-(4- dimethylaminobenzamido)aniline and 2-(4-methoxyphenyl)benzimidazole-5-carboxylate by standard conditions. [M+H]+ calcd for C30H27N5O3: 506.21 ; found: 507.02. EXAMPLE 345
[1273] N-(4-(4-Dimethylaminobenzamido)phenyl)-lH-benzimidazole-5- carboxamide (Compound 445)
Figure imgf000245_0001
[1274] Compound 445 was prepared from 4-(4- dimethylaminobenzamido)aniline and benzimidazole-5-carboxylate by standard conditions. [M+H]+ calcd for C23H21N5O2: 400.17; found: 400.01.
EXAMPLE 346
[1275] N-(2-(4-(4-(2-Morpholinoethyl)piperidino)phenyl)-lH-benzimidazol-5- yl)-4-morpholinobenzamide (Compound 446)
Figure imgf000245_0002
[1276] Compound 446 was prepared from 4-morpholinobenzoate and 5- amino-2-(4-(4-(2-morpholinoethyl)piperidino)phenyl)benzimidazole by standard conditions. [M+H]+ calcd for : C35H42N6O3; 595.33 found: 595.12.
EXAMPLE 347
[1277] N-(2-(4-(4-Morpholinocarbonyl)piperidino)phenyl)-lH-benzimidazol- 5-yl)-4-morpholinobenzamide (Compound 447)
Figure imgf000245_0003
[1278] Compound 447 was prepared from 4-morpholinobenzoate and 5- amino-2-(4-(4-morpholinocarbonyl)piperidino)phenylbenzimidazole by standard conditions. [M+H]+ calcd for C34H38N6O4: 595.30; found: 595.13. EXAMPLE 348
[1279] N-(2-(4-(4-Morpholinocarbonylmethyl)piperazino)phenyl)-lH- benzimidazo -5-yl)-4-morpholinobenzamide (Compound 448)
Figure imgf000246_0001
[1280] Compound 448 was prepared from 4-morpholinobenzoate and 5- amino-2-(4-(4-morpholinocarbonylmethyl)piperazino)phenylbenzimidazole by standard conditions. [M+H]+ calcd for C34H39N7O4: 610.31 ; found: 610.11.
EXAMPLE 349
[1281] 4-(5-Methylsulfonylamido)-lH-benzimidazol-2-yl)-N-(4- morpholinophenyl benzamide (Compound 449)
Figure imgf000246_0002
[1282] Compound 449 was prepared from 4-morpholinoaniline and 4-(5- methylsulfonylamino-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C25H25N5O4S: 492.17; found: 491.97.
EXAMPLE 350
[1283] 4-(5-Cyano-lH-benzimidazol-2-yl)-N-(4-morpholinophenyl)benzamide (Compound 450)
Figure imgf000246_0003
[1284] Compound 450 was prepared from 4-morpholinoaniline and 4-(5- cyano-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C25H21N5O2: 424.18; found: 423.95.
EXAMPLE 351
[1285] 4-(5-(3-Methyl-5-oxo-2,5-dihydro-lH-pyrazol-l-yl)-lH-benzimidazol- 2-yl)-N-(4-morpholinophenyl)benzamide (Compound 451)
Figure imgf000247_0001
[1286] Compound 451 was prepared from 4-morpholinoaniline and 4-(5-(3- methyl-5-oxo-2,5-dihydro-lH-pyrazol-l-yl)-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for CisHaeNeCh: 495.22; found: 495.01.
EXAMPLE 352
[1287] 5-Amino-(2-(4-(4-morpholinocarbonylmethyl)piperazino)phenyl)-lH- benzimidazole (Compound 452)
Figure imgf000247_0002
[1288] Compound 452 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitroaniline and 2-(4-(4- morpholinocarbonylmethyl)piperazino)benzaldehyde. [M+H]+ calcd for C23H28N6O2: 421.23; found: 420.98.
EXAMPLE 353
[1289] 4-(5- Amino- lH-benzimidazol-2-yl)-N-(4- morpholinophenyl)benzamide (Compound 453)
Figure imgf000247_0003
[1290] Compound 453 was prepared from 4-morpholinoaniline and 4-(5- amino-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C24H23N5O2: 414.19; found: 413.97.
EXAMPLE 354
[1291] 4-(5-Acetamino-lH-benzimidazol-2-yl)-N-(4- morpholinophenyl)benzamide (Compound 454)
Figure imgf000247_0004
[1292] Compound 454 was prepared from 4-morpholinoaniline and 4-(5- acetamino-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C26H25N5O3: 456.20; found: 455.95.
EXAMPLE 355
[1293] 4-(5-(2,2,2-Trifluoroethyl)amino-lH-benzimidazol-2-yl)-N-(4- morpholinophenyl)benzamide Compound 455)
Figure imgf000248_0001
[1294] Compound 455 was prepared from 4-morpholinoaniline and 4-(5- bis(2,2,2-trifluoroethyl)amino-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C26H24F3N5O2: 496.19; found: 496.02.
EXAMPLE 356
[1295] 4-(5-bis(2,2,2-Trifluoroethyl)amino-lH-benzimidazol-2-yl)-N-(4- morpholinophenyl benzamide (Compound 456)
Figure imgf000248_0002
[1296] Compound 456 was prepared from 4-morpholinoaniline and 4-(5- bis(2,2,2-trifluoroethyl)amino-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for CasHasFeNsOa: 578.19; found: 578.04.
EXAMPLE 357
[1297] 4-(5-Morpholino-lH-benzimidazol-2-yl)-N-(4- morpholinophenyl)benzamide (Compound 457)
Figure imgf000248_0003
[1298] Compound 457 was prepared from 4-morpholinoaniline and 4-(5- morpholino-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C28H29N5O3: 484.23; found: 484.01. EXAMPLE 358
[1299] 4-(lH-Benzimidazol-2-yl)-N-(4-morpholinophenyl)benzamide
(Compound 458)
Figure imgf000249_0001
[1300] Compound 458 was prepared from 4-morpholinoaniline and 4-(lH- benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C24H22N4O2: 399.17; found: 398.98.
EXAMPLE 359
[1301] 4-(5-Hydroxy-lH-benzimidazol-2-yl)-N-(4- morpholinophenyl)benzamide (Compound 459)
Figure imgf000249_0002
[1302] Compound 459 was prepared from 4-morpholinoaniline and 4-(5- hydroxy-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C24H22N4O3: 415.17; found: 415.05.
EXAMPLE 360
[1303] 4-(5-Methoxy- lH-benzimidazol-2-yl)-N-(4- morpholinophenyl)benzamide (Compound 460)
Figure imgf000249_0003
[1304] Compound 460 was prepared from 4-morpholinoaniline and 4-(5- methoxy-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C25H24N4O3: 429.18; found: 428.97.
EXAMPLE 361
[1305] 4-(lH-Benzimidazol-2-yl)-N-(4-(4- cyclopropanecarbonylpiperazino)phenyl)benzamide (Compound 461)
Figure imgf000249_0004
[1306] Compound 461 was prepared from
cyclopropanecarbonyl)piperazinoaniline and 4-( lH-benzimidazol-2-yl)benzoate standard conditions. [M+H]+ calcd for C28H27N5O2: 466.22; found: 465.99.
EXAMPLE 362
[1307] 4-(5- Amino- lH-benzimidazol-2-yl)-N-(4-(4- cyclopropanecarbon lpiperazino)phenyl)benzamide (Compound 462)
Figure imgf000250_0001
[1308] Compound 462 was prepared from 4-(4- cyclopropanecarbonyl)piperazinoaniline and 4-(5-amino- lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for 02»ϋ2»Ν602: 481.23; found: 481.05.
EXAMPLE 363
[1309] 4-(5-(2,2,2-Trifluoroethoxy)- lH-benzimidazol-2-yl)-N-(4- morpholinophenyl benzamide (Compound 463)
Figure imgf000250_0002
[1310] Compound 463 was prepared from 4-morpholinoaniline and 4-(5- (2,2,2-trifluoroethoxy)-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C26H23F3N4O3: 497.17; found: 496.97.
EXAMPLE 364
[1311] N,N'-(4,4'-(l,3,4-Oxadiazole-2,5-diyl)bis(4,l-phenylene))bis(4- dimethylaminobenzamide) (Compound 464)
Figure imgf000250_0003
[1312] Compound 464 was prepared according to the procedure described in Scheme IV from 4,4'-(l,3,4-oxadiazole-2,5-diyl)bis(4,l-phenylene)diamine and 4- dimethylaminobenzoate. 1H NMR (500MHz, DMSO- d6) δ 10.20 (s, 2H), 8.06 (dq, / = 2, 9 Hz, 8H), 7.90 (d, / = 9 Hz, 4H), 6.77 (d, / = 9 Hz, 4H), 3.01 (s, 12H). EXAMPLE 365
[1313] N,N'-bis(2-(4-Morpholinophenylamino)-2-oxoethyl)biphenyl-4,4' dicarboxamide ompound 465)
Figure imgf000251_0001
[1314] Compound 465 was prepared according to the procedure described in Scheme IV from 4-morpholinoaniline, glycine, and 4,4'-biphenyldicarboxylate. [M+H]+ calcd for Css^NeOe: 677.30; found: 677.23.
EXAMPLE 366
[1315] 4'-(2-(4-Morpholinophenylamino)-2-oxoethylcarbamoyl)biphenyl-4- carboxamide ompound 466)
Figure imgf000251_0002
[1316] Compound 466 was prepared according to the procedure described in Scheme IV from 4-morpholinoaniline, glycine, and 4,4'-biphenyldicarboxylic acid. [M+H]+ calcd for C26H25N3O5: 460.18; found: 459.92.
EXAMPLE 367
[1317] N-(2-(4-Morpholinophenyl)amino-2-oxoethyl)-4- dimethylaminobenzamide (Compound 467)
Figure imgf000251_0003
[1318] Compound 467 was prepared according to the procedure described in Scheme Γ from 4-morpholinoaniline, glycine, and 4-dimethylaminobenzoate. 1H NMR (500MHz, CDCI3) δ 8.46 (s, 1H), 7.74 (s, / = 9 Hz, 2H), 6.82 (t, / = 5.5 Hz, 1H), 6.68 (d, / = 9 Hz, 2H), 4.25 (d, / = 5.5 Hz, 2H), 3.85 (m, 4H), 3.11 (m, 4H), 3.04 (s, 6H). EXAMPLE 368
[1319] N,N'-bis(5-(Furan-2-yl)-lH-pyrazol-3-yl)biphenyl-4,4'-dicarboxamide (Compound 4
Figure imgf000252_0001
[1320] Compound 468 was prepared from 3-amino-5-(2-furanyl)pyrazole and 4,4'-biphenyldicarboxylate. [M+H]+ calcd for CisftiNeC : 505.16; found: 504.93.
EXAMPLE 369
[1321] N,N'-bis(5-(Thiophen-2-yl)-lH-pyrazol-3-yl)biphenyl-4,4'- dicarboxamide Compound 469)
Figure imgf000252_0002
[1322] Compound 469 was prepared from 3-amino-5-(2-thienyl)pyrazole and 4,4'-biphenyldicarboxylate. [M+H]+ calcd for CisHaiNeOiSi: 537.12; found: 536.93.
EXAMPLE 370
[1323] 1,1' -bis( 1 ,4-Phenylene)bis(3-(5-(4-methoxyphenyl)- l -pyrazol-3- yl)thiourea) (Compound 470)
Figure imgf000252_0003
[1324] Compound 470 was prepared from 3-amino-5-(4- methoxyphenyl)pyrazole and 1,4-phenylenediamine. [M+H]+ calcd for C28H27N8O2S2: 571.17; found: 570.89.
EXAMPLE 371
[1325] N-(5-(4-Methoxyphenyl)-lH-pyrazol-3-yl)-N'-(5-(4-methylphenyl)- lH-pyrazol-3-yl)tere hthalamide (Compound 471)
Figure imgf000252_0004
[1326] Compound 471 was prepared from 3-amino-5-(4- methoxyphenyl)pyrazole, 3-amino-5-(4-methylphenyl)pyrazole, and terephthalic acid. [M+H]+ calcd for CisHasNeOs: 493.20; found: 492.92.
EXAMPLE 372
[1327] N,N'-bis(5-(4-Methylphenyl)-lH-pyrazol-3-yl)terephthalamide
(Compound 472)
Figure imgf000253_0001
[1328] Compound 472 was prepared from 3-amino-5-(4- methylphenyl)pyrazole and terephthalic acid. [M+H]+ calcd for C28H25N6O2: 477.20; found: 476.92.
EXAMPLE 373
[1329] N,N'-bis(5-(4-Methoxyphenyl)-lH-pyrazol-3-yl)terephthalamide (Compound 473)
Figure imgf000253_0002
[1330] Compound 473 was prepared from 3-amino-5-(4- methoxyphenyl)pyrazole and terephthalic acid. [M+H]+ calcd for C28H25N6O4: 509.19; found: 508.91.
EXAMPLE 374
[1331] N,N'-bis(5-(4-Methoxyphenyl)-lH-pyrazol-3-yl)biphenyl-4,4'- dicarboxamide Compound 474)
Figure imgf000253_0003
[1332] Compound 474 was prepared from 3-amino-5-(4- methoxyphenyl)pyrazole and biphenyl-4,4'-dicarboxylic acid. [M+H]+ calcd for C34H29N6O4: 585.23; found: 585.01. EXAMPLE 375
[1333] N,N'-bis(5-Phenyl-lH-pyrazol-3-yl)biphenyl-4,4'-dicarboxamide (Compound 475)
Figure imgf000254_0001
[1334] Compound 475 was prepared from 3-amino-5-phenylpyrazole and biphenyl-4,4'-dicarboxylic acid. [M+H]+ calcd for C32H25N6O2: 525.20; found: 524.98.
EXAMPLE 376
[1335] N,N'-bis(5-(4-Methylphenyl)-lH-pyrazol-3-yl)biphenyl-4,4'- dicarboxamide (Com ound 476)
Figure imgf000254_0002
[1336] Compound 476 was prepared from 3-amino-5-(4- methylphenyl)pyrazole and biphenyl-4,4'-dicarboxylic acid. [M+H]+ calcd for C34H29N6O2: 553.24; found: 553.06.
EXAMPLE 377
[1337] N,N'-bis(5-(4-Methoxyphenyl)-lH-pyrazol-3-yl)-3(E),3'(E)-(l,4- phenylene)bis(acr lamide) (Compound 477)
Figure imgf000254_0003
[1338] Compound 477 was prepared from 3-amino-5-(4- methoxyphenyl)pyrazole and 3(E),3'(E)-(l,4-phenylene)bis(acrylic acid). [M+H]+ calcd for C32H28N6O4: 561.23; found: 561.05.
EXAMPLE 378
[1339] 4,4'-(l,3-Phenylenebis(methylene)bis(azanediyl)bis(methylidene)bis(3- methyl-1 -phenyl- lH-pyrazol-5(4H)-one) (Compound 478)
Figure imgf000255_0001
[1340] Compound 478 was prepared from 3-methyl-l -phenyl- lH-pyrazol- 5(4H)-one and l,3-phenylenebis(methylamine). [M+H]+ calcd for C3oH28N6 02: 505.23; found: 505.07.
EXAMPLE 379
[1341] N-(2-(4-(Pyridin-2-yl)phenyl)-lH-benzimidazol-5-yl)benzamide (Compound 479)
Figure imgf000255_0002
[1342] Compound 479 was prepared from 5-amino-2-(4-(pyridin-2-yl)phenyl)- lH-benzimidazole and benzoate by standard conditions. [M+H]+ calcd for C25Hi8N40: 391.16; found: 390.91.
EXAMPLE 380
[1343] 4-(5-Cyclopropylpropiolamido-lH-benzimidazol-2-yl)-iV-(4- morpholinophenyl)benzamide (Compound 480)
Figure imgf000255_0003
[1344] Compound 480 was prepared from 4-morpholinoaniline and 4-(5- amino-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C30H27N5O3: 506.22; found: 506.01.
EXAMPLE 381
[1345] 4-(5-Trifluoromethoxy-lH-benzimidazol-2-yl)-N-(4- morpholinophenyl)benzamide Compound 481)
Figure imgf000255_0004
[1346] Compound 481 was prepared from 4-morpholinoaniline and 4-(5- trifluoromethoxy-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C25H21F3N4O3: 483.17; found: 482.93.
EXAMPLE 382
[1347] 4-(5- Aminosulfonyl- lH-benzimidazol-2-yl)-N-(4- morpholinophenyl)benzamide (Compound 482)
Figure imgf000256_0001
[1348] Compound 482 was prepared from 4-morpholinoaniline and 4-(5- aminosulfonyl-lH-benzimidazol-2-yl)benzoate by standard conditions. [M+H]+ calcd for C24H23N5O4S: 478.16; found: 477.93.
EXAMPLE 383
[1349] N-(2-(4-(4-Dimethylaminophenylcarbamoyl)piperidino)- 1H- benzimidazol-5-yl -dimethylaminobenzamide (Compound 483)
Figure imgf000256_0002
[1350] Compound 483 was prepared from 4-dimethylaminoaniline, 4- dimethylaminobenzoate, and 1 -(5-amino- lH-benzimidazol-2-yl)piperidino-4-carboxylic acid by standard conditions. [M+H]+ calcd for C30H35N7O2: 526.29; found: 526.13.
EXAMPLE 384
[1351] N-(4-(4-Ethylaminobenzoyl)phenyl)-4-morpholinobenzamide
(Compound 484)
Figure imgf000256_0003
[1352] Compound 484 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C26H27N3O3: 430.03; found: 430.03. EXAMPLE 385
[1353] N-(4-(4-Aminobenzoyl)phenyl)-4-morpholinobenzamide (Compound
485)
Figure imgf000257_0001
[1354] Compound 485 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C24H23N3O3: 402.08; found: 402.03.
EXAMPLE 386
[1355] N-(4-(4-(2-Thienyl)carboxamido)benzoyl)phenyl)-4-fluorobenzamide (Compound 486)
Figure imgf000257_0002
[1356] Compound 486 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-fluorobenzoate. [M+H]+ calcd for C25H17FN2O3S: 445.00; found: 444.94.
EXAMPLE 387
[1357] N-(l-(4-Cyclopropanecarboxamidophenyl)-lH-indazol-5-yl)-4-(4-iert- butyloxycarbonyl iperazino)benzamide (Compound 487)
Figure imgf000257_0003
[1358] Compound 487 was prepared according to the procedure described in Scheme Γ from 5-amino-l-(4-aminophenyl)indazole and 4-(4-tert- butyloxycarbonylpiperazino)benzoate. [M+H]+ calcd for C33H36N6O4: 581.28; found: 581.15.
EXAMPLE 388
[1359] N-(l-(4-Cyclopropanecarboxamidophenyl)-lH-indazol-5-yl)-4-(4- cyclopropanecarbon lpiperazino)benzamide (Compound 488)
Figure imgf000258_0001
[1360] Compound 488 was prepared according to the procedure described in
Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4- cyclopropanecarbonylpiperazino)benzoate. [M+H]+ calcd for C32H32N6O3: 549.25; found: 549.16.
EXAMPLE 389
[1361] N-(4-(4-(2-Thienylcarboxamido)benzoyl)phenyl)-4- morpholinobenzamide (Compound 489)
Figure imgf000258_0002
[1362] Compound 489 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone and 4-morpholinobenzoate. 1H NMR (500MHz, CD3OD) δ 7.98 (d, / = 5 Hz, 1H), 7.90 (dd, / = 2.5, 10.6 Hz, 6H), 7.82 (m, 4H), 7.76 (d, / = 5 Hz, 1H), 7.20 (t, / = 5 Hz, 1H), 7.03 (d, / = 10.6 Hz, 2H), 3.33 (m, 4H), 2.98 (m, 4H).
EXAMPLE 390
[1363] N-(4-(4-(3-Thienylcarboxamido)benzoyl)phenyl)-4- morpholinobenzamide (Compound 490)
Figure imgf000259_0001
[1364] Compound 490 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H25N3O4S: 512.11; found: 512.09.
EXAMPLE 391
[1365] N-(4-(4-(2-(5-Methylthienyl)carboxamido)benzoyl)phenyl)-4- morpholinobenzamide (Compound 491)
Figure imgf000259_0002
[1366] Compound 491 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C30H27N3O4S: 526.14; found: 526.13.
EXAMPLE 392
[1367] N-(4-(4-(2-Thienyl)carboxamido)benzoyl)phenyl)-4-(2- hydroxyethoxy)benzamide (Compound 492)
H
Figure imgf000259_0003
[1368] Compound 492 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-(2-hydroxyethoxy)benzoate. [M+H]+ calcd for C27H22N2O5S: 487.06; found: 487.05.
EXAMPLE 393
[1369] N-(4-(4-(2-Methoxyethylamino)benzoyl)phenyl)-4- morpholinobenzamide (Compound 493)
Figure imgf000260_0001
[1370] Compound 493 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C27H29N3O4: 460.06; found: 460.12.
EXAMPLE 394
[1371] N-(4-(4-(2-(3-Methylthienyl)carboxamido)benzoyl)phenyl)-4- morpholinobenzamide (Compound 494)
Figure imgf000260_0002
[1372] Compound 494 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C30H27N3O4S: 526.14; found: 526.13.
EXAMPLE 395
[1373] 4-Morpholino-N-(4-(4-(thiophen-2- ylmethylamino)benzoyl)phenyl)benzamide (Compound 495)
Figure imgf000260_0003
[1374] Compound 495 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H27N3O3S: 498.13; found: 498.05.
EXAMPLE 396
[1375] N-(4-(4-(2-(4-Methylthienyl)carboxamido)benzoyl)phenyl)-4- morpholinobenzamide (Compound 496)
Figure imgf000261_0001
[1376] Compound 496 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C30H27N3O4S: 526.14; found: 526.06.
EXAMPLE 397
[1377] 4-Morpholino-N-(4-(4- (cyclopropylmethylamino)benzoyl)phenyl)benzamide (Compound 497)
Figure imgf000261_0002
[1378] Compound 497 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C28H29N3O3: 456.07; found: 456.31.
EXAMPLE 398
[1379] N-(4-(4-(4-Morpholinobenzamido)benzoyl)phenyl)pyrimidine-5- carboxamide (Compound 498)
Figure imgf000261_0003
[1380] Compound 498 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H25N5O4: 508.06; found: 508.04.
EXAMPLE 399
[1381] N-(4-(4-(4-Morpholinobenzamido)benzoyl)phenyl)-lH-pyrrole-2- carboxamide (Compound 499)
Figure imgf000262_0001
[1382] Compound 499 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H26N4O4: 495.06; found: 495.28.
EXAMPLE 400
[1383] 3-Methyl-N-(4-(4-(4-morpholinobenzamido)benzoyl)phenyl)-lH- pyrazole-5-carboxamide (Compound 500)
Figure imgf000262_0002
[1384] Compound 500 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H27N5O4: 510.08; found: 510.06.
EXAMPLE 401
[1385] N-(4-(4-(4-Morpholinobenzamido)benzoyl)phenyl)-lH-pyrazole-4- carboxamide
[1386] (Compound 501)
Figure imgf000262_0003
[1387] Compound 501 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C28H25N5O4: 496.05; found: 496.09.
EXAMPLE 402
[1388] N-(4-(4-(4-(4-Hydroxypiperidin- 1 - yl)benzamido)benzoyl)phenyl)thiophene-2-carboxamide (Compound 502)
Figure imgf000263_0001
[1389] Compound 502 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-(4-hydroxypiperidinyl)benzoate. [M+H]+ calcd for C30H27N3O4S: 526.14; found: 525.99.
EXAMPLE 403
[1390] N-(4-(4-(4-Morpholinobenzamido)benzoyl)phenyl)biphenyl-4- carboxamide (Compound 503)
Figure imgf000263_0002
[1391] Compound 503 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C37H31N3O4: 582.19; found: 582.16.
EXAMPLE 404
[1392] N-(4-(4-(4-(4-Hydroxypiperidin- 1 - yl)benzamido)benzoyl)phenyl)pyridine-4-carboxamide (Compound 504)
Figure imgf000263_0003
[1393] Compound 504 was prepared according to the procedure described in Scheme Γ from 4,4' -diaminobenzophenone and 4-(4-hydroxypiperidinyl)benzoate. [M+H]+ calcd for C31H28N4O4: 521.10; found: 521.06.
EXAMPLE 405
[1394] N-(4-(4-(4-(4-Hydroxypiperidin- 1 - yl)benzamido)benzoyl)phenyl)pyridine-2-carboxamide (Compound 505) OH
Figure imgf000264_0001
[1395] Compound 505 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone and 4-(4-hydroxypiperidinyl)benzoate. [M+H]+ calcd for C31H28N4O4: 521.10; found: 521.06.
EXAMPLE 406
[1396] N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)-lH-pyrrole-2-carboxamide (Compound 506)
Figure imgf000264_0002
[1397] Compound 506 was prepared according to the procedure described Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4-hydroxypiperidin- yl)benzoate. [M+H]+ calcd for C30H28N6O3: 521.22; found: 521.06.
EXAMPLE 407
[1398] (+)-N-(4-(5-(4-(3-Aminopyrrolidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)thiophen -2-carboxamide (Compound 507)
Figure imgf000264_0003
[1399] Compound 507 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(3-aminopyrrolidin-l- yl)benzoate. [M+H]+ calcd for C29H27N6O2S: 523.19; found: 523.02.
EXAMPLE 408
[1400] N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)-lH-pyrazole-3-carboxamide (Compound 508)
Figure imgf000265_0001
[1401] Compound 508 was prepared according to the procedure described Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4-hydroxypiperidin- yl)benzoate. [M+H]+ calcd for C29H27N7O3: 522.22; found: 522.05.
EXAMPLE 409
[1402] N-(4-(5-(4-(4-Hydroxymethylpiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)thiophene-2-carboxamide (Compound 509)
Figure imgf000265_0002
[1403] Compound 509 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4-hydroxymethylpiperidin- l-yl)benzoate. [M+H]+ calcd for C31H29N5O3S: 552.20; found: 552.05.
EXAMPLE 410
[1404] N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)-lH-indole-6-carboxamide (Compound 510)
Figure imgf000265_0003
[1405] Compound 510 was prepared according to the procedure described Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4-hydroxypiperidin- yl)benzoate. [M+H]+ calcd for C34H30N6O3: 571.24; found: 571.16. EXAMPLE 411
[1406] N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)-lH-indole-5-carboxamide Compound 511)
Figure imgf000266_0001
[1407] Compound 511 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4-hydroxypiperidin-l- yl)benzoate. [M+H]+ calcd for C34H30N6O3: 571.24; found: 571.16.
EXAMPLE 412
[1408] N-(4-(5-(4-(4-(2-Hydroxyethyl)piperidin-l-yl)benzamido)-lH-indazol- l-yl)phenyl)thiophene-2-carboxamide (Compound 512)
Figure imgf000266_0002
[1409] Compound 512 was prepared according to the procedure described in Scheme Γ from 5-amino-l-(4-aminophenyl)indazole and 4-(4-(2-hydroxyethyl)piperidin- l-yl)benzoate. [M+H]+ calcd for C32H31N5O3S: 566.21 ; found: 566.11.
EXAMPLE 413
[1410] N-(4-(5-(4-(4-Cyclopropylcarbonylpiperiazin-l-yl)benzamido)-lH- indazol-l-yl)phenyl)thiophene-2-carboxamide (Compound 513)
Figure imgf000266_0003
[1411] Compound 513 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4- cyclopropylcarbonylpiperazin-l-yl)benzoate. [M+H]+ calcd for C33H30N6O3S: 591.21; found: 591.14.
EXAMPLE 414
[1412] N-(4-(5-(4-(4-Mopholinopiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)thiophene-2-carboxamide (Compound 514)
Figure imgf000267_0001
[1413] Compound 514 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4-morpholinopiperidin-l- yl)benzoate. [M+H]+ calcd for C34H35N6O3S: 607.25; found: 607.19.
EXAMPLE 415
[1414] N-(l-(4-Aminophenyl)-lH-indazol-5-yl)-4-(4-hydroxypiperidin-l- yl)benzamide (Com ound 515)
Figure imgf000267_0002
[1415] Compound 515 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4-hydroxypiperidin-l- yl)benzoate. [M+H]+ calcd for C25H25N5O2: 428.20; found: 427.93.
EXAMPLE 416
[1416] N-(4-(5-(4-(4-((l^-Imidazol-l-yl)methyl)-4-hydroxypiperidin-l- yl)benzamido)- lH-indazol- 1 -yl)phenyl)thiophene-2-carboxamide (Compound 516)
Figure imgf000268_0001
[1417] Compound 516 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4-((lH-imidazol-l- yl)methyl)-4-hydroxypiperidin-l-yl)benzoate. [M+H]+ calcd for C34H31N7O3S: 618.22; found: 618.15.
EXAMPLE 417
[1418] 4-Cyano-N-(4-(5-(4-mopholinobenzamido)-lH-indazol-l- yl)phenyl)benzamide (Compound 517)
Figure imgf000268_0002
[1419] Compound 517 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C32H26N6O3: 543.21; found: 543.08.
EXAMPLE 418
[1420] N-(4-(5-(4-(l,4-Dioxa-8-azaspiro[4,5]decan-8-yl)benzamido)-lH- indazol-l-yl)phenyl)thiophene-2-carboxamide (Compound 518)
Figure imgf000268_0003
[1421] Compound 518 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(l,4-dioxa-8- azaspiro[4,5]decan-8-yl)benzoate. [M+H]+ calcd for C32H29N5O4S: 580.19; found: 580.07. EXAMPLE 419
[1422] N-(4-(5-(4-Fluorobenzamido)-lH-indazol-l-yl)phenyl)-lH-indole-5- carboxamide (Compound 519)
Figure imgf000269_0001
[1423] Compound 519 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-fluorobenzoate. [M+H]+ calcd for C29H20FN5O2: 490.16; found: 490.01.
EXAMPLE 420
[1424] (+)-N-(4-(5-(4-(3-Hydroxymethyl)piperidin-l-yl)benzamido)-lH- indazol-l-yl)phenyl)thiophene-2-carboxamide (Compound 520)
Figure imgf000269_0002
[1425] Compound 520 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(3-hydroxymethyl)piperidin- l-yl)benzoate. [M+H]+ calcd for C31H29N5O3S: 552.20; found: 552.07.
EXAMPLE 421
[1426] (+)-N-(l-(4-(4-(Hexahydropyrrolo[l,2-a]pyrazin-2(lH)- izamido)phen l)- lH-indazol-5-yl)thiophene-2-carboxamide (Compound 521)
Figure imgf000269_0003
[1427] Compound 521 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(hexahydropyrrolo[l,2- a]pyrazin-2(lH)-yl)benzoate. [M+H]+ calcd for C32H30N6O2S: 563.22; found: 563.12. EXAMPLE 422
[1428] N-(l -(4-(4-(4-Dimethylaminopiperidin- 1 -yl)benzamido)phi
indazol-5-yl)thiophene-2-carboxamide (Compound 522)
Figure imgf000270_0001
[1429] Compound 522 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4-dimethylaminopiperidin- l-yl))benzoate. [M+H]+ calcd for C32H32N6O2S: 565.23; found: 565.14.
EXAMPLE 423
[1430] N-(4-(5-(lH-Indole-6-carboxamido)-lH-indazol-l-yl)phenyl)-lH- indole-6-carboxamide Compound 523)
Figure imgf000270_0002
[1431] Compound 523 was prepared according to the procedure described in Scheme Γ from 5-amino-l-(4-aminophenyl)indazole and lH-indole-6-carboxylic acid. [M+H]+ calcd for C31H22N6O2: 511.18; found: 511.02.
EXAMPLE 424
[1432] (+)-N-(l-(4-(4-(3-Dimethylaminopyrrolidin-l-yl)benzamido)phenyl)- lH-indazol-5-yl)thiophene-2-carboxamide (Compound 524)
Figure imgf000270_0003
[1433] Compound 524 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(3-dimethylaminopyrrolidin- l-yl)benzoate. [M+H]+ calcd for C31H30N6O2S: 551.22; found: 551.10. EXAMPLE 425
[1434] (±)-N-( 1 -(4-(4-((2-Hydroxyethyl)methylamino)benzamido)phi indazol-5-yl)thiophene-2-carboxamide (Compound 525)
Figure imgf000271_0001
[1435] Compound 525 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-((2- hydroxyethyl)methylamino)benzoate. [M+H]+ calcd for C28H25N5O3S: 512.17; found: 512.02.
EXAMPLE 426
[1436] N-(l -(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)- lH-indazol- 5-yl)thiophene-2-carboxamide Compound 526)
Figure imgf000271_0002
[1437] Compound 526 was prepared according to the procedure described Scheme Γ from 5-amino-l-(4-aminophenyl)indazole and 4-(4-hydroxypiperidin- yl))benzoate. [M+H]+ calcd for C30H27N5O3S: 538.18; found: 538.06.
EXAMPLE 427
[1438] N-(4-(5-(lH-Indole-5-carboxamido)-lH-indazol-l-yl)phenyl)-lH- indole-5-carboxamide Compound 527)
Figure imgf000271_0003
[1439] Compound 527 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and lH-indole-5-carboxylic acid. [M+H]+ calcd for C31H22N6O2: 511.18; found: 511.03.
EXAMPLE 428
[1440] N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)thiophene-2-carboxamide (Compound 528)
Figure imgf000272_0001
[1441] Compound 528 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4-hydroxypiperidin-l- yl)benzoate. [M+H]+ calcd for C30H27N5O3S: 538.18; found: 538.06.
EXAMPLE 429
[1442] 4-Morpholino-N-(4-(5-(4-morpholinobenzamido)-lH-indazol-l- yl)phenyl)piperidine-l-carboxamide (Compound 529)
[1443] Compound 529 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C34H39N7O4: 610.31; found: 610.25.
EXAMPLE 430
[1444] N-(l-(4-Cyclopropylmethylamino)phenyl)-lH-indazol-5-yl)-4- morpholinobenzamide (Compound 530)
Figure imgf000272_0003
[1445] Compound 530 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C28H29N5O2: 468.23; found: 468.08.
EXAMPLE 431
[1446] N-(l-(4-Ethylamino)phenyl)-lH-indazol-5-yl)-4-morpholinobenzamide (Compound 531)
Figure imgf000273_0001
[1447] Compound 531 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C26H27N5O2: 442.22; found: 442.05.
EXAMPLE 432
[1448] Phenyl 4-(5-(4-morpholinobenzamido)-lH-indazol-5- yl)phenylcarbamate (Compound 532)
Figure imgf000273_0002
[1449] Compound 532 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. 1H NMR (500MHz, DMSO-d6) δ 10.49 (s, 1H), 9.97 (s, 1H), 8.97 (s, 1H), 8.03 (d, / = 7.5 Hz, 2H), 7.91 (d, / = 8 Hz, 2H), 7.68 (m, 3H), 7.56 (d, / = 9 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 7.26 (m, 3H), 7.03 (d, / = 7.5 Hz, 2H), 3.74 (m, 4H).
EXAMPLE 433
[1450] N-(4-(5-(4-morpholinobenzamido)- lH-indazol-5- yl)phenyl)morpholine-4-carboxamide (Compound 533)
Figure imgf000274_0001
[1451] Compound 533 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C29H30N6O4: 527.23; found: 527.00.
EXAMPLE 434
[1452] N-(l-(4-Cyclopropanecarboxamido)phenyl)-2-oxoindolin-5-yl)4- dimethylaminobenzamide (Compound 534)
Figure imgf000274_0002
[1453] Compound 534 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)oxindole and 4-dimethylaminobenzoate. [M+H]+ calcd for C27H26N4O3: 455.20; found: 455.00.
EXAMPLE 435
[1454] 4-Morpholino-N-(l-(4-(thiazol-2-ylmethylamino)phenyl)-lH-indazol- 5-yl)benzamide (Compound 535)
Figure imgf000274_0003
[1455] Compound 535 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. 1H NMR (500MHz, CDC13) δ 8.17 (s, 1H), 8.12 (s, 1H), 7.85 (m, 3H), 7.78 (m, 1H), 7.59 (d, / = 9 Hz, 1H), 7.49 (d, / = 8 Hz, 1H), 7.30 (m, 1H), 6.95 (d, / = 8 Hz, 2H), 6.82 (d, / = 8.5 Hz, 2H), 4.76 (s, 2H), 3.89 (t, / = 4 Hz, 4H), 3.29 (t, / = 4.5 Hz, 4H). EXAMPLE 436
[1456] 4-Morpholino-N-( 1 -(4-(thiazol-2-ylmethylideneamino)phe]
indazol-5-yl)benzamide (Compound 536)
Figure imgf000275_0001
[1457] Compound 536 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. No data.
EXAMPLE 437
[1458] 4-Morpholino-N-(l-(4-morpholinophenyl)-lH-indazol-5-yl)benzamide (Compound 537)
Figure imgf000275_0002
[1459] Compound 537 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C28H29N5O3: 484.23; found: 484.11.
EXAMPLE 438
[1460] 4-Morpholino-N-(2-(4-morpholinophenyl)-2H-indazol-5-yl)benzamide (Compound 538)
Figure imgf000275_0003
[1461] Compound 538 was prepared according to the procedure described in Scheme IV from 5-amino-2-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C28H29N5O3: 484.23; found: 484.13. EXAMPLE 439
[1462] (+)-N-(4-(5-(4-(3-Hydroxypyrrolidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)thiophen -2-carboxamide (Compound 539)
Figure imgf000276_0001
[1463] Compound 539 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(3- hydroxypyrrolidinyl)benzoate. [M+H]+ calcd for C29H25N5O3S: 524.17; found: 524.04.
EXAMPLE 440
[1464] 4-Morpholino-N-(2-(4-nitrophenyl)-2H-indazol-5-yl)benzamide (Compound 540)
Figure imgf000276_0002
[1465] Compound 540 was prepared according to the procedure described in Scheme IV from 5-amino-2-(4-nitrophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C24H21N5O4: 444.16; found: 444.27.
EXAMPLE 441
[1466] 4-Morpholino-N-(l-(4-(3-(2-morpholinoethyl)ureido)phenyl)-lH- indazol-5-yl)phenyl) benzamide (Compound 541)
Figure imgf000276_0003
[1467] Compound 541 was prepared according to the procedure described in Scheme Γ from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C31H35N7O4: 570.28; found: 570.21. EXAMPLE 442
[1468] 4-Morpholino-N-(2-(4-acetylphenyl)-2H-indazol-5-yl)benzamide (Compound 542)
Figure imgf000277_0001
[1469] Compound 542 was prepared according to the procedure described in Scheme IV from 5-amino-2-(4-acetylphenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C26H24N4O3: 441.18; found: 441.02.
EXAMPLE 443
[1470] N-(2-(4-Cyanophenyl)-2H-indazol-5-yl)-4-(4-hydroxypiperidin-l- yl)benzamide (Compound 543)
Figure imgf000277_0002
[1471] Compound 543 was prepared according to the procedure described in Scheme IV from 5-amino-2-(4-acetylphenyl)indazole and 4-(4-hydroxypiperidin-l- yl)benzoate. [M+H]+ calcd for C26H23N5O2: 438.19; found: 438.05.
EXAMPLE 444
[1472] N-(4-(5-(Cyclopropanecarboxamido)-lH-indazol-l-yl)phenyl)-4- morpholinobenzamide (Compound 544)
Figure imgf000277_0003
[1473] Compound 544 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C28H27N5O3: 482.21; found: 482.05. EXAMPLE 445
[1474] N-(4-(5-(4-Morpholinobenzamido)-lH-indazol-l-yl)phi
opiperidine-l-carboxamide (Compound 545)
Figure imgf000278_0001
[1475] Compound 545 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C30H30N6O4: 539.23; found: 539.12.
EXAMPLE 446
[1476] 4-Methyl-N-(4-(5-(4-morpholinobenzamido)-lH-indazol-l- yl)phenyl)thiazole-5-carboxamide (Compound 546)
Figure imgf000278_0002
[1477] Compound 546 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C29H26N6O3S: 539.19; found: 539.09.
EXAMPLE 447
[1478] N-(4-(5-(4-Morpholinobenzamido)-lH-indazol-l-yl)phenyl)thiazole-5- carboxamide (Compound 547)
Figure imgf000278_0003
[1479] Compound 547 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. 1H NMR (500MHz, DMSO-d6) δ 10.66 (s, 1H), 10.12 (s, 1H), 9.34 (s, 1H), 8.75 (s, 1H), 8.40 (s, 1H), 8.36 (s, 1H), 7.94 (dd, J = 3, 9 Hz, 4H), 7.87 (d, / = 9 Hz, 1H), 7.81 (m, 3H), 7.05 (d, / = 9 Hz, 2H), 3.76 (m, 4H).
EXAMPLE 448
[1480] N-(4-(5-(4-Morpholinobenzamido)-lH-indazol-l-yl)phenyl)thiazole-2- carboxamide (Compound 548)
Figure imgf000279_0001
[1481] Compound 548 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C28H24N6O3S: 525.16; found: 525.04.
EXAMPLE 449
[1482] N-(l-(4-(l-(Hydroxyimino)ethyl)pheyl)-lH-indazol-5- yl)morpholinobenzamide (Compound 549)
Figure imgf000279_0002
[1483] Compound 549 was prepared according to the procedure described in Scheme Γ from 5-amino-l-(4-acetylphenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C26H25N5O3: 456.20; found: 456.07.
EXAMPLE 450
[1484] 4-Methyl-N-(4-(5-(4-morpholinobenzamido)-lH-indazol-l- yl)phenyl)piperazin -l-carboxamide (Compound 550)
Figure imgf000279_0003
[1485] Compound 550 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C30H33N7O3: 540.26; found: 540.15.
EXAMPLE 451
[1486] (+)-N-(4-(5-(4-(3-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)thiophen -2-carboxamide (Compound 551)
Figure imgf000280_0001
[1487] Compound 551 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(3- hydroxypiperidinyl)benzoate. [M+H]+ calcd for C30H27N5O3S: 538.18; found: 538.06.
EXAMPLE 452
[1488] N-(l-(4-Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-2- morpholinopyrimidine-5-carboxamide (Compound 552)
Figure imgf000280_0002
[1489] Compound 552 was prepared according to the procedure described in Scheme Γ from 5-amino-l-(4-aminophenyl)indazole and 2-morpholino-5- pyrimidinecarboxylate. [M+H]+ calcd for C26H25N7O3: 484.20; found: 484.01.
EXAMPLE 453
[1490] N-(l-(4-Aminophenyl)-lH-indazol-5-yl)-4-(lH-imidazol-l- yl)benzamide (Compoun
Figure imgf000280_0003
[1491] Compound 553 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-imidazolylbenzoate. 1H NMR (500MHz, Acetone-J6) δ 9.78 (s, 1H), 8.45 (s, 1H), 8.20 (m, 4H), 7.82 - 7.67 (m, 5H), 7.42 (d, / = 8.5 Hz, 2H), 7.16 (s, 1H), 6.87 (d, / = 8.5 Hz, 2H), 4.93 (s, 2H).
EXAMPLE 454
[1492] N-(4-(5-(4-(lH-Imidazol-l-yl)benzamido)-lH-indazol-l- yl)phenyl)thiophene- -carboxamide (Compound 554)
Figure imgf000281_0001
[1493] Compound 554 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-imidazolylbenzoate. [M+H]+ calcd for CasHaoNeOaS: 505.15; found: 505.00.
EXAMPLE 455
[1494] N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)pyrimidine-5-carboxamide Compound 555)
Figure imgf000281_0002
[1495] Compound 555 was prepared according to the procedure described Scheme Γ from 5-amino-l-(4-aminophenyl)indazole and 4-(4-hydroxypiperidin- yl)benzoate. [M+H]+ calcd for C30H27N7O3: 534.22; found: 534.09.
EXAMPLE 456
[1496] N-(4-(5-(4-(Tetrahydropyran-4-yl)amino)benzamido)-lH-indazol-l- yl)phenyl)thiophene-2-carboxamide (Compound 556)
Figure imgf000281_0003
[1497] Compound 556 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(tetrahydropyran-4- yl)aminobenzoate. [M+H]+ calcd for C30H28N5O3S: 538.19; found: 538.08.
EXAMPLE 457
[1498] N-(l-(4-Aminophenyl)-lH-indazol-5-yl)-lH-indole-6-carboxamide (Compound 557)
Figure imgf000282_0001
[1499] Compound 557 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and indole-6-carboxylic acid. [M+H]+ calcd for C22H17N5O: 368.14; found: 367.90.
EXAMPLE 458
[1500] N-(l-(4-(Cyclopropylcarboxamido)phenyl)-lH-indazol-5-yl)-lH- indole-6-carboxamide (Compound 558)
Figure imgf000282_0002
[1501] Compound 558 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and indole-6-carboxylic acid. 1H NMR (500MHz, Acetone-d<5) δ 10.64 (s, 1H), 9.65 (m, 2H), 8.79 (s, 1H), 8.54 (m, 1H), 8.21 (m, 2H), 7.91 - 7.67 (m, 8H), 7.54 (m, 1H), 6.58 (m, 1H), 1.82 (m, 1H), 0.94 (m, 2H), 0.82 (m, 2H).
EXAMPLE 459
[1502] N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)-l -meth l- lH-indole-5-carboxamide (Compound 559)
Figure imgf000282_0003
[1503] Compound 559 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(4-hydroxypiperidin-l- yl)benzoate. [M+H]+ calcd for C35H32N6O3: 585.25; found: 585.19.
EXAMPLE 460
[1504] N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-benzimidazol-l- yl)phenyl) cycloprop lcarboxamide (Compound 560)
Figure imgf000283_0001
[1505] Compound 560 was prepared according to the procedure described Scheme IV from 5-amino-l-(4-aminophenyl)benzimidazole and 4-(4-hydroxypiperidin- yl)benzoate. [M+H]+ calcd for C29H29N5O3: 496.24; found: 496.08.
EXAMPLE 461
[1506] N-(4-(5-(lH-Indole-6-carboxamido)-lH-benzimidazol-l-yl)phenyl)- lH-indole-6-carboxamide (Compound 561)
Figure imgf000283_0002
[1507] Compound 561 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)benzimidazole and indole-6-carboxylic acid. [M+H]+ calcd for C31H22N6O2: 511.19; found: 511.01.
EXAMPLE 462
[1508] N-(l-(4-(4-Dimethylaminobenzamido)phenyl)-lH-benzimidazol-5- yl)thiophene-2-carboxamide (Compound 562)
Figure imgf000283_0003
[1509] Compound 562 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)benzimidazole and 4- dimethylaminobenzoate. [M+H]+ calcd for C27H23N5O2S: 482.16; found: 481.98.
EXAMPLE 463
[1510] N-(4-(5-(4-Morpholinobenzamido)-lH-benzimidazol-l- yl)phenyl)cyclopropylcarboxamide (Compound 563)
Figure imgf000284_0001
[1511] Compound 563 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)benzimidazole and 4-morpholinobenzoate. [M+H]+ calcd for C28H27N5O3: 482.22; found: 482.05.
EXAMPLE 464
[1512] N-(4-(5-(lH-Indole-5-carboxamido)-lH-benzimidazol-l-yl)phenyl)- lH-indole-5-carboxamide Compound 564)
Figure imgf000284_0002
[1513] Compound 564 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)benzimidazole and indole-5-carboxylic acid. [M+H]+ calcd for C31H22N6O2: 511.19; found: 511.07.
EXAMPLE 465
[1514] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-(lH-imidazol-l- yl)benzamide) (Compound 565)
Figure imgf000284_0003
[1515] Compound 565 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-(imidazol-l-yl)benzoate. [M+H]+ calcd for C32H25N7O2: 540.21; found 539.97.
EXAMPLE 466
[1516] N,N'-(4,4'-Oxabis(4,l-phenylene))bis(4-(lH-imidazol-l-yl)benzamide) (Compound 566)
Figure imgf000285_0001
[1517] Compound 566 was prepared according to the procedure described in Scheme IV from 4,4'-oxabisphenylamine and 4-(imidazol-l-yl)benzoate. [M+H]+ calcd for C32H24N6O3: 541.20; found 541.05.
EXAMPLE 467
[1518] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-(lH-pyrazol-l- yl)benzamide) (Compound 567)
Figure imgf000285_0002
[1519] Compound 567 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-(pyrazol-l-yl)benzoate. [M+H]+ calcd for C32H25N7O2: 540.21; found 539.97.
EXAMPLE 468
[1520] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-(lH-pyrrol-l- yl)benzamide) (Compound 568)
Figure imgf000285_0003
[1521] Compound 568 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-(pyrrol-l-yl)benzoate. [M+H]+ calcd for C34H27N5O2: 538.22; found 538.09. EXAMPLE 469
[1522] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-hydroxybenzamide) (Compound 569)
Figure imgf000286_0001
[1523] Compound 569 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-hydroxybenzoate. [M+H]+ calcd for C26H21N3O4: 440.15; found 439.94.
EXAMPLE 470
[1524] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(3-hydroxybenzamide) (Compound 569)
Figure imgf000286_0002
[1525] Compound 570 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 3-hydroxybenzoate. [M+H]+ calcd for C26H21N3O4: 440.15; found 493.94.
EXAMPLE 471
[1526] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-methoxybenzamide) (Compound 571)
Figure imgf000286_0003
[1527] Compound 571 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-methoxybenzoate. [M+H]+ calcd for C28H25N3O4: 468.18; found 468.01.
EXAMPLE 472
[1528] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(lH-indole-2-carboxamide) (Compound 572)
Figure imgf000287_0001
[1529] Compound 572 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and indole-2-carboxylic acid. [M+H]+ calcd for C30H23N5O2: 486.19; found 486.10.
EXAMPLE 473
[1530] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-(4- hydroxyphen l)benzamide) (Compound 573)
Figure imgf000287_0002
[1531] Compound 573 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-(4-hydroxyphenyl)benzoate. [M+H]+ calcd for C38H29N3O4: 592.22; found 592.12.
EXAMPLE 474
[1532] N,N'-(4,4'-Oxabis(4,l-phenylene))bis(4-aminobenzamide) (Compound
574)
Figure imgf000287_0003
[1533] Compound 574 was prepared according to the procedure described in Scheme Γ from 4,4'-oxabisphenylamine and 4-aminobenzoate. [M+H]+ calcd for C26H22N4O3: 439.17; found 439.00.
EXAMPLE 475
[1534] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(lH-indole-6-carboxamide) (Compound 575)
Figure imgf000287_0004
[1535] Compound 575 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and indole-6-carboxylic acid. [M+H]+ calcd for C30H23N5O2: 486.19; found 486.03.
EXAMPLE 476
[1536] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(lH-indole-5-carboxamide) (Compound 576)
Figure imgf000288_0001
[1537] Compound 576 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and indole-5-carboxylic acid. [M+H]+ calcd for C30H23N5O2: 486.19; found 486.03.
EXAMPLE 477
[1538] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-(2- hydroxyethylamino benzamide) (Compound 577)
Figure imgf000288_0002
[1539] Compound 577 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-(2-hydroxyethylamino)benzoate. [M+H]+ calcd for C30H32N5O4: 526.25; found: 526.08.
EXAMPLE 478
[1540] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4- methanesulfonamidobenzamide (Compound 578)
Figure imgf000288_0003
[1541] Compound 578 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-methanesulfonamidobenzoate. [M+H]+ calcd for C28H27N5O6S2: 594.14; found 594.00. EXAMPLE 479
[1542] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-icri- butyloxycarboxamidobenzamide (Compound 579)
Figure imgf000289_0001
[1543] Compound 579 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-te/t-butyloxycarboxamidobenzoate. [M+H]+ calcd for C36H39N5O6: 638.29; found 638.20.
EXAMPLE 480
[1544] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-aminobenzamide) (Compound 580)
Figure imgf000289_0002
[1545] Compound 580 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-aminobenzoate. [M+H]+ calcd for C26H23N5O2: 438.19; found 438.05.
EXAMPLE 481
[1546] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-(2- aminoacetamidobenzamide (Compound 581)
Figure imgf000289_0003
[1547] Compound 581 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-(2-aminoacetamido)benzoate. [M+H]+ calcd for C30H29N7O4: 552.23; found 552.12.
EXAMPLE 482
[1548] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(l-methyl-lH-indole-5- carboxamide) (Compound 582)
Figure imgf000290_0001
[1549] Compound 582 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and l-methylindole-5-carboxylic acid. [M+H]+ calcd for C32H27N5O2: 514.22; found 514.11.
EXAMPLE 483
[1550] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(thiophene-2-carboxamide) (Compound 583)
Figure imgf000290_0002
[1551] Compound 583 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and thiophene-2-carboxylic acid. [M+H]+ calcd for C22H17N3O2S2: 420.08; found 419.91.
EXAMPLE 484
[1552] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(4-pyrrolidinebenzamide) (Compound 584)
Figure imgf000290_0003
[1553] Compound 584 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-pyrrolidinebenzoate. [M+H]+ calcd for C34H35N5O2: 546.28; found 546.07.
EXAMPLE 485
[1554] N,N'-(4,4'-Oxabis(4,l-phenylene))bis(lH-indole-5-carboxamide) (Compound 585)
Figure imgf000290_0004
[1555] Compound 585 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and indole-5-carboxylic acid. [M+H]+ calcd for C30H22N4O3: 487.17; found 486.98.
EXAMPLE 486
[1556] N,N'-(4,4'-Oxabis(4,l-phenylene))bis(4-N-methyl-N-(2- hydroxyethyl)aminobenzamide) (Compound 586)
Figure imgf000291_0001
[1557] Compound 586 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-iV-methyl-iV-(2- hydroxyethyl)aminobenzoate. [M+H]+ calcd for C32H34N4O5: 555.25; found 555.12.
EXAMPLE 487
[1558] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(l-methyl-l,4- benzoxazine-6-carboxamide) (Compound 587)
Figure imgf000291_0002
[1559] Compound 587 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 1 -methyl- l,4-benzoxazine-6-carboxylic acid. [M+H]+ calcd for C32H31N5O4: 550.24; found 550.05.
EXAMPLE 488
[1560] N,N'-(4,4'-Carbonylbis(4,l-phenylene))bis(4-aminobenzamide) (Compound 588)
Figure imgf000291_0003
[1561] Compound 588 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone and 4-aminobenzoate. [M+H]+ calcd for C27H22N4O3: 451.17; found 450.94. EXAMPLE 489
[1562] N,N'-(4,4'-Carbonylbis(4,l-phenylene))bis(4-fert- butyloxycarbamidobenzamide (Compound 589)
Figure imgf000292_0001
[1563] Compound 589 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4— tert-butyloxycarbamidobenzoate. [M+H]+ calcd for C37H38N4O7: 651.27; found 651.10.
EXAMPLE 490
[1564] N,N'-(4,4'-Azanediylbis(4,l-phenylene))bis(lH-benzimidazole-5- carboxamide) (Compound 590
Figure imgf000292_0002
[1565] Compound 590 was prepared according to the procedure described in Scheme Γ from 4,4'-diaminodiphenylamine and benzimidazole-5-carboxylic acid. [M+H]+ calcd for C28H21N7O2: 488.18; found 488.02.
EXAMPLE 491
[1566] 4-(4-Cyclopropylcarbonyl)piperazin-l-yl-iV-(4-(4- ethylaminobenzoyl)phenyl)benzamide (Compound 591)
Figure imgf000292_0003
[1567] Compound 591 was prepared according to the procedure described Scheme IV from 4,4' -diaminobenzophenone and (4-(4-cyclopropylcarbonyl)piperazin- yl)benzoate. [M+H]+ calcd for C30H32N4O3: 497.12; found: 497.33. EXAMPLE 492
[1568] 4-Morpholino-N-(4-(4-diethylaminobenzoyl)phenyl)benzamide (Compound 592)
Figure imgf000293_0001
[1569] Compound 592 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C28H31N3O3: 458.09; found: 458.31.
EXAMPLE 493
[1570] 4-Morpholino-N-(4-(4-propylaminobenzoyl)phenyl)benzamide (Compound 593)
Figure imgf000293_0002
[1571] Compound 593 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C27H29N3O3: 444.06; found: 444.31.
EXAMPLE 494
[1572] 4-Morpholino-N-(4-(4-allylaminobenzoyl)phenyl)benzamide
(Compound 594)
Figure imgf000293_0003
[1573] Compound 594 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C27H27N3O3: 442.04; found: 442.30. EXAMPLE 495
[1574] 4-Morpholino-N-(4-(4-(furan-2- carboxamido)benzoyl)phenyl)benzamide (Compound 595)
Figure imgf000294_0001
[1575] Compound 595 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H25N3O5: 496.05; found: 496.09.
EXAMPLE 496
[1576] N-(l-(4-Acetylpheyl)-lH-indazol-5-yl)morpholinobenzamide
(Compound 596)
Figure imgf000294_0002
[1577] Compound 596 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-acetylphenyl)indazole and 4-morpholinobenzoate. [M+H]+ calcd for C26H24N4O3: 441.18; found: 441.02.
EXAMPLE 497
[1578] 4-Morpholino-N-(4-(4-(pyridine-4- carboxamido)benzoyl)phenyl)benzamide (Compound 597)
Figure imgf000294_0003
[1579] Compound 597 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C30H27N4O4: 507.20; found: 507.02. EXAMPLE 498
[1580] 4-Morpholino-N-(4-(4-(pyridine-3- carboxamido)benzoyl)phenyl)benzamide (Compound 598)
Figure imgf000295_0001
[1581] Compound 598 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C30H26N4O4: 507.08; found: 507.09.
EXAMPLE 499
[1582] 4-Morpholino-N-(4-(4-(2- methoxycarbonylethyl)aminobenzoyl)phenyl)benzamide (Compound 599)
Figure imgf000295_0002
[1583] Compound 599 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C28H29N3O5: 488.07; found: 488.08.
EXAMPLE 500
[1584] 4-Morpholino-N-(4-(4-(isoxazole-5- carboxamido)benzoyl)phenyl)benzamide (Compound 600)
Figure imgf000295_0003
[1585] Compound 600 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C28H24N4O5: 497.04; found: 497.03. EXAMPLE 501
[1586] 4-(4-Cyclopropylcarbonyl)piperazin-l-yl-N-(4-(4- aminobenzoyl)phenyl)benzamide (Compound 601)
Figure imgf000296_0001
[1587] Compound 601 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and (4-(4-cyclopropylcarbonyl)piperazin-l- yl)benzoate. [M+H]+ calcd for C28H28N4O3: 469.07; found: 469.09.
EXAMPLE 502
[1588] 4-Morpholino-N-(4-(4-(l,2,4-triazole-3- carboxamido)benzoyl)phenyl)benzamide (Compound 602)
Figure imgf000296_0002
[1589] Compound 602 was prepared according to the procedure described in Scheme lY from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C27H24N6O4: 497.04; found: 497.03.
EXAMPLE 503
[1590] 4-Morpholino-N-(4-(4-(pyridazine-4- carboxamido)benzoyl)phenyl)benzamide (Compound 603)
Figure imgf000296_0003
[1591] Compound 603 was prepared according to the procedure described in Scheme lY from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H25N5O4: 508.06; found: 508.04. EXAMPLE 504
[1592] 4-Morpholino-N-(4-(4-(3-cyclopropylpyrazole-5- carboxamido)benzoyl)phenyl)benzamide (Compound 604)
Figure imgf000297_0001
[1593] Compound 604 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C31H30N5O4: 536.23; found: 536.10.
EXAMPLE 505
[1594] 4-Morpholino-N-(4-(4-(l,2,3-thiodiazol-4- carboxamido)benzoyl)phenyl)benzamide (Compound 605)
Figure imgf000297_0002
[1595] Compound 605 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C27H23N5O4S: 514.09; found: 514.04.
EXAMPLE 506
[1596] 4-Morpholino-N-(4-(4-(thiazole-4- carboxamido)benzoyl)phenyl)benzamide (Compound 606)
Figure imgf000297_0003
[1597] Compound 606 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C28H24N4O4S: 513.10; found: 513.03. EXAMPLE 507
[1598] 4-Morpholino-N-(4-(4-(imidazole-4- carboxamido)benzoyl)phenyl)benzamide (Compound 607)
Figure imgf000298_0001
[1599] Compound 607 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C28H26N5O4: 496.20; found: 496.02.
EXAMPLE 508
[1600] 4-Morpholino-N-(4-(4-(5-methylisoxazole-3- carboxamido)benzoyl)phenyl)benzamide (Compound 608)
Figure imgf000298_0002
[1601] Compound 608 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H26N4O5: 511.06; found: 511.07.
EXAMPLE 509
[1602] 4-Morpholino-N-(4-(4-(oxazole-4- carboxamido)benzoyl)phenyl)benzamide (Compound 609)
Figure imgf000298_0003
[1603] Compound 609 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C28H24N4O5: 497.04; found: 497.03. EXAMPLE 510
[1604] 4-Morpholino-N-(4-(4-(l,2,3-triazole-4- carboxamido)benzoyl)phenyl)benzamide (Compound 610)
Figure imgf000299_0001
[1605] Compound 610 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C27H24N6O4: 497.04; found: 497.03.
EXAMPLE 511
[1606] 4-Morpholino-N-(4-(4-(pyridine-2- carboxamido)benzoyl)phenyl)benzamide (Compound 611)
Figure imgf000299_0002
[1607] Compound 611 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C30H26N4O4: 507.08; found: 507.02.
EXAMPLE 512
[1608] 4-Morpholino-N-(4-(4-(pyridazine-3- carboxamido)benzoyl)phenyl)benzamide (Compound 612)
Figure imgf000299_0003
[1609] Compound 612 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H25N5O4: 508.06; found: 508.29. EXAMPLE 513
[1610] 4-Morpholino-N-(4-(4-(l -methyl- lH-pyrazole-3- carboxamido)benzoyl)phenyl)benzamide (Compound 613)
Figure imgf000300_0001
[1611] Compound 613 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H27N5O4: 510.08; found: 510.06.
EXAMPLE 514
[1612] 4-Morpholino-N-(4-(4-(pyrazine-2- carboxamido)benzoyl)phenyl)benzamide (Compound 614)
Figure imgf000300_0002
[1613] Compound 614 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C29H25N5O4: 508.06; found: 508.04.
EXAMPLE 515
[1614] 4-Morpholino-N-(4-(4-(thiophene-2- carbanylcarboxamido)benzoyl)phenyl)benzamide (Compound 615)
Figure imgf000300_0003
[1615] Compound 615 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C30H25N3O5S: 540.12; found: 540.03. EXAMPLE 516
[1616] 4-Morpholino-N-(4-(4-acetylcarboxamido)benzoyl)phenyl)benzamide (Compound 616)
Figure imgf000301_0001
[1617] Compound 616 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C27H25N3O5: 472.03; found: 472.06.
EXAMPLE 517
[1618] 3-Chloro-4-morpholino-N-(4-(4-aminobenzoyl)phenyl)benzamide (Compound 617)
Figure imgf000301_0002
[1619] Compound 617 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 3-chloro-4-morpholinobenzoate. [M+H]+ calcd for C24H23CIN3O3: 436.14; found: 435.97.
EXAMPLE 518
[1620] 3-Chloro-4-morpholino-N-(4-(4-(thiophene-2- carboxamido)benzoyl)phenyl)benzamide (Compound 618)
Figure imgf000301_0003
[1621] Compound 618 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 3-chloro-4-morpholinobenzoate. [M+H]+ calcd for C29H25CIN3O4S: 546.13; found: 546.08. EXAMPLE 519
[1622] 4-Morpholino-N-(4-(4-(2,6-dichloropyridine-4- carboxamido)benzoyl)phenyl)benzamide (Compound 619)
Figure imgf000302_0001
[1623] Compound 619 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C30H24CI2N4O4: 576.07; found: 576.15.
EXAMPLE 520
[1624] 4-Morpholino-N-(4-(4-(2-chloro-6-methylpyridine-4- carboxamido)benzoyl)phenyl)benzamide (Compound 620)
Figure imgf000302_0002
[1625] Compound 620 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C31H27CIN4O4: 556.05; found: 556.17.
EXAMPLE 521
[1626] 4-Morpholino-N-(4-(4-(2-chloropyridine-4- carboxamido)benzoyl)phenyl)benzamide
[1627] (Compound 621)
Figure imgf000302_0003
[1628] Compound 621 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone and 4-morpholinobenzoate. [M+H]+ calcd for C30H25CIN4O4: 542.02; found: 541.92. EXAMPLE 522
[1629] 4-(6-(2-Methylthiazol-4-ylmethoxy)-lH-benzo[J]imidazol-2-yl)-N-(4- morpholinophenyl)
[1630] benzamide Compound 622)
Figure imgf000303_0001
[1631] Compound 622 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(2-methylthiazol-4-yl)methoxy-3,4-dinitrobenzene and 4- (4-(4-morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C29H27N5O3S: 526.18; found: 526.06.
EXAMPLE 523
[1632] 4-(Cyclopropanecarboxamido)-N-(4-(N-(4-(4- (cyclopropanecarboxamido)benzamido)phenyl)cyclopanecarboxamido)phenyl)benzamide (Compound 62
Figure imgf000303_0002
[1633] Compound 623 was prepared by a general amide formation reaction from cyclopropanecarboxylic acid and compound 580. [M+H]+ calcd for C38H35N5O5: 642.26; found 642.19.
EXAMPLE 524
[1634] 4-(6-(Pyridin-2-ylmethoxy)-lH-benzo[J]imidazol-2-yl)-N-(4- morpholinophenyl)benzamide (Compound 624)
Figure imgf000303_0003
[1635] Compound 624 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(pyridin-2-ylmethoxy)-3,4-dinitrobenzene and 4-(4-(4- morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C30H27N5O3: 506.21 ; found: 506.06.
EXAMPLE 525
[1636] 4-(Dimethylamino)-N-(4-(4-(6-methoxy-lH-benzo[J]imidazol-2- yl)benzamido)phen l)benzamide (Compound 625)
Figure imgf000304_0001
[1637] Compound 625 was prepared according to the procedure similar to that described in Scheme ΠΙ from 4-(6-methoxy-lH-benzo[d]imidazol-2-yl)benzoic acid, 1,4- phenylenediamine, and 4dimethylaminobenzoic acid. [M+H]+ calcd for C30H27N5O3: 506.21 ; found: 506.05.
EXAMPLE 526
[1638] 4-(Dimethylamino)-N-(4-(6-(4-(dimethylamino)benzamido)-lH-indol- 3-yl)phenyl)benzamide (Compound 626)
Figure imgf000304_0002
[1639] Compound 626 was prepared according to the procedure described in Scheme Γ from 6-amino-3-(4-aminophenyl)-lH- indole and 4-dimethylaminobenzoate. [M+H]+ calcd for C32H31N5O2: 518.15; found: 518.09.
EXAMPLE 527
[1640] N,N'-((Methylazanediyl)bis(4,l-phenylene))bis(4- dimethylaminobenzamide) (Compound 627)
Figure imgf000304_0003
[1641] Compound 627 was prepared by reductive methylation of compound
580. EXAMPLE 528
[1642] 4-(6-((3-Methyl-l,2,4-oxadiazol-5-yl)methoxy)-lH-benzo[J]imidazol- 2-yl)-N-(4-morpholinophenyl)benzamide (Compound 628)
Figure imgf000305_0001
[1643] Compound 628 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(3-methyl-l,2,4-oxadiazol-5-yl)methoxy-3,4- dinitrobenzene and 4-(4-(4-morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C2SRMOA: 511.20; found: 511.04.
EXAMPLE 529
[1644] 4-(6-((5-Methylisoxazol-3-yl)methoxy)-lH-benzo[J]imidazol-2-yl)-N- (4-morpholinophen l)benzamide (Compound 629)
Figure imgf000305_0002
[1645] Compound 629 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(5-methylisoxazol-3-yl)methoxy-3,4-dinitrobenzene and 4-(4-(4-morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C29H27N5O4: 510.21 ; found: 510.06.
EXAMPLE 530
[1646] 4-(6-((5-Cyclopropyl-l,3,4-oxadiazol-2-yl)methoxy)-lH- benzo[d]imidazol-2- l)-N-(4-morpholinophenyl)benzamide (Compound 630)
Figure imgf000305_0003
[1647] Compound 630 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(5-cyclopropyl-l,3,4-oxadiazol-2-yl)methoxy-3,4- dinitrobenzene and 4-(4-(4-morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for CsoHasNeC^: 537.22; found: 537.06. EXAMPLE 531
[1648] 4-(Dimethylamino)-N-(2-(4-dimethylaminophenyl)-lH-imidazo[4,5- b]pyridin-6-yl)benzamide (Compound 631)
Figure imgf000306_0001
[1649] Compound 631 was prepared according to the procedure similar to that described in Scheme ΙΠ from 4-dimethylaminobenzoic acid and 6-amino-2-(4- dimethylaminophenyl)-lH-imidazo[4,5-b]pyridine. [M+H]+ calcd for C23H24N6O: 401.20; found 401.07.
EXAMPLE 532
Figure imgf000306_0002
[1650] Compound 632 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-allyloxy-3,4-dinitrobenzene and 4-(4-(4- morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C27H26N4O3: 455.21; found: 455.00.
EXAMPLE 533
[1651] 2-(4-Methoxyphenyl)-5-methyl-N-(2-(4-morpholinophi
benzo[d]imidazol- -yl)- lH-imidazole-4-carboxamide (Compound 633)
Figure imgf000306_0003
[1652] Compound 633 was prepared according to the procedure similar to that described in Scheme ΙΠ from 2-(4-methoxyphenyl)-lH-imidazole-4-carboxylic acid and 6-amino-2-(4-morpholinophenyl)benzimidazole. [M+H]+ calcd for C29H28N6O3: 509.22; found 509.11. EXAMPLE 534
[1653] 4-(5-Methoxy-lH-imidazo[4,5-b]pyridin-2-yl)-N-(4- morpholinophenyl)benzamide (Compound 632)
Figure imgf000307_0001
[1654] Compound 634 was prepared according to the procedure similar to that described in Scheme ΠΙ from 4-(5-methoxy-lH-imidazo[4,5-b]pyridin-2-yl)benzoic acid and 4-morpholinoaniline. [M+H]+ calcd for C24H23N5O3: 430.18; found 429.96.
EXAMPLE 535
[1655] N-Cyclopropyl-4-(6-methoxy-lH-benzo[d]imidazol-2-yl)benzamide (Compound 635)
Figure imgf000307_0002
[1656] Compound 635 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-methoxy-3,4-dinitrobenzene and 4- cyclopropylaminocarbonylbenzaldehyde. [M+H]+ calcd for C18H17N3O2: 308.14; found: 308.16.
EXAMPLE 536
[1657] N-(lH-indazol-5-yl)-4-(6-methoxy-lH-benzo[J]imidazol-2- yl)benzamide (Compound 636
Figure imgf000307_0003
[1658] Compound 636 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-methoxy-3,4-dinitrobenzene and 4-(lH-indazol-5- yl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C22H17N5O2: 384.15; found: 384.20.
EXAMPLE 537
[1659] 4-(6-(2-Methoxyethyloxy)-lH-benzo[J]imidazol-2-yl)-N-(4- morpholinophenyl)benzamide Compound 637)
Figure imgf000307_0004
[1660] Compound 637 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(2-methoxyethyloxy)-3,4-dinitrobenzene and 4-(4-(4- morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C27H28N4O4: 473.21 ; found: 473.08.
EXAMPLE 538
[1661] 4-(5-(Benzo[J]thiazol-2-yl)-lH-benzo[J]imidazol-2-yl)-N-(4- morpholinophenyl)benzamide Compound 638)
Figure imgf000308_0001
[1662] Compound 638 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(benzothiazol-2-yl)-3,4-dinitrobenzene and 4-(4-(4- morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C31H25N5O2S: 532.18; found:532.07.
EXAMPLE 539
[1663] 4-(6-Benzyloxy-lH-benzo[J]imidazol-2-yl)-N-(4- morpholinophenyl)benzamide
[1664] (Compound 639)
Figure imgf000308_0002
[1665] Compound 639 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-benzyloxy-3,4-dinitrobenzene and 4-(4-(4- morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C27H28N4O4: 473.21 ; found: 473.08.
EXAMPLE 540
[1666] 4-(6-Cyclopropylmethoxy-lH-benzo[(i]imidazol-2-yl)-N-(4- morpholinophenyl)benzamide (Compound 640)
Figure imgf000308_0003
[1667] Compound 640 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-cyclorpopylmethoxy-3,4-dinitrobenzene and 4-(4-(4- morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C28H28N4O3: 469.22; found: 469.03.
EXAMPLE 541
[1668] 4-(6-(4-Cyanobenzyloxy)-lH-benzo[J]imidazol-2-yl)-N-(4- morpholinophen l)benzamide (Compound 641)
Figure imgf000309_0001
[1669] Compound 641 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(4-cyanobenzyloxy)-3,4-dinitrobenzene and 4-(4-(4- morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C32H27N5O3: 530.21 ; found: 530.10.
EXAMPLE 542
[1670] 4-(6-(2-(Morpholinoethyloxy)-lH-benzo[J]imidazol-2-yl)-N-(4- morpholinophenyl benzamide (Compound 642)
Figure imgf000309_0002
[1671] Compound 642 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(2-morpholinoethyloxy)-3,4-dinitrobenzene and 4-(4-(4- morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C30H33N5O4: 528.25; found: 528.15.
EXAMPLE 543
[1672] 4-(6-(2-(Diethylamino)ethyloxy)-lH-benzo[J]imidazol-2-yl)-N-(4- morpholinophen l)benzamide (Compound 643)
Figure imgf000309_0003
[1673] Compound 643 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(2-diethylaminoethyloxy)-3,4-dinitrobenzene and 4-(4-(4- morpholinophenyl)aminocarbonylbenzaldehyde. [M+H]+ calcd for C30H35N5O3: 514.27; found: 514.13.
EXAMPLE 544
[1674] (N-(4-(6-Phenyl-lH-benzo[J]imidazol-2-yl)phenyl)-lH-pyrrole-2- carboxamide (Compound
Figure imgf000310_0001
[1675] Compound 644 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-phenyl-3,4-dinitrobenzene, 4-nitrobenzaldehyde, and 2- pyrrolecarboxylic acid. [M+H]+ calcd for C24Hi8N40: 379.15; found: 378.96.
EXAMPLE 545
[1676] l-Methyl-(N-(4-(6-phenyl-lH-benzo[J]imidazol-2-yl)phenyl)-lH- pyrrole-2-carboxamide (Compound 645)
Figure imgf000310_0002
[1677] Compound 645 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-phenyl-3,4-dinitrobenzene, 4-nitrobenzaldehyde, and 1- methylpyrrole-2-carboxylic acid. [M+H]+ calcd for C25H2oN40: 393.17; found: 392.99.
EXAMPLE 546
[1678] (4-(6-(3-Hydroxyphenyl)-lH-benzo[J]imidazol-2-yl)-N-lH-indol-6- yl)benzamide (Compound 646)
Figure imgf000310_0003
[1679] Compound 646 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(3-hydroxyphenyl)-3,4-dinitrobenzene and 4-(6- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C28H2oN402: 445.16; found: 445.00. EXAMPLE 547
[1680] (4-(6-(4-Hydroxyphenyl)-lH-benzo[J]imidazol-2-yl)-N-lH-indol-6- yl)benzamide (Compound 647
Figure imgf000311_0001
[1681] Compound 647 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(4-hydroxyphenyl)-3,4-dinitrobenzene and 4-(6- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C28H20N4O2: 445.16; found: 445.00.
EXAMPLE 548
[1682] (4-(6-(4-Methoxyphenyl)-lH-benzo[J]imidazol-2-yl)-N-lH-indol-6- yl)benzamide (Compound 648
Figure imgf000311_0002
[1683] Compound 648 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(4-methoxyphenyl)-3,4-dinitrobenzene and 4-(6- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C29H22N4O2: 459.17; found: 458.97.
EXAMPLE 549
[1684] (4-(6-(4-Hydroxyphenyl)-lH-benzo[J]imidazol-2-yl)-N-(4- morpholinophenyl)benzamide (Compound 649)
Figure imgf000311_0003
[1685] Compound 649 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(4-hydroxyphenyl)-3,4-dinitrobenzene and 4-(4- morpholinopheyl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C30H26N4O3: 491.20; found: 491.03. EXAMPLE 550
[1686] N-(l^-indol-6-yl)-4-(6-(P idin-3-yl)-lH-benzo[J]imidazol-2-yl)- benzamide (Compound 650
Figure imgf000312_0001
[1687] Compound 650 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(3-pyridinyl)-3,4-dinitrobenzene and 4-(6- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C27H19N5O: 430.16; found: 429.96.
EXAMPLE 551
4-(6-(3,5-Dimethylisoxazol-4-yl)-lH-benzo[J]imidazol-2-yl)-N-(lH-indol-6- yl)benzamide (Compoun
Figure imgf000312_0002
[1688] Compound 651 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(3,5-dimethylisoxazol-4-yl)-3,4-dinitrobenzene and 4-(6- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C27H21N5O2: 448.17; found: 447.97.
EXAMPLE 552
(4-(6-(4-Methoxyphenyl)-lH-benzo[(i]imidazol-2-yl)-N-(4-morpholinophenyl)benzamide (Compound 652)
Figure imgf000312_0003
[1689] Compound 652 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(4-methoxyphenyl)-3,4-dinitrobenzene and 4-(4- morpholinopheyl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C31H28N4O3: 505.22; found: 505.07.
EXAMPLE 553 4-(6-((5-Cyanothiophen-2-yl)methoxy)-lH-benzo[(i]imidazol-2-yl)-N-(4- morpholinophenyl)benzamide (Compound 653)
Figure imgf000313_0001
[1690] Compound 653 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(5-cyanothiophen-2-yl)methoxy)-3,4-dinitrobenzene and 4-(4-morpholinopheyl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C30H25N5O3S: 536.17; found: 536.05.
EXAMPLE 554
N-(lH-Indol-5-yl)-4-(6-methox - lH-benzo[d]imidazol-2-yl)benzamide (Compound 654)
Figure imgf000313_0002
[1691] Compound 654 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitroanisole and 4-(5- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C23Hi8N402: 383.14; found: 383.01.
EXAMPLE 555
N-(l-Methylindol-5-yl)-4-(6-methoxy-lH-benzo[(i]imidazol-2-yl)benzamide (Compound 655)
Figure imgf000313_0003
[1692] Compound 655 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitroanisole and 4-(5-(l- methylindolyl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C24H20N4O2: 397.16; found: 396.97.
EXAMPLE 556
4-(6-((3-Methyl-l,2,4-oxadiazol-5-yl)methoxy)-lH-benzo[J]imidazol-2-yl)-N-(l-methyl- lH-indol-5-yl)benzamide (Compound 656)
Figure imgf000314_0001
[1693] Compound 656 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(3-methyl-l,2,4-oxadiazol-5-yl)methoxy-3,4- dinitrobenzene and 4-(5-(l-methylindolyl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C27H22N6O3: 479.18; found: 479.01.
EXAMPLE 557
N-(4-(l,4-Dioxa-8-azaspiro[4.5]decan-8-yl)phenyl)-4-(6-methoxy-lH-benzo[(i]imidazol- 2-yl)benzamide (Compound 657)
Figure imgf000314_0002
[1694] Compound 657 was prepared according to the procedure similar to that described in Scheme ΙΠ from 3,4-dinitroanisole and 4-(4-(l,4-dioxa-8-azaspiro[4.5]decan- 8-yl)phenyl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C28H28N4O4: 485.21 ; found: 485.09.
EXAMPLE 558
4-(6-Methoxy-lH-benzo[<i]imidazol-2-yl)-N-(l-methylindolin-5-yl)benzamide
(Compound 658)
Figure imgf000314_0003
[1695] Compound 658 was prepared according to the procedure similar to that described in Scheme ΠΙ from 3,4-dinitroanisole and 4-(5-(l- methylindolinyl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C24H22N4O2: 399.17; found: 398.99.
EXAMPLE 559
4- (6-((3-Methyl-l,2,4-oxadiazol-5-yl)methoxy)-lH-benzo[J]imidazol-2-yl)-N-(lH-indol-
5- yl)benzamide (Compound 659)
Figure imgf000315_0001
[1696] Compound 659 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(3-methyl-l,2,4-oxadiazol-5-yl)methoxy-3,4- dinitrobenzene and 4-(5-indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C26H20N6O3: 465.16; found: 464.98.
EXAMPLE 560
4-(6-((3-Methyl-l,2,4-oxadiazol-5-yl)methoxy)-lH-benzo[J]imidazol-2-yl)-N-(lH-indol- 6-yl)benzamide (Compound 660)
Figure imgf000315_0002
[1697] Compound 660 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(3-methyl-l,2,4-oxadiazol-5-yl)methoxy-3,4- dinitrobenzene and 4-(6-indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C26H20N6O3: 465.16; found: 465.04.
EXAMPLE 561
4-(6-(2-Methoxyethoxy)-lH-benzo[<i]imidazol-2-yl)-N-(lH-indol-5-yl)benzamide (Compound 661)
Figure imgf000315_0003
[1698] Compound 661 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-(5- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C25H22N4O3: 427.17; found: 426.99.
EXAMPLE 562
4-(6-(2-Methoxyethoxy)-lH-benzo[J]imidazol-2-yl)-N-(2-methyl-lH-indol-5- yl)benzamide (Compound 662)
Figure imgf000316_0001
[1699] Compound 662 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-(2-methyl-5- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C26H24N4O3: 441.18; found: 441.02.
EXAMPLE 563
4-(6-(2-Methoxyethoxy)-lH-benzo[<i]imidazol-2-yl)-N-(lH-indol-2-yl)benzamide (Compound 663)
Figure imgf000316_0002
[1700] Compound 663 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-(2- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C25H22N4O3: 427.17; found: 426.99.
EXAMPLE 564
4-(6-(2-Methoxyethoxy)-lH-benzo[<i]imidazol-2-yl)-N-(lH-indol-6-yl)benzamide (Compound 664)
Figure imgf000316_0003
[1701] Compound 664 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-(6- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C25H22N4O3: 427.17; found: 426.99.
EXAMPLE 565
4-(6-(2-Methoxyethoxy)-lH-benzo[(i]imidazol-2-yl)-N-(lH-pyrrolo[2,3-b]pyridin-5- yl)benzamide (Compound 665
Figure imgf000316_0004
[1702] Compound 665 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-(lH- pyrrolo[2,3-b]pyridin-5-yl)aminocarbonyl)benzaldehyde. 1H NMR (500MHz, CD3OD) δ 8.45 (s, 1H), 8.35 (s, 1H), 8.19 (d, / = 8.5 Hz, 2H), 8.15 (d, / = 8.5 Hz, 2H), 7.55 (d, / = 9 Hz, 1H), 7.42 (d, / = 3.5 Hz, 1H), 7.15 (s, 1H), 7.05 (d, / = 9 Hz, 1H), 6.51 (d, / = 3.5 Hz, 1H), 4.19 (t, / = 4.5 Hz, 2H), 3.79 (t, / = 4.5 Hz, 2H), 3.31 (s, 3H).
EXAMPLE 566
4-(6-(2-Methoxyethoxy)-lH-benzo[<i]imidazol-2-yl)-N-(2-oxoindolin-5-yl)benzamide (Compound 666)
Figure imgf000317_0001
[1703] Compound 666 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-((2- oxoindolin-5-yl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C25H22N4O4: 443.16; found: 443.05.
EXAMPLE 567
4-(6-(2-Methoxyethoxy)-lH-benzo[(i]imidazol-2-yl)-N-(lH-pyrrolo[2,3-b]pyridin-6- yl)benzamide (Compound 667)
Figure imgf000317_0002
[1704] Compound 667 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-(lH- pyrrolo[2,3-b]pyridin-6-yl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C24H2iNs03: 428.17; found: 428.00.
EXAMPLE 568
4-(6-(2-Methoxyethoxy)-lH-benzo[(i]imidazol-2-yl)-N-(lH-pyrrolo[3,2-c]pyridin-6- yl)benzamide (Compound 668
Figure imgf000317_0003
[1705] Compound 668 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-(lH- pyrrolo[3,2-c]pyridin-6-yl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C24H21N5O3: 428.17; found: 428.07.
EXAMPLE 569
4-(6-((4-Cyanobenzyl)oxy)-lH-benzo[<i]imidazol-2-yl)-N-cyclopropylbenzamide
(Compound 669)
Figure imgf000318_0001
[1706] Compound 669 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(4-cyanobenzyl)oxy-3,4-dinitrobenzene and 4- (cyclopropylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C25H20N4O2: 409.16; found: 409.04.
EXAMPLE 570
N-(4-(4-Hydroxypiperidin-l-yl)phenyl)-4-(6-(2-methoxyethoxy)-lH-benzo[(i]imidazol-2- yl)benzamide (Compound 670)
Figure imgf000318_0002
[1707] Compound 670 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-(4-(4- hydroxylpiperidin-l-yl)phenyl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C28H30N4O4: 487.23; found: 487.05.
EXAMPLE 571
4-(6-((5-Cyanothiophen-2-yl)methoxy)-lH-benzo[(i]imidazol-2-yl)-N-(lH-indol-6- yl)benzamide (Compound 671)
Figure imgf000318_0003
[1708] Compound 671 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(5-cyanothiophen-2-yl)methoxy)-3,4-dinitrobenzene and 4-(indol-6-yl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C28H19N5O2S: 490.13; found: 489.95.
EXAMPLE 572
4-(6-(2-Hydroxyethoxy)-lH-benzo[<i]imidazol-2-yl)-N-(lH-indol-6-yl)benzamide (Compound 672)
Figure imgf000319_0001
[1709] Compound 672 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(2-hydroxyethoxy)-3,4-dinitrobenzene and 4-(6- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C24H20N4O3: 413.15; found: 412.96.
EXAMPLE 573
Methyl 2-((2-(4-((lH-indol-6-yl)carbamoyl)phenyl)-lH-benzo[<i]imidazol-6- yl)oxy) acetate (Compound 673)
Figure imgf000319_0002
[1710] Compound 673 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(methoxycarbanylmethoxy)-3,4-dinitrobenzene and 4-(6- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C25H20N4O4: 441.15; found: 440.96.
EXAMPLE 574
4-(6-(2-Methoxyethoxy)-lH-benzo[<i]imidazol-2-yl)-N-(l-(2-hydroxyethyl)indol-5- yl)benzamide (Com ound 674)
Figure imgf000319_0003
[1711] Compound 674 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-(l-(2- hydroxyethyl)-5-indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C27H26N4O4: 471.20; found: 471.05.
EXAMPLE 575 4-(6-(2-Methoxyethoxy)-lH-benzo[J]imidazol-2-yl)-N-(l-(2-methoxyethyl)-2- methylindol-5-yl)benzamide Compound 675)
Figure imgf000320_0001
[1712] Compound 675 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-(l-(2- methoxyethyl)2-methyl-5-indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C29H30N4O4: 499.24; found: 499.06.
EXAMPLE 576
4-(6-(2-Methoxyethoxy)-lH-benzo[(i]imidazol-2-yl)-N-(l-(2-morpholinoethyl)indol-5- yl)benzamide (Com ound 676)
Figure imgf000320_0002
[1713] Compound 676 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(2-methoxyethoxy-3,4-dinitrobenzene and 4-(l-(2- morpholinoethyl)-5-indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C31H33N5O4: 540.26; found: 540.10.
EXAMPLE 577
(6-Phenyl-lH-benzo[(i]imidazol-2-yl)-N-(4-morpholinophenyl)benzamide (Compound 677)
Figure imgf000320_0003
[1714] Compound 677 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-phenyl-3,4-dinitrobenzene and 4-(4- morpholinopheyl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C30H26N4O2: 475.22; found: 475.03.
EXAMPLE 578
(6-Phenyl-lH-benzo[<i]imidazol-2-yl)-N-lH-indol-6-yl)benzamide (Compound 678)
Figure imgf000321_0001
[1715] Compound 678 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-phenyl-3,4-dinitrobenzene and 4-(6- indolylaminocarbonyl)benzaldehyde. [M+H]+ calcd for C28H20N4O: 429.16; found: 428.95.
EXAMPLE 579
(4-(6-(3-Hydroxyphenyl)-lH-benzo[(i]imidazol-2-yl)-N-(4-morpholinophenyl)benzamide (Compound 679)
Figure imgf000321_0002
[1716] Compound 679 was prepared according to the procedure similar to that described in Scheme ΠΙ from l-(3-hydroxyphenyl)-3,4-dinitrobenzene and 4-(4- morpholinopheyl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C30H26N4O3: 491.20; found: 491.03.
EXAMPLE 580
Cyclopropyl(4-(4-(6-(4-hydroxyphenyl)-lH-benzo[(i]imidazol-2-yl)phenyl)piperazin-l- yl)methanone (Compound 680
Figure imgf000321_0003
[1717] Compound 680 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(4-hydroxyphenyl)-3,4-dinitrobenzene and 4-(4- (cyclopropylcarbonylpiperazin-l-yl)benzaldehyde. [M+H]+ calcd for C27H26N4O2: 439.21 ; found: 438.93.
EXAMPLE 581
N-(2-(4-(Cyclopropanecarboxamido)phenyl)-2H-indazol-5-yl)-4-(4-hydroxypiperidin-l- yl)benzamide (Compound 681)
Figure imgf000322_0001
[1718] Compound 681 was prepared according to the procedure similar to that described in Scheme IV from 4-(4-hydroxypiperidin-l-yl)benzoic acid, cyclopropanecarboxylic acid, and 2-(4-aminophenyl)-5-amino-2H-indazole. [M+H]+ calcd for C29H29N5O3: 496.23; found 496.05.
EXAMPLE 582
4-(6-(2-Hydroxyethoxy)-lH-benzo[<i]imidazol-2-yl)-N-(4-morpholinophenyl)benzamide (Compound 682)
Figure imgf000322_0002
[1719] Compound 682 was prepared according to the procedure similar to that described in Scheme ΙΠ from l-(4-methoxyphenyl)-3,4-dinitrobenzene and 4-(4- morpholinopheyl)aminocarbonyl)benzaldehyde. [M+H]+ calcd for C26H26N4O4: 459.20; found: 458.97.
EXAMPLE 583
N-(4-(4-(Cyclopropanecarboxamido)benzoyl)phenyl)-4-(4-hydroxypiperidin-l- yl)benzamide (Compound 683
Figure imgf000322_0003
[1720] Compound 683 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, cyclopropanecarboxylic and 4-(4- hydroxypiperidin-l-yl)benzoic acids. A solution of 4,4'-diaminobenzophenone (Aldrich, 150 mg, 0.71 mmol), 4-fluorobenzoic acid (Aldrich, 129 mg, 0.92 mmol), HATU (Aldrich, 349 mg, 0.92 mmol) and diisopropylethylamine (Aldrich, 160 μί, 0.92 mmol) in dimethylformamide (6 mL) was heated to 100 °C for 12h. The reaction was cooled to room temperature and water (10 mL) was slowly added. The resulting solid was filtered and recrystallized from hot methanol to give N-(4-(4-aminobenzoyl)phenyl)-4- fluorobenzamide (147 mg, 0.44 mmol, 62%).
[1721] A solution of cyclopropanecarbonyl chloride (Aldrich, 448 mg, 4.31 mmol) in 5 mL of methylene chloride was slowly added over 5 minutes to N-(4-(4- aminobenzoyl)phenyl)-4-fluorobenzamide (1.2 g, 3.59 mmol) in 20 mL of methylene chloride containing 3 mL of pyridine. The reaction was stirred at room temperature for 12 h then quenched with 40 mL of water. The layers were separated and the aqueous layer was extracted with ethyl acetate (2 X 50 mL). The combined organics were washed with 0.5 N HC1 (100 mL), brine (100 mL), dried over sodium sulphate, and filtered. Concentration of the organics provided N-(4-(4-
(cyclopropanecarboxamido)benzoyl)phenyl)-4-fluorobenzamide (1.3 g, 3.23 mmol) as a tan solid which was used without further purification.
[1722] To a solution of N-(4-(4-(cyclopropanecarboxamido)benzoyl)phenyl)- 4-fluorobenzamide (1.3 g, 3.23 mmol) in dimethylsulfoxide (35 mL) was added 4- hydroxypiperidine (Aldrich, 5.2 g, 51.5 mmol) in a single portion. The reaction was heated to 110 °C for 24 h then cooled to room temperature. Water (100 mL) was slowly added to the reaction at room temperature over 3 h with stirring. Upon completion the reaction was allowed to stir an additional 12 h, then filtered under vacuum. The tan precipitate was washed with water (50 mL), methanol (50 mL) and dried under vacuum to yield compound 683 (1.2 g, 2.48 mmol) as a tan solid. [M+H]+ calcd for C29H30N3O4: 484.22; found: 484.01.
EXAMPLE 584
N- (4- (4- (4-morpholinobenzamido)benzoyl)phenyl) - 1 H-pyrazole- 3 -carboxamide
(Compound 684)
Figure imgf000323_0001
[1723] Compound 684 was prepared according to the procedure described Scheme IV from 4,4'-diaminobenzophenone, 3-pyrazolecarboxylic and morpholinobenzoic acids.
[M+H]+ calcd for C28H25N5O4: 496.05; found: 496.02. EXAMPLE 585
N-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- lH-pyrrole-2- carboxamide (Compound 685
Figure imgf000324_0001
[1724] Compound 685 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30N4O4: 523.12; found: 523.09.
EXAMPLE 586
N-(4-(4-(4-(4-Hydroxypiperidin-l-yl)benzamido)benzoyl)phenyl)pyrimidine-5- carboxamide Compound 686)
Figure imgf000324_0002
[1725] Compound 686 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, pyrimidine-5-carboxylic and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H27N5O4: 522.09; found: 522.08.
EXAMPLE 587
N-Cyclopropyl-4-(4-(4-(4-hydroxypiperidin-l-yl)benzamido)benzoyl)benzamide
(Compound 687)
Figure imgf000324_0003
[1726] Compound 687 was prepared according to the procedure described in Scheme IV from N-cyclopropyl-4-(4-aminobenzoyl)benzamide and 4-(4- hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C29H30N3O4: 484.22; found: 484.08.
EXAMPLE 588
N-(4-(4-(4-(4-Hydroxypiperidin-l-yl)benzamido)benzoyl)phenyl)-lH-indolyl-3- carboxamide (Com ound 688)
Figure imgf000325_0001
[1727] Compound 688 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 3-indolecarboxylic and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H30N4O4: 559.15; found: 559.14.
EXAMPLE 589
N-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- lH-indolyl-4- carboxamide (Com ound 689)
Figure imgf000325_0002
[1728] Compound 689 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 4-indolecarboxylic and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H30N4O4: 559.15; found: 559.14.
EXAMPLE 590
N-(4-(4-(4-(4-Hydroxypiperidin-l-yl)benzamido)benzoyl)phenyl)-lH-indolyl-7- carboxamide (Compound 690)
Figure imgf000326_0001
[1729] Compound 690 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 7-indolecarboxylic and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H30N4O4: 559.15; found: 559.07.
EXAMPLE 591
iV-(4-(4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)-4-hydroxypiperidine- 1 - carboxamide (Com ound 691)
Figure imgf000326_0002
[1730] Compound 691 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 4-hydroxypiperidine, and 4-(4- hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C31H35N4O5: 543.26; found: 543.07.
EXAMPLE 592
N-(4-(4-(4-(4-hydroxypiperidin-l-yl)benzamido)benzoyl)phenyl)-lH-pyrrolo[2,3- b]pyridine-5-carboxamide Compound 692)
Figure imgf000326_0003
[1731] Compound 692 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, lH-pyrrolo[2,3-b]pyridine-5-carboxylic and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H29N5O4: 560.14; found: 560.08. EXAMPLE 593
N-(4-(4-(4-(4-hydroxypiperidin-l-yl)benzamido)benzoyl)phenyl)benzo[b]thiophene-2- carboxamide (Com ound 693)
Figure imgf000327_0001
[1732] Compound 693 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 2-benzothiophenecarboxylic and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H29N3O4S: 576.20; found: 576.08.
EXAMPLE 594
4-Azido-N-(4-(4-(4-morpholinobenzamido)benzoyl)phenyl)benzamide (Compound 694)
Figure imgf000327_0002
[1733] Compound 694 was prepared according to the procedure described in Scheme lY from 4,4'-diaminobenzophenone, 4-azidobenzoic and 4-morpholinobenzoic acids. 1H NMR (500 MHz, DMSO-d6) δ 10.56 (s,lH), 10.28 (s, 1H), 8.04 (d, / = 8.8 Hz, 2H), 7.97 (d, / = 9.0 Hz, 2H), 7.96 (d, / = 8.8 Hz, 2H), 7.91 (d, / = 9.0 Hz, 2H), 7.76 (d, / = 8.5 Hz, 2H), 7.74 (d, / = 8.8 Hz, 2H), 7.28 (d, / = 8.5 Hz, 2H), 7.03 (d, / = 9.0 Hz, 2H), 3.75-3.73 (m, 4H), 3.27-3.25 (m, 4H).
EXAMPLE 595
N-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)-4-methyl- lH-pyrrole-2- carboxamide (Com ound 695)
Figure imgf000327_0003
[1734] Compound 695 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 4-methyl-2-pyrrolecarboxylic and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30N4O4: 523.12; found: 523.09.
EXAMPLE 596
N-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- lH-pyrrole-3- carboxamide (Com ound 696)
Figure imgf000328_0001
[1735] Compound 696 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 3-pyrrolecarboxylic and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H28N4O4: 509.09; found: 509.05.
Example 597
iV-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- lH-pyrrole-2- carboxamide (Com ound 697)
Figure imgf000328_0002
[1736] Compound 697 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 2-pyrrolecarboxylic and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H28N4O4: 509.09; found: 509.05.
EXAMPLE 598
N-(4-(4-(4-(4-Hydroxypiperidin-l-yl)benzamido)benzoyl)phenyl)-4-(3-hydroxypropyl) piperazine-l-carboxamide (Compound 698)
Figure imgf000329_0001
[1737] Compound 698 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone, 4-(3-hydroxypropyl)piperazine, and 4-(4- hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C33H40N5O5: 586.30; found: 586.20.
Example 599
N-(4-(4-(4-(4-Hydroxypiperidin-l-yl)benzamido)benzoyl)phenyl)-4,5,6,7-tetrahydro-lH- indole-2-carboxamide ompound 699)
Figure imgf000329_0002
[1738] Compound 699 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone, 4,5,6,7-tetrahydroindole-2-carboxylic and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H34N4O4: 563.18; found: 563.19.
Example 600
(+)-N-(4-(4-(4-(3-(Hydroxymethyl)piperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1H- pyrrole-2-carboxamide (Compound 700)
Figure imgf000329_0003
[1739] Compound 700 was prepared according to the procedure described in Scheme IV from 4,4' -diaminobenzophenone, 2-pyrrolecarboxylic and 4-(3- hydroxymethylpiperidin-l-yl)benzoic acids. 1H NMR (400 MHz, DMSO-J6) δ 10.25 (s, 1H), 10.07 (s, 1H), 7.98 (dd, J = 9.0, 10 Hz, 4H), 7.91 (d, J = 9.0 Hz, 2H), 7.77 (dd, J = 1.6, 8.7 Hz, 4H), 7.16 (bm, 1H), 7.02 (s, 1H), 7.01 (d, / = 9.0 Hz, 2H), 6.22 (m, 1H), 4.59 (t, / = 5.3 Hz, 1H), 1H), 3.88 (m, 2H), 2.86 (t, / = 12 Hz, 1H), 1.75 (m, 4H), 1.54 (m, 2H), 1.21 (m, 2H).
Example 601
N,N'-(Ethene- 1 , 1 -diylbis(4, 1 -phenylene))bis(4-(dimethylamino)benzamide) (Compound 701)
Figure imgf000330_0001
[1740] Compound 701 was prepared according to the procedure described in Scheme IV from 4,4'-(ethene-l,l-diyl)dianiline and 4-N,N-dimethylaminobenzoic acid. 1H NMR (500 MHz, DMSO-d6) δ 9.94 (s, 2H), 7.86 (d, / = 8.8 Hz, 4H), 7.77 (d, / = 8.5 Hz, 4H), 7.26 (d, / = 8.3 Hz, 4H), 6.75 (d, / = 8.8 Hz, 4H), 5.38 (s, 2H), 2.99 (s, 12H).
Example 602
N,N'-(Ethene- 1 , 1 -diylbis(4, 1 -phenylene))bis(l -methyl- lH-indole-5-carboxamide)
(Compound 702)
Figure imgf000330_0002
[1741] Compound 702 was prepared according to the procedure described in Scheme IV from 4,4'-(ethene-l,l-diyl)dianiline and l-methylindole-5-carboxylic acid. 1H NMR (500 MHz, CDC13) δ 8.20 (s, 2H), 7.93 (s, 2H), 7.79 (dd, / = 1.7, 8.5 Hz, 2H), 7.66 (dd, / = 1.7, 6.8 Hz, 4H), 7.42 (d, / = 2.3 Hz, 2H), 7.39 (d, / = 8.5 Hz, 4H), 7.15 (d, / = 2.3 Hz, 2H), 6.61 (d, / = 2.9 Hz, 2H), 5.44 (s, 2H), 3.86 (s, 6H).
Example 603
N,N'-(((Methoxyimino)methylene)bis(4,l-phenylene))bis(lH-indole-5-carboxamide) (Compound 703)
Figure imgf000331_0001
[1742] Compound 703 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone and l-methylindole-5-carboxylic acid. [M+H]+ calcd for C32H25N5O3: 528.10; found: 528.15.
Example 604
(Z/E)-N-(4-((4-(Cyclopropanecarboxamido)phenyl)(methoxyimino)methyl)phi
indole-5-carboxamide (Compound 704)
Figure imgf000331_0002
[1743] Compound 704 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, cyclopropanecarboxylic, and indole-5- carboxylic acids.
[M+H]+ calcd for C27H24N4O3: 453.03; found: 453.03.
Example 605
iV-(4-(4-( lH-Pyrrole-2-carboxamido)benzoyl)phenyl)- 1 -(2-morpholinoethyl)- lH-indole- 5-carboxamide (Compound 705)
Figure imgf000331_0003
[1744] Compound 705 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 2-pyrrolecarboxylic, and l-(2- morpholinoethyl)indole-5-carboxylic acids. [M+H]+ calcd for C33H31N5O4: 562.16; found: 562.11.
Example 606
(+)-N-(4-(4-(4-(2-(Hydroxymethyl)morpholino)benzamido)benzoyl)phenyl)-lH-pyrrole- 2-carboxamide (Compound 706)
Figure imgf000332_0001
[1745] Compound 706 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 2-pyrrolecarboxylic, and 4-(2- hydroxymethyl)morpholino-4-)benzoic acids. [M+H]+ calcd for C30H28N4O5: 525.21 ; found: 524.98.
Example 607
(+)-N-(4-(4-(4-(3-(Hydroxymethyl)piperidin-l-yl)benzamido)benzoyl)phenyl)-lmethyl- lH-pyrrole-2-carboxamide (Compound 707)
Figure imgf000332_0002
[1746] Compound 707 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and 4-(3- hydroxymethylpiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H32N4O4: 537.24; found: 537.06.
Example 608
(+)-N-(4-(4-(4-(3-Hydroxypyrrolidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- 1H- pyrrole-2-carboxamide (Compound 708)
Figure imgf000332_0003
[1747] Compound 708 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and 4-(3- hydroxypyrrolidin-l-yl)benzoic acids. [M+H]+ calcd for C30H28N4O4: 509.21 ; found: 508.98.
EXAMPLE 609 N-(4-(4-(4-(4-Hydroxypiperidin-l-yl)benzamido)benzoyl)phenyl)-4- morpholinecarboxamide Compound 709)
Figure imgf000333_0001
[1748] Compound 709 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, morpholine, and 4-(4-hydroxypiperidin-l- yl)benzoic acid. [M+H]+ calcd for C30H32N4O5: 529.12; found: 529.03.
Example 610
(+)-N-(4-(4-(4-(2-(Hydroxymethyl)morpholino)benzamido)benzoyl)phenyl)- 1 -methyl- 1H- pyrrole-2-carboxamide (Compound 710)
Figure imgf000333_0002
[1749] Compound 710 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and 4-(2- hydroxymethyl)morpholino-4-)benzoic acids. [M+H]+ calcd for C31H30N4O5: 539.22; found: 539.02.
Example 611
N-(4-(4-(4-(4-(Cyclopropanecarbonyl)piperazin- 1 -yl)benzamido)benzoyl)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamide (Compound 711)
Figure imgf000333_0003
[1750] Compound 711 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and 4-(4- cyclopropanecarbonyl)piperazinobenzoic acids. [M+H]+ calcd for C34H33N5O4: 576.25; found: 576.08.
Example 612
(R)-N-(4-(4-(4-(3-Hydroxypyrrolidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- 1H- pyrrole-2-carboxamide (Compound 712)
Figure imgf000334_0001
[1751] Compound 712 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and (R)-4-(3- hydroxypyrrolidin-l-yl)benzoic acids. [M+H]+ calcd for C30H28N4O4: 509.21 ; found: 508.98.
Example 613
(5,)-N-(4-(4-(4-(3-Hydroxypyrrolidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- 1H- pyrrole-2-carboxamide (Compound 713)
Figure imgf000334_0002
[1752] Compound 713 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and (S)-4-(3- hydroxypyrrolidin-l-yl)benzoic acids. 1H NMR (400 MHz, Acetone-J6) δ 9.49 (s, 1H), 9.38 (s, 1H), 8.02 (d, / = 8.8 Hz, 2H), 7.95 (t, / = 9 Hz, 3H), 7.78 (d, / = 7 Hz, 3H), 7.03 (dd, J = 2, 4 Hz, 1H), 6.97 (t, / = 2 Hz, 1H), 6.61 (d, J = 9 Hz, 2H), 6.11 (dd, J = 2.5, 4 Hz, 1H), 4.60 (m, 1H), 3.99 (s, 3H), 3.59 - 3.42 (m, 3H), 3.31 (m, 1H), 2.20-2.14 (m, 3H).
Example 614
4-Azido-N-(4-(4-(4-(dimethylamino)benzamido)benzoyl)phenyl)benzamide (Compound 714)
Figure imgf000335_0001
[1753] Compound 714 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 4-azidobenzoic, and 4- dimtheylaminobenzoic acids. [M+H]+ calcd for C29H24N6O3: 505.19; found 504.93.
Example 615
N-(4-(4-(3-Fluoro-4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- 1H- pyrrole-2-carboxamide Compound 715)
Figure imgf000335_0002
[1754] Compound 715 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)-3-fluorobenzoic acids. [M+H]+ calcd for C31H29FN4O4: 541.22; found: 541.05.
Example 616
(E/Z)-N-(4-((4-(4-(4-Hydroxypiperidin- 1 - yl)benzamido)phenyl)(methoxyimino)methyl)phenyl)- 1 -methyl- lH-pyrrole-2- carboxamide (Compound 716
Figure imgf000335_0003
[1755] Compound 716 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H33N5O4: 552.16; found: 552.05. Example 617
N-(4-(4-(4-(4-Hydroxypiperidin-l-yl)benzamido)benzoyl)phenyl)-lH-pyrazole-5- carboxamide (Compound 717
Figure imgf000336_0001
[1756] Compound 717 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 5-pyrazolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H27N5O4: 510.18; found: 509.99.
Example 618
N-(4-(4-(3-Trifluoromethyl-4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamide Compound 718)
Figure imgf000336_0002
[1757] Compound 718 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)-3-trifluoromethylbenzoic acids. [M+H]+ calcd for C32H30F3N4O4: 591.22; found: 591.07.
Example 619
N-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- lH-pyrazole-4- carboxamide (Com ound 719)
Figure imgf000336_0003
[1758] Compound 719 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 4-pyrazolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H27N5O4: 510.18; found: 509.99.
Example 620
iV-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- lH-pyrazole- 5-carboxamide (Com ound 720)
Figure imgf000337_0001
[1759] Compound 720 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-5-pyrazolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H29N5O4: 524.11; found: 524.03.
Example 621
N-(4-(4-(2-Methyl-4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- 1H- pyrrole-2-carboxamide Compound 721)
Figure imgf000337_0002
[1760] Compound 721 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)-2-methylbenzoic acids. [M+H]+ calcd for C32H33N4O4: 537.25; found: 537.06.
Example 622
iV-(4-(4-(3-Methoxy-4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- lH-pyrrole-2-carboxamide (Compound 722)
Figure imgf000338_0001
[1761] Compound 722 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)-3-methoxybenzoic acids. [M+H]+ calcd for C32H33N4O5: 553.25; found: 553.06.
Example 623
5-Chloro-iV-(4-(4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -isopropyl- lH-pyrrole-2-carboxamide Compound 723)
Figure imgf000338_0002
[1762] Compound 723 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 5-chloro-l-isopropyl-2-pyrrolecarboxylic, and 4-(4-hydroxypiperidin-l-yl)-3-trifluoromethylbenzoic acids. [M+H]+ calcd for C33H33CIN4O4: 585.22; found: 585.06.
Example 624
iV-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -isopropyl- 1H- pyrrole-2-carboxamide Compound 724)
Figure imgf000338_0003
[1763] Compound 724 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-isopropyl-2-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)-3-trifluoromethylbenzoic acids. 1H NMR (400 MHz, CD3OD) δ 7.93-7.81 (m, 10H), 7.22 (dd, / = 1.7, 2.7 Hz, 1H), 7.05 (d, J = 9 Hz, 2H), 7.00 (dd, / = 1.7, 4 Hz, 1H), 6.22 (dd, / = 2.7, 4 Hz, 1H), 5.51 (s, 1H), 3.84 (m, 3H), 3.10 (m, 2H), 1.9 (m, 2H), 1.64 (m, 2H), 1.50 (s, 3H), 1.48 (s, 3H).
Example 625
N-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- lH-pyrazole- 4-carboxamide (Com ound 725)
Figure imgf000339_0001
[1764] Compound 725 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-4-pyrazolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H29N5O4: 524.11; found: 524.03.
Example 626
Methyl 5-((4-(4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)carbamoyl)- 1H- pyrrole-2-carboxylate Compound 726)
Figure imgf000339_0002
[1765] Compound 726 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-isopropyl-2-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)-3-trifluoromethylbenzoic acids. [M+H]+ calcd for C32H30N4O6: 567.13; found: 567.04.
Example 627
iV-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- lH-pyrazole- 3-carboxamide (Compound 727)
Figure imgf000340_0001
[1766] Compound 727 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-3-pyrazolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H29N5O4: 524.11; found: 524.03.
Example 628
N-(4-(4-(3-Methyl-4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- 1H- pyrrole-2-carboxamide Compound 728)
Figure imgf000340_0002
[1767] Compound 728 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)-3-methylbenzoic acids. [M+H]+ calcd for C32H33N4O4: 537.25; found: 537.11.
Example 629
N-(4-(4-(4-(4-Hydroxypiperidin-l-yl)benzamido)benzoyl)phenyl)-l-vinyl-4,5,6,7- tetrahydro-lH-indole-2-carboxamide Compound 729)
Figure imgf000340_0003
[1768] Compound 729 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-vinyl-4,5,6,7-tetrahydroindole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C36H36N4O4: 589.27; found: 589.12. Example 630
N-(4-(4-(2-Chloro-4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- 1H- pyrrole-2-carboxamide (Compound 730)
Figure imgf000341_0001
[1769] Compound 730 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-2-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)-2-chlorobenzoic acids. [M+H]+ calcd for C31H30CIN4O4: 557.20; found: 556.98.
EXAMPLE 631
iV-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- lH-pyrrole- 3- carboxamide (Compound 731)
Figure imgf000341_0002
[1770] Compound 731 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-methyl-3-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30N4O4: 523.12; found: 522.95.
Example 632
iV-(4-(4-(2-Chloro-4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -ethyl- 1H- pyrrole-2-carboxamide (Compound 732)
Figure imgf000341_0003
[1771] Compound 732 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-ethyl-2-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. 1H NMR (400 MHz, CD3OD) δ 7.89-7.79 (m, 10H), 7.02 (m, 4H), 6.15 (m, 1H), 4.41 (q, / = 7.5 Hz, 2H), 3.82 (m, 3H), 3.07 (dt, / = 3, 13 Hz, 2H), 1.96 (m, 2H), 1.60 (m, 2H), 1.39 (t, / = 7.1 Hz, 3H).
EXAMPLE 633
N-(4-(4-(4-(4-Hydroxypiperidin-l-yl)benzamido)benzoyl)phenyl)-4-oxo-4,5,6,7- tetrahydro-iH-indole-3-carboxamide Compound 733)
Figure imgf000342_0001
[1772] Compound 733 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 4-oxo-4,5,6,7-tetrahydroindole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500MHz, DMSO- d6) δ 12.91 (s, 1H), 12.20 (s, 1H), 10.24 (s, 1H), 7.98 (d, J = U Hz, 2H), 7.90 (q, / = 2, 14 Hz, 4H), 7.79 (m, 4H), 7.62 (s, 1H), 7.03 (d, / = 10 Hz, 2H), 4.72 (d, / = 8 Hz, 1H), 3.73 (m, 3H), 3.06 (m, 2H), 2.89 (t, / = 8, 10 Hz, 2H), 2.61 (m, 2H), 2.11 (m, 2H), 1.82 (m, 2H), 1.47 (m, 2H).
EXAMPLE 634
N- (4- (4- (4- (4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl) -2,5 -dimethyl- 1 H- pyrrole-3-carboxamide Compound 734)
Figure imgf000342_0002
[1773] Compound 734 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, 2,5-dimethyl-3-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500MHz, DMSO-d6) δ 10.99 (s, 1H), 10.23 (s, 1H), 9.52 (s, 1H), 7.98 (dd, / = 12, 12 Hz, 4H), 7.89 (d, / = 8 Hz, 2H), 7.72 (dd, / = 8, 12 Hz, 4H), 7.02 (d, / = 10 Hz, 2H), 6.40 (s, 1H), 4.71 (d, / = 3 Hz, 1H), 3.72 (m, 3H), 3.05 (m, 2H), 1.83 (m, 2H), 1.45 (m, 2H).
EXAMPLE 635
N-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 ,2,5-trimethyl- 1H- pyrrole-3-carboxamide Compound 735)
Figure imgf000343_0001
[1774] Compound 735 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l,2,5-trimethyl-3-pyrrolecarboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500MHz, DMSO-d6) δ 10.24 (s, 1H), 9.57 (s, 1H), 7.98 (dd, / = 10, 16 Hz, 4H), 7.89 (d, / = 8 Hz, 2H), 7.72 (dd, / = 10, 12 Hz, 4H), 7.02 (d, / = 8 Hz, 2H), 6.49 (s, 1H), 4.71 (d, / = 4 Hz, 1H), 3.72 (m, 3H), 3.41 (s, 3H), 3.06 (m, 2H), 1.86 (m, 2H), 1.48 (m, 2H).
Example 636
iV-(4-(4-(2-Chloro-4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 - cyanomethyl-lH-pyrrole-2-carboxamide Compound 736)
Figure imgf000343_0002
[1775] Compound 736 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-cyanomethyl-2-pyrrolecarboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H29N5O4: 548.22; found: 548.07.
Example 637
N-(4-(4-(4-(4-(3-Hydroxypropyl)piperazin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -methyl- lH-pyrrole-2-carboxamide (Compound 737)
Figure imgf000344_0001
[1776] Compound 737 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-ethyl-2-pyrrolecarboxylic, and 4-(4-(3- hydroxypropyl)piperazin-l-yl)benzoic acids. [M+H]+ calcd for C33H36N5O4: 566.28; found: 566.12.
Example 638
iV-(4-(4-(2-Chloro-4-(4-hydroxypiperidin- 1 -yl)benzamido)benzoyl)phenyl)- 1 -vinyl- 1H- pyrrole-2-carboxamide Compound 738)
Figure imgf000344_0002
[1777] Compound 738 was prepared according to the procedure described in Scheme IV from 4,4'-diaminobenzophenone, l-vinyl-2-pyrrolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500MHz, DMSO-d6) δ 10.38 (s, 1H), 10.35 (s, 1H), 7.99 (d, / = 8 Hz, 2H), 7.90 (m, 4H), 7.77 (d, J = 10 Hz, 4H), 7.63 (s, 1H), 7.20 (s, 1H), 7.02 (d, / = 10 Hz, 2H), 6.34 (s, 1H), 5.42 (d, / = 12 Hz, 1H), 4.88 (d, / = 8 Hz, 1H), 4.71 (d, / = 4 Hz, 1H), 3.81 (m, 3H), 3.05 (m, 2H), 1.83 (m, 2H), 1.47 (m, 2H).
Example 639
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)pyrimidine-5- carboxamide (Com ound 739)
Figure imgf000344_0003
[1778] Compound 739 was prepared according to the general procedure described in Scheme IV. Preparation of N-(4-nitrophenyl)benzene- 1,4-diamine: Benzene- 1,4-diamine (5.4 g, 50 mmol) and l-fluoro-4-nitrobenzene (5.3 mL, 50 mmol) were dissolved in 75 mL dimethylsulfoxide and potassium carbonate (13.8 g, 100 mmol) was added. The reaction mixture was heated in an oil bath at 90 °C and stirred overnight under nitrogen atmosphere. The reaction mixture was cooled to room temperature and added to 250 mL water in a slow stream and stirred till a solid was precipitated out. The reaction mixture was filtered out and the resulting dark brown solid was washed with plenty of water. Flash column chromatography on silica gel eluted with 20% to 40% Ethyl acetate in hexanes provided the title compound (6.1 g, 53% yield).
[1779] Preparation of 4-(4-hydroxypiperidin-l-yl)-N-(4-((4- nitrophenyl)amino)phenyl)-benzamide: N-4(-4-nitrophenyl)benzene-l,4-diamine (1.15 g, 5.0 mmol) and 4-(4-hydroxypiperidine-l-yl)benzoic acid (1.2 g, 5.5 mmol) were dissolved in 20 mL pyridine and EDCI (1.2 g, 6.0 mmole) added and stirred at room temperature under nitrogen atmosphere overnight. Water (80 mL) was added and the mixture was stirred for an extra 15 minutes till a solid was precipitated out. The reaction mixture was filtered and the resulting red-color solid was washed with water, ethyl acetate, and hexanes, then dried to give the title compound (1.6 g, 80% yield.) This compound was used for next step without any further purification.
[1780] Preparation of Compound 739: 4-(4-Hydroxypiperidin-l-yl)-N-(4-((4- nitrophenyl)amino)phenyl)benzamide (1.8 g, 4.2 mmol) was hydrogenated using palladium hydroxide (1.6 g) in absolute ethanol (75 mL). The reaction mixture was stirred under hydrogen gas balloon overnight. It was filtered through celite and evaporated to dryness to give 4-(4-hydroxypiperidin-l-yl)-N-(4-((4- nitrophenyl)amino)phenyl)benzamide over 98% pure (1.6 g, 95% yield). Part of the product (22 mg, 0.05 mmol) and pyrimidine-4-carboxylic acid (8 mg, 0.06 mmole) were dissolved in 1 mL pyridine and was added EDCI (19 mg, 0.1 mmol). The reaction mixture was stirred at room temperature under nitrogen atmosphere overnight. Water (5 mL) was added and the mixture was stirred for an extra 15 minutes till a solid was precipitated out. The reaction mixture was filtered and the resulting red -color solid was washed with water, ethyl acetate, hexanes, and then dried to give crude compound 739 (20 mg 78% yield). Further purification was carried on using prep HPLC for the final sample. [M+H]+ calcd for CagHasNeOs: 509.22; found 508.98.
Example 640
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)nicotinamide (Compound 740)
Figure imgf000346_0001
[1781] Compound 740 was prepared according to the procedure described Scheme IV from 4,4' -diaminodiphenylamine, nicotinic and 4-(4-hydroxypiperidin- yl)benzoic acids. [M+H]+ calcd for C30H29N5O3: 508.23; found 507.97.
Example 641
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-4,5,6,7- tetrahydro-lH-indole-2-carboxamide (Compound 741)
Figure imgf000346_0002
[1782] Compound 741 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, 4,5,6,7-tetrahydro-lH-indole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H35N5O3: 550.27; found 550.09.
Example 642
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrolo[2,3-b]pyridine-5-carboxamide Compound 742)
Figure imgf000346_0003
[1783] Compound 742 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, lH-pyrrolo[2,3-b]pyridine-5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H30N6O3: 547.24; found 547.12. Example 643
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- lH-pyrrole-2- carboxamide (Com ound 743)
Figure imgf000347_0001
[1784] Compound 743 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, lH-pyrrole-2-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29N5O3: 496.23; found 496.02.
Example 644
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- 1H- pyrrole-2-carboxamide Compound 744)
Figure imgf000347_0002
[1785] Compound 744 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, l-methylpyrrole-2-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O3: 510.24; found 519.99.
Example 645
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)- 1 -methyl-N-(4-(l -methyl- 1H- pyrrole-2-carboxamido henyl)- lH-pyrrole-2-carboxamide (Compound 745)
Figure imgf000347_0003
[1786] Compound 745 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, l-methylpyrrole-2-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C36H36N6O4: 617.28; found 617.27.
Example 646
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- lH-pyrrole-3- carboxamide (Com ound 746)
Figure imgf000348_0001
[1787] Compound 746 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, lH-pyrrole-3-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29N5O3: 496.23; found 496.02.
Example 647
N,N'-(Azanediylbis(4,l-phenylene))bis(4-(4H-l,2,4-triazol-4-yl)benzamide) (Compound 747)
Figure imgf000348_0002
[1788] Compound 747 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-(4H-l,2,4-triazol-4-yl)benzoic acid. [M+H]+ calcd for C30H23N9O2: 542.20; found 541.99.
Example 648
N,iV'-(Azanediylbis( -phenylene))bis(4-acetylbenzamide) (Compound 748)
Figure imgf000348_0003
[1789] Compound 748 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-acetylbenzoic acid. [M+H]+ calcd for C30H25N3O4: 492.18; found 492.00.
Example 649
N-(4-((4- Aminophenyl)amino)phenyl)-4-(4-hydroxypiperidin- 1 -yl)benzamide (Compound 749)
Figure imgf000349_0001
[1790] Compound 749 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-(4-hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C25H26N4O3: 403.21; found 403.04.
Example 650
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- lH-indole-5- carboxamide (Com ound 750)
Figure imgf000349_0002
[1791] Compound 750 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, lH-indole-5-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H31N5O3: 546.24; found 546.04.
Example 651
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- lH-indole-6- carboxamide (Com ound 751)
Figure imgf000349_0003
[1792] Compound 751 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, lH-indole-6-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H31N5O3: 546.24; found 546.11.
Example 652
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- lH-indole-3- carboxamide (Com ound 752)
Figure imgf000350_0001
[1793] Compound 752 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, lH-indole-3-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H31N5O3: 546.24; found 545.97.
Example 653
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)
cyclopropanecarboxamide Compound 753)
Figure imgf000350_0002
[1794] Compound 753 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, cyclopropanecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C28H30N4O3: 471.23; found 471.05.
Example 654
N^N1 '-(Azanediylbis(4,l-phenylene))diterephthalamide (Compound 754)
Figure imgf000351_0001
[1795] Compound 754 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine and 4-carbamoylbenzoic acid. [M+H]+ calcd for C28H23N5O4: 494.18; found 494.00.
Example 655
N-(4-((2-Fluoro-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrole-2-carboxamide (Compound 755)
Figure imgf000351_0002
[1796] Compound 755 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H28FN5O3: 514.22; found: 513.98.
Example 656
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrole-2-carboxamide Compound 756)
Figure imgf000351_0003
[1797] Compound 756 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H28FN5O3: 514.22; found: 513.98.
Example 657 N-(4-((2-Fluoro-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1,5- dimethyl-lH-pyrrole-2-carboxamide Compound 757)
Figure imgf000352_0001
[1798] Compound 757 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1,5-dimethyl-lH- pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H32FN5O3: 542.25; found: 542.06.
Example 658
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 ,5-dimethyl- lH-pyrrole-2-carboxamide Compound 758)
Figure imgf000352_0002
[1799] Compound 758 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, l,5-dimethyl-lH-pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found: 524.03.
Example 659
N-(4-((2-Fluoro-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -ethyl- lH-pyrrole-2-carboxamide Compound 759)
Figure imgf000352_0003
[1800] Compound 759 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -ethyl- lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd C31H32FN5O3: 524.25; found: 542.06.
Example 660
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-l,5- dimethyl-lH-pyrrole-2-carboxamide Compound 760)
Figure imgf000353_0001
[1801] Compound 760 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1,5-dimethyl-lH- pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H32FN5O3: 542.25; found: 542.06.
Example 661
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)-5-methyl- 1H- pyrrole-2-carboxamide Compound 761)
Figure imgf000353_0002
[1802] Compound 761 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 5-methyl-lH-pyrrole-2-carboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. 1H NMR (400 MHz, Acetone-J6) δ 10.54 (s, 1H), 9.14 (s, 1H), 8.93 (s, 1H), 7.90 (d, / = 9 Hz, 2H), 7.70 (d, / = 8.9 Hz, 2H), 7.64 (d, / = 9.0 Hz, 2H), 7.18 (s, 1H), 7.07 (dd, / = 3.0, 9.0 Hz, 4H), 7.00 (d, / = 9.0 Hz, 2H), 6.84 (t, / = 3.4 Hz, 1H), 5.89 (t, / = 3.4 Hz, 1H), 3.85 (m, 2H), 3.75 (m, 2H), 3.08 (ddd, / = 3.0, 3.2, 11 Hz, 2H), 2.32 (s, 3H), 1.94 (m, 2H), 1.60 (m, 2H).
Example 662
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-5- methyl-lH-pyrrole-2-carboxamide (Compound 762)
Figure imgf000354_0001
[1803] Compound 762 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-f uorobenzene-l,4-diamine, 5-methyl-lH-pyrrole- 2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30FN5O3: 528.23; found: 528.02.
Example 663
5-Formyl-iV-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrole-2-carboxamide Compound 763)
Figure imgf000354_0002
[1804] Compound 763 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 5-formyl-lH-pyrrole-2-carboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H29N5O4: 524.11; found: 524.03.
Example 664
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrole-3-carboxamide Compound 764)
Figure imgf000354_0003
[1805] Compound 764 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, lH-pyrrole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H28FN5O3: 514.22; found 513.98.
Example 665 N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -ethyl- lH-pyrrole-3-carboxamide (Compound 765)
Figure imgf000355_0001
[1806] Compound 765 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, l-ethyl-lH-pyrrole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H32FN5O3: 542.25; found: 542.06.
Example 666
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-3-carboxamide (Compound 766)
Figure imgf000355_0002
[1807] Compound 766 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- lH-pyrrole- 3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30FN5O3: 528.23; found 528.02.
Example 667
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -ethyl- 1H- pyrrole-3-carboxamide (Compound 767)
Figure imgf000355_0003
[1808] Compound 767 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -ethyl- lH-pyrrole-3-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found: 524.03.
Example 668
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- 1H- pyrrole-3-carboxamide Compound 768)
Figure imgf000356_0001
[1809] Compound 768 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-3-carboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O3: 510.24; found 509.99.
Example 669
N-Cyclopropyl-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)benzamide (Compound 769)
Figure imgf000356_0002
[1810] Compound 769 was prepared according to the procedure described in Scheme IV from cyclopropylamine, 4-(4-aminophenylamino)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C28H30N4O3: 471.23; found 471.05.
Example 670
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-6- methylpicolinamide Compound 770)
Figure imgf000356_0003
[1811] Compound 770 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 6-methylpicolinic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H31N5O3: 522.24; found 522.08.
Example 671
N-(4-((4-(( lH-Indol-6-yl)carbamoyl)phenyl)amino)phenyl)-4-(4-hydroxypiperidin- 1 - yl)benzamide (Com ound 771)
Figure imgf000357_0001
[1812] [Compound 771 was prepared according to the procedure described in Scheme IV from 6-aminoindole, 4-(4-aminophenylamino)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H31N5O3: 546.24; found 546.04.
Example 672
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -(2- hydroxyethyl)-lH-indole-6-carboxamide Compound 772)
Figure imgf000357_0002
[1813] Compound 772 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, l-(2-hydroxyethyl)-lH-indole-6-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C35H35N5O4: 590.27; found 590.20.
Example 673
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- 1H- indole-2-carboxamide (Compound 773)
Figure imgf000358_0001
[1814] Compound 773 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-indole-2-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H33N5O3: 560.26; found 560.02.
Example 674
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- 1H- indole-3-carboxamide Compound 774)
Figure imgf000358_0002
[1815] Compound 774 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-indole-3-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H33N5O3: 560.26; found 560.02.
Example 675
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -(2- hydroxyethyl)-lH-indole-5-carboxamide Compound 775)
Figure imgf000358_0003
[1816] Compound 775 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, l-(2-hydroxyethyl)-lH-indole-5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C35H35N5O4: 590.27; found 590.06.
Example 676 N-(4-((4-(lH-Pyrrole-2-carboxamido)phenyl)amino)phenyl)-l-(2-hydroxyethyl)-lH- indole-6-carboxamide (Compound 776)
Figure imgf000359_0001
[1817] Compound 776 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, l-(2-hydroxyethyl)-lH-indole-6-carboxylic, and 2-pyrrolecarboxylic acids. [M+H]+ calcd for C28H25N5O3 : 480.20 ; found 480.03.
Example 677
N-(4-((4-(lH-Pyrrole-2-carboxamido)phenyl)amino)phenyl)- 1 -(2-hydroxyethyl)- 1 - methyl- lH-indole-6-carboxamide (Compound 777)
Figure imgf000359_0002
[1818] Compound 777 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, l-(2-hydroxyethyl)-lH-indole-6-carboxylic, and l-methyl-2-pyrrolecarboxylic acids. [M+H]+ calcd for C29H27N5O3: 494.21 ; found 494.06.
Example 678
(+)-N-(4-((4-(4-(3-(Hydroxymethyl)piperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- indole-6-carboxamide (Compound 778)
Figure imgf000359_0003
[1819] Compound 778 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, lH-indole-6-carboxylic, and 4-(3- hydroxymethylpiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H33N5O3: 560.26; found: 560.08.
Example 679 (+) -N-(4-((4- (4- (3 - (Hydroxymethyl)pi
pyrrole-2-carboxamide (Compound 779)
Figure imgf000360_0001
[1820] Compound 779 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, lH-pyrrole-2-carboxylic, and 4-(3- hydroxymethylpiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O3: 510.24; found: 509.99.
Example 680
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -(2- morpholinoethyl)- -indole-5-carboxamide (Compound 780)
Figure imgf000360_0002
[1821] Compound 780 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, l-(2-morpholinoethyl)-lH-indole-5- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C39H42N6O4 : 659.33; found 659.20.
Example 681
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)morpholine-4- carboxamide (Compound 781)
Figure imgf000360_0003
[1822] Compound 781 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 4-morpholinecarbonyl chloride, and 4-(4- hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C29H33N5O4 : 516.25; found 516.07.
Example 682
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- lH-pyrazole-3- carboxamide (Com ound 782)
Figure imgf000361_0001
[1823] Compound 782 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, lH-pyrazole-3-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C28H28N6O3 : 497.22; found 496.97.
Example 683
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- lH-pyrazole-4- carboxamide (Com ound 783)
Figure imgf000361_0002
[1824] Compound 783 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, lH-pyrazole-4-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C28H28N6O3 : 497.22; found 496.97.
Example 684
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- 1H- pyrazole-3-carboxamide Compound 784)
Figure imgf000361_0003
[1825] Compound 784 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrazole-3-carboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H30N6O3 : 511.24; found 511.01.
Example 685
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- 1H- pyrazole-4-carboxamide (Compound 785)
Figure imgf000362_0001
[1826] Compound 785 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrazole-4-carboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H30N6O3 : 511.24; found 511.01.
Example 686
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- 1H- pyrazole-5-carboxamide (Compound 786)
Figure imgf000362_0002
[1827] Compound 786 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrazole-5-carboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H30N6O3 : 511.24; found 511.01.
Example 687
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)butamide
(Compound 787)
Figure imgf000363_0001
[1828] Compound 787 was prepared according to the procedure described Scheme IV from 4,4' -diaminodiphenylamine, butanoic, and 4-(4-hydroxypiperidin- yl)benzoic acids. [M+H]+ calcd for C28H32N4O3: 473.25; found: 473.01.
Example 688
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)-4-methyl- 1H- pyrrole-3-carboxamide (Compound 788)
Figure imgf000363_0002
[1829] Compound 788 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, 4-methyl-lH-pyrrole-3-carboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O3: 510.24; found: 509.99.
Example 689
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 ,2,5-trimethyl- lH-pyrrole-3-carboxamide Compound 789)
Figure imgf000363_0003
[1830] Compound 789 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, l,2,5-trimethyl-lH-pyrrole-3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H35N5O3 : 538.27; found 538.08.
Example 690 N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-2,5-dimethyl- lH-pyrrole-3-carboxamide Compound 790)
Figure imgf000364_0001
[1831] Compound 790 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 2,5-dimethyl-lH-pyrrole-3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found 525.10.
Example 691
N-(4-((4-(3,3-Dimethylureido)phenyl)amino)phenyl)-4-(4-hydroxypiperidin-l- yl)benzamide (Compound 791
Figure imgf000364_0002
[1832] Compound 791 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, N, iV-dimethylchloroformate, and 4-(4- hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C27H31N5O3 : 474.24; found 473.95.
Example 692
4-Hydroxy-N-(4-((4-(4-(4-hydroxypiperidin- 1 - yl)benzamido)phen l)amino)phenyl)piperidine- 1 -carboxamide (Compound 792)
Figure imgf000364_0003
[1833] Compound 792 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, (4-hydroxypiperidin-l-yl)carbonyl chloride, and 4-(4-hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C30H35N5O4: 530.28; found: 530.04.
Example 693
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-2,3-dimethyl- lH-indole-5-carboxamide Compound 793)
Figure imgf000365_0001
[1834] Compound 793 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 2,3-dimethyl-lH-indole-5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C35H35N5O3: 574.27; found 574.06.
Example 694
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- 1H- indole-5-carboxamide Compound 794)
Figure imgf000365_0002
[1835] Compound 794 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-indole-5-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H33N5O3: 560.26; found 560.02.
Example 695
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- 1H- indole-6-carboxamide Compound 795)
Figure imgf000365_0003
[1836] Compound 795 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-indole-6-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H33N5O3: 560.26; found 560.07.
Example 696
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamidee Compound 796)
Figure imgf000366_0001
[1837] Compound 796 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, 1 -methyl- 1H- pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30CIN5O3: 544.20; found 544.02.
Example 697
N-(4-((4-(4-((2-Hydroxyethyl)(methyl)amino)benzamido)phenyl)amino)phenyl)-l- methyl-lH-pyrrole-2-carboxamide Compound 797)
Figure imgf000366_0002
[1838] Compound 797 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and (4- (2-hydroxyethyl)methylamino)benzoic acids. [M+H]+ calcd for C28H29N5O3: 484.24; found: 484.01.
Example 698
1 -Methyl-N-(4-((4-(4-(4-methylpiperazin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrole-2-carboxamide (Compound 798)
Figure imgf000367_0001
[1839] Compound 798 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 4- (4-methylpiperazin-l-yl)benzoic acids. [M+H]+ calcd for C30H32N6O2: 509.27; found: 509.05.
Example 699
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-4-acetyl-3,5- dimethyl-lH-pyrrole-2-carboxamide Compound 799)
Figure imgf000367_0002
[1840] Compound 799 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 4-acetyl-3,5-dimethyl-lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H35N5O4: 566.27; found 566.09.
Example 700
N-(4-((4-(4-(4-Hydroxymethylpiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- lH-pyrrole-2-carboxamide (Compound 800)
Figure imgf000367_0003
[1841] Compound 800 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 4- (4-hydroxymethylpiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found: 523.64.
Example 701 N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- lH-imidazole-2- carboxamide (Compound 801
[1842] Compound 801 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, lH-imidazole-2-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C28H28N6O3: 497.22; found 496.97.
Example 702
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- 1H- imidazole-4-carboxamide Compound 802)
Figure imgf000368_0002
[1843] Compound 802 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, 1 -methyl- lH-imidazole-4-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H30N6O3: 511.24; found 511.01.
Example 703
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- 1H- imidazole-5-carboxamide Compound 803)
Figure imgf000368_0003
[1844] Compound 803 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, 1 -methyl- lH-imidazole-5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H30N6O3: 511.24; found 511.01.
Example 704
tert-Butyl 4-(4-((4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl) carbamoyl)phenyl)piperazine-l-carboxylate (Compound 804)
Figure imgf000369_0001
[1845] Compound 804 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 4-(4-i-BOC-piperazin-l-yl)benzoic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C40H46N6O5: 691.35; found 691.23.
Example 705
(+)-Benzyl 2-((4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl) carbamoyl)pyrrolidine-l-carboxylate (Compound 805)
Figure imgf000369_0002
[1846] Compound 805 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, l-benzyloxycarbanylpyrrolidine-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C37H39N5O5: 634.30; found 634.15.
Example 706
N-(4-((4-(lH-Pyrrole-2-carboxamido)phenyl)amino)phenyl)-4-morpholino-lH-pyrrole-2- carboxamide (Compound 806)
Figure imgf000370_0001
[1847] Compound 806 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, lH-pyrrole-2-carboxylic, and 4- morpholino-lH-pyrrole-2-carboxylic acids. 1H NMR (400 MHz, Acetone-J6) δ 10.75 (s, 1H), 10.31 (s, 1H), 9.01 (s, 1H), 8.91 (s, 1H), 7.62 (d, / = 8.6 Hz, 4H), 7.04 (m, 5H), 6.67 (s, 1H), 6.58 (s, 1H), 6.18 (s, 1H), 4.04 (dq, / = 1.8, 7 Hz, 2H), 3.72 (m, 4H), 1.19 (dq, / = 1.8, 7 Hz, 4H).
Example 707
N-(4-((4-Amino-2-fluorophenyl)amino)phenyl)-4-(4-hydroxypiperidin-l-yl)benzamide (Compound 807)
Figure imgf000370_0002
[1848] Compound 807 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine and 4-(4- hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C24H25FN4O2: 421.20; found 420.98.
Example 708
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamide (Compound 808)
Figure imgf000370_0003
[1849] Compound 808 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- lH-pyrrole- 2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30FN5O3: 528.23; found 528.02. Example 709
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-indole- -carboxamide (Compound 809)
Figure imgf000371_0001
[1850] Compound 809 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- lH-indole- 6-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H32FN5O3: 578.25; found 578.04.
Example 710
(+)-N-(4-((4-(4-(3-Hydroxypyrrolidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- lH-pyrrole-2-carboxamide (Compound 810)
Figure imgf000371_0002
[1851] Compound 810 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 4- (3-hydroxypyrrolidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29N5O3: 496.23; found: 495.95.
Example 711
(5,)-N-(4-((4-(4-(2-(Hydroxymethyl)pyrrolidin-l-yl)benzamido)phenyl)amino)phenyl)-l- methyl-lH-pyrrole-2-carboxamide (Compound 811)
Figure imgf000371_0003
[1852] Compound 811 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and (S)- 4-(2-hydroxymethylpyrrolidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O3: 510.24; found: 510.06.
Example 712
N-(4-((4-(4-(2-Hydroxyethyl)benzamido)phenyl)amino)phenyl)- 1 -methyl- lH-pyrrole-2- carboxamide (Compound 812
Figure imgf000372_0001
[1853] Compound 812 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 4- (2-hydroxyethyl)benzoic acids. [M+H]+ calcd for C27H26N4O4: 471.20; found: 470.92.
Example 713
4-Azido-N-(4-((4-(4-(4-hydroxypiperidin-l- yl)benzamido)phen l)amino)phenyl)benzamide (Compound 813)
Figure imgf000372_0002
[1854] Compound 813 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 4-azidobenzoic, and 4-(4-hydroxypiperidin- l-yl)benzoic acids. [M+H]+ calcd for C31H29N7O3: 548.23; found 548.07.
Example 714
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -ethyl- 1H- pyrrole-2-carboxamide Compound 814)
Figure imgf000372_0003
[1855] Compound 814 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -ethyl- lH-pyrrole-2-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found: 524.03.
Example 715
N-(4-((4-(3-Fluoro-4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamide Compound 815)
Figure imgf000373_0001
[1856] Compound 815 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 3- fluoro-4-(4-hydroxypiperidin-l-yl)benzoic acids. 1H NMR (400 MHz, Acetone-J6) δ 9.25 (s, IH), 8.94 (s, IH), 7.75 (dd, / = 1.9, 8.4 Hz, IH), 7.69 (m, 3H), 7.63 (d, / = 8.8 Hz, 2H), 7.22 (s, IH), 7.08 (m, 5H), 6.89 (m, 2H), 6.05 (m, IH), 3.95 (s, 3H), 3.47 (m, 2H), 2.95 (ddd, / = 3, 9.8, 12.4 Hz, 2H), 1.67 (m, 2H), 1.27 (m, 2H).
Example 716
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)-2-
(trifluoromethyl)phenyl)amino)phenyl)- 1 -methyl- lH-pyrrole-2-carboxamide (Compound 816)
Figure imgf000373_0002
[1857] Compound 816 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-trifluoromethylbenzene-l,4-diamine, 1-methyl- lH-pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30F3N5O3: 578.24; found: 578.04.
Example 717
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)-2-(cyano)phenyl)amino)phenyl)-l- methyl-lH-pyrrole-2-carboxamide (Compound 817)
Figure imgf000374_0001
[1858] Compound 817 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-cyanobenzene-l,4-diamine, 1 -methyl- lH-pyrrole- 2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30N6O3: 535.25; found: 535.04.
Example 718
N-(4-((4-(2-Chloro-4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamide Compound 818)
Figure imgf000374_0002
[1859] Compound 818 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 2- chloro-4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30CIN5O3: 544.20; found: 544.02.
Example 719
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -isopropyl- 1H- pyrrole-2-carboxamide Compound 819)
Figure imgf000374_0003
[1860] Compound 819 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -isopropyl- lH-pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H35N5O3: 538.27; found: 538.08.
Example 720 N-(4-((4-(4-(4-Hydroxy-4-trifluoromethylpiperidin- 1 - yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- lH-pyrrole-2-carboxamide (Compound 820)
Figure imgf000375_0001
[1861] Compound 820 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 4- (4-hydroxy-4-trifluoromethylpiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30F3N5O3: 578.23; found 578.04.
Example 721
(+)-N-(4-((4-(4-(2-Hydroxymethylmorpholi-4-no)benzamido)phenyl)amino)phenyl)-l- methyl-lH-pyrrole- -carboxamide (Compound 821)
Figure imgf000375_0002
[1862] Compound 821 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 4- (2-hydroxymethylmorpholi-4-no)benzoic acids. [M+H]+ calcd for C30H31N5O4: 526.24; found: 525.99.
Example 722
(+)-N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)pyrrolidine-2- carboxamide (Compound 822
Figure imgf000375_0003
[1863] Compound 822 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, pyrrolidine-2-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H33N5O3: 500.26; found 499.94.
Example 723
N-(4-((4-(4-(l,4-Dioxa-8-azaspiro[4.5]decan-8-yl)benzamido)phenyl)amino)phenyl)-l- methyl-lH-pyrrole-2-carboxamide Compound 823)
Figure imgf000376_0001
[1864] Compound 823 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 4- (l,4-dioxa-8-azaspiro[4.5]decan-8-yl)benzoic acids. [M+H]+ calcd for C32H33N5O4: 552.25; found: 552.05.
Example 724
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -vinyl- 1H- pyrrole-2-carboxamide Compound 824)
Figure imgf000376_0002
[1865] Compound 824 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -vinyl- lH-pyrrole-2-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H31N5O3: 522.24; found 522.01.
Example 725
3-Fluoro-4-(4-hydroxypiperidin- 1 -yl)-N-(4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido) phenyl)amino) henyl)benzamide (Compound 825)
Figure imgf000376_0003
[1866] Compound 825 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 3-fluoro-4-(4-hydroxypiperidin-l- yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C36H38FN5O4: 624.29; found 624.13.
Example 726
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-4-(4- hydroxypiperidin-l- l)benzamide (Compound 826)
Figure imgf000377_0001
[1867] Compound 826 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine and 4-(4- hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C36H38CIN5O4: 640.26; found 640.12.
Example 727
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)-2-
(methoxycarbonyl)phenyl)amino)phenyl)- 1 -methyl- lH-pyrrole-2-carboxamide
(Compound 827)
Figure imgf000377_0002
[1868] Compound 827 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-methoxycarbonylbenzene-l,4-diamine, 1-methyl- lH-pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H33N5O5: 568.26; found: 568.05.
Example 728
5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)-2-((4-( 1 -methyl- lH-pyrrole-2- carboxamido)phenyl)
amino )benzoic acid (Compound 828)
Figure imgf000378_0001
[1869] Compound 828 was prepared by hydrolysis of Compound 827.
[M+H]+ calcd for C31H31N5O5: 554.24; found: 554.01.
Example 729
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -cyanomethyl- lH-pyrrole-2-carboxamide Compound 829)
Figure imgf000378_0002
[1870] Compound 829 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, l-cyanomethyl-lH-pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30N6O3: 535.24; found: 535.04.
Example 730
Ethyl 2-(2-chloro-5-((4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino) phenyl)carbamoyl -lH-pyrrol-l-yl)acetate (Compound 830)
Figure imgf000378_0003
[1871] Compound 830 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, 5-chloro-l-ethoxycarbonylmethyl-lH- pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H34CIN5O5: 616.22; found: 616.06.
Example 731
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)-2-fluorophenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamide (Compound 831)
Figure imgf000379_0001
[1872] Compound 831 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- lH-pyrrole- 2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30FN5O3: 528.23; found 528.02.
Example 732
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)-2-chlorophenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamide (Compound 832)
Figure imgf000379_0002
[1873] Compound 832 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, 1 -methyl- 1H- pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30CIN5O3: 544.20; found 544.02.
Example 733
N-(5-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)pyridin-2-yl)- 1 -methyl- lH-pyrrole-2-carboxamide (Compound 833)
Figure imgf000379_0003
[1874] Compound 833 was prepared according to the procedure described in Scheme IV from N 5-(4-aminophenyl)pyridine-2,5-diamine, 1 -methyl- lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H30N6O3: 511.24; found 511.01. Example 734
N-(3-Cyano-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-4-(4- hydroxypiperidin-l- l)benzamide (Compound 834)
Figure imgf000380_0001
[1875] Compound 834 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-cyanobenzene-l,4-diamine and 4-(4- hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C37H38N6O4: 631.30; found: 631.11.
Example 735
iV-(4-((4-(4-(4-(2-Hydroxyethoxy)piperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole- -carboxamide (Compound 835)
Figure imgf000380_0002
[1876] Compound 835 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 4- (4-(2-hydroxyethoxy)piperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H37N5O4: 568.28; found: 568.12.
Example 736
2-(2-((4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)carbamoyl)- lH-pyrrol-l-yl)acetic acid (Compound 836)
Figure imgf000380_0003
[1877] Compound 836 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, l-methoxycarbonylmethyl-lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H31N5O5: 554.23; found: 554.01.
Example 737
iV-(4-((4-(3-Methyl-4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamide Compound 837)
Figure imgf000381_0001
[1878] Compound 837 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 3- methyl-4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found: 524.03.
Example 738
(+)-N-(4-((4-(4-(4-(2,6-Dimethyl)morpholi-4-no)benzamido)phenyl)amino)phenyl)-l- methyl-lH-pyrrole-2-carboxamide (Compound 838)
Figure imgf000381_0002
[1879] Compound 838 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 4- (2,6-dimethylmorpholi-4-no)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found: 524.03.
Example 739
N-(4-((4-(3-Methoxy-4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamide Compound 839)
Figure imgf000381_0003
[1880] Compound 839 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 3- methoxy-4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O4: 540.25; found: 540.03.
Example 740
N-(4-((4-(3-Trifluoromethyl-4-(4-hydroxypiperidin- 1 - yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- lH-pyrrole-2-carboxamide (Compound 840)
Figure imgf000382_0001
[1881] Compound 840 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-2-carboxylic, and 3- trifluoromethyl-4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30F3N5O3: 578.23; found: 578.04.
Example 741
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-2,4-dimethyl- lH-pyrrole-3-carboxamide Compound 841)
Figure imgf000382_0002
[1882] Compound 841 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 2,4-dimethyl-lH-pyrrole-3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found 524.03.
Example 742
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -(2- hydroxyethyl)-lH-pyrrole-2-carboxamide (Compound 842)
Figure imgf000383_0001
[1883] Compound 842 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, l-(2-hydroxyethyl)-lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O4: 540.25; found: 540.03.
Example 743
1 -Ethyl-N-(3-fluoro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- lH-pyrrole-2-carboxamide Compound 843)
Figure imgf000383_0002
[1884] Compound 843 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -ethyl- lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H32FN5O3: 542.25; found: 542.06.
Example 744
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-indole-2-carboxamide Compound 844)
Figure imgf000383_0003
[1885] Compound 844 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- lH-indole- 2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H32FN5O3: 578.25; found 578.11. Example 745
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-5- methyl-lH-indole-2-carboxamide Compound 845)
Figure imgf000384_0001
[1886] Compound 845 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- lH-indole- 5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H32FN5O3: 578.25; found 578.11.
Example 746
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-indole-2-carboxamide Compound 846)
Figure imgf000384_0002
[1887] Compound 846 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, 1 -methyl- lH-indole- 2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H32CIN5O3: 594.22; found 594.11.
Example 747
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-5- methyl-lH-indole-2-carboxamide Compound 847)
Figure imgf000384_0003
[1888] Compound 847 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, 1 -methyl- lH-indole- 5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H32CIN5O3: 594.22; found 594.11.
Example 748
N-(4-((2-Cyano-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -ethyl- lH-pyrrole-2-carboxamide Compound 848)
Figure imgf000385_0001
[1889] Compound 848 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-cyanobenzene-l,4-diamine, 1 -ethyl- lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H32N6O3: 549.25; found: 549.08.
Example 749
iV-(3-Methyl-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamide Compound 849)
Figure imgf000385_0002
[1890] Compound 849 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-methylbenzene-l,4-diamine, 1 -methyl- 1H- pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found 524.03.
Example 750
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)-2-methylphenyl)- 1 - methyl- lH-pyrrole-2-carboxamide (Compound 850)
Figure imgf000386_0001
[1891] Compound 850 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-3-methylbenzene-l,4-diamine, 1 -methyl- 1H- pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found 524.03.
Example 751
iV-(4-((2-Methyl-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - ethyl- lH-pyrrole-2-carboxamide Compound 851)
Figure imgf000386_0002
[1892] Compound 851 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-methylbenzene-l,4-diamine, 1 -ethyl- lH-pyrrole- 2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. 1H NMR (400 MHz, Acetone-d6) δ 9.09 (s, 1H), 8.95 (s, 1H), 7.89 (d, / = 9.0 Hz, 2H), 7.66 (m, 3H), 7.54 (dd. / = 2.4, 8.6 Hz, 1H), 7.16 (d, / = 8.6 Hz, 1H), 6.99 (m, 3H), 6.94 (dd, / = 2.6, 4.0 Hz, 1H), 6.89 (d, / = 9.0 Hz, 2H), 6.57 (s, 1H), 6.09 (dd, / = 2.6, 4.0 Hz, 1H), 4.46 (q, / = 7.1 Hz, 2H), 3.85 (m, 1H), 3.75 (dt, / = 4.4, 13 Hz, 2H), 3.08 (ddd, / = 3.2, 9.8, 13.0 Hz, 2H), 2.26 (s, 3H), 1.93 (m, 2H), 1.60 (m, 2H), 1.39 (t, / = 7.1 Hz, 3H).
Example 752
N-(3-Cyano-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-3-carboxamide Compound 852)
Figure imgf000386_0003
[1893] Compound 852 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-cyanobenzene-l,4-diamine, 1 -methyl- lH-pyrrole- 3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30N6O3: 535.25; found: 535.04.
Example 753
N-(4-((2-Cyano-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-3-carboxamide Compound 853)
Figure imgf000387_0001
[1894] Compound 853 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-cyanobenzene-l,4-diamine, 1 -methyl- lH-pyrrole- 3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30N6O3: 535.25; found: 535.04.
Example 754
(R)-N-(4-((4-(4-(3-Hydroxypyrrolidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- lH-pyrrole-3-carboxamide (Compound 854)
Figure imgf000387_0002
[1895] Compound 854 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1 -methyl- lH-pyrrole-3-carboxylic, and (R)- 4-(3-hydroxypyrrolidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29N5O3: 496.23; found: 495.95.
Example 755
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-4,5-dimethyl- lH-pyrrole-3-carboxamide (Compound 855)
Figure imgf000388_0001
[1896] Compound 855 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 4,5-dimethyl-lH-pyrrole-3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found: 524.03.
Example 756
Methyl 5-((4-((4-(4-(4-hydroxypiperidin-l- yl)benzamido)phenyl)amino)phenyl)carbamoyl)-lH-pyrrole-2-carboxylate (Compound 856)
Figure imgf000388_0002
[1897] Compound 856 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 5-methoxycarbonyl-lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H31N5O5: 554.13; found: 554.07.
Example 757
(R)-N-(4-((2-Fluoro-4-(4-(3-hydroxypyrrolidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole- -carboxamide (Compound 857)
Figure imgf000388_0003
[1898] Compound 857 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- lH-pyrrole- 3-carboxylic, and (R)-4-(3-hydroxypyrrolidin-l-yl)benzoic acids. [M+H]+ calcd for C29H28FN5O3: 514.22; found: 513.98. Example 758
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-4- (methoxymethyl)-l -meth l- lH-pyrrole-2-carboxamide (Compound 858)
Figure imgf000389_0001
[1899] Compound 858 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 4-methoxymethyl-l -methyl- lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H36N5O4: 554.28; found: 554.07.
Example 759
N-(4-((2-Fluoro-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-3-carboxamide (Compound 859)
Figure imgf000389_0002
[1900] Compound 859 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- lH-pyrrole- 3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30FN5O3: 528.23; found 528.02.
Example 760
N-(4-((2-Fluoro-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrole-3-carboxamide ompound 860)
Figure imgf000389_0003
[1901] Compound 860 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, lH-pyrrole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H28FN5O3: 514.22; found 513.98.
Example 761
N-(4-((4-(lH-Pyrrole-3-carboxamido)phenyl)amino)-3-fluorophenyl)-l-methyl-lH- pyrrole-2-carboxamide (Compound 861)
Figure imgf000390_0001
[1902] Compound 861 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine and lH-pyrrole-3- carboxylic acid. [M+H]+ calcd for C23H20FN5O2: 418.16; found 417.88.
Example 762
N-(4-((4-(lH-pyrrole-3-carboxamido)phenyl)amino)-3-fluorophenyl)-lH-indole-5- carboxamide (Compound 862)
Figure imgf000390_0002
[1903] Compound 862 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, lH-indole-5- carboxylic, and lH-pyrrole-3-carboxylic acids. [M+H]+ calcd for C26H20FN5O2: 454.16; found 453.91.
Example 763
N-(4-((4-(4-(Dimethylamino)benzamido)phenyl)amino)phenyl)-lH-pyrrole-3- carboxamide (Compou
Figure imgf000390_0003
[1904] Compound 863 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 4-dimethylaminobenzoic, and lH-pyrrole-
3- carboxylic acids. [M+H]+ calcd for C26H25N5O2: 440.20; found 439.94.
Example 764
4- Azido-N-(4-((4-(4-(dimethylamino)benzamido)phenyl)amino)phenyl)benzamide (Compound 864)
Figure imgf000391_0001
[1905] Compound 864 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 4-dimethylaminobenzoic, and 4- azidobenzoic acids.
[M+H]+ calcd for C28H25N7O2: 492.21 ; found 491.97.
Example 765
N-(4-((4-(4-(lH-Pyrrole-3-carboxamido)benzamido)phenyl)amino)phenyl)-lH-pyrrole-3- carboxamide (Compound 865)
Figure imgf000391_0002
[1906] Compound 865 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 4-aminobenzoic, and lH-pyrrole-3- carboxylic acids.
[M+H]+ calcd for C29H24N6O3: 505.19; found 504.93.
Example 766
(R)-N-(4-((4-(4-(3-Hydroxypyrrolidin-l-yl)benzamido)phenyl)amino)phenyl)-2,4- dimethyl-lH-pyrrol -3-carboxamide (Compound 866)
Figure imgf000391_0003
[1907] Compound 866 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 2,4-dimethyl-lH-pyrrole-3-carboxylic, and (R)-4-(3-hydroxypyrrolidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O3: 510.24; found: 509.99.
Example 767
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)-5-methyl- 1H- pyrrole-3-carboxamide (Compound 867)
Figure imgf000392_0001
[1908] Compound 867 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 5-methyl-lH-pyrrole-3-carboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O3: 510.24; found: 509.99.
Example 768
N-(3-Cyano-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -ethyl- lH-pyrrole-2-carboxamide (Compound 868)
Figure imgf000392_0002
[1909] Compound 868 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-cyanobenzene-l,4-diamine, 1 -ethyl- lH-pyrrole-2- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H32N6O3: 549.25; found: 549.08.
Example 769
N-(3-Cyano-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrole-3-carboxamide (Compound 869)
Figure imgf000393_0001
[1910] Compound 869 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-cyanobenzene-l,4-diamine, lH-pyrrole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H28N6O3: 521.22; found: 521.00.
Example 770
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-2,4- dimethyl-lH-pyrrole-3-carboxamide Compound 870)
Figure imgf000393_0002
[1911] Compound 870 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 2,4-dimethyl-lH- pyrrole-3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H32FN5O3: 542.25; found 542.06.
Example 771
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrole-3-carboxamide Compound 871)
Figure imgf000393_0003
[1912] Compound 871 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, lH-pyrrole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H28C1N503: 530.19; found 529.97. Example 772
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)j
methyl- lH-pyrrole-3-carboxamide (Compound 872)
Figure imgf000394_0001
[1913] Compound 872 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, 1 -methyl- 1H- pyrrole-3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30CIN5O3: 544.20; found 544.02.
Example 773
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrazole-4-carboxamide (Compound 873)
Figure imgf000394_0002
[1914] Compound 873 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, 1 -methyl- 1H- pyrazole-4-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29CIN6O3: 545.20; found 544.96.
Example 774
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrazole-5-carboxamide (Compound 874)
Figure imgf000394_0003
[1915] Compound 874 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- 1H- pyrazole-5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29FN6O3: 529.23; found 529.03.
Example 775
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrazole-5-carboxamide Compound 875)
Figure imgf000395_0001
[1916] Compound 875 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, 1 -methyl- 1H- pyrazole-5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29CIN6O3: 545.20; found 544.96.
Example 776
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrazole-4-carboxamide Compound 876)
Figure imgf000395_0002
[1917] Compound 876 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- 1H- pyrazole-4-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29FN6O3: 529.23; found 529.03.
Example 777
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)-2-methylphenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-2-carboxamide (Compound 877)
Figure imgf000396_0001
[1918] Compound 877 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-methylbenzene-l,4-diamine, 1 -methyl- 1H- pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found 524.03.
Example 778
N-(4-((2-Cyano-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrole-3-carboxamide (Compound 878)
Figure imgf000396_0002
[1919] Compound 878 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-cyanobenzene-l,4-diamine, lH-pyrrole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H28N6O3: 521.22; found: 521.00.
Example 779
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -ethyl- lH-pyrrole-2-carboxamide Compound 879)
Figure imgf000396_0003
[1920] Compound 879 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, 1 -ethyl- lH-pyrrole- 2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H32CIN5O3: 558.22; found 558.06. Example 780
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- indole-5-carboxamide ompound 880)
Figure imgf000397_0001
[1921] Compound 880 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, lH-indole-5- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H30CIN5O3: 580.20; found 580.00.
Example 781
N-(3-Fluoro-4-((4-(4-(4-ethoxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-lH- pyrrole-3-carboxamide ompound 881)
Figure imgf000397_0002
[1922] Compound 881 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, lH-pyrrole-3- carboxylic, and 4-(4-ethoxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H32FN5O3: 542.25; found: 542.06.
Example 782
N-(3-Fluoro-4-((4-(4-(4-ethoxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-l- methyl-lH-pyrazole- -carboxamide (Compound 882)
Figure imgf000397_0003
[1923] Compound 882 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- 1H- pyrazole-5-carboxylic, and 4-(4-ethoxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33FN6O3: 557.26; found: 557.11.
Example 783
N-(4-((5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)pyridin-2-yl)amino)phenyl)- 1 -methyl- lH-pyrrole-3-carboxamide (Compound 883)
Figure imgf000398_0001
[1924] Compound 883 was prepared according to the procedure described in Scheme IV from N -(4-aminophenyl)pyridine-2,5-diamine, 1 -methyl- lH-pyrrole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H30N6O3: 511.24; found 511.01.
Example 784
N-(6-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)pyridin-3-yl)- 1 -methyl- lH-pyrrole-3-carboxamide (Compound 884)
Figure imgf000398_0002
[1925] Compound 884 was prepared according to the procedure described in Scheme IV from N -(4-aminophenyl)pyridine-2,5-diamine, 1 -methyl- lH-pyrrole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H30N6O3: 511.24; found 511.01.
Example 785
N-(4-((2-Cyano-4-(4-(4-trifluoromethylpiperidin-l-yl)benzamido)phenyl)amino)phenyl)- lH-pyrrole-3-carboxamide (Compound 885)
Figure imgf000399_0001
[1926] Compound 885 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-cyanobenzene-l,4-diamine, lH-pyrrole-3- carboxylic, and 4-(4-trifluoromethylpiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H27F3N6O2: 573.21; found: 573.05.
Example 786
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-4- methyl-lH-pyrrole- -carboxamide (Compound 886)
Figure imgf000399_0002
[1927] Compound 886 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 4-methyl-lH-pyrrole- 3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30FN5O3: 528.24; found: 528.02.
Example 787
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-5- methyl-lH-pyrrole-3-carboxamide (Compound 887)
Figure imgf000399_0003
[1928] Compound 887 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 5-methyl-lH-pyrrole- 3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30FN5O3: 528.24; found: 528.08. Example 788
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- indole-5-carboxamide Compound 888)
Figure imgf000400_0001
[1929] Compound 888 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, lH-indole-5- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H30FN5O3: 564.23; found 564.07.
Example 789
N-(4-((2-Cyano-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- indole-5-carboxamide Compound 889)
Figure imgf000400_0002
[1930] Compound 889 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-cyanobenzene-l,4-diamine, lH-indole-5- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H30N6O3: 571.25; found: 571.02.
Example 790
N-(4-((2-Cyano-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrazole-5-carboxamide Compound 890)
Figure imgf000400_0003
[1931] Compound 890 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-cyanobenzene-l,4-diamine, 1 -methyl- 1H- pyrazole-5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H29N7O3: 536.24; found: 536.05.
Example 791
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 ,3-dimethyl- lH-pyrazole-4-carboxamide Compound 891)
Figure imgf000401_0001
[1932] Compound 891 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, l,3-dimethyl-lH-pyrazole-4-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H32N6O3: 525.25; found 525.05.
Example 792
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-l,3- dimethyl-lH-pyrazole-4-carboxamide Compound 892)
Figure imgf000401_0002
[1933] Compound 892 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1,3-dimethyl-lH- pyrazole-4-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31FN6O3: 543.24; found 543.07.
Example 793
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 ,5-dimethyl- lH-pyrazole-4-carboxamide (Compound 893)
Figure imgf000402_0001
[1934] Compound 893 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, l,5-dimethyl-lH-pyrazole-4-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H32N6O3: 525.25; found 525.05.
Example 794
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-l,5- dimethyl-lH-pyrazole-4-carboxamide (Compound 894)
Figure imgf000402_0002
[1935] Compound 894 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1,5-dimethyl-lH- pyrazole-4-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31FN6O3: 543.24; found 543.07.
Example 795
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-l,5- dimethyl-lH-pyrazole-4-carboxamide (Compound 895)
Figure imgf000402_0003
[1936] Compound 895 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, 1,5-dimethyl-lH- pyrazole-4-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31CIN6O3: 559.21 ; found 559.00. Example 796
N-(3-Chloro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-l,3- dimethyl-lH-pyrazole-4-carboxamide (Compound 896)
Figure imgf000403_0001
[1937] Compound 896 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, 1,3-dimethyl-lH- pyrazole-4-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31CIN6O3: 559.21; found 559.00.
Example 797
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-3,5-dimethyl- lH-pyrazole-4-carboxamide (Compound 897)
Figure imgf000403_0002
[1938] Compound 897 was prepared according to the procedure described in Scheme IV from 4,4' -diaminodiphenylamine, 3,5-dimethyl-lH-pyrazole-4-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H32N6O3: 525.25; found 525.05.
Example 798
N-(4-((2-Fluoro-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrazole-5-carboxamide (Compound 898)
Figure imgf000403_0003
[1939] Compound 898 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1 -methyl- 1H- pyrazole-5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29FN6O3: 529.23; found: 529.03.
Example 799
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)- 1,4,5,6- tetrahydrocyclopenta c]pyrazole-3-carboxamide (Compound 899)
Figure imgf000404_0001
[1940] Compound 899 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 1,4,5, 6-tetrahydrocyclopenta[c]pyrazole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H32N6O3: 537.25; found 537.06.
Example 800
N-(4-((4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 -ethyl-5- methyl-lH-pyrrole-2-carboxamide Compound 900)
Figure imgf000404_0002
[1941] Compound 900 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, l-ethyl-5-methyl-lH-pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H35N5O3: 538.27; found: 538.08.
Example 801
N-(4-((4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-5- hydroxymethyl-lH-pyrrole-2-carboxamide (Compound 901)
Figure imgf000405_0001
[1942] Compound 901 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 5-hydroxymethyl-lH-pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H33N5O5: 568.16; found: 568.05.
Example 802
Methyl 4-((4-((4-(4-(4-hydroxypiperidin-l- yl)benzamido)phenyl)amino)phenyl)carbamoyl)-lH-pyrrole-2-carboxylate (Compound 902)
Figure imgf000405_0002
[1943] Compound 902 was prepared according to the procedure described in Scheme IV from 4,4'-diaminodiphenylamine, 5-methoxycarbonyl-lH-pyrrole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O4: 526.12; found: 526.06.
Example 803
N-(3-Fluoro-4-((2-fluoro-4-(4-(4-hydroxypiperidin- 1 - yl)benzamido)phen l)amino)phenyl)- lH-pyrrole-2-carboxamide (Compound 903)
Figure imgf000405_0003
[1944] Compound 903 was prepared according to the procedure described in Scheme IV from 4,4'-diamino-2,2'-difluorodiphenylamine, lH-pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H27F2N5O3: 532.21; found: 532.00. Example 804
N-(3-Fluoro-4-((2-fluoro-4-(4-(4-hydroxypiperidin-l- yl)benzamido)phenyl)amino)phenyl)- 1 -methyl- lH-pyrazole-5-carboxamide (Compound 904)
Figure imgf000406_0001
[1945] Compound 904 was prepared according to the procedure described in Scheme IV from 4,4'-diamino-2,2'-difluorodiphenylamine, 1 -methyl- lH-pyrazole-5- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H28F2N6O3: 547.22; found: 547.05.
Example 805
N-(3-Fluoro-4-((2-fluoro-4-(4-(4-hydroxypiperidin- 1 - yl)benzamido)phen l)amino)phenyl)- lH-pyrrole-3-carboxamide (Compound 905)
Figure imgf000406_0002
[1946] Compound 905 was prepared according to the procedure described in Scheme IV from 4,4'-diamino-2,2'-difluorodiphenylamine, lH-pyrrole-3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H27F2N5O3: 532.21; found 532.00.
Example 806
N-(4-((2-Fluoro-4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-5- methyl-lH-pyrrole-3-carboxamidee Compound 906)
Figure imgf000406_0003
[1947] Compound 906 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-f uorobenzene-l,4-diamine, 5-methyl-lH-pyrrole- 3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30FN5O3: 528.23; found: 528.02.
Example 807
N-(4-((2-Fluoro-4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)-4- methyl-lH-pyrrole-3-carboxamidee Compound 907)
Figure imgf000407_0001
[1948] Compound 907 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 4-methyl-lH-pyrrole- 3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30FN5O3: 528.23; found: 528.02.
Example 808
N-(4-((2-Chloro-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrole-3-carboxamidee Compound 908)
Figure imgf000407_0002
[1949] Compound 908 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, lH-pyrrole-3- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H28C1N503: 530.19; found 529.97.
Example 809
N-(4-((2-Chloro-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1 - methyl- lH-pyrrole-3-carboxamidee (Compound 909)
Figure imgf000408_0001
[1950] Compound 909 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-chlorobenzene-l,4-diamine, 1 -methyl- 1H- pyrrole-3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30CIN5O3: 544.20; found 544.02.
Example 810
N-,N'-(Azanediylbis(3-fluoro-4, 1 -phenylene))bis(4-(4-hydroxypiperidin- 1 -yl)benzamide) (Compound 910
Figure imgf000408_0002
[1951] Compound 910 was prepared according to the procedure described Scheme IV from 4,4'-diamino-2,2'-difluorodiphenylamine and 4-(4-hydroxypiperidin- yl)benzoic acid. [M+H]+ calcd for C36H37F2N5O4: 642.28; found 642.12
Example 811
N-(4-((2-Fluoro-4-(4-(4,4-difluoropiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- pyrrole-3-carboxamidee Compound 911)
Figure imgf000408_0003
[1952] Compound 911 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, lH-pyrrole-3- carboxylic, and 4-(4,4-difluoropiperidin-l-yl)benzoic acids. 1H NMR (400 MHz, Acetone-J6) δ 10.54 (s, 1H), 9.39 (s, 1H), 8.88 (s, 1H), 7.92 (m, 3H), 7.69 (d, / = 8.8 Hz, 2H), 7.54 (m, 1H), 7.43 (d, / = 8.8 Hz, 1H), 7.25 (t, / = 9.2 Hz, 1H), 7.07 (t, / = 8.8 Hz, 4H), 6.91 (s, 1H), 6.85 (q, / = 2.3 Hz, 1H), 6.71 (q, / = 1.6 Hz, 1H), 3.55 (t, / = 5.8 Hz, 4H), 2.11 (m, 4H).
Example 812
N-(4-((2-Fluoro-4-(4-(4-hydroxypiperidin- 1 -yl)benzamido)phenyl)amino)phenyl)- 1H- indole-5-carboxamidee (Compound 912)
Figure imgf000409_0001
[1953] Compound 912 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, lH-indole-5- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H30FN5O3: 564.23; found 564.07.
Example 813
N-(3-Fluoro-4-((4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)amino)phenyl)- 1,4,5- trimethyl-lH-pyrrole-3-carboxamide Compound 913)
Figure imgf000409_0002
[1954] Compound 913 was prepared according to the procedure described in Scheme IV from N7-(4-aminophenyl)-2-fluorobenzene-l,4-diamine, 1,4,5-trimethyl-lH- pyrrole-3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H34FN5O3: 556.26; found: 556.03.
Example 814
iV-,iV-(Oxybis(4, 1 -phenylene))bis(4-(4-hydroxypiperidin- 1 -yl)benzamide) (Compound 914)
Figure imgf000409_0003
[1955] Compound 914 was prepared according to the procedure described in Scheme IV from 4,4'-oxydianiline and 4-(4-hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C36H38N4O5: 607.28; found 607.21.
Example 815
iV-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenoxy)phenyl)- 1 -methyl- lH-pyrrole- 2-carboxamide (Com ound 915)
Figure imgf000410_0001
[1956] Compound 915 was prepared according to the procedure described in Scheme IV from 4,4' -oxydianiline, 1 -methyl- lH-pyrrole-2-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30N4O4: 511.23; found 511.01.
Example 816
iV-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenoxy)phenyl)- lH-pyrrole-2- carboxamide (Com ound 916)
Figure imgf000410_0002
[1957] Compound 916 was prepared according to the procedure described in Scheme IV from 4,4' -oxydianiline, lH-pyrrole-2-carboxylic, and 4-(4-hydroxypiperidin- l-yl)benzoic acids. [M+H]+ calcd for C29H28N4O4: 497.21; found 496.97.
Example 817
N-(4-(4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenoxy)phenyl)-lH-indole-6- carboxamide (Compound 917)
Figure imgf000410_0003
[1958] Compound 917 was prepared according to the procedure described Scheme IV from 4,4' -oxydianiline, lH-indole-6-carboxylic, and 4-(4-hydroxypiperidin- yl)benzoic acids. [M+H]+ calcd for C33H30N4O4: 547.23; found 547.05.
Example 818
iV-(4-(4-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)phenoxy)phenyl)- 1 -methyl- lH-indole-3- carboxamide (Com ound 918)
Figure imgf000411_0001
[1959] Compound 918 was prepared according to the procedure described in Scheme IV from 4,4' -oxydianiline, 1 -methyl- lH-indole-3-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H32N4O4: 561.24; found
561.10.
Example 819
N-(4-(4-Aminophenox henyl)-4-(4-hydroxypiperidin- 1 -yl)benzamide (Compound 919)
Figure imgf000411_0002
[1960] Compound 919 was prepared according to the procedure described in Scheme IV from 4,4' -oxydianiline and 4-(4-hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C24H25N3O3: 404.19; found 404.05.
Example 820
N-(3-((lH-Indol-6-yl)amino)-3-oxopropyl)-4-(4-(4-hydroxypiperidin-l- yl)benzamido)benzamide Compound 920)
Figure imgf000411_0003
[1961] Compound 920 was prepared according to the procedure described in Scheme IV from 6-aminoindole, 3-aminopropanoic, 4-aminobenzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C30H31N5O4: 526.24; found
525.99.
Example 821
N-(4-(5-(4-(4-Methoxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 -yl)phenyl)thiophene-2- carboxamide (Com ound 921)
Figure imgf000412_0001
[1962] Compound 921 was prepared according to the general procedure described in Scheme IV. Preparation of 4-fluoro-N-(lH-indazol-5-yl)benzamide: 1H- Indazol-5-amine (5.5g, 41 mmol), hydroxybenzotriazole (558 mg, 4.13 mmol), triethylamine (6.3 mL, 45 mmol), and 4-fluorobenzoic acid (6.36 g, 45 mmol) were taken up in DMF (207 mL) and stirred. EDC (8.7 g, 45 mmol) was added to the solution last. After the addition, the solution was stirred at room temperature for 4 h. Water was then added to the solution and stirred for 10 min. The formed precipitate was filtered and washed well with water, followed by hexanes. The solid was dried under vacuum to give 10.3 g (98%) of the product as a light purple solid.
[1963] Preparation of N-(l-(4-aminophenyl)-lH-indazol-5-yl)-4- fluorobenzamide: 4-Fluoro-N-(lH-indazol-5-yl)benzamide (10.3 g, 40 mmol), 4- fluoronitrobenze (4.3 mL, 40 mmol) and cesium carbonate (13 g, 40 mmol) were taken up in DMSO (400 mL). The solution was heated to 100 °C and stirred for 24 h. After the solution was cooled it was diluted with water until a precipitate formed and stirred well for 5 min. Filtration gave a yellow solid, which was then washed well with water, followed by hexanes. After the solid was dried under vacuum it was taken up in ethanol and stirred at RT under nitrogen. The solution was treated with Pd(OH)2 (100 mg) and placed under a balloon of H2 gas. After stirring at RT for 24 h, the catalyst was removed via filtration through celite. The filtrate was concentrated under reduced pressure to give 9.36 g (67%) of a crude product as a yellow solid
[1964] Preparation of N-(4-(5-(4-fluorobenzamido)-lH-indazol-l- yl)phenyl)thiophene-2-carboxamide: N-(l-(4-Aminophenyl)-lH-indazol-5-yl)-4- fluorobenzamide (400 mg, 1.15 mmol) was taken up in anhydrous pyridine (5.8 mL) and stirred at RT. Thiophene-2-carbonyl chloride (0.15 mL, 1.44 mmol) was then added dropwise and the solution was stirred at RT for 4 h. Added water, EtOAc and hexanes to the solution and stirred vigorously for 1 h. to form a precipitate. Filtered off the solid and dried under vacuum to obtain 539 mg (94%) of the product as an off-white solid.
[1965] Preparation of Compound 921: N-(4-(5-(4-Fluorobenzamido)-lH- indazol-l-yl)phenyl)thiophene-2-carboxamide (25 mg, 0.05 mmol), 4-methoxypiperidine (165 mg, 1.09 mmol), cesium carbonate (357 mg, 1.09 mmol) and DMSO (1 mL) were added to a microwave vial. The mixture was heated in a microwave at 130 °C for 5 h. Water was added to the cooled solution and shaken vigorously, which formed a precipitate. The solid was filtered and washed with water, followed by hexanes. Took up the solid with a CH2Cl2/MeOH mixture and concentrated under reduced pressure onto silica. Purification via flash chromatography (0-10% MeOH/ CH2C12) produced 18.6 mg
(61%) of compound 921. 1H NMR (500MHz, DMSO-d6) 10.41 (s, 1H), 10.06 (s, 1H), 8.37 (s, 1H), 8.32 (s, 1H), 8.05 (d, / = 5 Hz, 1H), 7.94 (d, / = 9 Hz, 2H), 7.88 (d, / = 9 Hz, 2H), 7.86 (d, / = 1 Hz, 1H), 7.83 (d, / = 9 Hz, 2H), 7.77 (d, / = 9.5 Hz, 1H), 7.77 (d, / = 9 Hz, 2H), 7.24 (dd, / = 4, 5 Hz, 1H), 7.00 (d, / = 9 Hz, 2H), 5.75 (s, 3H), 3.66-3.63 (m, 2H), 3.07-3.02 (m, 2H), 1.94-1.88 (m, 2H), 1.52-1.45 (m, 2H).
Example 822
iV-(4-(5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 - yl)phenyl)benzo[d thiazole-5-carboxamide (Compound 922)
Figure imgf000413_0001
[1966] Compound 922 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, benzo[d]thiazole-5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H28N6O3S: 589.19; found: 589.12.
Example 823
iV-(4-(5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 - yl)phenyl)isonicotinamide (Compound 923)
Figure imgf000414_0001
[1967] Compound 923 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, isonictinic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H28N6O3: 533.22; found: 533.14.
Example 824
N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(4-(2- hydroxyethyl)piperidin-l- l)benzamide (Compound 924)
Figure imgf000414_0002
[1968] Compound 924 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(4- (2-hydroxyethyl)piperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O3: 524.26; found: 524.10.
Example 825
(+)-N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(3-hydroxypiperidin- l-yl)benzamide (Com ound 925)
Figure imgf000414_0003
[1969] Compound 925 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(3- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29N5O3: 496.23; found: 496.14.
Example 826
N-(l-(4-(2,2-Difluorocyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(4- hydroxypiperidin-l-yl)benzamide (Compound 926)
Figure imgf000415_0001
[1970] Compound 926 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 2,2- difluorocyclopropanecarboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500MHz, DMSO-d6) δ 7.38 (s, IH), 7.37 (m, IH), 7.04 (d, / = 5 Hz, IH), 7.94 (d, / = 8.5 Hz, 2H), 6.98 (d, / = 9 Hz, 2H), 6.87 (d, / = 11 Hz, 2H), 6.85 (d, / = 9 Hz, 2H), 6.19 (d, / = 9 Hz, 2H), 3.01-2.93 (m, 3H), 2.22 (ddd, J = 3, 10.5, 13 Hz, 2H), 1.94-1.88 (m, IH), 1.32-1.27 (m, IH), 1.16-1.12 (m, 2H), 1.07-1.00 (m, IH), 0.82-0.74 (m, 2H).
Example 827
iV-(4-(5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 -yl)phenyl)- 1 -methyl- 1H- indole-6-carboxamide (Compound 927)
Figure imgf000415_0002
[1971] Compound 927 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 1 -methyl- lH-indole-6-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C35H32N6O3: 585.25; found: 585.15.
Example 828
(+)-N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(3- hydroxymethylpiperidin-l- l)benzamide (Compound 928)
Figure imgf000415_0003
[1972] Compound 928 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(3- hydroxymethylpiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O3: 510.24; found: 510.12. Example 829
N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(4-oxopiperidin-l- yl)benzamide (Com ound 929)
Figure imgf000416_0001
[1973] Compound 929 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(4- oxopiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H27N5O3: 494.21; found: 494.06.
Example 830
N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-l -methyl- lH-indole-5- carboxamide (Compound 930
Figure imgf000416_0002
[1974] Compound 930 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 1- methyl-lH-indole-5-carboxylic acids. [M+H]+ calcd for C27H23N5O2: 450.19; found: 450.06.
Example 831
N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(4- (hydroxyimino)piperidin-l- l)benzamide (Compound 931)
Figure imgf000416_0003
[1975] Compound 931 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(4- (hydroxyimino)piperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H28N6O3: 509.22; found: 509.10.
Example 832 (+)-N-(l-(4-(2-Methylcyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(4- hydroxypiperidin-l- l)benzamide (Compound 932)
Figure imgf000417_0001
[1976] Compound 932 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 2-methylcyclopropanecarboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O3: 510.24; found: 510.13.
Example 833
N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(4-hydroxy-4- (pyrrolidin-l-ylmethyl)piperidin-l-yl)benzamide (Compound 933)
Figure imgf000417_0002
[1977] Compound 933 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(4- hydroxy-4-(pyrrolidin- 1 -ylmethyl)piperidin- 1 -yl)benzoic acids .
Example 834
N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(2- hydroxyethylamino)benzamide Compound 934)
Figure imgf000417_0003
[1978] Compound 934 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(2- hydroxyethylamino)benzoic acids. [M+H]+ calcd for C26H25N5O3: 456.20; found 456.03.
Example 835
(+)-N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-((2,3- dihydroxypropyl)amino)benzamide (Compound 935)
Figure imgf000418_0001
[1979] Compound 935 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4- (2,3-dihydroxypropylamino)benzoic acids. [M+H]+ calcd for C27H27N5O4: 486.21 ; found 486.03.
Example 836
N-( 1 -(4-(Cyclopropanecarboxamido)phenyl)- lH-indazol-5-yl)-4-(4-methoxypiperidin- 1 - yl)benzamide (Com ound 936)
Figure imgf000418_0002
[1980] Compound 936 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(4- methoxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O3: 510.24; found: 510.12.
Example 837
N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(4-(3- hydroxypropyl)piperazin-l- l)benzamide (Compound 937)
Figure imgf000418_0003
[1981] Compound 937 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(4- (3-hydroxypropyl)piperazin-l-yl)benzoic acids. [M+H]+ calcd for C31H34N6O3: 539.17; found: 539.16.
Example 838
(+)-N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(3- hydroxypyrrolidin-l-yl)benzamide (Compound 938)
Figure imgf000419_0001
[1982] Compound 938 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(3- hydroxypyrrolidin-l-yl)benzoic acids. 1H NMR (500MHz, CD3OD) δ 8.19 (s, IH), 8.17 (s, IH), 7.86 (d, / = 8.5 Hz, 2H), 7.77 (d, / = 8.5 Hz, 2H), 7.70-7.63 (m, 4H), 6.62 (d, / = 8.5 Hz, 2H), 4.55 (s, IH), 3.56-3.50 (m, 2H), 3.43 (dd, / = 3, 9 Hz, IH), 2.20-2.13 (m, IH), 2.08-2.04 (m, IH), 1.83-1.78 (m, IH), 1.28 (s, IH), 1.00-0.97 (m, 2H), 0.90-0.86 (m, 2H).
Example 839
N-( 1 -(4-(Cyclopropanecarboxamido)phenyl)- lH-indazol-5-yl)- 1 -(2-hydroxyethyl)- 1H- indole-5-carboxamide Compound 939)
Figure imgf000419_0002
[1983] Compound 939 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and l-(2- hydroxyethyl)-lH-indole-5-carboxylic acids. [M+H]+ calcd for C28H25N503: 480.20; found 480.03.
Example 840
N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-4-(4- hydroxymethylpiperidin-l- l)benzamide (Compound 940)
Figure imgf000419_0003
[1984] Compound 940 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(4- hydroxymethylpiperidin-l-yl)benzoic acids. 1H NMR (500MHz, DMSO-d6) δ 10.38 (s, IH), 10.04 (s, IH), 8.36 (s, IH), 8.31 (s, IH), 7.88 (d, / = 9 Hz, 2H), 7.81-7.75 (m, 6H), 7.69 (d, / = 8.5 Hz, 2H), 7.01 (d, / = 9.5 Hz, 2H), 4.72 (d, / = 4 Hz, 2H), 1.85-1.79 (m, 2H), 1.46-1.42 (m, 2H), 0.86-0.81 (m, 4H).
Example 841
N-( 1 -(4-(Cyclopropanecarboxamido)phenyl)- lH-indazol-5-yl)- 1 -(3-hydroxypropyl)- 1H- indole-6-carboxamide (Compound 941)
Figure imgf000420_0001
[1985] Compound 941 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and l-(3- hydroxypropyl)-lH-indole-6-carboxylic acids. [M+H]+ calcd for C29H27N5O3: 494.21; found: 494.00.
Example 842
N-(l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)-lH-indole-5-carboxamide (Compound 942)
Figure imgf000420_0002
[1986] Compound 942 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 1H- indole-5-carboxylic acids. [M+H]+ calcd for C26H21N5O2: 436.17; found: 436.02.
Example 843
(+)-4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-((trans)-2- phenylcyclopropanecarboxamido henyl)- lH-indazol-5-yl)benzamide (Compound 943)
Figure imgf000420_0003
[1987] Compound 943 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 2-trans- phenylcyclopropanecarboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C35H33N5O3: 572.26; found 572.17. Example 844
N-(3-(4-(Cyclopropanecarboxamido)phenyl)-lH-indol-6-yl)-l -methyl- lH-indole-5- carboxamide (Compound 944)
Figure imgf000421_0001
[1988] Compound 944 was prepared according to the general procedure described in Scheme IV. Preparation of 3-bromo-6-nitro-lH- indole: To a solution of 6- nitro-lH- indole (3.00g, 18.5 mmol) in methylene chloride (100 mL) was added N- bromosuccinimide (3.29 g, 18.5 mmol) as four equal portions over 2 h. The reaction was stirred overnight, and the formed precipitate was filtered off and rinsed with water. The collected, biphasic filtrate was separated by removing the organic phase and extracting the aqueous phase with methylene chloride (3 x 200 mL). The combined organic phases were concentrated to give a crude solid. The solids collected from the filtration and the extractions were recrystallized using methanol/water and gave 3-bromo-6-nitro-lH- indole (3.95 g, 16.4 mmol, 89%) as a yellow solid after filtration.
[1989] Preparation of 3-bromo-6-nitro-l-(phenylsulfonyl)-lH- indole: Sodium hydride (461 mg, 11.5 mmol) was slowly added to a solution of 3-bromo-6-nitro-lH- indole (2.32 g, 9.61 mmol) in tetrahydrofuran (10.0 mL). After stirring for 5 min, benzenesulfonyl chloride (1.47 mL, 11.5 mmol) was added dropwise over 10 min. The reaction was stirred an additional 1.5 h before quenching with 5.0 mL of methanol, followed by 10.0 mL water and 20.0 mL methylene chloride. The precipitate was filtered off and washed with an excess of methylene chloride and methanol to give a creme- colored powder for 3-bromo-6-nitro-l-(phenylsulfonyl)-lH-indole (2.80 g, 7.35 mmol, 76%).
[1990] Preparation of 3-bromo-l-(phenylsulfonyl)-lH-indol-6-amine: To a slurry of 3-bromo-6-nitro-l-(phenylsulfonyl)-lH- indole (2.80 g, 7.35 mmol) in ethanol (73.5 mL) was added a solution of tin (II) chloride monohydrate (6.63 g, 29.4 mmol) in water (11.0 mL) at 30 °C. Once the addition was complete, the reaction was heated to reflux for 3.5 h, then quenched with 2.0 N sodium hydroxide to a pH of 8. The remaining slurry was diluted with ethyl acetate (100 mL), and the aqueous layer was removed and filtered. The organic phase was washed with 2.0 N sodium hydroxide (2 x 100 mL), and the combined aqueous layers were extracted with ethyl acetate (3 x 200 mL). The combined organic phases were concentrated to give a tacky, orange solid for 3-bromo-l- (phenylsulfonyl)-lH-indol-6-amine (2.35 g, 6.69 mmol, 91%).
[1991] Preparation of 3-(4-nitrophenyl)-lH-indol-6-amine: A 1.0 M aqueous potassium carbonate solution (9.96 mL, 9.96 mmol) was added to a mixture of 3-bromo- l-(phenylsulfonyl)-lH-indol-6-amine (1.00 g, 2.84 mmol), (4-nitrophenyl)boronic acid (1.19 g, 7.12 mmol) and palladium tetrakis(triphenylphosphine) (164 mg, 0.14 mmol) in tetrahydrofuran (13.7 mL). The biphasic mixture was heated in a microwave at 130 °C for 10 min and was then diluted with a saturated solution of sodium bicarbonate (10.0 mL) and ethyl acetate (10.0 mL). The organic layer was washed with a saturated solution of sodium bicarbonate (2 x 10.0 mL), and the combined aqueous layers were extracted with ethyl acetate (3 x 30.0 mL). The combined organic phases were dried over magnesium sulfate, filtered and concentrated. The crude residue was purified by flash chromatography (10-25-50-71% ethyl acetate/hexane) to give an orange solid for 3-(4-nitrophenyl)-l- (phenylsulfonyl)-lH-indol-6-amine (726 mg, 1.85 mmol, 65%).
3-(4-nitrophenyl)-lH-indol-6-amine. To a solution of the protected indol-6-amine (300 mg, 0.76 mmol) in methanol (9.00 mL) was added potassium hydroxide (941 mg, 16.8 mmol). The reaction was warmed to 70 °C for 4 h. After that time, the reaction was diluted with water (10.0 mL) and methylene chloride (15.0 mL) and the organic phase was removed. The aqueous layer was extracted with methylene chloride (3 x 15.0 mL), and the combined organic phases were concentrated. The crude residue that remained was purified by flash chromatography (10-25-50% ethyl acetate/hexane) to give a burgundy red solid for 3-(4-nitrophenyl)-lH-indol-6-amine (66.3 mg, 0.26 mmol, 34%).
[1992] Preparation of l-methyl-N-(3-(4-nitrophenyl)-lH-indol-6-yl)-lH- indole-5-carboxamide: A mixture of 3-(4-nitrophenyl)-lH-indol-6-amine (66.3 mg, 0.26 mmol), 1 -methyl- lH-indole-5-carboxylic acid (50.4 mg, 0.29 mmol), hydroxybenzotriazole (3.5 mg, 0.03 mmol) and triethylamine (40.1 μί, 0.29 mmol) in DMF (1.00 mL) was stirred for 5 min before l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (55.2 mg, 0.29 mmol) was added. The reaction was stirred overnight at room temperature and was then diluted with water (5.0 mL). The precipitate that formed was filtered off and sequentially washed with excess methylene chloride and methanol. The solid was recrystallized using hot methanol and gave a bright yellow solid for l-methyl-N-(3-(4-nitrophenyl)-lH-indol-6-yl)-lH-indole-5-carboxamide (59.8 mg, 0.15 mmol, 56%) after filtration.
[1993] Preparation of N-(3-(4-aminophenyl)-lH-indol-6-yl)-l -methyl- 1H- indole-5-carboxamide: To a slurry of l-methyl-N-(3-(4-nitrophenyl)-lH-indol-6-yl)-lH- indole-5-carboxamide (59.0 mg, 0.14 mmol) in ethanol (1.50 mL) under an atmosphere of nitrogen was added 20 wt% palladium hydroxide on carbon (5.9 mg, 10 wt%), followed by a balloon of hydrogen. The reaction was stirred overnight at room temperature and was then filtered through a pad of Celite, rinsing with excess methanol and methylene chloride. The filtrate was concentrated to give a grey-pink solid for N-(3-(4- aminophenyl)-lH-indol-6-yl)-l -methyl- lH-indole-5-carboxamide (56.9 mg, 0.14 mmol, 100%).
[1994] Preparation of Compound 944: A mixture of N-(3-(4-aminophenyl)- lH-indol-6-yl)-l -methyl- lH-indole-5-carboxamide (55.8 mg, 0.15 mmol), cyclopropanecarboxylic acid (12.8 μί, 0.16 mmol), hydroxybenzotriazole (1.9 mg, 0.02 mmol) and triethylamine (22.5 μί, 0.16 mmol) in N,N-dimethylformamide (1.00 mL) was stirred for 5 min before l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (30.9 mg, 0.16 mmol) was added. The reaction was stirred overnight at room temperature and was then diluted with water (5.0 mL).
[1995] The precipitate that formed was filtered off and sequentially washed with excess methylene chloride and methanol. The solid was recrystallized using hot methanol and gave a yellow solid for N-(3-(4-(cyclopropanecarboxamido)phenyl)-lH- indol-6-yl)-l -methyl- lH-indole-5-carboxamide (46.8 mg, 0.10 mmol, 70%) after filtration. MS [M+H]+ calcd for C28H24N4O2: 449.04; found: 449.05.
Example 845
1 -(4-(Cyclopropanecarboxamido)phenyl)-N-(4-(4-hydroxypiperidin- 1 -yl)phenyl)- 1H- indazole-5-carboxamide Compound 945)
Figure imgf000423_0001
[1996] Compound 945 was prepared according to the general procedure described in Scheme IV. Preparation of iV-(4-(4-hydroxypiperidin-l-yl)phenyl)-lH- indazole-5-carboxamide: lH-indazole-5-carboxylic acid hydrochloride (100 mg, 0.50 mmol), hydroxybenzotriazole (7 mg, 0.05 mmol), triethylamine (0.2 mL, 1.3 mmol), and l-(4-aminophenyl)piperidin-4-ol (193 mg, 1.00 mmol) were taken up in DMF (2.51 mL) and stirred. EDC (106 mg, 0.05 mmol) was added to the solution last. After the addition, the solution was stirred at room temperature for 24 h. The solution was partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine and dried over Na2S04. Filtration and concentration gave the crude amide. Purification via flash chromatography 0-10% MeOH/CH2Cl2 gave 55 mg (32%) of the product as a white solid.
[1997] Preparation of l-(4-aminophenyl)-iV-(4-(4-hydroxypiperidin-l- yl)phenyl)- lH-indazole-5-carboxamide: N-(4-(4-Hydroxypiperidin- 1 -yl)phenyl)- 1H- indazole-5-carboxamide (10 mg, 0.03 mmol), 4-fluoronitrobenze (3.1 uL, 0.03 mmol) and potassium carbonate (4 mg, 0.03 mmol) were taken up in DMSO (0.3 mL). The solution was heated to 120 °C and stirred for 24 h. After the solution was cooled it was diluted with water until a precipitate formed and stirred well for 5 min. Filtration gave a yellow solid, which was then washed well with water, followed by hexanes. After the solid was dried under vacuum it was taken up in methanol and stirred at RT under nitrogen. The solution was treated with Pd(OH)2 (3 mg) and placed under a balloon of H2 gas. After stirring at RT for 24 h, the catalyst was removed via filtration through celite. The filtrate was concentrated under reduced pressure to give 10.23 mg (80%) of a crude product.
[1998] Preparation of Compound 945: l-(4-Aminophenyl)-N-(4-(4- hydroxypiperidin-l-yl)phenyl)-lH-indazole-5-carboxamide (10 mg, 0.02 mmol), EDC (6.7 mg, 0.03 mmol) and cyclopropanecarboxylic acid (2.1 mg, 0.02 mmol) were taken up in pyridine (0.23 mL). The solution was heated to 60 °C and stirred for 1 h. The solution was partitioned between CH2C12 and water. The aqueous layer was extracted with CH2C12. The combined organic layers were washed with brine and dried over Na2S04. Filtration and concentration gave the crude cyclopropyl amide. Purification via flash chromatography 0-10% MeOH/CH2Cl2 gave 8.8 mg (76%) of Compound 945.
[M+H]+ calcd for
Figure imgf000424_0001
496.23; found: 496.02.
Example 846
4-(5-(cyclopropanecarboxamido)- lH-indol- 1 -yl)-N-(4-(4-hydroxypiperidin- 1 - yl)phenyl)benzamide (Compound 946)
Figure imgf000425_0001
[1999] Compound 946 was prepared according to the procedure described in Scheme IV from l-(4-aminophenyl)-lH-indole-5-carboxylic acid, cyclopropanecarboxylic acid, and 4-(4-hydroxypiperidin-l-yl)aniline. [M+H]+ calcd for C30H30N4O3: 495.23; found: 495.08.
Example 847
N-(l-(4-(Cyclopropylcarbamoyl)phenyl)-lH-indol-5-yl)-l-(2-hydroxyethyl)-lH-indole-5- carboxamide (Compound 947)
Figure imgf000425_0002
[2000] Compound 947 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indol-l-yl)benzoic acid, cyclopropaneamine, and l-(2- hydroxy ethyl)- lH-indole-5-carboxylic acid. [M+H]+ calcd for C29H26N4O3: 479.20; found: 479.01.
Example 848
(±)-4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-(2- hydroxymethylcyclopropanecarboxamido)phenyl)-lH-indazol-5-yl)benzamide
(Compound 948
Figure imgf000425_0003
[2001] Compound 948 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 2- hydroxymethylcyclopropanecarboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500 MHz, CD3OD) δ 8.21 (m, 2H), 7.88 (d, / = 9.1 Hz, 2H), 7.79 (d, / = 8.8 Hz, 2H), 7.74-7.65 (m, 4), 7.04 (d, / = 8.8 Hz, 2H), 3.84-3.77 (m, 3H), 3.09-3.04 (m, 2H), 1.98-1.96 (m, IH), 1.65-1.58 (m, 4H), 1.22-1.19 (m, IH), 0.94-0.88 (m, 2H).
Example 849 N-Cyclopropyl-l-(4-(4-(4-hydroxypiperidin-l-yl)benzamido)phenyl)-lH-indole-5- carboxamide (Compound 949)
Figure imgf000426_0001
[2002] Compound 949 was prepared according to the procedure described in Scheme IV from cylopropylamine, l-(4-aminophenyl)-lH-indole-5-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N4O3: 495.24; found:
495.08.
Example 850
N-Cyclopropyl- 1 -(4-((4-(4-hydroxypiperidin- 1 -yl)phenyl)carbamoyl)phi
indazole-5-carboxamide Compound 950)
Figure imgf000426_0002
[2003] Compound 950 was prepared according to the procedure described in Scheme IV from cylopropylamine, l-(4-carboxyphenyl)-lH-indazole-5-carboxylic acid, and 4-(4-hydroxypiperidin-l-yl)aniline. [M+H]+ calcd for C29H29N5O3: 496.23; found: 496.02.
Example 851
4-(4-(Allyloxy)piperidin- 1 -yl)-iV-( 1 -(4-(cyclopropylcarbamoyl)phenyl)- lH-indol-5- yl)benzamide (Compound 951)
Figure imgf000426_0003
[2004] Compound 951 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indol-l-yl)benzoic acid, cyclopropaneamine, and 4-(4- allyloxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C33H34N4O3: 535.26 535.10.
Example 852
N-Cyclopropyl-4-(5-(4-((2-hydroxyethyl)(methyl)amino)benzamido)- lH-indol- 1 - yl)benzamide (Compound 952)
Figure imgf000427_0001
[2005] Compound 952 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indol-l-yl)benzoic acid, cyclopropaneamine, and 4-(N-2- hydroxyethyl-N-methylamino)benzoic acid. [M+H]+ calcd for C28H28N4O3: 469.22; found 468.96.
Example 853
4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-(thiazol-2-ylcarbamoyl)phenyl)-lH-indol-5- yl)benzamide (Compound 953)
Figure imgf000427_0002
[2006] Compound 953 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indol-l-yl)benzoic acid, 2-aminothiazole, and 4-(4- hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C30H27N5O3S: 538.18; found: 539.02.
Example 854
4- (4-Hydroxypiperidin-l-yl)-N-(l-(4-(4-methylthiazol-2-ylcarbamoyl)phenyl)-lH-indol-
5- yl)benzamide (
Figure imgf000427_0003
[2007] Compound 954 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indol-l-yl)benzoic acid, 2-amino-4-methylthiazole, and 4-(4-hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C31H29N5O3S: 552.10; found: 552.05.
Example 855
4-(4-Hydroxypiperidin- 1 -yl)-iV-(l -(4-(2-methyl- lH-indole-5-ylcarbamoyl)phenyl)- 1H- indol-5-yl)benzamide (Compound 955)
Figure imgf000428_0001
[2008] Compound 955 was prepared according to the procedure described in Scheme IV from 5-amino-2methylindole, 4-(5-amino-lH-indol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500MHz, DMSO-d6) δ 10.85 (s, 1H), 10.11 (s, 1H), 9.90 (s, 1H), 8.17 (d, / = 8.5 Hz, 2H), 8.14 (d, / = 2 Hz, 1H), 7.88 (d, / = 9 Hz, 2H), 7.86 (d, / = 2 Hz, 1H), 7.77 (d, / = 8.5 Hz, 2H), 7.75 (d, / = 3 Hz, 1H), 7.65 (d, / = 9 Hz, 1H), 7.56 (dd, / = 2, 9 Hz, 1H), 7.33 (dd, / = 1.5, 8.5 Hz, 1H), 7.23 (d, / = 8.5 Hz, 1H), 7.00 (d, / = 9 Hz, 2H), 6.74 (d, / = 3.5 Hz, 1H), 6.11 (t, / = 1 Hz, 1H), 4.71 (d, / = 4 Hz, 1H), 3.72-3.66 (m, 3H), 3.00 (dd, / = 3, 10 Hz, 2H), 2.37 (s, 3H), 1.83-1.80 (m, 2H), 1.47-1.40 (m, 2H).
Example 856
4-(4-Hydroxypiperidin- 1 -yl)-N-(l -(4-(( 1 -(2-morpholinoethyl)- lH-indol-5- yl)carbamoyl)phenyl)-lH-indol-5-yl)benzamide (Compound 956)
Figure imgf000428_0002
[2009] Compound 956 was prepared according to the procedure described in Scheme IV from l-(2-morpholinoethyl)-5-amino-lH-indole, 4-(5-amino-lH-indol-l- yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C41H42N6O4: 683.33; found: 683.31.
Example 857
N-(5-Fluoropyridin-2-yl)-4-(5-(4-(4-hydroxypiperidin-l-yl)benzamido)-lH-indol-l- yl)benzamide (Compound 957)
Figure imgf000429_0001
[2010] Compound 957 was prepared according to the procedure described in Scheme IV from 2-amino-5-fluoropyridine, 4-(5-amino-lH-indol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500MHz, DMSO-d6) δ 11.01 (s, 1H), 9.90 (s, 1H), 8.42 (d, / = 3.5 Hz, 1H), 8.27 (d, / = 4 Hz, 1H), 8.24 (dd, / = 1.5, 6.5 Hz, 2H), 8.14 (d, / = 2 Hz, 1H), 7.88 (d, / = 9 Hz, 2H), 7.84-7.80 (m, 1H), 7.78-7.77 (m, 1H), 7.76 (t, / = 3.5 Hz, 2H), 7.66 (d, / = 9 Hz, 1H), 7.56 (dd, / = 2, 9 Hz, 1H), 7.00 (d, / = 9 Hz, 2H), 6.75 (d, / = 3.5 Hz, 1H), 4.70 (d, / = 4 Hz, 1H), 3.71-3.66 (m, 3H), 3.03-2.98 (m, 1H), 1.83-1.79 (m, 2H), 1.47-1.40 (m, 2H).
Example 858
4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-((lH-indol-6-yl)carbamoyl)phenyl)-lH-indol-5- yl)benzamide (Compound 958)
Figure imgf000429_0002
[2011] Compound 958 was prepared according to the procedure described in Scheme IV from 6-aminoindole, 4-(5-amino-lH-indol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500MHz, DMSO-d6) δ 11.05 (s, 1H), 10.23 (s, 1H), 9.90 (s, 1H), 8.18 (d, / = 8.5 Hz, 2H), 8.13 (d, / = 2 Hz, 1H), 8.10 (s, 1H), 7.87 (d, / = 10 Hz, 2H), 7.77 (d, / = 9 Hz, 2H), 7.74 (d, / = 3.5 Hz, 1H), 7.65 (d, / = 9 Hz, 1H), 7.56 (dd, / = 2, 9.5 Hz, 1H), 7.48 (d, / = 8.5 Hz, 1H), 7.29 (m, 2H), 6.99 (d, / = 9 Hz, 2H), 6.74 (d, / = 3 Hz, 1H), 6.38 (m, 1H), 4.70 (d, / = 4.5 Hz, 1H), 3.69 (m, 3H), 1.80 (m, 2H), 1.44 (m, 2H).
Example 859
4- (4-Hydroxypiperidin-l-yl)-N-(l-(4-(cyclopropylcarbamoyl)phenyl)-2-methyl-lH-indol-
5- yl)benzamide (Compound 959)
Figure imgf000430_0001
[2012] Compound 959 was prepared according to the procedure described in Scheme IV from 4-(5-amino-2-methyl-lH-indol-l-yl)benzoic acid, cyclopropaneamme, and 4-(4-hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C31H32N4O3: 509.25; found: 509.12.
Example 860
N-( 1 -(4-(Cyclopropylcarbamoyl)phenyl)- lH-indol-5-yl)- 1 -(2-morpholinoethyl)- 1H- indole-5-carboxamide (Compound 960)
Figure imgf000430_0002
[2013] Compound 960 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indol-l-yl)benzoic acid, cyclopropaneamme, and l-(2- morpholinoethyl)-lH-indole-5-carboxylic acid. [M+H]+ calcd for C33H33N5O3: 548.26; found 548.13.
Example 861
N-Cyclopropyl-4-(5-(4-(4-methylpiperazin- 1 -yl)benzamido)- lH-indol- 1 -yl)benzamide (Compound 961)
Figure imgf000430_0003
[2014] Compound 961 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indol-l-yl)benzoic acid, cyclopropaneamme, and 4-(4- methylpiperazin-l-yl)benzoic acid. [M+H]+ calcd for C30H31N5O2: 494.25; found 494.06.
Example 862
Ethyl 2- (5 - (4- (5 - (4- (4-hydroxypiperidin- 1 -yl)benzamido) - 1 H-indol- 1 -yl)benzamido) - 1 H- indol-l-yl)acetate (Compound 962)
Figure imgf000431_0001
[2015] Compound 962 was prepared according to the procedure described in Scheme IV from ethyl 5-amino-lH- indole- 1 -acetate, 4-(5-amino-lH-indol-l-yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C39H37N5O5: 656.28; found 656.23.
Example 863
N-( 1 -(4-((( lH-Indol-2-yl)methyl)carbamoyl)phenyl)- lH-indol-5-yl)- 1 -(2-hydroxyethyl)- lH-indole-5-carboxamide (Compound 963)
Figure imgf000431_0002
[2016] Compound 963 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indol-l-yl)benzoic acid, 2-aminomethylindole, and l-(2- hydroxyethyl)-lH-indole-5-carboxylic acid. 1H NMR (500MHz, DMSO-d6) δ 10.14 (s, 1H), 9.42 (s, 1H), 8.31 (dd, J = 1.0, 5.5 Hz, 2H), 8.14 (d, / = 8.5 Hz, 2H), 8.06 (t, J = 5.5 Hz, 1H), 7.87 (dd, / = 1.5, 9 Hz, 1H), 7.74 (d, / = 8 Hz, 1H), 7.66 (d, J = 9 Hz, 2H), 7.62 (d, J = 2 Hz, 1H), 7.61 (s, 1H), 7.57 (d, / = 3 Hz, 1H), 7.55 (d, J = 9 Hz, 1H), 7.37 (d, J = 2.5 Hz, 1H), 7.11 (ddd, / = 1, 7, 9 Hz, 1H) 7.03 (ddd, / = 1, 7, 8.5 Hz, 1H), 6.70 (d, J = 3.5 Hz, 1H), 6.56 (d, J = 3.5 Hz, 1H), 4.82 (d, / = 5.5 Hz, 2H), 4.35 (t, / = 5.5 Hz, 2H), 3.92 (q, / = 5 Hz, 2H), 3.31 (d, J = 5 Hz, 1H).
Example 864
2-(5-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indol-l-yl)benzamido)-lH-indol- l-yl)acetic acid (Compound 964)
Figure imgf000431_0003
[2017] Compound 964 was prepared by hydrolysis of Compound 962.
[M+H]+ calcd for C37H33N5O5: 628.25; found 628.14.
Example 865
(+)-N-Cyclopropyl-4-(5-(4-(3-(hydroxymethyl)piperidin- 1 -yl)benzamido)- lH-indol- 1 - yl)benzamide (Compound 965)
Figure imgf000432_0001
[2018] Compound 965 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indol-l-yl)benzoic acid, cyclopropaneamine, and 4-(3- (hydroxymethyl)piperazin-l-yl)benzoic acid. [M+H]+ calcd for C31H32N4O3: 509.25; found: 509.05.
Example 866
4-(4-Hydroxypiperidin- 1 -yl)-N-(l -(4-(( 1 -(2-methoxyethyl)-2-methyl- lH-indol-5- yl)carbamoyl)phenyl)-lH-indol-5-yl)benzamide (Compound 966)
Figure imgf000432_0002
[2019] Compound 966 was prepared according to the procedure described in Scheme IV from ethyl 5-amino-2-methyl-l-(2-methoxyethyl)-lH-indole, 4-(5-amino-lH- indol-l-yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C39H39N5O4: 642.31 ; found: 642.26.
Example 867
N-Cyclopropyl-4-(5-(4-( 1 , 1 -dioxidothiomorpholino)benzamido)- lH-indol- 1 - yl)benzamide (Compound 967)
Figure imgf000432_0003
[2020] Compound 967 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indol-l-yl)benzoic acid, cyclopropaneamine, and 4-(l,l- dioxidothiomorpholino)piperazin-l-yl)benzoic acid. 1H NMR (500MHz, DMSO-i¾) δ 9.98 (s, 1H), 8.53 (d, / = 4 Hz, 1H), 8.13 (d, / = 1.5 Hz, 1H), 8.02 (d, / = 8.5 Hz, 2H), 7.94 (d, / = 9 Hz, 2H), 7.72 (m, 3H), 7.62 (d, / = 9 Hz, 1H), 7.55 (dd, J = 2, 9 Hz, 1H), 7.14 (d, / = 9 Hz, 2H), 6.73 (d, / = 3 Hz, 1H), 3.93 (bs, 4H), 3.14 (bs, 4H), 2.89 (m, 1H), 0.72 (m, 2H), 0.61 (m, 2H).
Example 868
N-(l-(4-((lH-Indol-6-yl)carbamoyl)phenyl)-lH-indol-5-yl)-4- (morpholinomethyl)benzamide (Compound 968)
Figure imgf000433_0001
[2021] Compound 968 was prepared according to the procedure described in Scheme IV from 6-aminoindole, 4-(5-amino-lH-indol-l-yl)benzoic, and 4- (morpholinomethyl)benzoic acids. [M+H]+ calcd for C35H31N5O3: 570.24; found: 570.14.
Example 869
N-(l-(2-(Cyclopropylamino)-2-oxoethyl)-lH-indol-5-yl)-4-(5-(4-(4-hydroxypiperidin-l- yl)benzamid -lH-indol-l-yl)benzamide (Compound 969)
Figure imgf000433_0002
[2022] Compound 969 was prepared by treatment of Compound 962 with cyclopropylamine. [M+H]+ calcd for C40H38N6O4: 667.30; found 667.31.
Example 870
N-(l-(2-((Cyanomethyl)amino)-2-oxoethyl)-lH-indol-5-yl)-4-(5-(4-(4-hydroxypiperidin- l-yl)benzamido)-lH-indol-l-yl)benzamide (Compound 970)
Figure imgf000434_0001
[2023] Compound 970 was prepared by treatment of Compound 962 with cyanoethylamine. [M+H]+ calcd for C39H35N7O4: 666.28; found 666.23.
Example 871
Methyl 2-(2-(5-(4-(5-(4-(4-hydroxypiperidin-l-yl)benzamido)-lH-indol-l-yl)benzamido)- lH-indol- -yl)acetamido)acetate (Compound 971)
Figure imgf000434_0002
[2024] Compound 971 was prepared by treatment of Compound 962 with methyl aminoacetate. [M+H]+ calcd for C4oH38N606: 699.29; found 699.25.
Example 872
N-(l-(4-((lH-Indol-6-yl)carbamoyl)phenyl)-lH-indol-5-yl)-l-(2-morpholinoethyl)-lH- indole-5-carboxamide (Compound 972)
Figure imgf000434_0003
[2025] Compound 972 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indol-l-yl)benzoic acid, 6-aminoindole, and l-(2- morpholinoethyl)-lH-indole-5-carboxylic acid. [M+H]+ calcd for C38H34N6O3: 623.27; found 623.15.
Example 873
Ethyl 4- (5 - (4- (5 - (4- (4-hydroxypiperidin- 1 -yl)benzamido) - 1 H-indol- 1 -yl)benzamido) - 1 H- indol-l-yl)butanoate (Compound 973)
Figure imgf000435_0001
[2026] Compound 973 was prepared according to the procedure described in Scheme IV from ethyl 4-(5-amino-lH-indol-l-yl)butanoate, 4-(5-amino-lH-indol-l- yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C41H41N5O5: 684.31 ; found 684.19.
Example 874
4-(5-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indol-l-yl)benzamido)-lH-indol- l-yl)butanoic acid (Compound 974)
Figure imgf000435_0002
[2027] Compound 974 was prepared hydrolysis of Compound 973. [M+H]+ calcd for C39H37N5O5: 656.28; found 656.17.
Example 875
Methyl 2-(2-(5-(4-(5-(4-(4-hydroxypiperidin-l-yl)benzamido)-lH-indol-l-yl)benzamido)- lH-indol-l-yl)acetamido)acetate (Compound 975)
Figure imgf000435_0003
[2028] Compound 975 was prepared by hydrolysis of Compound 971. [M+H]+ calcd for CsgHseNeOe: 685.27; found 685.14.
Example 876
N-(3-(4-Aminophenyl)-lH-indazol-6-yl)-4-(4-hydroxypiperidin-l-yl)benzamide
(Compound 976)
Figure imgf000436_0001
[2029] Compound 976 was prepared according to the procedure described Scheme IV from 6-amino-3-(4-aminophenyl)-lH-indazole, and 4-(4-hydroxypiperidin- yl)benzoic acid. [M+H]+ calcd for C25H25N5O2: 428.20; found 428.07.
Example 877
N-(3-(4-(Cyclopropanecarboxamido)phenyl)- lH-indazol-6-yl)-4-(4-hydroxypiperidin- 1 - yl)benzamide (Compound 977)
Figure imgf000436_0002
[2030] Compound 977 was prepared according to the procedure described in Scheme IV from 6-amino-3-(4-aminophenyl)-lH-indazole, cyclopropanecarboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30N4O3: 495.11; found: 495.08.
Example 878
N-(4-(6-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-3-yl)phenyl)-lH-pyrrole-2- carboxamide (Com ound 978)
Figure imgf000436_0003
[2031] Compound 978 was prepared according to the procedure described in Scheme IV from 6-amino-3-(4-aminophenyl)-lH-indazole, pyrrole-2-carboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H28N6O3: 521.22; found 521.07.
Example 879
N-(3-(4-((lH-Indol-6-yl)carbamoyl)phenyl)-lH-indol-6-yl)-l-methyl-lH-pyrrole-2- carboxamide (Compound 979)
Figure imgf000437_0001
[2032] Compound 979 was prepared according to the procedure described in Scheme IV from 4-(6-amino-lH-indol-3-yl)benzoic acid, l-methylpyrrole-2-carboxylic acid, and 6-aminoindole. [M+H]+ calcd for C29H23N5O2: 474.05; found: 474.02.
Example 880
N-(3-(4-(4-(4-Hydroxypiperidin-l-yl)benzamido)phenyl)-lH-indol-6-yl)-l -methyl- 1H- pyrrole-2-carboxamide Compound 980)
Figure imgf000437_0002
[2033] Compound 980 was prepared according to the procedure described in Scheme IV from 6-amino-3-(4-aminophenyl)indole, l-methylpyrrole-2-carboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H31N5O3: 534.15; found: 534.09.
Example 881
N-(3-(4-((4-(4-Hydroxypiperidin- 1 -yl)phenyl)carbamoyl)phenyl)- lH-indol-6-yl)- 1 - methyl- lH-pyrrole-2-carboxamide (Compound 981)
Figure imgf000437_0003
[2034] Compound 981 was prepared according to the procedure described in Scheme IV from 4-(6-amino-lH-indol-3-yl)benzoic acid, l-methylpyrrole-2-carboxylic acid, and 4-(4-hydroxypiperidin-l-yl)aniline. [M+H]+ calcd for C32H31N5O3: 534.15; found: 534.09.
Example 882
N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-pyrazolo[3,4-c]pyridin-l- yl)phenyl)-l -methyl- lH-pyrrole-2-carboxamide (Compound 982)
Figure imgf000438_0001
[2035] Compound 982 was prepared according to the procedure described in Scheme IV from l-(4-aminophenyl)-lH-pyrazolo[3,4-c]pyridin-5-amine, 1- methylpyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H29N7O3: 536.23; found 536.05.
Example 883
2-(4-(4-((l-(4-(Cyclopropanecarboxamido)phenyl)-lH-indol-5- yl)carbamoyl)phenyl)piperazin-l-yl)acetic acid (Compound 983)
Figure imgf000438_0002
[2036] Compound 983 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indole, cyclopropanecarboxylic acid, and 4- (4-(hydroxycarbonylmethyl)piperazin-l-yl)benzoic ester. 1H NMR (500MHz, Acetone- d6) δ 9.27 (s, IH), 8.25 (s, IH), 8.07 (dd, J = 2, 6.5 Hz, 2H), 7.95 (d, / = 9 Hz, 2H), 7.82 (s, IH), 7.60 (dd, / = 2, 6.5 Hz, 2H), 7.59-7.58 (m, 3H), 7.04 (d, / = 9 Hz, 2H), 6.70 (d, / = 3 Hz, IH), 3.39 (m, 3H), 2.17 (m, IH), 1.29 (m, 8H), 0.77-0.74 (m, 2H), 0.65-0.64 (m, 2H).
Example 884
4- (4-Hydroxypiperidin-l-yl)-N-(l-(4-(cyclopropylcarbamoyl)phenyl)-3-acetyl-lH-indol-
5- yl)benzamide (Com ound 984)
Figure imgf000438_0003
[2037] Compound 984 was prepared according to the procedure described in Scheme IV from 4-(5-amino-3-acetyl-lH-indol-l-yl)benzoic acid, cyclopropaneamine, and 4-(4-hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C32H32N4O4: 537.24; found: 537.06.
Example 885
4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-(cyclopropylcarbamoyl)phenyl)-lH-indazol-5- yl)benzamide (Com ound 985)
Figure imgf000439_0001
[2038] Compound 985 was prepared according to the procedure described in Scheme IV from 4-(5-amino-lH-indazol-l-yl)benzoic acid, cyclopropaneamine, and 4-(4- hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C29H29N5O3: 496.23; found 496.09.
Example 886
1 -(4- Aminophenyl)-iV-(4-(4-hydroxypiperidin- 1 -yl)phenyl)- lH-indazole-5-carboxamide (Compound 986)
[2039] Compound 986 was prepared according to the procedure described in Scheme IV from l-(4-aminophenyl-lH-indazol-5-yl)carboxylic acid, and 4-(4- hydroxypiperidin-l-yl)aniline. [M+H]+ calcd for C25H25N5O2: 428.20; found: 428.00.
Example 887
tert-Butyl 2-((4-(5-(4-morpholinobenzamido)-lH-indazol-l-yl)phenyl)amino)acetate (Compound 987)
Figure imgf000439_0003
[2040] Compound 987 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, i-butyl bromoacetate, and 4- morpholinobenzoic acid. 1H NMR (500MHz, CDC13) δ 8.15 (s, 1H), 8.09 (s, 1H), 7.98 (s, 1H), 7.84 (d, / = 7.5 Hz, 2H), 7.55 (d, / = 9 Hz, 1H), 7.48 (d, / = 10 Hz, 1H), 7.46 (d, / = 7 Hz, 2H), 7.26 (s, 1H), 6.90 (d, / = 7.5 Hz, 2H), 6.71 (d, / = 7 Hz. 2H), 4.45 (s, 1H), 3.87-3.83 (m, 6H), 3.27-3.25 (m, 4H), 1.51 (m, 9H).
Example 888
N-(4-(5-(Benzyloxy)- lH-indazol- 1 -yl)phenyl)-4-(4-hydroxypiperidin- 1 -yl)benzamide (Compound 988)
Figure imgf000440_0001
[2041] Compound 988 was prepared according to the procedure described in Scheme IV from 5-benzyloxy-l-(4-aminophenyl)indazole and 4-(4-hydroxypiperidin-l- yl)benzoic acid. [M+H]+ calcd for C32H30N4O3: 519.23; found: 519.11.
Example 889
N-(4-(5-(4-Fluorobenz (Compound 989)
Figure imgf000440_0002
[2042] Compound 989 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, isonicotinic, and 4-fluorobenzoic acids.
[M+H]+ calcd for C26Hi8FN502: 452.14; found: 451.95.
Example 890
N-(4-(5-(Hydroxy)- lH-indazol- 1 -yl)phenyl)-4-(4-hydroxypiperidin- 1 -yl)benzamide (Compound 990)
Figure imgf000440_0003
[2043] Compound 990 was prepared according to the procedure described in Scheme IV from 5-hydroxy-l-(4-aminophenyl)indazole and 4-(4-hydroxypiperidin-l- yl)benzoic acid. [M+H]+ calcd for C25H24N4O3: 429.18; found: 429.07.
Example 891
4-(Dimethylamino)-N-(4-(6-(4-(dimethylamino)benzamido)-l-(phenylsulfonyl)-lH-indol- 3-yl)phenyl)benzamide Compound 991)
Figure imgf000441_0001
[2044] Compound 991 was prepared according to the procedure described in Scheme IV from 6-amino-3-(4-aminophenyl)-l-(phenylsulfonyl)indole and 4- dimethylaminobenzoic acid. [M+H]+ calcd for CssHssNsC S: 658.31; found: 658.19.
Example 892
N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-benzo[d]imidazol-l-yl)phenyl)-lH- indole-6-carboxamide Compound 992)
Figure imgf000441_0002
[2045] Compound 992 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)benzimidazole, 6-indolecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H30N6O3: 571.25; found: 571.15.
Example 893
N-(4-(5-(Cyclopropanecarboxamido)- lH-indazol- 1 -yl)phenyl)-4-(4-hydroxypiperidin- 1 - yl)benzamide (Compound 993)
Figure imgf000442_0001
[2046] Compound 993 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500MHz, Acetone-J6) δ 9.55 (s, IH), 9.48 (s, IH), 8.34 (m, IH), 8.19 (m, IH), 8.07 (d, / = 8.5 Hz, IH), 7.94 (d, / = 9 Hz, IH), 7.86 (d, / = 9 Hz, IH), 7.80 - 7.69 (m, 4H), 7.61 (m, IH), 7.04 (d, / = 9 Hz, 2H), 3.80 (m, 3H), 3.11 (m, IH), 2.09 (m, 2H), 1.94 (m, IH), 1.80 (m, IH), 1.60 (m, IH), 0.93 (m, 2H), 0.80 (m, 2H).
Example 894
(+)-N-(4-(5-(Cyclopropanecarboxamido)-lH-indazol-l-yl)phenyl)-4-(3,4-c i'- dihydroxypiperidin-l- l)benzamide (Compound 994)
Figure imgf000442_0002
[2047] Compound 994 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopropanecarboxylic, and 4- (3,4-ds-dihydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29N5O4: 512.22; found 512.09.
Example 895
4-(2-Hydroxyethoxy)-N-(4-(5-(4-(2-hydroxyethoxy)benzamido)-lH-indazol-l- yl)phenyl)benzamide ompound 995)
Figure imgf000442_0003
[2048] Compound 995 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and 4-(2-hydroxyethoxy)benzoic acid. [M+H]+ calcd for C31H29N4O6: 553.21; found: 553.10.
Example 896
iV-(4-(5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 -yl)phenyl)thiazole-2- carboxamide (Com ound 996)
Figure imgf000443_0001
[2049] Compound 996 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, thiozole-2-carboxylic and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H26N6O3S: 539.19; found: 539.02.
Example 897
N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l-yl)phenyl)-2- (methylamino)isonicotinamide Compound 997)
Figure imgf000443_0002
[2050] Compound 997 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 2-(methylamino)isonicotinic and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H31N7O3: 562.26; found: 562.13.
Example 898
N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l-yl)phenyl)-2- (methyl)isonicotinamide (Compound 998)
Figure imgf000443_0003
[2051] Compound 998 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 2-methylisonicotinic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H30N6O3: 547.14; found:
547.12.
Example 899
4-((4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)carbamo l)pyridine 1 -oxide (Compound 999)
Figure imgf000444_0001
[2052] Compound 999 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 4-carboxypyridine 1 -oxide, and 4- (4-hydroxypiperidin-l-yl)benzoic acid. [M+H]+ calcd for C3iH28N604: 549.12; found: 549.08.
Example 900
4-(2-Hydroxyethoxy)-N-(4-(5-(4-(4-hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 - yl)phenyl)benzamide Compound 1000)
Figure imgf000444_0002
[2053] Compound 1000 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 4-(2-hydroxyethoxy)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H33Ns05: 592.18; found: 592.15.
Example 901
4-(2-Hydroxyethoxy)-N-(l-(4-isobutyramidophenyl)-lH-indazol-5-yl)benzamide
(Compound 1001)
Figure imgf000444_0003
[2054] Compound 1001 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, isobutyric, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H31N5O3: 498.24; found 498.11.
Example 902
N-(l -(4-(Cyclopent- 1 -enecarboxamido)phenyl)- lH-indazol-5-yl)-4-(4-hydroxypiperidin- l-yl)benzamide (Com ound 1002)
Figure imgf000445_0001
[2055] Compound 1002 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, cyclopentenecarboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H31N5O3: 522.24; found 522.14.
Example 903
1 -(2-Hydroxyethyl)-N-(4-(5-(4-(4-hydroxypiperidin- 1 -yl)benzamido)- IH-indazol- 1 - yl)phenyl)-lH-indole-5-carboxamide Compound 1003)
Figure imgf000445_0002
[2056] Compound 1003 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, l-(hydroxyethyl)indole-5- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C36H34N6O4: 615.26; found 615.20.
Example 904
1 -Methyl-N-(4-(5-( 1 -methyl- lH-indole-5-carboxamido)- IH-indazol- 1 -yl)phenyl)- 1H- indole-5-carboxamide (Compound 1004)
Figure imgf000446_0001
[2057] Compound 1004 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and l-methylindole-5-carboxylic acid.
[M+H]+ calcd for C33H26N6O2: 539.21; found: 539.11.
Example 905
N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l-yl)phenyl)-lH- pyrrolo[3,2-b]pyridine-6-carboxamide Compound 1005)
Figure imgf000446_0002
[2058] Compound 1005 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, lH-pyrrolo[3,2-b]pyridine-6- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H29N703:572.24; found: 572.16.
Example 906
4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-(3-methylbut-2-enamido)phenyl)-lH-indazol-5- yl)benzamide (Com ound 1006)
Figure imgf000446_0003
[2059] Compound 1006 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 3-methyl-2-butenoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C3oH3iNs03: 510.24; found
510.13.
Example 907
N-(l-(4-(lH-Pyrrole-2-carboxamido)phenyl)-lH-indazol-5-yl)-l -methyl- lH-indole-5- carboxamide (Compound 1007)
Figure imgf000447_0001
[2060] Compound 1007 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 2-pyrrolecarboxylic, and 1- methylindole-5-carboxylic acids. [M+H]+ calcd for 02»ϋ22Ν602: 475.18; found: 474.97.
Example 908
1 -(2-Hydroxyethyl)-N-( 1 -(4-( 1 -methyl- lH-indole-5-carboxamido)phenyl)- lH-indazol-5- yl)-lH-indole-5-carboxamide (Compound 1008)
Figure imgf000447_0002
[2061] Compound 1008 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, l-(2-hydroxyethyl)indole-5- carboxylic, and l-methylindole-5-carboxylic acids. 1H NMR (500MHz, Acetone-^) δ 9.67 (s, IH), 9.59 (s, IH), 8.55 (s, IH), 8.35 (m, 2H), 8.26 (s, IH), 8.14 (d, / = 8 Hz, 2H), 7.90 (m, 4H), 7.81 (d, / = 8.5 Hz, 2H), 7.59 (d, / = 8.5 Hz, IH), 7.53 (d, / = 9 Hz, IH), 7.44 (d, / = 2.5 Hz, IH), 7.36 (d, / = 3 Hz, IH), 6.60 (m, 2H), 4.37 (t, / = 5.5 Hz, 2H), 3.94 (t, / = 3.5 Hz, 2H), 3.91 (s, 3H).
Example 909
N-( 1 -(4-( lH-Pyrrole-2-carboxamido)phenyl)- lH-indazol-5-yl)- 1 -(2-hydroxyethyl)- 1H- indole-5-carboxamide Compound 1009)
Figure imgf000447_0003
[2062] Compound 1009 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 2-pyrrolecarboxylic, and l-(2- hydroxyethyl)indole-5-carboxylic acids. [M+H]+ calcd for C29H24N6O3: 505.19; found 505.10.
Example 910 tert-Butyl (4-((4-(5-(4-fluorobenzamido)-lH-indazol-l- yl)phenyl)carbamoyl)phenyl)carbamate (Compound 1010)
Figure imgf000448_0001
[2063] Compound 1010 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 4-(tert-butoxycarbamoyl)benzoic, and 4-fluorobenzoic acids. [M+H]+ calcd for C32H28FN5O4: 566.21; found 566.02.
Example 911
iV-(4-(5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 -yl)phenyl)pyridazine-4- carboxamide (Com ound 1011)
Figure imgf000448_0002
[2064] Compound 1011 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, pyridazine-4-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H27N7O3: 534.23; found: 534.09.
Example 912
N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l-yl)phenyl)-5- methylisoxazole-3-carboxamide ompound 1012)
Figure imgf000448_0003
[2065] Compound 1012 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 5-methylisoxazole-3-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H26N6O4: 537.33; found: 537.12.
Example 913 N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l-yl)phenyl)-6- methylpicolinamide Compound 1013)
Figure imgf000449_0001
[2066] Compound 1013 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 6-methylpicolinic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H30N6O3: 547.14; found:
547.12.
Example 914
iV-(4-(5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 -yl)phenyl)pyrimidine-4- carboxamide (Com ound 1014)
Figure imgf000449_0002
[2067] Compound 1014 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, pyrimidine-4-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H27N7O3: 534.10; found:
534.16.
Example 915
iV-(4-(5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 -yl)phenyl)- 1 -methyl- 1H- indole-5-carboxamide (Compound 1015)
Figure imgf000449_0003
[2068] Compound 1015 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, l-methylindole-5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C35H32N6O3: 585.25; found: 585.20. Example 916
N-(4-(5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 -yl)phei
hydroxypropyl)-lH-indole-6-carboxamide (Compound 1016)
Figure imgf000450_0001
[2069] Compound 1016 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, l-(3-hydroxypropyl)-lH-indole-6- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500MHz, CD3OD) δ 8.23 (s, 1H), 8.21 (s, 1H), 8.16 (s, 1H), 7.98 (d, / = 8.5 Hz, 2H), 7.88 (d, / = 8.5 Hz, 2H), 7.77-7.65 (m, 7H), 7.44 (d, / = 3Hz, 1H), 7.03 (d, / = 9 Hz, 2H), 6.55 (d, / = 3 Hz, 1H), 4.40 (t, / = 6.5 Hz, 2H), 3.83-3.76 (m, 3H), 3.56 (t, / = 6.5 Hz, 2H), 3.05 (t, / = 10 Hz, 2H), 2.12-2.07 (m, 2H), 1.98-1.94 (m, 2H), 1.64-1.57 (m, 2H).
Example 917
N-( 1 -(4-Benzamidophenyl)- lH-indazol-5-yl)-4-(4-hydroxypiperidin- 1 -yl)benzamide (Compound 1017)
Figure imgf000450_0002
[2070] Compound 1017 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H3oN503: 532.23; found: 532.13.
Example 918
N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l-yl)phenyl)-lH-indole-2- carboxamide (Com ound 1018)
Figure imgf000450_0003
[2071] Compound 1018 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, indole-2-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H30N6O3: 571.25; found: 571.16.
Example 919
N-(l-(4-(2-Hydroxy-2-methylpropanamido)phenyl)-lH-indazol-5-yl)-4-(4- hydroxypiperidin-l- l)benzamide (Compound 1019)
Figure imgf000451_0001
[2072] Compound 1019 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 2-hydroxy-2-methylpropanoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H31N5O4: 514.24; found 514.11.
Example 920
4-Hydroxy-N-(4-((4-(5-(4-(4-hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 - yl)phenyl)carbamo l)phenyl)piperidine- 1 -carboxamide (Compound 1020)
Figure imgf000451_0002
[2073] Compound 1020 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 4-(4-hydroxypiperidin-l- yl)carbamoylbenzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C38H39N7O5: 674.30; found 674.33.
Example 921
iV-(l-(4-(l -Methyl- lH-pyrrole-2-carboxamido)phenyl)- lH-indazol-5-yl)- lH-indole-5- carboxamide (Compound 1021)
Figure imgf000452_0001
[2074] Compound 1021 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, l-methyl-2-pyrrolecarboxylic, and indole-5-carboxylic acids. [M+H]+ calcd for 02»ϋ22Ν602: 475.04; found: 475.03.
Example 922
N-(l-(4-(l -Methyl- lH-pyrazole-5-carboxamido)phenyl)- lH-indazol-5-yl)- lH-indole-5- carboxamide (Compound 1022
Figure imgf000452_0002
[2075] Compound 1022 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, l-methyl-5-pyrazolecarboxylic, and indole-5-carboxylic acids. [M+H]+ calcd for C27H21N7O2: 476.02; found: 476.11.
Example 923
N-(l-(4-(5-Aminopicolinamido)phenyl)-lH-indazol-5-yl)-lH-indole-5-carboxamide (Compound 1023)
Figure imgf000452_0003
[2076] Compound 1023 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 5-aminopicolic, and indole-5- carboxylic acids. [M+H]+ calcd for C28H21N7O2: 488.04; found: 488.06.
Example 924
l-(2-Hydroxyethyl)-iV-(4-(5-(l -(2-hydroxyethyl)- lH-indole-5-carboxamido)- lH-indazol- l-yl)phenyl)-lH-indole-5-carboxamide (Compound 1024)
Figure imgf000453_0001
[2077] Compound 1024 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole and l-(2-hydroxyethyl)indole-5- carboxylic.
[M+H]+ calcd for C35H31N6O4: 599.24; found: 599.08.
Example 925
5-Cyano-N-(4-(5-(4-(4-hydroxypiperidin-l-yl)benzamido)-lH-indazol-l- yl)phenyl)picolinamide Compound 1025)
Figure imgf000453_0002
[2078] Compound 1025 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 5-cyanopicolic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H27N7O3: 558.13; found: 558.13.
Example 926
N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l-yl)phenyl)-lH- pyrrolo[3,2-b]pyridine-5-carboxamide Compound 1026)
Figure imgf000453_0003
[2079] Compound 1026 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, lH-pyrrolo[3,2-b]pyridine-5- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H29N7O3: 572.24; found: 572.16.
Example 927
N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l-yl)phenyl)-lH- pyrrolo[2,3-b]pyridine-5-carboxamide (Compound 1027)
Figure imgf000454_0001
[2080] Compound 1027 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, lH-pyrrolo[2,3-b]pyridine-5- carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H29N7O3: 572.24; found: 572.17.
Example 928
iV-(4-(5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 -yl)phenyl)-4-methyl- 1H- pyrrole-2-carboxamide (Compound 1028)
Figure imgf000454_0002
[2081] Compound 1028 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 4-methylpyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30N6O3: 535.13; found: 535.10.
Example 929
N-(4-(5-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indazol-l-yl)phenyl)-lH-pyrrole-3- carboxamide (Com ound 1029)
Figure imgf000454_0003
[2082] Compound 1029 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, pyrrole-3-carboxylic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H28N6O3: 521.11; found: 521.13.
Example 930
Ethyl 4-(5-(4-(4-hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 -yl)benzoate
(Compound 1030)
Figure imgf000455_0001
[2083] Compound 1030 was prepared according to the procedure described in Scheme IV from ethyl 4-(5-amino-lH-indazol-l-yl)benzoate and 4-(4-hydroxypiperidin- l-yl)benzoic acid. [M+H]+ calcd for C28H28N4O4: 485.21; found: 485.09.
Example 931
N-(l-(4-((lH-Indol-6-yl)carbamoyl)phenyl)-lH-indazol-5-yl)-4-(4-hydroxypiperidin-l- yl)benzamide (Com ound 1031)
Figure imgf000455_0002
[2084] Compound 1031 was prepared according to the procedure described in Scheme IV from 6-aminoindole, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H30N6O3: 571.24; found 571.16.
Example 932
N-(l-(4-((lH-Indol-5-yl)carbamoyl)phenyl)-lH-indazol-5-yl)-4-(4-hydroxypiperidin-l- yl)benzamide (Com ound 1032)
Figure imgf000455_0003
[2085] Compound 1032 was prepared according to the procedure described in Scheme IV from 5-aminoindole, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H30N6O3: 571.24; found 571.17.
Example 933
4-(4-Hydroxypiperidin- 1 -yl)-iV-(l -(4-((2-methyl- lH-indol-5-yl)carbamoyl)phenyl)- 1H- indazol-5-yl)benzamide (Compound 1033)
Figure imgf000456_0001
[2086] Compound 1033 was prepared according to the procedure described in Scheme IV from 2-methyl-5-aminoindole, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C35H32N6O3: 585.25; found 585.20.
Example 934
4-(4-Hydroxypiperidin- 1 -yl)-iV-(l -(4-(( 1 -methyl- lH-indol-5-yl)carbamoyl)phenyl)- 1H- indazol-5-yl)benzamide Compound 1034)
Figure imgf000456_0002
[2087] Compound 1034 was prepared according to the procedure described in Scheme IV from l-methyl-5-aminoindole, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C35H32N6O3: 585.25; found 585.20.
Example 935
4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-(isopropylcarbamoyl)phenyl)-lH-indazol-5- yl)benzamide (Com ound 1035)
Figure imgf000456_0003
[2088] Compound 1035 was prepared according to the procedure described in Scheme IV from isopropylamine, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H31N5O3: 498.24; found 498.11.
Example 936 4-Amino-N-(4-(5-(4-fluorobenzamido)-lH-indazol-l-yl)phenyl)benzamide (Compound 1036)
Figure imgf000457_0001
[2089] Compound 1036 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, 4-aminobenzoic, and 4- fluorobenzoic acids. [M+H]+ calcd for C27H20FN5O2: 466.16; found 465.99.
Example 937
iV-(4-(5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)- IH-indazol- 1 -yl)phenyl)- 1 -methyl- 1H- pyrrole-2-carboxamide Compound 1037)
Figure imgf000457_0002
[2090] Compound 1037 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indazole, l-methylpyrrole-2-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H30N6O3: 535.13; found: 535.10.
Example 938
iV-(4-(5-(4-(4-Hydroxypiperidin- 1 -yl)benzamido)- lH-indol- 1 -yl)phenyl)- 1 -methyl- 1H- indole-5-carboxamide (Compound 1038)
Figure imgf000457_0003
[2091] Compound 1038 was prepared according to the procedure described in Scheme IV from 5-amino-l-(4-aminophenyl)indole, 1 -methyl- lH-indole-5-carboxylic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C36H33N5O3: 584.26; found: 584.12.
Example 939
Ethyl 4-(5-( 1 -(2-hydroxyethyl)- lH-indole-5-carboxamido)- IH-indazol- 1 -yl)benzoate (Compound 1039)
Figure imgf000458_0001
[2092] Compound 1039 was prepared according to the procedure described in Scheme IV from ethyl 4-(5-amino-lH-indazol-l-yl)benzoate and l-(2- hydroxyethyl)indole-5-carboxylic acid. [M+H]+ calcd for C27H24N4O4: 469.18; found
469.03.
Example 940
N-( 1 -(4-(Cyclopropylcarbamoyl)phenyl)- lH-indazol-5-yl)- 1 -(2-hydroxyethyl)- lH-indole- 5-carboxamide (Com ound 1040)
Figure imgf000458_0002
[2093] Compound 1040 was prepared according to the procedure described in Scheme IV from cyclopropylamine, 4-(5-amino-lH-indazol-l-yl)benzoic, and l-(2- hydroxyethyl)indole-5-carboxylic acids. [M+H]+ calcd for C28H25N5O3: 480.20; found 480.03.
Example 941
N-(Cyclopropylmethyl)-4-(5-(4-(4-hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 - yl)benzamide (Com ound 1041)
Figure imgf000458_0003
[2094] Compound 1041 was prepared according to the procedure described in Scheme IV from cyclopropylmethylamine, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O3: 510.24; found
510.06.
Example 942
4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-((5-methylthiazol-2-yl)carbamoyl)phi
indazol-5-yl)benzamide (Compound 1042)
Figure imgf000459_0001
[2095] Compound 1042 was prepared according to the procedure described in Scheme IV from 5-methylthiazol-2-ylamine, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H28N6O3S: 553.19; found 553.06.
Example 943
N-(l-(lH-Indol-5-yl)-lH-indazol-5-yl)-4-(4-hydroxypiperidin-l-yl)benzamide
(Compound 1043)
Figure imgf000459_0002
[2096] Compound 1043 was prepared according to the procedure described in Scheme IV from 5-amino-l-(indol-5-yl)indazole and 4-(4-hydroxypiperidin-l-yl)benzoic acid.
[M+H]+ calcd for C27H26N5O2: 452.21; found: 452.02.
Example 944
4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-((2-morpholinoethyl)carbamoyl)phenyl)-lH- indazol-5-yl)benzamide Compound 1044)
Figure imgf000459_0003
[2097] Compound 1044 was prepared according to the procedure described in Scheme IV from 2-morpholinoethylamine, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C32H36N6O4: 569.28; found:
569.33.
Example 945
N-(Cyanomethyl)-4-(5-(4-(4-hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 - yl)benzamide (Compound 1045)
Figure imgf000460_0001
[2098] Compound 1045 was prepared according to the procedure described in Scheme IV from cyanomethylamine, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C28H26N6O3: 495.21 ; found 495.01.
Example 946
4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-((4-methylthiazol-2-yl)carbamoyl)phenyl)-lH- indazol-5-yl)benzamide ompound 1046)
Figure imgf000460_0002
[2099] Compound 1046 was prepared according to the procedure described in Scheme IV from 4-methylthiazol-2-ylamine, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H28N6O3S: 553.29; found 553.06.
Example 947
4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-(thiazol-2-ylcarbamoyl)phenyl)-lH-indazol-5- yl)benzamide (Com ound 1047)
Figure imgf000460_0003
[2100] Compound 1047 was prepared according to the procedure described in Scheme IV from thiazol-2-ylamine, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H26N6O3S: 539.18; found
539.02.
Example 948
tert-Butyl ( l-(4-(5-(4-(4-hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 - yl)benzoyl)piperidin-4-yl)carbamate (Compound 1048)
Figure imgf000461_0001
[2101] Compound 1048 was prepared according to the procedure described in Scheme IV from tert-butyl piperidin-4-ylcarbamate, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. 1H NMR (500MHz, DMSO-d6) δ 10.07 (s, IH), 8.39 (d, / = 0.5 Hz, 2H), 7.92 (d, / = 9 Hz, IH), 7.87 (m, 4H), 7.80 (dd, / = 2, 9 Hz, IH), 7.57 (d, / = 6.5 Hz, 2H), 7.00 (d, / = 9 Hz, 2H), 6.90 (d, / = 7.5 Hz, IH), 4.70 (d, / = 4 Hz, IH), 4.30 (bs, IH), 3.70 (m, 4H), 3.52 (m, 2H), 3.00 (m, 4H), 1.80 (m, 4H), 1.44 (m, 2H), 1.37 (s, 9H).
Example 949
4-(4-Hydroxypiperidin- 1 -yl)-N-(l -(4-(4-hydroxypiperidine- 1 -carbonyl)phi
indazol-5-yl)benzamide Compound 1049)
Figure imgf000461_0002
[2102] Compound 1049 was prepared according to the procedure described in Scheme IV from 4-hydroxypiperidine, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H33N5O4: 540.25; found:
540.10.
Example 950
tert-Butyl 4- (4- (5 - (4- (4-hydroxypiperidin- 1 -yl)benzamido) - 1 H-indazol- 1 -yl)b
piperidine-l-carbox late (Compound 1050)
Figure imgf000461_0003
[2103] Compound 1050 was prepared according to the procedure described in Scheme IV from 4-amino-l-tert-butoxycarbonylpiperidine, 4-(5-amino-lH-indazol-l- yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C36H42N6O5: 639.32; found 583.24 (- ί-butyl group).
Example 951
4- (4-Hydroxypiperidin- 1 -yl)-iV- ( 1 - (4- (morpholine-4-carbonyl)phenyl) - 1 H-indazol- 5 - yl)benzamide (Com ound 1051)
Figure imgf000462_0001
[2104] Compound 1051 was prepared according to the procedure described in Scheme IV from morpholine, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H31N5O4: 526.24; found 526.13.
Example 952
4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-(piperidin-4-ylcarbamoyl)phenyl)-lH-indazol-5- yl)benzamide (Com ound 1052)
Figure imgf000462_0002
[2105] Compound 1052 was prepared by hydrolysis of Compound 1050.
[M+H]+ calcd for C31H34N6O3: 539.27; found 539.16.
Example 953
N-( 1 -(4-(4-Aminopiperidine- 1 -carbonyl)phenyl)- lH-indazol-5-yl)-4-(4-hydroxypiperidin- l-yl)benzamide (Com ound 1053)
Figure imgf000462_0003
[2106] Compound 1053 was prepared by hydrolysis of Compound 1048.
[M+H]+ calcd for C31H34N6O3: 539.27; found 539.16.
Example 954
iV-Benzyl-4-(5-(4-(4-hydroxypiperidin- 1 -yl)benzamido)- lH-indazol- 1 -yl)benzamide (Compound 1054)
Figure imgf000463_0001
[2107] Compound 1054 was prepared according to the procedure described in Scheme IV from benzylamine, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C33H31N5O3: 546.24; found 546.11.
Example 955
N-( 1 -(4-(Cyclopropylcarbamoyl)phenyl)- lH-indazol-5-yl)- 1 -(2-hydroxyethyl)- lH-indole- 6-carboxamide (Compound 1 55)
Figure imgf000463_0002
[2108] Compound 1055 was prepared according to the procedure described in Scheme IV from cyclopropylamine, 4-(5-amino-lH-indazol-l-yl)benzoic, and l-(2- hydroxyethyl)indole-6-carboxylic acids. [M+H]+ calcd for C28H25N5O3: 480.20; found: 480.03.
Example 956
l-(2-Hydroxyethyl)-N-(l-(4-((l-methyl-lH-indol-5-yl)carbamoyl)phenyl)-lH-indazol-5- yl)-lH-indole-5-carboxamide Compound 1056)
Figure imgf000463_0003
[2109] Compound 1056 was prepared according to the procedure described in Scheme IV from 5-amino-l-methylindole, 4-(5-amino-lH-indazol-l-yl)benzoic, and l-(2- hydroxyethyl)indole-5-carboxylic acids. [M+H]+ calcd for C34H28N6O3: 569.22; found 569.13.
Example 957
N-Cyclopropyl-4-(5-(4-(4-hydroxypiperidin-l-yl)benzamido)-lH-benzo[(i]imidazol-l- yl)benzamide (Compound 1057)
Figure imgf000464_0001
[2110] Compound 1057 was prepared according to the procedure described in Scheme IV from cyclopropylamine, 4-(5-amino-lH-benzo[<i]imidazol-l-yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C29H29N5O3: 496.24; found: 496.09.
Example 958
iV-Cyclopropyl-4-(5-(4-(4-hydroxypiperidin- 1 -yl)benzamido)- lH-indol- 1 -yl)benzamide (Compound 1058)
Figure imgf000464_0002
[2111] Compound 1058 was prepared according to the procedure described in Scheme IV from cyclopropylamine, 4-(5-amino-lH-indol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C30H30N4O3: 495.23; found:
495.14.
Example 959
N-(l-(4-(Cyclopropylcarbamoyl)phenyl)-lH-benzo[(i]imidazol-5-yl)-lH-indole-6- carboxamide (Compound 1059
Figure imgf000464_0003
[2112] Compound 1059 was prepared according to the procedure described in Scheme IV from cyclopropylamine, 4-(5-amino-lH-benzo[<i]imidazol-l-yl)benzoic, and 6-indolecarboxylic acids. [M+H]+ calcd for C26H21N5O2: 436.18; found: 436.03.
Example 960
N-(l-(4-(Cyclopropylcarbamoyl)phenyl)-lH-benzo[(i]imidazol-5-yl)-lH-indole-2- carboxamide (Compound 1060)
Figure imgf000465_0001
[2113] Compound 1060 was prepared according to the procedure described in Scheme IV from cyclopropylamine, 4-(5-amino-lH-benzo[d]imidazol-l-yl)benzoic, and 2-indolecarboxylic acids. [M+H]+ calcd for C26H21N5O2: 436.18; found: 436.03.
Example 961
N-(3-(4-(lH-Pyrrole-2-carboxamido)phenyl)-lH-indol-6-yl)-l -methyl- lH-indole-5- carboxamide (Compou
Figure imgf000465_0002
[2114] Compound 1061 was prepared according to the procedure described in Scheme IV from 6-amino-3-(4-aminophenyl)indole, 2-pyrrolecarboxylic, and 1-methyl- indole-5-carboxylic acids. [M+H]+ calcd for C29H23N5O2: 474.05; found: 474.09.
Example 962
N-(l-(2-Hydroxyethyl)-lH-indol-5-yl)-4-(5-(4-(4-hydroxypiperidin-l-yl)benzamido)-lH- indazol-l-yl)benzamide Compound 1062)
Figure imgf000465_0003
[2115] Compound 1062 was prepared according to the procedure described in Scheme IV from 5-amino-l-(2-hydroxyethyl)indole, 4-(5-amino-lH-indazol-l-yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C36H34N6O4: 615.26; found 615.18.
Example 963
4-(4-Hydroxypiperidin- 1 -yl)-iV-(l -(4-(( 1 -methyl- lH-indol-5-yl)carbamoyl)phenyl)- 1H- indol-5-yl)benzamide (Compound 1063)
Figure imgf000466_0001
[2116] Compound 1063 was prepared according to the procedure described in Scheme IV from 5-amino-l-methylindole, 4-(5-amino-lH-indol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C36H33N5O3: 584.27; found: 584.19.
Example 964
N-(4-(6-(4-(4-Hydroxypiperidin-l-yl)benzamido)-lH-indol-3-yl)phenyl)-l -methyl- 1H- indole-5-carboxamide (Compound 1064)
Figure imgf000466_0002
[2117] Compound 1064 was prepared according to the procedure described in Scheme IV from 6-amino-3-(4-aminophenyl)indole, l-methylindole-5-carboxylic, and 4- (4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C36H33N5O3: 584.21 ; found: 584.19.
Example 965
4-(4-Hydroxypiperidin- 1 -yl)-N-(l -(4-(( 1 -(2-morpholinoethyl)- lH-indol-5- yl)carbamoyl henyl)-lH-indazol-5-yl)benzamide (Compound 1065)
Figure imgf000466_0003
[2118] Compound 1065 was prepared according to the procedure described in Scheme IV from 5-amino-l-(2-morpholinoethyl)indole, 4-(5-amino-lH-indazol-l- yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C40H41N7O4: 684.32; found 684.32.
Example 966 tert-Butyl 2-(5-(4-(5-(4-(4-hydroxypiperidin-l-yl)benzamido)-lH-indazol-l- izamido -lH-indol-l-yl)acetate (Compound 1066)
Figure imgf000467_0001
[2119] Compound 1066 was prepared according to the procedure described in Scheme IV from tert-butyl 5-aminoindol-l-ylacetate, 4-(5-amino-lH-indazol-l- yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C40H40N6O5: 685.31; found 685.27.
Example 967
4-(4-Hydroxypiperidin-l-yl)-N-(l-(4-((l-methyl-lH-imidazo[4,5-b]pyridin-6- yl)carbamoyl)phenyl)-lH-indol-5-yl)benzamide (Compound 1067)
Figure imgf000467_0002
[2120] Compound 1067 was prepared according to the procedure described in Scheme IV from l-methyl-lH-imidazo[4,5-b]pyridin-6-ylamine, 4-(5-amino-lH-indol-l- yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H31N7O3: 586.26; found: 586.14.
Example 968
N-(l-(4-((lH-Pyrrolo[2,3-b]pyridin-5-yl)carbamoyl)phenyl)-lH-indol-5-yl)-4-(4- hydroxypiperidi -l-yl)benzamide (Compound 1068)
Figure imgf000467_0003
[2121] Compound 1068 was prepared according to the procedure described in Scheme IV from 5-amino-lH-Pyrrolo[2,3-b]pyridine, 4-(5-amino-lH-indol-l-yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C34H30N6O3: 571.25; found: 571.16. Example 969
4- (4-Hydroxypiperidin-l-yl)-N-(l-(4-((5-methylthiazol-2-yl)carbamoyl)phenyl)-lH-indol-
5- yl)benzamide (Compound 1069)
Figure imgf000468_0001
[2122] Compound 1069 was prepared according to the procedure described in Scheme IV from 2-amino-5-methylthiazole, 4-(5-amino-lH-indol-l-yl)benzoic, and 4-(4- hydroxypiperidin-l-yl)benzoic acids. [M+H]+ calcd for C31H29N5O3: 552.09; found:
552.12.
Example 970
N-(4-(3-cyclopropyl-5-(4-(4-hydroxypiperidin- 1 -yl)benzamido)- lH-indol- 1 -yl)phenyl)- 1 - methyl- lH-pyrrole- -carboxamide (Compound 1070)
Figure imgf000468_0002
[2123] Compound 1070 was prepared according to the procedure described in Scheme IV from 3-amino-l-methylpyrrole, 4-(5-amino-3-cyclopropyl-lH-indol-l- yl)benzoic, and 4-(4-hydroxypiperidin-l-yl)benzoic acids. 1H NMR (400 MHz, Acetone- d6) δ 9.13 (s, 1H), 9.12 (s, 1H), 8.08 (d, J = 1.8 Hz, 1H), 8.04 (d, J = 8.8 Hz, 2H), 7.93 (d, / = 9 Hz, 2H), 7.45 (m, 3H), 7.40 (dd, / = 1.8, 8.8 Hz, 1H), 7.02 (d, / = 9 Hz, 1H), 7.02 (d, / = 9 Hz, 2H), 6.75 (t, / = 2.6 Hz, 1H), 6.68 (dd, / = 1.8, 2.8 Hz, 1H), 6.20 (s, 1H), 3.84 (m, 2H), 3.77 (s, 3H), 3.74 (m, 2H), 3.08 (ddd, / = 3.2, 9.8, 13 Hz, 2H), 1.95 (m, 2H), 1.75 (m, 1H), 1.61 (m, 2H), 0.90 (m, 2H), 0.80 (m, 2H).
EXAMPLE 971
[2124] The following additional compounds are known and prepared according to standard literature procedures and Table 1 summarises the structure and names of the compounds. Table 1
Figure imgf000469_0001
Figure imgf000470_0001
Cpd # Structure Name
1717 A/-(2-Phenyl-1 /-/-benzimidazol- 5-yl)-4-pyrrolylbenzamide
H
1718 4-Dimethylamino-/V-(2-(4- methoxyphenyl)-1 H- benzimidazol-5-yl)benzamide
H
1719 (4-(5-(4-
Pyrrolidinobenzamido)-1 H- benzimidazol-2-yl)benzoic acid
H
1720 4-Fluoro-/V-(2-phenyl-1 H- benzimidazol-5-yl)benzamide
H
1721 4-Dimethylamino-/V-(2-phenyl- 1 /-/-benzimidazol-5- yl)benzamide
H
1722 2,2'-(1 ,3-
Phenylenebis(methylidene)dib enzohydrazide
1723 4-Methoxy-/V-(2-phenyl-1 H- benzimidazol-5-yl)benzamide
H
1724 3-Methoxy-/V-(2-phenyl-1 H- benzimidazol-5-yl)benzamide
H
1725 4-Trifluoromethoxy-/V-(2- phenyl-1 /-/-benzimidazol-5- yl)benzamide
H Cpd # Structure Name
1726 A/-(2-Phenyl-1 /-/-benzimidazol- 5-yl)-3(£)-phenylacrylamide
H
1727 A/-(2-Phenyl-1 /-/-benzimidazol- 5-yl)isonicotinamide
H
1728 Methyl (4-(5-(4-
I
dimethylaminobenzamido)-1 H- benzimidazol-2-yl)benzoate
H /
1729 A/-(2-(4-Methoxyphenyl)-1 H- benzimidazol-5-yl)-4- pyrrolylbenzamide
H
1730 A/-(2-(4-Methoxyphenyl)-1 H- benzimidazol-5-yl)-3- chlorobenzamide
H
1731 A/-(2-(4-Dimethylaminophenyl)- 1 /-/-benzimidazol-5-yl)-3- chlorobenzamide
H
1732 A/-(2-(4-Benzylphenyl)-1 H- benzimidazol-5-yl)-4- dimethylaminobenzamide
H
1733 A/-(2-(4-Dimethylaminophenyl)- 1 /-/-benzimidazol-5-yl)-1 H- indole-5-carboxamide
Figure imgf000472_0001
1734 I A/-(2-(1 -Methyl-1 H-indol-5- yl)benzimidazol-5-yl)-4- dimethylaminobenzamide
H Cpd # Structure Name
1735 I A/-(2-(1 -Methyl-1 H-indol-6- yl)benzimidazol-5-yl)-4- dimethylaminobenzamide
H
1736 A/-(2-(1 H-lndol-5- yl)benzimidazol-5-yl)-4- dimethylaminobenzamide
H
1737 I A/-(2-(1 H-lndol-6- yl)benzimidazol-5-yl)-4- dimethylaminobenzamide
H
1738 I 4-Dimethylamino-/V-(2-(3- dimethylaminophenyl)-1 H- benzimidazol-5-yl)benzamide
H
1739 O Methyl 4-(2-(4- methoxyphenyl)-1 H- benzimidazol-5-ylcarbamoyl)- benzoate
H
1740 4-(2-(4-Methoxyphenyl)-1 H- benzimidazol-5-ylcarbamoyl)- benzohydrazide
H
1741 O 4-(2-(4-Methoxyphenyl)-1 H- benzimidazol-5-ylcarbamoyl)- benzoic acid
H
1742 O Methyl 4-(2-(4- dimethylaminophenyl)-1 H- benzimidazol-5-ylcarbamoyl)- benzoate
H
1743 A/,/V'-(4,4'-Carbonylbis(4,1 - phenylene))dibenzamide o o
o Cpd # Structure Name
1 744 4,4'-(5,5'-Bibenzimidazole-2,2'- diyl)bis(/V,/V-dimethylaniline)
1 745 4,4'-(5,5'-Bibenzimidazole-2,2'- diyl)bis(anisole)
1 746 4-Amino-/V-(4-(5-(4- aminobenzamido)-1 H- benzimidazol-2- yl)phenyl)benzamide
H
1 747 A/-Phenyl-4-(5-benzamido-1 H- benzimidazol-2-yl)benzamide
H
Certain Pharmaceutical Agents
[2125] In certain embodiments, at least one compound disclosed herein, or pharmaceutically acceptable salt, ester, amide, and/or prodrug thereof, either alone or combined with one or more pharmaceutically acceptable carriers, forms a pharmaceutical agent. Techniques for formulation and administration of compounds of the present embodiments may be found for example, in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, 18th edition, 1990, which is incorporated herein by reference in its entirety.
[2126] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is prepared using known techniques, including, but not limited to mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tabletting processes.
[2127] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is a liquid (e.g. , a suspension, elixir and/or solution). In certain of such embodiments, a liquid pharmaceutical agent comprising one or more compounds of the present embodiments is prepared using ingredients known in the art, including, but not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
[2128] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is a solid (e.g., a powder, tablet, and/or capsule). In certain of such embodiments, a solid pharmaceutical agent comprising one or more compounds of the present embodiments is prepared using ingredients known in the art, including, but not limited to, starches, sugars, diluents, granulating agents, lubricants, binders, and disintegrating agents.
[2129] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is formulated as a depot preparation. Certain such depot preparations are typically longer acting than non-depot preparations. In certain embodiments, such preparations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. In certain embodiments, depot preparations are prepared using suitable polymeric or hydrophobic materials (for example an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
[2130] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments comprises a delivery system. Examples of delivery systems include, but are not limited to, liposomes and emulsions. Certain delivery systems are useful for preparing certain pharmaceutical agents including those comprising hydrophobic compounds. In certain embodiments, certain organic solvents such as dimethylsulfoxide are used.
[2131] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments comprises one or more tissue- specific delivery molecules designed to deliver the pharmaceutical agent to specific tissues or cell types. For example, in certain embodiments, pharmaceutical agents include liposomes coated with a tissue- specific antibody.
[2132] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments comprises a co- solvent system. Certain of such co-solvent systems comprise, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such co- solvent systems are used for hydrophobic compounds. A non-limiting example of such a co-solvent system is the VPD co-solvent system, which is a solution of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80™ , and 65% w/v polyethylene glycol 300. The proportions of such co-solvent systems may be varied considerably without significantly altering their solubility and toxicity characteristics. Furthermore, the identity of co-solvent components may be varied: for example, other surfactants may be used instead of Polysorbate 80™; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.
[2133] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments comprises a sustained-release system. A non-limiting example of such a sustained-release system is a semi-permeable matrix of solid hydrophobic polymers. In certain embodiments, sustained-release systems may, depending on their chemical nature, release compounds over a period of hours, days, weeks or months.
[2134] Certain compounds used in pharmaceutical agent of the present embodiments may be provided as pharmaceutically acceptable salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc.
[2135] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments comprises an active ingredient in a therapeutically effective amount. In certain embodiments, the therapeutically effective amount is sufficient to prevent, alleviate or ameliorate symptoms of a disease or to prolong the survival of the patient being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art.
[2136] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is formulated as a prodrug. In certain embodiments, prodrugs are useful because they are easier to administer than the corresponding active form. For example, in certain instances, a prodrug may be more bioavailable (e.g., through oral administration) than is the corresponding active form. In certain instances, a prodrug may have improved solubility compared to the corresponding active form. In certain embodiments, a prodrug is an ester. In certain embodiments, such prodrugs are less water soluble than the corresponding active form. In certain instances, such prodrugs possess superior transmittal across cell membranes, where water solubility is detrimental to mobility. In certain embodiments, the ester in such prodrugs is metabolically hydrolyzed to carboxylic acid. In certain instances the carboxylic acid containing compound is the corresponding active form. In certain embodiments, a prodrug comprises a short peptide (polyaminoacid) bound to an acid group. In certain of such embodiments, the peptide is metabolized to form the corresponding active form.
[2137] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is useful for treating a conditions or disorder in a mammalian, and particularly in a human patient. Suitable administration routes include, but are not limited to, oral, rectal, transmucosal, intestinal, enteral, topical, suppository, through inhalation, intrathecal, intraventricular, intraperitoneal, intranasal, intraocular and parenteral (e.g., intravenous, intramuscular, intramedullary, and subcutaneous). In certain embodiments, pharmaceutical intrathecals are administered to achieve local rather than systemic exposures. For example, pharmaceutical agents may be injected directly in the area of desired effect (e.g., in the renal or cardiac area).
[2138] In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is administered in the form of a dosage unit (e.g., tablet, capsule, bolus, etc.). In certain embodiments, such dosage units comprise a compound disclosed herein in a dose from about 1 g/kg of body weight to about 50 mg/kg of body weight. In certain embodiments, such dosage units comprise a compound disclosed herein in a dose from about 2 g/kg of body weight to about 25 mg/kg of body weight. In certain embodiments, such dosage units comprise a compound disclosed herein in a dose from about 10 g/kg of body weight to about 5 mg/kg of body weight. In certain embodiments, pharmaceutical agents are administered as needed, once per day, twice per day, three times per day, or four or more times per day. It is recognized by those skilled in the art that the particular dose, frequency, and duration of administration depends on a number of factors, including, without limitation, the biological activity desired, the condition of the patient, and tolerance for the pharmaceutical agent.
[2139] In certain embodiments, a pharmaceutical agent comprising a compound of the present embodiments is prepared for oral administration. In certain of such embodiments, a pharmaceutical agent is formulated by combining one or more compounds of the present embodiments with one or more pharmaceutically acceptable carriers. Certain of such carriers enable compounds of the present embodiments to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient. In certain embodiments, pharmaceutical agents for oral use are obtained by mixing one or more compounds of the present embodiments and one or more solid excipient. Suitable excipients include, but are not limited to, fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). In certain embodiments, such a mixture is optionally ground and auxiliaries are optionally added. In certain embodiments, pharmaceutical agents are formed to obtain tablets or dragee cores. In certain embodiments, disintegrating agents (e.g. , cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate) are added.
[2140] In certain embodiments, dragee cores are provided with coatings. In certain of such embodiments, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to tablets or dragee coatings.
[2141] In certain embodiments, pharmaceutical agents for oral administration are push-fit capsules made of gelatin. Certain of such push-fit capsules comprise one or more compounds of the present embodiments in admixture with one or more filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In certain embodiments, pharmaceutical agents for oral administration are soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In certain soft capsules, one or more compounds of the present embodiments are be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.
[2142] In certain embodiments, pharmaceutical agents are prepared for buccal administration. Certain of such pharmaceutical agents are tablets or lozenges formulated in conventional manner.
[2143] In certain embodiments, a pharmaceutical agent is prepared for administration by injection (e.g., intravenous, subcutaneous, intramuscular, etc.). In certain of such embodiments, a pharmaceutical agent comprises a carrier and is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks' s solution, Ringer' s solution, or physiological saline buffer. In certain embodiments, other ingredients are included (e.g. , ingredients that aid in solubility or serve as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents and the like. Certain pharmaceutical agents for injection are presented in unit dosage form, e.g. , in ampoules or in multi-dose containers. Certain pharmaceutical agents for injection are suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Certain solvents suitable for use in pharmaceutical agents for injection include, but are not limited to, lipophilic solvents and fatty oils, such as sesame oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, and liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, such suspensions may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
[2144] In certain embodiments, a pharmaceutical agent is prepared for transmucosal administration. In certain of such embodiments penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
[2145] In certain embodiments, a pharmaceutical agent is prepared for administration by inhalation. Certain of such pharmaceutical agents for inhalation are prepared in the form of an aerosol spray in a pressurized pack or a nebulizer. Certain of such pharmaceutical agents comprise a propellant, e.g. , dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In certain embodiments using a pressurized aerosol, the dosage unit may be determined with a valve that delivers a metered amount. In certain embodiments, capsules and cartridges for use in an inhaler or insufflator may be formulated. Certain of such formulations comprise a powder mixture of a compound of the present embodiments and a suitable powder base such as lactose or starch.
[2146] In certain embodiments, a pharmaceutical agent is prepared for rectal administration, such as a suppositories or retention enema. Certain of such pharmaceutical agents comprise known ingredients, such as cocoa butter and/or other glycerides. [2147] In certain embodiments, a pharmaceutical agent is prepared for topical administration. Certain of such pharmaceutical agents comprise bland moisturizing bases, such as ointments or creams. Exemplary suitable ointment bases include, but are not limited to, petrolatum, petrolatum plus volatile silicones, lanolin and water in oil emulsions such as Eucerin™, available from Beiersdorf (Cincinnati, Ohio). Exemplary suitable cream bases include, but are not limited to, Nivea™ Cream, available from Beiersdorf (Cincinnati, Ohio), cold cream (USP), Purpose Cream™, available from Johnson & Johnson (New Brunswick, New Jersey), hydrophilic ointment (USP) and Lubriderm™, available from Pfizer (Morris Plains, New Jersey).
[2148] In certain embodiments, the formulation, route of administration and dosage for a pharmaceutical agent of the present embodiments can be chosen in view of a particular patient's condition. (See e.g., Fingl et al. 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p. 1, which is incorporated herein by reference in its entirety). In certain embodiments, a pharmaceutical agent is administered as a single dose. In certain embodiments, a pharmaceutical agent is administered as a series of two or more doses administered over one or more days.
[2149] In certain embodiments, a pharmaceutical agent of the present embodiments is administered to a patient between about 0.1% and 500%, 5% and 200%, 10% and 100%, 15% and 85%, 25% and 75%, or 40% and 60% of an established human dosage. Where no human dosage is established, a suitable human dosage may be inferred from ED50 or ID50 values, or other appropriate values derived from in vitro or in vivo studies.
[2150] In certain embodiments, a daily dosage regimen for a patient comprises an oral dose of between 0.1 mg and 2000 mg, 5 mg and 1500 mg, 10 mg and 1000 mg, 20 mg and 500 mg, 30 mg and 200 mg, or 40 mg and 100 mg of a compound of the present embodiments. In certain embodiments, a daily dosage regimen is administered as a single daily dose. In certain embodiments, a daily dosage regimen is administered as two, three, four, or more than four doses.
[2151] In certain embodiments, a pharmaceutical agent of the present embodiments is administered by continuous intravenous infusion. In certain of such embodiments, from 0.1 mg to 500 mg of a composition of the present embodiments is administered per day. [2152] In certain embodiments, a pharmaceutical agent of the present embodiments is administered for a period of continuous therapy. For example, a pharmaceutical agent of the present embodiments may be administered over a period of days, weeks, months, or years.
[2153] Dosage amount, interval between doses, and duration of treatment may be adjusted to achieve a desired effect. In certain embodiments, dosage amount and interval between doses are adjusted to maintain a desired concentration on compound in a patient. For example, in certain embodiments, dosage amount and interval between doses are adjusted to provide plasma concentration of a compound of the present embodiments at an amount sufficient to achieve a desired effect. In certain of such embodiments the plasma concentration is maintained above the minimal effective concentration (MEC). In certain embodiments, pharmaceutical agents of the present embodiments are administered with a dosage regimen designed to maintain a concentration above the MEC for 10-90% of the time, between 30-90% of the time, or between 50-90% of the time.
[2154] In certain embodiments in which a pharmaceutical agent is administered locally, the dosage regimen is adjusted to achieve a desired local concentration of a compound of the present embodiments.
[2155] In certain embodiments, a pharmaceutical agent may be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Compositions comprising a compound of the present embodiments formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
[2156] In certain embodiments, a pharmaceutical agent is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. Certain Combination Therapies
[2157] In certain embodiments, one or more compounds of the present embodiments are co-administered with one or more other pharmaceutical agents. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the same disease or condition as the one or more compounds of the present disclosure. In certain embodiments, such one or more other pharmaceutical agents are designed to treat a different disease or condition as the one or more compounds of the present disclosure. In certain embodiments, such one or more other pharmaceutical agents are designed to treat an undesired effect of one or more compounds of the present disclosure. In certain embodiments, one or more compounds of the present disclosure are co-administered with another pharmaceutical agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more compounds of the present disclosure and one or more other pharmaceutical agents are administered at the same time. In certain embodiments, one or more compounds of the present disclosure and one or more other pharmaceutical agents are administered at the different times. In certain embodiments, one or more compounds of the present disclosure and one or more other pharmaceutical agents are prepared together in a single formulation. In certain embodiments, one or more compounds of the present disclosure and one or more other pharmaceutical agents are prepared separately.
[2158] In certain embodiments, the compounds disclosed herein are administered as combination therapies with EPO or erythropoiesis stimulating agents. In some embodiments, the erythropoiesis stimulating agent is a synthetic protein produced by recombinant DNA technology in mammalian cells into which the human erythropoietin gene has been introduced, e.g., rHuEPO, Epoetin alfa (marketed as Epogen® and Procrit® and identical to endogenous EPO), Epoetin beta (marketed only in Europe as NeoRecormon®), Darbepoetin Alfa (marketed as Aranesp®), or a methoxy polyethylene glycol-conjugated form of epoetin beta (marketed as Micera®). In certain embodiments, the erythropoiesis stimulating agent is Hematide™ or CNTO-530.
[2159] In some embodiments, examples of pharmaceutical agents that are administered with compounds disclosed herein include, but are not limited to, anti-cancer treatments, including, but not limited to, chemotherapy and radiation treatment; corticosteroids, including but not limited to prednisone; immunoglobulins, including, but not limited to intravenous immunoglobulin (IVIg); analgesics (e.g., acetaminophen); anti- inflammatory agents, including, but not limited to non-steroidal anti-inflammatory drugs (e.g., ibuprofen, COX-1 inhibitors, and COX-2, inhibitors); salicylates; antibiotics; antivirals; antifungal agents; antidiabetic agents (e.g. , biguanides, glucosidase inhibitors, insulins, sulfonylureas, and thiazolidenediones); adrenergic modifiers; diuretics; hormones (e.g. , anabolic steroids, androgen, estrogen, calcitonin, progestin, somatostan, and thyroid hormones); immunomodulators; muscle relaxants; antihistamines; osteoporosis agents (e.g., biphosphonates, calcitonin, and estrogens); prostaglandins, antineoplastic agents; psychotherapeutic agents; sedatives; poison oak or poison sumac products; antibodies; and vaccines.
Methods of Treatment
[2160] In certain embodiments, compounds or pharmaceutical agents disclosed herein are EPO receptor partial agonists or selective EPO receptor partial agonists. In some embodiments, EPO receptor partial agonists or selective EPO receptor partial agonists are administered in a dosing regimen such that the first dose results in a biological activity of EPO receptor that is of the same type as that resulting from the presence of naturally occurring EPO, but which is less than the maximum effect induced by EPO, and at least a second dose is administered, which is substantially the same as the first dose, and which also results in a biological activity of EPO receptor that is of the same type as that resulting from the presence of naturally occurring EPO, but which is less than the maximum effect induced by EPO. For example, in some embodiments the first dose will result in EPO receptor biological activity that is of the same type as that resulting from the presence of naturally occurring EPO, but which is less than 95%, or less than 90%, or less than 80%, or less than 70%, or less than 60%, or less than 50%, or less than 40%, or less than 30%, or less than 20%, or less than 10%, or less than 5% of the maximum biological EPO receptor activity induced by EPO, and the at least a second dose results in substantially the same biological activity of EPO receptor as the first dose.
[2161] Some embodiments of the present invention include methods for treating a disorder associated with erythropoiesis in a patient in need of such treatment. Some such methods include administering an initial effective amount of a non-peptidyl small molecule mimetic of EPO to the patient, and administering a second effective amount of the mimetic of EPO to the patient, wherein the initial and the second effective amounts are substantially the same over the period of administration of said mimetic of EPO. Some embodiments include administering a third effective amount of the mimetic of EPO to the patient. Some embodiments include administering one or more subsequent effective amounts of the mimetic of EPO to the patient. In some embodiments, the initial and the second effective amounts are the same. In some embodiments, the initial effective amount and the subsequent effective amounts are the same. In some embodiments, the period of administration is at least daily, at least weekly, or at least monthly.
[2162] Some embodiments include methods for treating a disorder associated with erythropoiesis in a patient in need of such treatment. Some such methods include administering an effective amount of a non-peptidyl small molecule mimetic of EPO to the patient, wherein the amount administered to the patient is not titrated over the period of time for administration. In some such methods, at least two successive effective amounts are administered to the patient. In some embodiments, the period of time for administration is daily, weekly, or monthly.
[2163] In some of the foregoing methods, the disorder associated with erythropoiesis comprises anemia. In some embodiments, the anemia is associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, anemia of chronic disease, congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or HIV infection.
[2164] In some of the foregoing methods, the mimetic of EPO comprises an EPO receptor partial agonist. In some embodiments, the mimetic of EPO activates EPO receptor signaling through the PI3K-GATA1 pathway.
[2165] More embodiemtns of the present invention include uses of a non- peptidyl small molecule mimetic of EPO for treating a disorder associated with erythropoiesis in a patient in need of such treatment. Some such uses include administering an initial effective amount of the mimetic of EPO to the patient, and administering a second effective amount of the mimetic of EPO to the patient, wherein the initial and the second effective amounts are substantially the same over the period of administration of said mimetic of EPO.
[2166] Some embodiments include administering a third effective amount of the mimetic of EPO to the patient. Some embodiments include administering one or more subsequent effective amounts of the mimetic of EPO to the patient. In some embodiments, the initial and the second effective amounts are the same. In some embodiments, the initial effective amount and the subsequent effective amounts are the same. In some embodiments, the period of administration is at least daily, at least weekly, or at least monthly.
[2167] More embodiments include uses of a non-peptidyl small molecule mimetic of EPO for treating a disorder associated with erythropoiesis erythropoiesis in a patient in need of such treatment. Some such embodiments include administering an effective amount of the mimetic of EPO to the patient, wherein the amount administered to the patient is not titrated over the period of time for administration.
[2168] In some embodiments, at least two successive effective amounts are administered to the patient. In some embodiments, the period of time for administration is daily, weekly, or monthly.
[2169] In some embodiments, the disorder associated with erythropoiesis comprises anemia. In some embodiments, the anemia is associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, anemia of chronic disease, congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or ΗΓ infection.
[2170] In some of the foregoing uses, the mimetic of EPO comprises an EPO receptor partial agonist. In some of the foregoing uses the mimetic of EPO activates EPO receptor signaling through the PI3K-GATA1 pathway.
[2171] In some embodiments, compounds of any of Formulae I to X, or any compound specifically disclosed herein, is a hematopoietic growth factor mimetic, a hematopoietic growth factor receptor agonist, or a hematopoietic growth factor receptor antagonist. In some embodiments, compounds of any of Formulae I to X, or any compound specifically disclosed herein, is an EPO mimetic. In some embodiments, compounds of any of Formulae I to X, or any compound specifically disclosed herein, is a selective EPO receptor agonist. In some embodiments, compounds of any of Formulae I to X, or any compound specifically disclosed herein, is a selective EPO receptor partial agonist. In some embodiments, compounds of any of Formulae I to X, or any compound specifically disclosed herein, is a selective EPO receptor antagonist. In some embodiments, compounds of any of Formulae I to X, or any compound specifically disclosed herein, is a selective EPO receptor binding compound.
[2172] In some embodiments, compounds disclosed herein are used in a method of modulating an EPO receptor activity in a cell, said method comprising contacting a cell with a compound of any of Formulae I to X, or any compound specifically disclosed herein.
[2173] Some embodiments disclosed herein provide a method for identifying a compound that modulates an EPO receptor activity, comprising contacting a cell that expresses an EPO receptor with a compound of any of Formulae I to X, or any compound specifically disclosed herein, and monitoring an effect of the compound on the cell.
[2174] Some embodiments disclosed herein provide a method of treating a patient for a disorder requiring EPO receptor modulation, comprising administering to the patient a therapeutically effective amount of a compound of any of Formulae I to X, or any compound specifically disclosed herein. In some embodiments, EPO receptor modulation is EPO receptor activation. In some embodiments, EPO receptor modulation is EPO receptor partial activation. In some embodiments, EPO receptor modulation is EPO receptor inactivation.
Indications
[2175] Some compounds and compositions provided herein can be used to treat various disorders associated with EPO receptor activity, e.g., anemia. In certain embodiments, the anemia is associated with other disorders. For example, anemia may be associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, or anemia of chronic disease, e.g., congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or HIV infection.
EXAMPLES
Example 1— EPO-dependent cell viability assay
[2176] Erythroid cells were treated with various concentrations of recombinant human EPO, Compound 101, or Compound 102, and the viability of treated cells was measured. The maximum efficacies of Compounds 101 and 102 was approximately 40% of the efficacy of EPO, corresponding to EPO EC4o of approximately 0.02 U/ml (FIG. 3). The typical EPO concentration in blood is approximately 0.01 U/ml, with a range from about 0.006 U/ml to about 0.032 U/ml. Compound 101 and Compound 102 exhibited an erythropoietic efficacy that was a fraction of the maximum effect induced by EPO, but greater than would be predicted for EPO at typical serum concentrations. Example 2— Relative differentiation of human bone marrow cells
[2177] CD34+ human bone marrow cells (BM-HCs) were treated with various concentrations of recombinant human EPO, Compound 101, Compound 102, or control. The number of cells expressing the erythrocyte- specific marker, CD235a (glycophorin A), was measured. Treatment of cells with 10 nm Compound 101 increased the level of expression of CD235a above the level of expression observed in cells treated with 0.01 U/ml EPO (normal serum EPO concentration is about 0.01 U/mL, with a range 0.006- 0.032 U/mL) (FIG. 4). The level of expression of CD235a in cells treated with 10 nm Compound 101 was approximately 37% of the level of expression of CD235a in cells treated with 2.0 U/ml EPO.
Example 3— Selective Agonists Partially Induce BFU-E Colony Formation in Human CD34+ Bone Marrow Cells
[2178] CD34+ human bone marrow cells were incubated with recombinant human EPO, Compound 101, or control. The formation of BFU-E colonies was measured. , The results are summarized in Table 1. Compound 101 stimulated the formation of BFU-E colonies with partial efficacy (31%) when incubated with BM-HCs.
TABLE 1
Figure imgf000487_0001
Example 4— Activation of EPO receptor-PI3K-GATAl Signaling
[2179] UT7 cells were treated with 10 nM Compound 102, 100 nM Compound 102, or control (vehicle). Phosphorylation of the EPO receptor was measured after 15 minutes or 45 minutes of treatment with Compound 101 or control (vehicle) (FIG. 5A). Phosphorylation of P13K was measured after 60 minutes of treatment with EPO, Compound 101, or control (vehicle) (FIG 5B). Phosphorylation of GATA1 was measured after 60 minutes treatment with Compound 102, EPO or control (vehicle) (FIG. 5C). Compound 102 stimulated phosphorylation of at least EPO receptor and GATA1. Compound 101 stimulated phosphorylation of at least P13K.
[2180] Binding of GATA1 to DNA was measured in an electrophoretic mobility shift assay for GATA1 in UT7 cells after 30 minute treatments with 1 U/ml EPO, 30 nM Compound 102, or 100 nM Compound 101. The result are summarized in FIG 6A and FIG. 6B. Compounds 101 and 102 induce binding of GATA1 to DNA.
[2181] UT7 cells transfected with EPO receptor- and GATA1- specific siRNAs were treated with 1 U/ml EPO, 30 nM Compound 101, or control (vehicle). The relative cell viability of the cells was measured (FIG. 7). Treatment with EPO receptor- and GATA1- specific siRNAs blocks activity of Compound 101.
Example 5
CD34+ cells treated with Compound 103
[2182] In CD34+ human bone marrow hematopoietic cells (BM-HCs), a representative analog, Compound 103, potently (2 nM EC50) increased the percentage of cells positive for the erythrocyte- specific marker CD235a (glycophorin A) with an efficacy partial (42%) to the maximal effect of EPO (3 U/ml), but greater than the efficacy of the normal serum EPO concentration (-0.01 U/ml). The erythropoietic effect of Compound 103 in BM-HCs was additive to the effect of EPO. Compound 103 stimulated the expression of several EPO responsive genes in CD34 positive BM-HCs, including hemoglobin a, EPO receptor, and the anti-apoptotic protein BCL2L1.
[2183] In addition, Compound 103 stimulated the formation of BFU-E colonies with partial efficacy (30%) when incubated with BM-HCs for 14 days. The effect of Compound 103 on BM-HCs was specific for the erythroid lineage. Compound 103 did not increase the percentage of BM-HCs positive for the megakaryocyte marker CD41 or the granulocyte marker CD15.
UT7EPO cells treated with Compound 103
[2184] Using human cell lines, the action of Compound 103 was determined to be dependent on the EPO receptor and involves the selective activation of the PI3K/AKT-GATA1 signaling pathway. In the human EPO-dependent cell line UT7EPO, Compound 103 blocked apoptosis induced by EPO withdrawal (10 nM EC50), and stimulated the expression of BCL2L1 with an efficacy comparable to EPO. Compound 103 stimulated the phosphorylation of EPOR, PI3K, and GATA1, and induced the binding of GATA1 to DNA. Incubation of UT7EPO cells with the PI3K inhibitor LY294002 blocked the effect of Compound 103 on cell survival. However, Compound 103 did not stimulate phosphorylation of STAT5 or ERK/MAPK, or induce STAT5 DNA binding. Transfection of UT7EPO cells with EPO receptor- and GATA1- specific siRNAs blocked the activity of Compound 103.
Mo7e cells treated with Compound 103
[2185] Compound 103 did not block apoptosis or stimulate BCL2L1 expression in the GM-CSF- and TPO-responsive human leukemia Mo7e cells that lack EPO receptor.
[2186] The foregoing data demonstrate that Compound 103 is a novel small molecule selective EPO receptor agonist that unlike erythropoiesis-stimulating agents, selectively activates the EPO receptor/PI3K/GATAl signal transduction pathway resulting in survival and differentiation of BM-HCs into erythrocytes, possibly through uniquely altering the conformation of the homodimeric EPO receptor. The selective agonists display an efficacy partial to the maximal effect induced by EPO, and lack excessive erythropoietic stimulation that may possibly contribute to the adverse effects of erythropoiesis-stimulating agents. Based on the novel profile of the series, several lead compounds that increase the percentage of CD235a positive BM-HCs with nanomolar potency, and display oral bioavailability in the rat and monkey, have been identified as potential preclinical development candidates.
[2187] All references cited herein, including but not limited to published and unpublished applications, patents, and literature references, are incorporated herein by reference in their entirety and are hereby made a part of this specification. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material. The term "comprising" as used herein is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
[2188] The above description discloses several methods and materials of the present invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention.

Claims

WHAT IS CLAIMED IS:
1. Use of a non-peptidyl small molecule mimetic of EPO in the preparation of a medicament for the treatment of a disorder associated with erythropoiesis by administering an initial effective amount of the mimetic of EPO, and a second effective amount of the mimetic of EPO, wherein the initial and the second effective amounts are substantially the same.
2. The use of claim 1, wherein the medicament is for the treatment of a disorder associated with erythropoiesis by further administering a third effective amount of the mimetic of EPO that is substantially the same as the initial and second effective amounts.
3. The use of claim 2, wherein the medicament is for the treatment of a disorder associated with erythropoiesis by further administering one or more subsequent effective amounts of the mimetic of EPO that is substantially the same as the initial, second, and third effective amounts.
4. The use of claim 1, wherein the initial and the second effective amounts are the same.
5. The use of claim 1, wherein the medicament is for the treatment of a disorder associated with erythropoiesis by administering a series of effective amounts that are substantially the same at least daily, at least weekly, or at least monthly.
6. Use of a non-peptidyl small molecule mimetic of EPO in the preparation of a medicament for the treatment of a disorder associated with erythropoiesis without titration of the amount of the mimetic of EPO administered.
7. The use of claim 6, wherein the medicament is for the treatment of a disorder associated with erythropoiesis by administering at least two successive effective amounts of the mimetic of EPO.
8. The use of claim 6, wherein the medicament is for the treatment of a disorder associated with erythropoiesis without titration over a period of time for administration that is daily, weekly, or monthly.
9. The use of claim 1 or 6, wherein the disorder associated with erythropoiesis comprises anemia.
10. The use of claim 9, wherein the anemia is associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, anemia of chronic disease, congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or HIV infection.
11. The use of any one of claims 1-10, wherein the mimetic of EPO is an EPO receptor partial agonist.
12. The use of any one of claims 1-11, wherein the mimetic of EPO activates EPO receptor signaling through the PI3K-GATA1 pathway.
13. A non-peptidyl small molecule mimetic of EPO for use in the treatment of a disorder associated with erythropoiesis by administering an initial effective amount of the mimetic of EPO, and a second effective amount of the mimetic of EPO, wherein the initial and the second effective amounts are substantially the same.
14. The mimetic of EPO of claim 13, for use in the treatment of a disorder associated with erythropoiesis by further administering one or more subsequent effective amounts of the mimetic of EPO that is substantially the same as the initial and second effective amounts.
15. The mimetic of EPO of claim 14, wherein the initial and the second effective amounts are the same.
16. The mimetic of EPO of claim 13, for use in the treatment of a disorder associated with erythropoiesis by administering a series of effective amounts that are substantially the same at least daily, at least weekly, or at least monthly.
17. A non-peptidyl small molecule mimetic of EPO for use in the treatment of a disorder associated with erythropoiesis without titration of the amount of the mimetic of EPO administered.
18. The mimetic of EPO of claim 17, for use in the treatment of a disorder associated with erythropoiesis by administering at least two successive effective amounts of the mimetic of EPO.
19. The mimetic of EPO of claim 17, for use in the treatment of a disorder associated with erythropoiesis without titration over a period of time for administration that is daily, weekly, or monthly.
20. The mimetic of EPO of claim 13 or 17, wherein the disorder associated with erythropoiesis comprises anemia.
21. The mimetic of EPO of claim 20, wherein the anemia is associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, anemia of chronic disease, congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or HIV infection.
22. The mimetic of EPO of any one of claims 13-21, wherein the mimetic of EPO is an EPO receptor partial agonist.
23. The mimetic of EPO of any one of claims 13-22, wherein the mimetic of EPO activates EPO receptor signaling through the PI3K-GATA1 pathway.
24. A method of treating a disorder associated with erythropoiesis in a patient in need of such treatment, said method comprising:
administering an initial effective amount of a non-peptidyl small molecule mimetic of EPO to the patient; and
administering a second effective amount of the mimetic of EPO to the patient,
wherein the initial and the second effective amounts are substantially the same.
25. The method of claim 24, further comprising administering a third effective amount of the mimetic of EPO to the patient that is substantially the same as the initial and second effective amounts.
26. The method of claim 25, further comprising administering one or more subsequent effective amounts of the mimetic of EPO to the patient that is substantially the same as the initial, second, and third effective amounts.
27. The method of claim 24, wherein the initial and the second effective amounts are the same.
28. The method of claim 24, comprising administering a series of effective amounts that are substantially the same to the patient at least daily, at least weekly, or at least monthly.
29. A method of treating a disorder associated with erythropoiesis to a patient in need of such treatment, said method comprising:
administering an effective amount of a non-peptidyl small molecule mimetic of EPO to the patient, wherein the amount administered to the patient is not titrated over the period of time for administration.
30. The method of claim 29, wherein one or more subsequent effective amounts of the mimetic of EPO are administered to said patient.
31. The method of claim 29, wherein the period of time for administration includes administration daily, weekly, or monthly.
32. The method of any one of claims 24 or 29, wherein the disorder associated with erythropoiesis comprises anemia.
33. The method of claim 32, wherein the anemia is associated with chronic kidney disease, cancer, palliative cancer therapy, chemotherapy, anemia of chronic disease, congestive heart failure, rheumatoid arthritis, COPD, chronic inflammatory conditions, or HIV infection.
34. The method of any one of claims 24-33, wherein the mimetic of EPO is an EPO receptor partial agonist.
35. The method of any one of claims 24-34, wherein the mimetic of EPO activates EPO receptor signaling through the PI3K-GATA1 pathway.
36. The use of claim 1 or 6, compound of claim 13 or 17, or method of claim 24 or 29, wherein the mimetic of EPO comprises a compound of Formula (IX) having the structure:
Figure imgf000494_0001
(IX)
or a pharmaceutically acceptable salt thereof;
wherein:
Figure imgf000494_0002
Z is s or -C(=E3)-;
each E is separately selected from the group consisting of -CR10a- and N (nitrogen);
each R10a is separately selected from the group consisting of H (hydrogen), halogen, Ci-C6 alkyl optionally substituted with up to five fluoro, and Ci-C6 alkoxy optionally substituted with up to five fluoro;
E3 is O (oxygen), N-NHRQ or N-ORQ where RQ in the definition of E3 is selected from the group consisting of hydrogen, CrC6 alkyl, C2-C6 alkenyl, -(CH^ , and -C(=0)(CH2)mRRA; R is selected from the group consisting of Ci-C6 alkyl, aryl, and heteroaryl;
A9 is hydrogen or Ci-C6 alkyl;
A10 is selected from the group consisting of Ci-C6 alkyl, C2-C6 alkenyl, -C(=0)RA, -C(=0)C(=0)RA ,-(CH2)RB, -(CH2)ORB;
RA is selected from the group consisting of Ci-C6 alkyl, C3-C7 cycloalkyl, heterocycle, polycyclic heterocyclyl, aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R1, R2, and R3;
R is selected from the group consisting of hydrogen, Ci-C6 alkyl, Ci-C6 alkoxy, C2-C6 alkenyl, C3-C7 cycloalkyl, and heteroaryl;
G4 is selected from the group consisting of polycyclic heterocyclyl, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6;
each R1 is separately selected from the group consisting of halogen, cyano, Ci-C6 heteroalkyl, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
each R is separately selected from the group consisting of halogen, -C CH^OR1, -(CH^OR1, -NRJRK, -(CH^SR1, -C(=0)RL, -(CH2)mRL, C C6 heteroalkyl, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci- C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted C3-C7 cycloalkyl where said C3-C7 cycloalkyl is further optionally fused with aryl or heteroaryl;
each R is separately selected from the group consisting of halogen, -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mS(0)o_2RM, -(CH2)mNHS(O)0-2RM,-(CH2)mCN, -(CH2)mRp, Ci-C6 alkyl Ci-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, Ci-C6 haloalkyl, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl polycyclic heterocyclyl, and heteroaryl in the definition of R are each optionally substituted with halogen, hydroxy, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, -C(=0)ORM, or -NRJRK;
each R4 is separately selected from the group consisting of halogen, cyano, Ci-C6 heteroalkyl, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
each R5 is separately selected from the group consisting of halogen, -C CH^OR1, -(CH^OR1, -NRJRK, -(CH^SR1, -(CH2)mC(=0)RL, - (CH2)mRL, Ci-C6 heteroalkyl, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C3-C7 cycloalkyl, and an optionally substituted Ci-C6 haloalkyl;
each R6 is separately selected from the group consisting of halogen, -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, - (CH2)mS(0)o_2RM, -(CH2)mNHS(0)o_2RM,-(CH2)mCN, -(CH2)mRp, C C6 alkyl, Ci-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl, said heterocycle, aryl, polycyclic heterocyclyl, and heteroaryl in the definition of R6 are each optionally substituted with halogen, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Cp C6 alkoxy, -C(=0)ORM, or -NRJRK;
R is selected from the group consisting of Ci-C6 alkyl, C3-C6 cycloalkyl, C3-C8 cycloalkenyl, Ci-C6 heteroalkyl, Ci-C6 heteroalkenyl, Ci-C6 heteroalkynyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of R are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle, or RG is -ORL or -NRPRL;
each R1 is separately selected from the group consisting of hydrogen, Ci- C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C7 cycloalkyl, C C6 haloalkyl, C C6 heteroalkyl, and Ci-C6 heterohaloalkyl;
each -NR T R K is separately selected, wherein R T and R K are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl optionally substituted with up to 5 fluoro, -(CH2)mOR , -(CH2)mNR R , - (CH2)mR , C3-C7 cycloalkyl, heterocycle, aryl and heteroaryl, said C3-C7 cycloalkyl, heterocycle, aryl and heteroaryl in the definition of R T and R K are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off of R T and R K are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -(CH2)mNRKARKB; or -NRJRK is an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom;
each RJA is independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
each -NR KA R KB is separately selected, wherein R KA and R KB are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
each RM is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, and -(CH2)mRp;
each -NRNR° is separately selected, wherein RN and R° are each independently selected from the group consisting of hydrogen, -(CH2)mNRNARNB, aryl and heteroaryl, said aryl and heteroaryl in the definition of RN and R° are each independently optionally substituted with one or more substituents selected from the group consisting of -(CH2)mNROAROB, halo, C C6 alkyl, C C6 haloalkyl, Ci-C6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off of RN and R° are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -NRNARNB,
each -NRNARNB is separately selected, wherein RNA and RNB are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl; each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, CrC6 alkyl, and Ci-C6 haloalkyl;
Rp is selected from the group consisting of hydrogen and CrC6 alkyl; each RL is independently selected from the group consisting of C3-C7 cycloalkyl, optionally substituted CrC6 alkyl, optionally substituted CrC6 alkoxy, -(CH2)mORLA, -(CH2)mNRLBRLC, aryl and heteroaryl, said aryl and heteroaryl in the definition of RL are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, CrC6 alkoxy, -(CH2)mNR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of RL are each optionally substituted with one or more halo, Ci-C6 alkyl, C C6 haloalkyl, C C6 alkoxy, or -(CH2)mNRLFRLG;
each RLA is independently selected from the group consisting of hydrogen, CrC6 alkyl, and CrC6 haloalkyl;
R LB and R L"C are each independently selected from the group consisting of hydrogen, CrC6 alkyl, CrC6 haloalkyl, and CrC6 heteroalkenyl, said CrC6 alkyl, Ci-C6 haloalkyl, and Ci-C6 heteroalkenyl each optionally substituted with one or more halogen, cyano, or -(CH2)mC(=0)OH; or LB LC
— NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each -NR LD R LE is separately selected, wherein R LD and R LE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted CrC6 alkyl, said aryl and heteroaryl in the definition of
LD LE
IT" and are each optionally substituted with Ci-C6 alkyl or Ci-C6 alkoxy; or
-NR LD R LE is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and Ci-C6 alkyl; or
-NR LF R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
R is selected from the group consisting of CrC6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; and
each m is independently 0, 1, 2, or 3.
37. The use of claim 1 or 6, compound of claim 13 or 17, or method of claim 24 or 29, wherein the EPO mimetic comprises a compound of Formula (I) having the structure:
K ^ LT G
(I)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof;
wherein:
Figure imgf000499_0001
O
,X I L / NRGRH or A-J is R and Q-G is O ;
A1 is selected from the group consisting of C3-C7 cycloalkenyl, C3-C7 cycloalkyl, Ci-C6 alkyl, C2-C6 alkenyl, Ci-C6 alkoxy, -(CH2)mNRPRL, heterocycle, aryl, and heteroaryl, said C3-C7 cycloalkenyl, C3-C7 cycloalkyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected
1 2 3
from the group consisting of R , R , and R , said aryl and heteroaryl in the definition of A1 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
J is selected from the group consisting of -(CH2)rNR C(=0)(CH2)m- and -(CH2)rNRB(CH2)m-, and -(CH2)r-;
G1 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G1 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
A is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group
1 , R2 3 2 consisting of R , and R , said aryl and heteroaryl in the definition of A are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
G is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G2 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
J is selected from the group consisting of an optionally substituted aryl, -(CH2)mNRBC(=0)(CH2)m-, -(CH2)rO(CH2)m-, -(CH2)rNRB(CH2)m-, and - (CH=CH)m-;
Q is selected from the group consisting of an optionally substituted aryl, -(CH2)rNRBC(=0)(CH2)m-, -(CH2)rO(CH2)m-, -(CH2)rNRB(CH2)m-, and - (CH=CH)r-;
A4 is selected from the group consisting of C3-C7 cycloalkenyl, C3-C7 cycloalkyl, Ci-C6 alkyl, Ci-C6 heteroalkyl, C2-C6 alkenyl, Ci-C6 alkoxy, -(CH2)mNRPRL, heterocycle, aryl, and heteroaryl, said C3-C7 cycloalkenyl, C3-C7 cycloalkyl, Ci-C6 alkyl, Ci-C6 heteroalkyl, C2-C6 alkenyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 , and said aryl and heteroaryl in the definition of A4 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
G4 is selected from the group consisting of C3-C7 cycloalkenyl, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G4 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
A5 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 , said aryl and heteroaryl in the definition of A 5 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
RA is selected from the group consisting of -(CH2)PRL, -(CH2)pORL, -S02RL, -C(=0)RL, -C(=0)NRNR°, -(CH2)PNRNR° , an aryl and an heteroaryl, said aryl and heteroaryl in the definition of RA are each optionally substituted with halogen, cyano, Ci-C6 haloalkyl, Ci-C6 alkyl, Ci-C6 alkoxy, C3-C7 cycloalkyl, C3- C7 cycloalkenyl, -C(=0)NRNR°, -OC(=0)NRNR°, -NHC(=0)NRNR°, -0(CH2)qNRNR°, -NH(CH2)qNRNR°, -(CH2)PNRNR°, an optionally substituted aryl and an optionally substituted heteroaryl, and said aryl and heteroaryl in the definition of RA are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle; each R is separately selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C6 alkenyl, and an optionally substituted C3-C7 cycloalkyl;
each -NR C RD is separately selected, wherein each R C is independently selected from the group consisting of hydrogen and an optionally Ci-C6 alkyl, and each RD is independently selected from the group consisting of aryl and heteroaryl, said aryl and heteroaryl in the definition of RD are each optionally substituted with halogen, cyano, Ci-C6 alkyl, Ci-C6 alkoxy, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, -C(=0)NRNR°, -OC(=0)NRNR°, -NHC(=0)NRNR°, -0(CH2)qNRNR°, -NH(CH2)qNRNR° -(CH2)PNRNR°, an optionally substituted aryl and an optionally substituted heteroaryl, and said aryl and heteroaryl in the definition of are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
each E F ately selected, wherein each E
-NR R is separ R is independently selected from the group consisting of hydrogen and an optionally Ci-C6 alkyl, and each R is independently selected from the group consisting of aryl and heteroaryl, said aryl and heteroaryl in the definition of R are each optionally substituted with halogen, cyano, CrC6 alkyl, CrC6 alkoxy, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, -C(=0)NRNR°, -OC(=0)NRNR°, -NHC(=0)NRNR°, -0(CH2)qNRNR°, -NH(CH2)qNRNR° -(CH2)PNRNR°, an optionally substituted aryl and an optionally substituted heteroaryl, and said aryl and heteroaryl in the definition of R are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
G thin the definition of G H
R wi -NR R is selected from the group consisting of Ci-C6 alkyl, C3-C6 cycloalkyl, C3-C8 cycloalkenyl, Ci-C6 heteroalkyl, Ci-C6 heteroalkenyl, CrC6 heteroalkynyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of RG are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle, or G
R is L -OR or -NRPRL;
H G H
R within the definition of -NR R is selected from the group consisting of hydrogen, Ci-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, and C1-C3 haloalkyl, or
G H
-NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each R1 is separately selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; each R is separately selected from the group consisting of halogen, -C CH. OR1, -(CH^OR1, -NRJRK, -(CH^SR1, -C(=0)RL, -(CH2)mRL, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and an optionally substituted C3-C7 cycloalkyl where said C3-C7 cycloalkyl is further optionally fused with aryl or heteroaryl;
each R is separately selected from the group consisting of halogen, -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mS(0)o_2RM, -(CH2)mNHS(0)o_2RM, -(CH2)mN02, -(CH2)mCN, - (CH2)mRp, Ci-C6 alkyl Ci-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, CrC6 haloalkyl, heterocycle, aryl, and heteroaryl, said heterocycle, aryl and heteroaryl in the definition of R are each optionally substituted with halogen, cyano, C C6 alkyl, C C6 haloalkyl, C C6 alkoxy, or -NRJRK;
each R4 is separately selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
each R5 is separately selected from the group consisting of halogen, -C CH^OR1, -(CH^OR1, -NRJRK, -(CH^SR1, -C(=0)RL, -(CH2)mRL, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
each R6 is separately selected from the group consisting of halogen, -(CH2)mORG, -NRLC(=0)RM, -NRLC(=0)ORM, -NRLC(=0)NRNR°, -NRNR°, -(CH2)mS(O)0-2RM, -(CH2)mNHS(0)o-2RM, -(CH2)mN02, -(CH2)mCN, - (CH2)mRp, Ci-Ce alkyl, C C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, heterocycle, aryl, and heteroaryl, said heterocycle, aryl and heteroaryl in the definition of R6 are each optionally substituted with halogen, cyano, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or - NRJRK; each R is separately selected from the group consisting of hydrogen, Ci- C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C7 cycloalkyl, C C6 haloalkyl, C C6 heteroalkyl, and Ci-C6 heterohaloalkyl;
each -NR T R K is separately selected, wherein R T and R K are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl optionally substituted with up to 5 fluoro, -(CH2)mORJA, -(CH2)mNRJBRJC, - (CH2)mR , C3-C7 cycloalkyl, heterocycle, aryl and heteroaryl, said C3-C7 cycloalkyl, heterocycle, aryl and heteroaryl in the definition of R T and R K are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off of R T and R K are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -(CH2)mNRKARKB; or -NRJRK is an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom; or -NR T R K is an optionally substituted Ci-C6 alkylideneamino;
each RJA is independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
each -NR KA R KB is separately selected, wherein R KA and R KB are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
each RM is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, and -(CH2)mRp;
each -NRNR° is separately selected, wherein RN and R° are each independently selected from the group consisting of hydrogen, -(CH2)mNRNARNB, aryl and heteroaryl, said aryl and heteroaryl in the definition of RN and R° are each independently optionally substituted with one or more substituents selected from the group consisting of -(CH2)mNROAROB, halo, C C6 alkyl, C C6 haloalkyl, Ci-C6 alkoxy, aryl and heteroaryl, said aryl and heteroaryl substituent off of RN and R° are each optionally substituted with one or more halo, CrC6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -NRNARNB,
each -NRNARNB is separately selected, wherein RNA and RNB are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
each -NROAROB is separately selected, wherein ROA and ROB are each independently selected from the group consisting of hydrogen, CrC6 alkyl, and Ci-C6 haloalkyl;
Rp is selected from the group consisting of hydrogen and CrC6 alkyl; RL is selected from the group consisting of C3-C7 cycloalkyl, optionally substituted CrC6 alkyl, optionally substituted CrC6 alkoxy, -(CH2)mORLA, -
(CH2)mNR LB R LC , aryl and heteroaryl, said aryl and heteroaryl in the definition of RL are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, -(CH2)mNR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of RL are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, C C6 alkoxy, or -(CH2)mNRLFRLG;
RLA is selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
R LB and R L"C are each independently selected from the group consisting of
LB LC
hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, and Ci-C6 heteroalkenyl; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each -NR LD R LE is separately selected, wherein R LD and R LE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted Ci-C6 alkyl, said aryl and heteroaryl in the definition of
LD LE
R"" and R"" are each optionally substituted with Ci-C6 alkyl or Ci-C6 alkoxy; or
-NR LD R LE is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and Ci-C6 alkyl; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
L is selected from the group consisting of -0(CH2)pO-, C1-C7 alkyl, C1-C7 heteroalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, an optionally substituted heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl, or L is selected from the group consisting of L 1 -L2 , L 1 -O-L 2 , L 1 -S- L2, LX-NR9-L2, iA-lA-L3, LX-L2-L3-L4, L1-C(=E)-L2, and I CR L2;
L1 is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
L is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
L is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
L4 is an optionally substituted aryl;
E is O (oxygen), N-NHRQ or N-ORQ where RQ in the definition of E is selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C6 alkenyl, -(CH2)mRR, and -C(=0)(CH2)mRR;
R is selected from the group consisting of Ci-C6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
R 7' and R 8° are each independently selected from the group consisting of hydrogen, Ci-C6 alkyl, Ci-C6 heteroalkyl, and -OH; or CR 7 R 8 is a three - to eight- membered optionally substituted carbocycle, which optionally has one to three additional hetero atoms incorporated in the ring;
R9 is selected from the group consisting of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, C3-C7cycloalkylC(0)- and Ci-C6 alkylC(O)-;
each m is independently 0, 1, 2, or 3;
each p is independently 0, 1, 2, 3, 4, 5, or 6;
each q is independently 1, 2, 3, 4, 5, or 6;
each r is independently 1, 2, 3, or 4; and
any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
38. The use of claim 1 or 6, compound of claim 13 or 17, or method of claim 24 or 29, wherein the mimetic of EPO comprises a compound of Formula (II) having the structure:
Figure imgf000507_0001
(ID
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof;
wherein:
A6 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R11, R12, and R13, said aryl and heteroaryl in the definition of A6 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
G6 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R14, R15, and R16, said aryl and heteroaryl in the definition of G6 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
L6 is an optionally substituted aryl, or an optionally substituted heteroaryl; where the aryl and heteroaryl in the definition of L6 are optionally fused with a nonaromatic heterocycle or a nonaromatic carb from the
group consisting of an optionally substituted
Figure imgf000507_0002
, and an
optionally substituted
E 2 is O (oxygen) or N-OR D where R D in the definition of E 2 is selected from the group consisting of hydrogen and an optionally substituted Ci-C6 alkyl; each R11 is separately selected from the group consisting of halogen, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
each R12 is separately selected from the group consisting of -0(CH2)mORA, -(CH2)mORA, -NRBRC, and -(CH2)mSRA;
each R 13 is separately selected from the group consisting of -(CH2)mOR D , -NRERF, -S(0)o-2RD, -(CH2)mN02, -(CH2)mCN, and -(CH2)mRG;
each R14 is separately selected from the group consisting of halogen, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
each R15 is separately selected from the group consisting of -0(CH2)mORA, -(CH2)mORA, -NRBRC, and -(CH2)mSRA;
each R16 is separately selected from the group consisting of -(CH2)mORD, -NRERF, -(CH2)mS(O)0-2RD, -(CH2)mN02, -(CH2)mCN, and -(CH2)mRG;
E6 is CR17 when the dashed line between E6 and X represents a double bond; or E6 is CR17R17 when the dashed line between E6 and X represents a single bond;
F6 is CR18 when the dashed line between F6 and Y represents a double bond; or F6 is CR18R18 when the dashed line between F6 and Y represents a single bond;
each R 17 is independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-C4 alkoxy, an optionally substituted C3-C7 cycloalkyl, and an optionally substituted C1-C4 alkyl;
each R 18 is independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-C4 alkoxy, an optionally substituted C3-C7 cycloalkyl, and an optionally substituted C1-C4 alkyl;
RA is selected from the group consisting of hydrogen, Ci-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C7 cycloalkyl, CrC6 haloalkyl, CrC6 heteroalkyl, and Ci-C6 heterohaloalkyl; each B C separately selected, wherein B C
-NR R is R and R are each independently selected from the group consisting of hydrogen, -S02R , - C(=0)RH, -C(=0)NRERF, heterocycle, Ci-C6 alkyl, C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, C3-C7 cycloalkyl, CrC6 haloalkyl, CrC6 heteroalkyl,
B C
and Ci-C6 heterohaloalkyl, where the Ci-C6 alkyl in the definition of R and R is optionally substituted with an optionally substituted aryl or an optionally substituted heteroaryl and where the C3-C7 cycloalkyl and the heterocycle in the definition of B C
R and R are optionally fused with an aryl or heteroaryl; or -
B C
NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or B C
-NR R is an optionally substituted CrC6 alkylideneamino; each RD is independently selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted CrC6 heteroalkyl, and -(CH2)mRG;
each E F E F
-NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted CrC6 heteroalkyl, and
G E F
-(CH2)mR"; or -NR R is an optionally substituted Ci-C6 alkylideneamino; or -
E F
NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;R is selected from an optionally substituted aryl and an optionally substituted heteroaryl;
R is selected from the group consisting of hydrogen, C1-C3 alkyl, an optionally substituted C1-C3 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C7 cycloalkyl, C1-C3 haloalkyl, and an optionally substituted aryl or heteroaryl;
X and Y are independently selected from N (nitrogen), NH, CR19, and each R and R are independently selected from the group consisting of hydrogen and an optionally substituted C1-C4 alkyl;
each m is independently 0, 1, or 2; and
any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
39. The use of claim 1 or 6, compound of claim 13 or 17, or method of claim
24 or 29, wherein the mimetic of EPO comprises a compound of Formula (III) having the structure:
Figure imgf000510_0001
(III)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof;
wherein:
A is selected from the group consisting of aryl, heteroaryl, isoindolinyl, indenyl, dihydroindenyl, tetrahydroisoquinolinyl, and tetrahydronaphthalenyl, each optionally substituted with one or more substituents selected from the group consisting of 21 22 , and 23 7
R , R R , said aryl and heteroaryl in the definition of A are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle; or A is C3-C7 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of 21 22 23 7
R , R , and R , said C3-C7 cycloalkyl in the definition of A is fused with an optionally substituted aryl or optionally substituted heteroaryl; each 21
R is independently selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle; each 22
R is independently selected from the group consisting of - (CH2)mORA, -0(CH2)mORA, -C(=0)ORA, -0(CH2)0NRBRc, -(CH2)mNRBRc, -C(=0)NRBRc, and -(CH2)mSRA; each R is independently selected from the group consisting of phenyl, -NHC(=NH)NH2, -(CH2)mORD, -C(=NNRBRC)H, -NRLC(=0)NRBRc, -C(=0)NRDN(=CHRG), -(CH2)mS(0)o_2RD, -(CH2)mN02, -(CH2)mCN, and -
(CH2)mR G 23
, said phenyl in the definition of R is substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-C3 alkyl, an optionally substituted C C3 alkoxy, -0(CH2)mORA, -(CH2)mNRBRc;
J is selected from the group consisting of -(CH2)n[NHC(=0)](CH2)0[N =0)](CH2)p-, -(CH2)n[NHC(=0)](CH2)0[NH]q-,
-NH[C(=0)][C(=0)]NH- and
Figure imgf000511_0001
;
Q 7 28
is selected from the group consisting of O (oxygen), -NR -, aryl, and arylamido; or Q is null;
28
each R is independently selected from the group consisting of hydrogen and an optionally substituted C1-C4 alkyl;
G is selected from the group consisting aryl, heteroaryl, and heterocycle, each optionally substituted with one or more substituents selected from the group
24 25 26 G 7 consisting of R , R , and R , said aryl and heteroaryl in the definition of are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
24
each R is independently selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted heterocycle;
R 25
each is independently selected from the group consisting of - (CH2)mORA, -0(CH2)mORA, -C(=0)ORA, -0(CH2)0NRBRc, -(CH2)mNRBRc, -(CH2)mC(=0)NRBRc, -C(=NNRBRC)H, and -(CH2)mSRA;
each R26 is independently selected from the group consisting of phenyl, -NHC(=NH)NH2, -(CH2)mORD, -C(=NNRBRC)H, -NRLC(=0)NRBRc, -C(=0)NRDN(=CH)RG, -(CH2)mS(0)o-2RD, -(CH2)mN02, -(CH2)mCN, - (CH2)mRG, said phenyl in the definition of R23 is substituted with -(CH2)mNRBRc; 1 2 3
X\ X", and XJ are each independently selected from N (nitrogen) and
CR27;
27
R is selected from the group consisting of hydrogen, halogen, and an optionally substituted CrC4 alkyl;
RA is selected from the group consisting of hydrogen, Ci-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C7 cycloalkyl, and CrC6 haloalkyl;
each B C B C
-NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, -S02R , - C(=0)RH, -(CH2)nORH, -(CH2U1, -(CH2)mRJ, -(CH2)nC(=0)NRERF, - (CH2)nNRERF, -S02NRERF, heterocycle, C C6 alkyl, C C6 haloalkyl, C C6 heteroalkyl, C3-C7 cycloalkyl, and Ci-C6 heterohaloalkyl where the C3-C7 cycloalkyl and the heterocycle are each optionally fused with an optionally substituted aryl or optionally substituted heteroaryl; or B C
-NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom, said optionally substituted non-aromatic heterocycle is optionally fused with an optionally substituted aryl or optionally substituted heteroaryl;
each RD is independently selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and -(CH2)mRI;
each E F is separately selected, wherein E F
-NR R R and R are each independently selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted heterocycle, and G E F
-(CH2)mR ; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;or -
E F
NR R is CrC6 alkylideneamino substituted with an optionally substituted aryl; each R is independently selected from an optionally substituted aryl and an optionally substituted heteroaryl;
each R is independently selected from the group consisting of hydrogen, C1-C3 alkoxy, C1-C3 alkyl, C1-C3 haloalkyl, an optionally substituted aryl and an optionally substituted heteroaryl; each R is independently selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl;
each RJ is independently selected from the group consisting of aryl and heteroaryl, each substituted with one or more -NR E R F ;
each RL is independently selected from the group consisting of C3-C7 cycloalkyl, optionally substituted CrC6 alkyl, optionally substituted CrC6 alkoxy, -(CH2)mORLA, -(CH2)mNRLBRLC, aryl and heteroaryl, said aryl and heteroaryl in the definition of RL are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, CrC6 alkoxy, -(CH2)mNR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of RL are each optionally substituted with one or more halo, Ci-C6 alkyl, C C6 haloalkyl, C C6 alkoxy, or -(CH2)mNRLFRLG;
each RLA is independently selected from the group consisting of hydrogen, CrC6 alkyl, and CrC6 haloalkyl;
R LB and R L"C are each independently selected from the group consisting of hydrogen, CrC6 alkyl, CrC6 haloalkyl, and CrC6 heteroalkenyl; or -NR LB R LC is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each -NR LD R LE is separately selected, wherein R LD and R LE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted Ci-C6 alkyl, said aryl and heteroaryl in the definition of
IT LD" and LE are each optionally substituted with CrC6 alkyl or CrC6 alkoxy; or
-NR LD R LE is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and CrC6 alkyl; or
-NR LF R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each m is independently 0, 1, or 2;
each n is independently 0, 1, 2, 3, or 4;
each o is independently 1, 2, or 3;
each p is independently 0, 1, 2, or 3; each q is independently 0 or 1 ; and
any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
40. The use of claim 1 or 6, compound of claim 13 or 17, or method of claim
24 or 29, wherein the mimetic of EPO comprises a compound of Formula (IV) having the structure:
|8 (-)8
A8 - J L8-Q\G8
(IV)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof;
wherein:
A is selected from the group consisting of heterocycle, aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 31 , R 32 , and R 33 , said aryl and heteroaryl in the definition of A 8 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
G is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 34 , R 35 , and R 36 , said aryl and heteroaryl in the definition of G 8 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
J is selected from the group consisting of aryl, heteroaryl, heterocycle, -C(=0)-, -(CH=CH)_ -OC(=0)-, -NHC(=0)NH- -NHC(=S)NH- -S(=0)2- NH2- -OC(=S)-, -NHC(=S)-, -(CH2)„NH-,
- =0)](CH2)0NHC(=0)(CH2)p-, -(CH2)n[NHC(=0)](CH2)0[NH]q-,
Figure imgf000514_0001
, and ; or J8 is null;
is selected from the group consisting of aryl, heteroaryl, heterocycle, -(CH=CH)-, -OC(=0)-, -NHC(=0)NH- -NHC(=S)NH- -S(=0)2- -OC(=S)-, -NHC(=S)-, -(CH2)„NH- -(CH2)n[NHC(=0)](CH2)0NHC(=0)(CH2)p-, -(CH2)n[NHC(=0)](CH2)0[NH]q-,
Figure imgf000515_0001
and R27 R28 ; 8 is null;
Figure imgf000515_0002
X 5 is selected from the group consisting of N (nitrogen) and CR 39 ;
Y5 is selected from the group consisting of N (nitrogen) and CR40;
each R is independently selected from the group consisting of hydrogen, halogen, and an optionally substituted CrC4 alkyl;
each R 28 is independently selected from the group consisting of hydrogen and an optionally substituted CrC4 alkyl;
each R 31 is independently selected from the group consisting of halogen, cyano, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl; each R is independently selected from the group consisting of halogen, -(CH2)mORA, -NRBRC, and -(CH2)mSRA;
R 33
each is independently selected from the group consisting of halogen, -C(=0)OH, -(CH2)mORD, -NRERF, -NRLC(=0)NRBRc, -(CH2)mS(O)0_2RD, - (CH2)mN02, -(CH2)mCN, and -(CH2)mRG;
each R34 is independently selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
35
each R is independently selected from the group consisting of halogen, C(=0)OH, -(CH2)mORA, -NRBRC, -C(=0)NRBRc, and -(CH2)mSRA;
each R36 is independently selected from the group consisting of halogen, -(CH2)mORD, -NRERF, -NRLC(=0)NRBRc, -(CH2)mS(O)0_2RD, -(CH2)mN02, - (CH2)mCN, and -(CH2)mRG;
each R39 and R40 are independently selected from the group consisting of hydrogen, halogen, -OH, -NHR , and an optionally substituted Ci-C4 alkyl;
each RA is independently selected from the group consisting of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl;
B C B C
each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, -S02R , - C(=0)RH, -C(=0)C(=0)RH, -(CH2)mC(=0)ORH, -C(=0)NRERF, -(CH2)mRG, - (CH2)mORH, -(CH2)mRH, Ci-C6 alkyl, C3-C7 cycloalkyl, C2-C6 alkenyl, non- aromatic heterocycle, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl where the C3-C7 cycloalkyl and the non-aromatic heterocycle are optionally fused with an an optionally substituted aryl or an optionally substituted
-NR B R C
heteroaryl; or is an optionally substituted non-aromatic heterocycle
B C
linked through a ring nitrogen atom; or -NR R is an optionally substituted Ci-C6 alkylideneamino ;
each RD is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, and -(CH2)mR each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 haloalkyl, an optionally
G E F
substituted C C6 heteroalkyl, and -(CH2)mR ; or -NR R is an optionally substituted Ci-C6 alkylideneaminyl; or -NR E R F is an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom;
each R is independently selected from an optionally substituted aryl and an optionally substituted heteroaryl;
R is selected from the group consisting of hydrogen, C1-C3 alkyl, C1-C3 haloalkyl, C3-C7 cycloalkyl, and an optionally substituted aryl or an optionally substituted heteroaryl;
each RL is independently selected from the group consisting of C3-C7 cycloalkyl, optionally substituted Ci-C6 alkyl, optionally substituted Ci-C6 alkoxy, -(CH2)mORLA, -(CH2)mNRLBRLC, aryl and heteroaryl, said aryl and heteroaryl in the definition of RL are each independently optionally substituted with one or more substituents selected from the group consisting of halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, -(CH2)mNR LD R LE , aryl and heteroaryl, said aryl and heteroaryl substituent off of RL are each optionally substituted with one or more halo, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkoxy, or -(CH2)mNRLFRLG;
each RLA is independently selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6 haloalkyl;
R LB and R L"C are each independently selected from the group consisting of
LB LC
hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, and Ci-C6 heteroalkenyl; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each -NR LD R LE is separately selected, wherein R LD and R LE are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, and optionally substituted Ci-C6 alkyl, said aryl and heteroaryl in the definition of
LD LE
R"" and R"" are each optionally substituted with Ci-C6 alkyl or Ci-C6 alkoxy; or
-NR LD R LE is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, and CrC6 alkyl; or
-NR LF R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each -NR LF R LG is separately selected, wherein R LF and R LG are each independently selected from the group consisting of hydrogen, and CrC6 alkyl; or
-NR LF R LG is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each m is independently 0, 1, or 2;
each n is independently 0, 1, 2, 3, or 4;
each o is independently 1, 2, or 3;
each p is independently 0, 1, 2, or 3;
each q is independently 0 or 1 ; and
any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
41. The use of claim 1 or 6, compound of claim 13 or 17, or method of claim
24 or 29, wherein the mimetic of EPO comprises a compound of Formula (V) having the structure:
Figure imgf000518_0001
(V)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof;
wherein:
G4 is selected from the group consisting of is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R43 and R44, said aryl and heteroaryl in the definition of G4 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
Q is selected from the group consisting of an ester, an amide, a urea, a carbamide, a thioamide, a sulfonamide; or Q is selected from the group consisting of -C(=0)0- -C(=0)NR -, -C(=0)NHN=CH-, -NR43C(=0)NR -, -NR45C(=0)(CH2)mO- -OC(=0)NR45-, -C(=S)NR45-, -NR45S(0)i_2-, C C6
alkylideneamino, and
Figure imgf000519_0001
; or when Y3 is C (carbon) substituted with -Q3- G4 then Q3 is optionally fused with Z1 to form a five-member ring heterocycle;
L3 is selected from the group consiting of -C(=0)NR45-, -O-Ci-Cs-alkyl, -C(=NR45)-, -NR45C(=0)-(CH2)mC(=0)NR45-, and -NR45C(=0)- (CH2)mNR45C(=0)-;
Q4 is selected from the group consisting of of NR48, and O (oxygen); or Q4 is null;
A4 is selected from the group consisting of Ci-C6 alkyl, C2-C6 alkenyl, C2- C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, a Ci-C6 heteroalkyl, phenyl, pyridinyl, imidazolyl, and thienyl, each optionally substituted with one or more substituents selected from the group consisting of R41 and R42;
Figure imgf000519_0002
X2", and X 3J are each independently selected from N (nitrogen) and
CR46;
Y 1 , Y2 , and Y 3 are each independently selected from N (nitrogen) and
CR47;
Z, Z 1 , and Z 2 are each independently selected from C (carbon), CH, and N (nitrogen);
R41 is independently selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl;
each R 42 is independently selected from the group consisting of - (CH2)mORA, -0(CH2)mORA, -NRBRC, -C(=0)NRBRc, -C(=NNRBRC)H, - (CH2)mSRA, -(CH2)mRK, -0(CH2)mRK;
or R41 and R42 are linked to form an optionally substituted ring; each R is independently selected from the group consisting of halogen, cyano, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl;
each R44 is independently selected from the group consisting of - (CH2)mORA, -0(CH2)mORA, -NRBRC, -C(=0)NRBRc, -C(=NNRBRC)H, - (CH2)mSRA, -(CH2)mRK, -0(CH2)mRK;
each R45 is independently selected from the group consisting of hydrogen, an optionally substituted C1-C4 alkyl, and an optionally substituted CrC6 heteroalkyl;
each R46 and R47 is independently selected from the group consisting of hydrogen, halogen, an optionally substituted Ci-C6 alkyl, and an optionally substituted CrC6 heteroalkyl;
R 48 is selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, and an optionally substituted Ci-C6 heteroalkyl;
each RA is independently selected from the group consisting of hydrogen, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl;
each -NR B R C is separately selected, wherein R B and R C are each independently selected from the group consisting of hydrogen, -S02R , - C(=0)RF, -(CH2)mRF, -S02NRDRE, -C(=0)NRDRE, -(CH2)mNRDRE, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and Ci- C6 heterohaloalkyl where the alkyl and the heteroalkyl are optionally fused with an aryl or heteroaryl; or -NR B R C is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -NR B R C is an optionally substituted Ci-C6 alkylideneamino;
each -NR D R E is separately selected, wherein R D and R E are each independently selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, an G D E optionally substituted Ci-C6 heteroalkyl, and -(CH2)mR ; or -NR R is an optionally substituted Ci-C6 alkylideneaminyl; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each R is independently selected from the group consisting of hydrogen, an optionally substituted C1-C4 alkyl, an optionally substituted C1-C4 haloalkyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, aryl and heteroaryl, where the aryl and heteroaryl in the definition of RF are each optionally substituted with -C(=0)NRDRE or -NRDRE;
each R is independently selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl;
each R is independently selected from the group consisting of -C(=0)NRDRE, -NRDRE, an optionally substituted aryl and an optionally substituted heteroaryl;
each m is independently 0, 1, or 2; and
each dashed line represents an optional double bond.
42. The use of claim 1 or 6, compound of claim 13 or 17, or method of claim 24 or 29, wherein the mimetic of EPO comprises a compound of Formula (VI) having the structure:
Figure imgf000521_0001
(VI)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof;
wherein:
E is selected from the group consisting of O (oxygen), S (sulfur), NR41 and CR42R43;
R41 is selected from the group consisting of hydrogen, halogen, cyano, c
-C(=0)R , Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and an optionally substituted Ci-C6 alkyl;
R and R are each independently selected from the group consisting of hydrogen, halogen, -ORAA, -ORcc, -NRARB, -NRCRD, -SRAA, -(CH2)mRE, -CONR R , an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl; or CR R is an optionally substituted C3-C7 cycloalkyl;
X\ X", and XJ are each independently selected from the group consisting of N (nitrogen) and CR41;
G9 is selected from the group consisting of aryl and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R44 and R45, said aryl and heteroaryl in the definition of G9 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
each R44 is separately selected from the group consisting of halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
each R45 is separately selected from the group consisting of hydrogen, halogen, -ORAA, -ORcc, -NRARB, -NRCRD, -SRAA, -(CH2)mRE, C C6 haloalkyl, Ci-C6 heteroalkyl, and an optionally substituted Ci-C6 alkyl;
each RAA is independently selected from the group consisting of hydrogen, -(CH2)mS02RF, -(CH2)mC(=0)RF, -(CH2)mC(=0)NRcRD, an optionally substituted Ci-C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, and an optionally substituted C3-C7 cycloalkyl, where said C3-C7 cycloalkyl is optionally fused with an aryl or heteroaryl;
BB
each R is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, an optionally substituted C3-C7 cycloalkyl, and (CH2)mR ;
-NR A R B A B each is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, -(CH2)mS02R , -(CH2)mC(=0)RF, -(CH2)mC(=0)NRcRD , an optionally substituted C C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, and an optionally substituted C3-C7 cycloalkyl, where said C3-C7 cycloalkyl is optionally fused with an aryl or heteroaryl; or -NR A R B is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom optionally fused with an aryl or heteroaryl; or
-NR A R B is an optionally substituted Ci-C6 alkylideneamino;
each -NR C RD is separately selected, wherein R C and RD are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, an optionally
E C D
substituted C3-C7 cycloalkyl, and (CH2)mR ; or -NR R is an optionally substituted Ci-C8 alkylideneamino; or -NR C R D is an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom;
each R is separately selected from the group consisting of an optionally substituted aryl and an optionally substituted heteroaryl;
each R is separately selected from the group consisting of hydrogen, a an optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted aryl and an optionally substituted heteroaryl;
L9 is selected from the group consisting of -(CH2)mC(=0)NR46(CH2)q-, -(CH2)mC(=0)NR46(CH2)qC(=0)NR46-, -S(0)2NH-, O (oxygen), -NR46-, -OC(=0)0-, -OC(=0)NH-, -NHC(=0)NH-, -NHC=SNH-, -C(=NR46)-, -C(=0)NR46-, -C(=S)NR46-; or L9 is null;
each R46 is independently selected from the group consisting of hydrogen, Ci-C6 haloalkyl, and an optionally substituted Ci-C6 alkyl;
each m is independently 0, 1, or 2;
each q is independently 1, 2, 3, 4, 5, or 6; and
any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
43. The use of claim 1 or 6, compound of claim 13 or 17, or method of claim
24 or 29, wherein the mimetic of EPO comprises a compound of Formula (VII) having the structure:
Figure imgf000524_0001
(VII)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof;
wherein:
G10 is selected from the group consisting of Ci-C6 alkyl, Ci-C6 alkoxy, C2- C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, heterocycle, aryl and heteroaryl, each optionally substituted
51 52 with one or more substituents selected from the group consisting of R , R , and R53, said aryl and heteroaryl in the definition of G10 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
Q10 is selected from the group consisting of Q11, Qu-Q12, and Qu-Q12-
Q13;
Q 11 13
and Q are each independently selected from the group consisting of piperazinyl, -C(=0)0- -C(=0)NR51-, -NR51C(=0)NR51-, -OC(=0)NR51-, -C(=S)NR51-, -NR51S(0)i_2- -(CH2)mC(=0)NR51(CH2)q-, and
-(CH2)mC(=0)NR51(CH2)qC(=0)NR51-;
Q 12
is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocycle; each R51 is separately selected from the group consisting of hydrogen, halogen, cyano, an optionally substituted Ci-C6 alkyl, an optionally substituted Ci- C6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
each R52 is separately selected from the group consisting of -(CH2)mORA, -(CH2)mNRBRc, -(CH2)mS02NRBRc , and -(CH2)mSRA;
53 D each R is separately selected from the group consisting of -(CH2)mOR , - (CH2)mNRERF, -(CH2)mS(0)o-2RD, -(CH2)mN02, -(CH2)mCN, and -(CH2)mRG; each R is separately selected from the group consisting of hydrogen, -(CH2)mORA, -(CH2)mNRBRc, -0(CH2)mNRBRc, -C(=0)NRBRc, -(CH2)mSRA, -(CH2)mRG, -0(CH2)mRG, -(CH2)mS02NRBRc -(CH2)mCN, an optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted Ci-C6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
each RA is separately selected from the group consisting of hydrogen, an optionally substituted CrC6 alkyl, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted C3-C7 cycloalkenyl, an optionally substituted CrC6 haloalkyl, and an optionally substituted Ci-C6 heteroalkyl;
B C B C
each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, -(CH2)mS02R , - (CH2)mCORH, -(CH2)mCONRERF, an optionally substituted C C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, an optionally substituted C3-C7 cycloalkyl, and -(CH2)mRG, where said C3-C7 cycloalkyl is optionally fused with an aryl or
B C
heteroaryl; or -NR R or is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom optionally fused with an aryl or heteroaryl; or
— NR B R C
is an optionally substituted Ci-C8 alkylideneamino;
each RD is separately selected from the group consisting of hydrogen, an optionally substituted Ci-C8 alkyl, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted C3-Q cycloalkenyl, an optionally substituted Ci-C8 haloalkyl, and an optionally substituted Ci-C8 heteroalkyl;
E F E F
each -NR R is separately selected, wherein R and R are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C8 alkyl, an optionally substituted Ci-C8 alkoxy, an optionally substituted C2-C8 alkenyl, an optionally substituted C2-C8 alkynyl, an optionally
CH2)mR G E F
substituted C3-C7 cycloalkyl, and ( ; or -NR R or is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom; or -
NR C R D is an optionally substituted Ci-C8 alkylideneamino;
each RG is separately selected from a substituted or unsubstituted aryl and a substituted or unsubstituted heteroaryl;
each R is separately selected from the group consisting of hydrogen, a Ci- C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Cp C6 haloalkyl, Ci-C6 heteroalkyl, an optionally substituted heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl;
X 11, X2", and X 3J are each independently selected from the group consisting of N (nitrogen) and CR47;
each R 47 is separately selected from the group consisting of hydrogen, halogen, an optionally substituted Ci-C6 alkyl, and an optionally substituted Ci-C6 heteroalkyl
each m is independently 0, 1, 2, or 3; and
any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
44. The use of claim 1 or 6, compound of claim 13 or 17, or method of claim
24 or 29, wherein the mimetic of EPO comprises a compound of Formula (X) having the structure:
. J1 ° ^Q1 °
A1 0 L10 G10
(X)
or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, or prodrug thereof;
wherein:
A10 is selected from the group consisting of Ci-C6 alkyl, Ci-C6 alkoxy, C2- C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R 1 , R2 , and R 3 , said aryl and heteroaryl in the definition of A10 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle; G is selected from the group consisting of Ci-C6 alkyl, Ci-C6 alkoxy, C2- C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, heterocycle, aryl, and heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of R4, R5, and R6, said aryl and heteroaryl in the definition of G10 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
J10 is a 1-8 atom long spacer containing at least 2 heteroatoms separated by 2 bonds and comprising one or more groups selected from -S(0)2NRA-, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted heterocycle, and an optionally substituted heteroalkylheterocycle; including the proviso that J10 is not a 1-8 atom spacer containing at least 2 heteroatoms separated by 3 or 4 bonds and comprising one or more groups selected from an optionally substituted Ci-C6 heteroalkyl, an optionally substituted heterocycle, and an optionally substituted heteroalkylheterocycle;
Q10 is a 1-8 atom long spacer containing at least 2 heteroatoms separated by 2 bonds and comprising one or more groups selected from -S(0)2NRA-, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted heterocycle, and an optionally substituted heteroalkylheterocycle;
L10 is a 2-14 atom long linker comprising one or more groups selected from -O- (oxygen), -C(=0)-, -C(=S)-, -NRA- -S(O)0-2- -NRAS(0)i_2NRA- and -NRAS(0)i_20-, and one or more groups selected from -O- (oxygen), -C(=0)-, -C(=S)-, -NRA- -S(0)o-2- -NRAS(0)i_2NRA- and -NRAS(0)i_20- an optionally substituted C1-C10 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; where the an optionally substituted aryl and an optionally substituted heteroaryl in the definition of L10 are each further optionally fused with an optionally substituted nonaromatic heterocycle or an optionally substituted nonaromatic carbocycle;
R1 is selected from the group consisting of halogen, optionally substituted Ci-C6 alkyl, an optionally substituted Ci-C6 alkoxy, an optionally substituted C2- C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3- C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, and an optionally substituted Ci-C6 heteroalkyl; R 2 is selected from the group consisting of halogen, -OR A , -NRB RC , -
SRA;
R3 is selected from the group consisting of -ORD, -NRERF, -S(O)0-2RD, -N02, -CN, and -(CH2)mRG, ;
R4 is selected from the group consisting of halogen, optionally substituted CrC6 alkyl, an optionally substituted CrC6 alkoxy, an optionally substituted C2- C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C3- C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, , an optionally substituted Ci-C6 heteroalkyl;
R5 is selected from the group consisting of -ORA, -NRBRC, -SRA;
R6 is selected from the group consisting of -ORD, -NRERF, -S(O)0-2RD, -NO2, -CN, and -(CH2)mRG;
each RA is separately selected from the group consisting of hydrogen, -S02RF, -C(=0)RF, -C(=0)NRcRD, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3- C7 cycloalkyl, C3-C7 cycloalkenyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, and Ci-C6 heterohaloalkyl, where the CrC6 alkyl, C3-C7 cycloalkyl, CrC6 heteroalkyl, and Ci-C6 heterohaloalkyl in the definition of RA are optionally substituted;
each -NR B R C is separately selected, wherein R B and R C are each independently selected from the group consisting of hydrogen, -S02R , - C(=0)RH, -C(=0)NRERF, Ci-Ce alkyl, C2-C4 alkenyl, an optionally substituted C2- C4 alkynyl, C3-C7 cycloalkyl, Ci-C6 haloalkyl, Ci-C6 heteroalkyl, heterocycle, and CrC6 heterohaloalkyl where the cycloalkyl and the heterocycle are optionally fused with an aryl or heteroaryl; or -NR B R C is an optionally substituted non- aromatic heterocycle linked through a ring nitrogen atom; or -NR B R C is an optionally substituted Ci-C6 alkylideneamino;
each RD is independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted Ci-C6 haloalkyl, an optionally substituted Ci-C6 heteroalkyl, an optionally substituted heterocyle, and -(CH2)mRG;
each -NR E R F is separately selected, wherein R E and R F are each independently selected from the group consisting of hydrogen, an optionally substituted Ci-C6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted C2-C4 alkynyl, an optionally substituted C3-C7 cycloalkyl, an optionally substituted CrC6 haloalkyl, an optionally substituted CrC6 heteroalkyl, an
G E F
optionally substituted heterocycle, and -(CH2)mR ; or -NR R is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen atom;
each RG is separately selected from an optionally substituted aryl and an optionally substituted heteroaryl;
each R is separately selected from the group consisting of hydrogen, a Ci- C6 alkyl, a CrC6 haloalkyl, a CrC6 heteroalkyl, a C3-C6 cycloalkyl, an optionally substituted heterocycle, and an optionally substituted aryl or an optionally substituted heteroaryl; and
each m is independently 0, 1, or 2.
PCT/US2011/061247 2010-11-18 2011-11-17 Use of hematopoietic growth factor mimetics WO2012068406A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/885,148 US20140243324A1 (en) 2010-11-18 2011-11-17 Use of hematopoietic growth factor mimetics
CN2011800627578A CN103282034A (en) 2010-11-18 2011-11-17 Use of hematopoietic growth factor mimetics
EP11793596.5A EP2642994A2 (en) 2010-11-18 2011-11-17 Use of hematopoietic growth factor mimetics
JP2013540029A JP6261340B2 (en) 2010-11-18 2011-11-17 Use of hematopoietic growth factor mimics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41527010P 2010-11-18 2010-11-18
US61/415,270 2010-11-18

Publications (2)

Publication Number Publication Date
WO2012068406A2 true WO2012068406A2 (en) 2012-05-24
WO2012068406A3 WO2012068406A3 (en) 2012-11-01

Family

ID=45217688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/061247 WO2012068406A2 (en) 2010-11-18 2011-11-17 Use of hematopoietic growth factor mimetics

Country Status (5)

Country Link
US (1) US20140243324A1 (en)
EP (1) EP2642994A2 (en)
JP (1) JP6261340B2 (en)
CN (1) CN103282034A (en)
WO (1) WO2012068406A2 (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102766135A (en) * 2012-07-09 2012-11-07 云南大学 Dihydrofuran indenoane-imidazole salts compound and preparation method thereof
WO2015074123A1 (en) * 2013-11-25 2015-05-28 Novogen ltd Functionalised and substituted indoles as anti-cancer agents
WO2017039318A1 (en) * 2015-09-01 2017-03-09 Kainos Medicine, Inc. Benzimidazole derivatives for dna methylation inhibitors
US9603836B2 (en) 2014-05-15 2017-03-28 Iteos Therapeutics Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
US9724351B2 (en) 2012-08-23 2017-08-08 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
US9873690B2 (en) 2015-03-17 2018-01-23 Pfizer Inc 3-indol substituted derivatives, pharmaceutical compositions and methods for use
EP3256449A4 (en) * 2015-02-11 2018-11-14 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers
WO2019100106A1 (en) * 2017-11-24 2019-05-31 The University Of Sydney Antibacterial compounds and methods of use thereof
EP3424924A4 (en) * 2016-03-11 2019-08-07 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Urea compound, preparation method therefor and medical use thereof
US10544095B2 (en) 2015-08-10 2020-01-28 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
US10800768B2 (en) 2016-12-22 2020-10-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US10806785B2 (en) 2016-12-22 2020-10-20 Incyte Corporation Immunomodulator compounds and methods of use
WO2020239658A1 (en) * 2019-05-29 2020-12-03 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2020239660A1 (en) * 2019-05-29 2020-12-03 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
US11307462B2 (en) 2018-03-30 2022-04-19 Lg Chem, Ltd. Liquid crystal aligning agent composition, method for preparing liquid crystal alignment film using same, and liquid crystal alignment film and liquid crystal display using same
WO2022123314A1 (en) * 2020-12-11 2022-06-16 Tmem16A Limited Benzimidazole derivatives for treating respiratory disease
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2023287128A1 (en) * 2021-07-12 2023-01-19 한양대학교 에리카산학협력단 Indazole yl benzimidazole derivative or pharmaceutically acceptable salt thereof, and use thereof
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US11673883B2 (en) 2016-05-26 2023-06-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11718605B2 (en) 2016-07-14 2023-08-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11767321B2 (en) 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
EP4265246A1 (en) * 2022-04-22 2023-10-25 Université Paris Cité Compounds inducing production of proteins by immune cells
EP4265247A1 (en) * 2022-04-22 2023-10-25 Université Paris Cité Compounds inducing production of proteins by immune cells
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2968371T3 (en) 2013-10-10 2024-05-09 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
CN109312157A (en) * 2016-04-04 2019-02-05 加利福尼亚大学董事会 The LLS compound for the treatment of cancer
CN112321513B (en) * 2020-11-06 2022-12-23 药康众拓(江苏)医药科技有限公司 Heterocyclic compound and preparation method and application thereof
CN114853679A (en) * 2021-02-04 2022-08-05 清药同创(北京)药物研发中心有限公司 Benzimidazole ENL protein inhibitor and preparation method and application thereof
WO2024077093A2 (en) * 2022-10-04 2024-04-11 University Of Rochester Staphylococcus aureus pbp4 inhibitors and method of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037905A1 (en) 2001-10-30 2003-05-08 Amedis Pharmaceuticals Limited Silicon compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0866700A4 (en) * 1995-11-13 1999-04-07 Smithkline Beecham Corp Hemoregulatory compounds
WO2009155362A1 (en) * 2008-06-19 2009-12-23 Ligand Pharmaceuticals Inc. Small molecule hematopoietic growth factor mimetic compounds and their uses
WO2010029300A1 (en) * 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
AR075835A1 (en) * 2009-03-12 2011-04-27 Biolipox Ab BIS-AROMATIC COMPOUNDS FOR USE AS LTC4 SINTASA INHIBITORS
ES2749504T3 (en) * 2009-10-13 2020-03-20 Ligand Pharm Inc Small Molecular Mimetic Compounds of Hematopoietic Growth Factor and Their Uses
WO2011151618A2 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037905A1 (en) 2001-10-30 2003-05-08 Amedis Pharmaceuticals Limited Silicon compounds

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ADAMSON JW.: "The anemia of inflammation/malignancy: mechanisms and management", HEMATOLOGY AM SOC HEMATOL EDUC PROGRAM., vol. 2008, 2008, pages 159 - 65
BAINS; TACKE, CURR. OPIN. DRUG DISCOV DEVEL., vol. 6, no. 4, July 2003 (2003-07-01), pages 526 - 43
FERREIRA R ET AL.: "GATA1 function, a paradigm for transcription factors in hematopoiesis", MOL CELL BIOL, vol. 25, 2005, pages 1215 - 27
GREENE; WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS
JELKMANN, W., INTERNAL MEDICINE, vol. 43, no. 8, August 2004 (2004-08-01)
RICHMOND TD ET AL.: "Turning cells red: signal transduction mediated by erythropoietin", TRENDS CELL BIOL, vol. 15, 2005, pages 146 - 155, XP004777064, DOI: doi:10.1016/j.tcb.2005.01.007
RIZZO JD ET AL.: "Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guidelines update", J CLIN ONCOL, vol. 26, 2008, pages 132 - 149
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
TACKE; ZILCH, ENDEAVOUR, NEW SERIES, vol. 10, 1986, pages 191 - 197

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102766135A (en) * 2012-07-09 2012-11-07 云南大学 Dihydrofuran indenoane-imidazole salts compound and preparation method thereof
US9724351B2 (en) 2012-08-23 2017-08-08 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
US11014935B2 (en) 2012-08-23 2021-05-25 Janssen Biopharma, Inc. Compounds for the treatment of paramyxovirus viral infections
WO2015074123A1 (en) * 2013-11-25 2015-05-28 Novogen ltd Functionalised and substituted indoles as anti-cancer agents
US10398679B2 (en) 2014-05-15 2019-09-03 Iteos Therapeutics Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors
US9603836B2 (en) 2014-05-15 2017-03-28 Iteos Therapeutics Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
US9949951B2 (en) 2014-05-15 2018-04-24 Iteos Therapeutics Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
US10590078B2 (en) 2015-02-11 2020-03-17 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers
EP3256449A4 (en) * 2015-02-11 2018-11-14 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers
US9873690B2 (en) 2015-03-17 2018-01-23 Pfizer Inc 3-indol substituted derivatives, pharmaceutical compositions and methods for use
US10544095B2 (en) 2015-08-10 2020-01-28 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
WO2017039318A1 (en) * 2015-09-01 2017-03-09 Kainos Medicine, Inc. Benzimidazole derivatives for dna methylation inhibitors
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US11866435B2 (en) 2015-12-22 2024-01-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3424924A4 (en) * 2016-03-11 2019-08-07 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Urea compound, preparation method therefor and medical use thereof
AU2017230437B2 (en) * 2016-03-11 2020-11-26 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Urea compound, preparation method therefor and medical use thereof
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11673883B2 (en) 2016-05-26 2023-06-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US11718605B2 (en) 2016-07-14 2023-08-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US11339149B2 (en) 2016-12-22 2022-05-24 Incyte Corporation Heterocyclic compounds as immunomodulators
US10800768B2 (en) 2016-12-22 2020-10-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US10806785B2 (en) 2016-12-22 2020-10-20 Incyte Corporation Immunomodulator compounds and methods of use
US11787793B2 (en) 2016-12-22 2023-10-17 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2019100106A1 (en) * 2017-11-24 2019-05-31 The University Of Sydney Antibacterial compounds and methods of use thereof
US11307462B2 (en) 2018-03-30 2022-04-19 Lg Chem, Ltd. Liquid crystal aligning agent composition, method for preparing liquid crystal alignment film using same, and liquid crystal alignment film and liquid crystal display using same
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US11124511B2 (en) 2018-03-30 2021-09-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11414433B2 (en) 2018-05-11 2022-08-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
US10906920B2 (en) 2018-05-11 2021-02-02 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2020239660A1 (en) * 2019-05-29 2020-12-03 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2020239658A1 (en) * 2019-05-29 2020-12-03 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
US11767321B2 (en) 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
US11807638B2 (en) 2020-10-05 2023-11-07 Enliven Inc. 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US12084443B2 (en) 2020-11-06 2024-09-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
WO2022123314A1 (en) * 2020-12-11 2022-06-16 Tmem16A Limited Benzimidazole derivatives for treating respiratory disease
WO2023287128A1 (en) * 2021-07-12 2023-01-19 한양대학교 에리카산학협력단 Indazole yl benzimidazole derivative or pharmaceutically acceptable salt thereof, and use thereof
EP4265246A1 (en) * 2022-04-22 2023-10-25 Université Paris Cité Compounds inducing production of proteins by immune cells
WO2023203161A1 (en) * 2022-04-22 2023-10-26 Universite Paris Cite Compounds inducing production of proteins by immune cells
WO2023203162A1 (en) * 2022-04-22 2023-10-26 Universite Paris Cite Compounds inducing production of proteins by immune cells
EP4265247A1 (en) * 2022-04-22 2023-10-25 Université Paris Cité Compounds inducing production of proteins by immune cells

Also Published As

Publication number Publication date
WO2012068406A3 (en) 2012-11-01
CN103282034A (en) 2013-09-04
JP6261340B2 (en) 2018-01-17
EP2642994A2 (en) 2013-10-02
JP2014502266A (en) 2014-01-30
US20140243324A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
JP6238942B2 (en) Hematopoietic growth factor mimicking small molecule compounds and their use
JP6261340B2 (en) Use of hematopoietic growth factor mimics
JP6219882B2 (en) IRE-1α inhibitor
JP5662143B2 (en) 2-Oxo-3-benzylbenzoxazol-2-one derivatives as Met kinase inhibitors for the treatment of tumors and related compounds
AU2005299720B2 (en) Thrombopoietin activity modulating compounds and methods
JP5174665B2 (en) 1-acyl dihydropyrazole derivatives
EP1951667A2 (en) Thrombopoietin activity modulating compounds and methods
WO2009155362A1 (en) Small molecule hematopoietic growth factor mimetic compounds and their uses
BRPI0923819A2 (en) pharmaceutical compounds
JP2020503268A (en) Piperazine derivatives as selective HDAC1,2 inhibitors
JP2000143635A (en) Arterialization inhibitor
BRPI0618806A2 (en) Substituted 5-phenyl-3,6-dihydro-2-oxo-6h- [1,3,4] thiadiazines
BRPI0923913B1 (en) PIRIDAZINONE DERIVATIVES, THEIR USE AND PREPARATION PROCESS, MEDICINES AND KIT
KR20100135248A (en) Indolinone compound
CA3026252A1 (en) Autotaxin inhibitors
MX2008006653A (en) Thrombopoietin activity modulating compounds and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11793596

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013540029

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011793596

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13885148

Country of ref document: US